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1011-119 Rosuvastatin Enhances Arteriogenesis in a Murine 
Disease Model of ApoE Deﬁciency
Imo Hoefer, Felix Hedwig, Benjamin Meder, Susann Ulusans, Caroline Bergmann, 
Stephanie Fischer, Niels van Royen, Ivo Buschmann, Research Group for 
Arteriogenesis, Internal Medicine, Freiburg, Germany, University of Amsterdam, 
Amsterdam, The Netherlands
Background: Recruitment, proliferation and growth of pre-existent arteriolar anastomoses 
to functional collateral arteries (arteriogenesis) serves as an efﬁcient mechanism 
to prevent devastating consequences of atherosclerotic vessel occlusion. Current 
pharmaceutical treatment options for atherosclerosis focus on improving the lipid proﬁle 
by lowering LDL-cholesterol levels through HMG-CoA reductase inhibitors (statins). Since 
both, arteriogenesis and cholesterol-lowering act together in the improvement of the 
clinical outcome, we tested the effect of rosuvastatin, the most effective statin to date, 
on arteriogenesis. 
Methods: Seventy-two ApoE-/- mice received either PBS (control) or rosuvastatin (10mg/
kg) subcutaneously once daily after ligation of the right femoral artery. Following seven 
days or six months of rosuvastatin treatment, hind limb perfusion was assessed using 
ﬂuorescent microspheres. Blood was collected for evaluation of circulating endothelial 
progenitor cells (EPC). Histological tissue specimens of the hind limb and the aortic arch 
were taken and atherosclerotic plaque area of the aorta was quantiﬁed. 
Results: Rosuvastatin treatment signiﬁcantly decreased the aortic atherosclerotic plaque 
area and improved plaque composition. The amount of circulating EPC was not affected 
by the treatment. Hind limb perfusion was signiﬁcantly enhanced by rosuvastatin seven 
days after femoral ligation (PBS: 26.6 ± 5.3%, rosuvastatin: 35.3 ± 3.7 % of normal; 
p<0.001) and retained a greater level of improvement after six months (PBS: 49.1 ± 6.1%, 
rosuvastatin: 56.0 ± 5.6 %; p<0.05). We have previously demonstrated the importance of 
monocyte-induced arteriogenesis at the sites of vascular ischemic damage. Quantitative 
immunohistology revealed an improved migratory ability of monocytes to the site of 
collateral artery growth. 
Conclusion: Rosuvastatin positively modulates arteriogenesis in atherosclerotic ApoE-/- 
mice, in the absence of mobilization of EPC. Rosuvastatin also reduced the atherosclerotic 
burden in these mice.
1011-120 Wine Components Activate t-PA Gene Transcription 
Through the JNK and p38 Mitogen Activated Protein 
Kinase Pathways
Edlue Moyo Tabengwa, Stacey L. Drawz, Wensheng Pan, Hernan E. Grenett, Francois 
M. Booyse, University of Alabama at Birmingham, Birmingham, AL
Background: Moderate wine consumption has been correlated to reduced risk for 
coronary artery disease (CAD) and may be mediated, in part, by increased ﬁbrinolysis 
induced by individual wine components (ethanol and polyphenol quercetin). We have 
shown that ethanol and quercetin upregulate endothelial cell (EC) t-PA gene transcription 
and ﬁbrinolysis. These studies examined the involvement of signaling pathways, ie. 
mitogen-activated protein kinases (MAPKs) p38, ERK-1/2 and JNK in ethanol-/quercetin-
induced t-PA gene transcription in cultured human ECs.
Methods: Cultured ECs were incubated in the absence/presence of ethanol (0.1%, v/v) or 
quercetin (1 µM) and MAPK activation measured (Western blot). ECs were pre-incubated 
in the absence/presence of speciﬁc MAPK inhibitors (10-50µM, 45 min) followed by 
incubation in the absence/presence of ethanol (0.1%, v/v) or quercetin (1 µM) to assess 
their individual contribution to ethanol-/quercetin-mediated t-PA expression (mRNA [8 hr, 
real-time PCR] and antigen [24 hr, Western blot]).
Results: Ethanol treatment resulted in rapid/transient activation of p38 and JNK and 
delayed activation of ERK1/2. Quercetin treatment resulted in rapid/sustained activation 
of p38 and rapid/transient activation of JNK and ERK1/2. Both the ethanol- and quercetin-
induced t-PA expression (mRNA/antigen) expression was completely inhibited by the p38 
inhibitor and slightly reduced by the JNK inhibitor. The ERK1/2 inhibitor had no effect on 
either the ethanol- or the quercetin-induced t-PA antigen/mRNA expression.
Conclusions: These results show for the ﬁrst time that wine components, ethanol and 
quercetin, upregulate t-PA gene transcription via the activation of p38 and JNK signaling 
pathways. These data suggest a mechanism by which wine components (i.e. ethanol 
and quercetin) act through a common signaling pathway to coordinately increase t-PA 
gene transcription and hence t-PA-mediated EC ﬁbrinolysis. Increased EC ﬁbrinolysis by 
wine components will be expected to provide protection by promoting clot lysis, thereby 
reducing the overall risk for early thrombotic and later atherothrombotic complications 
associated with coronary heart disease.
1011-121 The Thrombus Becomes Stiffer In the First 3 Hours: In 
Vivo Assessment with Palpography
Johannes A. Schaar, Frits Mastik, Elza D. van Deel, Cornelis Slager, Patrick W. Serruys, 
Dirk J. Duncker, Anton FW van der Steen, ErasmusMC, Rotterdam, The Netherlands, 
The Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands
Vulnerable plaques can lead to thrombus development. The aging of a thrombus cannot 
be assessed in vivo with currently available imaging methods. Nothing is known about the 
time course of this process especially in the very early phase of development.
Palpography assesses the mechanical properties of biological tissue. We hypothesize that 
the organization process in a thrombus starts early after introduction and that stiffness is 
increasing over time.
Methods: In 7 anesthetic and surgical prepared pigs thrombus formation was introduced 
in both femoral arteries by applying electrical DC current to the outer vessel wall. The 
current caused a vessel injury. Over this injury thrombus was formed, which left a lumen 
through which the blood pressure could act as the driving force to strain the thrombus. 
Ten thrombi were formed. Palpograms were recorded at 6 time points after thrombus 
introduction (5, 20, 45, 75, 105, 180 min). Results:
Initially thrombi are soft and stiffened dramatically in the ﬁrst 20 minutes with a strain 
reduction of about 50% (see ﬁgure). Further stiffening took considerable more time, but 
could be observed to the end of the experiment. The relation between the time and strain 
is highly signiﬁcant (R2=0.59; p < 0,0001).
Conclusion: This is the ﬁrst time the in vivo development of a thrombus in an artery could 
be monitored with special emphasis on the organization of the thrombus. A vast parts of 
the organization process take place within 20 min after thrombus introduction. 
1011-122 Effect of Atrial Fibrillation on Local Expression of 
Tissue Factor in the Left Atrium and Left Atrial 
Appendage.
Laura Diamandopoulos, Clegg Honeycutt, Josiah Wilcox, Jonathan Langberg, David 
Harrison, Samuel Dudley, Emory University, Atlanta, GA
Background: Atrial ﬁbrillation (AF) is the most common cardiac arrhythmia. Its major 
complication is thromboembolic stroke, commonly from thrombi formed in the left atrial 
appendage. We have shown that nitric oxide (NO), an important regulator of intravascular 
coagulation, is decreased in the left atrial appendage in AF. NO regulates coagulation in 
part by inhibiting tissue factor (TF), the ﬁrst step in activation of the extrinsic pathway of 
coagulation.
Hypothesis: AF not only reduces left atrial NO production and eNOS expression but also 
increase expression of the prothrombotic factor, TF.
Methods: In a porcine model of AF, animals underwent AV nodal ablation and implantation 
of a dual-chamber pacemaker. Control pigs were AV-sequentially paced at 100 bpm while 
experimental pigs were paced at 100 bpm in the ventricle and 600 bpm in the atrium to 
induce atrial ﬁbrillation. One week later, TF protein was quantiﬁed by western blotting and 
immunohistochemistry and TF activity was assessed by immunostaining for tissue factor-
factor VIIa complexes in the left atrium, left atrial appendage, right atrium and aorta.
Results: By western blotting, tissue factor protein was increased 3-fold in the left atrium 
(p=0.016) and 4.5-fold in the left atrial appendage (p=0.0036) of pigs with atrial ﬁbrillation 
vs. sinus rhythm (n=5 for each group). AF did not alter TF expression in the right atrium 
(p=0.063) or aorta (p=0.077). By immunostaining, AF markedly increased both TF and 
TF/VIIa complexes in the left atrium and left atrial appendage.
Conclusion: These data show that AF induces a local prothrombotic milieu in the left 
atrium and left atrial appendage, possibly related to changes in the redox environment 
in these chambers. This local increase in thrombogenicity might account for the high rate 
of thrombus formation in these chambers and subsequent risk of stroke. Understanding 
the mechanism for this phenomenon might offer a selective therapeutic target to prevent 
stroke in patients with AF.
1011-123 Atorvastatin Attenuates Vascular Glomeruli 
Athersoclerosis in Experimental Hypercholesterolemia
Nalini M. Rajamannan, Pamela S. Gallagher, Thuy Anh Le, Sanjay Pandya, Joseph 
McConnell, Ravinder Singh, Jason Gocek, Frank Caira, Malayannan Subramaniam, 
Thomas C. Spelsberg, Northwestern University, Chicago, IL, Mayo Clinic, Rochester, MN
Background: Recent studies link early renal insufﬁciency to increased cardiovascular risk 
factors. Chronic renal nephrosclerosis is a common cause for end stage renal disease and 
an indication for hemodialysis. We studied a model of experimental hypercholesterolemia 
with and without atorvastatin to determine the cellular mechanisms of nephrosclerosis. 
Methods: 48 Watanabe rabbits were assigned to one of 3 groups: control, cholesterol 
(0.25%) diet, cholesterol (0.25%) plus atorvastatin (2.5 mg/kg), and normal diet for six 
months. The kidneys were studied and serum creatnine levels were measured. Electron 
Microscopy, immunohistologic staining and Western Blots were performed. The following 
atherosclerotic markers were tested including: macrophage (RAM11), α-actin smooth 
muscle, and Proliferating Cell Nuclear Antigen (PCNA). Bone matrix expression was 
determined by western blot for osteopontin and osteocalcin. Results: Serum creatnine 
levels (0.9+/-0.03mg/dl control vs 1.3+/-0.43mg/dl chol, p<0.05) macrophage, α-actin, 
osteopontin, osteocalcin and PCNA were increased in the vascular glomeruli from 
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the cholesterol treated rabbits. Atorvastatin decreased the amount of atherosclerosis, 
proliferation and bone matrix protein expression with no signiﬁcant change in the 
serum creatnine levels (1.12+/-0.25) in these treated kidneys. Conclusion: Experimental 
hypercholesterolemia induces proliferation and osteopontin expression in the glomeruli 
that may potentially be modiﬁed with the use of a lipid-lowering agent.
1011-124 Comparison of Bio-histo-chemical Tissue Activities 
of Caspase-1and-3 in MRI Visualized Neo-intimal Sub-
renal Aortic Dissection in a Watanabe Hereditable 
Hyperlipidemic (WT) Rabbit Model
Henning Steen, Antonina Kolmakova, Matthias Stuber, Rene Rodriguez, Joao Augusto 
Lima, Subroto Chatterjee, Johns Hopkins University, Baltimore, MD
Background: Caspase-1/-3 (Cas-1/-3) play a critical role in vascular smooth muscle cell 
(VSMC) apoptosis leading to atherosclerotic neo-intimal dissection (NiD)/plaque rupture 
(PR) whereas previously Cas-1 was considered the major contributor to this process. We 
hypothesized that in MRI localized NiD/PR Cas-3 rather than -1 is the major contributor 
to VSMC apoptosis by employing immuno-histochemistry and Western immuno-blot 
assays.
Methods: We imaged 14 WT rabbits (I=5WTas control, II=6WT fed with high cholesterol 
diet for 3 months, III=5WT with similar diet but balloon induced endothelial denudation) 
after Russel`s viper venom induced NiD/PR using 3D black blood fast spin-echo 1.5T 
vessel wall images. After sacriﬁce, Cas-1/-3 tissue levels of MRI visualized NiD/PR were 
analyzed qualitatively via immuno-histochemistry and quantitatively via Western Blots.
Results: Tissue levels of 6 MRI localized NiD/PR (II=3,III=3) areas strongly reacted 
with Cas-3 (Fig.D) and moderately with Cas-1 antibody (Fig.C) when compared to non-
ruptured tissue (Fig.A,B). In Western immunoblot assays Cas-3 precursor was similar in 
I-III, however, levels of active Cas-3 (17kDa, Fig.E) were markedly increased in NiD/PR 
sections of II and III as compared to I (Cas-3 not observed).
Discussion: In in-vivo MRI detected NiD/PR, immuno-histochemical and Western Blot 
analysis showed evidence that co-localized Cas-3 rather than Cas-1 is the prominent 
apoptotic molecule in the cascade of VSMC apoptosis.
1011-125 Risk Marker or Risk Factor? : C-Reactive Protein 
Stimulates Smooth Muscle Cell Migration via an 
Integrin-Dependent Mechanism
Marvin J. Slepian, Behrooz Dehdashti, Luke Whitesell, University of Arizona, Tucson, AZ
C-Reactive Protein (CRP) has emerged as a signiﬁcant inﬂammatory risk marker of 
coronary artery disease activity. However, its role as a causal factor in the pathogenesis 
of atherosclerosis is incompletely deﬁned. We examined the effect of smooth muscle cell 
(SMC) migratory and adhesive behavior in vitro; speciﬁcally its effect on: 1. haptotactic 
migration, 2. selective substrate adhesion, 3. surface integrin expression and 4. integrin 
dependency on CRP-modulated migration. Rat aortic SMC monolayers were scrape-
wounded, washed and incubated in DME + 10% FCS with human CRP (1-50mg/L). 
Migration at 48h was determined as mean area of SMCs emerging from wound edges. 
SMCs were incubated in medium + CRP (50mg/L)(24h) and β1 and β3 integrin expression 
was determined via ﬂow cytometry. Identically treated SMCs were harvested, seeded 
(104 SMC/cm2) on ﬁbronectin (FN) or vitronectin (VN) coated dishes, incubated for 1h, 
washed and adherent cells counted and reported as mean SMCs/100x ﬁeld. Finally, 
integrin-dependency of CRP-modulated migration was assessed as above with addition 
of functional blocking antibodies to integrins β1 and β3. Non-CRP treated SMCs served 
as controls for all studies except integrin blocking studies. Results: CRP increased SMC 
migration in a concentration-dependent manner, with 172% + 8 of control at 50mg/L. CRP 
increased β3 integrin expression (133% + 7) with no effect on β1 integrin expression. 
CRP altered SMC adhesion, with enhanced adhesion on VN (92 + 6 vs. 68 + 10 (control), 
p<0.01) with no change in FN adhesion. In integrin blocking studies the mean % migration 
relative to CRP-treated (10mg/L) controls for anti- β3 and anti-β1 groups was 64 + 9 
(p<0.01) and 96 + 7 (p=ns). Conclusion: CRP directly alters SMC migratory and adhesive 
behavior. This effect appears to involve mechanisms mediated via β3 integrins as 
evidenced by increased β3 integrin expression and adhesion to β3-dependent substrate 
(VN), with reduced CRP-mediated migration with anti-β3 integrin Ab exposure. Blockade 
of CRP effects at the SMC level may be an additional therapeutic strategy for limiting 
atherosclerotic progression.
1011-126 No Interference of Pentaerythrityl Tetranitrate with 
Mitochondrial Aldehyde Dehydrogenase Activity as a 
Possible Explanation for the Lack of in vitro and in vivo 
Tolerance Induction by this Organic Nitrate
Andreas Daiber, Meike Coldewey, Matthias Oelze, Philip Wenzel, Karsten Sydow, 
Dirk Stalleicken, Alexander Mülsch, Thomas Münzel, Universitätsklinikum Hamburg-
Eppendorf, Hamburg, Germany, Universitätsklinik Mainz, Mainz, Germany
Background: Mitochondrial aldehyde dehydrogenase (ALDH-2) was recently identiﬁed 
to be essential for bio-activation of glyceryl trinitrate (GTN) (Chen et al 2002, Sydow et al 
2004, De La Lande et al 2004 und Zhang et al 2004). In the present study we assessed 
whether ALDH-2 also contributes to the bio-activation of pentaerythrityl tetranitrate 
(PETN).
Methods: Vasodilator potency of organic nitrates was assessed by isometric tension 
studies using phenylephrine-constricted rat aortic rings. NO downstream-signalling 
was measured by organic nitrate-induced activation of sGC (cGMP levels) and cGK-I 
(phosphorylation state of the vasodilator-activated phosphoprotein (VASP)). Mitochondrial 
reactive oxygen species formation was detected by luminol-enhanced chemiluminescence 
and ALDH-2 activities were determined by an HPLC-based assay.
Results: The ALDH-2 inhibitor benomyl reduced the vasodilator potency of GTN, PETN 
and its trinitrate (PETriN), whereas vasodilator responses to other organic nitrates and the 
endothelium-dependent vasodilator acetylcholine were not affected. Similarly, benomyl 
decreased GTN and PETN-elicited phosphorylation of the cGMP-activated protein 
kinase substrate VASP, but not that elicited by other nitrates. The vasodilator potency of 
organic nitrates correlated with their potency to inhibit ALDH-2 dehydrogenase activity 
in mitochondria from rat heart, and to increase mitochondrial superoxide formation, as 
detected by chemiluminescence. In contrast, mitochondrial ALDH-2 esterase activity was 
not affected by PETN and its metabolites.
Conclusion: We conclude that mitochondrial ALDH-2, speciﬁcally its esterase activity, 
contributes to bio-activation of the organic nitrates with high vasodilator potency, such as 
GTN and PETN, but not for the less potent nitrates. Interestingly, ALDH-2 esterase activity 
was inhibited by GTN only, not by PETN and PETriN, which are also bio-activated by this 
enzyme. This difference might explain why GTN elicits mitochondrial superoxide formation 
and nitrate tolerance with the highest potency. Preliminary data of an in vivo PETN study 
demonstrate that this concept holds also true for chronic PETN administration.
1011-127 Homocysteine Impairs Endothelial Cell Survival by 
Repressing the Transcriptional Activity of the Fibroblast 
Growth Factor 2 Promoter
Po-Yuan Chang, Shao-Chun Lu, Chii-Ming Lee, Wen-Huei Huang, Yi-Jie Chen, Warren 
S.L. Liao, Chu-Huang Chen, Yuan-Teh Lee, National Taiwan University College of 
Medicine, Taipei, Taiwan,ROC, Baylor College of Medicine, Houston, TX
Background: Homocysteine-associated atherosclerosis is characterized by concomitant 
reduction in proliferation and increased apoptosis of vascular endothelial cells (EC). 
Because ﬁbroblast growth factor 2 (FGF2) is essential for EC proliferation and survival, 
we investigated whether the effects of homocysteine may in part be through the inhibition 
of FGF2 gene transcription.
Methods: Expression proﬁles of FGF2 and vascular endothelial growth factor (VEGF), 
two important mitogenic and antiapoptotic proteins, were examined in bovine aortic 
and human coronary EC incubated with graded concentrations of homocysteine. DNA 
synthesis (by 3H-thymidine incorporation), cell viability (by MTT assay), and cell cycle 
progression were evaluated.
Results: Homocysteine reduced the protein and mRNA levels of FGF2, but not VEGF, 
in a time- and concentration-dependent manner. It had no effect on the expression of 
either the FGF2 or the VEGF receptors. In concomitance with FGF2 downregulation, DNA 
synthesis, G1-S transition, and cell viability were all suppressed in homocysteine-treated 
EC. Supplementation with FGF2, but not VEGF, signiﬁcantly attenuated the negative 
effects of homocysteine on EC proliferation. To conﬁrm that FGF2 downregulation is an 
important cause of homocysteine-induced impairment of EC survival, we investigated the 
effects of homocysteine on the transcriptional activity of FGF2 promoter. FGF2-luciferase 
reporters containing serial deletions of the FGF2 5’-ﬂanking regions were constructed and 
examined for FGF2 promoter activities after transient transfection into EC. Our studies 
identiﬁed a short FGF2 promoter region (between -126 and +24 bp) whose transcriptional 
activity can be repressed by homocysteine.
Conclusion: Homocysteine selectively downregulates FGF2 expression by repressing 
the FGF2 promoter activity in cultured arterial EC, thereby impairing FGF2-regulated 
survival mechanisms that cannot be restored by VEGF. Thus, protection of FGF2 
expression is critical to the maintenance of endothelial integrity in the presence of 
hyperhomocysteinemia.
1011-128 Moderate Ethanol Activates JNK and ERK to Repress 
Human Endothelial Cell PAI-1 Expression: Potential 
Cardioprotection via Enhanced Fibrinolysis
Hernan E. Grenett, Marcelo Garces, Pamela Lucchesi, Paul Wolkowicz, University of 
Alabama at Birmingham, Birmingham, AL
Background: Fibrinolytic activity is impaired in various disease states such as coronary 
artery disease (CAD). This has been attributed to elevated plasminogen activator 
inhibitor-1 (PAI-1) activity. We have shown that moderate, cardioprotective ethanol 
represses endothelial cell (EC) PAI-1 gene expression in a time- and dose-dependent 
manner. Because the mitogen-activated protein kinases (MAPKs), p38, JNK, and the 
extracellular signal-regulated kinase (ERK1/2), activate transcription factors and regulate 
gene transcription, we elucidated (i) whether ethanol activates EC MAPK signaling and (ii) 
whether MAPKs repress PAI-1 expression in ECs exposed to ethanol.
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Methods: ECs were incubated in the absence or presence of 0.1% ethanol for 0-30 
min. MAPK activation was evaluated by Western analysis using antibodies against the 
phosphorylated, active forms of p38, JNK, and ERK1/2. To determine which MAPK 
represses EC PAI-1 expression in the presence of ethanol, ECs were pre-incubated with 
inhibitors of p38 (SB-203580), JNK (SP-600125), or ERK1/2 (U-0126) for 45 min, then 
with 0.1% ethanol for 0-8 hr. Total EC RNA was extracted and its PAI-1 mRNA content 
was analyzed using RT-PCR.
Results: EC p38, JNK, and ERK1/2 were activated 2.5 to 15min following the addition 
of 0.1% ethanol to the culture medium. SP-600125 and U-0126, but not SB-203580, 
abolished the repression of PAI-1 expression that occurs with moderate ethanol. 
Conclusions: Ethanol activates all EC MAPKs but only JNK and ERK1/2 mediate ethanol 
repression of EC PAI-1 gene transcription. Future studies will examine the mechanisms by 
which JNK and ERK1/2 suppress PAI-1 gene expression.
1011-129 Increased Levels of Proinﬂammatory Markers are 
Associated to the Presence of Mutations of LDL 
Receptor/ApoB 100 Genes
Andrzej Bolewski, Robert Plewa, Tomasz Siminiak, Henryk Wysocki, District Hospital, 
Poznan, Poland
Background: Mutations of LDL receptor or ApoB100 gene are associated with higher 
risk of atherosclerosis and coronary heart disease. Several studies have shown that 
inﬂammation plays an important role in the pathogenesis of atherosclerosis. Soluble cell 
adhesion molecules are indicators of the inﬂammatory process.
Aim: To evaluate the plasma levels of soluble vascular cell adhesion molecule-1 (sICAM-1), 
intercellular adhesion molecule-1 (sICAM-1) and soluble Selectins P, E and L in patients 
with hypercholesterolemia with or without mutations of LDL receptor or ApoB100 gene.
Methods: The study group consisted of 34 consecutive hypercholesterolemic patients 
(mean serum cholesterol level 294±44 mg%; age 58±14; 13 females) without statin 
treatment in the past. We analyzed the LDL receptor and Apo B 100 gene using the 
single-strand conﬁrmation polymorphism (SSCP) and direct sequencing technique.
We found 8 mutations of LDL receptor or ApoB100 gene (group A = mutation, B = no 
mutation). Circulating sVCAM-1, sICAM-1, sP-Selectin, sE-Selectin and sL-Selectin 
levels were determined by commercially available ELISA kits (R&D System Europe Ltd).
All statistical analyses were performed with Mann-Whitney nonparametric test. All values 
are expressed as mean± SEM.
Results: There were no differences between group A and B in levels of sVCAM-1 
(A:793±49 vs B:797±38, p=NS) and sL-Selectin (A:930±58 vs B: 996±28, p=NS). The 
levels of sICAM-1 (A:312±17 vs B:389±37, p<0,05), sP-Selectin (A:87±12 vs B:56±4, 
p<0,03) and sE-Selectin (A:64±8 vs B:35±3, p<0,006) were signiﬁcantly higher in group 
with mutation in LDLr/ApoB100 genes.
In conclusion, the presence of mutation LDL receptor or ApoB100 genes can increase 
the plasma concentration of sICAM-1, sP-Selectin and sE-Selectin. This proinﬂammatory 
effect can be responsible for the higher risk of the development and progression of 
atherosclerosis.
1011-130 Transfer of Endothelial Progenitor and Bone-Marrow 
Derived Cells Inﬂuences Atherosclerotic Plaque Size 
and Composition in Apolipoprotein E Deﬁcient Mice
Jacob George, Anastasia Abashisdze, Hylton Miller, Gad Keren, Tel Aviv Sourasky 
Medical Center, Tel Aviv, Israel
Recent clinical trials employ cell therapy with bone marrow (BM) derived cells or with 
endothelial progenitor cells (EPCs) in several cardiovascular disorders. We tested the 
hypothesis that transfer of BM cells or spleen cell derived EPCs, by differentiation in 
vivo into endothelial cells, could increase plaque endothelialization, thereby reducing 
atherosclerosis and stabilizing morphologic lesion phenotype.
Thirty-four apoE deﬁcient mice aged 10 weeks served as recipients. Age matched apoE 
deﬁcient mice (10 per group) were sacriﬁced and their BM and spleen removed. BM 
cells were labeled with a ﬂuorescentic dye and 106 cells/mouse injected intravenously. 
Splenocytes were loaded on a ﬁcoll-gradient, grown for 5 days on ﬁbronectin-coated 
plates with endothelial-cell medium and 106 labeled cells/animal injected intravenously 
to a second group of recipient mice. Control group did not receive cell transfer. Upon 
sacriﬁce, 10 weeks after initial cell injection, plaque size and character were studied, 
lipid proﬁle analyzed, plasma cytokine assayed, and reverse transcriptase-polymerase 
chain reaction (RT-PCR) performed on aortas for the detection of mRNA for cytokines 
and metalloproteinases.
Spleen-cell derived EPC contained a signiﬁcantly larger number of cells double positive for 
acetylated LDL and lectin as compared with BM derived cells. Both EPC and BM-derived 
cells labeled ﬂuorescentically were found abundantly in the spleen yet also in the lesions 
of the recipient mice. Aortic-sinus lesion size was signiﬁcantly increased in mice receiving 
BM cells and in the EPC-treated group as compared with controls (a 54% and a 34% 
increase, respectively). Mice receiving EPCs exhibited plaques with larger lipid cores and 
thinner ﬁbrous caps evident by masson’s trichrome staining. RT-PCR analysis of aortas 
revealed similar expression of mRNA for interferon-gamma, matrix metalloproteinase-9 
and tissue inhibitor of metalloproteinase 1 and 2, yet reduced expression of mRNA for 
IL-10 in both cell-transfer groups.
Transfer of BM-derived cells and EPCs may result in an increase in atherosclerotic lesion 
size, whereas EPC transfer could potentially inﬂuence plaque stability.
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1012-95 Neurohormonal Activation in Isolated Right Ventricular 
Systolic Failure 
Jessica Spates, Maninder Bedi, Shobit Madan, Michele Svitek, Carrie Melegari, Michael 
Mathier, Linda Cadaret, Dennis McNamara, Srinivas Murali, University of Pittsburgh, 
Pittsburgh, PA
Pulmonary arterial hypertension (PAH) is a progressive disease that often leads to right 
ventricular (RV) systolic failure and death. Neurohormonal activation is well documented 
in patients (pts) with left ventricular failure, and correlates with survival. We sought to 
evaluate if neurohormonal activation predicts prognosis in RV failure secondary to PAH.
Methods: Demographic data, plasma levels of Atrial Natriuretic Peptide (ANP), B-type 
Natriuretic Peptide (BNP), Endothelin-1 (ET), Angiotensin II (AT II), Norepinephrine (NE), and 
clinical events (hospitalization for decompensated RV failure, death) were evaluated in 33 
WHO class III- IV PAH pts (21 primary, 10 secondary; 26 females; age 50.2±11 years; LVEF 
59%; pulmonary artery mean pressure 50.7±10.6 mm Hg; right atrial mean pressure12.5±8.9 
mm Hg) on chronic prostanoid therapy. The mean follow up was 43±26 months.
Results: Mean plasma neurohormone levels were elevated in PAH pts: ANP=145±108 
(normal 25-77 pg/ml), BNP=329± 349(normal< 80 pg/ml), ET=11.2±5.3 (normal 4.0-9.0 
pg/ml), AT II=92±86 (normal 10-50ng/L), and NE=858±493 (normal 112-658 pg/ml),. One 
and two year event free survival was signiﬁcantly worse in patients with ANP >100 pg/ml 
(p=0.04), ET > 10 pg/ml (p=0.04), AT II > 60 ng/l (p=0.03), BNP > 100 pg/ml (p=0.01) and 
NE > 800 pg/ml (p=0.06). Mean plasma neurohormone levels did not correlate with PA 
or RA pressures.
Conclusions: 1) As in left ventricular failure, neurohormonal activation is present in 
RV systolic failure due to PAH. 2) The degree of neurohormonal activation predicts the 
occurrence of adverse clinical events. We speculate that neurohormonal blockade therapy 
may have clinical beneﬁt in PAH patients with RV systolic failure.
1012-96 Septal/Free-Wall Curvature Ratio Measured by Cardiac 
Magnetic Resonance Imaging: An Accurate Index for 
the Estimation of Right Ventricular Systolic Pressure.
Santo Dellegrottaglie, Javier Sanz, Michael Poon, Martin Goyenechea, Roxana Sulica, 
Juan F. Viles-Gonzalez, Frank Macaluso, Valentin Fuster, Sanjay Rajagopalan, Z. and M. 
A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY
Background: Alterations in left ventricular geometry are commonly observed in 
patients with pulmonary hypertension (PH). The precise relationship of these geometric 
deformations to the hemodynamics between right and left ventricles is not well known. We 
hypothesized that the ratio of interventricular septal curvature to left ventricular free-wall 
curvature (C-Ratio) measured by cardiac magnetic resonance imaging is predictive of 
right ventricular systolic pressure (RVSP). 
Methods: 31 patients (mean age 51±14 years) with clinically suspected PH, who 
underwent right heart catheterization and cardiac magnetic resonance (True-FISP; 1.5 T 
scanner) on the same day, were studied. Short-axis images were selected at the basal left 
ventricular level. The curvature values for the septum and the free-wall were measured in 
end-systole using a dedicated workstation and expressed as C-Ratio. Systolic transmural 
pressures (dP) across the free-wall and the septum were assumed to be equivalent, 
respectively, to systolic blood pressure (SBP) and to the difference between SBP and 
RVSP. dP-Ratio was deﬁned as septal dP/free-wall dP. In Laplace’s law, wall stress is 
proportional to dP/(wall thickness x curvature). In absence of asymmetric hypertrophy, 
wall stress in the septum and the free-wall can be assumed to be similar. Thus any change 
in the dP-Ratio should affect C-Ratio proportionally. 
Results: PH was conﬁrmed (mean pulmonary artery pressure > 25 mmHg) in 23 (74%) 
patients. An inverse correlation between C-Ratio (mean 0.51±0.31) and RVSP (mean 
60±25 mmHg) was observed (r=-0.88; p<0.0001). Receiver operator curve analysis of 
C-ratio in predicting PH revealed a sensitivity of 96%, speciﬁcity of 100% and accuracy of 
97% (area under the curve=0.99; p<0.0001), using a best cut-off value of 0.82. A direct 
linear correlation between dP-Ratio (mean 0.50±0.23) and C-Ratio was observed (r=0.90; 
p<0.0001; C-Ratio=1.25 x dP-Ratio - 0.11), with a noninvasive estimation of RVSP by the 
formula: RVSP=SBP x (1.14 - C-Ratio)/1.25. 
Conclusion: Left ventricular C-Ratio obtained by magnetic resonance imaging is an 
accurate predictor of RVSP and may be a useful noninvasive index for determining the 
severity of PH.
1012-97 Cancer and Cardiogenic Shock Independently Predict 
Major Hemorrhage in Patients Receiving Thrombolysis 
for Acute Pulmonary Embolism
John Fanikos, Karen Fiumara, Nils Kucher, Samuel Z. Goldhaber, Brigham and Women’s 
Hospital, Boston, MA
Background: Thrombolysis may be live-saving in patients with acute pulmonary embolism 
(PE), but the risk of major hemorrhage increases compared with anticoagulation alone. 
Risk factors for major hemorrhage warrant further evaluation.
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Methods: We identiﬁed 94 PE patients at Brigham and Women´s Hospital (52±17 
years, 44% men, 14% cardiogenic shock, deﬁned as blood pressure < 90 mmHg or 
the administration of pressors), who received a continuous intravenous infusion of 100 
mg alteplase during a study period of 7 years. Major bleeding was deﬁned according to 
the Landefeld bleeding index: fatal bleeding; hemorrhage causing myocardial infarction, 
stroke, surgical intervention, blood transfusion > 4 units, drop in hematocrit >20%, or drop 
in systolic pressure to < 90 mmHg.
Results: Overall, 19 (20.2%) patients had major bleeding. The main site of bleeding was 
unknown in 8 (42%), gastrointestinal in 6 (32%), retroperitoneal in 2 (10%), intracranial 
in 1 (5.3%), and splenic in 1 (5.3%). Compared to patients with no or minor bleeding, 
cancer (36.8% vs. 6.7%; p=0.002), cardiogenic shock (38.9% vs. 8.0%; p=0.003), and 
renal dysfunction (36.8% vs. 10.7%; p=0.01) were more often present in patients who 
suffered major hemorrhage. In patients with major hemorrhage, the median INR prior 
to thrombolysis was higher (1.4, range 1.0-2.6 vs. 1.2, range 0.9-3.3; p=0.05), and the 
median hematocrit was lower (34, range 28-56 vs. 39, range 26-51; p=0.009). All 6 in-
hospital deaths occurred in patients with major bleeding, although bleeding was the 
clinical cause of death in only one. In multivariable analysis, cancer (OR 9.22, 95% CI 
1.75-48.58; p=0.009) and cardiogenic shock prior to thrombolysis (OR 8.54, 95% CI 1.96-
37.17; p=0.004) remained independent predictors of major hemorrhage after adjusting for 
age, sex, renal dysfunction, INR, and hematocrit values.
Conclusions: Major bleeding from PE thrombolysis appears to occur more often in 
routine clinical practice than in randomized controlled trials. Cancer and cardiogenic 
shock independently predict this life-threatening complication.
1012-98 Leukocyte activation, Platelet activation and 
formation of Platelet Leukocyte conjugates in Venous 
Thromboembolism
Julio A. Chirinos, Gustavo A. Heresi, Hermes Velasquez, Andres O. Soriano, Wenche 
Jy, Eugene Ahn, Joaquin J. Jimenez, Lawrence L. Horstman, Arley Peter, Juan P. 
Zambrano, Yeon S. Ahn, University of Miami School of Medicine, Miami, FL, and Wallace 
H. Coulter Platelet Laboratory, Miami, FL
Background: Platelets are key in the pathophysiology of VTE. Platelets and leukocytes 
interact in the milieu of a forming thrombus, which might lead to the formation of platelet-
leukocyte conjugates. The levels of these conjugates has not been studied in humans with 
VTE. We aimed to measure platelet activation, leukocyte activation and its correlation with 
the levels of platelet-leukocyte conjugates (PLT-LEU) in humans with VTE.
Methods: We studied 25 patients with VTE and compared them to 25 healthy controls. 
We used ﬂow cytometry to measure: (1) P-selectin (CD62P) expression in platelets; (2) 
CD11b expression in leukocytes; (3) PLT-LEU (percentage of leukocytes positive for 
CD41). The levels of these markers were compared with the Mann Whitney U test. The 
relationship between (logarithmically transformed) CD62P, CD11b and PLT-LEU were 
analyzed with simple linear and multiple regression.
Results: Platelet CD62P was markedly increased in patients with VTE (35.2 FL intensity; 
IQR=23.5-58.2) compared to controls (5 FL intensity; IQR=1.5-21.6; p<0.0001). CD11b 
expression in leukocytes was higher in patients with VTE (13.9 FL intensity; IQR=9.62-
21.2) than in controls (7.7 FL intensity; IQR=4.9-10.7; p=0.004). Increased PLT-LEU was 
also seen in the VTE group (61.7%; IQR=41.4-73.2) compared to normal controls (39.6%; 
IQR 21-58; p=0.01). There was a strong and highly signiﬁcant correlation between CD11b 
expression in leukocytes and PLT-LEU (r = 0.74; r2 = 0.55; p<0.0001) among patients 
with VTE (Figure 1). CD11b predicted PLT-LEU levels even after adjusting for CD62P (r2 
increase= 0.45; p=0.0008).
Conclusion: Our study demonstrates that marked activation of platelets and leukocytes 
occurs in humans with VTE and that venous thrombosis (or the accompanying inﬂammatory 
process) involves the formation of PLT-LEU. Our ﬁnding of a strong correlation between 
leukocytes activation and PLT-LEU is consistent with in vitro studies that showed that 
platelet adhesion to leukocytes upregulates Mac-1 (CD11b/Cd18) which itself supports 
interactions with platelets and supports the concept that platelets link thrombosis to 
inﬂammation via interactions with leukocytes.
1012-99 Pioglitazone, Peroxisome Proliferator-activated 
Receptor Gamma Agonist, Attenuates Monocrotaline-
and Chronic Hypoxia-induced Pulmonary Hypertension 
In Rats.
Xuebing Yu, Seiji Ayabe, Hajime Fujimoto, Minoru Ohno, The University of Tokyo, Tokyo, 
Japan
Peroxisome proliferator-activated receptor gamma (PPAR gamma) agonists have recently 
been introduced in clinical medicine to improve insulin resistance in type 2 diabetes. The 
potent anti-inﬂammatory actions of PPAR gamma agonists are recently illustrated by the 
fact that they have been used to treat primary inﬂammatory conditions, such as colitis. 
We hypothesized that PPAR gamma agonists may prevent the development of pulmonary 
hypertension. We studied the effect of pioglitazone, one of PPAR gamma agonists on 
the development of monocrotaline (MCT) - and chronic hypoxia- induced pulmonary 
hypertension in rats. Firstly, we studied the effect of pioglitazone on MCT (55mg/kg 
injection once)-induced pulmonary hypertension. Pioglitazone (10mg/kg chaw daily) 
signiﬁcantly attenuated the elevation of mean pulmonary arterial pressure (mmHg) in rats 
of 3-wk after MCT injection ( MCT group: 23.2±0.7 :pioglitazone+MCT 18.5±0.7, vehicle 
:14.1±0.5, n=8 at each, p<0.05 vs. each others). Right ventricular hypertrophy, medial wall 
thickness in pulmonary arteries corresponding to the respiratory and terminal bronchioles, 
and the degree of muscularization of more distal arteries were also less severe in 
pioglitazone-treated rats. Pioglitazone also inhibited the increase of oxidative stress in 
MCT-induced lung which was assessed with lipid peroxide contents and NAD(P)H oxidase 
activities. Pioglitazone also attenuated the MCT-induced inﬂammatory change assessed 
with immunohistochemistry assessed with ED-1(monocyte-macrophage) and MCP-1 
antibodies. Secondly we studied the effect of pioglitazone on pulmonary hypertension 
by chronic hypoxia with low barometer chamber of 0.5 atom for 3-wks. Pioglitazone also 
attenuated pulmonary hypertension( vehicle under hypoxia: 21.6±1.0, pioglitazone under 
hypoxia:18.1±0.8, vehicle in room air:15.1±0.5, n=6 at each, p<0.05 vs. each others) 
and other histological change. These data suggested that pioglitazone has therapeutic 
potentials to prevent the pulmonary hypertension.
1012-102 Echo-determined Pulmonary Vascular Capacitance 
Predicts Mortality in Primary Pulmonary Hypertension
Srijoy Mahapatra, Rick A. Nishimura, Mayo Clinic, Rochester, MN
Objectives: To determine if echo-determined pulmonary vascular capacitance predicts 
all-cause mortality in patients with primary pulmonary arterial hypertension.
Background: The prognosis of patients with primary pulmonary hypertension is variable 
and has been difﬁcult to predict using clinical or hemodynamic parameters. We 
hypothesized that pulmonary vascular capacitance would may add prognostic value to 
known markers of prognosis.
Methods: Since capacitance is directly proportional to stroke volume (SV) and inversely 
proportional to pulmonary artery pulse pressure (PP), we proposed a capacitance index 
equal to SV/PP. The PP was determined from Doppler measurement of systolic tricuspid 
regurgitation and diastolic pulmonary regurgitation velocities. The SV was derived from 
the pulsed Doppler interrogation of the left ventricular outﬂow tract to determine volumetric 
ﬂow. SV/PP was analyzed as a predictor of mortality, adjusting for other modiﬁers of risk 
including age, gender, WHO class, ejection fraction, right ventricular index of myocardial 
performance (RIMP), and catheter-derived measurements of mean pulmonary pressure, 
cardiac index, RA pressure, and pulmonary resistance.
Results: 50 patients (12 men) were included with a mean age of 50±9 years, ejection 
fraction 49±12 percent and RV systolic pressure of 90±21 mmHg. During follow up of 
1478±118 days, 11 patients died. In univariate analysis SV/PP was the strongest predictor 
of mortality with a risk ratio of 5.4 (95% CI 3.3-7.5) per each standard deviation decrease 
in SV/PP. WHO class, RIMP RA pressure, cardiac index, and pulmonary resistance were 
weaker predictors. In multivariate analysis, SV/PP continued to be the strongest predictor 
of mortality with a risk ratio of 1.9 (95% CI 1.5-3.0.) In quartile analysis the lowest SV/PP 
quartile had a 4-year mortality of 58% while the highest SV/PP had no deaths.
Conclusion: The capacitance index (SV/PP) is a non-invasive, powerful predictor of 
mortality in patients with pulmonary hypertension.
1012-103 Comparison of Noninvasive Cardiac Methods to 
Evaluate Pulmonary Hypertension in Patients with 
Scleroderma
Abel E. Moreyra, Vivien H. Hsu, Alan C. Wilson, Meir Shinnar, Daniel M. Shindler, 
Julianne E. Wilson, Ami Desai, James R. Seibold, UMDNJ-Robert Wood Johnson 
Medical School, New Brunswick, NJ
Background: Pulmonary hypertension (PAH) is a serious complication of scleroderma 
with important therapeutic implications. Methods: We prospectively studied 49 patients 
with scleroderma who underwent echocardiography (echo) and magnetic resonance 
imaging (MRI) within 4 hours of right heart catheterization. Pulmonary arterial (PA) 
pressure measured by catheterization was compared with right ventricular systolic 
pressure (RVSP) estimated by echo, and the diameter of the main PA measured by 
MRI. We deﬁned PAH as PA mean pressure at rest > 25 mm Hg, or pulmonary vascular 
resistance > 3 Wood units. The linear regression equation was used to compute cutpoints 
for echo and MRI parameters. Results: The cutpoint for echo estimated RVSP was 47 
mm Hg, and for MRI measured PA diameter was 29 mm. Plots of echo estimated RVSP 
and MRI measured PA diameter against PA mean pressure, r2 and predictive values are 
shown in the ﬁgure.
 
When the pulmonary vascular resistance deﬁnition of PAH was used, echo and MRI had 
positive predictive values of 0.56 and 0.45, and negative predictive values of 0.81 and 
0.86, respectively. 
Conclusions: In patients with scleroderma, noninvasive cardiac methods lack reliability 
as positive predictive tools for evaluation of PAH (range 0.45 to 0.68) although they 
carry better negative predictive values (range 0.74 to 0.86). Thus non-invasive tests may 
play a role in ruling-out rather than indicating the development of PAH in patients with 
scleroderma.
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1012-104 Pulmonary-Aortic Transit Time by Cardiac Magnetic 
Resonance Correlates With Pulmonary Artery Oxygen 
Saturation and Vascular Resistance by Right Heart 
Catheterization in Pulmonary Hypertension
Martin Goyenechea, Javier Sanz, Santo Dellegrottaglie, Roxana Sulica, Teresa Rius, 
Frank Macaluso, Paul Wisdom, Valentin Fuster, Sanjay Rajagopalan, Michael Poon, The 
Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, 
New York, NY
Background: Right heart catheterization (RHC) is the gold standard for diagnosis and 
assessment of therapeutic response in pulmonary hypertension (PH). However, it is an 
invasive procedure and is associated with signiﬁcant risks. Non-invasive parameters that 
could serve as potential surrogates for pulmonary hemodynamics and outcome could 
be valuable in this disease. The aim of this study is to compare RHC hemodynamic 
measurements with pulmonary-aortic transit time (PATT) as determined by cardiac 
magnetic resonance (CMR) time-resolved pulmonary angiography in patients with PH.
Methods: 37 patients with suspected PH (32 women, 5 men; age range 24-88 years) 
underwent CMR including a left anterior oblique contrast enhanced time resolved 3D 
angiogram of the aorta and pulmonary arteries. RHC was performed in the same day. 
Using a dedicated workstation for post-processing, circular regions of interest were drawn 
in the main pulmonary artery and the ascending aorta. Signal intensity-time curves were 
generated and the PATT was calculated measuring the time interval between the peak 
signal intensity in the pulmonary artery and in the aorta. 
Results: Of the 37 patients, 30 were conﬁrmed to have PH (mean pulmonary artery 
pressure >25 mm Hg at rest or 30 mm Hg with exercise) by RHC. There was a strong 
negative correlation between pulmonary artery oxygen saturation (PAOS) and PATT 
(r= -0.77, P<0.0001). There was a moderate correlation between PATT and pulmonary 
vascular resistance index (r=0.51, P=0.0013). No signiﬁcant correlation was noted 
between PATT and mean or systolic pulmonary pressures. 
Conclusion: PAOS is a reliable indicator of cardiac index and a strong predictor of clinical 
outcome in patients with PH. Our results demonstrated that PATT correlates negatively 
with PAOS and positively with PVRI. Thus PATT as determined by CMR time-resolved 
pulmonary angiography may be used as a noninvasive diagnostic technique for assessing 
and predicting outcome of this frequently undiagnosed disease.
1012-139 Triage Patients with Suspected Pulmonary Embolism in 
Emergency Department Using Hand-Carried Ultrasound 
Device
Nicolas Mansencal, Antoine Vieillard-Baron, Jean-Christian Farcot, Sophie Morelon, 
Mostafa El Hajjam, Ghislaine Dufaitre, Dominique Brun-Ney, Pascal Lacombe, Olivier 
Dubourg, AP-HP, Hôpital Ambroise Paré, Boulogne, France
Background: The diagnosis of pulmonary embolism (PE) remains difﬁcult in emergency 
department. Hand-carried ultrasound device (HCU) has been proposed as an 
echocardiographic tool at the bedside. The aim of our study was to determine the value of 
HCU for triage patients with suspected PE referred to emergency department.
Methods: We prospectively studied 103 consecutive patients (pts) with suspected 
PE in emergency department. After a clinical probability scoring system and D-dimer 
assessment, 27 pts were excluded (considered as no PE) and the other 76 pts (mean age 
62 ± 17 years) underwent venous ultrasonography (VU), transthoracic echocardiography 
(TTE) using HCU and helical CT. Patients with normal CT and deep venous thrombosis or 
high clinical probability underwent pulmonary angiography or lung scan. Each exam was 
obtained in a blind fashion. The diagnosis of deep venous thrombosis rested on venous 
incompressibility. Following TTE parameters were systematically performed: (1) right to 
left ventricular end-diastolic area ratio (RVEDA/LVEDA) in apical four-chamber view with 
a cut-off value of 0.6; (2) assessment of right ventricular regional wall motion.
Results: Pulmonary embolism was present in 31 pts. The sensitivity (Se) and speciﬁcity 
(Sp) of VU was respectively 58% and 93%. The Se of RVEDA/LVEDA and right ventricular 
dysfunction assessment was 55% and 35% and the Sp was 69% and 93%. The efﬁciency 
of TTE using RVEDA/LVEDA was better in pts with dyspnea (Se 73%, Sp 67% vs. 42% 
and 74% in pts with chest pain). Using HCU, the Se and Sp of a combined strategy (TTE 
with RVEDA/LVEDA and VU) was respectively 87% and 69%. The Se of this combined 
strategy was signiﬁcantly improved as compared to VU alone (p = 0.01), even when the 
Sp was lower (p = 0.003). Furthermore, in pts with dyspnea or with high clinical probability, 
this combined strategy had a high Se (97%) with a Sp of 67%.
Conclusion: This prospective study suggests that HCU may be a reliable tool using 2D 
simpliﬁed criterion for triage pts with suspected PE in emergency department. This strategy 
is particularly relevant in pts presenting with dyspnea or with high clinical probability.
POSTER SESSION
1013  Lipids, Diet, and Endothelial Function
Sunday, March 06, 2005, 9:00 a.m.-12:30 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 11:00 a.m.-Noon
1013-100 High Prevalence of Atherogenic Dense LDL in Patients 
With Advanced Atherosclerotic Despite Adequate Statin 
Therapy
Milind Y. Desai, Gary Gerstenblith, Sachin Agarwal, Margene Kennedy, Joao AC Lima, 
Annabelle Rodriguez, Johns Hopkins University, Baltimore, MD
Background: Statin mediated lowering of low density lipoprotein (LDL) leads to 
reduced cardiovascular (CV) risk, but events occur despite adequate LDL control. LDL 
is a heterogeneous molecule with many sub-fractions that respond differently to different 
therapies. Direct-LDL, the lipid rich sub-fraction, has 2 sub-types, based upon lipid 
content: “dense” (more atherogenic) and “buoyant” (less atherogenic). Dense-LDL (D-
LDL) responds to treatment with niacin or ﬁsh oil, and not statins. We sought to assess 
the distribution of D-LDL and its association with cardio-protective high density lipoprotein 
(HDL) sub-fractions in patients with advanced atherosclerosis, on adequate statin 
therapy. Methods: Plasma from 29 patients with advanced atherosclerosis (documented 
as prior CV event or by CV imaging), was analyzed for LDL and HDL sub-fractions by 
ultracentrifugation using vertical auto proﬁle (VAP) technique (Atherotech, Inc, Alabama). 
Direct LDL was measured in each patient and they were classiﬁed as follows: A (mostly 
buoyant), B (mostly dense) and A/B (intermediate). Results: All patients (33% diabetics, 
71% hypertensives, mean age 73 ± 4 years, 23 males) were on adequate statin therapy 
according to guidelines while 2 were on niacin and 3 on ﬁsh oil. The mean total LDL and 
direct LDL were 94 ± 23 and 80 ± 19 mg/dl respectively. The mean D-LDL was higher than 
buoyant LDL (49 ± 13 vs. 31 ± 12 mg/dl, respectively, p < 0.001). Sixty six % patients had 
pattern B, 24 % had pattern A/B and only 10 % had pattern A. The mean total HDL, HDL2 
and HDL3 were 49 ± 10, 11 ± 5, 38 ± 6 mg/dl, respectively. D-LDL had signiﬁcant inverse 
correlation with HDL2 and HDL3 (r = -0.5, p < 0.01 and r = -0.4, P < 0.05, respectively). 
Conclusion: A large proportion of patients, though adequately treated with statin therapy, 
have a high amount of atherogenic D-LDL, which is inversely related to HDL sub-fractions. 
In patients with advanced atherosclerosis, cholesterol sub-fraction analysis may provide 
additional prognostic value. Finally, further tailoring of lipid lowering therapy might be 
considered in view of disproportionately elevated D-LDL in these patients.
1013-101 Lipoprotein-Associated Phospolipase A2 Plasma 
Concentrations Predict Cardiovascular Events in 
Patients With Coronary Heart Disease
Wolfgang Koenig, Dorothee Twardella, Hermann Brenner, Dietrich Rothenbacher, 
University of Ulm Medical Center, Ulm, Germany, University of Heidelberg, Heidelberg, 
Germany
Background. Lipoprotein-associated phospolipase A2 (Lp-PLA2), an enzyme 
mainly produced by monocytes/macrophages and circulating primarily bound to LDL 
cholesterol, generates potent proinﬂammatory products and has been reported to predict 
cardiovascular events in initially healthy subjects. We sought to evaluate whether Lp-PLA2 
is also associated with prognosis in a large cohort of patients with clinically overt coronary 
heart disease (CHD).
Methods. Plasma concentrations of Lp-PLA2 were determined by ELISA (Diadexus Inc, 
South San Francisco, CA, USA) at baseline in a cohort of 1033 patients aged 30-70 years 
with CHD participating in an in-patient rehabilitation program after an acute coronary 
syndrome All patients were followed for a mean of 33.5 months and a combined endpoint 
(N= 71, 6.9%; fatal and non-fatal myocardial infarction (MI) and stroke) was used as the 
outcome variable. Life table methods and the Cox proportional hazards model were used 
to determine the prognostic value of Lp-PLA2.
Results. Baseline levels of Lp-PLA2 were higher in subjects who experienced an event 
compared to event free-subjects (194.6 ± 49.6 vs. 185.6 ± 62.6 ng/mL, p=0.05). Lp-PLA2 
was positively correlated with age (r=0.16, p<0.0001 and CRP r=0.22, p<0.0001), but 
not with body mass index (r=0.01, p=0.8) and HDL cholesterol (r=0.004, p=0.9). In a Cox 
model, Lp-PLA2 was associated with an increased risk of future cardiovascular events. 
After controlling for traditional risk factors, the hazard ratio (HR) was 1.93 (95% conﬁdence 
interval (CI) 1.01-3.69) and 1.97 (95% CI 1.04-3.73) when the second and third tertile 
were compared to the ﬁrst tertile. Further inclusion of C-reactive protein (CRP), cystatin C, 
and N-terminal proBNP in the model did not appreciably affect its predictive ability.
Conclusion. Elevated levels of Lp-PLA2 appear to be predictive of future coronary 
events in patients with manifest CHD independent of a variety of potential risk factors 
including markers of inﬂammation, renal function, and hemodynamic stress.
1013-105 Atherogenic Effects of a High-Fat Ketogenic Diet in 
Children
Petru Liuba, Erkki Pesonen, Tove Hallbook, Johan Lundgren, Pediatric Cardiology, 
University Hospital Lund, Lund, Sweden
Background_Previous studies have suggested that the high-fat (fat-to-protein & 
carbohydrates ratio= 4:1) ketogenic diet (HFD), a treatment of choice for epilepsy children 
with intractable seizures, could promote atherogenic lipid disturbances. To date, eventual 
adverse vascular effects of HFD have not been studied.
Methods_Fourteen epilepsy patients (mean age: 7.6 ± 4.5 y) placed on HFD were enrolled. 
Carotid artery intima-media thickness (IMT) and distensibility, along with plasma total 
cholesterol (TC), LDL, HDL, lipoprotein(a) and apolipoproteins A and B, were measured 
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before, 3 months, and 12 months after diet initiation. All ultrasound measurements were 
carried out using a computer-assisted software. Data are means±SD. Repeated ANOVA 
was used for statistical calculations.
Results_HFD was associated with increase in TC (from 4±0.8 mmol/l at baseline, to 
4.9±1.6 at 1 year; p=0.1), LDL (from 2.3±0.5 to 3.2±1.2 mmol/l; p<0.05) and apolipoprotein 
B (from 0.7±0.1 to 1±0.3 mmol/l; p<0.01). These biochemical changes were paralleled 
by a stepwise decrease of carotid distensibility (from 0.14±0.03 to 0.1±0.03 %, p<0.05; 
Figure). No differences were observed with regard to carotid IMT (from 0.36±0.04 to 
0.37±0.03 mm; p>0.5).
Conclusion_HFD seems to alter the arterial function, possibly in part through 
disturbances in lipid proﬁle. Further studies are warranted in order to conﬁrm or refute 
an eventual causal relationship between HFD and accelerated atherosclerosis in this 
category of patients.
1013-106 Drip Paper-Filtered and Boiled and Cotton-Filtered 
Coffee Preparations Reduce Lipid Peroxidation 
and Anthropometric Parameters in Primary 
Hypercholesterolemia
Rosana P. Costa, Maria C. Izar, Andreza O. Santos, Leonor E. Pinto, Silvia S. Ihara, 
Alberto A. Las Casas Jr, Waldir G. Relvas, Francisco A. Fonseca, Federal University of 
São Paulo, São Paulo, Brazil
Objective: Recently, large observational studies reported coffee consume as associated 
to lower risk of new onset diabetes. This study aimed to verify whether moderate 
consumption of drip-paper-ﬁltered (PF) or boiled and cotton-ﬁltered (CF) coffee could 
modify some anthropometric aspects related to insulin resistance and whether it would 
affect lipid proﬁle and lipid peroxidation in hypercholesterolemic patients.
Methods: A randomized crossover study was conducted on 60 outpatients with primary 
hypercholesterolemia under lipid lowering diet. Patients were randomly assigned to 
receive initially 250 mL per day of either paper or cotton-ﬁltered coffee for a six-week 
period. Lipid proﬁle was obtained after AHA/NCEP III diet (D) and at weeks 6 and 12 . In 
all visits, anthropometric and dietary registries were obtained. In addition, hydroperoxides 
were also estimated by FOX2. APOE genotypes were examined by PCR-RFLP. 
Results: In spite of similar diet components during the treatment periods, there was a 
modest, but signiﬁcant reduction in body weight (D=66.1±1.4, PF=65.7±1.5, CF=65.8±1.5 
kg, D > PF=CF; p< 0.05), BMI (D=27.1±0.5, PF=26.8±0.5, CF=26.9±0.5 kg/m2; p< 0.05, 
D > PF=CF), and waist circumference (D=87.5±1.4, PF=86.3±1.4, CF=86.4±1.4 cm; p< 
0.001, D > PF = CF) after either coffee preparation. Coffee did not affect lipid proﬁle, blood 
glucose or liver enzymes. Both coffee preparations markedly reduced lipoperoxidation 
(D=7.3±0.9, PF=2.9±0.6, CF=2.5±0.4 nmol/mL; p< 0.005, D > PF=CF), with a trend for 
higher caffeine consumption during treatment periods (p=0.08). These responses were 
not inﬂuenced by APOE genotypes (APOE E4 vs. Non-E4).
Conclusions: Moderate consumption of coffee prepared in the most usual fashion, 
promoted a protective effect on lipid peroxidation and improved anthropometric parameters 
without harmful effects on lipids and liver enzymes. These results can be explained by a 
postulated insulin-sensitizing effect of caffeine.
1013-107 Diabetics Beneﬁt From ‘Ultra-Low’ Levels of LDL-
Cholesterol
Christine L. Lange, Jeffrey T. Kuvin, Ayan R. Patel, Richard H. Karas, Tufts-New England 
Medical Center, Boston, MA
Background: Subjects with diabetes mellitus are at elevated risk of cardiovascular 
disease and beneﬁt from lipid-lowering therapy. Although recent guidelines recommend 
aggressive LDL-cholesterol lowering in high-risk individuals, whether or not ‘ultra-low’ 
LDL-cholesterol provides beneﬁt speciﬁcally in diabetics remains unclear. The current 
study was designed to determine whether subjects with diabetes beneﬁt from ‘ultra-low’ 
LDL-cholesterol levels as assessed by endothelial function testing.
Methods: Peripheral endothelial function was tested with brachial artery ultrasound in 
22 subjects with diabetes and 88 non-diabetics. All subjects had stable coronary artery 
disease and LDL-cholesterol <100mg/dL. Flow-mediated dilation (FMD) of the brachial 
artery following upper arm occlusion was deﬁned as the percent change in vessel 
diameter during reactive hyperemia.
Results: The average total cholesterol was higher in diabetics than in non-diabetics 
(147±16 vs. 131±22mg/dL, respectively; p<0.05). There were no differences in the 
average LDL-cholesterol (79±12 vs. 77±13mg/dL), HDL-cholesterol (41±11 vs. 38±10mg/
dL), or triglyceride levels (142±65 vs. 125±58mg/dL) in diabetics compared to non-
diabetics, respectively. The average FMD (8.0±4.7 vs. 7.6±3.8%) and percentage of 
subjects on statin therapy (95 vs. 85%) were not signiﬁcantly different between diabetics 
and non-diabetics, respectively. Amongst diabetics, those with ‘ultra-low’ (<80mg/dL) 
LDL-cholesterol had signiﬁcantly better endothelial function (FMD 9.8±4.2%) compared 
to those with ‘low’ (80-100mg/dL) LDL-cholesterol (FMD 5.5±4.2%; p=0.01). In the non-
diabetic population, FMD was similar in the ‘ultra-low’ LDL-cholesterol group compared to 
the ‘low’ LDL-cholesterol group (8.1±3.6 vs. 7.1±4.0%, respectively).
Conclusions: Diabetic subjects with coronary artery disease who have LDL-cholesterol 
levels <80mg/dL have signiﬁcantly better peripheral endothelial function compared to 
those with LDL-cholesterol 80-100mg/dL. Though additional clinical endpoint studies are 
needed, these data support recommendations for aggressive lowering of LDL-cholesterol 
in subjects with diabetes.
1013-108 Evidence of Myocardial Adrenergic Innervation 
Abnormalities in Hyperlipidemic Subjects
Mary E. Marketou, Evangelos A. Zacharis, Sophia I. Koukouraki, Vassilis K. 
Prassopoulos, Emmanuel S. Simantirakis, Stavros I. Chrysostomakis, Nikolaos S. 
Karkavitsas, Panos E. Vardas, Heraklion University Hospital, Heraklion, Greece
Background: Hyperlipidemia results in endothelial dysfunction and myocardial perfusion 
abnormalities even in the absence of any organic heart disease. We investigated the 
association of dyslipidemia with myocardial adrenergic innervation disturbances using I 
123 -meta-iodobenzylguanidine (I 123 -MIBG).
Methods: Our study included two groups - Group A comprised 15 hyperlipidemic 
subjects (10 men, aged 49±10 years, total cholesterol>240 mg/dl, LDL-C>160mg/dl) 
while 15 healthy volunteers, served as control subjects in Group B. All the participants 
had a normal echocardiogram and coronary angiogram and none had any disease 
that may have affected myocardial adrenergic innervation. All the subjects underwent 
planar and SPECT myocardial imaging of the heart after an intravenous infusion of 5mCi 
I 123 -MIBG. Heart to mediastinum ratio (H/M) was used for quantitative assessment 
of adrenergic innervation, 10 minutes and 4 hours after drug infusion, while SPECT 
scintigraphy evaluated the regional distribution of adrenergic activity.
Results: In Group A, total cholesterol and LDL-C levels were 298±122 and 169±76 mg/dl 
respectively while Group B recorded 140±52 and 80±36 mg/dl respectively (p<0.05). The 
H/M ratio at 10 min and 4 hours in Group A was 1.80± 0.21 and 1.75±0.20 respectively; 
signiﬁcantly lower than in Group B (2.25 ± 0.9 and 2.19 ± 0.10 respectively, p<0.05 for 
both). During SPECT scintigraphy, twelve Group A subjects (80%) showed regional 
disturbances in myocardial adrenergic activity. Ten subjects (66.6%) showed defects 
in the inferior wall, ﬁve (33.3%) displayed additional regional disturbance in myocardial 
adrenergic activity in the anterior wall and ﬁve subjects (33.3%) in the apex, while no 
regional disturbances were detected in Group B.
Conclusions: These results suggest that hyperlipidemia is associated with a high 
prevalence of myocardial adrenergic innervation disturbances. In identifying the various 
effects of hyperlipidemia on the myocardium, we may be able to shed additional light on 
its pathophysiological role in cardiovascular disease.
1013-109 Vitamin E Ameliorates the Beneﬁcial Effects of 
Atorvastatin on Endothelial Function and Inﬂammatory 
Process, in Patients With Ischemic Heart Failure
Charalambos A. Antoniades, Dimitris M. Tousoulis, Carmen Vasiliadou, Marina Toutouza, 
Costantinos Tentolouris, Kyriakoula Marinou, Charalambos Vlachopoulos, Marieta 
Harakida, Constantinos Tsiouﬁs, Christodoulos Stefanadis, Athens University Medical 
School, Athens, Greece
Background. Ischemic heart failure has been associated with endothelial dysfunction 
and increased levels of inﬂammatory markers such as interleukin-6 (IL-6), tumor necrosis 
factor alpha (TNF-a) and soluble vascular cell adhesion molecule (sVCAM-1). Statins 
as well as antioxidant vitamins, improve endothelial function in patients with coronary 
atherosclerosis, while their role in heart failure is unknown. We assessed the effect of 
atorvastatin alone or combined with vitamin E on endothelial function and inﬂammatory 
process in patients with ischemic heart failure.
Methods. Thirty-eight patients with ischemic heart failure (NYHA II-IV) were enrolled. 
Forteen patients received atorvastatin 10mg/day (ATR), 12 patients received atorvastatin 
10 mg/day plus vitamin E 400IU/day (ATR+E) and 12 received no treatment for 4 weeks 
(Controls). Forearm blood ﬂow was measured using strain-gauge plethysmography. 
Endothelium dependent dilation (EDD) and endothelium independent dilation (EID) were 
expressed as the % change of ﬂow from baseline to the maximum ﬂow during reactive 
hyperemia or after sublingual nitroglycerin administration respectively.
Results. EDD was signiﬁcantly improved in ATR group (from 45.3±5.8 to 91.1±11.1%, 
p<0.01), while it was slightly increased ATR+E (from 45.8±4.7 to 55±5.2%, p<0.05) and 
remained unaffected in controls (from 45.16±5.2 to 40.0±5.15%, p=ns). Levels of IL-6, 
sVCAM-1 and TNF-a were decreased only in ATR group (from 8.24±0.73, 693±77 and 
3.73±0.49 to 5.81±0.8 pg/ml, 490±53 ng/ml and 2.62±0.16 pg/ml respectively, p<0.05 
for all) while remained unaffected in ATR+E (from 7.35±1.28, 815±68 and 4.19±0.49 to 
5.14±1.34 pg/ml, 792±72 ng/ml and 4.34±0.32 pg/ml respectively, p=ns for all) and in 
controls (from 7.14±0.81, 724±100 and 4.76±0.52 to 5.93±0.83 pg/ml, 718±102 ng/ml 
and 4.43±0.52 pg/ml respectively, p=ns for all). EID remained unchanged in all groups 
(from 64±8, 66±12 and 71±6 to 66±9%, 72±13% and 68±9% respectively, p=ns for all)
Conclusions. Atorvastatin improves endothelial function and reduces inﬂammatory 
process in patients with heart failure while co-administration of vitamin E and atorvastatin 
may ameliorate these beneﬁcial effects.
1013-110 AHA-Recommended Intakes of Omega-3 Fatty Acids 
Improve Cardiac Autonomic Tone but Do Not Reduce 
Inﬂammatory Markers
William S. Harris, James H. O’Keefe, Jr., Saint Luke’s Mid America Heart Institute, 
Kansas City, MO, University of Missouri-Kansas City, Kansas City, MO
Background: The cardioprotective effects of omega-3 fatty acids (�-3 FA) have been 
documented in both epidemiological and randomized controlled trials. They are presumed 
to reduce susceptibility to fatal arrhythmias, but whether this is mediated by changes 
in myocardial membrane lipid composition or extra-cardiac (e.g., autonomic) factors is 
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not known. These FA may also have antiinﬂammatory properties. The effects of AHA-
recommended intakes of ω-3 FA on cardiac function, autonomic balance and inﬂammatory 
cytokines have not been reported.
Methods: Eighteen white males with documented CHD (age, 68±6.5 yrs; BMI, 30±4.4) 
and ejection fractions of <40% were randomized to either placebo or ω-3 FA (1.0 g 
EPA+DHA, Ocean-Nutrition Canada) for two, 4-month periods and then crossed over to 
the alternate treatment for another 4-months. At the end of each period, a non-invasive 
cardiovascular proﬁle was obtained (CVProﬁlor DO-2020, Hypertension Diagnostics) 
which included measures of large and small artery compliance, heart rate (HR), blood 
pressure, and estimates of cardiac function. The rate of HR recovery post stress test was 
also assessed as were fasting serum levels of C-reactive protein, interleukin-6 and tumor 
necrosis factor-α.
Results: Supplementation with 1 g of ω-3 FA reduced resting pulse (67±11 to 63±12 
bpm, p=0.01), and increased left ventricular ejection time (319±27 to 329±29 ms, p=0.03) 
and stroke volume (80±14 to 85±15 mL, p=0.001). HR recovery at 1-minute post exercise 
tended to increase (n=14; 25.8±10.2 to 29.1±10.2 bpm, p=0.07). There was no signiﬁcant 
effect on blood pressure, arterial compliance or inﬂammatory markers.
Conclusion: Although AHA-recommended intakes of long-chain ω-3 FA did not lower 
serum levels of inﬂammatory cytokines, they did produce a favorable shift in cardiac 
autonomic balance. This would be expected to reduce risk for sudden cardiac death 
regardless of changes in myocardial lipid membrane FA composition.
1013-111 Han Chinese vs. Caucasian Americans: Differing Effects 
of Traditional Cardiovascular Risk Factors on the 
Presence of Coronary Artery Disease
Hanbin Cui, Jeffrey L. Anderson, John F. Carlquist, Joseph B. Muhlestein, Tami L. Bair, 
Brianna S. Ronnow, Benjamin D. Horne, ZhangChong Cui, LDS Hospital, Salt Lake City, 
UT, First Hospital of Xi’an JiaoTong University, Xi’an, People’s Republic of China
Introduction. Hypertension, smoking, hyperlipidemia, diabetes mellitus, and family 
history are risk factors for the development of coronary artery disease (CAD), but studies 
of these have been performed primarily among Western Caucasian populations. Whether 
these risk factors have a similar effect on CAD among non-Western populations eating 
predominantly non-Western diets is not well studied.
Methods. We evaluated patients undergoing coronary angiography from two distinct 
races: 1) Han Chinese from the heartland of China: Xian City, Lanjou City, Hanjou City 
(China cohort, n=667), and 2) Caucasians of Northern European descent from Salt 
Lake City, Utah, USA (Utah cohort, n=686). Baseline demographics, cardiovascular risk 
factors, and angiographic CAD status were collected on each patient. Cases had 1-3 
vessel CAD (≥70% stenosis); controls had angiographically normal coronaries. Results 
were compared between the two populations.
Results. Average age at angiography in the Xian cohort (59±10 years) was lower than 
in the Utah group (65±11 years, p<0.001), although more females were seen in Xian 
than Utah (47% vs. 29%, respectively, p<0.001). Signiﬁcant differences in risk factor 
prevalence was found for hyperlipidemia (18% vs. 44%, p<0.001), diabetes (11% vs. 
16%, p=0.004), and smoking (46% vs. 23%, p<0.001). In Xian, CAD was predicted by 
smoking (smokers: 71% CAD, non-smokers: 54% CAD, p<0.001), hypertension (yes: 
72%, no: 52%, p<0.001), hyperlipidemia (yes: 71%, no: 59%, p=0.02), age (CAD mean: 
61±9 years, no CAD: 55±11, p<0.001), and sex (male: 67%, female: 56%, p=0.006), but 
not diabetes or family history. Risk factors for CAD were the same among the Utah cohort, 
except that diabetes did predict CAD and hypertension did not.
Conclusions. In this angiographic study of two distinct populations differing by both 
race and dietary life style, traditional cardiovascular risk factors remained independent 
predictors of CAD though some differences in the strength of effect of various factors 
were found. This suggests that regardless of race or dietary background, traditional 
cardiovascular risk factors remain important and, when possible, should be modiﬁed.
1013-112 n-3 Polyunsaturated Fatty Acid Markedly Reduces 
Upper Limit of Vulnerability Shocks
Nipon Chattipakorn, Parwis Fotuhi, Siriporn Chattipakorn, Krekwit Shinlapawittayatorn, 
Wanna Suriyasataporn, Chiang Mai University, Chiang Mai, Thailand
n-3 Polyunsaturated fatty acids such as docosahexaenoic acid (DHA) have been 
demonstrated to raise the arrhythmia threshold and prevent ventricular ﬁbrillation (VF). 
However, its effect on VF induction by shocks delivered during the vulnerable period of a 
cardiac cycle has not been investigated. In the present study, we tested the hypothesis that 
the upper limit of vulnerability (ULV) shock strength is decreased after DHA administration. 
Methods: In 5 pigs, 10 S1s (square, 5-ms) were delivered from an electrode at the RV 
apex at 300 ms coupling interval. Shocks (S2, biphasic, 6/4 ms) were delivered from the 
RV-SVC electrodes after the last S1. The control ULV was determined at the beginning 
of the study using an up/down protocol and T-wave scanning method. Then, a solution 
containing 10 gm of DHA was infused intravenously within 90 minutes. The ULV (DHA-
ULV) was determined again after DHA administration. Heart rate and blood pressure 
(BP) were monitored throughout the study. Results: DHA-ULV (416±59 V, 12±3 J) was 
signiﬁcantly decreased compared to the control ULV (478±32 V and 16±3 J, see Figure). 
The ULV reduction was ~13% by voltage and ~25% by total energy. The mean S1-S2 
coupling interval, Systolic BP, and heart rate recorded before and after DHA administration 
were not different (P=0.7). Conclusion: DHA signiﬁcantly decreases the ULV, indicating 
additional evidence that it can 1) prevent the occurrence of VF, and 2) narrow a window of 
VF induction caused by a shock delivered during the vulnerable period.
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1014-131 Electrocardiographic Strain Pattern and Albuminuria 
Additively Predict New-Onset Congestive Heart Failure 
in Hypertensive Patients: The LIFE Study
Peter M. Okin, Kristian Wachtell, Richard B. Devereux, Markku S. Nieminen, Lasse 
Oikarinen, Matti Viitasalo, Lauri Toivonen, Hans Ibsen, Michael H. Olsen, Knut Borch-
-Johnsen, Lars H. Lindholm, Sverre E. Kjeldsen, Björn Dahlöf, for the LIFE Study 
Investigators, Weill Medical College of Cornell University, New York, NY
Background: Albuminuria (Alb), a measure of renal microvascular damage, and ECG 
strain, a marker of left ventricular hypertrophy (LVH) and coronary heart disease, each 
predict development of congestive heart failure (CHF). However, whether combining alb 
and strain improves prediction of new CHF is unclear.
Methods: 7786 hypertensive patients in the LIFE study without a history of CHF were 
treated with atenolol- or losartan-based regimens and followed for 4.7±1.1 years. Alb was 
deﬁned by a urine albumin/creatinine ratio >3.5 mg/mmol and ECG strain by a downsloping 
convex ST segment with inverted asymmetrical T-wave in lead V5 and/or V6.
Results: New-onset CHF occurred in 231 (3.0%) and CHF death in 21 patients (0.3%). 
5-year event rates were highest when both strain and alb were present, intermediate 
when either was present, and lowest when neither strain nor alb were present. In Cox 
multivariate analyses controlling for age, gender, race, history of ischemic heart disease, 
myocardial infarction, peripheral vascular disease, stroke or diabetes, baseline fasting 
glucose, total and HDL cholesterol, systolic and diastolic pressure, baseline severity 
of LVH by Cornell product and Sokolow-Lyon voltage, and treatment with losartan vs 
atenolol, the combination of strain and alb predicted new CHF and CHF mortality, with the 
presence of both alb and strain associated with the highest risks.
Conclusion: Combined alb and ECG strain increase the risk of new-onset CHF and CHF 
mortality in hypertensive patients. 
CHF and CHF-Mortality in Relation to ECG Strain and Albuminuria 
Outcome Event Strain-/Alb- (n=5262)
Strain-/Alb+ 
(n=1689)
Strain+/Alb- 
(n=483)
Strain+/Alb+ 
(n=352) p value
5-Year Event Rates by Life-Table Analyses (%)
New CHF 1.81 4.93 8.04 10.35 <0.0001
CHF Death 0.14 0.41 0.53 2.35 <0.0001
Univariate Cox Models: Hazard Ratios (95% CI)
New CHF 1 2.9 (2.2-4.0) 4.6 (3.1-6.9) 5.8 (3.8-8.8) <0.001
CHF Death 1 3.3 (1.1-10.3) 3.8 (0.8-19.0) 19.7 (6.6-58.7) <0.001
Multivariate Cox Models: Hazard Ratios (95% CI)
New CHF 1 2.1 (1.5-2.8) 2.6 (1.7-4.0) 2.8 (1.8-4.4) <0.001
CHF Death 1 2.1 (0.7-6.7) 1.9 (0.4-9.8) 9.0 (2.8-28.5) 0.002
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1014-132 Regression of Electrocardiographic Left Ventricular 
Hypertrophy and Decreased Incidence of New-Onset 
Atrial Fibrillation in Hypertensive Patients: The LIFE 
Study
Peter M. Okin, Kristian Wachtell, Richard B. Devereux, Katherine E. Harris, Sverker Jern, 
Sverre E. Kjeldsen, Stevo Julius, Lars H. Lindholm, Markku S. Nieminen, Jonathan M. 
Edelman, Björn Dahlöf, for the LIFE Study Investigators, Weill Medical College of Cornell 
University, New York, NY
Background: Atrial ﬁbrillation (AF) is associated with increased risk of cardiovascular 
events, particularly stroke, making prevention of new-onset AF a clinical priority. Although 
the presence and severity of Cornell product (CP) ECG left ventricular hypertrophy 
(LVH) are predictors of the development of AF, whether regression of ECG LVH per se is 
associated with a decreased incidence of new-onset AF is unclear.
Methods: ECG LVH was evaluated over time in 8831 hypertensive patients without AF at 
baseline in the LIFE study. Patients were treated with losartan- or atenolol-based regimens 
and followed with serial ECGs at 6 months and then yearly until death or study end. ECG 
LVH was measured using gender-adjusted CP ({RaVL+SV3 [+6 mm in women]}*QRS 
duration) criteria.
Results: After mean follow-up of 4.7±1.1 years, new-onset AF occurred in 701 patients 
(7.9%). Compared with patients who did not develop AF, hypertensive patients who 
developed AF were at baseline older, more likely to be white, male, have histories of 
myocardial infarction, ischemic heart disease, stroke or congestive heart failure, had 
greater LVH by CP, higher serum total cholesterol levels and albuminuria, lower diastolic 
and higher systolic pressures, similar reduction in diastolic pressure but greater reduction 
in systolic pressure (-33.7±21.2 vs -29.2±19.2 mm Hg, p<0.001) than patients who did 
not develop AF. In Cox analyses adjusting for treatment effects, baseline differences in 
risk factors for AF, baseline and in-treatment blood pressure, and baseline severity of 
ECG LVH by CP, lower in-treatment ECG LVH by CP was associated with a 12.4% lower 
rate of new-onset AF: adjusted hazard ratio of 0.876 (95% CI 0.795-0.966, p<0.001) for 
every 1050 mm•msec (1 SD) decrease in CP, with persistence of the beneﬁt of losartan vs 
atenolol therapy on developing AF (HR 0.826, 95% CI 0.711-0.959, p=0.012).
Conclusion: Lower ECG LVH by CP during antihypertensive therapy is associated with a 
lower likelihood of new-onset AF, independent of blood pressure lowering and treatment 
modality in essential hypertension. These ﬁndings suggest that antihypertensive therapy 
targeted at regression or prevention of ECG LVH may reduce the incidence of AF.
1014-133 Echocardiographic Determinants of New-onset 
Atrial Fibrillation in Patients with Hypertension and 
Electrocardiographic Left Ventricular Hypertrophy:  
The LIFE Study.
Kristian Wachtell, Vittorio Palmieri, Eva Gerdts, Michael H. Olsen, Markku S. Nieminen, 
Kurt Boman, Vasilios Papademetriou, Jens Rokkedal, Björn Dahlöf, Richard B. 
Devereux, Glostrup University Hospital, Glostrup, Denmark, Weill Medical College of 
Cornell University, New York, NY
Background: New-onset atrial ﬁbrillation (AF) is frequent in hypertensive patients. 
However it is not known whether this is due to structual or functional left ventricular (LV) 
impairment.
Methods: A total of 960 prospectively identiﬁed patients with essential hypertension and 
evidence of LV hypertrophy on a screening electrocardiogram underwent echocardiography 
at enrolment and after 1 to 4 years of treatment in the Losartan Intervention For Endpoint 
prevention in hypertension (LIFE) trial, of whom 925 were in sinus rhythm at baseline. AF 
was reported by the investigator during 4,379 patient-years of follow-up.
Results: New-onset atrial ﬁbrillation occurred in 58 patients (rate of 13.1/1000 patient-
years of follow-up. Compared to patients remaining in sinus rhythm, those developing 
AF had similar aortic and mitral valvular disease, left atrial size, LV mass and systolic 
function at enrolment. Patients remaining in sinus rhythm had a reduction in left atrial 
size compared to an increase in those with new-onset AF (-0.09±0.54 vs. 0.13±0.56 cm, 
p=0.008) without differences in LV mass (-21.3±20.4 vs. -20.5±24.9 g/m2) or wall thickness 
reduction (-0.08±0.06 vs. -0.08±0.06). Furthermore, patients remaining in sinus rythm 
had, compared to those with new-onset atrial ﬁbrillation, increases in LV midwall fractional 
shortening (1.23±2.3 vs. -0.01±3.1%, p=0.003) more improvement in stress-corrected 
midwall shortening, a measure of myocardial contractility (9.2±13.9 vs. 1.8±18.1%, 
p<0.001). New-onset AF was independently associated with older age (HR=1.052 per 
year, [95%CI: 1.01-1.096], p=0.018), less improvement in midwall function (HR=0.86 per 
%, [95%CI: 0.78-0.95], p=0.004), greater increase in left atrial size (HR=1.59 per cm, 
[95%CI: 0.97-2.60], p=0.06), and higher in-treatment systolic blood pressure (HR=0.98 
per mmHg, [95%CI: 0.97-0.99], p=0.023).Conclusion: Patients who develop new-onset 
atrial ﬁbrillation during systematic antihypertensive treatment have less reduction in left 
atrial size and less improvement in systolic function but similar LV mass reduction in 
response to blood pressure lowering.
1014-134 The Role of Humoral, Inﬂammatory, and Arterial 
Elasticity Status in Hypertensive Subjects With 
Paroxysmal Atrial Fibrillation: Chasing Etiological 
Bonds in a Vicious Circle
Ioannis Skiadas, Konstantinos Tsiouﬁs, Dimitris Chatzis, Kyriakos Dimitriadis, Apostolis 
Kakavas, Alexandros Katsimichas, Ioannis Vlasseros, Christodoulos Stefanadis, Ioannis 
Kallikazaros, Hippokration Hospital, Athens, Greece
Background: Currently the emerging role of hypertension in paroxysmal atrial ﬁbrillation 
(PAF) is widely suggested. We investigated the correlations between mechanical 
arterial properties, the inﬂammatory-humoral status, and paroxysmal atrial ﬁbrillation in 
hypertensives.
Methods: Our study population consisted of 22 consecutive non-diabetic hypertensive 
patients on sinus rhythm [aged 64 years, 17 males, ofﬁce blood pressure (BP) = 152/87 
mmHg] with a history of PAF and 18 hypertensives matched for major confounding 
factors without a history of PAF. Blood samples were drawn for determination of brain 
natriuretic peptide (BNP), and the high-sensitivity C-reactive protein (hs-CRP) according 
to established methods. Aortic stiffness was evaluated on the basis of pulse wave velocity 
(PWV) by means of a computerized method (Complior SP).
Results: The two hypertensive groups were similar regarding demographics but 
hypertensives with PAF compared to those without PAF had increased body mass index 
(28.1±3 vs 26.9±3 kg/m2, p<0.05), higher percentage of smoking (46 vs 28%, p<0.005), 
and signiﬁcantly increased left ventricular mass index, left atrial volume, and aortic PWV 
(126±21 vs 112±21 gr/m2, 53±10 vs 39±8 ml and 11.6±2 vs 8.2±1 m/sec, respectively, 
p<0.05 for all cases). In addition, hypertensives with PAF had signiﬁcantly increased 
hs-CRP, and BNP values compared to those without PAF (2.3±1 vs 1.3±0.8 mg/l, and 
120±11 vs 41±5 pg/ml, respectively; p<0.005 for both cases). Logistic regression analysis 
revealed that age, ofﬁce systolic BP, and left atrial size were the signiﬁcant determinants 
of PAF in this population (p<0.05 for all cases).
Conclusions: Hypertensives with PAF are characterized by more pronounced impairment 
of aortic elasticity, greater activation of subclinical inﬂammatory process, and augmented 
BNP values. Future prospective studies are needed to determine whether hypertensives 
with increased arterial stiffness and especially with elevated hs-CRP, and BNP levels are 
more prone to develop PAF.
1014-135 Female Sex and Effect of Losartan Versus Atenolol 
in Patients With Hypertension and Left Ventricular 
Hypertrophy. The LIFE Study
Ingrid Os, Suzanne Oparil, Sverre E. Kjeldsen, Eva Gerdts, Darcy A. Hille, Paulette A. 
Lyle, Fetnat Fouad-Tarazi, Bjorn Dahlof, Richard B. Devereux, Stevo Julius, Merck & Co., 
Inc., West Point, PA
Background: Hypertension contributes signiﬁcantly to cardiovascular (CV) morbidity 
and mortality in both sexes, although women are considered to be at lower risk than 
men. Several studies have reported sex differences in left ventricular (LV) adaptation to 
hypertension. The aim of this study was to analyze sex-related CV morbidity and mortality 
during losartan- versus atenolol-based treatment in patients with hypertension and LV 
hypertrophy (LVH).
Methods: 4963 women and 4230 men from the Losartan Intervention For Endpoint 
reduction in hypertension (LIFE) study entered into this post hoc analysis of treatment 
effects over 4.7 years of follow-up on the primary composite endpoint (CV mortality, 
stroke, and myocardial infarction [MI]) and other prespeciﬁed endpoints.
Results: Fewer women in the losartan group compared to the atenolol group had a 
primary endpoint (215 [18.2 per 1000 patient-years] vs 261 [22.5], p=0.032). No gender 
interaction was found. Stroke occurred in 109 vs 154 women (adjusted hazard ratio 
[HR]=0.70 [95% CI 0.55-0.90], p=0.005). No between-treatment difference was observed 
in MI (HR=1.02 [0.74-1.39], ns) or CV mortality (HR=0.86 [0.64-1.14], ns). Total mortality 
in women was reduced more in the losartan group (HR=0.77 [0.63-0.95], p=0.014), with 
a borderline signiﬁcant gender interaction (p=0.051 for the adjusted analysis, p=0.049 for 
the unadjusted). More females required hospitalization for angina in the losartan group 
compared to the atenolol group (HR=1.70 [1.16-2.52], p=0.007), and a signiﬁcant gender 
interaction was observed (p=0.012). New-onset diabetes was less frequent in the losartan 
group (HR=0.75 [0.59-0.94], p=0.015).
Conclusion: In accordance with main results from the LIFE study, risk reductions for 
the primary composite endpoint, stroke, and new-onset diabetes were more pronounced 
with losartan- versus atenolol-based treatment in female patients with hypertension and 
LVH. Total mortality in women was reduced more in the losartan group, with a borderline 
signiﬁcant gender interaction. More females required hospitalization for angina in the 
losartan group compared to the atenolol group, and a signiﬁcant gender interaction was 
observed.
1014-136 The Relation of the Metabolic Syndrome to the Odds of 
Diastolic versus Systolic Hypertension
Stanley S. Franklin, Michael G, Barboza, Jose R. Pio, Tony K. Khan, Nathan D. Wong, 
University of California, Irvine, Irvine, CA
Background: Although elevated blood pressure (BP) is a component of the metabolic 
syndrome (MetS), the comparative relation of the MetS to the odds of different hypertensive 
subtypes: isolated diastolic hypertension (IDH), systolic-diastolic hypertension (SDH), 
and isolated systolic hypertension (ISH), has not been deﬁned. 
Methods: In a cross-sectional study of 2753 subjects not receiving antihypertensive 
medications and with sufﬁcient covariates to diagnose MetS (weighted to a US. Population 
of 117.8 million) age 18 and over of the Fourth National health and Nutrition Examination 
Survey (NHANES) 1999-2000, we determined the odds of these hypertensive subtypes 
in relation to MetS, as deﬁned by the National Cholesterol Education Program (NCEP). 
The analysis was stratiﬁed by age, gender, and JNC-7 BP classiﬁcation. Multiple logistic 
regression was used to examine the odds of each hypertensive subtype in relation to the 
presence of MetS. 
Results: Of the untreated hypertensive population, IDH comprised 21.3% SDH 22.9% 
and ISH 55.8%. The mean age, % women and mean BP were 37.7 years, 34%, and 
128.7/92.9 for IDH; 52.3 years, 40%, and 158.2/97.8 for SDH; and 63.0 years, 65%, and 
151.5/72.6 for ISH. The prevalence of MetS in those with IDH, SDH, and ISH were 59.3%, 
54.9%, and 30.8%, respectively, among men (p=0.02 across BP subtypes), but markedly 
higher at 92.5%, 71.6%, and 49.2%, respectively among women (p=0.002 across BP 
subtypes). There was greater obesity, higher triglyceride, and lower HDL-C in subjects 
with IDH and SDH versus ISH (p<0.01). Using persons with <3 MetS risk factors as the 
reference group and adjusting for age, gender, total cholesterol, and smoking, odds (and 
95% CI) for those with MetS (3 or more MetS risk factors) were 12.3 (6.0-25.3, p<0.001) 
for IDH, 4.2 (2.2-78, p<0.001) for SDH, and 1.4 (0.9-2.1, p=0.1) for ISH. 
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Conclusions: The MetS is associated with signiﬁcantly greater odds of having IDH and 
SDH in young and middle-aged persons than in middle-aged and older persons who most 
commonly have ISH. MetS and its components of obesity, high triglycerides, and low 
HDL-C are important predisposing factors in the odds of diastolic (IDH and SDH) versus 
systolic hypertension (ISH).
1014-137 Impact Of Antihypertensive Therapy On The Incidence 
Of Coronary Revascularization In High-risk Patients: 
The International Verapamil Sr-Trandolapril Study 
(INVEST)
Efrain Gaxiola, Qian Zhou, Stuart Kupfer, Annette Champion, Carl Pepine, University of 
Florida College of Medicine, Gainesville, IL
Background: Patients with CAD frequently require surgical (CABG) or percutaneous 
coronary intervention (PCI). We assessed the impact of two antihypertensive strategies 
on the incidence of repeat coronary revascularization in hypertensive patients with CAD 
in the INVEST trial.
Methods: 22,576 hypertensive patients with CAD were randomized to either a verapamil-
SR(Ve) based or an atenolol-based (At) strategy. Average follow-up was 61,835 patient 
years. Risk for the primary outcome (death, nonfatal MI, or nonfatal stroke) was equivalent 
between strategies.
Results: Incidence of new revascularization was similar between strategies (Ve 2.5%, 
At 2.4%, P=0.80). Baseline factors associated with increased risk of revascularization 
in all patients were US residency, prior CABG/PCI, hypercholesterolemia, male gender, 
unstable angina, and diabetes (each P<0.01). Patients with new revascularization had 
lower average follow-up BP control rates than patients without revascularization (JNC VI 
44.7% vs 60.2%, P<0.001). Low (<70 mmHg) and high (>=90 mmHg) average follow-up 
diastolic BP were associated with increased revascularization incidence (Figure).
Conclusion: Risk for revascularization is associated with poor BP control and baseline 
US residency, revascularization, hypercholesterolemia, and male gender in hypertensive 
CAD patients. A verapamil SR strategy is an alternative to an atenolol strategy for 
prevention of adverse CV outcomes, including revascularization, in this population. 
1014-138 The Relation Between Aortic Pulse Pressure and 
Coronary Artery Disease: a coronary angiographic 
study
Gokhan Alici, Gokmen Bellur, Zeki Ongen, Vural Ali Vural, Seckin Pehlivanoglu, Hasim 
Mutlu, Sedat Tavsanoglu, Cerrahpasa Faculty of Medicine, Istanbul, Turkey
Background: Pulse pressure(difference between systolic and diastolic pressure) is a 
signiﬁcant marker of cardiovascular morbidity, independently of mean blood pressure,and 
60 mmHg level should be considered as the threshold at risk both in normotensive and 
hypertensive populations.We investigated the relation between aortic PP and the presence 
and extent of CAD in patients undergoing diagnostic coronary angiography(CAG).
Methods and Results:The study group consisted of 550 patients (363 men,187 
women),and of them 47.1% hypertensive,23.3% diabetics,18.9% had hypercholesterolemia 
and 37.8% were smoking.The patients were classiﬁed into 3 groups according to severity 
of CAD:normal CAG, non-critically CAG,and critically CAG (>50% stenosis) group.
Then,we evaluated patients in two different groups,PP <60 mmHg and ≥60 mmHg.In 
univariate analysis gender and hypercholesterolemia showed no statistically signiﬁcant 
differences between both groups. However, diabetes, hypertension and smoking rates 
were signiﬁcantly higher in ≥60 mmHg PP group, and p value was <,0.001,<0.001 
and <0.01,respectively. The mean age was 55.24 ±11.98 in <60 mmHg PP group and 
61.31±9.34 in the other group (p<0.01).Although systolic blood pressure level was 
higher in ≥60 mmHg PP group (160.43±21.14 vs. 126.43±13.57,p<0.001),diastolic blood 
pressure level showed no signiﬁcant differences between both groups.In the <60 mmHg 
PP group,the ratio of patients having normal CAG was signiﬁcantly higher (56.4% vs. 
6.2%, p<0.001),and also,the critically CAG rate was lower than the other group (35.3% 
vs. 84.8%, p<0.001).In multivariate analysis,smoking (odds ratios (OR) 2.344,95% 
conﬁdence intervals (CI),1.416-3.879),male gender (OR 5.858, 95%CI,3.425-10.019) and 
PP≥60 mmHg (OR 25.788, 95%CI,14.001-47.498) were evaluated as an independent 
indicator of critically CAD besides the well-known other major risk factors (hypertension,d
iabetes,and hypercholesterolemia). 
Conclusions: Although in recent studies the correlation between PP and CAD is 
disappeared in multivariate analysis, in our study,we demonstrate that, aortic PP ≥60 
mmHg is related to the risk of critically CAD as an independent factor.
1014-140 Levels of Soluble Adhesion Molecules Concentrations 
in Uncomplicated Systemic Hypertension: The Effect of 
Treatment With Angiotensin Receptor Blockade
Yeo-Shin Hwang, Ye-Hsu Lu, Ching-Cheng Lin, Wen-Chan Tsai, Cardiology and 
Immunology, Dept. of Internal Medicine, Kaohsiung Medical University Hospital, 
Kaohisung, Taiwan,ROC
Background: Controversy exists as whether individual with hypertension without risk 
factors (RF) for atherosclerosis have increased concentrations of ciculating adhesion 
molecules (AM). The aim of the study was to determine whether levels of soluble (s) 
adhesion molecules [sE-selectin, intercellular adhesion molecule-1 (sICAM-1), vascular 
cell adhesion molecule- (sVCAM-1) and von Willebrand factor (vWF)] are elevated in 
uncomplicated essential hypertension (EHT) without other RFs.
Methods: A total of 61 uncomplicated EHT (M/F = 33/28) with age 51±11 y, without 
DM, dyslipidemia, obesity and 17 normotensive (NT) controls were enrolled. BPs were 
measured by 24-hr ambulatory BP monitoring (ABPM, SL 90207) in all participants. 18 
Hypertensives (JNC VII criteria) were treated with irbesartan (IRB, mean dose 243±63 
mg/d). Plasma levels of E-selectin, sCAMs and vWF were measured by ELISA kit (R&D).
Results: The mean 24h ABP in NT group was 119±7/75±8 mmHg; while in HT group 
was 143±14/91±10 mmHg. Compared with NT group, the HT group had signiﬁcant higher 
levels of ICAM-1 (318±18 vs. 236±61 ng/ml, p = 0.009) and trend toward increase in 
E-selectin (39±16 vs. 51±24 ng/ml, p = 0.054). There were no signiﬁcant changes in 
sVCAM-1 and vWF expression in HT and controls. By correlation analysis, when pooled 
NT subjects and HT pts as a group, we observe signiﬁcant correlation between systolic 
BP (SBP) and sICAM-1 (r = 0.30, p = 0.009) and E-selectin (r = 0.333, p = 0.003), diastolic 
BP and E-selectin (r = 0.29, p = 0.010). However, nearly signiﬁcant correlation between 
DBP and sICAM (r = 0.22, p = 0.054) was found. Two months treatment with IRB led 
to a signiﬁcant decline in BP (142±13/88±9 to 125±10/78±5 mmHg, p = 0.001) and a 
signiﬁcant decrease of E-selectin (55±29 vs. 44±28 ng/ml, p = 0.010). However, we did 
not observe changes of sVCAM-1 and vWF after IRB.
Conclusions: Pts with uncomplicated EHT without other RFs for atherosclerosis had 
signiﬁcant elevation of ICAM-1 and E-selectin. In HT pts, treated with ARB irbesartan 
resulted in a signiﬁcant decrease in E-selectin and BP. These ﬁndings suggest that 
besides reduction of BP, there was beneﬁcial effect of ARBs on suppressing endothelial 
activation in EHT.
1014-141 Treatment of Pregnancy Induced Hypertension With 
Intravenous Nitroglycerine: A Randomized, Double 
Blind Placebo Controlled Study
Khurshid Iqbal, Mehboob Ali Dar, Nisar Ahmed Tramboo, Nighat Firdous, Bashir Ahmad 
Naikoo, Khalid Mohiuddin, Shahida Mir, Syed Manzoor Ali, Aijaz Ahmad Lone, Masooma 
Rizvi, Sheri Kashmir Institute of Medical Sciences, Srinagar, India, Government Medical 
College, Srinagar, India
BACKGROUND: The present study was performed to determine the efﬁcacy of 
intravenous infusion of nitroglycerin (NTG), a nitric oxide donor for acute control of 
severe hypertension in pregnancy at term & to study the safety and effects of intravenous 
nitroglycerin on fetal and maternal outcome. Deﬁciency of nitric oxide (NO) has been 
hypothesized in the pathogenesis of pre-eclamptic disorders.
METHODS: In this double blind, placebo controlled study sixty pregnant women with 
severe hypertension at or beyond 36 weeks of gestation were randomized to receive 
either nitroglycerine or a matched placebo infusion. Patients with severe gestational 
hypertension (BP > 160/110mmHg) despite oral antihypertensive treatment, with or 
without superimposed pre-eclampsia or eclampsia were taken. They received either 
intravenous NTG as a continuous infusion, starting at 5µg/min with increments of 5µg/min 
until the goal BP or a dose of 300µg/min was reached (group 1) or equivalent drop rate of 
plain ﬂuid in the placebo group (Group 2). Maternal BP, maternal heart rate (MHR), fetal 
heart rate (FHR) and any signs of fetal distress were monitored. Condition of the newborn 
babies was estimated by APGAR score. The goal was to achieve a SBP of 120-140mmHg 
and /or DBP of 90-100mmHg.
RESULTS: There was a statistically signiﬁcant fall in blood pressure in both groups 
(Group 1, initial SBP166.41±13.15, DBP127.10 ±13.64, post-treatment SBP127.10 
±13.64, DBP 85.93±8.31 (p 0.001); Group 2 initial SBP185.93±8.31, DBP 111.05±5.24and 
post-treatment SBP135.33±16.31, DBP 92.48±12.69 ( p 0.001). However, BP control 
was achieved faster in NTG group. The time to delivery in both the groups was similar. 
There was no signiﬁcant change in fetal heart rate in the 2 groups. However there was 
signiﬁcant maternal tachycardia in response to nitroglycerin; initial MHR 89.24±12.45 , 
post-treatment 99.69±14.65 ( p 0.001). There was no maternal or fetal death .
CONCLUSION: Parenteral nitroglycerin given in continuous infusion of incremental 
doses is an effective agent in acute lowering of high blood pressure in term gravidas. It 
appears to be safe both for the mother and the fetus. The side effects of treatment are 
transient and mainly maternal.
1014-142 AT-1 Receptor Antagonism With Candesartan Cilexitil 
Improves Endothelial Function in Patients With 
Hypertension and Coronary Artery Disease: a Double-
Blind, Randomized, Placebo-Controlled Trial
Pasquale Perrone Filardi, Gregorio Brevetti, Antonio Silvestro, Luigi Corrado, Maria 
Caﬁero, Roberta Camerino, Antonio Maglione, Massimo Chiariello, Institute of 
Cardiology, “Federico II University”, Naples, Italy
Background. Endothelial dysfunction (ED) predicts adverse prognosis in patients with 
coronary artery disease (CAD) and hypertension (HTN). Since reversibility of ED has 
been reported to be associated with more favorable prognosis in HTN, evaluation of the 
effect of therapy on ED maybe clinically relevant.
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Methods. We studied 28 patients with controlled HTN and asymptomatic CAD while on 
β-blocker and nitrate therapy, with evidence of ED assessed by ultrasound measurement 
of % hyperemic ﬂow-mediated dilation (FMD) of the brachial artery. FMD was evaluated 
at screening and after a 2 week run-in and only patients with reduced (<25th percentile 
of an age and sex-matched normal population) and stable (variation between the 2 
measurements within the reproducibility range) FMD were randomized to a double-blind, 
2-month treatment period with either placebo (PL) or candesartan cilexitil (C) 16 mg once-
daily on top of therapy.
Results. At baseline systolic (119+10 vs 126+16 mmHg) and diastolic (79+9 vs 78+8 
mmHg) did not signiﬁcantly differ in the C and PL groups. At the end of treatment diastolic 
pressure signiﬁcantly decreased in the C group (72+12; p<0.01 vs baseline). Effects of 
treatment of endothelial function are reported in the Table: 
Placebo(N=14) Candesartan (N=14)
Baseline 2 Months Baseline 2 Months
Brachial artery diameter (mm) 5.04±0.71 5.02±0.65 4.59±0.9 4.48±0.7
Baseline ﬂow (cm/sec) 105±24 102±21 101±28 107±32
Hyperemic ﬂow (cm/sec) 327±88 342±66 360±88 374±63
FMD (%) 4.5±1.9 5.6±2.3 4.8±2.1 7.5±2.9*
*=different from baseline p<0.01;
Conclusions. In stable patients with HTN and CAD, with sustained ED despite therapy, 
C improves ED within 2 months without signiﬁcant hemodynamic effects. This action may 
favourably inﬂuence cardiovascular risk proﬁle in such patients.
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1041-100 Interindividual Response To Hypoxia Is Related To 
Common E-Nos And Hif-1a Variants
Suresh Ramamurthy, James P. Maloney, Krista C. Stanton, Medical College of 
Wisconsin, Milwaukee, WI, Vanderbuilt University Medical Center, Nashville, TN
Introduction: Tissue hypoxia is a central feature of ischemic diseases. The individual 
response to hypoxia varies. For instance, blood monocytes of patients with coronary 
artery disease show marked differences in VEGF gene regulation during acute hypoxia 
that predict collateralization. An intriguing group for study to explore genetic variation in the 
hypoxic response cascade are subjects who vacation in hypoxic mountain altitudes, who 
serve as a means to identify genes important for cardiac ischemia and collateralization.
Hypothesis: The subset of individuals who develop a brisk phenotype (acute mountain 
sickness, AMS) during a stay at high altitudes are more likely to have variants in genes of 
the hypoxia response pathway that lead to a brisk hypoxic response.
Methods:  We studied the association of AMS phenotype severity in 96 subjects who 
traveled overnight to altitudes above 8,000 ft. with genotype for common functional SNP 
(single nucleotide polymorphisms) variants in the hypoxia response pathway, including 
eNOS,NOS Glu298Asp, and HIF1alpha Pro582Ser (eNOS, n=48). DNA samples 
were collected by buccal swabs. AMS severity was measured by quantitative Lake 
Louise symptom scores (range 0-27). Genotypes were determined by Taqman assays. 
Association was determined by 2-tailed Fisher exact testing.
Results: eNOS T-786C heterozygosity (TC) was less common in subjects who 
developed AMS (score > 10) than in subjects who were free of AMS (score <3, TC 
odds ratio 5.4; p=.02).
Conclusion: The variant eNOS promoter “C” allele variant may blunt the symptom 
response to acute hypoxia. Association of poor coronary collateralization with the eNOS 
T-786C TC carrier state is plausible and should be tested.
1041-101 A Central Role for Nicotinic Cholinergic Receptor-
Dependent Pathways in Regulation of Endothelial Cell 
Migration - Novel Insights into Angiogenesis
Edwin Chang, Martin Ng, Akiko Ishii, Bingyin Wang, John P. Cooke, Falk Cardiovascular 
Research Center, Stanford U., Stanford, CA
Background: Nicotine (NIC) can accelerate the growth of atheroma and tumor via 
promotion of neovascularization. These effects of NIC are mediated by endothelial 
nicotinic cholinergic receptors (nAChR) at concentrations found in smokers. NAChR-
mediated angiogenesis and their relationship to established angiogenic factors such as 
vascular endothelial growth factor (VEGF) and basic ﬁbroblast growth factor (FGF) are 
largely unknown.
Methods: To compare NIC with different angiogenic factors, human microvascular 
endothelial cells (HMVECs) were treated with either vehicle, NIC (10-10 to 10-4M), VEGF 
(10ng/ml) or FGF (10ng/ml) with or without co-administration of the nAChR antagonist, 
hexamethonium (HEX, 10-4M). HMVEC migration, a key angiogenic step, was tested by 
standardized wounding assays. HMVEC gene expression proﬁling was performed using 
cDNA microarrays (Stanford, 43,000 elements) after exposure to vehicle or angiogenic 
factor for 2, 6 and 24 hours (n=5 hybridizations per angiogenic factor per time point).
Results: NIC induced dose-dependent HMVEC migration (maximal @ 10-8M, p<0.001 vs. 
control (CTRL)) which was equivalent in magnitude to bFGF but less than VEGF (p=0.12 
vs. FGF; p<0.01 vs. VEGF). HEX addition abolished migration induced by NIC and bFGF 
(p=NS vs. CTRL for both) and partially inhibited migration by VEGF (52% reduction with 
VEGF + Hex vs. VEGF alone; p<0.01). All angiogens exerted increasing transcriptional 
effects over 24h. NIC signiﬁcantly upregulated 798 and down regulated 734 genes by 24h. 
14% and 12% of FGF (n=259) and VEGF-induced (n=196) genes respectively were also 
transcriptionally regulated by NIC. All 3 angiogens induced altered regulation of genes 
implicated in angiogenesis, atherogenesis, cell proliferation, inﬂammation, apoptosis and 
G-protein signaling.
Conclusion: Nicotine promotes angiogenesis via stimulation of nAChR-dependent 
endothelial cell migration. nAChR-associated pathways are involved in mediating 
endothelial cell migration in response to VEGF and FGF. nAChR activation induced 
profound transcriptional effects which are substantially interrelated to but distinct from 
those induced by VEGF and FGF.
1041-102 A High-Fat Western Diet Induces Recruitment of Bone 
Marrow-Derived Cells to Expanding Adipose Tissue 
Compartments
Dmitry Traktuev, Constance Temm, Carrie A. Pell, Jingling Li, Brian H. Johnstone, Mervin 
C. Yoder, Jr., Keith L. March, Indiana University School of Medicine, Indianapolis, IN
Introduction: Adipose stromal cells (ASC) possess the ability to differentiate into adipocytes 
as well as other cell lineages. ASC express surface markers shared with hematopoietic 
stem cells (HSC), such as CD34 (human) and Sca-1 (mouse). We aimed to determine 
whether ASC originate from bone marrow precursors then engraft into adipose tissue.
Methods: Obesity was induced in chimeric mice expressing GFP in the bone marrow. 
Bone marrow (BM) of 8 wk old C57BL/6J mice was ablated by irradiation, followed by 
transplantation with BM isolated from transgenic beta-actin GFP mice. At 3 months, 
half of the mice were placed on high fat diet (HFD) and the others served as controls 
(normal chow). After 1 month cells were isolated form adipose tissue and analyzed by ﬂow 
cytometry and confocal microscopy for GFP, Sca-1, CD45 and CD31 expression.
Results: The total mass of fat increased by 5-10-fold when mice were maintained on HFD. 
This increase was accompanied by a 1.5-fold reduction in the concentration (cells / g) of 
total Sca-1+ cells. The absolute number of Sca-1+/GFP- cells (pre-existing tissue resident 
cells) increased <2-fold, while the absolute number of Sca-1+/GFP+ cells increased by 
10-15-fold, with the concentration increasing by 2.5-fold. As expected, the data showed 
that resident stromal cell differentiation increased adipose mass; however, there was 
also recruitment of bone-marrow-derived cells to the adipose stromal compartment. A 
2-fold higher concentration of cells expressing the leukocytic CD45 marker were present 
in adipose tissue of HFD mice compared to mice on normal diet. This increase in CD45+ 
cell content was predominantly explained by 4-fold increase in CD45+/GFP+ cell content, 
conﬁrming that HFD enhances localization of leukocytes to adipose tissue. Adipose tissue 
sections revealed Sca-1 staining cells are isolated as well as, less commonly, associated 
with vascular networks.
Conclusions: Diet-induced expansion of adipose stromal compartment occured in part 
through mobilization of BM-derived cells. This was accompanied by an increase in a 
distinct BM-derived leukocyte population. These observations may suggest approaches 
to manipulating the presence and sequelae of obesity.
1041-105 Nitric Oxide Does Not Improve Collateral Dependent 
Blood Flow
Barend Mees, Shawn Wagner, Elena Ninci, Silvia Tribulova, Rien van Haperen, Sawa 
Kostin, Matthias Heil, Rini de Crom, Wolfgang Schaper, Erasmus Medical Center, 
Rotterdam, The Netherlands, Max-Planck-Institute for Physiological and Clinical 
Research, Bad Nauheim, Germany
Background: Nitric Oxide is a powerful vasodilator and angiogenic mediator. It has been 
shown to improve blood ﬂow recovery and enhance capillary growth in ischemic hind limbs. 
Since it is increasingly recognized that blood ﬂow deﬁcits caused by occlusion or stenosis 
of a major artery can only be efﬁciently compensated for by arteriogenesis, we investigated 
the role of Nitric Oxide in collateral growth, using two transgenic mouse models.
Methods: Right femoral artery ligation was performed in wild type C57Bl6 mice (n=23) 
(WT), eNOS knockout (KO) mice (n=26) and mice overexpressing eNOS (n=21) (TG). 
Laser Doppler (LD) blood ﬂow measurements of both feet and MRI ﬂow measurements 
of the vessels in m. gastrocnemius (MG) were performed. At day 7 and 21 mice were 
sacriﬁced for histological analysis, i.e. morphometry of collateral arteries in m. adductor 
and capillary count in MG. All measurements are expressed as right-to-left ratios.
Results: LD and MRI measurements showed an increased blood ﬂow in feet of eNOS TG 
mice immediately after surgery, but no differences at later time points. In ischemic feet of 
eNOS KO mice LD showed a decreased blood ﬂow at all time points. MRI demonstrated 
that there was a delayed but no deﬁcient collateral dependent blood ﬂow to the MG.
Conclusion: eNOS overexpression did not improve collateral dependent blood ﬂow, apart 
from an acute vasodilation effect. eNOS deﬁciency led to decreased blood ﬂow in the 
ischemic feet but not to decreased collateral dependent ﬂow in MG. 
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1041-106 CD34+ Cells Exhibit Increased Potency and Safety 
for Therapeutic Neovascularization Post Myocardial 
Infarction Compared with Total Mononuclear Cells
Atsuhiko Kawamoto, Kengo Kusano, Toshinori Murayama, Hiroto Iwasaki, Akira 
Oyamada, Marcy Silver, Marianne Kearney, Christine Hulbert, Mary Gavin, Hong Ma, 
Takayuki Asahara, Douglas W. Losordo, Kobe Institute of Biomedical Research and 
Innovation, Kobe, Japan, St. Elizabeth’s Medical Center, Boston, MA
Background: We compared the therapeutic potential of puriﬁed CD34+ cells (known 
to be enriched for endothelial progenitors, EPCs) with that of total mononuclear cells 
(tMNCs) for preservation/ recovery of myocardial tissue integrity and function post-
myocardial infarction (MI). 
Methods: CD34+ cells were puriﬁed from peripheral blood tMNCs of a healthy volunteer 
by magnetic cell sorting after 5-day administration of G-CSF. MI was induced by ligating 
LAD of nude rats. PBS, 5X103/ kg CD34+ cells (lo34), 5X105/ kg tMNCs (midMNC), 5X105/ 
kg CD34+ cells (mid34) or high number (approximately 5X107/ kg) of tMNCs (hiMNC) 
containing mid dose (5X105/ kg) CD34+ cells, were transplanted intramyocardially 10 
minutes after MI (n=9~11 in each group). Histological and functional outcomes were 
compared among the groups. 
Results: Hematoxylin-Eosin staining revealed massive hemorrhagic MI in 9 out of 11 
rats of hiMNC group on day 3, but in only 2-4 out of 9-10 rats in other groups on day 3 
(P<0.01). Capillary density on day 28 determined by isolectin B4 staining was signiﬁcantly 
greater in mid34 group (706.6±35.2/ mm2) than PBS, lo34, midMNC and hiMNC groups 
(398.3±9.8, 379.0±18.4, 452.8±27.1 and 527.6±37.5/ mm2, respectively) (P<0.001). 
Percent ﬁbrosis area on day 28 by Masson-Trichrome staining was smaller in mid34 group 
(15.9±1.5%) than PBS, lo34, midMNC and hiMNC groups (24.5±1.4, 27.2±2.4, 23.8±2.7 
and 22.6±3.1%, respectively) (P<0.05). Echocardiographic fractional shortening was 
signiﬁcantly higher in mid34 (29.7±1.3%) than PBS, lo34, midMNC and hiMNC groups 
(23.2±2.5, 23.5±1.2, 23.6±1.5 and 24.9±1.7%, respectively) (P<0.05). Echocardiographic 
regional wall motion score was better preserved in mid34 group (22.3±0.5) than PBS, 
midMNC and hiMNC groups (24.8±0.4, 24.7±0.4 and 24.1±0.6, respectively) (P<0.05). 
All histological and functional parameters were similar in PBS, lo34, midMNC and hiMNC 
groups. 
Conclusion: CD34+ cells exhibit superior potency for preserving myocardial integrity and 
function post-MI. Despite equal dosing of CD34+ cells, unselected cells did not achieve 
equivalent therapeutic effects.
1041-107 Enhanced Angiogenesis: Head to Head Comparison 
of Freshly Aspirated Bone Marrow vs. Bone Marrow-
Derived Mesenchymal Stem Cells in the Mouse Hind-
Limb Ischemia Model
Stephan Zbinden, Leonardo Clavijo, Hakim Morsli, Gil Jin Jang, James A. Andrews, 
Eugenio Stabile, Tim Kinnaird, Mary Susan Burnett, Stephen E. Epstein, MedStar 
Research Institute, Washington, DC
BACKGROUND: Several studies have shown that cell therapy, using various cell types, 
enhances ischemia-induced collateral ﬂow. However, no direct efﬁcacy comparisons 
between different cell types have been made. Therefore, we compared the collateral 
ﬂow recovery-inducing capacity of freshly aspirated bone marrow cells (BMCs) vs. bone 
marrow-derived mesenchymal stem cells (MSCs) in mice.
HYPOTHESIS: Freshly aspirated BMCs are as effective as MSCs in promoting blood ﬂow 
recovery in an ischemic mouse hindlimb model.
METHODS: Hindlimb ischemia was induced in BalbC mice by surgically ligating the 
superﬁcial femoral artery. After 24 h, the adductor muscle was injected with either media 
(vehicle control), ﬁltered freshly aspirated BMCs, or MSCs (isolated by separation of 
CD34/CD45 negative cells from cultured bone marrow). Cells were injected at a dose of 
3x105 (3 groups, n=7 animals per group). Blood ﬂow recovery was measured weekly for 28 
days by Laser Doppler. Mice were also scored for severity of limb ambulatory impairment 
and tissue ischemia.
RESULTS: In control mice, ischemic limb ﬂow returned to about 30% of the non-ischemic 
limb on day 28; however, treatment with BMCs or MSCs increased ﬂow in the ischemic 
limb on day 28 to 60% and to 53%, respectively, vs. the non-ischemic limb. Differences in 
collateral blood ﬂow recovery between the two cell-treated groups vs. the control group 
were highly signiﬁcant (p=0.009, by ANOVA), but there was no difference between BMC 
and MSC-treated mice (p=0.82). Further, there was signiﬁcantly less severe ambulatory 
impairment and tissue ischemia in the cell-treated groups vs. control (both=p=<0.001).
CONCLUSION: BMCs and MSCs, in a dose of 3x105, are equally and highly effective in 
improving collateral blood ﬂow in comparison to vehicle control-treated mice in a mouse 
hind limb ischemia model. These results indicate the need for more comparative studies 
among the different options for cell therapy designed to enhance collateral ﬂow.
1041-108 Combinatorial Therapy Using Angiopoietin-1 Plasmid 
Gene and Autologous Bone Marrow Mononuclear Cell 
Implantation Promotes Functional Angiogenesis in a 
Rabbit Model of Hindlimb Ischemia
Koichi Kobayashi, Takahisa Kondo, Mika Aoki, Natsuo Inoue, Osamu Yoshida, Mejeong 
Lee, Ping Li, Kimihiro Komori, Toyoaki Murohara, Nagoya University, Nagoya, Japan
Background: Autologous bone marrow cell (BMC) implantation into ischemic tissues has 
been shown to enhance angiogenesis in humans. But a large amount of BM is needed, 
which is a major limitation. Angiopoietin-1 (Ang-1) is requisite for vascular maturation 
during angiogenesis. We examined the impacts of combinatorial Ang-1 plasmid gene 
and low dose autologous BMC therapy on therapeutic angiogenesis in a rabbit model of 
hindlimb ischemia.
Methods: NZW rabbits (n = 40) were subjected to unilateral hindlimb ischemia and 
randomly divided into 4 groups at day7; PBS (control), 500 µg Ang-1 plasmid (Ang-1), 
1×106 autologous BM-mononuclear cells (MNC) (BMC) and combination of Ang-1 gene 
and BM-MNCs (combination). Meanwhile, we injected recombinant human Ang-1 protein 
and/or BMC in mouse ear and examined the vessel structure within the ear skin.
Results: Five weeks after hindlimb ischemia, the Ang-1 group had a greater angiographic 
score (p<0.05) and capillary density (p<0.01) than the control group. However, the Ang-
1 sole therapy did not improve transcutaneous oxygen pressure (TcO2) and skin ulcer 
score, indicating little improvement of functional microcirculation. On the other hand, 
the combination group showed signiﬁcant improvement in not only angiographic score 
(p<0.05) and capillary density (p<0.01) but also TcO2 (p<0.05) and skin ulcer score. 
These effects were more remarkable in the combination group compared to the BMC 
sole therapy group. In the mouse ear model, Ang-1 protein induced aberrant neovessels, 
which were ameliorated by co-injection of BMC.
Conclusion: Ang-1 alone may not be sufﬁcient for functional microvascular 
neoangiogenesis despite an increased collateralization. In contrast, BMC therapy, as low 
as 106 cells/animal, can induce functional microvascular angiogenesis but its efﬁcacy 
was limited due to only modest increase in collateral vessels. The combination therapy 
of Angiopoietin-1 and BM-MNCs, however, promoted functional angiogenesis possibly 
through maturation of new blood vessels. Our new gene and cell therapy technique would 
enhance therapeutic angiogenesis with autologous BM-MNC and could save the amount 
of BM aspiration.
1041-109 Local Gene Transfer of Angiopoietin-2 Accelerates 
Collateralization of the Rat Ischemic Hindlimb
Michael C. Lekas, Warren Ball, Michael J B Kutryk, Qiuwang Zhang, Duncan J. Stewart, 
University of Toronto, Toronto, ON, Canada, St. Michael’s Hospital, Toronto, ON, Canada
Background: Tissue ischemia results in production of vascular endothelial growth 
factor (VEGF) and the Angiopoietins (Ang), ligands for the Tie2 receptor. In the rodent 
ischemic hindlimb model, we noted an early (day 1) 2-fold rise in the ratio of Ang-2:Ang-1 
mRNA expression in the ischemic leg. We propose Ang-2 may be a context-dependent 
antagonist acting initially to release endothelial cells (EC) from tonic inhibition by Ang-1, 
but at later time points acquiring agonist activity to promote neovascular maturation. Thus, 
Ang-2 is an attractive candidate for therapeutic angiogenesis as it combines two activities 
critical for post-natal neovascularization. Therefore, we tested the hypothesis that Ang-2 
gene transfer would be more effective in restoring blood ﬂow to the ischemic limb than 
treatment with Ang-1.
Methods: Hindlimb ischemia was induced (day 0) in Sprague-Dawley rats (450-600 g). 
Plasmid DNA (500µg) encoding human Ang-1 (n=9), Ang-2 (n=9), VEGF (n=8) or empty 
vector (control, n=8) was injected intramuscularly at day 7 into the ischemic hindlimb. 
Non-invasive, serial measurement (day 0-35) of leg perfusion was performed with Laser 
doppler imaging expressed as a ratio of ischemic (I) to non-ischemic (NI) leg. Angiography 
was performed on day 35 for determination of an angiographic score. Quantitative analysis 
of mRNA expression was performed by real-time RT-PCR (ABI) for human Ang-1, Ang-2 
and VEGF transgene expression.
Results: Hindlimb perfusion ratio was decreased in all groups immediately after sugery. 
On day 7, no difference in perfusion ratio (mean±SEM) was noted among groups (Ang-1, 
0.46±0.04, Ang-2, 0.48±0.03, VEGF, 0.47±0.03, control 0.45±0.04). At day 35, perfusion 
ratio was increased (p<0.05) relative to baseline in Ang-1 (0.56±0.06), Ang-2 (0.70±0.05), 
VEGF (0.63±0.05)-treated groups, but not in controls (0.46±0.04). Ang-2 treatment 
resulted in greater blood ﬂow than Ang-1 and controls (p<0.05). Angiographic scores 
were highest in Ang-2 and VEGF treated groups.
Conclusions: In this model of chronic hindlimb ischemia, early Ang-2 gene transfer 
results in enhanced leg perfusion, and may be a more effective single angiogenic agent 
than Ang-1 alone.
1041-110 The Role of Metallothionein as an Arteriogenic Gene in 
a Murine Hind Limb Ischemia Model
Hakim Morsli, Stephan Zbinden, Leonardo C. Clavijo, Gil Jin Jang, Cheol Whan Lee, 
Joseph M. Devaney, James A. Andrews, Stephen E. Epstein, Mary Susan Burnett, 
MedStar Research Institute, Washington, DC
Background: Metallothionein (Mt) is a potent immunomodulatory molecule shown to play 
a protective role in cerebral ischemia, as well as ischemia-reperfusion injury in murine 
heart. Using microarrays to assess the time course of gene expression during collateral 
development in a mouse model of acute hind limb ischemia, we found that Mt mRNA levels 
were elevated in the adductor muscle following femoral artery ligation. It is our hypothesis 
that: Metallothionein is a critically important factor in the development of collaterals and in 
enhancing collateral ﬂow in the murine hind limb ischemia model.
Methods: Using Affymetrix GeneChips, gene expression was measured in the adductor 
muscle of C57BL/6J mice at 6 hours and 1, 3, 7 and 14 days following ligation of the 
femoral artery. Results were conﬁrmed using TaqMan. To test our hypothesis, Sv129 
wild-type (WT, n=10) and Sv129 Mt knockout (KO) mice (n=9) underwent ligation of the 
left femoral artery. Flow recovery was assessed using Laser Doppler Perfusion Imaging 
(LDPI) over a 4 week period and expressed as a ratio of ischemic to normal limb ﬂow.
Results: Following femoral artery ligation, levels of Mt1 mRNA were elevated in the 
mouse adductor muscle (8.1 fold at 6 hours, 40.8 fold at 1 day, 20.4 fold at 3 days) 
compared to baseline, and a 4 fold increase in the ligated animals was observed in 
comparison to sham operated mice at day one. Sv129 Mt knockout mice exhibited a 
signiﬁcant impairment in ﬂow recovery when compared to the Sv129 wild type mice. [Mt 
KO vs. WT: LDPI ratio Ischemic/Normal limb ﬂow: p=0.028, using an analysis of variance 
test for repeated measures on day 7, 14, 21, and 28].
Conclusions: Mt gene expression is highly upregulated in the adductor muscle of 
mice following induction of acute hind limb ischemia. Sv129 Mt knockout mice exhibit 
a signiﬁcant impairment in collateral ﬂow recovery following femoral artery ligation 
when compared to the Sv129 wild type mice. These data support our hypothesis that 
metallothionein plays an important role in the development of collaterals in this model of 
murine hind limb ischemia.
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1041-111 A Novel Gutless Adenoviral Vector Encoding 
Sphingosine Kinase Promotes Arteriogenesis And 
Improves Perfusion In A Rabbit Hindlimb Ischemia 
Model
Jaeung Lee, Jinho Shin, Woohyuk Song, Hyunjoong Kim, Seunghwan Lee, S. Chiu 
Wong, Jay E. Edelberg, Gene Liau, Mun K. Hong, Weill Cornell Medical College, New 
York, NY, Novartis Company, Cambridge, MA
Background: We previously demonstrated that sphingosine kinase (SPK) increases the 
level of extracellular sphingosine-1-phosphate and promote arteriogenesis in a mouse 
matrigel model. The present study was designed to test the hypothesis that SPK gene 
transfer using a novel “gutless” adenoviral vector (AGV) can enhance arteriogenesis.
Methods: Thirty-ﬁve male New Zealand white rabbits were assigned to three groups: 
SPK group (n=13), null group (n=13, vector without SPK gene), and control group of 
saline injection (n=9). At day 10 after the induction of unilateral hind-limb ischemia, gene 
vectors or buffer were introduced and the effect examined at day 30, using calf blood 
pressure, quantitative angiographic analysis, and histology. Due to similar results, the null 
and buffer groups were combined and compared with the SPK group.
Results: SPK group resulted in higher systolic blood pressure ratio (compared with the 
contralateral normal leg) than control groups (0.89±0.04 and 0.77±0.04, respectively; 
p=0.01). Angiographic endpoint, the collateral vessel count, was signiﬁcantly higher in the 
SPK group (11.9±3.3 versus 8.27±2.1, p<0.01). Histologic analysis showed signiﬁcantly 
increased larger neovessels (arterioles with well-deﬁned muscular medial layer) in the 
SPK group compared with the control groups (3.42±1.21 versus 2.26±1.29, p<0.05).
Conclusions: This study shows that SPK promotes arteriogenesis and may be an 
important angiogenic target to improve perfusion in ischemic tissues.
1041-112 Transgenic Mice with Transforming Growth Factor 
(TGF)-β Type II Receptor Dysfunction Have Attenuated 
Hypoxia-Induced Pulmonary Hypertension and 
Remodeling
Ji-An Feng, Suzanne Oparil, Peng Li, Dongqi Xing, Rosa Serra, Yiu-Fai Chen, University 
of Alabama at Birmingham, Birmingham, AL
We have shown that mice exposed to chronic hypoxia exhibit increased pulmonary 
arterial pressure and vascular remodeling with increased deposition of extracellular matrix 
(ECM) in lung. TGF-β is known to increase production of ECM in pulmonary ﬁbroblasts, 
suggesting a role for TGF-β in hypoxia-induced pulmonary hypertension and remodeling. 
This study tested the hypothesis that mice with dominant-negative TGF-β type II receptors 
(DNIIR) exhibit blunting of pulmonary hypertension and remodeling in response to 
hypoxia. Adult male wildtype (WT) and DNIIR mice were exposed to air or 10% O2 for 6 
wks. Mean RV pressure (MRVP) was measured in spontaneously breathing mice as an 
index of pulmonary hypertension. RV free wall and the left ventricle and septum (LV+S) 
were weighed. Cross sections of lung were immunostained with α-smooth muscle actin 
(α-SMA) antibody for quantitaion of transformation of alveolar ﬁbroblasts. Tissue weights 
were normalized by body weight using ANCOVA. Results (means±SE, n=7, * p<0.05, 
vs. Air groups. Δ p<0.05, vs. WT groups.) are shown in the table. Exposure to hypoxia 
increased MRVP, RV weight and number of α-SMA positive alveolar cells in WT mice. 
RV hypertension and hypertrophy and myoﬁbroblast transformation were attenuated in 
DNIIR hypoxic mice compared to WT hypoxic mice. These data support our hypothesis 
that endogenous TGF-β plays an important role in regulating hypoxia-induced pulmonary 
hypertension and remodeling, and cardiac hypertrophy via the TGF−β type II receptor.
WT DNIIR
Air Hypoxia Air Hypoxia
MRVP (mmHg) 7.7±0.3 12.6±0.4* 7.4±0.3 10.1±0.5*Δ
RV weight(mg) 23.8±0.5 34.2±0.9* 25.0±0.8 29.5±1.4*Δ
LV+S weight(mg) 87.4±1.7 86.3±1.5 93.9±0.6 93.1±1.4
�-SMA cells/100 alveoli 5.1±0.6 30.4±3.2* 5.1±0.7 9.4±1.8*Δ
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1042-131 Octogenarians Do Not Have an Increased Risk of Stroke 
After Carotid Artery Stenting With Embolic Protection
Deepak P. Vivek, Hitinder S. Gurm, David S. Lee, Michael H. Yen, Robert B. Fathi, Samir 
Kapadia, Christopher Bajzer, Jay S. Yadav, The Cleveland Clinic Foundation, Cleveland, OH
Background: The use of carotid artery stenting with embolic protection devices (EPD) 
has been shown to provide salutary outcomes in high-risk patients when compared with 
carotid endarterectomy (CEA). However, there are few data regarding the safety of carotid 
stenting with EPD in octogenarians.
Methods: A total of 350 consecutive patients undergoing carotid artery stenting with 
EPD at the Cleveland Clinic Foundation from August 1999 through October 2003 were 
included in our analysis. We compared the risk of stroke after carotid stenting between 
octogenarians to those of younger patients (age < 80). The primary outcome was stroke 
at 30-days.
Results: Octogenarians comprised 16% of our cohort (n=55). In comparison to younger 
patients (n=295), octogenarians had a lower incidence of prior transient ischemic attack 
(11% vs. 29%, P=0.03) and a trend towards a lower percentage of diabetes (29% vs. 42%, 
P=0.07). After a follow-up period of 30-days, there were a total of 9 strokes (2.6%) in our 
entire cohort. The incidence of stroke in octogenarians was 1.8% (n=1) whereas 8 strokes 
(2.7%) occurred in patients less than 80 years old (P=1.0) (see ﬁgure).
Conclusions: Octogenarians do not have an increased risk of stroke after carotid artery 
stenting with EPD compared to younger patients. In light of the increased stroke risk in 
elderly patients undergoing CEA, carotid stenting with EPD should be considered the 
preferred revascularization modality in this challenging patient population.
 
1042-132 Mitochondrial K-ATP Channel Opener Inhibits DNA 
Damage and Apoptosis in Rabbit Spinal Cords 
Following Ischemia-Reperfusion Injury
Glen Roseborough, Daqing Gao, Lei Chen, Micheal Trush, G. Melville Williams, Chiming 
Wei, Johns Hopkins University, Baltimore, MD
Objectives: The current study was designed to investigate the effects of diazoxide (DZ, 
mitochondrial K-ATP channel opener), on mitochondrial structure and DNA damage-
repair system in a rabbit model of spinal cord ischemia-reperfusion injury following aortic 
clamping.
Methods and Results: Rabbit spinal cord ischemia (30 min) and reperfusion (1 hr) (SCI) 
with (SCI+DZ group, n=6) or without (SCI only group, n=6) DZ was performed with aortic 
clamping method. The neurological functional score was signiﬁcantly improved in SCI+DZ 
group (4.1±0.2) compared with SCI group (1.1±0.2, P<0.01). Mitochondrial superoxide 
(O-2) and H2O2 levels (determined by chemiluminescent) were markedly decreased in 
SCI+DZ group compared with SCI group. DZ decreased DNA damage (8-oxoG), and 
increase DNA repair enzymes (MYH and OGG1, determined by immunohistochemical 
staining [IHCS] and western blot analysis [WB]) (Table: *P<0.05 vs SCI). Furthermore, 
DZ decreased apoptosis (TUNEL), and inhibited caspase-dependent apoptotic pathway 
(caspase-3) and caspase-independent apoptotic pathway (apoptosis-inducing factor 
[AIF], and poly (ADP-ribose) polymerase-1 [PARP]) (determined by IHCS and WB).
Conclusion: These studies indicated that mitochondrial K-ATP channel opener improves 
neurological function, increases DNA repair and decreases DNA damage product as well 
as inhibits caspase-dependent and caspase-independent apoptotic pathways in spinal 
cord following ischemia-reperfusion injury.
DNA Damage-Repair and Apoptosis In Sinal Cord Ischemia-Reperfusion Injury 
Study 8-oxoG (%)
MYH 
(score)
OGG1 
(score)
TUNEL 
(%)
Cas-3 
(score)
AIF 
(score)
PARP 
(score)
SCI
(n=6) 8.5±1.2 0.6±0.2 0.8±0.2 7.5±1.3 2.4±0.2 3.2±0.5 3.5±0.3
SCI+DZ
(n=6) 2.2±0.4* 2.1±0.3* 2.4±0.2* 1.1±0.2* 0.2±0.1* 0.3±0.1* 0.2±0.1*
1042-135 Simvastatin Preserves Renal Microvascular Structure in 
Renal Artery Stenosis
Xiang-Yang Zhu, Alejandro R. Chade, Erik L. Ritman, Amir Lerman, Lilach O. Lerman, 
Mayo Clinic, Rochester, MN
Background: Statins have beneﬁcial effects on peripheral and coronary vascular structure 
regardless of cholesterol reduction, but their effects on a kidney with renal artery stenosis 
(RAS) remain unknown. We hypothesized that alterations in renal microvascular structure 
in RAS would be improved by chronic simvastatin treatment, due to its antioxidant and 
anti-inﬂammatory properties. 
Methods: Normocholesterolemic pigs were studied after 12 weeks of RAS, RAS+ 
simvastatin (RAS+S, 80mg/d), or controls (n=6 each group). Kidney samples were 
scanned ex-vivo using unique 3D micro-CT, and the spatial density of renal microvessels 
(<500µm) tomographically determined. Renal expression of NAD(P)H oxidase (p47phox, 
gp91 phox) and nuclear factor �B (NFkB) were determined.
Results: RAS and RAS+S had similar cholesterol level, degree of RAS, and increased 
arterial pressure. Compared to normal, RAS showed a decrease in spatial density of cortical 
microvessels (68.7±9.6 vs. 115.6±20.2 vessels/cm2, p<0.05), which was normalized in 
RAS+S (97.3±11.3 vessels/cm2). Additionally, RAS increased renal p47 phox, gp91 phox, 
and NFkB expression, which were all preserved by simvastatin intervention. 
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Conclusions: RAS-invoked changes in renal microvascular architecture are accompanied 
by increased oxidative stress and inﬂammation and preserved by chronic simvastatin 
treatment independent of its lipid-lowering properties. These ﬁndings suggest a protective 
role for simvastatin in the stenotic kidney. 
1042-136 Quantitative Assessment of Renal Blood Flow During 
Selective Renal Angiography Using the Kidney Frame 
Count (KFC)
Ajay J. Kirtane, Pedro Martinezclark, Allen Chang, Duane S. Pinto, Lawrence A. Garcia, 
Roger J. Laham, C. Michael Gibson, Beth Israel Deaconess Medical Center, Harvard 
Medical School, Boston, MA, PERFUSE Angiographic Core Laboratory, Boston, MA
Background: Currently renal blood ﬂow is evaluated qualitatively. We sought to 
quantitatively evaluate renal blood ﬂow from clinical angiograms using an established frame 
counting method that has been successfully applied to assess coronary blood ﬂow.
Methods: 42 angiograms obtained at framespeeds of 15-30 frames/second were 
analyzed from 23 patients with normal renal function who underwent selective renal 
angiography following coronary angiography and/or percutaneous coronary intervention. 
A measure of time for contrast to traverse the renal vasculature, the Kidney Frame Count 
(KFC), was prospectively assessed using distal landmarks in different segments/poles 
of the kidney.
Results: Use of an interlobar branch as a distal landmark was associated with signiﬁcant 
anatomic variability (11.7 ± 4.1 vs. 16.4 ± 6.7 frames for upper vs. lower interlobar, 
p<0.001) and too low (fast) KFC to offer potential discriminatory power. A more distal 
cortical landmark was associated with the greatest reproducibility and discriminatory 
capacity. The correlation between KFC measures from upper vs. lower cortical poles was 
good (r=0.77, p<0.001). However, because renal blood ﬂow is phasic and occurs largely 
during systole, the KFC was signiﬁcantly inﬂuenced by the timing of injection within the 
cardiac cycle, with a 12 frame difference between KFC derived from injections immediately 
post-systole vs. early diastole (37.0 ± 8.2 frames vs. 24.9 ± 6.8 frames, p<0.0001). In 
multivariate analyses, higher (slower) KFC was associated with higher baseline creatinine 
(p<0.001), greater patient weights (p=0.002), slower heart rates (p<0.001), beta-blocker 
use (p=0.004), more contrast dye administered prior to the renal angiogram (p<0.001), 
and non-smoking patient status (p<0.001).
Conclusion: Although KFC could be quantitated from the angiogram, care must be 
taken to adjust for the timing of injection and other factors that inﬂuence heart rate. Based 
upon these analyses, we propose methodology and report a series of normal values to 
serve as a point of reference for further studies.
1042-137 Plasma Fibrin D-Dimers Are Highly Elevated In Patients 
With Acute Aortic Dissection.
Holger Eggebrecht, Christoph K. Naber, Christian Bruch, Knut Kroeger, Clemens von 
Birgelen, Axel Schmermund, Thomas Bartel, Klaus Mann, Raimund Erbel, University of 
Duisburg-Essen, Essen, Germany
Background: Rapid diagnosis and initiation of treatment is pivotal for patients with acute 
aortic dissection (AD). So far, there is no laboratory test to aid the diagnosis.
Patients and Methods: Plasma ﬁbrin D-dimers, white blood cell (WBC) count, C-reactive 
protein (CRP), and ﬁbrinogen were determined in 64 chest-pain (CP) patients (acute 
AD, n = 16; pulmonary embolism [PE], n = 16; acute myocardial infarction [AMI], n = 16; 
non-cardiac CP, n = 16); 32 asymptomatic patients with chronic AD served as a control 
group.
Results: All acute AD patients showed highly elevated D-dimer values that were similar 
to PE patients (2,238 ± 1,765 µg/l vs. 1,531 ± 837 µg/l, p = 0.15) but signiﬁcantly higher 
than in chronic AD, AMI, or CP patients (p < 0.001). The WBC count was signiﬁcantly 
increased in patients with acute AD compared with the other groups (p < 0.001); in 
addition, CRP values differed only non-signiﬁcantly from PE patients(p = 0.71). There 
were no differences in the ﬁbrinogen levels between the groups.
Conclusions: D-dimers are highly elevated in both acute PE and acute AD. Patients 
with acute AD show signiﬁcant systemic inﬂammatory reactions. Measurement of D-
dimers may be a valuable addition to the current diagnostic work-up of patients with 
suspected AD. 
1042-138 Alterations of Matrix Metalloproteinase Expression and 
Activation in Dissecting Aortic Wall from Patients With 
and Without Marfan’s Syndrom
Guanggen Cui, Chang-Cheng Chen, Hillel Laks, Joseph Perloff, Mark Plunkett, Fardad 
Esmailian, Latha Polavaram, Luyi Sen, UCLA Medical Center/UCLA School of Medicine, 
Los Angeles, CA
Background: Remodeling of the aortic wall by inﬂammation cells activation and 
overexpression of matrix metalloproteinases (MMPs) has been characterized in 
atherosclerotic abdominal aortic aneurysm. However, the alteration of MMP proﬁle in the 
aortic dissection has not been well deﬁned. Methods: To examine the alteration of the 
MMPs proﬁle in the aortic wall and to further elucidate the mechanism of this alteration, 
23 patients who underwent surgical treatment of aortic dissection (AD) were included. 
Among them, 6 patients have Marfan’s Syndrome. Ascending aorta tissue samples from 
20 donor hearts were used as normal control (NC). Protein expression level of MMP1, 
MMP2, MMP3, MMP9, MMP13 and Tissue Inhibitors of MMPs (TIMP) 1 and TIMP2 were 
determined by quantitative Western Blot analysis. MMP activity was further examined by 
zymographic analysis.Results: The latent form of MMP2 level corresponding to actin value 
was only slightly increased in AD group, but the active form of MMP2 was signiﬁcantly 
increased in AD (0.48±0.21 vs. 0.73±0.28, p<0.05). In contrast, a remarkable increase 
of both latent and active forms of MMP9 was found in AD (0.87±0.25 and 0.99±0.38, 
respectively) compared with that in NC (0.37±0.22 and 0.42±0.15, respectively) (p<0.05). 
Zymographic analysis also shows the increase of MMP9 activity (123%) is greater than 
MMP2 activity (68%) in AD. MMP1 and MMP13 levels were also signiﬁcantly increased 
in AD group (0.82±0.29 and 0.74±0.31, respectively) compared with that in NC group, 
(0.57±0.17and 0.28±0.12, respectively) (p<0.05), but the activity of both collagenases 
was only slightly increased. MMP3 level was not signiﬁcantly changed in AD. TIMP1 
level was signiﬁcantly decreased in AD (0.37±0.14 vs. 0.71±0.23, p<0.01), but TIMP2 
remained unchanged. In patients with Marfan’s syndrome, besides 2 fold higher in the 
expression level of both latent and active forms of MMP9, otherwise their MMP proﬁle 
was not distinguishable compared with that in AD patients without Marfan’s syndrome. 
Conclusion: Our results suggest that the alteration of the expression and activation of 
matrix collagenases and gelatinases may play an important role in the pathogenesis of 
aortic dissection.
1042-139 Delayed Hyperenhancement On CT In Abdominal Aortic 
Aneurysm Wall.
Akiko Sakuta, Yoshikazu Aoka, Yasunari Sakomura, Noriko Nishii, Shigeyuki Aomi, Tokyo 
Women’s Medical University, Tokyo, Japan
Background: Abdominal aortic aneurysm (AAA) is a potentially fatal disease that arises 
through a chronic degenerative process associated with atherosclerosis of the aortic wall. 
Recent studies have demonstrated that inﬂammatory response plays an important role in 
atherosclerosis. On the otherhand, delayed hyperenhancement (DE) of aortic wall on CT is 
an important sign for inﬂammation in patients with Takayasu arteritis or inﬂammatory AAA. 
We hypothesized that DE could be detected in the wall of typical atherosclerotic AAA.
Materials and Methods: CT was performed in consequtive 119 patients with clinically 
atherosclerotic AAA (neither inﬂammatory AAA nor Takayasu arteritis was included). 
We evaluated 1) DE in the wall of AAA 2) relationship between DE and size of AAA, 
3) relationship between DE and CRP and risk factors for atherosclerosis, such as age, 
sex, hypertension, hyperlipidemia, diabetes and smoking. We also assessed pathological 
ﬁndings of the resected aortic wall in 12 patients.
Results:  In 71 out of 119AAA patients (59.7%), DE of aortic wall was demonstrated. 
AAA size was signiﬁcantly larger in patients with DE than in patients without DE. 20 out 
of 71 patients with DE underwent graft surgery. Pathology of aortic wall samples obtained 
during surgery revealed that inﬂammatory cell inﬁltrated largely in AAA with DE than in 
AAA without DE, indicating that chronic inﬂammation was occurring in AAA wall.
Conclusions
These data suggest that DE of aortic wall on CT could be a useful sign for the chronic 
inﬂammation of AAA wall, and that inﬂammatory process might play a critical role in AAA 
expansion, leading to the possibility of anti-inﬂammatory therapy against AAA.
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1042-140 Role of Soluble Cell Adhesion Molecules in Assessing 
Disease Activity in Takayasu’s Arteritis
Naveen K. Garg, Vinod Chandran, Naresh Kumar Tripathy, Soniya Nityanand, Nakul 
Sinha, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Background: Takayasu’s arteritis (TA) is a large vessel vasculitis affecting the aorta and 
its main branches. The disease process can be arrested if treated with immunosuppressive 
therapy in early active phase. However, there is no good marker of disease activity. This 
study was done to investigate the role of endothelium derived soluble cell adhesion 
molecules in these patients and to correlate them with disease activity.
Methods: Thirty ﬁve patients of Takayasu’s arteritis diagnosed and classiﬁed as per 
American College of Rheumatology Criteria were studied (Active TA-20, Inactive TA-
15). All patients with Active TA received Azathioprine 2 mg/kg/day and Prednisolone 1 
mg/kg/day (tapered to 7.5 mg/day at 6 months) for 1 year. The soluble cell adhesion 
molecules [E-Selectin (sE-Selectin), Vascular Cell Adhesion Molecule-1 (sVCAM-1) and 
Intercellular Adhesion Molecule-1 (sICAM-1)] were detected by quantitative Enzyme 
Linked Immunosorbent Assay (ELISA) in the sera of all patients and 17 healthy controls. 
In patients with active TA, levels were measured again after 1 year of immunosuppressive 
therapy and were compared with baseline values. 
Results: The levels of sE-Selectin were signiﬁcantly elevated in the patients as compared 
to the controls (54.3 + 35.1 vs.36.5+13.0; p<0.05). However, levels of sVCAM-1 (269.7 
+ 268.9 vs.141.2 + 76.1; p>0.05) and sICAM-1 (280.7 + 177.0 vs.198.3 + 74.3; p>0.05) 
were comparable in patients and controls. There was no signiﬁcant difference in the levels 
of adhesion molecules between the active and inactive groups [sE-Selectin; 44.9 + 20.3 
vs.66.9 + 46.2 (p >0.05), sVCAM-1; 245.9 + 214.5 vs.301.5 + 333.6 (p>0.05), sICAM-1; 
260.9 + 167.9 vs.307.1 + 191.0 (p>0.05)].There was no correlation between the levels of 
Erythrocyte Sedimentation Rate, C-Reactive Protein and the levels of sE-Selectin, sVCAM-
1 and sICAM-1. In the longitudinal study, none of these soluble cell adhesion molecule 
levels showed any signiﬁcant change after 1 year of immunosuppressive therapy.
Conclusion: Our data suggests that sE-Selectin may have an important role in the 
pathogenesis of Takayasu’s arteritis. But, soluble cell adhesion molecules are not the 
markers of disease activity.
1042-141 Implications of Periaortic Hematoma in Patients with 
Acute Aortic Dissection: Insights from the International 
Registry of Aortic Dissection (IRAD)
Debabrata Mukherjee, Kim A. Eagle, Arturo Evangelista, Udo Sechtem, Toru Suzuki, 
Santi Trimarchi, Alfredo Llovet, Truls Myrmel, Patrick T. O’Gara, Jianming Fang, Jeanna 
V. Cooper, Jae K. Oh, James L. Januzzi, Stuart Hutchison, Rossella Fattori, Linda 
A. Pape, Eric M. Isselbacher, Christoph A. Nienaber, on behalf of the International 
Registry of AorticDissection (IRAD) investigators, University of Michigan, Ann Arbor, MI, 
University of Rostock, Rostock, Germany
Background: We analyzed the clinical features, diagnosis, ﬁndings, management and in-
hospital outcomes of patients with periaortic hematoma and acute aortic dissection
Methods: We studied 971 patients with acute aortic dissection with available imaging data 
on presentation with presence or absence of periaortic hematoma.
Results: Patients [n=227 (23.4%)] with periaortic hematoma were more likely to be 
female, have a history of hypertension and atherosclerosis and were more likely to present 
early to the hospital. At presentation, they had greater frequencies of shock, cardiac 
tamponade, coma and/or altered consciousness. Clinical outcomes were signiﬁcantly 
worse in patients with periaortic hematoma including signiﬁcantly higher mortality [33% 
vs 20.3%, p<0.001]. A multivariate model demonstrated periaortic hematoma to be an 
independent predictor of mortality in patients with aortic dissection [OR 1.71, 95% CI 
1.15 - 2.54, P=0.007]. Multivariate analysis in patients with periaortic hematoma identiﬁed 
older age, in hospital renal failure, hypotension/shock or cardiac tamponade and prior 
history of aortic dissection to be independent predictors of in-hospital death [Table 1].
Conclusions: This study provides insight into proﬁles, presentation and outcomes of 
patients with periaortic hematoma and acute aortic dissection. Early identiﬁcation and 
aggressive management of patients with periaortic hematoma may potentially improve 
clinical outcomes.
Clinical outcome and multivariate predictors of mortality in  
patients with aortic dissection 
Periaortic hematoma [+]
N=227
Periaortic 
hematoma [--]
N=744
P value
Mortality [overall] 75 [33.0%] 151 [20.3%] <0.001
--Mortality [Type A] 55 [35.7%] 125 [28.3%] 0..084
--Mortality [Type B] 20 [27.4%] 26 [8.6%] <0.001
Multivariate Predictors of mortality in patients with periaortic hematoma
Age > 70 years 2.19 [1.01 - 4.75] 0.045
Female gender 1.96 [0.91 - 4.21] 0.083
In hospital renal failure 6.33 [1.94 - 20.60] 0.002
Shock/hypotension/
tamponade 4.48 [1.99 - 10.1] <0.001
Presenting syncope 3.08 [1.21 - 7.83] 0.018
1042-142 Raised Levels of Interleukin-6 are Strongly Predictive of 
Short Term Outcome in Patients With Ischaemic Strokes
Loukianos S. Rallidis, Michalis Vikelis, Katerina Kaliva, Georgios Liakos, Ioannis Rizos, 
Dimitrios T. Kremastinos, University General Hospital, Attikon, Athens, Greece, Athens 
Naval Hospital, Athens, Greece
Background: elevated levels of interleukin-6 (IL-6) are associated with adverse outcome 
in coronary patients, especially in the setting of acute coronary events. We examined the 
short-term prognostic value of IL-6 in patients (pts) with ischaemic strokes.
Methods: we recruited 113 consecutive pts, under the age of 65 years (mean age=53±8 
years, men=71) who admitted to the Neurology Department with the diagnosis of non-
haemorrhagic stroke. Pts in atrial ﬁbrillation were excluded. The diagnosis was conﬁrmed 
with a computed tomography or magnetic resonance imaging of the brain within 24 hours 
of the admission. IL-6 levels were determined within 24 hours from admission by high 
sensitivity enzyme-linked immunoassay.
Results: 8 pts had an eventful in-hospital course. As event was deﬁned a deterioration in 
neurological status which was fatal in 7 cases. The table presents the results.
eventful course (n=8) uneventful course (n=105) p
age (years) 56±13 54±7 NS
male/female 4/4 67/38 NS
hypertension (%) 87.5 62 0.02
diabetes mellitus (%) 75 29.5 0.02
smoking (%) 50 59 NS
total cholesterol (mg/dl) 215±68 233±53 NS
interleukin-6 (pg/ml) 20.4 (9.2-26) 4 (2.2-8.5) 0.002
In a logistic regression model with outcome as dependent variable and age, sex, 
hypertension, diabetes mellitus, smoking, hypercholesterolaemia (total cholesterol>220 mg/
dl) and IL-6 as predictor variables, IL-6 was an independent predictor of short-term outcome 
with an adjusted odds ratio for event of 3.4 (95% conﬁdence interval 1.3-9.1, p=0.01).
Conclusions: increased levels of IL-6 in pts with ischaemic strokes predict a worse short-
term prognosis. Whether increased IL-6 levels represent an epiphenomenon or play an 
active role in the deterioration of non-haemorrhagic strokes remains to be elucidated.
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1043-119 Who Has Resistance to Weight Loss and Rebounds 
Weight Gain?
Kazuko Masuo, Tomohiro Katsuya, Yuxiao Fu, Hiromi Rakugi, Toshio Ogihara, Michael 
L. Tuck, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan, 
Sepulveda VA Medical Center and UCLA School of Medicine, Sepulveda, CA
Background A successful weight loss (WL) program is essential for treatment for obesity 
related-diseases. As the majority of individuals do not succeed in WL or WL maintenance, 
the present study evaluates the mechanisms of how individuals had resistance to WL or 
rebound weight gain.
Methods 225 overweight Japanese men enrolled in a WL program. They were measured 
BMI, total body fat mass, blood pressure (BP), plasma norepinephrine (NE) and leptin 
levels and genotypes of α2 (418C/G, ADRA), β2 (Arg16Gly, ADRB2-16, Gln27Gly, ADRB2-
27) and β 3(Try64Arg, ADRB3)-adrenoreceptors every 6 months for 2 years. Maintenance 
of WL was deﬁned as a signiﬁcant WL (≥10% reduction from entry) at 6 months and 
maintenance of WL for the following 18 months (WL-sensitive group). Rebound weight 
was deﬁned as a signiﬁcant WL at 6 months but subsequent weight gain over the next 18 
months. WL resistance was deﬁned as failure to WL over 24 months.
Results 65 subjects maintained WL, 74 had rebound weight gain and 53 had resistance 
to WL. BMI at entry was similar among the 3 groups, whereas total fat mass at entry was 
greater in the group with WL-resistance > rebound weight gain > maintenance of WL. In 
all subjects, total fat mass, diastolic BP, plasma NE and leptin at entry were signiﬁcant 
determinant factors for changes in fat mass over 24 months (P=.006). Ratios of plasma 
NE and leptin to fat mass did not change over 24 months. The ratio of NE to fat mass was 
lower in subjects with maintenance of WL < rebound weight < WL resistance. The ratio of 
leptin to fat mass was greater in subjects with WL-resistance > maintenance = rebound 
weight. WL-resistant subjects had frequently C allele in ADRB2-27 (P=.003) and C allele 
in ADRB3 (P=.003) than WL-sensitive subjects. Subjects with rebound weight gain had 
frequently G allele in ADRA (P=.011), C allele in ADRB2-16 (P=.004), G allele in ADRB2-
27 (P<.001), T allele in ARDB3 (P=.029) than subjects with maintenance of WL.
Conclusions These results demonstrate that degree of adiposity and sympathetic 
overactivity appear to predict individuals who have resistance to WL and rebound weight 
gain. The different relations in sympathetic activity and leptin to adipose-mass appear to 
be linked to genetic background.
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1043-120 Aldosterone Blockade Alteres Intracellular Ca2+ 
Handling and Improves Impaired Contractile And 
Relaxation Reserve In Patients With Mild Dilated 
Cardiomyopathy
Hideo Izawa, Kohzo Nagata, Koji Obata, Tomoko Kato, Hiroyuki Asano, Satoru Ohshima, 
Akira Yamada, Yosuke Murase, Satoshi Isobe, Sahoko Ichihara, Yasuya Inden, Kenji 
Okumura, Toyoaki Murohara, Mitsuhiro Yokota, Nagoya University, Nagoya, Japan, Mie 
University, Tsu, Japan
Background. Aldosterone blockade is reported to reduce mortality in patients with 
heart failure, but the underlying mechanisms are uncertain. This study was designed to 
investigate effects of spironolactone on myocardial property associated with alteration 
of sarcoplasmic reticulum (SR) functions in patients with mild dilated cardiomyopathy 
(DCM).
Methods. We calculated the maximum ﬁrst derivative of left ventricular (LV) pressure 
(LV dP/dtmax) and the LV pressure half-time (T1/2) during right atrial pacing in 12 DCM 
patients with a New York Heart Association functional class I, and 7 control subjects. 
LV endomyocardial tissue was obtained in the DCM patients, and mRNA levels of Ca2+-
handling proteins were quantiﬁed by use of a quantitative reverse transcription-polymerase 
chain reaction method. The DCM patients were then treated with spironolactone in addition 
to their drug regimen for 12 months, after which the same procedures were performed.
Results. The increase in LV dP/dtmax and the decrease in T1/2 during pacing were 
attenuated in the DCM patients compared with those in control subjects (LV dP/dtmax; 
9+/-4% vs. 24+/-5%, T1/2; 8+/-3% vs. 14+/-3%). After treatment with spironolactone, the 
increase in LV dP/dtmax (16+/-5%) and the decrease in T1/2 (13+/-3%) during pacing were 
ameliorated in the DCM patients. Both mRNA expressions of SR Ca2+-ATPase (SERCA2) 
and ryanodine receptor-2 (RYR2) before treatment with spironolactone were signiﬁcantly 
increased compared with those after treatment, whereas no signiﬁcant changes in the 
mRNA expressions of phospholamban, calsequestrin, and Na+/Ca2+ exchanger were 
apparent between before and after treatment.
Conclusions. These results suggest that spironolactone causes up-regulation of both 
SERCA2 and RYR2 mRNAs, resulting in altered Ca2+ handling, and improves impaired LV 
contractile and relaxation reserve in mild DCM patients.
1043-121 Efﬁcacy and Safety of the Novel Selective Nicotinic 
Receptor Partial Agonist Varenicline for Smoking 
Cessation
Cheryl Oncken, Eric Watsky, Karen Reeves, Rich Anziano, The Varenicline Study Group, 
University of Connecticut School of Medicine, Farmington, CT, Pﬁzer Global Research 
and Development, Groton/New London, CT
Background: Varenicline is a selective nicotinic receptor partial agonist in development as 
a novel treatment for smoking cessation. We evaluated the efﬁcacy, safety, and tolerability 
of different varenicline doses for smoking cessation in cigarette smokers.
Methods: Varenicline was evaluated in healthy smokers (18-65 years) in two phase 2 
multicenter, double-blind, randomized, placebo-controlled trials. In study 1, subjects were 
randomized to varenicline 0.3 mg once daily (n=128), 1.0 mg once daily (n=128), or 1.0 
mg twice daily (n=127) for 6 weeks plus placebo for 1 week versus 150 mg sustained-
release bupropion twice daily (titrated over Week 1; n=128) or placebo (n=127) for 7 
weeks. In study 2, subjects were randomized to varenicline 0.5 mg twice daily with and 
without titration (n=259), 1.0 mg twice daily with and without titration (n=259), or placebo 
(n=129) for 12 weeks.
Results: As shown in Table 1, smoking cessation rates were signiﬁcantly higher for 
varenicline 1.0 mg once daily and bupropion compared with placebo. The efﬁcacy of 
varenicline was greatest with 1.0 mg twice daily. Varenicline was safe and well tolerated; 
titration in study 2 mitigated the mild to moderate self-limiting nausea. 
Table 1 
4-week
ﬂoating window
(any 28-day period)
continuous quit rates
(CQRs)
Carbon monoxide-
conﬁrmed
4-week CQRs
(Week 9-12
analysis)
P-value
vs placebo
Study 1
0.3 mg varenicline once daily
1.0 mg varenicline once daily
1.0 mg varenicline twice daily
150 mg bupropion twice daily
Placebo
28.6%
37.3%
48.0%
33.3%
17.1%
ns
P=0.0003
P<0.0001
P=0.0022
-
Study 2
0.5 mg twice daily pooled
1.0 mg twice daily pooled
Placebo
45.1%
50.6%
12.4%
P<0.0001
P<0.0001
-
ns = non-signiﬁcant
Conclusion: Varenicline 1.0 mg to 2.0 mg daily promoted smoking cessation and was 
well tolerated. Varenicline 1.0 mg twice daily was associated with a higher smoking quit 
rate than bupropion or placebo.
1043-122 A Clinically Practicable Diagnostic Score For Metabolic 
Syndrome Improves Its Predictivity Of Diabetes Mellitus
Alejandro Macchia, Gianni Tognoni, Luigi Tavazzi, Maria Grazia Franzosi, Giacomo 
Levantesi, Rosa Maria Marﬁsi, Gian Luigi Nicolosi, Roberto Marchioli, Consorzio Mario 
Negri Sud, Santa Maria Imbaro, Italy
Background: Metabolic syndrome (MS) is associated with late onset diabetes. However, 
diagnostic criteria for each individual component of MS are based on categorical/arbitrary 
cut points.
Objective:To generate a diagnostic score for MS (MS-Score) aimed at predicting 
diabetes by giving appropriate weight to individual components used for the diagnosis 
of MS.
Methods:Out of 11,323 patients with prior MI and followed for 3.5 years in the GISSI-
Prevenzione study, 3,855 subjects with diabetes at baseline or missing information 
were excluded. Cox model including age, sex, glycemia, HDL-cholesterol, triglycerides, 
hypertension, and body mass index was ﬁtted to create the MS-score. The prognostic 
performance of the MS-score was compared to that of the diagnostic criteria of MS as 
deﬁned by NCEP/ATPIII (MS-ATP).
Results:900 out of 7,468 patients developed diabetes during follow-up. As compared 
with patients in the lowest quintile (Q1) of the score, those who were classiﬁed in the 2nd 
to the 5th quintile had signiﬁcantly higher relative risks of becoming diabetic (Q2 1.46, Q3 
1.98, Q4 3.29, Q5 6.35). A cut-off point of 28 for the MS-Score was the best compromise 
between sensitivity and speciﬁcity for MS diagnosis. 310 (7.0%) subjects out of 4,419 
without MS according to the MS-Score developed diabetes, while 630 out of 3,049 
(20.7%) subjects with MS according to the MS-Score became diabetic (RR 3.22, 95% 
CI 2.81 to 3.68, P<0.0001). Comparing the performance of MS-Score to that of MS-ATP, 
four groups of patients were identiﬁed: 3,523 patients without MS according to both MS-
ATP and MS-Score criteria (incidence of diabetes 6.8%, RR = 1.00), 896 patients with 
MS according to ATP-III criteria but not to the MS-Score criterion (incidence of diabetes 
8.0%, RR 1.20, 95% CI 0.92 to 1.56, P = 0.18), 1,214 patients with MS according to MS-
Score but not to the ATP-III criteria (incidence of diabetes 17.8%, RR 2.84, 95% CI 2.36 
to 3.42, P < 0.0001), and 1,835 with MS according to both diagnostic criteria (incidence of 
diabetes 22.6%, RR 3.68, 3.14 to 4.32, P < 0.0001).
Conclusion:The MS-Score improves the prediction of diabetes development by using 
the full informative content of the individual components for diagnosis of MS.
1043-123 Black Hypertensives Have Signiﬁcantly Lower B-
Natriuretic Peptide Levels Than South Asians Or Whites
Andrew Sharp, Simon Thom, Alun Hughes, Darrel Francis, Alice Stanton, Eoin O’Brien, 
Desmond Fitzgerald, Denis Shields, Neil Poulter, Peter Sever, Jamil Mayet, International 
Centre for Circulatory Health, St Mary’s Hospital and Imperial College, London, United 
Kingdom, Royal College of Surgeons of Ireland, Dublin, Ireland
Background: B-Natriuretic peptide is rapidly becoming incorporated into the management 
algorithms for exacerbations of heart failure. Uses are expanding, with suggested roles 
in the risk stratiﬁcation of acute coronary syndromes, the identiﬁcation of diastolic 
dysfunction, and the screening of populations for cardiovascular abnormalities or future 
cardiovascular risk. Several factors are known to inﬂuence baseline levels of BNP, with 
age, gender, renal function and cardiac structural abnormalities chief amongst them. Little 
is known about the effects of ethnicity on BNP. This sub-study of the Anglo-Scandinavian 
Cardiac Outcomes Trial (ASCOT) looks at a cohort of hypertensives and assesses 
variations in BNP levels according to ethnicity.
Methods: This ASCOT sub-study examined 562 subjects recruited from a single centre (53 
Black, 42 South Asian, 28 of mixed ethnicity and 439 White), located in an ethnically diverse 
area of North-West London, England, to see if ethnic factors inﬂuenced BNP levels.
Results: There was clear evidence of a difference in BNP between ethnicities. Blacks 
had signiﬁcantly lower BNP levels (16.5pg/ml) than either Whites (28.5pg/ml, p<0.0001) 
or South Asians (24.6pg/ml, p=0.02). Multivariate analysis conﬁrmed ethnicity remained 
highly signiﬁcant (p=0.001) even after correction for other factors inﬂuencing BNP, namely 
age (p<0.0001), renal function (p=0.0005) and LVMI (p=0.04). Also included in the 
analysis were gender, ejection fraction, body surface area, diabetes and smoking, which 
were found to not have a signiﬁcant effect on BNP.
Conclusion: White hypertensives have a 73% higher baseline level of BNP than Blacks, 
while South Asians have intermediate levels.
Previously published studies on the clinical applications of BNP should be interpreted in 
light of these ﬁndings
1043-124 Effect of Hormone Replacement Therapy on Plasma 
Lipoproteins and Apolipoproteins, Endothelial Function 
and Myocardial Perfusion in Postmenopausal Women 
With Estrogen Receptor-Alpha IVS1-401 C/C Genotype 
and Established Coronary Artery Disease
Ayse Emre, Sinan Sahin, Can Erzik, Mahmut Cakmak, Dilaver Oz, Ekrem Ucer, Aycan 
Esen, Muhammed Gurdogan, Ali Buturak, Birsen Ersek, Siyami Ersek Thoracic and CV 
Surgery Center, Istanbul, Turkey, Marmara University Medical Faculty, Istanbul, Turkey
Background: Associations between various estrogen receptor-� (ER) polymorphisms 
and clinical phenotypes have been studied, including body mass index, lipid levels and 
coronary atherosclerosis. We studied 48 postmenopausal women to determine the effect 
of ER-� IVS1-401 polymorphism on the response to treatment with hormone replacement 
therapy (HRT).
Methods: The study had a randomized, double-blind, placebo-controlled and crossover 
design. Patients were divided into 2 groups according to ER-� IVS1-401 polymorphism: 
CC genotype (n=9); CT or TT genotype (n=39). HRT was given continuously for 4 weeks, 
with 4-week washout periods between the treatment periods. Brachial artery doppler and 
Tl-201 scintigraphy were performed at the end of each treatment period. Blood samples 
were taken for hormone, lipoprotein, apolipoprotein and C-reactive protein levels.
Results: HRT lowered total cholesterol, LDL-c and Apo-B levels from baseline values 
(all p<0.05) and to a similar degree in CC and CT/TT genotype patients. HRT increased 
estradiol, HDL-c and Apo-1 levels relative to baseline values, but to a greater degree in 
CC patients (p=0.04, p=0.05, and p=0.04 by ANOVA, respectively). HRT increased C-
reactive protein levels signiﬁcantly only in the CT/TT patients (p<0.05). HRT increased 
peak forearm blood ﬂow, brachial artery diameter during reactive hyperemia and 
endothelium-dependent dilation (EDD) in both groups, but to a greater degree in CC 
patients (p=0.03, p=0.03, and p=0.04 by ANOVA, respectively). Total stress (TSS) and 
redistribution scores (TRS) were also more markedly reduced in CC patients (p=0.04, and 
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p=0.05 by ANOVA, respectively). The increase in estradiol levels was strongly correlated 
with the improvement in EDD (r=0.66, p<0.01), which in turn showed negative correlation 
with TSS (r=-0.62, p<0.01) and TRS (r=-0.52,p<0.05) in the CC genotype group.
Conclusion: These data suggest that the improvement in EDD and the reduction 
in perfusion abnormalities by increasing estradiol levels with HRT in postmenopausal 
women with coronary artery disease may differ with respect to different genotypes, the 
effect being more prominent in those patients with ER-� IVS1-401 CC genotype.
1043-125 Follow-Uup of Patients With Left Ventricular Left 
Ventricular (LV) Enlargement: Endothelium-Dependent 
Coronary Vasodilation and Brain Natriuretic Peptide 
(BNP) as Predictors of Mid-Term LV Remodeling
Yuichi Ninomiya, Shuichi Hamasaki, Keishi Saihara, Yutaka Otsuji, Sanemasa Ishida, 
Tetsuro Kataoka, Hideki Okui, Koji Orihara, Tsuyoshi Fukudome, Takuro Shinsato, 
Tomoko Ichiki, Etsuko Mizoguchi, Shinichi Minagoe, Chuwa Tei, Kagoshima University, 
Kagoshima, Japan
Background: The present study investigated the mechanisms of left ventricular (LV) 
remodeling by assessing the role of coronary hemodynamics in association with brain 
natriuretic peptide (BNP) in the prediction of improvement in LV remodeling in patients 
with LV enlargement. 
Methods and Results: The study population consisted of 39 patients (mean age, 58±17 
years) with left ventricular enlargement (LV end-diastolic diameter>55 mm) and normal 
coronary arteries underwent Doppler ﬂow study of the left anterior descending coronary 
artery. Vascular reactivity was examined by intra-coronary administration of papaverine 
(12.5 mg / 20 sec), acetylcholine (Ach) (3 and 30µg / 2min), and nitroglycerin (200µg 
/ 20 sec) using a Doppler guidewire. Echocardiographic assessment was performed at 
baseline and repeated at follow-up (mean intervals, 266±48 days). The percent change 
during follow-up in LV ejection fraction, Mitral E-to-A ratio, LV end-diastolic diameter 
(LVDd), LV end-diastolic volume (LVEDV), and LV mass were estimated. The percent 
increase in coronary blood ﬂow (CBF) induced by Ach had inverse correlations with 
the percent change in LVDd (r=−0.53, p<0.05), LVEDV (r=−0.51, p<0.05), and LV mass 
(r=−0.61, p<0.01), whereas BNP had positive correlations with the percent change in 
LVDd (r=0.45, p<0.02), LVEDV (r=0.45, p<0.05), and LV mass (r=0.50, p<0.01). 
Conclusions: These results demonstrate that impaired endothelium-dependent 
vasodilation of the resistance coronary artery has an inhibiting effect on improvement in 
mid-term LV remodeling. Furthermore, elevated levels of BNP may identify patients who 
are at risk of developing LV remodeling.
1043-126 Prevalence, Proﬁle, and Predictors of Aspirin 
Resistance Measured By the Ultegra Rapid Platelet 
Function Assay-ASA in Patients with Coronary Artery 
Disease
Wai-Hong Chen, Pui-Yin Lee, William Ng, Jeanette Yat-Yin Kwok, Xi Cheng, Hung-Fat 
Tse, Chu-Pak Lau, Queen Mary Hospital, The University of Hong Kong, Hong Kong, 
People’s Republic of China
Background: Aspirin resistance has been linked to ischemic events in patients with 
cardiovascular disease. We studied aspirin resistance in patients with coronary artery 
disease (CAD) using a point-of-care platelet inhibition assay which has been shown to 
correlate with adverse outcome after percutaneous coronary intervention.
Methods: Platelet inhibition was measured using the Ultegra Rapid Platelet Function 
Assay-ASA (RPFA-ASA; Accumetrics, San Diego, CA) in 468 CAD patients receiving 
aspirin ≥ 4 weeks. Results are expressed as Aspirin Reaction Units (ARU). ARU ≥ 550 
indicates the absence of aspirin-induced platelet dysfunction based on correlation with 
epinephrine-induced light transmission aggregometry.
Results: Aspirin resistance was noted in 128 (27.4%) patients with the following 
characteristics: age 66.7±10 years, female 46.1%, current smoker 11.5%, diabetes 
mellitus 39.1%, hypertension 72.7%, hyperlipidemia 68.8%, renal insufﬁciency 18.8%, 
and aspirin dose 80 to 100 mg in 90.6%. Predictors of aspirin resistance are listed in 
the Table.
Conclusion: More than a quarter of CAD patients are resistant to aspirin’s antiplatelet 
effect. Elderly, female, renal insufﬁciency, a low hemoglobin level, and a low prescribed 
dose of aspirin are predictors of aspirin resistance. Alternate or additional antiplatelet 
therapy may be considered in this population at increased risk of ischemic events.
Predictors of Aspirin Resistance 
Univariate Predictors
p value Odds Ratio 95% Conﬁdence Intervals
Age 0.002 1.03 1.010, 1.049
Women <0.0001 2.53 1.651, 3.863
Hemoglobin 0.000 0.58 0.502, 0.675
Renal insufﬁciency 0.011 2.15 1.213, 3.800
Aspirin dose 0.002 0.99 0.975, 0.998
Multivariate Predictors
Hemoglobin 0.000 0.60 0.513, 0.694
Aspirin dose 0.017 0.99 0.978, 0.998
1043-127 Adverse Events With Concomitant Amiodarone and 
Statin Therapy
Alawi A. Alsheikh-Ali, Richard H. Karas, Tufts-New England Medical Center, Boston, MA
Background: Increased risk of an adverse drug interaction has been reported with 
concomitant simvastatin and amiodarone use, both of which are metabolized by CYP3A4. 
We sought to explore the clinical signiﬁcance of the observed simvastatin-amiodarone 
interaction, and determine if this risk applies to other commonly used statins.
Methods: We reviewed adverse event reports (AERs) to the Food and Drug 
Administration from 1990 through March 2002. The percentage of statin-associated AERs 
noting concomitant amiodarone use was determined for simvastatin, atorvastatin and 
pravastatin. Atorvastatin, like simvastatin is metabolized by CYP3A4, whereas pravastatin 
is not. AERs affecting the following organs were analyzed: muscle, liver, pancreas, and 
bone marrow.
Results: Concomitant amiodarone use was reported in similar proportions of the 
simvastatin and atorvastatin-associated AERs (1% versus 0.7% respectively, p = ns). 
In contrast, fewer of the pravastatin-associated AERs noted concomitant amiodarone 
use (0.4%, p<0.05 versus simvastatin). Muscle toxicity was the most commonly reported 
statin-amiodarone adverse event (77% of AERs). Reported adverse events tended to 
occur in older male patients (mean age 76), who were on multiple other drugs (mean 
number of other drugs 5). The simvastatin-amiodarone AERs had a larger mean statin 
dose than the atorvastatin-amiodarone AERs (37 mg versus 15 mg respectively, p=0.001), 
and were more likely to list hospitalization as an outcome (75% versus 36% respectively, 
p=0.001). Death occurred in 6% of the simvastatin-amiodarone AERs versus 14% of the 
atorvastatin-amiodarone AERs (p=ns). As a control, a similar analysis of concomitant 
usage of diuretics, ACE-inhibitors, digoxin and warfarin demonstrated no signiﬁcant 
differences between the three statin-treated groups.
Conclusion: Atorvastatin, but not pravastatin, carries a similar risk of adverse drug 
interaction when used with amiodarone, as does simvastatin. While the absolute risk 
of adverse events with statins is low, clinicians should be vigilant about muscle related 
complaints in patients on a statin and amiodarone. Use of a statin not metabolized by 
CYP3A4 may be appropriate in this setting.
1043-128 Platelet Clumping In Peripheral Smear In Patients On IV 
Tiroﬁban (glycoprotein IIb/IIIa Inhibitor).
Nagender Mankan, Mohammad Razaq, Anil Gupta, Ashok Khanna, Shafkat Hussain, 
Gloria Fernandez, Coney Island Hospital, Brooklyn, NY
Background: Peripheral blood smears from ﬁngerstick specimens normally show 
a variable number of platelet clumps. This is believed to be due to platelet activation 
during the preparation and exposure of GpIIb/IIIa receptors. Congenital lack of GpIIb/
IIIa receptors such as seen in Glanzman’s thrombasthenia is characterized by presence 
of single unclumped platelets in peripheral blood smears. GpIIb/IIIa antagonists such 
as Tiroﬁban cause Glanzman’s thrombasthenia-like defect and would be expected to 
inhibit platelet clumping in peripheral blood smears. Tiroﬁban, is increasingly used by 
cardiologists for the treatment of acute coronary syndrome. It is given intravenously and 
thought to be particularly effective because of inhibition of the ﬁnal common pathway of 
platelet aggregation.
Methodology/results: We retrospectively analyzed blood smears from ﬁngerstick 
preparations of 20 patients on Tiroﬁban and 20 controls, for the presence of platelet 
clumps. The patients were referred to the hematology service by cardiologists, mostly 
for workup of anemia or presence of hypercoagulable state. Slides were prepared from 
patients while they were on Tiroﬁban infusion. All 40 slides were blinded. 200 platelets 
were counted on each slide at 50x magniﬁcation by hematology fellows under the 
supervision of hematology attending physicians. Platelets were classiﬁed as single 
unclumped platelets, platelets in clumps of 2, 3, 4, or 5 and over. More than 90% of 
platelets were single unclumped in 16 of 20 patients on Tiroﬁban, while more than 90% of 
platelets were single unclumped in only 2 of 20 patients in the control group.
Conclusion: GpIIb/IIIa antagonists are increasingly used for patients with acute coronary 
syndrome. The inhibition of platelet clumping in peripheral blood smears of patients on 
these agents has not been studied. We found a signiﬁcant decrease of platelet clumping 
in patients on Tiroﬁban as compared to controls. Further study is needed to conﬁrm 
this observation and correlate it with the clinical beneﬁt in patients with acute coronary 
syndrome. This will be a simple, inexpensive test that may be used to correlate with 
response or possible need for dose adjustment.
1043-129 St. John’s Wort Enhances the Platelet Inhibitory Effect 
of Clopidogrel in Clopidogrel “Resistant” Healthy 
Volunteers
Wei C. Lau, David GM Carville, Kirk E. Guyer, Charlene J. Neer, Eric R. Bates, University 
of Michigan Health System, Ann Arbor, MI, Indiana University, South Bend, IN
Background: We previously reported that the variability in platelet aggregation inhibition 
with clopidogrel correlated with the metabolic activity of cytochrome P450 (CYP)3A4. St 
John’s Wort (SJW), an herb, genetically induces CYP3A4 expression mediated by nuclear 
pregnane X receptor response element to increase hepatic CYP3A4 enzymatic activity. 
This study was designed to determine whether SJW would enhance the platelet inhibitory 
effect of clopidogrel in non-responder and low-responder (clopidogrel “resistant”) 
subjects.
Methods: We identiﬁed 5 healthy clopidogrel “resistant” subjects (relative decrease in 
platelet aggregation < 30% using Plateletworks™ whole blood aggregometry and 20µM 
ADP at 0, 2, 4, and 6 hours after clopidogrel 450 mg). After a 14 day washout period, 
subjects were treated with SJW 300 mg, three times daily for 14 days. Platelet aggregation 
was again measured at 0, 2, 4, and 6 hours after clopidogrel 450 mg. With each subject 
as his own control, the platelet aggregation proﬁle of clopidogrel was compared before 
and after SJW.
Results: After coadministration with SJW, clopidogrel signiﬁcantly inhibited platelet 
aggregation (Figure). Similar results were obtained with light transmission aggregometry.
Conclusion: This herb-drug interaction increases CYP3A4 activity, converting clopidogrel 
non- and low-responders to clopidogrel responders.
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1043-130 N-Terminal Pro-B-Type Natriuretic Peptide as a 
Prognostic Marker in Acute Coronary Syndrome
Sung Uk KWON, Kyung Kee Baek, Seong-Hoon Lim, Jung-Il Park, Soo-Jin Lim, Dae-
Kyung Cho, Sun-Woon Kim, Jin Ho Choi, Hyun-Cheol Gwon, Sang Hoon Lee, Kyung 
Pyo Hong, Jeong Euy Park, Eun-Seok Jeon, Sungkyunkwan University School of 
Medicine, SEOUL, South Korea
Background: The N-terminal fragment of the BNP prohormone (NT-proBNP), which is 
synthesized by cardiac ventricles in response to increased wall stress, may be a prognostic 
marker in ACS. We assessed the relation between NT-pro BNP levels on admission and 
major adverse cardiovascular events (MACEs) in a cohort of patients with ACS.
Methods: From October 2002 to April 2004, a prospective study of 176 patents with 
78 ST-elevation myocardial infarction (STEMI), 32 non-ST elevation MI (NSTEMI) and 
66 unstable angina (UA) was carried out. Blood samples for NT-proBNP determination 
were obtained on admission. Patients were followed concerning MACEs (death, MI, heart 
failure, stroke, revascularization) for 7 months in median.
Results: 22 patients (13%) had events. Mean NT-proBNP levels were signiﬁcantly lower 
in event-free survivors than in patients with events (1342±1598 versus 6129±6522 pg/
mL, p <0.0001). The optimal cut-off value of NT-proBNP levels using receiver-operating-
characteristic curve was 1445 pg/mL (Figure 1). The unadjusted risk ratio of patients 
with NT-proBNP levels greater than the threshold was 7.0 (95% CI, 2.6 to 19.0). In a 
multivariate Cox regression model including clinical background factors and other 
biochemical markers, the NT-proBNP levels were the most powerful indicator of MACEs 
(risk ratio, 8.0 [95% CI, 1.7 to 37.1]).
Conclusion: A single measurement of NT-proBNP on admission appears to be useful as 
a prognostic factor to predict MACEs in patients after ACS. 
1043-133 Are Claims of Non-inferiority of Ximelagatran Relative 
to Warfarin in SPORTIF-V Sufﬁciently Justiﬁed?
Sanjay Kaul, George Diamond, Cedars-Sinai Medical Center, Los Angeles, CA
Background: Non-inferiority (NI) trials are analyzed by: a) a test of a one-sided 
hypothesis that the new treatment is inferior to standard (active control) treatment by a 
pre-deﬁned margin; and b) determination of fraction of the control effect retained by the 
new treatment.
Objective: We performed sensitivity analyses to assess the impact of choice of margin 
and fraction on data from SPORTIF V, a trial of ximelagatran (X) versus warfarin (W) for 
prevention of stroke and systemic embolism in nonvalvular atrial ﬁbrillation.
Methods: Annualized event rates were 1.65% for X and 1.19% for W, an absolute 
difference of 0.45% (95% CI, -0.13-1.03%). Because the upper bound of 1.03% lies 
below the pre-speciﬁed margin of 2%, investigators concluded that NI was established. 
Sensitivity analyses were performed across 3 margins and fractions (table). The margins 
correspond to a relative risk (RR) of 2.68, 1.84 and 1.42. A margin of <1.2 RR and a 
fraction of 0.5 are commonly accepted criterion for NI. A 1-tailed P value of <0.025 was 
used to conclude NI.
Results: NI is established at a margin >1.0% and a fraction of <0.3, but not at lower 
margins or higher fractions. In contrast to the “ofﬁcial” conclusion of NI based on marginal 
analysis, the fractional analyses do not support NI in SPORTIF-V.
Conclusions: Because NI depends on one’s choice of margin and fraction, a sensitivity 
analysis should be performed to deﬁne the robustness of these choices. Lower margin 
and higher fraction indicates stronger evidence of non-inferiority.
 
Margin (%/yr) Fraction, active control
2.0 1.0 0.5 0.8 0.5 0.3
P value <0.0001 0.034 0.438 0.645 0.124 0.025
1043-134 The Impact Of Gender Difference In The Effects Of 
Preinfarction Angina On Microvascular Damage With 
Reperfused Myocardial Infarction
Shinobu Hosokawa, Yoshikazu Hiasa, Yoshikazu Ohara, Naoki Suzuki, Takefumi 
Takahashi, Tokushima Red Cross Hospital, Komatsushima, Japan
Objectives: Few studies have addressed gender differences in evoking preconditioning. 
In experimental study, it was reported that the preconditioning effect disappeared 
after gonadectomy. We sought to determine the effects of preinfarction angina (PA) on 
myocardial damage and gender difference. 
Methods: We studied 194 patients with anterior myocardial infarction who underwent 
successful angioplasty. All patients underwent myocardial contrast echocardiography 
2weeks after PCI. Contrast defect was calculated as contrast defect area/myocardial 
area. Typical angina occurring in the 24hr preceding myocardial infarction, was present in 
88(23women) patients; group PA and absent in 106(30women) patients; group non-PA. All 
women are postmenoposal women. 
Results: The contrast defect size and peak CPK of women were signiﬁcantly higher 
than that of men in group PA(18±5%vs10±4%,p<0.01 and 5000±751U/L vs2478±283IU/
L,p<0.005). The functional status of the myocardium among group PA, as expressed by risk 
area wall motion score index, was better in men than in women at 14days(1.1±0.5vs1.8±0.6; 
p<0.01) and at 6 month (0.8±0.4vs1.6±0.7;p<0.01). However there were no signiﬁcant 
difference in group non-PA. Multivariate regression analysis showed that women (p<0.01) 
was the signiﬁcant índependent preditor for microvascular damage. 
Conclusions: These ﬁndings suggest that preconditioning effects was attenuated in 
women with reperfused anterior myocardial infarction.
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1044-95 Effective Attenuation of Electronegative LDL-Induced 
Endothelial Cell Apoptosis by Gene Silencing of the 
Lectin-Like Receptor for Oxidized LDL
Jonathan Lu, Jun-Hai Yang, Hsin-Hung Chen, Chao-Yuh Yang, Philip D. Henry, Jeffrey P. 
Walterscheid, Joel D. Morrisett, Tatsuya Sawamura, Chu-Huang Chen, Baylor College of 
Medicine, Houston, TX, National Cardiovascular Research Institute, Osaka, Japan
Background: We showed previously that L5, a highly electronegative LDL subfraction 
isolated from hypercholesterolemic human plasma, can induce marked apoptosis 
in vascular endothelial cells (EC). LOX-1 is a lectin-like receptor known to mediate 
various effects of experimentally oxidized LDL. To conﬁrm the contribution of LOX-1 to 
atherosclerosis, we examined its role in L5-induced EC apoptosis in the absence of in 
vitro oxidation.
Methods: L5 was isolated from hypercholesterolemic (LDL-C > 160 mg/dL) human 
plasma LDL following subfractionation with ion exchange chromatography. LOX-1 
expression and apoptotic signaling were examined in bovine aortic EC (BAEC) exposed 
to L5 with or without LOX-1 gene silencing by a combination of speciﬁc siRNAs against 
the bovine LOX-1.
Results: In cultured BAEC, L5 (50 µg/mL) induced a twofold increase in LOX-1 expression 
and a 40% to 50% apoptosis within 24 hours. Concomitantly, the protein and mRNA 
levels of ﬁbroblast growth factor 2 (FGF2), a potent antiapoptotic protein, was reduced by 
half. FGF2-dependent Akt phosphorylation and Bcl-2 expression were also signiﬁcantly 
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reduced. In BAEC transfected with a combination of 4 LOX-1-speciﬁc siRNAs, the baseline 
LOX-1 protein level was decreased by 80% and the L5-induced augmentation of LOX-1 
expression was prevented. LOX-1 gene silencing with LOX-1 siRNAs also signiﬁcantly 
attenuated the inhibitory effects of L5 on FGF2 expression, Akt phosphorylation, and Bcl-
2 expression. Neutralizing the LOX-1 receptor with a speciﬁc neutralizing antibody, JTX-
20, yielded similar protective effects against L5 in a concentration-dependent manner.
Conclusions: L5, a circulating proapoptotic LDL subfraction, stimulated the expression of 
the LOX-1 receptor in vascular EC. By genetic silencing or pharmacological neutralization 
of LOX-1, the apoptotic signaling of L5 can be effectively attenuated. Because EC apoptosis 
contributes to the initiation and progression of atherosclerosis, our results conﬁrm the role 
of LOX-1 in transducing the atherogenic signaling of LDL in hypercholesterolemia.
1044-96 Effects of Macrophage Colony-Stimulating Factor on 
Cholesterol Biosynthesis in Mice
Subhash Tripathi, Shuang Chen, Arun Shukla, Petros Anagnostidis, Pinky Tripathi, 
Terence Doherty, Sara Bassilian, Wai-Nang Paul Lee, Prediman Shah, Tripathi B. 
Rajavashisth, Cedars-Sinai Medical Center, Los Angeles, CA, Harbor-UCLA Medical 
Center, Torrance, CA
Macrophage-colony stimulating factor (M-CSF or CSF-1) has been found to reduce total 
serum cholesterol levels when administered to patients. Conversely, osteopetrotic (Csf1op/
Csf1op) mice that lack M-CSF due to a structural gene defect exhibit hypercholesterolemia. 
The cholesterol lowering effect of M-CSF may be anti-atherogenic. Studies have also 
shown that increased expression of M-CSF in the vessel wall promotes experimental 
atherosclerosis. The underlying mechanism for these paradoxical effects of M-CSF 
remains unknown. We hypothesized that M-CSF may regulate cholesterol homeostasis 
by direct effects on de novo cholesterol biosynthetic pathway. Selective metabolic labeling 
experiments using D2O in drinking water and D6-labeled dietary cholesterol combined with 
mass spectrometric analyses to differentiate and quantify relative proportions of absorbed 
and newly synthesized cholesterol in three lines of mice (knockout for M-CSF (Csf1op/Csf1op), 
heterozygous for M-CSF allele (Csf1op/Csf1+) and wild type for M-CSF allele [Csf1+/Csf1+]) 
demonstrated that effects of M-CSF deﬁciency on serum cholesterol levels were a function 
of altered de novo cholesterol synthesis. Mouse microarrays hybridized with complementary 
RNA from livers of mutant mice showed at least 2-fold reduction (Csf1op/Csf1op vs. Csf1+/
Csf1+) in 11 of 22 SREBP target genes that contribute to cholesterol metabolism including 
those encoding HMG CoA-synthase, HMG CoA-reductase and acetyl-coenzyme A. 
Treatment of bone marrow macrophages (BMM) from and Csf1op/Csf1op mice with M-CSF 
(500 ng/mL) under serum free conditions resulted in a signiﬁcant increase in mRNA levels 
of HMG CoA-synthase, HMG CoA-reductase and squalene synthase but had no effect on 
mRNA levels of SREBPs. M-CSF treatment showed an increase in the levels of nuclear 
SREBP-2 protein. This effect of M-CSF was mediated by an increase in the levels of serine 
protease S1P in a dose-dependent manner. 
Conclusion: M-CSF regulates the expression of genes that encode key enzymes for 
cholesterol biosynthetic pathway. By regulating proteolysis of the cholesterol sensor 
assembly, M-CSF may play a key role in cholesterol biosynthesis.
1044-97 Fatty Acid Oxidation Regulates The Expression Of 
Sterol Regulatory Binding Protein 1
Paul E. Wolkowicz, Claudio Gomez, Ferdinand Urthlaler, Hernan E. Grenett, University 
of Alabama at Birmingham, Birmingham, AL
Sterol regulatory element binding proteins (SREBPs) are cell regulators of adiposity. 
SREBP-1 governs the expression of enzymes catalyzing de novo fatty acid synthesis 
while SREBP-2 controls de novo cholesterol biosynthesis. Thus we tested whether 
fatty acid oxidation (FAO) inﬂuences the expresion of these two regulators of de novo 
lipogenesis.
Overnight fasted or fed male rats (n=8 per) were given (i) an i.p injection of 10mg/kg tetra-
decylglycidic acid (TDGA), a speciﬁc inhibitor of FAO, or (ii) albumin vehicle. Two sets of 
experiments then were performed.
First, epididymal fat pad (EFP) mRNA was isolated 2-12 hr after TDGA treatment and 
analyzed for SREBP-1 and -2 mRNAs. TDGA suppressed EFP SREBP-1 expression 
in fasted but not fed rats (Fig) in a time- and dose-dependent manner. TDGA did not 
affect SREBP-2 mRNA. Thus inhibiting FAO selectively abolishes adipose SREBP-1 
expression.
Second, a ~470bp fragment of the SREBP-1c promoter was ligated into a luciferase (Luc) 
reporter vector. Transient transfection studies showed that TDGA decreased SREBP1c 
promoter-driven Luc activity by 50%.
Thus FAO regulate the expression of SREBP-1 both in vivo and in vitro. FAO, therefore, 
exerts an important but previously unrecognized inﬂuence on the expression of SREBP1, 
the cell regulator of de novo fatty acid synthesis.
1044-98 Potential of Biongineered Nanoemulsions in Rapid 
Therapy of Dyslipidemia
Manoj Varshney, Jaiwei Chen, Brij M. Moudgil, Dinesh O. Shah, Jawahar L. Mehta, University 
of Florida, Gainesville, FL, University of Arkansas for Medical Sciences, Little Rock, AR
Background: A nanoemulsion (NE) engineered in our laboratory is a self-assembly of 
oil, water and emulsiﬁer molecules that is stabilized by a ﬁlm of biocompatible emulsiﬁer 
molecules (size<100nm). Being a hydrophobic core of these NE, they can be potentially 
useful for extracting hydrophobic molecules from blood and thus potentially useful in 
treating dyslipidemias.
Methods and Results: Heparinized human blood samples were incubated with 
engineered NE, and total cholesterol, triglyceride, and HDL concentrations monitored. 
Control samples were incubated with PBS. Lipid panel was determined enzymatically using 
Bioscanner2000 device and PTS test strips, while LDL concentration was determined by a 
direct method. NE reduced LDL by 25-35 % (n=5, P =0.005), and most importantly raised 
HDL 3-fold (N=5, P<0.001) (table). The increase in HDL was dependent NE concentration- 
and the incubation time-dependent (N=5, P<0.01), and became evident as early as 30 
minutes after incubation. These effects persisted throughout the experiment. In addition, 
NE increased HDL by >300% (P<0.01) and reduced total cholesterol by 20-30% (P<0.01) 
upon incubation of blood from LDLR-null mice. Intravenous NE administration to LDLR-
null mice increased HDL levels increased after one hour (P<0.01). 
Lipid Panel Control(mM)
NE
(mM/L)
Cholesterol, Total 4.10±0.25 3.55±0.40
Triglyceride 2.52±0.42 1.96±0.28
HDL-C 0.78±0.12 >2.10±0.04*
Direct LDL 2.35±0.27 1.63±0.16*
Discussion: These data show the potential of NE in treating dyslipidemia rapidly. It is 
likely that the hydrophobic core of the NE selectively absorbs LDL-C, thereby reducing 
LDL and enhancing the HDL- concentration in blood.
1044-99 JTT-705 Blocks Cell Proliferation and Angiogenesis 
Through p38 Kinase/p27kip1 and Ras/p21waf1 
Pathways
Shin-ichiro Miura, Akira Kawamura, Hiroaki Tanigawa, Masahiro Fujino, Keisuke 
Okamura, Yoshino Matsuo, Yoshinari Uehara, Keijiro Saku, Fukuoka University School of 
Medicine, Fukuoka, Japan
The excessive proliferation and migration of vascular smooth muscle cells (SMCs) 
participate in atherosclerotic plaque growth and instability. We examined the direct role 
of a newly developed chemical inhibitor of cholesteryl ester transfer protein, JTT-705, on 
SMC proliferation and angiogenesis in endothelial cells (ECs). JTT-705 inhibited human 
coronary artery SMC proliferation as assessed by the MTS assay. JTT-705 induced the 
phosphorylation of p38 mitogen-activated protein kinase (MAPK) and extracellular-signal-
regulated kinases (ERK) but not Jun N-terminal kinases based on immunoblotting using 
phospho-speciﬁc antibodies in SMCs. In addition, the anti-proliferative effects of JTT-705 
were blocked by p38 MAPK inhibitor, but not by ERK inhibitor, in SMCs. JTT-705 induced 
the upregulation of p-p21waf1, and this effect was blocked by dominant-negative Ras 
(N17), but not inhibitors of p38 MAPK or ERK. In addition, JTT-705 also induced the 
upregulation of p27kip1, which was blocked by p38 MAPK inhibitor. Interestingly, culture 
medium from JTT-705-treated SMCs blocked human coronary artery EC tube formation 
in an in vitro model of angiogenesis indirectly via a decrease in vascular endothelial 
growth factor (VEGF) from SMCs and directly via an anti-proliferative effect in ECs. JTT-
705 blocked the proliferation of SMCs through the activation of p38 kinase/p27kip1 and 
Ras/p21Waf1 pathways, and simultaneously blocked EC tube formation associated with 
a decrease in VEGF production from SMCs and an anti-proliferative effect in ECs. These 
results constitute the ﬁrst evidence of a particular pleiotropic effect of JTT-705.
1044-103 Lipid Dynamics Due to Genetic Variability Is More 
Important Than Plasma Lipid Levels Alone for Coronary 
Restenosis
Pascalle S. Monraats, Jamal S. Rana, Aeilko H. Zwinderman, Willem R.P. Agema, John 
J.P. Kastelein, Moniek P.M. de Maat, Robbert J. de Winter, Rene A. Tio, Pieter A.F.M. 
Doevendans, Johannes Waltenberger, Rune R. Frants, Arnoud van der Laarse, Ernst 
E. van der Wall, J.Wouter Jukema, Leiden University Medical Center, Leiden, The 
Netherlands
Background: Polymorphisms at apolipoprotein loci affect lipid metabolism. This makes 
such genetically determined protein variants ideal candidates for inﬂuencing individual 
differences in susceptibility to abnormal lipid proﬁles. Due to overlapping pathophysiological 
processes involved in atherosclerosis and restenosis in the vascular wall, effect of genetic 
variation on lipid metabolism may play a role in restenosis. Therefore, we examined 26 
polymorphisms in 12 genes involved in lipid metabolism in a large cohort of consecutive 
patients that underwent percutaneous coronary intervention (PCI).
Methods: The GENetic DEterminants of Restenosis (GENDER) project is a multicenter 
follow-up study, including patients after successful PCI. Genotyping was determined by 
validated multilocus genotyping assay (Roche Molecular Systems).
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Results: A total of 3,146 patients (age 62.1±10.7 years) were followed for 10±2 months. 
Of these, 2,250 (71.5%) were male and 1,911 (60.7%) had hypercholesterolemia. Stenting 
was performed in 2,340 (74.4%) patients and 1,706 (54.2%) patients received lipid-
lowering medication. Post 30-day target vessel revascularisation (TVR) was necessary in 
304 patients (9.7%). No association was found between hypercholesterolemia or use of 
lipid lowering medication and TVR. However, we found two polymorphisms, the Gln360His 
in the apolipoprotein A4 (ApoA4) and the Arg158Cys polymorphism in the apolipoprotein 
E (ApoE) gene (p=0.003, RR=1.4, 95%CI; 1.05-1.87 and p=0.008, RR=1.4, 95%CI 1.09-
1.91, respectively), to be highly associated with TVR.
Conclusions: This study shows that there is no effect of hypercholesterolemia or 
use of lipid lowering medication on restenosis. However, vatiations in genes involved 
in lipid metabolism do seem to have predictive value. The Gln360His ApoA4 and the 
Arg158Cys ApoE-polymorphisms showed a signiﬁcant association with TVR and may 
explain variability observed in restenosis occurrence. It is hypothesised that not lipid 
concentration but the involvement of lipid dynamics in the vascular wall contribute to the 
process of restenosis. Genotyping can be used as a screening tool prior to PCI and help 
tailor individualized therapy.
1044-104 Frequencies Of Apolipoprotein A-V Polymorphisms, 
ApoA-V (G185C) And -1131T>C In Patients With 
Hypertriglyceridemia
Akira Matsunaga, Hideya Niimura, Hiroaki Arishima, Kazuo Ohwaki, Kazue Yonemura, 
Keijiro Saku, Fukuoka University, Fukuoka, Japan
Apolipoprotein (apo) A-V is a newly identiﬁed apolipoprotein related with hypertriglyceridemia 
in both human and mouse. In course of apo A-V gene analysis, we found a novel polymorphism 
of apoA-V gene, apoA-V (G185C) in Japanese patients with hypertriglyceridemia. Another 
polymorphism, T to C substitution which is located -1131 bp 5’ to the apo A-V gene, has been 
reported the relation with the hypertriglyceridemia. In this report the frequencies of G185C and 
-1131T>C polymorphisms were determined by restriction-fragment-length-polymorphisms. 
Blood speimens of 119 normolipidemic Japanese individuals, 80 men and 39 women aged 
58 ± 14, and 95 Japanese patients who had high fasten plasma triglycerides (>200mg/
dl), 76 men and 18 women aged 56 ± 12 were collected and analyzed. The frequencies 
of the C allele at codon 185 (0.205) and the T allele at -1131bp (0.511) in patitents with 
hypertriglyceridemia were signiﬁcantly higher than those in normolipidemic subjects (0.105 
and 0.315), respectively (p<0.05, p<0.01). These results suggest that the polymorphisms, 
G185C (c.553G>T) and -1131T>C were associated with hypertriglyceridemia.
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1068-100 Importance of Endothelial Progenitor Cell Activation 
to Improvement in Endothelial Function in Coronary 
Artery Disease Patients Undergoing Cardiac 
Rehabilitation
Jonathan D. Paul, Tiffany M. Powell, Michael Thompson, Moshe Benjamin, Maria 
Rodrigo, J. Philip McCoy, Gloria Zalos, Beverly Press, Mandy Murphy, Jonathan M. Hill, 
Gyorgy Csako, Richard O. Cannon, III, National Institutes of Health, Bethesda, MD, 
Suburban Hospital, Bethesda, MD
Objective- Patients with coronary artery disease (CAD) have reduced endothelial 
progenitor cells (EPCs) which may contribute to endothelial dysfunction and cardiovascular 
risk. We hypothesized that repetitive exercise might increase EPCs with improvement in 
endothelial function.
Methods- 28 CAD patients participated in a 3 month cardiac rehabilitation program, with 
1 hour exercise sessions 3 times weekly; all were on medical management that included 
statins. Mononuclear cells were isolated from blood and cultured in ﬁbronectin-coated 
wells, with replating of 106 nonadherent cells/well at 48 hours to remove progenitor cells 
from adherent mature endothelial cells. EPC colony-forming units (CFU) were identiﬁed 
as cell clusters with endothelial outgrowth at 7 days. Endothelial function was determined 
by ﬂow-mediated dilation (FMD) of the brachial artery in response to post-ischemic 
hyperemia (% change from resting diameter).
Results- At 3 months, average energy expenditure (METs) per session increased from 
14.7±1.2 to 19.5±1.3 (P<0.001 vs. baseline) and treadmill exercise duration (modiﬁed 
Bruce protocol) increased from 14.0±0.6 to 15.3±0.5 minutes (P<0.001 vs. baseline). 
EPC-CFUs (8 wells counted) increased from 9.6±1.7 at baseline to 26.0±4.9 at 3 months 
(P<0.01). Sixteen patients showed improved FMD, from 5.1% to 7.7%; their baseline EPC-
CFU values, METs per session, improvement in exercise time, and changes in weight and 
in lipid, glucose and hsC-reactive protein levels over 3 months were no different than 
patients without improved FMD. However, patients with improved FMD had substantially 
greater EPC-CFU at 3 months (35.8±7.4 vs. 13.1±3.3, P<0.01) and greater increases in 
EPC-CFU from baseline (27.3±7.5 vs. 3.1±4.1, P<0.01) compared with non-responders. 
For the entire group, improvement in FMD correlated signiﬁcantly with increase in EPC-
CFU during the 3 month program (P<0.05).
Conclusions- Cardiac rehabilitation beneﬁts exercise performance in CAD participants. 
However, improvement in endothelial function--and by extension, cardiac risk--may be dependent 
on mobilization or activation of progenitor cells with endothelial differentiation potential.
1068-101 Impact of Angiotensin Receptor Blockers on Coronary 
Atherosclerosis: A 3D Intravascular Ultrasound Study
Katsuhisa Waseda, Yukio Ozaki, Tatsuya Yasukawa, Hiroyuki Shinjo, Hiroaki Takashima, 
Tomohiro Kono, Yasuo Kuroda, Yoshinori Wakita, Kenji Asai, Yasushi Kuhara, Takashi 
Kosaka, Takayuki Ito, Aichi Medical University, Nagakute, Japan, Fujita Health University, 
Toyoake, Japan
Background: Although it has been reported that the administration of angiotensin 
receptor blockers (ARB) can improve long-term outcome in patients with ischemic 
heart disease, the inﬂuence of ARB on the progression and regression of coronary 
atherosclerosis has not yet been investigated.
Method: Serial (baseline and 6-month follow-up) IVUS imagings of the left main coronary 
artery were performed in 68 patients who underwent percutaneous coronary intervention 
for LAD or circumﬂex artery. Patients were subsequently treated with a combination of �-
blockers, calcium channel blockers, and ARB according to physician’s guidance. Patients 
on ACE inhibitors were excluded from this study. Volumetric analysis throughout the left 
main coronary artery (mean length; 3.2±1.5 mm) was performed, and volume index (VI; 
volume/length) was calculated for vessel (VVI), lumen (LVI), and plaque (PVI).
Results: VVI, LVI and PVI at baseline were similar between the non-ARB group (n=48) 
and the ARB group (n=20). The non-ARB group did not show signiﬁcant serial change 
in VVI, LVI, and PVI. However, the ARB group showed 10% decrease in PVI (p<0.01) at 
follow-up. In the ARB group, �PVI was signiﬁcantly lower (p<0.01), and �LVI tended to be 
higher (p=0.06) compared to the non-ARB group (table).
Conclusion: This preliminary analysis suggests that ARB may prevent the progression 
of coronary atherosclerosis. A long-term randomized follow-up study with and without 
ARB is warranted in a large patient population.
 
Non-ARB (n=48) ARB (n=20) p
Baseline (mm2/mm)
VVI 24.9±6.2* 24.0±5.0† ns
LVI 15.2±4.6* 14.1±4.7† ns
PVI 9.7±3.3* 9.9±2.3‡ ns
Follow-up (mm2/mm)
VVI 25.2±6.3* 24.0±5.4† ns
LVI 14.9±4.5* 15.0±4.7† ns
PVI 10.3±4.0* 9.0±2.5‡ ns
Difference (mm2/mm)
ΔVVI 0.21±0.37 0.02±0.53 ns
ΔLVI -0.31±0.37 0.92±0.54 0.06
ΔPVI 0.56±0.35 -0.90±0.26 <0.01
Difference: Follow-up minus Baseline, * † p=ns, ‡ p<0.01
1068-102 Impact of Platelet Glycoprotein Ia Genetic 
Polymorphisms C807T and A1648G, on P-Selectin 
Release During the Acute Phase of Premature 
Myocardial Infarction
Dimitris M. Tousoulis, Charalambos A. Antoniades, Carmen Vasiliadou, Costantinos 
Tentolouris, Kyriakoula Marinou, Marina Toutouza, Nikolaos Koumallos, Nikos 
Papageorgiou, Christos Pitsavos, Christodoulos Stefanadis, Athens University Medical 
School, Athens, Greece
Background: The platelet membrane glycoprotein Ia (GPIa) is a primary receptor 
for collagen, participating in platelets activation during the acute phase of myocardial 
infarction (MI). Silent genetic polymorphism C807T seems to affect the expression 
of GPIa, while A1648G polymorphism leads to a Glu/Lys substitution on GPIa. We 
investigated the impact of these polymorphisms on P-selectin levels during the acute 
phase of premature MI.
Methods: This study enrolled 50 young patients with ﬁrst incidence of non-fatal, premature 
MI (46.2±5.2 years old). Blood samples were taken within the ﬁrst 24 hours after MI and 
1 year later. Distributions of the C807T and A1648G polymorphisms were investigated by 
genotyping DNA by PCR, while platelets activation was assessed by measuring plasma 
soluble P-selectin with ELISA.
Results: Patients were divided into groups according to C807T or G1648A polymorphisms 
respectively. During the acute phase of MI, both 807CT (n=20) and 807TT (n=14) 
genotypes were associated with signiﬁcantly higher levels of P-selectin (62.81±4.98 ng/ml 
and 72.3±6.2 ng/ml respectively) compared to 807CC (n=16, 37.0±2.57 ng/ml, p<0.01 for 
both). One year after the incident, P-selectin levels were signiﬁcantly decreased in both 
807 CT and 807TT (52.37±4.55 and 45.76±4.24 ng/ml respectively, p<0.01 compared 
to acute phase), but remained signiﬁcantly higher than in 807CC (37.4±2.85, p<0.05 
for both). No signiﬁcant difference was observed in P-selectin levels between 1648AG 
(n=14, 56.1±9.4 ng/ml) and 1648GG (n=36, 57.55±47.56 ng/ml, p=NS) genotypes 
during the acute phase of MI, while it was similarly decreased in both 1648AG and 
1648GG genotypes (41.6±6.5 and 47.36±3.16 ng/ml, p<0.01 compared to acute phase 
respectively), one year after MI.
Conclusions: This study suggests that genetic polymorphism C807T but not G1648A, 
on platelet glycoprotein Ia may affect the release of P-selectin, during the acute phase of 
premature MI. These ﬁndings provide evidence for a possible role of this polymorphism, 
on platelet activation during the acute phase of myocardial infarction.
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1068-103 Soluble CD40L And Prothrombotic State In Major 
Depression: Effect of SSRI Therapy
Roberto Leo, Manfredi Tesauro, Lucia De Luca, Giovanni Battista Forleo, Fabrizio 
Clementi, Giorgio Di Lorenzo, Alberto Siracusano, Francesco Romeo, University of “Tor 
Vergata”, Rome, Italy
Background A number of epidemiological studies have documented that major depression 
(MD) is a risk factor for primary and secondary prevention of coronary artery disease 
(CAD). Of recent interest is the role of inﬂammation in the atherogenesis and its potential 
association with MD. MD is frequently associated with the induction of cytokines, upregulation 
of endothelial adhesion molecules, even in patients with stable clinical conditions The aim of 
this study was to characterize the in vivo expression of soluble CD40L (sCD40L) in MD, to 
correlate it with the extent of the prothrombotic state and to investigate if it may be modiﬁed 
by serotonine selective reuptake inhibitors (SSRIs) treatment..
Methods and Results We studied 46 MD (DSM-IV) young patients never treated or in 
a pharmacological wash-out period without conventional risk factors for CAD and 46 
matched healthy subjects. MD patients displayed signiﬁcantly higher circulating levels 
of sCD40L, TNF-alpha, IL-1beta, and IL-6 levels, with statistically signiﬁcant direct 
correlations between sCD40L and either IL-6 or TNF-alpha. Therefore, to examine the 
correlation between enhanced sCD40L and coagulative activation, we measured FVIIa 
levels, as a marker of extrinsic pathway activation, and F1+2, as an index of thrombin 
generation. MD patients showed increased levels of FVIIa and F1+2 compared with 
controls. A signiﬁcant direct correlation was observed between sCD40L and both FVIIa 
and F1+2. Moreover, sCD40L was positively associated with in vivo platelet activation, as 
reﬂected by sP-selectin. SSRI by sertraline or citalopram was associated with comparable, 
signiﬁcant reduction in sCD40L, FVIIa and F1+2. 
Conclusions The present study demonstrates that elevated sCD40L levels can be 
found in patients with MD and could represent a biochemical link between an ongoing 
inﬂammatory state, endothelial damage, coagulative activation and the occurrence 
of in vivo platelet activation. SSRIs therapy may signiﬁcantly reduce sCD40L and the 
prothrombotic state.
1068-104 Differences in Risk Proﬁles of Men and Women 
With Coronary Endothelial Dysfunction and Early 
Atherosclerosis
Eric H. Yang, Abhiram Prasad, Ryan J. Lennon, Lilach O. Lerman, Amir Lerman, Mayo 
College of Medicine, Rochester, MN
Background: Few studies have demonstrated the risk proﬁles of patients with coronary 
endothelial dysfunction and early atherosclerosis. In particular, potential gender 
differences in cardiac risk proﬁles during the early stages of coronary artery disease have 
not been explored.
Objective: The purpose of this study was to determine the differences in cardiac risk 
proﬁles of men and women with early atherosclerosis as detected by coronary endothelial 
dysfunction.
Methods: Seven hundred nineteen patients with chest pain and < 30% epicardial 
coronary artery stenosis who underwent invasive coronary endothelial assessment with 
acetylcholine were studied. The patients were divided into 4 groups: men with normal 
endothelial function (n = 105), men with abnormal endothelial function (n = 171), women 
with normal endothelial function (n = 195), and women with abnormal endothelial function 
(n = 248). Comparisons of risk proﬁles were made within each gender between patients 
with normal and abnormal endothelial dysfunction.
Results: 
Male Female
Endothelial Function Endothelial Function
Normal
(N=105)
Abnormal
(N=171)
Normal
(N=195)
Abnormal
(N=248)
Age (years) 44.2 + 11.7 48.5 + 12.5* 51.0 + 12.3 53.1 + 11.5
Hypertension, No. (%) 36 (34%) 66 (39%) 73 (38%) 108 (44%)
History of smoking, No. (%) 58 (53%) 98 (57%) 79 (40%) 115 (46%)
Body mass index (kg/m2) 27.5 + 4.3 29.3 + 4.8* 27.6 + 6.5 29.3 + 7.2*
Diabetes, No. (%) 1 (1%) 19 (11%)* 10 (5%) 24 (10%)
Mean arterial pressure (mm Hg) 96.3 + 13.7 98.7 + 13.9 103.1 + 15.9 103.8 + 16.1
Total Cholesterol (mg/dl) 183.8 + 38.1 189.5 + 43.6 200.4 + 46.4 197.0 + 37.6
LDL (mg/dl) 111.3 + 33.8 116.6 + 38.1 114.4 + 36.3 111.8 + 35.3
HDL (mg/dl) 42.6 + 11.2 39.8 + 10.3 59.5 + 18.4 55.6 + 16.1*
Triglycerides (mg/dl ) ,median (Q1, Q3) 139 (98, 194) 146 (94, 211) 110 (72,163) 116 (83,174)
CRP (mg/dl), median (Q1,Q3) 0.3 (.1, .4) .3 (.1, .6) 0.2 (.1, .5) .4 (.2, .6)*
Insulin ( uIU/ml), median (Q1,Q3) 5.5 (3.3, 8.8) 6.2 (4.4, 13.0) 4.0 (2.3, 6.2) 4.7 (2.7, 9.0)*
Fibrinogen (mg/dl ), median (Q1,Q3) 222.0 (192, 261)
267 (231.0, 
296.0)*
262.0 (206.5, 
306.0)
264 (215.0, 
334.0)
* p < 0.05 versus same gender with normal endothelial function
Conclusion: Age, body mass index, diabetes, and greater activity of the clotting cascade 
appear to play a role in men with early atherosclerosis as detected by endothelial 
dysfunction, while insulin resistance, body mass index, low HDL, and inﬂammation 
play a role in women. Our results suggest that gender differences should be taken into 
consideration during evaluation of the risk proﬁle of patients with early atherosclerosis.
1068-105 Impaired Flow-Mediated Dilation and Risk of Restenosis 
in Patients Undergoing Coronary Stent Implantation
Giuseppe Patti, Vincenzo Pasceri, Rosetta Melﬁ, Costanza Goffredo, Massimo Chello, 
Andrea D’Ambrosio, Rosamaria Montesanti, Germano Di Sciascio, Campus Bio-Medico 
University, Rome, Italy, S. Filippo Neri Hospital, Rome, Italy
Background. Impaired endothelial function is a key event in the atherosclerosis process 
and predicts future cardiovascular events in subjects with and without coronary artery 
disease (CAD). We performed the ﬁrst prospective study evaluating whether early 
measurement of brachial artery endothelial-dependent dilation (ﬂow-mediated dilation, 
FMD) after coronary stenting could predict occurrence of in-stent-restenosis.
Methods. The study population included 136 patients (pts) with symptomatic CAD 
undergoing percutaneous coronary intervention (PCI) with stenting and at least 6 months 
follow-up. All pts underwent ultrasound detection of brachial artery reactivity 30 days 
after the procedure: FMD was investigated before and after 5 minutes of occlusion of the 
forearm circulation, nitroglycerin-mediated dilation (NTG) was measured before and after 
administration of sublingual nitrates.
Results. In-stent restenosis was demonstrated in 20 pts (15%), while 116 pts (85%) 
remained without clinical evidence of restenosis. FMD was signiﬁcantly impaired in pts 
with restenosis vs those without restenosis (percent diameter variation: +4.6±5.8% vs 
+9.5±6.6%, P=0.002); moreover, 4% of pts with FMD ≥7% (median value) developed in-
stent restenosis vs 28% of those with FMD <7%, P=0.0001. At multivariate analysis, FMD 
was the strongest predictor of restenosis (Hazard ratio 4.5, 95% CI 2.4-12.0); conversely, 
NTG did not independently predict the risk of restenosis (2.4, 95% CI 0.8-6.3).
Conclusions. This is the ﬁrst prospective study indicating that impaired FMD 
independently predicts occurrence of in-stent restenosis in pts undergoing PCI. Early 
evaluation of endothelial function after stenting may represent an useful screening tool to 
stratify pts according to future risk of restenosis.
1068-106 Methylenetetrahydrofolate Reductase (MTHFR) C677T 
Genetic Polymorphism and Failure of Thrombolysis in 
Patients With Acute Myocardial Infarction
Giuseppe Patti, Carolina Fossati, Vincenzo Pasceri, Barbara Giannetti, Annunziata 
Nusca, Simona Mega, Ombretta Annibali, Andrea D’Ambrosio, Giuseppe Avvisati, 
Germano Di Sciascio, Campus Bio-Medico University, Rome, Italy
Background. In patients with acute myocardial infarction, failure of thrombolysis is 
associated with unfavorable prognosis and genetic polymorphisms could be a contributing 
factor to this failure; 677TT homozygosis in the methylenetetrahydrofolate reductase 
(MTHFR) gene determines an enzymatic variant with reduced activity and subsequent 
hyper-homocysteinemia. Aim of the study was to investigate whether MTHFR C677T 
polymorphism is related to a persistently occluded infarct-related artery after thrombolysis 
for evolving myocardial infarction.
Methods. Coronary angiograms were performed in 101 patients post-myocardial 
infarction treated with intravenous thrombolysis ≤30-day prior, and the infarct-related 
artery was classiﬁed as occluded (N=40) or patent (N=61). In all patients MTHFR C677T 
polymorphism and circulating homocysteine levels were determined.
Results. Overall MTHFR 677TT frequency was 22%. Patients with MTHFR 677TT 
homozygosis had a signiﬁcantly higher prevalence of occluded infarct artery (73%) 
vs those with MTHFR 677CT/CC genotype (30%, P=0.0008); frequency of MTHFR 
677TT homozygosis was 4-fold higher in patients with occluded vs those with a patent 
vessel (40% vs 10%, P=0.0008). MTHFR 677TT genotype predicted the risk of failed 
thrombolysis with a speciﬁcity of 90% and multivariate analysis showed that MTHFR 
677TT homozygosis was independently associated with an occluded artery (odds ratio 
3.8, 95% conﬁdence interval 1.1-9.1; P=0.03). Patients with occluded infarct vessel and 
MTHFR 677TT genotype had the highest homocysteine levels (P=0.011).
Conclusions. Our ﬁndings indicate that in patients with acute myocardial infarction, 
MTHFR 677TT homozygous is independently associated with a persistently occluded 
infarct-related artery after thrombolysis. These results support recanalization therapies 
alternative or complementary to thrombolysis in patients with acute myocardial infarction 
and known MTHFR 677TT genotype.
1068-107 807 C/T Polymorphism of the Glycoprotein Ia Gene and 
Pharmacogenetic Modulation of Platelet Response to 
Sustained Dual Antiplatelet Treatment
Dominick J. Angiolillo, Esther Bernardo, Celia Ramirez, Antonio Fernández-Ortiz, Ugo 
Cavallari, Manel Sabaté, Pilar Jimenez-Quevedo, Fernando Alfonso, Javier Escaned, 
Camino Bañuelos, Rosana Hernandez-Antolin, Raul Moreno, Elisabetta Trabetti, Marco 
A. Costa, Theodore A. Bass, Pier F. Pignatti, Carlos Macaya, University of Florida - Shands 
Jacksonville, Jacksonville, FL, Hospital Clinico San Carlos Madrid, Madrid, Spain
The 807 C/T polymorphism of the glycoprotein (GP) Ia receptor (a major platelet-collagen 
receptor) has been associated with thrombotic risk. Further, this polymorphism has been 
suggested to modulate clopidogrel-induced antiplatelet effects in the early stages of 
treatment. The aim of this study was to assess the inﬂuence of this polymorphism on 
antiplatelet effects of long-term clopidogrel plus aspirin treatment. 
Methods: The 807 C/T polymorphism of the GPIa receptor gene was assessed in 82 pts 
with known coronary artery disease on combined clopidogrel (75 mg/d) and aspirin (100 
mg/d) treatment for at least 1 month. Pts were divided into two groups: carriers (CT + TT 
genotypes) and non-carriers (CC genotype) of the mutant T allele. Platelet aggregation 
was assessed using light transmittance aggregometry in platelet rich plasma after stimuli 
with ADP (20 µM), collagen (6µg/mL) and epinephrine (20 µM).
Results: Genotype distribution was as follows: 51/82 (62%) T allele carriers (43 CT and 
8 TT) and 31/82 (38%) non-carriers of the T allele. Carriers of the T allele had higher 
platelet aggregation than non-carriers of the T allele after stimuli with ADP, collagen and 
epinephrine.
ADP Collagen Epinephrine
C/C 41.4±14.8 27.2±16.5 22.5±10.9
C/T+T/T 48.1±14.4 34.9±16.8 29.4±15.5
p 0.048 0.048 0.025
Conclusion: The T allele of the 807C/T polymorphism of the GPIa receptor gene is 
associated with increased platelet aggregation, even in pts on sustained dual antiplatelet 
treatment. Such pharmacogenetic modulation of antiplatelet therapy may contribute to the 
increased thrombotic risk associated with the 807C/T polymorphism.
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1068-108 Assessment Of Individual Response To Aspirin Over 
Time: Is Aspirin Resistance A Sustained Phenomenon?
Dominick J. Angiolillo, Esther Bernardo, Celia Ramirez, Antonio Fernández-Ortiz, 
Manel Sabaté, Pilar Jimenez-Quevedo, Rosana Hernandez-Antolin, Raul Moreno, 
Javier Escaned, Camino Bañuelos, Fernando Alfonso, Marco A. Costa, Theodore Bass, 
Carlos Macaya, The Cardiovascular Center-Shands Jacksonville-University of Florida, 
Jacksonville, FL, San Carlos University Hospital, Madrid, Spain
Background: Aspirin resistance (AR) is commonly deﬁned as an an incomplete inhibition 
of platelet function despite the use of therapeutic doses proven to be clinically effective. 
AR has been associated with an increased risk of cardiovascular events, although 
data are controversial. Such conﬂicting results may be due to a variation in individual 
response to ASA over time suggesting that AR may not be a sustained and reproducible 
phenomenon. Aim of this study was to assess the prevalence and persistence over time 
of AR and its impact on platelet activation.
Methods: Three blood samples (Visit 1, Visit 2, and Visit 3) were drawn at one-month 
intervals in 52 patients (pts) with stable ischemic heart disease on treatment with ASA 
(100mg/d) and clopidogrel (75mg/d). AR was deﬁned by means of the PFA-100 system 
(Dade-Behring) using collagen/epinephrine coated cartridges (CEPI). In accordance 
with previous reports, patients with closure times (CT) of CEPI cartridges <193 seconds 
were deﬁned as AR. In addition, platelet activation (PA) was assessed in all samples by 
whole blood cytometry measuring glycoprotein (GP) IIb/IIIa activation (PAC-1 monoclonal 
antibody) following ADP 2µM stimuli.
Results: AR was detected in 18 pts (35%) at Visit 1, in 18 pts (35%) at Visit 2, and in 20 
pts (38%) at Visit 3. AR was conﬁrmed in all 3 visits in 10 pts (19%), while 22 pts (42%) 
were persitently sensitive to ASA in the 3 visits. A variable response to ASA at different 
time points was observed in the remaining 20 pts (39%). Increased GPIIb/IIIa activation 
(% of positive platelets, mean±SD) was observed in persitent AR compared to persistent 
ASA sensitive pts (47.1±22.0 vs 28.8±20.8, p=0.03).
Conclusions: Individual response to ASA may vary signiﬁcantly over time. The use of 
one single sample to assess AR may overestimate the prevalence of this phenomenon. 
Persistence of AR over time is associated with an increased platelet reactivity. Identiﬁcation 
of AR through repetitive assessments may allow to better identify pts at an increased 
cardiovascular risk. 
1068-109 Low Fibrin Monomer (soluble ﬁbrin) Concentration 
Predicts Troponin-T Positive Cardiac Event Free 
Survival at 30 Days Follow-Up after Hospitalization  
with Acute Chest Pain.
Trygve Brügger-Andersen, Volker Pönitz, Heidi Grundt, Øyvind Hetland, David Pritchard, 
Dennis W. T. Nilsen, Sentralsjukehuset i Rogaland, Stavanger, Norway
Background: Fibrin monomer (FM) is a marker of thrombin activity, and increased plasma 
concentrations may reﬂect a thrombogenic state. The aim of the study was to identify 
chest pain patients at risk of future acute coronary syndrome (ACS).
Methods: As troponin T (TnT) is a sensitive marker of myocardial injury in ACS, new 
TnT positive events at 30-days follow-up in 891 patients hospitalized with acute chest 
pain were assessed with respect to FM concentration at admission. FM was measured 
by ELISA-methodology in citrated plasma samples harvested immediately following 
admission. Data were analysed by grouping the patients into tertiles according to FM 
concentrations; Tertile 1 (T1) ≤2.0 mg/L, Tertile 2 (T2) >2.0 mg/L & ≤5.2 mg/L, Tertile 3 
(T3) > 5.2 mg/L).
Results: At inclusion, 372 participants presented a TnT release (>0.05 ng/ml) and 519 
were either TnT negative or had a TnT release ≤ 0.05ng/ml. At 30-days follow-up 34 
patients had suffered an adverse TnT positive event (deﬁned as TnT >0.05ng/ml and 
a typical MI pattern). Follow-up event-rates, grouped according to ﬁbrin monomer at 
admittance, are given in Table I. The odds ratio for a future TnT positive event being in T1 
rather than T2 or T3 is 0.33 (p=0.012)
Conclusion: Low ﬁbrin monomers are associated with 30 day event free survival whilst 
elevated levels may predict future occlusive plaque rupture in patients hospitalized with 
acute chest pain.
 
Table I. Number and proportion of patients with a TnT positive cardiac event 30 days following hospitalization 
for acute chest pain (n=891) in the upper (T3), middle (T2) and lower (T1) tertiles of plasma ﬁbrin monomer at 
admission. (OR=Odds ratio)
Fibrin monomer tertile T1 T2 T3
Patients with future TnT positive event, n ( %) 5 (1.7%) 17 (5.9%) 12 (4.1%)
OR for TnT event within 30 days of hospitalization (p) 1.0 3.6 (0.007) 2.5 (0.047)
OR for TnT event free survival within 30 days (p) 0.33 (0.012) 1.0
1068-110 Impaired Mobilization of Circulating Endothelial 
Progenitor Cells in Patients With Diabetes Undergoing 
Coronary Stenting
Kreton Mavromatis, Muhammad R. Ishaque, Dorothy House, Johnson Pereira, Diane J. 
Sutcliffe, Jayne Danley, Grant Anderson, Peter C. Block, William S. Weintraub, W. Robert 
Taylor, Arshed A. Quyyumi, Emory University, Atlanta, GA, Atlanta VA Medical Center, 
Decatur, GA
Background: Rapid re-endothelialization of the denuded vasculature after angioplasty 
(PTCA) can prevent restenosis. Circulating endothelial progenitor cells (CEPCs) appear 
to play a crucial role in the repair process after vascular injury. Some patients, including 
diabetics, have an increased rate of restenosis after PTCA, but whether this is due to 
impaired CEPC activity is unknown. We hypothesized that CEPCs will be stimulated in 
patients after vascular injury from PTCA, and that their mobilization will be impaired in 
patients with diabetes.
Methods: Patients had blood samples drawn immediately before (baseline), and after 1 
day, 1 week, and 4 weeks following elective PTCA and stenting. CEPCs were cultured 
on ﬁbronectin plates from blood mononuclear cells, and endothelial colony forming units 
(CFU) were counted after 7 days. Patients with recent infarction or without stable statin 
therapy were excluded.
Results: Sixty-six patients, 11 female with a mean age 61 years, were enrolled. Compared 
to baseline, CEPC counts rose following coronary PTCA and stenting by 108+/-26% at 
1 day, 155+/-93% at 1 week, and 83+/-21% after 4 weeks (ANOVA p=0.016). Baseline 
CEPC counts were similar in diabetic and non-diabetic subjects (124+/-14 vs. 101+/-12 
CFU). There was a greater magnitude increase in CEPCs that was more sustained over 
the 4 week period in the 36 non-diabetic patients (p=0.011, ANOVA) as compared to 
the 30 diabetic patients (p=0.061, ANOVA). Thus, compared to baseline, CEPCs were 
139+/-16% higher in non-diabetics after 4 weeks, compared to a 19+/-16% change in 
diabetics, (p=0.005 between groups). There were no differences in age, gender, or statin 
use between the non-diabetic and diabetic patients.
Conclusions: Vascular injury during coronary PTCA and stenting promotes mobilization 
of CEPCs. This mobilization is attenuated in its’ extent and duration in diabetic patients. 
Impaired CEPC response to vascular injury may contribute to delayed endothelialization 
and thus to an increased risk of restenosis in diabetic subjects.
1068-111 Risk and Trends of Recurrent Ischemic Stroke Following 
Incident Atrial Fibrillation: Data from 2 Decades (1980-
2000)
Yoko Miyasaka, Marion E. Barnes, Stephen S. Cha, Kent R. Bailey, James B. Seward, 
Walter P. Abhayaratna, Bernard J. Gersh, Teresa S.M Tsang, Mayo Clinic, Rochester, MN
Background: We reported that ﬁrst ischemic stroke following incident atrial ﬁbrillation 
(AF) decreased signiﬁcantly in both men and women during 1980-2000, with concomitant 
increase in warfarin use over time. It is unknown as to whether the incidence of recurrent 
ischemic stroke following incident AF is also changing.
Methods: The complete medical records for residents of Olmsted County, MN, with an 
ECG-conﬁrmed diagnosis of ﬁrst AF between 1980 and 2000 were comprehensively 
reviewed. The overall and sex-speciﬁc incidence of recurrent stroke in AF patients were 
evaluated. Cox proportional hazards modeling was used to assess the risk factors and 
trends over time in recurrent stroke development following incident AF.
Results: A total of 4,117 subjects (72 + 15 years, 51% men) without ischemic stroke 
history at the time of AF onset, 446 (10.8%; 77 + 11 years, 38% men) had at least one 
ischemic stroke. Of the 446 patients, 46 (10%) developed recurrent ischemic stroke during 
a mean follow up of 2.7 ± 3.3 years. The Kaplan-Meier estimate of cumulative probability of 
recurrent ischemic stroke development (after an initial stroke post-AF) was 17% and 30% 
at 5 and 10 years, respectively. The risk of recurrent ischemic stroke has not increased 
signiﬁcantly by decade (p=0.86), and is not related to older age (p=0.21).
Conclusions: In this study, recurrent ischemic stroke after the ﬁrst stroke following 
incident AF occurred at a rate of approximately 3% per year. This rate did not increase or 
decrease signiﬁcantly over time, and did not vary by age or sex.
1068-112 Impaired Endothelium Independent Vasodilatation 
of the Brachial Artery in Patients with Limb-Girdle 
Muscular Dystrophy Indicates Smooth Muscle Cell 
Dysfunction.
Nickolaos Giatrakos, Maria Kinali, Francesco Muntoni, Petros Nihoyannopoulos, Imperial 
College School of Medicine, London, United Kingdom
Background: Sarcoglycan-deﬁcient Limb-Girdle Muscular Dystrophies (SD-LGMD) 
are caused by mutations in one of the genes of the sarcoglycan (SG) complex [alpha, 
beta, gamma and delta], encoding for transmembrane proteins part of the dystrophin-
glycoprotein complex. The alpha and gamma SGs are expressed in the skeletal and 
cardiac muscle while beta, delta are also expressed in smooth muscle cells (SMC), where 
they form a complex along with epsilon SG and sarcospan. Dilated cardiomyopathy is a 
frequent complication of the SD-LGMD, especially of beta and delta and this led to the 
suggestion that smooth muscle dysfunction could have a contributory role. This was also 
suggested by previous in vivo studies in animal models and in humans with SD-LGMD 
which showed abnormal coronary function. The aim of this study was to identify a vascular 
SMC dysfunction in SD-LGMD patients. In order to determine the maximum vasodilator 
response we used nitroglycerin (NTG) that served as an exogenous NO donor. That 
would be a measure of endothelium independent vasodilatation, reﬂecting the function 
of the SMC of the arterial wall.
Methods: The brachial artery was assessed in 8 patients with conﬁrmed diagnosis of SD-
LGMD (4 F, 4 M) mean age 20 yrs (range 7-33). Four patients had mutations in beta and 4 
in gamma SG. They were compared with ten age matched controls (5 F, 5 M). None of the 
subjects had history or risk factors for cardiovascular disease, were non-smokers and did 
not drink coffee or tea for at least 24 hours. They all had normal classic echocardiograms. 
NTG spray was given sublingually (0.4mg) and imagining was performed using the HDI 
5000 (Philips Medical Systems) and the 5-12 MHz linear transducer. The images were 
digitally stored and analysed ofﬂine using dedicated software (HDI-lab, Philips Medical 
Systems). The ECG was recorded during image acquisition and all measurements were 
performed at end diastole.
Results: SD-LGMD patients had signiﬁcantly lower vasodilation when compared to 
controls (13±2.6% vs.22±3%, p=0.01).
Conclusion: Vasodilator response to NTG is impaired in patients with SD-LGMD 
irrespective of the primary genetic defect. These results indicate a vascular SMC 
dysfunction in these patients.
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1069-95 Increased Arterial Stiffness and Wave Reﬂections 
Predict Severe Cardiovascular Events in Patients 
Undergoing Percutaneous Coronary Interventions
Thomas Weber, Johann Auer, Michael F. O´Rourke, Bernd Eber, Klinikum 
Kreuzschwestern, Wels, Austria, University of NSW, Sydney, Australia
Background: Aortic stiffness has been associated with the extent of coronary 
atherosclerosis in candidates for percutaneous coronary interventions (PCI). However, 
the inﬂuence of increased arterial stiffness and increased wave reﬂections on the long-
term course following PCI is unknown.
Methods: We prospectively measured indices of wave reﬂections (Augmentation-Index -
AIx, heart-rate corrected AIx - AIx@75, Augmented Pressure - AP) and of arterial stiffness 
(time to return of the reﬂected wave - Tr) non-invasively using applanation tonometry 
of the radial artery and a validated transfer function to obtain the corresponding aortic 
values in 267 consecutive patients undergoing PCI at our institution. Follow-up data were 
collected at hospital discharge, at 3 months and at 1 and 2 years. Primary endpoint was 
a combination of death, myocardial infarction, and clinical apparent restenosis (conﬁrmed 
by repeated angiography). Data are mean +/- standard deviation, statistics used were 
student´s t-test, Mann-Whitney U-test and logistic regression analysis.
Results: 64 patients reached the combined endpoint (event-group). Compared to the 203 
patients with an uneventful course, event group patients had increased wave reﬂections 
and arterial stiffness (AIx 29.9 +/- 12.5 vs 24.3 +/- 11.9%, p=0.001; AIx@75 25.7 +/- 10.6 
vs 20.1 +/- 9.9%, p=0.0001; AP 13.9 +/- 8.8 vs 10.5 +/- 7.2 mm Hg, p=0.001; Tr 129.5 
+/- 13.4 vs 135.7 +/- 11.5 msec, p=0.0004, respectively). Other univariate predictors of the 
combined endpoint were prior coronary artery bypass surgery, diabetes, extent of coronary 
atherosclerosis and treatment of more than one lesion. In the multivariate model, AIx, 
AIx@75, and Tr were independent predictors of the combined endpoint. Moreover, AIx@75 
was statistically signiﬁcant higher in patients who suffered from individual endpoints (13 
deaths, 20 myocardial infarctions, and 42 restenoses) versus patients who did not.
Conclusion: Increased arterial stiffness and wave reﬂections are independently 
associated with an unfavourable course following PCI.
1069-96 Arterial Stiffness And Carotid Diameter Are Increased In 
Normotensive Patients With Obstructive Sleep Apnea 
Luciano F. Drager, Luiz A. Bortolotto, Maria Cecília Lorenzi, Adelaide C. Figueiredo, 
Eduardo M. Krieger, Geraldo Lorenzi-Filho, Heart Institute (InCor) University of São 
Paulo Medical School, São Paulo, Brazil
Background: Obstructive sleep apnea (OSA) has been close related to hypertension and 
cardiovascular morbidity. Arterial stiffness is considered an independent risk marker to 
premature coronary artery disease and atherosclerosis. We assessed the hypothesis that 
arterial stiffness and carotid diameter are increased in OSA, independently of other risk 
factors.
Methods: All participants were submitted to a standard overnight polysomnography: 
normal results were considered when the apnea hypopnea index (AHI) 30 events per 
hour. Hypertension was excluded according current guidelines by experienced physicians 
not involved in the study. Twelve patients (43.7±1.6 years) with severe OSA and 12 mild-
to-moderate OSA patients (42.5±1.4 years) were submitted to carotid-femoral pulse 
wave velocity (PWV) analysis by non invasive automatic device Complior and carotid 
measurements by high-deﬁnition echotracking device (WTS). The data were compared 
with those obtained in 12 age and sex-matched healthy volunteers (42.1±1.73 years). 
Data were expressed as mean±SEM, and the difference among OSA groups and controls 
were tested by ANOVA.
Results: AHI was 54.9±7.2 events per hour in severe OSA, 14.2±1.8 in mild-to-moderate 
OSA and 3.1±0.3 in control group (p<0.0001). In comparison to control group, severe 
OSA patients showed a higher PWV (10.4±0.3 vs 8.7±0.2 m/s;p<0.0001) and a higher 
carotid diameter (7620.1±192.1 vs 6607.8±126.7 mm; p<0.0001). In mild-to-moderate 
OSA group, PWV and carotid diameter were not different of control group (9±0.2 vs 
8.7±0.2 m/s;p=1.0) and (7098±105.3 vs 6607.8±126.7 mm; p=0.08), respectively. Clinical 
and laboratory parameters were not different among the groups.
In the multivariate analysis, PWV levels were independently related to the AHI (R 
0.63;p=0.001). The intima media thickness was not different among the groups.
Conclusions: The date indicate that arterial stiffness and carotid diameter are increased in 
normotensive severe OSA patients and are independently associated with OSA severity. 
These results suggests an important role of OSA to atherosclerosis development.
1069-97 The Obstructive Sleep Apnea Syndrome in Essential 
Hypertensive Subjects Identiﬁes a State of Subclinical 
Inﬂammatory Processes, and Arterial Stiffening
Costas Thomopoulos, Konstantinos Tsiouﬁs, Anastasia Amﬁlochiou, Carmen Vasiliadou, 
Dimitris Chatzis, Apostolis Kakavas, Maria Papavasiliou, Christodoulos Stefanadis, 
Ioannis Kallikazaros, Hippokration Hospital, Athens, Greece
Background: Oxygen depletion in obstructive sleep apnea syndrome (OSAS) might be 
correlated to an enhanced inﬂammatory process at the wall of great elastic arteries. We 
evaluated the grade of subclinical inﬂammation, and arterial stiffening in hypertensive 
subjects with OSAS.
Methods: For this purpose, we studied aortic elasticity in 33 consecutive essential 
hypertensives [23 men, aged 49±6 years, 15 smokers, ofﬁce blood pressure (BP)= 
150±7/98±10 mmHg], with OSAS diagnosed by polysomnography [apnea/hypopnea index 
(AHI)>5], and in 27 essential hypertensives with negative polysomnography matched 
for age, smoking status, BP, and sex. Aortic pulse wave velocity (PWV) evaluated by a 
computerized device (Complior SP) was used as an index of aortic stiffness, and blood 
samples were drawn for the determination of lipidaemic proﬁle, and homocysteine (HC), 
hsCRP, ICAM-1 levels.
Results: Hypertensives with OSAS, compared to those without OSAS, exhibited increased 
body mass index (BMI), and greater values of HC, hsCRP, and ICAM-1 (30.9±4 vs 28.5±4 
kg/m2, 14.4±3 vs 11.7±4 µmol/L, 4.8±0.9 vs 2.1±0.9 mg/dl, 345±45 vs 223±56 ng/ml, 
respectively p<0.05 for all cases). The two groups did not differ regarding left ventricular 
mass index (107±20 vs 106±28 gr/m2, p=NS) while hypertensives with OSAS, compared 
to those without OSAS, had increased relative wall thickness, and PWV (0.48±0.06 vs 
0.42±0.06, and 7.93±0.9 vs 7.4±0.7 m/sec, respectively, p<0.05 for both cases).
In the OSAS group, AHI was positively related with BMI (r=0.45), ofﬁce systolic BP 
(r=0.37), PWV (r=0.47), and hsCRP values (r=0.46) (p<0.05 for all cases). Multiple linear 
regression analysis revealed that AHI was signiﬁcantly related to PWV, and hsCRP.
Conclusions: Hypertensives with OSAS exhibit increased levels of PWV, hsCRP, and 
ICAM-1, which might explain the contribution of low grade inﬂammation to enhanced 
arterial stiffness in this setting. In severe OSAS increased inﬂammation, and stiffening, 
predispose to adverse cardiovascular outcomes.
1069-98 Acute Systemic Inﬂammation Increases Stiffness of 
Large Arteries
Charalambos Vlachopoulos, Ioanna Dima, Konstantinos Aznaouridis, Carmen 
Vasiliadou, Nikolaos Ioakeimidis, Marina Toutouza, Christodoulos Stefanadis, Athens 
Medical School, Athens, Greece
Background. Aortic stiffness is an independent predictor of cardiovascular risk. An 
association between inﬂammation and increased arterial stiffness has been suggested. 
However, the causative relationship between inﬂammation and arterial stiffness has not 
been investigated.
Methods. 26 healthy individuals (age 36.2 yrs) were studied after Salmonella Typhi 
vaccination that produces a mild, systemic, acute and temporary inﬂammation, and 
after sham-vaccination. Aortic stiffness was evaluated with carotid-femoral pulse wave 
velocity (PWV). Inﬂammatory markers such as hsCRP and total matrix metalloproteinase 
9 (MMP-9) were measured in blood samples.
Results. Inﬂammation did not change systolic, diastolic and pulse pressures both at 8 
hours and 32 hours (P=NS). Inﬂammation led to a signiﬁcant increase in PWV (by 0.40 
m/sec, P<0.05) at 8 hours, denoting an increase in aortic stiffness. PWV values returned 
towards, but not completely, baseline values at 32 hours (increase by 0.19 m/sec, P=NS). 
These effects were associated with signiﬁcant increases in hsCRP and MMP-9 (ﬁgure). 
PWV at 8 hours was signiﬁcantly correlated with hsCRP both at 8 and 32 hours (r=0.48, 
P<0.05, and r=0.52, P<0.01, respectively).
Conclusions. Systemic inﬂammation leads to deterioration of large arteries stiffness 
through a cause-and-effect relationship with concomitant increases in inﬂammatory 
markers. These ﬁndings have important implications for the impact of inﬂammation on 
the cardiovascular system. 
1069-99 C-reactive Protein is Related to Arterial Wave Reﬂection 
and Stiffness in Asymptomatic Subjects From the 
Community
Iftikhar J. Kullo, James B. Seward, Kent R. Bailey, Lawrence F. Bielak, Brandon 
Grossardt, Patricia A. Peyser, Stephen T. Turner, Mayo Clinic, Rochester, MN, University 
of Michigan, Ann Arbor, MI
Background. Emerging data suggest that C-reactive protein (CRP), a marker of 
inﬂammation, is associated with changes in the functional properties of arteries. We 
investigated the relationship of CRP to measures of arterial wave reﬂection and stiffness 
(aortic augmentation index, (AIX), carotid-femoral pulse wave velocity (PWV), and pulse 
pressure) in 214 asymptomatic individuals from the community.
Methods. Subjects had a mean age of 59.6 years and 53% were men. CRP was measured 
by a high-sensitivity assay and values were log-transformed to reduce skewness. Radial 
artery pulse waveforms were obtained by applanation tonometry and an ascending aortic 
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pressure waveform derived by a validated transfer function. AIX is the difference between 
the ﬁrst and second systolic peak of the ascending aortic pressure waveform expressed 
as a percentage of the aortic pulse pressure. PWV was determined by sequentially 
recording ECG-gated carotid and femoral artery waveforms by applanation tonometry. 
Brachial artery pulse pressure was obtained using a random zero sphygmomanometer.
Results Log CRP was correlated with AIX (r = 0.24, P = 0.0005), PWV (r = 0.25, P = 
0.0002), and pulse pressure (r = 0.29, P = <0.0001). Multiple regression models were 
constructed to assess the relationship of log CRP with each of the arterial function 
measures (AIX, PWV, and pulse pressure) after adjustment for heart rate and height, 
and after additional adjustment for CHD risk factors including age, male sex, body mass 
index, mean arterial pressure, total cholesterol, HDL cholesterol, diabetes, and history of 
smoking. Log CRP was signiﬁcantly and positively associated with AIX, PWV, and pulse 
pressure after adjustment for these potential confounders.
Conclusion. CRP, a marker of systemic inﬂammation, is related to measures of arterial 
wave reﬂection and stiffness in asymptomatic subjects from the community. Causality 
cannot be inferred in this cross-sectional study and further studies are needed to assess 
whether reducing systemic inﬂammation will result in beneﬁcial effects on arterial function.
1069-135 Long-term Use of Pioglitazone Slows Arteriosclerotic 
Progression in Type-2 Diabetics
Tatsuaki Murakami, Masateru Ohnaka, Fukui Cardiovascular Center, Fukui, Japan
Background: Insulin resistance is thought to be highly involved in arteriosclerotic 
processes, but the long-term effects of insulin sensitizers remain unknown. We assessed 
hypothesis that long-term use of pioglitazone, an insulin sensitizer, slows ultrasonic 
manifestation of arteriosclerosis.
Methods: Thirty type-2 diabetic patients with suspected coronary artery disease were 
randomized to group-P where they received pioglitazone (30mg per day), or to group-
C where they continued therapy without thiazolidinedione for more than 1 year. We 
noninvasively quantiﬁed ﬂow mediated dilation of brachial artery after 5 minutes forearm 
occlusion (FMD) and arterial stiffness by brachial-to-ankle pulse wave velocity (PWV). 
Changes in FMD and PWV from the baseline through the follow-up point were compared 
between the 2 groups. 
Results: Group-P (n=15) manifested good compliance to the treatment and improvements 
in insulin resistant variables represented by HOMA-IR (p=0.01) while group-C showed no 
improvement. FMD (%) improved after medication in group-P (p<0.01) but not in group-
C. PWV (cm/sec) decreased in group-P(p=0.02) but increased in group-C (p=0.03). 
Changes of FMD or PWV did not correlate to those of HbA1c (FMD: r=0.17, p=0.76, 
PWV: r=0.15, p=0.82).
Conclusion: Long-term thiazolidinedione use improves endothelial function and arterial 
wall stiffness independent of blood glucose lowering, which may have beneﬁcial potentials 
for management of arteriosclerosis in type-2 diabetics.
Group-P baseline Group-P follow-up Group-C baseline Group-C follow-up
HOMA-IR 2.65± 1.45 2.23 ± 1.20 2.64 ± 1.29 2.66 ± 1.31
FMD (%) 4.0±1.6 7.0±2.9 4.2±1.9 4.3±1.6
PWV (cm/sec.) 1727±269 1644±232 1710±232 1797±215
1069-136 Effects of Peroxisome Proliferator-Activated Receptor 
(PPAR) - γ Ligands, Pioglitazone, on Endothelial 
Function and Nitrate Tolerance in Type 2 Diabetics With 
Stable Angina
Hideki Watanabe, Kunio Nakagawa, Masaaki Kakihana, Kinu Medical Association Hospital, 
Mitsukaido, Japan, Makabe-Silvertopia Facilities for Geriatric Care, Makabe, Japan
Background: Diabetic patients have endothelial dysfunction due to increased oxidative 
stress. Continuous nitroglycerin (NTG) therapy has been reported to increase oxidative 
stress due to increased angiotensin II, and to induce not only nitrate tolerance, but 
also NTG-induced endothelial dysfunction. PPAR-� ligands have been known to inhibit 
proatherogenic effects of angiotensin II. We assessed the effects of pioglitazone, a 
PPAR-� ligand, on endothelial function, nitrate tolerance, and NTG-induced endothelial 
dysfunction. Methods: Twenty type 2 diabetics with stable angina were randomized 
to receive pioglitazone (Piog group) or not to receive pioglitazone (Cont group). Flow-
mediated dilatation (FMD) and NTG-induced dilatation (NID) of brachial artery were 
measured by using ultrasound system. These measurements were performed at baseline, 
and then at 1 month after the therapy with pioglitazone (1 Mo) and 1 month after the 
therapy with pioglitazone and NTG patch 25 mg/day (2 Mo). Results: At baseline, there 
was no difference in FMD and NID between two groups. FMD was signiﬁcantly increased 
at 1 and 2 Mo in the Piog group, but was signiﬁcantly decreased at 2 Mo in the Cont group. 
NID did not change during the study in the Piog groups, but was signiﬁcantly decreased at 
2 Mo in the Cont group. Conclusion: Pioglitazone, a PPAR-� ligand, improves endothelial 
function, and prevents nitrate tolerance and NTG-induced endothelial dysfunction in type 
2 diabetics with stable angina.
Baseline 1 month 2 months
FMD (%) Pioglitazone group 3.6 ± 1.3 6.5 ± 1.3 * 6.9 ± 1.0 *†
Control group 3.6 ± 1.1 3.4 ± 1.2 2.1 ± 1.4 *
NID (%) Pioglitazone group 15.3 ± 2.1 15.5 ± 1.9 14.5 ± 2.8 †
Control group 15.2 ± 2.0 15.2 ± 2.2 11.0 ± 1.4 *
Data are means ± SD. *p<0.01 vs Baseline, †p<0.01 vs Control group. FMD, ﬂow-mediated 
dilatation; NID, nitroglycerin-induced dilatation.
1069-139 Diabetes Duration And Glycaemic Control Have A 
Different Effect On Endothelial Dysfunction In Children 
With Type I Diabetes.
Rosario Rossi, Elena Cioni, Annachiara Nuzzo, Lorenzo Iughetti, Barbara Predieri, Maria 
Grazia Modena, Institute of Cardiology of Modena and Reggio Emilia, Modena, Italy
Background: Endothelial dysfunction plays a pathophysiological role in the development 
of atherosclerosis in subjects with type 1 diabetes.
It is well known that an optimal glycaemic control does not prevent in any way the 
development of cardiovascular events. The aim of our study was to verify, in pediatric 
patients, if endothelial dysfunction was inﬂuenced by glycaemic control or by other 
independent parameters.
Methods: Noninvasive ultrasounds were used to measure brachial artery ﬂow-mediated 
dilation (FMD) responses in 34 children (mean age 10.8±3,4 years), with type 1 diabetes 
(mean diabetes duration 52±6.8 months, range: 5-170 months). For each patient 
we determined circulating levels of fasting plasma glucose, HbA1C, lipidic proﬁle and 
anthropometric parameters
Results: Mean fasting plasma glucose, HbA1C, total cholesterol, LDL cholesterol, HDL 
cholesterol, tryglicerides, BMI and FMD were, respectively, 226.5±101.8 mg/dl; 8.4±1.4%; 
166±31.5 mg/dl; 89.1±26.5 mg/dl; 61.9±13.9 mg/dl; 68.8±43.8 mg/dl; 19±2.4 e 6.8±1.4 
(SEM) %. In our patients FMD was signiﬁcantly correlated with diabetes duration (r=-0.45; 
p=0.008; see ﬁgure), while there was not correlation with other parameters, including 
glicaemic control evaluated by HbA1C dosage.
Conclusions: Flow mediated dilation is related with diabetes duration in pediatric patients 
This may explain early development of cardiovascular complications in adults with type I 
diabetes in spite of good glycaemic control.
1069-140 The Effects Of Quit Smoking On Coronary Endothelial 
Function In Patients With Recent Myocardial Infarction
Shinobu Hosokawa, Yoshikazu Hiasa, Yoshikazu Ohara, Naoki Suzuki, Takefumi 
Takahashi, Koichi Kishi, Ryuji Ohtani, Tokushima Red Cross Hospital, Komatsushima, 
Japan
Background: Smoking is associated with an increased risk and extent of advanced 
atherosclerotic vascular disease, but few studies have examined the clinical effect of quit 
smoking on human coronary endothelial function. OBJECTIVES: We sought to determine 
the effects of the quit smoking on endothelial function in patients with recent myocardial 
infarction. METHODS: Infarcted-not-related coronary artery of 73 patients with acute 
myocardial infarction undergoing successful angioplasty were examined in two groups: 
quit smoking group (n=45,38 Males,mean age 56 years),non smoking group (n=38,20 
Males, mean age 65 years). We infused acetylcholine into the coronary artery and the 
diameter was assessed by quantitative angiography at baseline and six months after 
PTCA. RESULTS: The mean % diameter change of baseline was signiﬁcantly constricted 
in the quit smoking group than in the non-smoking group(38%±5 vs 19%±5,p<0.05) . 
Howevew, coronary response after six month was signiﬁcantly decreased by quit smoking 
(from38%±5 to28%±4,p<0.05). Multiple regression analysis showed that quit smoking 
(p=0.03) was the signiﬁcant determinant factor for improvement of endothelial function. 
CONCLUSIONS: These ﬁndings suggest that just six months of quit smoking improves 
endothelial function of coronary artery in patients with recent myocardial infarction.
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1069-141 Diesel Exhaust Inhalation Causes Vascular Dysfunction 
and Impaired Endogenous Fibrinolysis: An Explanation 
for the Increased Cardiovascular Mortality Associated 
with Air Pollution
Nicholas L. Mills, Håkan Tornqvist, Simon D. Robinson, Kareen Darnley, Manuel 
Gonzales, Nicholas A. Boon, William MacNee, Ken Donaldson, Anders Blomberg, 
Thomas Sandstrom, David E. Newby, Centre for Cardiovascular Science, Edinburgh, 
United Kingdom, Respiratory Medicine and Allergy, Umeå, Sweden
Background: Although the mechanisms are unknown, air pollution is associated with an 
increase in cardiovascular morbidity and mortality. The study aim was to investigate the 
effects of diesel exhaust inhalation on vascular and endothelial function in man.
Methods: In a double blind randomised crossover study, 15 healthy men were exposed to 
dilute diesel exhaust (300 µg/m3) or air for one hour during intermittent exercise. Six hours 
following exposure, bilateral forearm blood ﬂow, and plasma ﬁbrinolytic and inﬂammatory 
factors were measured before and during unilateral intra-brachial bradykinin (100-1000 
pmol/min), acetylcholine (5-20 µg/min), and sodium nitroprusside (2-8 µg/min) infusions.
Results: There were no differences in whole blood leukocyte count, serum C-reactive 
protein concentrations or resting forearm blood ﬂow following exposure to diesel exhaust 
or air. There was a dose dependent increase in blood ﬂow with each vasodilator (p<0.001 
for all) that was attenuated following exposure to diesel exhaust: bradykinin (peak dose, 
21.4±2.4 to 18.0±1.2 mL/100 mL/min; p=0.006), acetylcholine (peak dose, 11.6±1.7 
to 9.8±0.9 mL/100 mL/min; p=0.07), and sodium nitroprusside (peak dose, 14.2±1.1 
to 11.1±0.7 mL/100 mL/min; p<0.001). Bradykinin caused a dose-dependent increase 
in plasma tissue plasminogen activator (tPA) release (p<0.001) that was suppressed 
following exposure to diesel (peak dose, 138±28 to 83±12 ng/100 mL/min; p<0.05: area 
under the curve decreased by 34%).
Conclusion: At levels commonly encountered in an urban environment, inhalation of 
diesel exhaust impairs vascular vasomotor and ﬁbrinolytic function in man. Our ﬁndings 
provide a potential mechanism whereby air pollution increases cardiovascular morbidity 
and mortality.
1069-142 Treatment With Recombinant Granulocyte Colony 
Stimulating Factor Improves Endothelial Function 
Despite Concomitant C-Reactive Protein Elevation
Ignatios Ikonomidis, Jonh Lekakis, Christos Papadimitriou, Athanasios Protogerou, 
Matina Makri, Paraskevi Katsichti, Georgia Vamvakou, Christos Papamichail, Athanasios 
Dimopoulos, Myron Mavrikakis, University of Athens, Athens, Greece
Granulocyte colony stimulating factor (GCSF) is used in mobilisation of endothelial 
progenitor cell. Concerns have been raised about GCSF-induced inﬂammation within the 
vascular wall. We examined the effects of GCSF administration on endothelium in vivo.
Methods: We studied 50 women with excised breast cancer. Forty-two patients received 
a 5-day course of s.c. GCSF (5µg/kg), o.d. after adjunctive chemotherapy and 8 received 
placebo. Flow-mediated, endothelium-dependent dilatation (FMD%) and nitrate-mediated, 
endothelium-independent dilatation (NMD%) of the brachial artery was assessed by 
ultrasonography at baseline before chemotherapy (FMD, NMD 0), before (FMD, NMD 1) 
and 2 hours (FMD, NMD 2) after the ﬁrst s.c. injection of GCSF or placebo and at the end 
(FMD, NMD 3) of a 5-day treatment with GCSF or placebo. CRP serum levels were also 
assessed at the above periods.
Results. FMD increased 2 hours after the ﬁrst GCSF injection (FMD2) and remained 
improved at the end of GCSF treatment (FMD3) compared to FMD before treatment 
(FMD1) (P<0.05, table). NMD remained unchanged throughout the study. CRP was 
increased at the end of GCSF treatment (CRP3). (p<0.05). There were no changes of 
FMD, NMD and CRP after placebo treatment.
Conlcusion. Treatment with GCSF improves endothelial function despite a concomitant 
increase of CRP levels and thus, may be safely used to facilitate neovascularisation and 
rendothelialisation after endothelial cell damage.
 
0 1 2 3
FMD (%) 4.9±3.2 4.3±3.3* 6.2±3.4 5.7±2.8
NMD (%) 15.8 ±7.3 14.9±8 13.3±4.1 14.5±4.5
CRP(mg/l) 0.6±0.2 0.59±0.2 0.75±1 1.4±2*
*p<0.05 for FMD1 vs. FMD2 and FMD3 and for CRP 3 vs. CRP0 ,CRP1,CRP2
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1070-119 Statin Therapy is Critical in Heart Failure Patients Who 
Meet National Cholesterol Education Panel High Risk 
Criteria
Richard A. Krasuski, Brad Smith, Karl C. Stajduhar, Michael D. Kwan, Robert Ellis, 
Autumn Dawn Galbreath, Gregory L. Freeman, Wilford Hall Medical Center, San 
Antonio, TX, University of Texas Health Science Center, San Antonio, TX
Background: Statins are a cornerstone in the treatment of coronary artery disease 
(CAD). Limited studies are available to guide statin use in patients with heart failure (HF). 
We sought to determine which HF patients beneﬁted most from statin therapy.
Methods: Medication use was assessed at study entry in 1028 patients randomized into 
a single-center, community-based, 18-month trial of HF disease management. Baseline 
demographics and clinical outcomes of the 520 statin users were compared to the 508 
patients not taking statins.
Results: Compared to nonusers, patients taking statins were slightly younger, more 
likely male, more likely to have CAD (81% vs. 60%, p<0.001) or documented myocardial 
infarction, and more likely to receive aspirin or beta-blockers. Diabetes frequency and 
echo ejection fractions were similar. All-cause mortality was 9% over a median of 18 
months. After adjustment for baseline differences, all-cause mortality was reduced by 
55% with statins (p<0.001), though no reduction in HF hospitalization was seen. Beneﬁt 
was seen regardless of gender, age, systolic or diastolic mechanism, or HF class. The 
greatest reduction in mortality was seen in patients with an ischemic HF etiology or 
diabetes (7 patients needed treatment to prevent 1 death).
Conclusions: Statins are very beneﬁcial in patients with HF, particularly when used in 
guideline-established, high risk groups. Until ongoing randomized trials are completed, 
providers would be wise to ensure adequate therapy in these patients.
1070-120 The Duration of Preprocedural Statin Treatment 
Is Essential for the Limitation of Stenting-Related 
Myocardial Injury
Michael Haude, Lothar Volbracht, Thomas Konorza, Igor Kordisch, Rainer Schulz, Gerd 
Heusch, Raimund Erbel, West German Heart Center Essen, Essen, Germany
Background: Stenting-related myocardial injury (MI) is caused by microembolisation of 
platelet aggregates and plaque debris together with inﬂammation. HMG-CoA reductase 
inhibitors (statins) have been shown to limit MI primary because of their pleiotropic effects. 
Nevertheless, the duration of statin pretreatment for the prevention of MI is unclear. Thus, 
we tested whether pre-procedural statin therapy of different duration has an impact on MI.
Methods: We stratiﬁed 1218 consecutive patients (pts) with uncomplicated stenting 
according to their pre-procedural status of statin therapy (1012 statin-pos. and 206 
statin-neg. pts). Peri-procedural MI was assessed by analysis of creatine kinase (CK); 
CK-MB and cardiac troponin I (TI) before, 6, 12, and 24 hours after the intervention. 
Statin pretreated pts were clustered according to the duration of statin pretreatment (see 
Fig. 1).
Results: Postinterventional maximum CK, CK-MB, and TI elevations were larger in statin-
neg. pts (68±62 vs 52±46 IU/L; 24±20 vs 18±18 IU/L; and 0.46±0.48 vs 0.38±0.42mg/L; 
all p<0.001). A statin pretreatment for at least 3 to 6 months is essential to maintain a 
constantly low incidence of stenting-related MI independent of the applied marker or its 
cut-off value (Fig. 1 illustrates CK data, ULN = upper limit of normal range).
Conclusions: Pre-procedural statin therapy is required for at least 3 to 6 months to limit 
stenting-related MI most effectively. 
1070-121 Undertreatment of Atherothrombotic Patients 
Worldwide: Baseline Data From the REACH REGISTRY
Philippe Gabriel Steg, Deepak L. Bhatt, E. Magnus Ohman, Joachim Rother, Peter W. F. 
Wilson, on Behalf of the REACH Registry Investigators, Hôpital Bichat, Paris, France
Background: Most of the currently available epidemiological data on atherothrombosis 
pertain to Europe, the Americas and Japan, address hospitalized patients and 
speciﬁc symptomatic settings (eg stroke or acute coronary syndromes as opposed to 
atherothrombosis).
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Aims: To describe baseline characteristics and management practices of atherothrombotic 
patients throughout the world. To assess adherence to guideline-recommended practice 
and achievement of therapeutic goals.
Methods: The REACH (REduction of Atherothrombosis for Continued Health) 
Registry is an international prospective observational registry of outpatients at risk of 
atherothrombotic events or with symptomatic atherothrombosis (documented coronary 
artery, cerebrovascular or peripheral arterial disease). Between December 2003 and July 
2004, >63,000 patients were enrolled in >5,000 sites in 43 countries in the Americas (NA, 
LA), Eastern and Western Europe (EE, WE), Australia/Middle East/Asia (AMEA).
Results: Selected preliminary results on 57,340 patients are shown in Table, the average 
age of the population was 68.4±10.2 years and 37% were females. 
Table. Regional comparison of risk factors
NA LA WE EE AMEA Signiﬁcance
N (% of total) 26086(45.5)
1741
(3.0)
16086
(28.1)
5515
(9.6)
7912
(13.8) p < 0.0001
BP <140/<90 (%) 60.0 46.9 40.1 34.9 46.4 p < 0.0001
TC <200 mg/dL (%) 72.1 57.9 52.6 35.8 61.0 p < 0.0001
Glucose (mg/dL) (SD) 121±42 123±48 118±41 111±37 124±46 p < 0.0001
Current smoker (%) 14.7 9.3 16.6 21.0 11.6 p < 0.0001
Use of at least one 
antiplatelet agent (%) 77.9 87.7 78.6 86.6 81.2 p < 0.0001
Use of statin (%) 76.1 62.7 69.7 56.8 65.7 p < 0.0001
Conclusions: There were substantial differences between geographic regions in terms 
of risk factors. However, in these 2004 data, there was consistent underachievement of 
therapeutic goals found across patient types and geographic areas.
1070-122 Association Between Time of Statin Initiation Following 
Hospital Discharge From Acute Myocardial Infarction 
and Risk of Recurrence and Mortality in Elderly Patients
Zheng Zhou, Elham Rahme, Louise Pilote, Montreal General Hospital, Montreal, PQ, 
Canada, McGill University, Montreal, PQ, Canada
Background Clinical studies have shown the beneﬁt of statin initiation after acute 
myocardial infarction (AMI). However, it is unclear, among users, how this effect can be 
modiﬁed by the difference in the timing of initiation after AMI.
Methods We created a retrospective cohort (1996-2000) using Quebec healthcare 
databases to compare post-AMI patients (≥ 65 years) differing in their time of statin 
initiation in the ﬁrst 90 days after discharge. Patients who started statin at discharge (early 
group) were compared to those who initiated statin 1 month later and up to 90 days post 
discharge (delayed group). Outcome of recurrent AMI or death was evaluated at 3, 6 
months and 1 year. In addition, the effect was evaluated for statin initiated anytime during 
the ﬁrst 90 days as compared to no use of statin. A multivariate Cox regression model 
was used in all comparisons. We used prescription time distribution matching and time-
dependent methods to control for survival bias between groups.
Results The early and delayed group consisted of 3,075 and 1,187 patients, respectively. 
During the 1 year follow up, no signiﬁcant difference in the outcome was detected 
between the early and delayed statin group. The adjusted hazard ratio (HR) for initiation 
since discharge versus between 30-90 days was 1.03 (95% CI 0.56-1.87) at 3 months and 
was 1.24 (0.96-1.62) at 1 year. Analyses restricted to ﬁrst time users or excluding very 
sick patients or those ≥ 85 years did not change the result. Our ﬁndings were not affected 
by changing the deﬁnition of delayed use within the 90-day period. Compared to no use, 
statin started during the ﬁrst 90 days was associated with a signiﬁcant risk reduction, 
which occurred as early as by 3 months (adjusted HR 0.84, 0.72-0.98) and persisted 
through the rest of follow up.
Conclusion Our study did not reveal any signiﬁcant difference in outcome resulting from 
a delay of statin initiation up to 30-90 days post discharge following AMI as compared with 
initiation at discharge. Statin initiated within the ﬁrst 90 days was associated with an early 
and sustained beneﬁt as compared to no use.
1070-123 Impact of Aggressive Treatment With Atorvastatin 
on Renal Function in Managed Care Patients With 
Coronary Heart Disease: The ALLIANCE Study
Michael J. Koren, Michael H. Davidson, The ALLIANCE Investigators, Jacksonville 
Center for Clinical Research, Jacksonville, FL, Chicago Center for Clinical Research, 
Chicago, IL
Background: Previous data suggest that atorvastatin may have nephroprotective effects, 
possibly as a result of vascular disease beneﬁts. The Aggressive Lipid-Lowering Initiation 
Abates New Cardiac Events (ALLIANCE) study is a recently completed prospective, 
randomized trial demonstrating that aggressive lipid lowering with atorvastatin signiﬁcantly 
reduced coronary events compared with usual care in patients with coronary heart 
disease (CHD) enrolled in managed care organizations and Veterans Affairs settings. We 
retrospectively analyzed whether or not treatment with atorvastatin versus usual care 
improved renal function in this population.
Methods: 2442 CHD patients with dyslipidemia were randomized to either an aggressive 
treatment arm using atorvastatin, or usual care. Atorvastatin-treated patients were titrated 
to an LDL-cholesterol goal of <80 mg/dL or a maximum atorvastatin dose of 80 mg/
d. Patients randomized to usual care continued their baseline lipid treatment, with any 
further changes in therapy directed by their primary attendant physician. Renal function 
was compared at baseline and at 48 months, using creatinine clearance (CrCl) calculated 
using the Cockroft-Gault formula.
Results: CrCl was similar in the two groups at baseline (mean [SD] CrCl = 88.6 [30.8] 
mL/min in the atorvastatin group and 87.2 [28.8] mL/min in the usual care group; P=0.32). 
After 48 months, there was a mean (SE) decline in CrCl of 4.4% (0.75) in the usual care 
group (mean = 83.0 mL/min; P=0.0001 compared with baseline). Over the same time 
period, CrCl did not change in the atorvastatin group (-0.06% [0.67]; mean = 88.3 mL/min; 
P=0.93 compared with baseline). The difference in mean change from baseline between 
the atorvastatin and usual care groups was highly signiﬁcant (P=0.0001). There were no 
signiﬁcant interactions between treatment and gender, age, or race. Blood pressure control 
was equivalent between groups. Safety and tolerability were similar in the two groups.
Conclusion: In addition to improved lipid control and reductions in coronary events, 
aggressive treatment with atorvastatin prevents deterioration in renal function compared 
with usual care in patients with CHD.
1070-124 Higher Statin Dose Is Associated With Lower All-cause 
Mortality: Evidence For A Dose-response Relationship 
In Primary Prevention
Herbert D. Aronow, Frederick F. Samaha, Mark Weiner, Stephen E. Kimmel, Dominic 
Roche, Monica Williams, Paula Jacobs, Michael S. Lauer, Philadelphia VA Medical 
Center/Hospital of the University of Pennsylvania, Philadelphia, PA, Cleveland Clinic 
Foundation, Cleveland, OH
Background: Observational and randomized secondary prevention studies suggest that 
the intensity of statin therapy is directly related to the degree of accrued clinical beneﬁt. It 
is not known whether statin dose is related to clinical outcome when utilized for primary 
prevention.
Methods: We conducted a retrospective cohort study relating maximum prescribed 
simvastatin dose to all-cause mortality among patients treated at the Philadelphia Veterans 
Administration Medical Center who had no history of coronary artery disease (CAD) or 
CAD risk equivalents. Clinical and pharmacy data were extracted from the electronic 
medical record. Vital status was ascertained using the Social Security Death Index.
Results: We identiﬁed 4,878 patients (median age 70; 96% men) treated with simvastatin 
for primary prevention between April 1994 and December 2003. The median duration 
of follow up was 743 days, during which time there were 191 deaths. In an unadjusted 
analysis, there was a stepwise decline in all-cause mortality associated with increasing 
daily simvastatin dose: 10 mg (32/222, 14.4%), 20 mg (75/1091, 6.9%), 40 mg (53/2137, 
2.5%), 80 mg (31/1428, 2.2%); log rank chi square 68.4, p<0.0001. In a Cox proportional 
hazards model adjusting for demographic characteristics, atherosclerosis risk factors and 
other medical comorbidities, increasing simvastatin dose was associated with reduced all-
cause mortality: 20 mg HR 0.56 [95% CI 0.37-0.86]; 40 mg HR 0.22 [95% CI 0.14-0.35]; 
and, 80 mg: HR 0.18 [95% CI 0.11-0.29], when compared with 10 mg daily.
Conclusion: In this cohort of elderly, primarily male patients without CAD or CAD 
risk equivalents, each successive increase in simvastatin dose was associated with a 
decrement in all-cause mortality. These data suggest that more aggressive cholesterol-
lowering therapy may be associated with superior clinical outcomes when employed for 
primary prevention. Randomized trials to test this hypothesis appear warranted.
1070-125 Meta-Analysis of Randomized Controlled Trials of 
Statin Therapy versus Placebo: Importance of Achieved 
Differences in LDL-Cholesterol
Jorge R. Kizer, Christopher Madias, Brian Wilner, Carl J. Vaughan, Alvin I. Mushlin, 
Andrew J. Vickers, Paula Trushin, Antonio M. Gotto, Richard C. Pasternak, Weill Cornell 
Medical Center, New York, NY
A variety of landmark randomized controlled trials (RCTs) have established the efﬁcacy 
of statins for the prevention of coronary heart disease (CHD) in patients at various levels 
of risk. Although most of the large trials conducted to date have found signiﬁcant beneﬁt, 
this has not been true of all published studies. We performed a systematic review of large-
scale trials of statins to assess the magnitude of beneﬁt across studies, & to examine 
differences in reported reductions in risk. Relevant studies were identiﬁed by MEDLINE 
search. We limited inclusion to RCTs of statins vs placebo/usual care for 1ry or 2ry 
prevention of CHD that enrolled >1,000 subjects, had follow-up >1 year, & ascertained 
CHD outcomes. Eleven RCT’s satisfying entry criteria were included (Figure). There was a 
sizable overall reduction in the risk of CHD (summary OR = .69, 95% CI .62-.73), but this 
occurred in the setting of signiﬁcant heterogeneity in trial results (P<.001). Weighted linear 
regression showed that a major component (adjusted R2=.57, P=.005) of the variability 
in treatment effects could be explained by the difference in post-treatment LDL (Figure). 
Large-scale clinical trials of statins demonstrate highly variable reductions in the relative 
risk of CHD that are related principally to achieved differences in LDL levels. These 
ﬁndings serve to conﬁrm the importance of LDL lowering as a determinant of statins’ 
cardiovascular beneﬁts & of post-treatment LDL differences to the design & interpretation 
of statin RCTs. 
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1070-126 Inhibition of Intestinal Cholesterol Absorption and 
Endogenous Cholesterol Synthesis by Ezetimibe/
Simvastatin in Humans
Thomas Sudhop, Dieter Lutjohann, Michael Reber, Diane L. Tribble, Patrice Gibbons, 
Aditi Sapre, Klaus von Bergmann, University of Bonn, Bonn, Germany, Merck Research 
Laboratories, Rahway, NJ
Background: Combining inhibition of cholesterol synthesis with inhibition of cholesterol 
absorption is a new concept in lowering LDL cholesterol (LDL-C).
Methods: This was a randomized, double-blind, placebo (PBO) controlled, 4-period 
crossover study to evaluate the effects of coadministering ezetimibe (EZE) 10 mg with 
simvastatin (SIMVA) 20 mg on cholesterol absorption and synthesis relative to either drug 
alone or to PBO. Each treatment period lasted 7 weeks.
Results: EZE alone and in combination with SIMVA (EZE/SIMVA) reduced cholesterol 
absorption by 65% and 59%, respectively (p<0.001 for both relative to PBO; Table). SIMVA 
did not affect cholesterol absorption. EZE increased lathosterol and the ratio of lathosterol/
cholesterol (markers of cholesterol synthesis) by 67% and 62%, respectively (p<0.001 
relative to PBO), whereas SIMVA and EZE/SIMVA reduced these markers (in the range 
of 50% to 70%) relative to PBO and EZE, respectively (p<0.001 for both). Cholesterol 
synthesis rates measured by the fecal balance method showed similar trends; however, the 
inhibitory effects of SIMVA and EZE/SIMVA were lower. EZE/SIMVA produced signiﬁcant 
reductions in LDL-C relative to PBO, EZE, and SIMVA and was well tolerated.
Conclusion: EZE and SIMVA maintain their respective independent effects on cholesterol 
absorption and synthesis when coadministered. Thus, by inhibiting both intestinal 
absorption and synthesis, EZE/SIMVA (10/20 mg) reduces plasma concentrations of 
LDL-C by more than 50%.
 
PBO EZE 10 SIMVA 20 EZE/SIMVA 10/20
Geometric mean (SD) (n=39) (n=39) (n=39) (n=39)
Cholesterol Absorption (%) 48.7 (11.6) 17.0 (19.4) 50.7 (12.2) 20.0 (14.5)
Lathosterol (mg/dL) 0.35 (0.14) 0.47 (0.15) 0.13 (0.05) 0.17 (0.05)
Lathosterol/Cholesterol Ratio 
(µg/mg) 1.50 (0.63) 2.43 (0.83) 0.79 (0.30) 1.24 (0.31)
Cholesterol synthesis (fecal 
balance, mg/day) 884 (649) 1851 (798) 787 (567) 1591 (755)
LDL-C (LS mean (SD) % 
change from baseline) 2.7 (1.3) -19.7 (1.3) -38.1 (1.3) -54.7 (1.3)
1070-127 Efﬁcacy and Safety of Ezetimibe/Simvastatin in Elderly 
Patients with Primary Hypercholesterolemia
Theodore Feldman, Neil Fraser, Arvind Shah, Darbie Maccubbin, Diane Tribble, Stephen 
Donahue, Miami Research Associates, Coral Gables, FL, Merck Research Laboratories, 
Rahway, NJ
Background: The incidence of cardiovascular disease increases with advancing age. 
Ezetimibe/simvastatin (EZE/SIMVA) inhibits both cholesterol absorption and biosynthesis 
and may help to optimize treatment of older individuals with hypercholesterolemia. 
Methods: This was a predeﬁned age subgroup analysis of data from a randomized, 
double-blind, placebo (Pbo)-controlled study. After washout and a 4-wk diet/Pbo run-in, 
1183 patients <65 years and 345 patients ≥65 years with LDL-C 145 - 250 mg/dL and 
triglycerides (TG) ≤350 mg/dL were randomized to: EZE/SIMVA (10/10, 10/20, 10/40, 
or 10/80 mg); SIMVA alone (10, 20, 40, or 80 mg); EZE 10 mg; or Pbo for 12 wks. The 
primary endpoint was % change from baseline in LDL-C for pooled EZE/SIMVA vs pooled 
SIMVA alone. 
Results: Treatment effects in older and younger patients were similar and consistent with 
the whole study cohort. Compared with SIMVA alone, EZE/SIMVA signiﬁcantly reduced 
LDL-C, non-HDL-C, apo B, TG, and C-reactive protein (CRP) (table). Increases in HDL-C 
were similar for both treatments. More older and younger patients receiving EZE/SIMVA 
vs SIMVA alone achieved LDL-C <70 mg/dL (34% vs 6% for <65 yrs and 53% vs 12% 
for ≥65 yrs; p<0.001 for both) or <100 mg/dL (76% vs 43% for <65 yrs and 87% vs 56% 
for ≥65 yrs ; p<0.001 for both). EZE/SIMVA was generally well tolerated in older and 
younger patients. 
Conclusion: EZE/SIMVA offers a highly efﬁcacious lipid-altering option for the treatment 
of primary hypercholesterolemia in elderly patients.
 
Parameter
LS Mean (SE) % Change from Baseline
<65 years ≥65 years
Pooled SIMVA
(N=470-485)
Pooled EZE/
SIMVA
(N=432-459)
Pooled SIMVA
(N=123-127)
Pooled EZE/
SIMVA
(N=134-145)
P-value 
for Pooled 
Comparisons2
LDL-C -38.0(0.6) -52.0(0.7) -42.8(1.2) -56.2(1.1) <0.001
Non-
HDL-C -35.1(0.6) -47.7(0.6) -39.2(1.1) -51.5(1.0) <0.001
Apo B -30.8(0.6) -41.5(0.6) -34.7(1.0) -44.8(1.0) <0.001
TG1 -20.9(1.4) -24.1(1.3) -20.8(2.6) -26.8(1.8) <0.010
CRP1 -16.2(3.0) -27.3(3.2) -17.1(4.6) -38.5(4.5) <0.001
HDL-C  6.7(0.6)  7.7(0.6)   7.4(1.1) 5.9(1.0)  NS
1median (SE for the median); 2p-value for EZE/SIMVA vs SIMVA in whole cohort can 
be applied to age subgroups. EZE: ezetimibe; SIMVA: simvastatin; LDL-C: low-density 
lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; Apo: apolipoprotein; 
TG: triglyceride; CRP: C-reactive protein; NS=not signiﬁcant
1070-128 Implications of the New Recommendations From the 
National Cholesterol Education Program Writing Group: 
Results From a National Survey of Lipid Management
Michael H. Davidson, David Maron, Gregg Fonarow, Kevin Maki, Thomas Pearson, Mary 
Dicklin, Radiant Development, Chicago, IL
Background: Recently, the National Cholesterol Education Program (NCEP) Writing 
Group recommended new optional modiﬁcations to the Adult Treatment Panel (ATP) III 
cholesterol goals.
Methods: NCEP Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II was 
designed to estimate the probability of achieving ATP III cholesterol goals among treated 
dyslipidemic patients. US physicians who were high prescribers of lipid-modifying 
medications (n=376) enrolled 10 or 20 consecutive patients (February-September 2003). 
Data associated with a single ofﬁce visit were entered into the NEPTUNE II software on 
a Personal Digital Assistant and uploaded to a central database via the Internet. An a 
posteriori analysis was performed to examine the fraction of patients at very high risk as 
well as the percentage of these with LDL-C values meeting the new, optional treatment 
target of <70 mg/dL.
Results: Of the 4885 patients, 2708 (55%) had coronary heart disease or risk equivalents. 
Of the 1447 patients with cardiovascular disease, 1082 (75%) had the additional risk 
factors listed in the table below and thus were classiﬁed as very high-risk patients, as 
outlined in the updated NCEP Writing Group recommendations. 
Cardiovascular Disease (n=1447) Plus Very High-Risk Criteria LDL-C
<100 mg/dL <70 mg/dL
n %
Diabetes 526 60 22
Cigarette smoking 214 54 19
Hypertension + HDL-C <40 mg/dL 369 65 19
Triglycerides ≥200 + HDL-C <40 mg/dL 254 65 21
Metabolic syndrome 849 61 19
All very high-risk 1082 60 18
Conclusion: In NEPTUNE II, a large proportion of patients with cardiovascular disease 
would be classiﬁed as very high risk, whereas a small minority has an LDL-C level that 
meets the new optional goal, indicating a need for more aggressive treatment.
1070-129 Ezetimibe Added to Rosuvastatin for Severely 
Hypercholesterolemic Patients: Effects on Low-Density 
Lipoprotein Cholesterol and C-Reactive Protein
Evan A. Stein, Susan Harris, Margo Schleman, Philip T. Sager, Metabolic & 
Atherosclerotic Research Center, Highland Heights, KY, AstraZeneca, Wilmington, DE
Background: Patients with severe hypercholesterolemia, including familial 
hypercholesterolemia, often need combination therapy to meet lipid goals. This study 
assessed the safety and additional lipid-modifying efﬁcacy of ezetimibe (EZE) 10 mg in 
high-risk, severely hypercholesterolemic patients who were receiving rosuvastatin (RSV) 
40 mg, with or without a bile acid sequestrant or niacin, and had not met the low-density 
lipoprotein cholesterol (LDL-C) goal of <100 mg/dL after at least 2.5 years.
Methods: This single-center, open-label, 12-week study (4522IL/0034 substudy) included 
73 patients aged 24 to 80 years. Original pre-treatment baseline study measurements 
were done after a dietary lead-in period (Diet-BL). Substudy measurements were obtained 
before adding EZE while patients were receiving RSV 40 mg (substudy baseline [RSV-
BL]) and 4, 8, and 12 weeks after addition of EZE.
Results: Table shows results as mean (SD) and mean % change after 12 weeks with 
RSV plus EZE compared with Diet-BL and RSV-BL. 
Diet-BL,
mg/dL
RSV-BL,
mg/dL
RSV +
EZE,
mg/dL
% change from
Diet-BL
% change from
RSV-BL
LDL-C 294 (65) 145 (32) 103 (27) -64* -28*
HDL-C 46 (10) 51 (11) 51 (12) +12* +1
Triglycerides 209 (117) 139 (74) 127 (66) -33* -5
Apolipoprotein B 255 (51) 137 (28) 112 (27) -55* -18*
* p < 0.001
HDL-C = high-density lipoprotein cholesterol
Addition of EZE to RSV resulted in LDL-C values <100 mg/dL in 52% (37/71) of patients. 
Median reductions in high-sensitivity C-reactive protein were 77% (p < 0.001) from Diet-
BL and 33% from RSV-BL. RSV and RSV plus EZE were well tolerated, with no hepatic 
enzyme or creatine kinase elevations.
Conclusion: The addition of EZE 10 mg to RSV 40 mg is well tolerated and results in 
signiﬁcant further reductions in LDL-C and apolipoprotein B that bring more than half of 
the patients to the LDL-C goal of <100 mg/dL.
1070-130 ‘Ultra-Low’ Levels of LDL-Cholesterol Confer Beneﬁt to 
the Endothelium, Particularly in Subjects with Low HDL-
Cholesterol
Jeffrey T. Kuvin, Ayan R. Patel, Kathleen A. Sliney, Natesa G. Pandian, Richard H. Karas, 
Tufts-New England Medical Center, Boston, MA
Background: Recent clinical trials indicate that aggressive lowering of LDL-cholesterol 
reduces cardiovascular events. However, the mechanisms by which ‘ultra-low’ LDL-
cholesterol provides beneﬁt remain unclear. This study was designed to determine the 
effect of ‘ultra-low’ LDL-cholesterol level on endothelial function. 
Methods: Peripheral vascular endothelial function testing was performed with brachial 
artery ultrasound in 110 subjects (cross-sectional observational study; 82 men, 28 
2005_10_VascularDiseaseHyper.indd   392 12/23/04   10:15:59 AM
JACC February 1, 2005 ABSTRACTS - Vascular Disease, Hypertension, and Prevention   393A 
Vascular D
isease, H
ypertension, and P
revention 
women) with stable coronary artery disease and LDL-cholesterol levels <100mg/dL. 
Flow-mediated dilation (FMD) following upper arm occlusion was deﬁned as the percent 
change in arterial diameter during reactive hyperemia relative to the baseline.
Results: Average total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride 
levels were 140±21, 78±13, 38±10, and 128±60mg/dL, respectively, and the average 
FMD of the brachial artery was 7.7±3.9%. 89% of subjects were taking statin therapy. In 
multivariate analysis, LDL-cholesterol was an independent predictor of FMD (p=0.010). 
The 63 subjects with ‘ultra-low’ (<80mg/dL) LDL-cholesterol had better endothelial 
function (FMD 8.4±3.8%) compared to the 47 subjects with ‘low’ (80-100mg/dL) LDL-
cholesterol (FMD 6.8±4.0%; p=0.03). The beneﬁcial effects of ‘ultra-low’ LDL-cholesterol 
on endothelial function were apparent in subjects with HDL-cholesterol <40mg/dL, but not 
in those with HDL-cholesterol >=40mg/dL.
Conclusions: In subjects with coronary artery disease, peripheral endothelial function is 
better in subjects with LDL-cholesterol <80mg/dL compared to those with LDL-cholesterol 
80-100mg/dL. This ﬁnding is particularly notable in subjects with low HDL-cholesterol 
levels. These data provide possible mechanistic insight into why and in whom lower LDL-
cholesterol levels are beneﬁcial.
POSTER SESSION
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1071-131 Expression of Atrial Genes during Cardiac Maturation in 
Infancy
Hetal Mehta, Devyani Chowdhury, Vincent Parnell, Kaie Ojamaa, Schneider children’s 
Hospital, New Hyde Park, NY, North Shore- Long Island Jewish Research Institute, 
Manhasset, NY
Experimental animal studies have shown that sarcoplasmic reticulum (SR) function 
is diminished in the developing heart, but this observation is less well documented in 
the immature human heart.This IRB approved study measured RNA expression of SR 
proteins in human atrial tissue during maturation in infancy. Atrial tissue from18 patients 
aged 2 days to 14 months undergoing surgery for congenital heart disease was collected. 
The diagnoses were varied, only samples from patients in whom the atria were unlikely 
to be affected hemodynamically or pathologically were analyzed. Biopsies from atrial 
appendage (~40 mg) were frozen in liquid nitrogen upon excision during surgery and 
stored until extracted for RNA. Tissue samples from normal human atria from 3 adults 
were obtained from Temple University’s heart transplant program. Real time RT-PCR 
was used to quantify mRNA of SR calcium ATPase (SERCA2a), phospholamban (PLN), 
sarcolipin (SLN), ryanodine receptor (RYD), Na-Ca-exchanger (NCX1), calsequestrin 
(CAQ), alpha- and beta-myosin heavy chains (MHC) and atrial natriuretic factor (ANF).
The mRNA levels were standardized to human ribosomal 36B4 mRNA and normalized 
to the pooled adult RNA samples. Two markers of hypertrophy and hemodynamic stress, 
ANF and beta-MHC, were not expressed differently from adult (1.19 +/- 0.11 and 1.11 
+/- 0.13, respectively). SERCA2a mRNA was 20% less and PLN mRNA 2-fold more than 
adult values resulting in a markedly lower SERCA/PLN ratio (0.46+/-0.18) than adult 
(indexed to 1.0). Sarcolemmal NCX1 mRNA was higher than adult (1.66+/-0.09), providing 
a NCX/SERCA ratio of 2.41+/-0.18 supporting a key role for NCX in calcium ﬂux in the 
maturing atria. SLN mRNA was signiﬁcantly lower (0.39+/-0.09) than adult. RYD mRNA 
in the newborn (<1 mo.) was lower than adult (0.35+/-0.06), but its expression increased 
linearly to adult values by 14 mo. of age. In conclusion, differential mRNA expression of 
SR proteins, SERCA2, RYD, PLN and SLN, as well as higher expression of sarcolemmal 
NCX in the maturing human atria lend support to diminished SR function, similar to that 
observed for developing ventricular muscle, and this may explain the increased calcium 
sensitivity of the immature heart.
1071-132 Direct Measurement of Nitric Oxide in Coronary 
Circulation: Development of Catheter-type Nitric Oxide 
Sensor
Yoji Neishi, Seiichi Mochizuki, Masami Goto, Teruyoshi Kume, Renan Sukmawan, 
Takahiro Kawamoto, Yasuo Ogasawara, Takehiro Miyasaka, Fumihiko Kajiya, Takashi 
Akasaka, Kiyoshi Yoshida, Kawasaki Medical School, Kurashiki, Japan, Okayama 
Univercity, Okayama, Japan
Background: In the coronary circulation, bioavailability of nitric oxide (NO) has been 
evaluated commonly by the change in coronary ﬂow velocity (CFV) after intracoronary 
administration of acetylcholine (ACh). However, the real-time change in NO concentration 
and its relation to CFV following injection of ACh are not known. Therefore, we have 
simultaneously measured CFV and plasma NO concentration in the coronary sinus by 
employing a newly developed catheter-type NO sensor.
Methods: An NO-sensitive electrode was located and ﬁxed in a 4-Fr catheter with a soft 
tip for protection of vascular wall. After calibrating with an NO-saturated pure water, the 
catheter-type NO sensor was located in the coronary sinus in anesthetized dogs (n=7). 
CFV was measured with a Doppler guide wire in the left anterior descending artery (LAD). 
We administrated ACh (0.4 or 1.0 µg/kg) into the LAD. ACh was repeated after 20-min 
infusion of NG-methyl-L-arginine (L-NAME, 10 µg/kg/min).
Results: Production of NO in the coronary vessels was successfully measured in the 
coronary sinus in all dogs studied. L-NAME decreased the basal NO concentration by 
3.1±0.8 nM (p<0.01 vs before L-NAME). ACh increased NO concentration in a dose-
dependent manner by 6.8±2.1 nM (p=0.008, 0.4 µg/kg) and by 8.2±2.5 nM (p=0.013, 1.0 
µg/kg, p=0.023 vs 0.4 µg/kg). ACh increased CFV by 95% with no signiﬁcant difference 
between the two doses of ACh (52.8±5.0 cm/sec for 0.4 µg/kg and 53.3±10.2 cm/sec 
for 1.0 µg/kg, p=0.67). The peak value of NO concentration was observed signiﬁcantly 
later than the peak of CFV (118±48 sec and 52±21, p=0.04, ACh=1.0 µg/kg). L-NAME 
suppressed the NO synthesis by ACh (1.9±0.6 nM, p=0.023 and 2.8±0.8 nM, p=0.045 
vs before L-NAME) with no signiﬁcant change in APV (27.2±2.0 cm/sec and 27.0±3.3 
cm/sec, p=0.94).
Conclusion: Production of NO in the coronary vessels can be evaluated in the coronary 
sinus. Although ACh increases CFV and NO concentration, CFV does not precisely reﬂect 
the bioavailability of NO in terms of magnitude and time course. The newly developed 
catheter-type NO sensor will contribute to the evaluation of bioavailability of NO in the 
coronary circulation.
1071-133 High Incidence of Sudden Cardiac Death With 
Conduction Disturbances and Atrial Cardiomyopathy 
Caused by a Nonsense Mutation in the STA Gene
Kenji Sakata, Masami Shimizu, Hidekazu Ino, Hidenobu Terai, Noboru Fujino, Kenshi 
Hayashi, Tetsuo Konno, Takashi Fujita, Hiroshi Mabuchi, Kanazawa University, 
Kanazawa, Japan
Background: Emery-Dreifuss muscular dystrophy (EDMD) is characterized by skeletal 
myopathy and cardiac involvement. The STA gene encodes emerin and is one of genes 
that is affected in EDMD. Although it has been reported that EDMD caused by STA gene 
mutation is associated with X-linked recessive inheritance, the genotype-phenotype 
correlations, with special reference to cardiac manifestations, are not well deﬁned.
Methods: We analyzed STA gene mutations in patients with EDMD. Mutations were 
screened by the PCR-SSCP method and direct sequencing analysis. Clinical phenotypes 
were determined using electrocardiography, echocardiography, and 24-hour Holter 
monitoring.
Results: We identiﬁed 16 carriers (7 males and 9 females) with a nonsense mutation 
leading to a single base substitution (1735 G to A) in exon 6 of the STA gene in the 2 
EDMD families. In the male carriers conduction disturbances, as well as atrial dilatation, 
developed in a progressive fashion over follow-up periods that ranged from 1 to 23 years. 
None of the patients demonstrated features suggestive of dilated cardiomyopathy at any 
age. Pacemakers were required for treatment of bradyarrhythmias (complete AV block, 
sinus node dysfunction, and atrial ﬁbrillation) in all 7 male carriers and in 2 of the 9 
female carriers. In addition, 2 of the 9 female carriers displayed atrial ﬁbrillation. In these 
2 families, 3 males without pacemaker implantation, who were not tested genetically, had 
died suddenly. In this cohort of patients, the majority of carriers with the mutation had not 
been clinically diagnosed as having EDMD prior to genetic testing because of extremely 
mild or non-existent skeletal myopathy.
Conclusion: EDMD caused by this mutation is characterized by atypical clinical features 
and infrequent X-linked inheritance, and may result in serious cardiac complications 
including sudden death. Screening for this mutation in patients with cardiac conduction 
disturbances and atrial cardiomyopathy is of signiﬁcant importance even in the absence 
of skeletal myopathy because it can be missed easily. Consideration should be given to 
methods of preventing possible sudden death in carriers with the STA gene mutation.
1071-134 Permeability and Directional Selectivity of Heterotypic 
Cx43-Cx45 Cardiac Gap Junctions
Faraz Sandhu, Sudhir Kapoor, Abbas Rampurwala, Eric C. Beyer, Alonso P. Moreno, 
Indiana University, Krannert Institute of Cardiology, Indianapolis, IN
Background: Gap Junctions- formed by the assembly of two connexons- function as 
conduits between cells that regulate exchange of various metabolites. Gap junctions 
present between myocytes have been implicated in various developmental and pathological 
processes, from differentiation, to arrhythmic dysfunction and scar tissue formation. It 
is hence vital that we understand their permeability properties to fully understand their 
performance.Connexin43 (Cx43) and connexin45 (Cx45) are co-expressed in the human 
heart. Preliminary studies have shown that in heterotypic channels, the direction of ﬂux 
of large molecules is dominant in the direction of Cx43 to Cx45. Since Cx45 is selective 
for cations, we were interested in studying if the permeability and directional selectivity is 
dependent on the charge or the size of the probe.
Methods: HeLa cells were transfected with either Cx 43 or Cx45 and stained with DiI 
or Green Cell trackers for identiﬁcation of heterotypic pairs. After 6 hours one cell of a 
pair was injected with Lucifer yellow (LY) or Rhodamine123 (R123) -which have similar 
molecular weight (LY:457; R346) but opposite charge (Ze-2 and Ze+1)- or with Neurobiotin 
(Nb), a smaller tracer (MW:287: Ze+1). The coupling percentage (CP) was calculated as 
the number of cells penetrated by the tracer over the total number of cells in contact with 
the injected cell, counted from digitized micrographs taken 5 min after injection. CP with 
NB was detected with Avidin-HRP antibodies.
Results: CP of LY injected into Cx43 was 59.01±4.08,44 (Mean ± SE,n), and that of Cx45 
was 10.66± 2.09,38. CP of R123 injected into Cx43 was 62.21± 3.55,28 and that of Cx45 
was 22.33 ± 3.55,30. CP of Nb injected into Cx43 was 78.89± 5.84,10 and that of Cx45 
was 84.13± 5.17,10. LY and R123 showed dominance in ﬂux from Cx43�Cx45, while NB 
appeared to be very permeable, with no directional selectivity.
We conclude that the permeability and directional selectivity of Cx43 and Cx45 does not 
depend on the charge of the tracer, rather it is dependent on its size. These data strongly 
suggests that heteromerization of connexins results in an effective way to modulate 
intercellular permeability and participate in mechanisms of metabolic regulation.
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1071-137 Transcriptional Analysis of Mouse Strains With 
Disparate Responses to Catecholamine Excess
Brian D. Hoit, Michael Zawaneh, Mu-Ya Liu, Wentong Pan, Joseph H. Nadeau, Ralph 
V. Shohet, Case Western Reserve University and University Hospitals of Cleveland, 
Cleveland, OH, University of Texas, Southwestern, Dallas, TX
Background We previously showed that compared to B6 mice, A/J mice develop more 
hypertrophy and ﬁbrosis and fail to downregulate and uncouple their �AR in response 
to isoproterenol (ISO) infusion. To determine whether this differential response was 
associated with dysregulation of genes involved in hypertrophy and heart failure pathways, 
we examined the hearts of ISO treated animals by microarray analysis.
Methods Male mice aged 12-15 weeks (20 B6, 20 A/J) were treated with either ISO 
(100 mg/kg/d subcutaneous, n=20) or equi-volume saline (n=20) for 5 days. Heart/body 
weight ratios increased with ISO, but to a greater extent in the A/J than B6 mice (33 
vs. 18%, p<0.05). RNA was isolated from individual hearts and pooled for dye-reversal 
hybridization to long oligo arrays. These included both the Operon V3 set of 3’ biased 
oligos and the MGH set of 5’ coding oligos. Transcripts similarly regulated on both sets 
have a high likelihood of subsequent conﬁrmation by other methods; 12 of 13 were 
conﬁrmed by real-time PCR.
Results In hearts exposed to ISO, ten genes were differentially (A/J:B6) up-regulated 
>2-fold on both sets of target oligos and 2 were downregulated. Osteoblast speciﬁc factor 
gene was up-regulated 18-fold in A/J vs B6. Other proteins encoded by these genes 
(2-6 fold) modulate extracellular matrix (follistatin-like 1, biglycan, asporin, matrix gamma-
carboxyglutamate protein, microﬁbrillar associated protein 5), or calcium (S100 calcium 
binding protein A10 and A11). Only S100 A10 was dysregulated in the mice receiving 
saline. Activities of other genes in pathways known to be involved in isoproterenol-induced 
hypertrophy and failure (MAPK, PI3K, calcineurin) were increased to a similar degree in 
B6 and A/J.
Conclusion Excess beta-adrenergic stimulation in the A/J strain preferentially activates 
several novel genes involved in extracellular matrix remodeling and calcium homeostasis, 
and several genes with unknown function. These studies should provide new insights into 
the molecular effects of excessive adrenergic activity.
1071-138 Effects of Lovastatin on the Proliferation and Cell Cycle 
of Rat Cardiac Fibroblasts Induced by Aldosterone In 
Vitro
Wei Cui, Huiping Feng, Baoen Shan, Yuming Hao, Jun Du, The Second Hospital of 
Hebei Medical University, Shijiazhuang, People’s Republic of China
Background: To investigate the effects of Lovstatin (Lov) on the proliferation and cell 
cycle of rat cardiac ﬁbroblasts (CFs) induced by aldosterone (ALD). 
Methods: CFs of neonatal Sprague-Dawley rats were isolated with trypsin digestion 
method and those growth-arrested were stimulated with 10-7 mol/L ALD in the presence 
of various concentrations of Lov and mevalonate (MVA). The DNA synthesis of CFs was 
determined by 3H-Thymidine (3H-TdR) incorporation. MTT colorimetry was adopted to 
evaluate cell number. Cell cycle was measured by ﬂow cytometric analysis. 
Results: Lov decreased 3H-TdR incorporation in CFs in a concentration-dependent 
manner. 3H-TdR incorporation values of 10-6 mol/L Lov and 10-5 mol/L Lov group (1292±152 
and 1030±163 cells per 5000 cells, respectively) were signiﬁcantly lower than those of the 
control (1879±169 per 5000 cells) (both P<0.01); A490 values of 10
-6 mol/L Lov and 10-5 
mol/L lov group (0.287±0.008, 0.231±0.007, respectively) were signiﬁcantly lower than 
those of the control (0.390±0.010) (P<0.01); Lov groups had increased percentage of 
cells in G0/G1 phase and reduced percentage of cells in S phase, PI values, DNA contents 
in a dose-dependent manner. The inhibitory effect of Lov could almost completely be 
reversed by MVA (10-3mol/L). 
Conclusion: The results indicate that Lov can signiﬁcantly inhibit CFs proliferation induce 
by ALD, and MVA pathway may play an important role in the CFs proliferation.
ORAL CONTRIBUTIONS
802  Beyond Low-Density Lipoprotein: 
Role of High-Density Lipoprotein and 
Triglycerides
Monday, March 07, 2005, 9:15 a.m.-10:30 a.m.
Orange County Convention Center, Room 304E
9:15 a.m.
802-3 Efﬁcacy and Safety of a Novel Cholesteryl Ester 
Transfer Protein Inhibitor Torcetrapib When 
Administered With and Without Atorvastatin to 
Subjects With a Low Level of High-Density Lipoprotein 
Cholesterol
Michael Davidson, James McKenney, James Revkin, Charles Shear, Rush-Presbyterian-
St Luke’s Medical Center, Chicago, IL, Pﬁzer Global Research and Development, 
Groton, CT
Background: Torcetrapib (T), a novel inhibitor of cholesteryl ester transfer protein (CETP), 
was evaluated in two phase 2 studies of subjects with low HDL-C levels.
Methods: Both studies were multi-center, double-blind, randomized trials in which 
subjects with low HDL-C (men <44 mg/dL; women <54 mg/dL) were randomized to 
receive T at 10, 30, 60, or 90 mg/day or placebo (~30 subjects per group). The studies 
were identical except that the ﬁrst study enrolled subjects not taking lipid-modifying 
therapy (162 subjects assigned to treatment), while the second study enrolled those who 
were eligible for statin therapy according to NCEP ATP III or who had LDL-C >130 mg/dL 
at screening (174 subjects assigned to treatment). Subjects in the second study received 
atorvastatin (A) 20 mg/day during an 8-week run-in period and after randomization during 
the 8-week treatment period with T.
Results: In the study of T alone, least squares mean changes from baseline relative to 
placebo at Week 8 ranged from +3.6 to +21.5 mg/dL (+9.0 to +54.5%) (p=0.0001 for 30-
mg and higher doses) for HDL-C and from +2.1 to -19.9 mg/dL (+3.0 to -16.5%) (p<0.001 
for 90-mg dose) for LDL-C. In the study of T with background A, least squares mean 
changes from baseline relative to placebo at Week 8 ranged from +3.7 to +16.5 mg/dL 
(+8.3 to +40.2%) (p=0.0001 for 30-mg and higher doses) for HDL-C and from +2.3 to 
-16.4 mg/dL (+2.7 to -18.9%) (p<0.01 for 60-mg and 90-mg doses) for LDL-C. LDL-C 
decreases with T were maintained on a background of A and were more homogeneous 
than with T alone. Particle size for both HDL and LDL increased with T. In both studies, 
there were no dose-related increases in adverse events. In some treatment groups, small 
increases in systolic and diastolic blood pressures were noted. There was no change in 
heart rate.
Conclusions: In subjects with low HDL-C levels, T resulted in substantial and dose-
dependent elevations in HDL-C, accompanied by moderate decreases in LDL-C at the 
higher doses. In statin-eligible low HDL-C subjects on a background of A, T resulted in a 
similar pattern of change in HDL-C and reductions in LDL-C that were more homogeneous 
than those obtained with T alone. T was generally well tolerated with and without A across 
the dose range.
9:30 a.m.
802-4 Additive Beneﬁcial Effects of Fenoﬁbrate Combined 
with Atorvastatin In the Treatment of Patients With 
Combined Hyperlipidemia
Kwang K. Koh, Seung H. Han, Michael J. Quon, Wook-Jin Chung, Mi-Seung Shin, Tae 
H. Ahn, In S. Choi, Eak K. Shin, Gachon Medical School, Incheon, South Korea, NIH, 
Bethesda, MD
Background: Biological mechanisms underlying statin and ﬁbrate therapies differ. 
Therefore, we compared vascular and metabolic responses (as well as adverse responses) 
to these therapies either alone or in combination in patients with combined hyperlipidemia.
Methods: This was a randomized, double-blind, placebo-controlled cross-over trial with 
three treatment arms (each 2 months) and two washout periods (each 2 months). Fifty-six 
patients were given atorvastatin 10 mg and placebo, atorvastatin 10 mg and micronized 
fenoﬁbrate 200 mg, or micronized fenoﬁbrate 200 mg and placebo daily during each 2 
month treatment period.
Results: Lipoproteins were changed to a greater extent with combined therapy when 
compared with atorvastatin or fenoﬁbrate alone. Flow-mediated dilator response to 
hyperemia and plasma hsCRP and ﬁbrinogen levels were changed to a greater extent with 
combined therapy when compared with atorvastatin or fenoﬁbrate alone (P<0.001, P=0.182, 
and P=0.015 by ANOVA, respectively). The effects of combined therapy or fenoﬁbrate alone 
on plasma adiponectin levels and insulin sensitivity (determined by Quantitative Insulin-
Sensitivity Check Index (QUICKI)) were signiﬁcantly greater than those of atorvastatin alone 
(P=0.022 for adiponectin and P=0.049 for QUICKI by ANOVA). Following combined therapy, 
improvement in ﬂow-mediated dilation correlated with changes in total cholesterol levels 
(r=-0.373 and p=0.005), triglycerides levels (r=-0.288 and p=0.032), and apolipoprotein B 
levels (r=-0.341, p=0.010). There were signiﬁcant correlations between percent changes 
in adiponectin levels and percent changes in QUICKI (r=0.283, p=0.034), apolipoprotein 
A-I (r=0.351, p=0.008) and insulin (r=-0.332, p=0.013) after combined therapy. No patients 
were withdrawn due to serious adverse effects.
Conclusions: Combination therapy is safe and has beneﬁcial additive effects on 
endothelial function in patients with combined hyperlipidemia.
9:45 a.m.
802-5 Seasonal Variations in Lipid Values in Patients 
Following ACS: PROVE IT - TIMI 22
Stephen D. Wiviott, Christopher P. Cannon, Kausik K. Ray, Sabina Murphy, Harold 
Darius, Alain Castaigne, Jose Antonio Velasco, Carolyn H. McCabe, C. Michael Gibson, 
Brigham and Women’s Hospital, Boston, MA, Beth Israel Deaconness Hospital, Boston, MA
Background: Seasonal variation in myocardial ischemic events has been reported 
with lowest rates in the summer. Recent data suggest a variation of lipids by season in 
untreated healthy individuals. We examined seasonal differences in lipid parameters in 
patients post-ACS treated with statin therapy.
Methods: PROVE IT - TIMI 22 compared intensive (atorva 80 mg) with standard statin 
therapy (prava 40 mg) in patients post-ACS. Seasons were deﬁned using a light seasons 
model centered on the equinoxes; winter (Nov 6 - Feb 4), spring (Feb 5 - May 6), summer 
(May 7 - Aug 5), fall (Aug 6 - Nov 5), and reversed for the Southern hemisphere. Lipids 
were classiﬁed by date drawn, and baseline values excluded. Comparisons were made 
by ANOVA.
Results: Among 4162 individuals (23,037 measures), LDL levels and TC/HDL ratio were 
lowest in the summer (ﬁgure, p<0.0001). Similar patterns were present in total cholesterol 
and triglycerides (p<0.001) with lowest values in the summer. In contrast, HDL values 
were highest in the summer (p<0.001). More patients met treatment goals (LDL < 100) 
in summer (74%) compared to winter (68%), spring (65%) or fall (70%). Similar patterns 
were seen in a ﬁxed effect model and when stratiﬁed by statin.
Conclusion: In patients post-ACS on ﬁxed doses of statin there was a seasonal variation 
in lipid parameters with more favorable patterns in summer months. This disparity may 
impact clinical monitoring of cholesterol goals and may help to provide insight into 
seasonal differences in ischemic events.
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802-6 The APOC3 Promoter Polymorphisms T-455C and C-
482T are Associated with the Metabolic Syndrome
Michael Miller, Jeffrey Rhyne, Valerie Beach, Richard Ericson, Monica Aggarwal, Anoop 
Misra, University of Maryland Medical Center, Baltimore, MD, All India Institute of 
Medical Sciences, New Delhi, India
Background: Aside from the recent association between the adiponectin I164T mutation 
and the Metabolic Syndrome (MS) (JACC 2004;43:1195), few studies have evaluated 
genetic polymorphisms that may contribute to the MS phenotype. One candidate, APOC3, 
modulates TG and HDL metabolism by inhibiting LPL and LCAT and APOC3 promoter 
polymorphisms T-455C / C-482T are associated with loss of insulin downregulation.
Methods: To assess genetic associations with MS, we genotyped 313 consecutive lipid 
clinic patients in New Delhi and Baltimore (mean age, 49 yrs) for 10 common variants in 
APOC3, APOE, B3AR, FABP2, GNB3, LPL and PPARs � and �. An additional 104 healthy 
age-related controls without MS were also studied.
Results: There was a signiﬁcantly greater prevalence of the APOC3 promoter variants 
-455 C/C and -482 T/T in lipid clinic patients compared to Controls (Table). Overall, there 
was a 2-fold greater likelihood of MS in lipid clinic patients who were homozygous for the 
-455C and -482T alleles compared to wild-type (p=0.0008). No other material differences 
were noted between the other genetic variants tested and rate of MS.
Conclusion: In addition to adiponectin I164T, these data support a potential role for 
APOC3 promoter polymorphisms in contributing to the MS phenotype. Identiﬁcation of 
genetic markers may advance efforts toward screening high risk individuals who may 
beneﬁt from intensive strategies aimed at reducing the clinical expression of MS and its 
potential adverse cardiovascular consequences.
HDL, TG and Prevalence of APOC3 Promoter Polymorphisms 
Group Mean HDL TG -455 C/C -482 T/T
Lipid Clinic:
New Delhi (n=138) 41 + 5 252 + 193 28% 19%
Lipid Clinic: Baltimore 
(n=175) 41 + 13 253 + 310 21% 18%
Healthy Controls
(n=104) 80 + 37 100 + 60 16% 11%
P Value
P < 0.0001 
compared to 
Controls
P < 0.0001 
compared to 
Controls
P=0.003 by 
chi-square 
analysis
P=0.0002 by chi-
square analysis
 
10:15 a.m.
802-7 Distribution of HDL Cholesterol Subfractions is Affected 
by Exercise and Predictable by APOA1 Gene Alleles
Gualberto Ruano, Richard L. Seip, Stefan Zoellner, Paul D. Thompson, Hartford 
Hospital, Hartford, CT, Genomas, Hartford, CT
Background: Apo AI is the primary component of high density lipoproteins (HDL) and 
plays a critical role in reverse cholesterol metabolism. The APOA1 gene has a well 
characterized SNP in its promoter, -75 G/A. The A allele frequency is 30% in persons 
of mixed European ancestry and has been implied in higher HDL responses to dietary 
polyunsaturated fatty acids. Exercise alters the distribution of HDL particles and Apo AI 
may mediate this effect.
Methods: Healthy normolipidemic adults volunteered for six months of supervised aerobic 
exercise and were genotyped for the APOA1 -75 G/A polymorphism. Five discrete HDL 
subpopulations were measured by NMR spectroscopy. Small and large HDL cholesterol 
concentrations were obtained by adding the subfractions, HDL 1+2+3 for small, and HDL 
4+5 for large, respectively.
Results: Exercise induced the following responses: 
Subject Group
Baseline HDL HDL Change with Exercise
Total Small Large Total Small Large
Total (n=75) 49.9± 1.9
13.8
± 0.8
36.9
± 2.2
-0.3
± 1.0
0.6
± 0.8
-0.9
± 1.3
G/G (n=22) 51.8± 2.2
15.3
± 0.9
36.4
± 2.5
0.3
± 1.2
-1.3
± 1.8
1.8
± 1.6
G/A + A/A (n=53) 48.1± 3.2
10.8
± 1.3
37.3
± 3.7
-1.3
± 1.8
4.7 **
± 1.3
-6.1 *
± 2.3
* p<0.005, ** p<0.0005 vs. change in (G/G) group.
The presence of the -75A allele effected an exercise-associated increase in small and a 
decrease in large HDL chol, whereas directionally and signiﬁcantly different changes were 
seen in G/G homozygotes, i.e., a decrease in small and an increase in large HDL chol.
Conclusions: Exercise elicited a transition from small to large HDL in some individuals 
and the opposite in others. The -75A allele of APOA1 may predict the polarity of this HDL 
subfraction switch. When translated into a DNA diagnostic, the APOA1 -75G/A promoter 
variant could be useful to tailor exercise to achieve desired changes in HDL proﬁles.
ORAL CONTRIBUTIONS
808  Pharmacologic Treatment of Insulin 
Resistance
Monday, March 07, 2005, 11:00 a.m.-12:15 p.m.
Orange County Convention Center, Room 304E
11:00 a.m.
808-3 Cortisol/Cortisone Ratio Predicts Impaired Fasting 
Glucose, Diabetes, and Coronary Artery Disease
Brianna S. Ronnow, John F. Carlquist, William L. Roberts, Benjamin D. Horne, Rebecca 
Nielson, Mark M. Kushnir, Alan L. Rockwood, Tami L. Bair, Jeffrey L. Anderson, LDS 
Hospital, Salt Lake City, UT, University of Utah, Salt Lake City, UT
Background: 11β-hydroxysteroid dehydrogenase (11�-HSD) isoforms regulate the 
oxidation of active cortisol (Cl) to inactive cortisone (Cn) in adipose tissue. An increased 
plasma Cl/Cn ratio might identify subjects with low tissue 11�-HSD activity, a risk factor for 
central adiposity and possibly insulin resistance, diabetes, and vascular disease.
Methods: We tested whether Cl/Cn (i) distinguishes between patients with normal fasting 
glucose (NFG; <110 mg/dL), impaired FG (IFG; 110-125), and diabetes (DM; ≥126 mg/dL) 
and (ii) is a risk marker for CAD and death or nonfatal MI. The study used a nested case-control 
cohort of 461 patients equally representing the 3 glycemic categories drawn from among 3000 
consecutive patients entered into the Intermountain Heart Collaborative Registry. Consenting 
patients had fasting blood drawn for FG and Cl/Cn during angiographic assessment for 
suspected CAD and were followed for 2.6 ± 1.4 y. Cl and Cn were assayed from cryogenically 
stored samples by LC-MS/MS. Non-parametric testing was used for comparing Cl/Cn among 
groups and logistic regression, entering lnCl/Cn, for predictive modeling.
Results: The study cohort consisted of equal numbers with NFG (153), IFG (155), and 
DM (153), matched for age (±5 y) and gender. Overall, age averaged 61 y; 72% were male; 
24%, smokers; 69% had angiographic CAD; 61%, hypertension; 57%, hyperlipidemia; 
24%, prior MI. During follow-up, 141 events occurred. Distribution of Cl/Cn was broad and 
rightward skewed, with a median of 6.61 (range, 0.94-198). Median Cl/Cn levels increased 
progressively by glycemic category: NFG=6.07, IFG=6.61, DM= 8.10 (p=0.006). When 
adjusted for standard risk factors, CAD severity, and presenting diagnosis, ln Cl/Cn 
independently predicted DM (OR 1.37/ln unit, CI 1.04-1.81, p=0.024) and CAD (OR 1.34, 
CI 1.00-1.78, p=0.048). Once CAD developed, however, ln Cl/Cn did not predict risk of 
subsequent death or MI.
Discussion: Among a high coronary risk case-control cohort, �Cl/Cn ratio predicted �risk 
of IFG, DM, and CAD. Plasma Cl/Cn may provide unique insights into the pathophysiology 
of insulin resistance syndrome and potentially represents a novel diagnostic test and a 
new target for treatment.
11:15 a.m.
808-4 Correlates of Visceral Adiposity in Perimenopausal 
Women: The SWAN Heart Study.
Lynda H. Powell, Kim Sutton-Tyrrell, Steven M. Hollenberg, Karen A. Matthews, 
Tene Lewis, Zhen Chen, Rush University Medical Center, Chicago, IL, University of 
Pittsburgh, Pittsburgh, PA
Introduction: One of the mechanisms by which the menopausal transition may increase 
CV risk in women is through the accumulation of visceral adiposity. We hypothesized 
that the balance of androgens to estrogen, not overall reductions in estrogen alone, was 
associated with increases in visceral adiposity in perimenopausal women.
Methods: We conducted a cross-sectional study of CT-assessed visceral adiposity and 3 
reproductive hormones--estradiol (E2), the Free Testosterone Index (FTI), and the ratio of 
FTI:E2 (ratio) in 557 Caucasian and African American women who were at various stages 
of the menopausal transition and not taking hormone therapy.
Results: There were no differences in the prevalence of visceral adiposity by ethnicity. 
There was no association between menopausal status, deﬁned by bleeding criteria, and 
visceral adiposity. E2, FTI, and the ratio were all strongly associated with visceral adiposity 
in unadjusted models. However, only the ratio remained signiﬁcant (HR=0.266, p=0.002) 
in a model adjusting for age (HR=-0.006, p=0.5), Framingham Risk Score (HR=0.019, 
p=0.002), BMI (HR=0.055, p<0.001), and physical activity (HR=-0.088, p=0.02).
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Conclusions: Progressive androgen predominance may be a new risk factor for visceral 
adiposity that is independent of risk incurred by age, total body fat, and standard CV risk 
factors. Being physically active may weaken the adverse effects of this natural transition 
in reproductive hormones on CV risk.
11:30 a.m.
808-5 Perimenopausal Hormone Status Correlates with 
Endothelial Function; the SWAN-Heart Study
Steven M. Hollenberg, Andrew Dumasius, Susan Colilla, Kelly Karavolos, Kim Sutton-
Tyrrell, Karen Matthews, Lynda Powell, Cooper University Hospital, Camden, NJ, Rush 
Medical College, Chicago, IL
Background: The risk of coronary heart disease in women rises dramatically after 
menopause. To elucidate mechanisms of the transition to increased susceptibility to 
atherosclerosis in women, a comprehensive analysis of vascular structure and function in 
perimenopausal women was performed in the SWAN-Heart study.
Methods: 609 women at various stages of the menopausal transition participating in the 
Study of Women Across the Nation (SWAN) had comprehensive analysis of vascular 
structure and function with EBCT for coronary artery calcium (CAC) and aortic calcium 
(AoC) and ultrasound to measure brachial ﬂow-mediated dilation (FMD), carotid average 
intimal-medial thickness (IMT), and pulse wave velocity (PWV). Studies were done fasting 
and off medications and tobacco. Serum hormone levels were drawn at annual follow-up.
Results: CAC correlated signiﬁcantly with the androgen/estrogen ratio and this correlation 
remained signiﬁcant after adjustment for age, obesity, and Framingham Risk Score 
(p=0.01). AoC also correlated with androgen/estrogen ratio after adjustment (p=0.04). 
Endothelial function, as assessed by FMD, correlated positively with estrogen levels (p= 
0.038) and negatively with testosterone levels (p=0.029). IMT correlated with androgen/
estrogen ratio (p=0.01).
Conclusions: Hormonal balance is altered during the perimenopausal transition, with 
decreasing circulating estrogen levels and increasing androgen levels. These data 
suggest that this altered balance decreases endothelial function and predisposes to the 
development of early atherosclerosis. Changes in androgen/estrogen balance may prove 
to be a trigger for accelerated atherosclerosis in the perimenopausal transition.
11:45 a.m.
808-6 Beneﬁcial Modiﬁcation of Oxidative Stress and 
Systemic Inﬂammation in Normotensive Patients With 
Diabetes Type 2 After Angiotensin-Converting Enzyme 
Inhibition Treatment
Mary E. Marketou, Evangelos A. Zacharis, Dragana Nikitovic, George E. Kochiadakis, 
Ioannis K. Karalis, Emmanuel S. Simantirakis, Flora Karageorgou, Panos E. Vardas, 
Cardiology Dept., Heraklion University Hospital, Heraklion, Greece
Background: Oxidative stress and inﬂammation are involved in cardiovascular 
complications of diabetes type II. We evaluated the effect of perindopril - an angiotensin-
converting enzyme inhibitor (ACE-I) on lipid peroxides, interleukin-6 (IL-6) and tumor 
necrosis factor-a (TNF-a) in normotensive patients (pts) with diabetes type II.
Methods: We studied 40 normotensive pts (22 women, 57 ± 8 years) with diabetes 
type II, a fair metabolic control (glycosylated hemoglobin < 7.5%) and a normal renal 
function. All pts had a normal echocardiogram and coronary angiogram. Perindopril was 
administered to 20 pts (4 mg/day) for 6 months, while the remaining 20 received placebo. 
Before entering the study and at 6 months under perindopril therapy, blood samples were 
taken to evaluate lipid peroxides (analyzed by a photometric assay, Oxystat, Biomedica), 
IL-6, TNF-a (determined by an Eliza method).
Results: No signiﬁcant changes in systolic blood pressure were observed before or 
after treatment (124±6 mmHg versus 119±12 mmHg, p= NS). Treatment with perindopril 
results in a signiﬁcant decrease in lipid peroxides, TNF-a, IL-6 in patients with diabetes 
type II (lipid peroxides: 370 ±110 µmol/l, TNF-a: 3.3 ± 0.9 pg/ml, IL-6: 2.9 ± 0.9 pg/ml 
before treatment compared to 264 ± 87 µmol/l, 2.0 ± 0.71 pg/ml, 1.8 ± 0.8 pg/ml after 
treatment respectively, p<0.05 for all). No signiﬁcant changes in the biomarkers evaluated 
were observed in the control group.
Conclusions: Perindopril therapy has a beneﬁcial effect on oxidative stress and 
inﬂammation markers in normotensive pts with diabetes type II. This may be associated 
with a cardioprotective action of ACE-I in diabetes type II, independently of their effect on 
blood pressure and may provide another important target for therapeutic intervention.
Noon
808-7 Comparative Metabolic Effects of Fenoﬁbrate and 
Atorvastatin In Patients With Combined Hyperlipidemia
Kwang K. Koh, Seung H. Han, Michael J. Quon, Woong C. Kang, Mi-Seung Shin, In S. 
Choi, Gachon Medical School, Incheon, South Korea, NIH, Bethesda, MD
Background: Biological mechanisms underlying statin and ﬁbrate therapies differ. 
Therefore, we compared metabolic responses (as well as adverse responses) to these 
therapies either alone or in combination in patients with combined hyperlipidemia.
Methods: This was a randomized, double-blind, placebo-controlled cross-over trial with 
three treatment arms (each 2 months) and two washout periods (each 2 months). Fifty-six 
patients were given atorvastatin 10 mg and placebo, atorvastatin 10 mg and micronized 
fenoﬁbrate 200 mg, or micronized fenoﬁbrate 200 mg and placebo daily during each 2 
month treatment period.
Results: Lipoproteins were changed to a greater extent with combined therapy when 
compared with atorvastatin or fenoﬁbrate alone. There were signiﬁcant inverse correlations 
between baseline adiponectin levels and baseline triglyceride levels (r=-0.277, p=0.039 
before atorvastatin; r=-0.335, p=0.012 before combined therapy; r=-0.288, p=0.032 before 
fenoﬁbrate). There were signiﬁcant correlations between baseline adiponectin levels 
and baseline HDL-cholesterol levels (r=0.284, p=0.034 before atorvastatin; r=0.258, 
p=0.049 before combined therapy; r=0.353, p=0.008 before fenoﬁbrate). The three 
therapies did not have signiﬁcantly different baseline insulin and glucose levels. However, 
the magnitude of reduction of insulin with combined therapy was signiﬁcantly greater 
than with atorvastatin alone (P=0.012 by ANOVA). The effects of combined therapy or 
fenoﬁbrate alone on plasma adiponectin levels and insulin sensitivity (determined by 
Quantitative Insulin-Sensitivity Check Index (QUICKI)) were signiﬁcantly greater than 
those of atorvastatin alone (P=0.022 for adiponectin and P=0.049 for QUICKI by ANOVA). 
There were signiﬁcant correlations between percent changes in adiponectin levels and 
percent changes in QUICKI (r=0.283, p=0.034), apolipoprotein A-I (r=0.351, p=0.008) 
and insulin (r=-0.332, p=0.013) after combined therapy. No patients were withdrawn due 
to serious adverse effects.
Conclusions: Combination therapy is safe and has beneﬁcial additive effects on insulin 
sensitivity in patients with combined hyperlipidemia.
POSTER SESSION
1097  Vascular Biology and Thrombosis: 
Basic Investigations
Monday, March 07, 2005, 1:30 p.m.-5:00 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 2:30 p.m.-3:30 p.m.
1097-95 Different Migration of Vascular Smooth Muscle Cells 
from Human Coronary Artery Bypass Vessels - Role of 
RhoA-ROCK pathway
Sabine Weiss, Karin Frischknecht, Helen Greutert, Andrea Jaschko, Thomas F. Lüscher, 
Thierry P. Carrel, Felix C. Tanner, Cardiovascular Research, Zürich, Switzerland, 
Cardiology, Zürich, Switzerland
Migration of vascular smooth muscle cells (VSMC) is involved in the pathogenesis of 
atherosclerosis and bypass graft disease. Long-term patency rates of coronary artery 
bypass grafts differ with graft origin; hence, we examined whether migration of VSMC from 
these vessels differs accordingly. Migration was analyzed in a modiﬁed Boyden chamber 
after stimulation with PDGF BB (1-10 ng/ml) or Tissue Factor/Factor VIIa complex (0.1-
1.0 nM). Migration to PDGF BB was lower in VSMC from internal mammary artery (MA) 
than saphenous vein (SV) (p<0.0001; n=5). A similar pattern occurred with Tissue Factor/
Factor VIIa complex (p<0.01; n=5). There was no difference in chemokinesis (p=n.s.; n=5) 
or cell attachment (p=n.s.; n=5). Expression of PDGF receptor α was slightly higher in MA 
than SV, while β did not differ. RhoA activity was determined by pulldown-assay, RhoA 
expression by Western blot analysis. PDGF induced a weak increase in RhoA activity 
in MA (p=n.s.; n=4), while this effect was much more pronounced in SV (p<0.05; n=4), 
resulting in a higher RhoA activity in SV (p=0.001 vs. MA). RhoA expression was identical 
in VSMC from MA versus SV and remained unaffected by PDGF. Stress ﬁber formation 
was determined by immunoﬂuorescence with TRITC-phalloidin. PDGF-induced stress 
ﬁber formation was less pronounced in MA than SV. Adenoviral overexpression of a 
constitutively active RhoA mutant showed maximal stress ﬁber formation in both MA and 
SV with or without PDGF. Transduction of a dominant negative RhoA mutant prevented 
stress ﬁber formation in MA and SV even in the presence of PDGF (n=4). Rosuvastatin 
(10-5 M) or hydroxyfasudil (10-5 M) almost completely inhibited migration in MA and SV 
without exerting any toxic effect as detected by LDH release (n=4); moreover, both drugs 
reduced PDGF-induced stress ﬁber formation to control level in MA and SV (n=4). We 
conclude that a) the RhoA-ROCK pathway is necessary for migration of human VSMC, b) 
the difference in migration of VSMC from MA and SV is related to different RhoA activity 
leading to different stress ﬁber formation, c) both statins and hydroxyfasudil may have 
beneﬁcial effects on patency rates of coronary artery bypass vessels via inhibition of 
VSMC migration.
1097-96 Evidence for Toll-Like Receptor 4-Signaling in Patients 
With Acute Coronary Syndrome
Heiko Methe, Jong-Oh Kim, Sieglinde Koﬂer, Michael Weis, Michael Nabauer, 
Massachusetts Institute of Technology, Cambridge, MA, Klinikum Grosshadern, Munich, 
Germany
Background: Though monocytes and macrophages have been implicated in the 
inﬂammatory component of atherosclerosis the underlying mechanisms remain largely 
unknown. We hypothesized that Toll-like receptor (TLR)-4 is involved in monocyte 
activation in accelerated forms of coronary artery disease (CAD).
Methods: Expression patterns of TLR4 and Myd88 in circulating CD14+-monocytes of 
patients with stable angina (SA), unstable angina (UA), acute myocardial infarction (AMI), 
and healthy controls were determined by ﬂow cytometry and RT-PCR. Signaling events 
downstream of TLR4 (IL-12, B7-1) after LPS stimulation and serum heat shock protein 
(HSP)60 levels were analyzed by ELISA, ﬂow cytometry and RT-PCR. A CHO-cell line that 
expresses CD25 in response to TLR4 activation was used to identify serum TLR4 ligands.
Results: Frequencies of TLR4+ monocytes and transcript levels of TLR4 and Myd88 were 
signiﬁcantly increased above controls and SA in UA and AMI. This was paralleled by 
increased expression of IL-12 and B7-1 in UA and AMI. Activation of TLR4-transfected 
CHO cells tracked with HSP60 serum levels that were signiﬁcantly elevated in UA and 
AMI. Activation could be inhibited by anti-HSP60 (table).
Conclusions: Acute coronary syndromes are associated with enhanced expression and 
downstream signaling of TLR4 in circulating monocytes. TLR4 activation can be blocked 
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by anti-HSP60 in vitro suggesting HSP60-mediated TLR4 activation as one signaling 
mechanism in immune-mediated progression of CAD0
.
TLR4 expression and signaling in CAD
control
(n=30) 
SA
(n=20)
UA
(n=40)
AMI
(n=28) 
P-value
UA, AMI vs.
SA, control
TLR4+/CD14+-
monocytes [%] 30.4±6.3 32.7±5.3 77.9±9.8 78.3±13.8 <0.005
TLR4 mRNA
[relative units] 0.92±0.11 0.96±0.18 1.78±0.26 1.82±0.33 <0.01
Myd88 mRNA
[relative units] 0.37±0.18 0.42±0.13 0.95±0.06 1.06±0.24 <0.05
IL-12 [pg/ml] 2.1±0.3 2.2±0.5 35.5±7.7 31.8±7.6 <0.005
B7-1+/CD14+-
monocytes [%] 2.4±2.3 3.4±2.4 27.3±14.2 22.6±10.9 <0.005
serum HSP60
[ng/ml] 41±54 263±94 1243±383 2342±687 <0.05
CD25+-CHO cells [%] 1.3±1.1 2.6±0.9 18.4±2.8 21.7±3.1 <0.002
CD25+-CHO cells [%] 
with anti-HSP60 1.2±0.9 1.4±1.2 2.3±1.9 2.4±1.3 0.56
1097-97 Homozygous Loss of Macrophage Colony-Stimulating 
Factor Receptor Markedly Reduces Atherosclerosis in 
Apolipoprotein E-Deﬁcient Mice
Tripathi B. Rajavashisth, Aatish Kumar, Chris Espinoza, Prediman Shah, Xu-Ming Dai, E. 
Richard Stanley, Cedars-Sinai Medical Center, Los Angeles, CA, Albert Einstein College 
of Medicine, New York, NY
Previous studies of mice with mutation that inactivates macrophage colony-stimulating 
factor (M-CSF or CSF-1), crossed onto atherosclerosis-prone backgrounds, have 
established the role of M-CSF in the formation of atheromatous lesions. M-CSF is a 
multifunctional protein that regulates the differentiation, proliferation and survival of 
mononuclear phagocytes by binding to a speciﬁc cell surface CSF-1 receptor (CSF-1R) 
encoded by the proto-oncogene c-fms. Using apolipoprotein (apo) E-deﬁcient mice, we 
now demonstrate that homozygous inactivation of Csf1r gene (Csf1r-/-) is associated with 
a marked reduction of aortic plaque areas in both male and female mice despite persistent 
hypercholesterolemia. Among apo E-/- mice, the frequency of atherosclerosis in aortic 
arch was 0/5 (Csf1r-/-), 12/13 (Csf1r+/-) and 15/15 (Csf1r+/+). The atherosclerotic plaque 
phenotype of Csf1-/- mice closely resembled the phenotype of CSF-1-null (Csf1op/Csf1op) 
mice, including reduced plaque lipid content and numbers of macrophages. The effect 
of Csf1r deﬁciency did not appear to be mediated by changes in circulating lipoproteins 
or M-CSF ligand, as the Csf1r-/- mice exhibited higher levels of atherogenic lipoproteins 
and dramatically increased levels of M-CSF. The effects of the Csf1r-null mutation on 
atherogenesis may have resulted from decreased circulating monocytes, reduced tissue 
macrophages, or from diminished arterial CSF-1R protein. Collectively, our results 
suggest an important role for M-CSF/CSF-1R-mediated signaling in the genesis and 
progression of atherosclerosis.
1097-98 Effects of Statins on Human Myeloid Dendritic Cells 
(DC): Suppression of DC-induced T Cell Stimulation and 
Th1-Differentiation
Atilla Yilmaz, Christine Reiss, Iwona Cicha, Christian Stumpf, Alexander Steinkasserer, 
Werner G. Daniel, Christoph D. Garlichs, University of Erlangen-Nuremberg, Erlangen, 
Germany
Background: Recent studies claimed that the beneﬁcial effects of statins in atherosclerosis 
might be partly mediated through immunomodulation. Dendritic cells (DC) are assumed 
to play a critical role in atherosclerosis. Thus, statins might affect DC-induced immune 
reactions. Therefore, we analyzed the effects of statins on DC-functions. 
Methods and Results: Immature DC (negative control: S-/L- DC) were differentiated 
from monocytes using GM-CSF and IL-4. Mature DC (positive control: S-/L+ DC) were 
generated by LPS-incubation (1 µg/mL, 24h). Previous to LPS-stimulation, incubation 
with simvastatin or atorvastatin (0.1 to 10 µM) of DC (S+/L+ DC) was performed for 
48h. Compared to S-/L+ DC, S+/L+ DC showed a signiﬁcantly lower expression of the 
costimulatory molecules CD83, CD40, CD86, and HLA-DR (FACS). In contrast, the 
expression of Toll-like receptors (TLR-2 and -4) was upregulated on S+/L+ DC. Statin 
preincubation suppressed signiﬁcantly FITC-dextran uptake by S+/L+ DC (endocytosis 
assay). Unexpectedly, the secretion of proinﬂammatory cytokines IL-6, IL-8, IL-12, and 
TNF-alpha from S+/L+ DC was signiﬁcantly enhanced by statins, while the release of 
the antiinﬂammatory IL-10 was not affected (cytokine bead array). To clarify whether 
statins inﬂuence the ability of DC to induce immune reactions, experiments with DC-T cell 
cocultures were performed. Statin preincubation signiﬁcantly reduced the ability of S+/L+ 
DC to induce T cell proliferation (CFSE-MLR) and Th1-differentiation, assessed by the 
reduction of IFN-gamma and IL-2 secretion by T cells. 
Conclusions: This study showed that statins signiﬁcantly suppressed the expression 
of costimulatory molecules on S+/L+ DC and their ability to take up antigens. In 
contrast, the expression of TLR-2 and -4 and the release of proinﬂammatory cytokines 
by S+/L+ DC were signiﬁcantly enhanced. However, DC-induced T cell stimulation 
and Th1-differentiation were suppressed by statins, providing an explanation for their 
immunosuppressive properties. Thus, immunomodulation by statins might contribute to 
their beneﬁcial effects in atherosclerosis and might provide a novel tool in the therapy of 
immunological disorders.
1097-99 Inhibition Of The Angiotensin Type 1 Receptor and 
Differential Regulation Of Inﬂammatory Genes in 
Human Vascular Endothelial Cells
Bobby V. Khan, Sushant Navalkar, Qamar A. Khan, Srikanth Sola, Muhammad Mir, 
Sampath Parthasarathy, Emory University School of Medicine, Atlanta, GA, Louisiana 
State University, New Orleans, LA
Background: Angiotensin II may contribute to the pathogenesis of atherosclerosis through 
activation of the endothelial inﬂammatory response. These effects may be inhibited in 
part by blockade of the angiotensin type 1 (AT1) receptor. We wished to investigate the 
effect of angiotensin II receptor blockade on the regulation of inﬂammatory genes such 
as mitogen activated protein (MAP) kinases and adhesion molecules in human vascular 
endothelial cells.
Methods: Human coronary artery endothelial cells (HCAEC) at no greater than the 
fourth passage, were pretreated with the AT1 receptor blocker losartan (100 nM) + the 
AT2 receptor blocker PD123319 (100 nM) for 24 hours. The cells were then exposed to 
the cytokine TNF-α (100 U/ml) for one hour. Using Western blot analysis, we determined 
the phosphorylation of the following MAP kinases: p38, ERK1, and ERK2. Using ELISA 
technique, we determined the gene expression of the inﬂammatory molecules vascular 
cell adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1).
Results: TNF-α strongly activated the phosphorylation of JNK, p38, ERK1, and ERK MAP 
kinases in HCAEC by Western blot analyses. Treatment with losartan suppressed TNF-� 
induced phosphorylation of JNK and p38 MAP kinase by 72% and 62%, respectively 
(p<0.05 for both), but had no signiﬁcant effect on ERK1 or ERK2. Using Northern blot 
analysis, losartan decreased TNF-α induced mRNA accumulation of VCAM-1 but did not 
affect mRNA accumulation of ICAM-1 in HCAEC. Furthermore, pretreatment of HCAEC 
with losartan and the AT2 receptor PD123319 (100 nM) returned TNF- α induction of 
VCAM-1 mRNA accumulation and the phosphorylation of JNK and p38 MAP kinases to 
control levels. No signiﬁcant changes in TNF-α induced mRNA accumulation of VCAM-1 
or phosphorylation of JNK, p38, ERK1, or ERK2 were observed in HCAEC pretreated 
with PD123319 only.
Conclusions: These ﬁndings suggest that there is differential regulation of MAP kinases 
and inﬂammatory genes by AT1 blockade in human vascular endothelial cells. Furthermore, 
these results suggest the presence of AT2 receptors in HCAEC and that inhibition of the 
AT1 receptor activates AT2 receptors in human vascular endothelial cells.
1097-103 Identiﬁcation of a 163-bp Region in the t-PA Gene 
Promoter Containing Response Elements for the 
Polyphenol, Quercetin
Wensheng Pan, Edlue Moyo Tabengwa, Francois M. Booyse, University of Alabama at 
Birmingham, Birmingham, AL
Background: Moderate wine (in particular red wine) consumption reduces the risk for 
coronary artery disease (CAD) and CAD-related mortality. We have demonstrated that 
wine polyphenols (catechin and quercetin) increase t-PA/u-PA gene transcription and 
ﬁbrinolytic activity in cultured human umbilical vein endothelial cells (ECs). Increased 
ﬁbrinolysis may contribute, in part, to the protective beneﬁts attributed to moderate wine 
consumption. These studies will identify response region(s) in the t-PA gene promoter 
responsible for the quercetin-induced upregulation of t-PA gene transcription.
Methods: Four t-PA promoter deletion constructs (pt-PA719/luc, -719; pt-PA500/luc, -500; 
pt-PA358/luc -358; and pt-PA198/luc, -198) and the identiﬁed quercetin-responsive 163-
bp sequence construct (p163/luc, -500 to -358, relative to start site) were generated and 
cultured ECs transiently transfected with all constructs. Transfected cultures, incubated in 
the absence/presence of quercetin (1µM), were lysed and luciferase activity measured. 
Electrophoresis mobility shift assays (EMSAs) were carried out, using nuclear extracts 
from quercetin- vs. buffer-treated ECs.
Results: Deletion analysis showed the pt-PA500/luc and larger constructs were 
responsive to quercetin, but the pt-PA358/luc and smaller constructs were unresponsive, 
showing that a 163-bp sequence located between position -500 and -358 is required 
for regulation of t-PA gene transcription by quercetin - quercetin increased luciferase 
activity 90% in the p163/luc construct, compared to controls. Quercetin-treated nuclear 
extracts showed increased binding of proteins to the identiﬁed 163-bp fragment (EMSAs) 
vs.buffer-treated extracts. 
Conclusion: Results demonstrate that the region located between position -500 to -358 
(163-bp fragment) of the human t-PA gene contains elements required for the quercetin-
induced regulation of t-PA gene transcription. These studies provide new insights into the 
molecular mechanism(s) by which individual wine components can induce EC t-PA gene 
expression and ﬁbrinolysis to provide the cardioprotection attributed to moderate wine 
consumption.
1097-104 MRI-Documented Neo-intimal Dissection (NiD) and Co-
localization of Novel Apoptotic Markers: Apolipoprotein 
C-1, Ceramide, and Caspase-3 in Watanabe Heritable 
Hyperlipidemic Rabbit Sub-renal Aorta
Henning Steen, ANtonina Kolmakova, Matthias Stuber, Rene Rodriguez, Subroto 
Chatterjee, Joao Augusto Lima, Johns Hopkins University, Baltimore, MD
Background: Apoptotic aortic vascular smooth muscle cell (VSMC) death is known to 
contribute to plaque vulnerability and -rupture (PR)/NiD. Human plasma apolipoprotein C-
I (apoC-I) has been implicated in apoptotic VSMC death via recruiting a neutral sphingo-
myelinase(N-SMase)-ceramide(Cer)-caspase-3(Cas-3)-pathway in vitro. We visualized 
NiD non-invasively in vivo by MRI and hypothesized that enhanced immuno-histochemical 
(IH) evidence of aforementioned apoptotic molecules could be detected and quantiﬁed in 
areas of visualized PR/NiD.
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Methods: We imaged 9 Watanabe hereditable hyperlipidemic rabbits (WHHL; 
I:3WHHL,II:6WHHL fed with high cholesterol diet for 3 months) before and after Russel`s 
viper venom induced PR/NiD using 3D black blood fast spin-echo vessel wall images on 
a 1.5T MR system (Philips). After sacriﬁce, MRI detected aortic plaque ruptures were 
analyzed qualitatively via IH and quantitatively via Western Blots.
Results: Three animals of group II had MRI-visualized PR/NiD (Fig.A) veriﬁed by histology 
(Fig.E). There, IH showed marked increases in apoC-1, Cer and Cas-3 (Fig.F-H,dashed 
arrows) compared to I(Fig.B-D). Western blots revealed increased (2.5fold±05) active N-
SMase and Cas-3 when compared to I.
Conclusion: In-vivo MRI visualized PR/NiD was accompanied by IH localization of apoC-
I, Cer and Cas-3 previously implicated in aortic VSMC apoptosis in-vitro and further 
incriminates these molecules in apoptosis induced atherosclerotic PR/NiD. 
1097-135 Alcohol Ampliﬁes Nitric Oxide Upregulation of t-PA 
Gene Expression in Endothelial Cells
Wensheng Pan, Edlue Moyo Tabengwa, Dale A. Parks, Francois M. Booyse, University 
of Alabama at Birmingham, Birmingham, AL
Background: Light-to-moderate consumption of alcoholic beverages reduces the risk 
for coronary artery disease (CAD) and CAD-related mortality. Alcohol increases human 
umbilical vein endothelial cell (EC) t-PA gene transcription, ﬁbrinolytic activity and nitric 
oxide (NO) production that may collectively contribute, in part, to the overall cardioprotection 
mechanisms attributed to moderate alcohol consumption. NO also plays an important 
basal regulatory role in the vasculature and has been shown to affect ﬁbrinolytic proteins, 
in vivo and in vitro. However, it is unknown whether alcohol may additionally amplify the 
independent NO-mediated effects on EC t-PA mRNA expression.
Methods: Conﬂuent cultured ECs were incubated in the absence/presence of alcohol 
(0.075%, v/v) and/or NO donor (DETA-NONate, 100 µM); and/or absence/presence of NO 
synthase inhibitor (L-NNA, NG-Nitro-L-arginine, 250 mM), prior to measurement of t-PA 
mRNA levels and ﬁbrinolytic activity. T-PA mRNA levels (real-time PCR) were expressed 
as the relative ratio of t-PA mRNA/18S mRNA and surface-localized EC ﬁbrinolytic activity 
quantitated by the direct conversion of EC-bound single-chain 125I-labeled Glu-Pmg.
Results: NO and alcohol both increase t-PA mRNA expression (~1.5- to 1.8-fold), 
however, the combined effect of alcohol plus NO was signiﬁcantly higher (~3-to 3.5- fold) 
than either inducer alone, as compared to buffer controls. Similarly, the concomitant 
expression of surface-localized ﬁbrinolytic activity in ECs treated with NO, alcohol and 
alcohol plus NO, were all signiﬁcantly higher than control levels (~3.6-fold, ~5.4-fold and 
~6.6 -fold, respectively). 
Conclusion: These combined results demonstrate that NO independently upregulates 
EC t-PA mRNA expression and concomitant ﬁbrinolytic activity and that this independent 
NO-induced upregulation of ﬁbrinolysis is further ampliﬁed by alcohol in cultured ECs. 
The signiﬁcant additional ampliﬁcation of NO-induced EC ﬁbrinolysis by alcohol will be 
expected to provide protection by promoting clot lysis, thereby reducing the overall risk for 
early thrombotic and later atherothrombotic complications associated with CAD.
1097-136 Interferon-beta Decreases Atherosclerotic Plaque Area 
in Apolipoprotein E -/- Mice
Matthew A. Hook, Matthew Kiedrowski, Zhongmin Zhou, Peter Heeger, Vincent Tuohy, 
Anjli Maroo, Eric Topol, Marc Penn, The Cleveland Clinic Foundation, Cleveland, OH
Background: Interferon-beta selectively inhibits the CD40 ligand-dependent expression of 
IL-12 by dendritic (antigen-presenting) cells, increases the IL-10/IL-12 ratio, and augments 
the differentiation of CD4+ T cells to the Th2 subclass. Interferon-beta further decreases 
the activity of MMP-9, ICAM-1 and interferon-gamma. Based on this beneﬁcial therapeutic 
proﬁle, we aimed to investigate the effect of interferon-beta on atherosclerosis.
Methods: Fourteen thirteen-week old C57 apoE -/- mice were divided into treatment and 
control groups. Both groups were fed a high fat western diet. Treatment animals received 
1 x 104 IU recombinant murine interferon-beta subcutaneously, every other day, for ten 
weeks. At the end of the treatment period, serum was collected for lipid analysis, and 
serial histological sections of the aortic root were obtained and stained at prespeciﬁed 
intervals. Atherosclerotic plaque area was quantitated in a blinded fashion. The plaque 
area for each section was measured as the difference between the lumen area and the 
area delineated by the internal elastic lamina. The results were normalized to total vessel 
area to eliminate confounding by variance in vessel size.
Results: Mean aortic root plaque area was 155,302 µm2 and 210,763 µm2 in the 
interferon-beta treated animals and control animals respectively. Mean plasma lipids were 
5.2 mg/dL (+/- 0.23) and 3.6 mg/dL (+/- 0.52) in the interferon-beta treated and control 
animals respectively. High-power magniﬁcation of stained serial sections of the aortic 
root demonstrated a marked reduction in the inﬂammatory cell inﬁltrate in interferon-beta 
treated mice.
Conclusion: Interferon-beta reduced atherosclerotic plaque area in apolipoprotein E 
deﬁcient mice compared to control animals. This reduction was independent of serum 
lipid content. Similarly, treatment with interferon-beta resulted in a marked reduction 
in inﬂammatory cells within the atherosclerotic lesion. These results suggest a role for 
interferon-beta in the treatment of atherosclerosis and demonstrate a need to further 
study the immunomodulating properties of this therapy.
1097-137 Aldehyde Dehydrogenase-positive Stem Cells From 
The Human Bone Marrow Differentiate Into Endothelial 
Cells More Efﬁciently Than Cd133+/cd34+ Endothelial 
Progenitor Cells
Shoukang Zhu, Chunming Dong, Tracy Gentry, Andrew Balber, Pascal J. Goldschmidt-
Clermont, Duke University Medical Center, Durham, StemCo Biomedicals, Inc, Durham, NC
Background: Emerging evidence supports that adult stem cells possess the 
developmental plasticity associated with embryonic stem cells_differentiating into cells 
of multi-lineages, including endothelial cells (EC). It remains to be elucidated, however, 
regarding the molecular determinants that identify the progenitor phenotype(s) that can 
differentiate into ECs efﬁciently. The 
Aim of this study was to determine if the aldehyde dehydrogenase (ALDH)-expressing 
primitive bone marrow stem cells that contain multiple progenitor types had higher EC 
differentiation potential than the pure CD133+/CD34+ endothelial progenitor cells (EPCs).
Methods: ALDHbr cells were isolated from human bone marrow by ﬂow cytometry 
using a ﬂuorescent substrate, ALDEFLUORTM. CD133+/CD34+ cells were isolated by 
immunoselection and FACS sorting. Cells were cultured in basal medium (BM: M199 
containing 20% of FBS) or in condition medium (CM: M199, 20%FBS, 10ng/ml VEGF, 
1ng/ml b-FGF, 2ng/ml IGF-1). Cells were also cultured in a transwell system in the 
presence of human aortic endothelial cells (HAECs) as feeders. Expression of VEGFR-2, 
CD31, von Willebrand factor, Ulex Lectin, LDL uptake & vascular tube formation were 
used to deﬁne the progenies as mature ECs. 
Results: ALDHbr cells differentiated into ECs in BM, CM and the transwell culture system 
in the presence of HAECs as feeder cells. Overall, 1.3% of the seeded ALDHbr cells 
differentiated into ECs on day 5 in BM, the addition of VEGF, bFGF & IGF-1 increased 
the differentiation capability (3.5%) of ALDHbr cells in CM. The differentiation capacity of 
ALDHbr cells was further increased in the transwell system (9.3%). In contrast, CD133+/
CD34+ cells displayed modest differentiation capacity (0.3%) in the presence of HAEC 
feeder cells, whereas very few cells differentiated into ECs in BM or CM. 
Conclusions: 1) ALDHbr cells represent a more efﬁcient population that can differentiate 
into ECs compared with CD133+/CD34+ cells, perhaps due to the presence of supporting 
cells in ALDHbr population; 2) Further work is needed to determine if ALDHbr cells are 
better ﬁtted for vascular repair or myocardial regeneration in vivo.
1097-138 Hyperglycaemia-induced Hypercholesterolemia in 
Cholesterol-fed Rabbits is Associated With Systemic 
and Vascular Oxidative Stress
Bertrand Collin, David Busseuil, Claudia Korandji, Marianne Zeller, Pierre Sicard, 
Alexandra Oudot, Gilles Rioufol, Gérard Finet, Laurence Duvillard, François Briot, Yves 
Cottin, Luc Rochette, University of Burgundy, Dijon, France
Background: Hypercholesterolemia and hyperglycaemia are pathophysiologic conditions 
where oxidative stress plays a key role in cardiovascular diseases. Animal studies are 
focused either on the effects of hypercholesterolemia or hyperglycaemia, but the inﬂuence 
of a cholesterol-rich diet (CRD) on glycaemia are unknown. The aim of our study was to 
assess the effects of CRD on glycaemia and oxidative stress (systemic and vascular).
Methods: 16 New-Zealand-White rabbits were randomized in either the CRD group (0.5 
%, n=8) or in a control group (CTRL, n=8) for 60 days. Total cholesterolemia (TC) and 
glycaemia were measured (mM) at baseline and at 60 days. The Antioxidant Capacity 
of Plasma (ACP) was assessed as a systemic marker of oxidative stress. Vascular 
oxidative stress mediated by O2
.- was measured with oxidative ﬂuorescence (OF) using 
dihydroethidium (% ﬂuorescence/mm2) and chemiluminescence (Arbitrary units/mg, AU/
mg). Immunohistochemistry assessed the expression of p67phox and p22phox sub-units 
of vascular NAD(P)H oxidase (NOX).
Results: TC and glycaemia were increased in the CRD group compared to CTRL 
(respectively: 22.8 ± 3.0 vs 0.6 ± 0.1 mM, p<0.001 and 13.8 ± 1.3 vs 7.9 ± 0.5 mM, 
p<0.01). The ACP was signiﬁcantly lower in the CRD group compared to CTRL (0.9 ± 0.1 
vs 1.2 ± 0.04, p<0.01). The OF was higher in the CRD group than in CTRL (25.5 ± 1.4 
vs 14.0 ± 1.9 % ﬂuorescence/mm2, p<0.001). The O2
.- production by vascular NOX was 
signiﬁcantly increased in the CRD group compared to CTRL (12,707 ± 2,634 vs 2,989 ± 
346 AU/mg, p<0.001). The expression of p22phox and p67phox was higher in the CRD 
group than in CTRL (respective scoring: 1.3 ± 0.2 vs 0.4 ± 0.2 p<0.01 and 1 ± 0.2 vs 0.3 
± 0.1, p<0.01).
Conclusion: Hypercholesterolemia induced a hyperglycaemia possibly related to liver 
dysfunction. These abnormalities are associated with systemic and vascular oxidative 
stress mediated by O2
.-. These ﬁndings are particularly relevant as they establish the 
fact that risk factors are interdependent. Further studies are necessary to investigate the 
respective contributions of cholesterolemia and glycaemia to oxidative stress and the 
clinical implication with regard to therapeutic choices.
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1097-139 The Heme Oxygenase-derived Carbon Monoxide 
Protects against Hypoxia-Induced Cell Death of Bovine 
Endothelial Cells through Suppression of NAD(P)H 
Oxidases
Seiji Ayabe, Hajime Fujimoto, Minoru Ohno, Ryozo Nagai, Department of Cardiovascular 
Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
Backgrounds; Oxidative stress is recently postulated to be associated with the hypoxia-
induced cell death pathway. Heme oxygenase-1 (HO-1) is a cytoprotective enzyme 
induced by various stresses, including hypoxia. This study aimed to examine the effects 
of low concentrations of carbon monoxide (CO, a HO-1-derived product) and HO-1 
adenoviral gene transfer on cell survival and intracellular oxidative stress under hypoxia.
Methods; Bovine aortic endothelial cells (BAECs) and human umbilical vein endothelial 
cells (HUVECs) were incubated for up to 48hrs under hypoxia or normoxia, with CO (250-
1000ppm), or following HO-1 gene transfer. Prolonged hypoxia decreased BAEC viability 
as conﬁrmed by trypan blue and WST-1 assays.
Results; In the presence of CO or following HO-1 gene transfer, hypoxia-induced reduction 
of viability was ameliorated. Cyclic GMP was partially responsible for cytoprotection, 
since the guanylate cyclase inhibitor ODQ partially blocked the cytoprotective effect. CO 
also prevented apoptosis under hypoxia, as shown with ﬂow cytometry using propidium 
iodide - annexin V assay. CO and HO-1 gene transfer also prevented decrease of the 
Bcl:Bax protein ratio under hypoxia. We conﬁrmed that hypoxia increased intracellular 
oxidative stress using 2,7-dichloroﬂuorescein, and this phenomenon was inhibited by N-
acetylcysteine. NADH/NADPH oxidase is an important source of reactive oxygen species 
in endothelium. In our study, hypoxia increased NADH/NADPH oxidase activity in BAECs 
and gp91(phox)/p22(phox) expression levels in HUVECs using each component-speciﬁc 
antibodies. Interestingly, CO and HO-1 gene transfer decreased these levels. These 
phenomena suggest that CO inhibited the superoxide production induced by hypoxia.
Conclusions; The HO-1-CO pathway has an important role to protect endothelial cells 
under hypoxia through inhibition of intracellular oxidative stress mediated by NAD(P)H 
oxidase.
1097-140 The Activated State Of Wnt Signaling In Endothelial 
Progenitor Cells Promotes Cell Proliferation With Little 
Effects On Differentiation
Shoukang Zhu, Chunming Dong, Tracy Gentry, Andrew Balber, Pascal J. Goldschmidt-
Clermont, Duke University Medical Center, Durham, NC, StemCo Biomedicals, Inc, 
Durham, NC
Background: Signaling by the canonical Wnt pathway has multiple functions in stem cells. 
It can either control stem cell expansion or inﬂuence cell lineage decisions by promoting 
speciﬁc fates at the expense of others. The Aim of this study was to determine the effect 
of Wnt signaling in the proliferation & differentiation of aldehyde dehydrogenase positive 
(ALDHbr) and CD133+/CD34+ endothelial progenitor cells (EPCs). 
Methods: CD133+/CD34+ EPCs were isolated from the human bone marrow by 
immunoselection and FACS sorting. ALDHbr primitive stem cells were isolated by FACS 
using ﬂuorescent ALDH substrate, ALDEFLUORTM. Cells were induced to undergo 
endothelial cell (EC) differentiation in M199 medium + VEGF, bFGF & IGF-1, or in a 
transwell culture system using human aortic endothelial cells as feeders. Mature ECs are 
characterized by the expression of CD31, von Willbrand factor, Ulex Lectin, VEGFR-2, 
LDL uptake & vascular tube formation. Activated state of Wnt signaling was maintained 
using lithium chloride (LiCl) treatment & lentivirus-mediated β-catenin overexpression. 
Results: LiCl treatment caused nuclear accumulation of β-catenin & TCF4, indicating 
activation of Wnt pathway in both cell populations. Incubation with 2 & 5 mM LiCl resulted 
in a dose-dependent increase in the number of cells collected at 5, 7 & 10 days after 
treatment, with the peak increase of 7.5 fold observed on day 7 at 5 mM LiCl in ALDHbr 
cells, compared with the same cells cultured in M199 alone (basal medium), whereas 
the addition of VEGF, bFGF & IGF-1 only caused a maximum of 2.9 fold increase on day 
10 in these cells. A markedly blunted proliferative response to LiCl was also detected in 
CD133+/CD34+ EPCs. Similar effects were demonstrated with β-catenin overexpression. 
In contrast, Wnt signaling did not affect the percentage of ALDHbr cells or CD133+/CD34+ 
EPCs differentiating into mature ECs.
Conclusions: 1) Wnt signaling selectively promotes proliferation of ALDHbr, and to a 
lesser degree of CD133+/CD34+ cells without affecting their differentiation toward EC 
lineage; 2) Further work is warranted to determine the functional signiﬁcance of Wnt 
activation in vivo in the context of cell therapeutics.
1097-141 Cytostasis Rather than Apoptosis: Smooth Muscle Cell 
Beta-3 Integrin Blockade Leads to Reversible Cell Cycle 
Arrest
Marvin J. Slepian, Behrooz Dehdashti, Anne Fritz, Luke Whitesell, University of Arizona, 
Tucson, AZ
Integrin-matrix interactions are vital in regulating many cell functions. We previously 
demonstrated that blockade of smooth muscle cell (SMC) β3 integrin-matrix interactions 
limits SMC migration and post-injury arterial thickening. The effect of β3 blockade on SMC 
cell cycle progression and survival is unknown. We examined the effect of β3 integrin 
blockade on: 1. SMC cell cycle progression, 2. reversible cell growth inhibition, and 3. 
Apoptosis.
Methods: For all studies adult rat aortic SMCs (3x104 cells/cm2) were incubated in DME 
+ 10% FCS (media) + cyclic GPenRGDSPA ((cRGD), 0.25 mM, β3 antagonist) for 24h. 
For cell cycle progression SMCs were stained with propidium iodide (PI) and analyzed 
via ﬂow cytometry for DNA content. p21 and p53 expression were determined via 
immunoblotting. Reversibility of integrin-mediated growth arrest was determined via serial 
quantitation of SMCs washed, replated and incubated in cRGD free-media. Induction of 
apoptosis was assessed via: 1. Annexin V staining (ﬂow cytometry), 2. DNA laddering, 3. 
EM morphology, 4. Caspase-3 expression. Identically treated SMC, w/o 24 h cRGD, were 
untreated controls. Campothecin-treated U937 cells were + apoptotic controls.
Results: β3 blockade lead to G1 cell cycle arrest (83.2+0.4% vs 68+5% (control), p=0.03). 
Consistent with arrest p21 expression was increased (300+20% vs control, p<0.001) however 
p53 was not induced. Upon cRGD washout SMCs rapidly returned to exponential growth 
(At 48 h: 7.2x106 cells/ml vs 7.5x106cells/ml (control), p=0.2). Despite growth arrest SMC 
remained viable with: 82% of SMCs Annexin V(-)/PI(-), No detectable DNA laddering, <10% 
SMCs exhibiting EM nuclear condensation, and no detectable Caspase-3 expression.
Conclusion: Blockade of SMC β3 integrin-matrix interactions leads to reversible G1 
cell cycle arrest. Despite arrest SMCs remain viable, with recoverable growth upon 
integrin antagonist washout. A minority of SMCs are committed to apoptosis. Induction 
of cytostasis rather than apoptosis suggests that anti-�3 integrin therapeutic strategies for 
restenosis may require extended antagonist exposure due to SMC growth recovery.
1097-142 Effects Of C-reactive Protein On Atherogenic Mediators 
And Adrenomedullin In Human Coronary Artery 
Endothelial And Smooth Muscle Cells
Yasuko Nagoshi, Kenji Kuwasako, Yuan-Ning Cao, Takuroh Imamura, Kazuo Kitamura, 
Tanenao Eto, First Internal of Medicine,University of Miyazaki, Miyazaki Medical College, 
Miyazaki, Japan
Evidence suggests that C-reactive protein (CRP) is an important risk factor for 
cardiovascular disease. Conversely, adrenomedullin (AM) is a potently hypotensive peptide 
that can inhibit the progression of atherosclerosis and counteract the pathogenic effects of 
oxidative stress on the vasculature. Although recombinant (r) CRP is known to augment 
the expression by cultured vascular cells of a variety of atherogenic mediators, including 
interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), plasminogen activator 
inhibitor-1 (PAI-1)and endothelin-1 (ET-1), nothing is known about their relationships 
in human coronary artery cells. Furthermore, the results of many earlier studies are 
complicated by the fact that the commercial rCRP preparations used were isolated from 
Escherichia coli culture supernatant and thus contained high concentrations of endotoxin. 
We examined the effects of recombinant human CRP (rhCRP) on the aforementioned 
atherogenic mediators in cultured human coronary artery endothelial and smooth muscle 
cells (HCAECs and HCASMCs). After removing endotoxin from commercial rhCRP 
preparations using the appropriate column, the puriﬁed (P)-rhCRP retained the ability 
to Ca++-dependently bind to phosphorylcholine, suggesting it is capable of forming the 
pentameric structure of the native protein. Nevertheless, P-rhCRP (50 mg/mL) did not 
augment secretion of IL-6 or MCP-1 from HCAECs, as the same concentration of non-
puriﬁed (NP)-rhCRP did. P-rhCRP did, however, elicit 2- to 3-fold increases in the secretion 
of IL-6 and MCP-1 from HCASMCs, though the effect was smaller than was obtained with 
NP-rhCRP. Production of PAI-1 and ET-1 was little affected by either rhCRP preparation 
in either cell type. We also found that P-rhCRP dose-dependently diminished AM release 
from both cell types, but did not affect the expression or function of the two endogenously 
expressed AM receptors. These ﬁndings highlight the importance of the purity of the rCRP 
preparations used to study CRP’s effects on vascular cell biology and show that CRP 
likely facilitates the development of atherosclerosis by increasing production of IL-6, MCP-
1 and PAI-1 while decreasing that of AM.
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1098-100 Abnormal Subendocardial Perfusion Detected By 
Cardiac Magnetic Resonance Imaging Correlates With 
Coronary Endothelial Dysfunction In Patients Without 
Coronary Heart Disease
Jochen Wöhrle, Nico Merkle, Hans A. Kestler, Olaf C. Grebe, Martin Höher, Matthias 
Kochs, Vinzenz Hombach, Thorsten Nusser, University of Ulm, Ulm, Germany
Background: Patients with angina but without coronary artery disease (CAD) show 
subendocardial perfusion defects in cardiac magnetic resonance imaging (MRI). Coronary 
endothelial dysfunction is common in patients suffering from angina without CAD.
We evaluated, whether there is a correlation between abnormal subendocardial perfusion 
in MRI and coronary endothelial dysfunction.
Methods: 13 patients without CAD were included. Biplane angiography and intracoronary 
doppler ﬂow measurements in the LAD were performed to calculate coronary blood 
ﬂow reserve. Endothelial function was studied at rest, during adenosine (140µg/min/kg 
body weight intravenously) and acetylcholine given intracoronarily (0.036, 0.36, 3.6 and 
18µg/ml, infusion rate 2ml/min). Cardiac MRI was performed on a 1.5T Philips Intera CV 
whole body scanner. For ﬁrst-pass-perfusion analysis a SSFP sequence with 3 short axis 
slices per heart beat using 0.025mmol Gd-DTPA/kg body weight was used at rest, during 
adenosine (140µg/min/kg body weight intravenously) and acetylcholine stimulation (3.6 or 
18µg/ml intracoronarily). Two observers quantitatively analyzed subendocardial perfusion 
with a ﬁrst-pass perfusion software (Philips Medical Systems). Normalized uplsopes and 
myocardial perfusion reserve were calculated. MRI was performed immediately after 
measurement of endothelial function.
Results: Subendocardial ischemia in SSFP sequences was seen visually in 7/13 patients. 
Patients with subendocardial perfusion defects had a lower coronary perfusion reserve 
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both during adenosine and acetylcholine stress, a signiﬁcant lower normalized upslope in 
MRI perfusion and a lower myocardial perfusion reserve for adenosine and acetylcholine 
compared to patients without subendocardial perfusion defects. We found a signiﬁcant 
correlation between the coronary blood ﬂow reserve and the myocardial perfusion reserve 
with intravenously applied adenosine (P<0.001) as well as with intracoronarily given 
acetylcholine (P<0.001).
Conclusions: In patients without CAD subendocardial perfusion defects seen in ﬁrst pass 
cardiac MRI perfusion correlates signiﬁcantly with coronary endothelial dysfunction.
1098-101 Assessment Of Sub-Endocardial Myocardial Perfusion 
Reserve by First Pass MRI in Patients with Diabetes 
Mellitus
Uzodinma R. Dim, Olakunle O. Akinboboye, Yi Wang, Nora Ngai, Sunil T. Mathew, Kathy 
McGrath, Marguerite Roth, Kenneth J. Nichols, William Schapiro, Nathaniel Reicheck, 
Saint Francis Hospital/ Stony Brook University, Roslyn, NY, Long Island Jewish Hospital, 
New Hyde Park, NY
Background: It is widely believed, but not shown that subendocardial (SE) (inner 50% 
of the myocardium) perfusion is less than transmural perfusion in patients with coronary 
microangiopathy. Gadolinium-enhanced ﬁrst-pass MRI’s spatial resolution has the unique 
ability to quantify SE perfusion.We hypothesized that SE myocardial perfusion reserve (MPR) 
is lower than transmural MPR in patients with type II diabetes, but no overt clinical CAD.
Methods: We measured MPR index (MPRI) by ﬁrst-pass gadolinium-enhanced MRI 
following I.V. adenosine-induced hyperemia and at rest in 20 diabetic patients without 
known CAD (75% M, 59 ± 9 yrs). A 1.5 T MRI scanner (Sonata, Siemens Med.) was 
used. Imaging was performed using a partial Fourier saturation recovery TurboFLASH 
sequence with TR/TE/TI/FA = 2.9ms/1.3ms/90ms/15°, data matrix 128x70, and voxel 
spatial resolution 3.5x1.9x8mm3 based on patient size .The steepness of the initial upslope 
phases of the ﬁrst pass signal intensity curves for the blood pool and myocardium (using 
6 equal sectors) were determined by using commercial software (MEDIS, Imaging Sys). 
Rest perfusion relative upslope (RPRU) and hyperemic perfusion relative upslope (HPRU) 
were computed as the ratios of myocardial curve upslope to blood pool curve upslope at 
rest and during hyperemia, and MPRI was computed as HPRU/RPRU. Results(mean of 
the 6 sectors) {see table}. 
RPRU HPRU MPRI
SE 12.0 ± 5.0 % 12.5 ± 4.0 % 1.1 ± 0.4
Trans 11.0 ± 4.0 % 13.5 ± 5.0 % 1.3 ± 0.4
p 0.0004 NS 0.0005
Conclusion: In diabetic patients subendocardial resting ﬂow is higher, but ﬂow reserve 
lower, than average transmural ﬂow.
1098-102 Coronary Artery Vasomotor Response to Cold Pressor 
Test: Assessment by Magnetic Resonance Imaging
Andressa Borges, Yi Wang, William Schapiro, Nathaniel Reichek, St. Francis Hospital, 
Roslyn, NY, Stony Brook University, SUNY, Stony Brook, NY
Coronary artery endothelial dysfunction (ED) impairs the increase in coronary arterial 
ﬂow and lumen size produced by cold pressor testing (CPT). We used cardiac MRI (CMR) 
to noninvasively measure coronary artery cross sectional area (CSA), mean diastolic 
coronary blood ﬂow (CBF) and mean diastolic ﬂow velocity (V) at baseline and at 90 
seconds of CPT, and before and serially after NTG 0.4 mg s.l. to assess endothelial-
independent coronary dilation. Findings were compared in control subjects (CONT, n=7, 
4 women; age 52±11yrs) and subjects with risk factors associated with ED (RISK, n=16, 
14 men; age 64±5 yrs): hypertension, hyperlipidemia, diabetes, smoking. Breath-hold 
turbo spin echo CMR (FOV 195x240 cm matrix 125x256) and segmented phase contrast 
turboFLASH CMR velocimetry were used to image a cross-section of the proximal left 
anterior descending coronary artery to assess CSA, CBF and V.
Results: CBF increased during CPT in CONT but was unchanged in RISK. No change 
in CSA was detected in either group. At peak NTG effect, CBF increased in both CONT 
and RISK. CSA also increased in CONT with a trend to increase in RISK. Changes in V 
paralleled changes in ﬂow throughout.
Conclusions: 1. Direct assessment of dynamic changes in coronary blood ﬂow and ﬂow 
velocity is possible using CMR. 2. Cardiac MRI may permit noninvasive assessment of 
coronary endothelial dysfunction.
CSA (cm2)
CONT
CSA (cm2)
RISK
CBF(ml/sec)
CONT
CBF(ml/sec)
RISK
V (cm/sec)
CONT
V (cm/sec)
RISK
Baseline 1 .12±.02 .15±.06 .21±.12 .39±.18 5.7±2.6 8.7±3.8
Cold Pressor .12±.02 .14±.05 .47±.27* .37±.15 8.0±4.0* 8.7±3.9
Baseline 2 .13±.04 .15±.06 .22±.12 .40±.18 6.0±3.0 9.3±3.9
NTG .18±.02** .19±.08# .52±.24* .74±.41*** 9.3±3.6# 12.1±5.2*
*p<.05 **p<.005 ***p<.0005 #p=.07 vs. baseline
1098-105 Can Coronary Flow Reserve Be Assessed Using The 
Thrombolysis In Myocardial Infarction (TIMI) Frame 
Count?
Hiroki Teragawa, Kentaro Ueda, Katsuji Okano, Takayuki Hidaka, Hiroaki Takemoto, 
Hiroshi Ogi, Yukiko Nakano, Tetsuji Shingu, Kazuaki Chayama, Yukihito Higashi, Masao 
Yoshizumi, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, 
Japan
Background: Coronary ﬂow reserve (CFR) reﬂects the function of vascular smooth muscle 
of coronary artery at the resistance vessel level and provides important information 
about coronary microvascular function in a clinical setting. We usually assess CFR using 
the Doppler ﬂow technique in the catheterization laboratory, however its adaptation is 
somewhat limited because of its cost-effectiveness. On the other hand, Thrombolysis In 
Myocardial Infarction (TIMI) frame count (TFC) is an index of coronary blood ﬂow and is 
reliable, reproducible, and easily measurable by counting the number of cine frames on 
coronary angiography. We examined whether CFR could be assessed based on TFC. 
Methods: Eighteen patients without signiﬁcant coronary stenosis were enrolled for the 
study. Adenosine (100µg/min) was infused into the left coronary ostium over 2 min. The 
diameter of the proximal segment of the left anterior descending coronary artery (LAD) 
was quantitatively measured. Coronary blood ﬂow (CBF) was calculated by quantitative 
angiography and Doppler ﬂow velocity measurements. CFR was deﬁned as the ratio of 
CBF after infusion of adenosine to baseline value. TFC was deﬁned as the number of cine 
frames required for contrast to reach standardized distal coronary landmarks in the LAD. 
TFC Index (TFCI) was deﬁned as the vessel area divided by TFC. TFCI reserve (TFCIR) 
was calculated as the ratios of TFCI after infusion of adenosine to the baseline values. 
These parameters were measured twice in each patient. Results: The CBF (ml/min), TFC, 
TFCI at baseline were 78±5, 38±3 and 0.10±0.01, respectively. After infusion of adenosine, 
these parameters were 271±21, 34±3, and 0.12±0.01, respectively. Consequently, CFR 
and TFCIR were 3.6±0.2 and 1.20±0.04, respectively. The TFCIR correlated positively with 
CFR (r = 0.44, p<0.01). Receiver-operating characteristics analysis demonstrated that 
TFCIR<1.12 was the cutoff value for predicting a reduced CFR (<3.0), with a sensitivity 
of 0.75 (9 / 12) and a speciﬁcity of 0.79 (19 / 24). Conclusion: These ﬁndings suggest that 
coronary microvascular function may be easily and cost-effectively assessed using TFC 
in the catheterization laboratory. 
1098-106 Quantitative Invasive Evaluation of the Mechanisms of 
Coronary Steal in Chronic Total Coronary Occlusions: 
The Contribution of Donor Artery Stenosis and 
Peripheral Microvascular Resistance
Gerald S. Werner, Andreas Krack, Gero Schwarz, Dirk Prochnau, Hans R. Figulla, 
Friedrich-Schiller-University, Jena, Germany
Background. Coronary steal can occur in collateral-dependent myocardium with 
pharmacologic vasodilation. This study assessed coronary steal in chronic total coronary 
occlusions (CTO) to determine its dependance on microvascular function and the 
resistance of the donor artery segment.
Methods. 38 patients with a CTO (>4 weeks duration) were included in this study. 
Intracoronary pressure and Doppler measurements were performed before and during 
recanalization. The collateral donor artery was evaluated by determining the fractional 
ﬂow reserve (FFR) at the takeoff of the largest collateral, and the coronary ﬂow reserve 
(CFR) during i.c. papaverine (8-12mg). Then the recanalization was done and a probing 
catheter advanced distal to the occlusion to record distal coronary ﬂow velocity (APVd) 
and distal pressure (Pd) in the collateral-dependent vascular bed. Collateral (RC) and 
peripheral (RP) resistance were calculated. These parameters were again obtained 
during intravenous adenosine (140µg/kg/min). At the end of the procedure the CFR was 
determined in the recanalized artery.
Results. Coronary steal was deﬁned by a decrease of APVd during adenosine infusion 
below 80% of baseline. This was observed in 19 patients (gr.S); an increase of APVd 
above 120% was observed in 13 patients (34%) indicating a positive collateral ﬂow 
reserve (gr.R); no change occurred in 6 patients. Clinical data of groups S and R were 
similar. With steal RC increased by 95% in gr.S whereas it fell by 28% in gr.R. The FFR 
in the donor artery segment was signiﬁcantly lower in gr.S (0.79±0.14) than in gr.R 
(0.88±0.10; p<0.05) although only 42% in gr.S showed an angiographically visible donor 
stenosis. While RP was already low in gr.S and not affected by adenosine, RP was higher 
in gr.R and fell by 45% during adenosine.
Conclusions. The present study demonstrates in man, that coronary steal is 
predominantly caused by an increased resistance in the donor artery segment before 
collateral takeoff as demonstrated by a lower FFR. A signiﬁcant decrease of the RP was 
observed only in gr.R, indicating that the lack of vasodilatory reserve of the myocardium 
distal to the occlusion contribute to coronary steal.
1098-107 Insights Into the Genomic Program of Monocytes for 
Collateral Vessel Development
Pascal Meier, Rainer Zbinden, Janine Antonov, David Tueller, Stephan Windecker, 
Bernhard Meier, Rolf Jaggi, Christian Seiler, University Hospital, Bern, Switzerland
Objectivs: The goal of this prospective study was to investigate the role of selected genes 
in human coronary collateral growth.
Background: Arteriogenesis refers to the development of collateral conductance arteries 
and is decisively mediated by circulating monocytes, which invade growing collateral 
arteries and act as suppliers of cytokines, chemokines and proteases.
Methods: Collateral ﬂow index (CFI) was measured invasively by a pressure guide wire in 
14 patients with and in 14 patients without coronary artery disease CAD. Ribonucleic acid 
was extracted from peripheral blood monocytes. Low density array technology was used 
to determine the differential expression of 96 selected genes. Expression values were 
normalized by 3 house-keeping genes.
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Results: 4 patients had well developed collateral vessels (collateral ﬂow index CFI ≥0.25) 
whereas 24 patients had poorly developed collaterals (CFI < 0.25). Gene expression 
analysis revealed statistically signiﬁcant differential expression (>1.5-fold change) of 
9 genes in patients with good compared to patients with poor collaterals: all 9 genes 
were up-regulated. 4 of those genes belong to the group of cytokine receptors (IL8RA, 
IL8RB, CSF3R, FLT1), 4 genes are encoding for cyto-/chemokines (IL1B, CCL2, TGFB2, 
ANGPT1), and one is a stress gene (SCARA3).
Conclusion: This study documents that gene expression in peripheral blood monocytes 
differs signiﬁcantly in patients with well developed compared to patients with poorly 
developed collaterals. The data suggest that those genes play a role in human collateral 
artery formation.
1098-108 Is There an Impaired Coronary Collateral Function in 
Patients With Diabetes Mellitus ? Invasive Assessment 
in Chronic Total Coronary Occlusions
Gerald S. Werner, Markus Ferrari, Dirk Prochnau, Philipp Bahrmann, Hans R. Figulla, 
Friedrich-Schiller-University, Jena, Germany
Background. The cardiovascular mortality is increased with diabetes mellitus. An impaired 
collateral function is a possible cause, but the clinical evidence are semiquantitative 
dissenting angiographic studies. In the present study we used an invasive assessment 
of collaterals in diabetic and nondiabetic patients with chronic total coronary occlusions 
(CTOs) as a human in vivo model of collateral development.
Methods. In 161 patients with a CTO (>2 weeks duration) coronary ﬂow velocity (APVd) 
and pressure (Pd) were measured distal to the occlusion by sensor wires before the ﬁrst 
balloon dilatation. Aortic pressure (PAo) and central venous presssure (CVP) were also 
recorded. From these parameters a collateral resistance index RC=(PAo-Pd)/APVd and a 
microvascular resistance index as RP=(Pd/APVd) were calculated. A collateral pressure 
index was calculated as (Pd-CVP)/(PAo-CVP). Fifty-three diabetic patients (33%) were 
compared to 108 nondiabetic patients. Data are x±SEM.
Results. RC and RP were not different in diabetic and nondiabetic patients (RC: 8.2±1.1 
vs. 7.8±0.8 mmHg/cm/s; RP: 5.9±0.8 vs. 5.3±0.5 mmHg/cm/s). However, the underlying 
hemodynamic parameters showed differences. Pd was higher in diabetic patients (48±2 
mmHg vs. 42±1 mmHg; p=0.005), who also had a higher prevalence of hypertension 
(88% vs. 72%; p=0.01) with higher PAo (107±2 mmHg vs. 102±2 mmHg; p=0.06). The 
collateral pressure index was higher in diabetic patients (0.41±0.01 vs. 0.45±0.02; 
p=0.04). In contrast the APVd tended to be lower in diabetic patients (10.1±0.9 cm/s vs. 
11.6±0.6 cm/s; p=0.17) with a signiﬁcantly lower contribution during diastole (7.8±0.9 
cm/s vs. 10.5±0.6 cm/s; p=0.02) while systolic APVd was similar. These differences were 
more pronounced in patients with a recent occlusion of 2-12 weeks duration.
Conclusions. The collateral resistance in diabetic patients is comparable to nondiabetics 
in case of a longstanding CTO. However, there is a reduced diastolic collateral ﬂow in the 
presence of higher perfusion pressures indicating differences in microvascular properties. 
There is a larger difference in collateral function in patients with recent CTOs as evidence 
of a delayed development.
1098-109 Is There Microvascular Hyper-reactivity in Patients With 
the Coronary Slow Flow Phenomenon?
Stuart P. Turner, John Francis Beltrame, University of Adelaide, Queen Elizabeth 
Hospital Campus, Woodville South, Australia
Background: The Coronary Slow Flow Phenomenon (CSFP) is a coronary microspastic 
disorder characterised by recurrent episodes of rest angina. Whether defective vasomotor 
mechanisms are responsible is unknown. The objective of this study was to determine if 
microvascular responses to vasodilator and/or constrictor agents differed between CSFP 
patients and controls.
Methods: Skin biopsies were obtained from 8 patients with the CSFP and 8 controls. 
Arterial microvessels (diameter; 441±29µm) were mounted in a small vessel wire 
myograph and endothelium-dependent vasodilator function assessed. Concentration 
contractile-response curves were determined for catecholamines, platelet derived 
vasoconstictors and endothelin-1.
Results: Endothelium-dependent vasodilator responses were intact in both study groups. 
There was no difference in responses to phenylephrine, noradrenaline, serotonin and a 
thromboxane analog. In contrast, CSFP patients were twice as sensitive to endothelin-1 
compared with controls (EC50 [ET-1]M; -8.2 vs. -8.6, p=0.001). 
Conclusion: Patients with the CSFP have intact endothelium-dependent vasodilator 
responses in subcutaneous microvessels and a selective hyperresponsiveness to 
endothelin-1. This implicates a generalised microvascular disorder with endothelin-1 
playing an important pathogenetic role.
1098-110 Leptin Is A Vasodilator In Human Saphenous Vein: 
Evidence For Divergence Of Resistance To Leptin’s 
Vascular And Metabolic Actions.
Aziz U. Momin, Ajay Shah, David Grieve, Catherine Driver, Ahmed El-Gamel, Jatin 
Desai, Lindsay John, Michael Marrinan, Roy Sherwood, Mark Kearney, Cardiovascular 
Division Kings College Hospital, London, United Kingdom, Cardiothoracic Department 
Kings College Hospital, London, United Kingdom
Background: Leptin is an important peptide in metabolic regulation, with obese patients 
often resistant to the effects of leptin. Recent, studies have suggested that leptin may 
also have vasoactive effects. We explored this possibility in patients undergoing coronary 
artery bypass surgery (CABG).
Methods: The vasoactive effect of leptin was assessed ex-vivo in saphenous vein (SV) 
rings obtained at time of CABG. 131 patients undergoing CABG were recruited (age 
66±0.9, (mean±SEM) 90% male).
Results: Patients had body mass index 26.8±0.4 kg/m2, waist 99.2±1.0 cm, systolic blood 
pressure 138.6±2.0 mmHg, diastolic blood pressure 74.4±1.2 mmHg, fasting glucose 
6.5±0.2mmol/L, LDL, 1.8±.06mmol/L, HDL 1.0±0.2mmol/L.Vasorelaxation to leptin (10-13-
10-7M) was assessed in preconstricted SV rings in all patients. Mean maximal relaxation 
to leptin was 24.5±1.6%; all rings relaxed fully to SNP. To explore the mechanism of 
leptin’s vasorelaxant effect we performed studies (n=8) in the presence of the non-
selective nitric oxide synthase inhibitor L-NMMA (10-4M). This had no effect on leptin-
induced vasorelaxation (17.4±3.4 versus 17.8±3.3%; P=0.9). Endothelial denudation had 
no effect on leptin-induced vasorelaxation (17.4±4.4 versus 22.5±3%; P=0.4). Since the 
central effect of leptin is thought to be mediated through potassium channels, we explored 
the possibility that its vascular actions are mediated in a similar fashion. In the presence of 
KCl 30mmol/L to inhibit hyperpolarisation, the vasodilator effect of leptin was completely 
blocked (12.6±5.6 versus 0.08±4.1%; P<0.001). To assess the relationship between 
total body fat and leptin’s vascular effect, we assessed the correlation between body 
mass index (range 16.5-39.1Kg/m2) and maximal leptin-induced vasodilatation (range 0-
102.9%). There was no correlation between these variables (r=0.05, P=0.55).
Conclusions: These data demonstrate for the ﬁrst time that leptin is a vasodilator peptide 
in human SV. Moreover, the actions of leptin are endothelial- and NO-independent. These 
data also show that the vasoactive effects of leptin are preserved in obese patients, 
supporting tissue speciﬁcity of leptin resistance.
1098-111 Oxidative Stress, as Indicated by the Redox States of 
Plasma Thiol/Disulﬁde Couples, is Associated With 
Myocardial Perfusion Defects in Men Without Clinical 
CAD
Jerome L. Abramson, Dean P. Jones, James D. Bremner, Arshed A. Quyyumi, Jack 
Goldberg, Viola Vaccarino, Emory University School of Medicine, Atlanta, GA, Vietnam 
Era Twin Registry, Seattle, WA
Background: Oxidative stress is thought to be involved in the pathogenesis of coronary 
artery disease (CAD). The redox states of the glutathione/glutathione disulﬁde couple (Eh 
GSH/GSSG) and the cysteine/cystine disulﬁde couple (Eh Cys/Cyss) are key markers of 
oxidative stress. However, whether these markers predict the presence of subclinical CAD 
in humans is unknown.
Methods: We examined 84 male twins aged 48 to 58 years who were free of clinical 
CAD. Eh GSH/GSSG and Eh Cys/Cyss were measured in plasma. Subclinical CAD was 
assessed by detection of perfusion defects in 20 myocardial segments after adenosine 
stress using [13N] ammonia positron emission tomography (PET). Generalized estimating 
equation (GEE) models were run to determine if redox states were associated with the 
odds of having a perfusion defect.
Results: Myocardial perfusion defects were observed in 20 individuals (23%). Age-
adjusted models showed that increases in Eh GSH/GSSG and Eh Cys/Cyss (indicating 
increased oxidative stress) were associated with a higher odds of having a perfusion 
defect. (Table). Results were similar in models that adjusted for obesity, lipids, and other 
factors.
Conclusions: Increases in Eh GSH/GSSG and Eh Cys/Cyss are associated with an 
elevated odds of having myocardial perfusion defects among male twins without clinical 
CAD. These results suggest that oxidative stress may predict subclinical CAD.
Thiol/Disulﬁde Redox States and the Odds of Having a Myocardial Perfusion Defect
Odds Ratio* 95% CI p-value
Eh GSH/GSSG
per SD increase (13.8 mv) 2.07 (1.23 - 3.74) <.01
Eh Cys/Cyss
per SD increase (5.4 mv) 2.08 (1.18 - 3.62) .01
*Odds ratios are adjusted for age. Odds ratios were similar after adjustment for obesity, 
lipids, blood pressure, and smoking.
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1098-112 Myeloperoxidase, a Novel Marker of Oxidative Stress, 
Predicts Subclinical Ischemia Detected by Means of 
Positron Emission Tomography
Viola Vaccarino, Marie-Luise Brennan, J. Douglas Bremner, Jerome L. Abramson, Carisa 
Maisano, Arshed A. Quyyumi, Jack Goldberg, Stanley L. Hazen, Emory University 
School of Medicine, Atlanta, GA, Cleveland Clinic Foundation, Cleveland, OH
Background. Myeloperoxidase (MPO), a leukocyte enzyme that promotes oxidation, is 
elevated in CAD, but it is not known whether it is also a marker of subclinical ischemia 
independent of C-reactive protein (CRP).
Methods. We examined 164 male twins aged 47 to 57 years, free of symptomatic CAD, 
participants in the ongoing Twins Heart Study. Subclinical ischemia was diagnosed by 
[13N] ammonia positron emission tomography (PET). Images were acquired at rest 
and after adenosine in 20 myocardial segments. Serum MPO and plasma CRP were 
measured before the scan. Generalized estimating equation (GEE) regression was used 
to account for correlations within twin pairs.
Results. Myocardial perfusion defects were observed in 50 individuals (30%). Most defects 
(82%) were reversible, indicating subclinical ischemia. Individuals with perfusion defects, 
particularly if reversible, had higher MPO levels (table). For each 50-unit increase in MPO 
levels, the odds of perfusion defects increased 6% (95% CI, 1%-10%), an association that 
was unchanged by accounting for CAD risk factors and intra-pair variability. CRP was also 
associated with perfusion defects, but there was no signiﬁcant correlation between MPO 
and CRP. When MPO and CRP were included simultaneously in the model, both MPO 
(p=0.037) and CRP(p=0.043) independently predicted perfusion defects.
Conclusions. MPO is an independent marker of subclinical ischemia. These ﬁndings 
support the role of oxidative stress in the pathogenesis of CAD.
Myocardial Perfusion Defects
None Fixed Reversible
MPO (pmol/L) 380 (ref.) 414 (p=0.77) 528 (p=0.01)
CRP (mg/L) 1.8 (ref.) 2.6 (p=0.89) 8.4 (p=0.04)
POSTER SESSION
1099  Lipids, Subclinical Atherosclerosis, 
and Emerging Risk Factors
Monday, March 07, 2005, 1:30 p.m.-5:00 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 2:30 p.m.-3:30 p.m.
1099-119 Contrast-Enhanced High Resolution MRI for 
Characteristics of Carotid Atheroma prolonged  
treated with Lipid-Lowering Therapy
Il Rhee, Samsung Medical Center, Seoul, South Korea
Background: It is recognized that vulnerable plaque largely accounts for the morbidity 
and mortality from atherosclerosis. Postmortem evidence indicated that plaque 
composition, rather than the degree of stenosis, is a key factor for plaque vulnerability. 
High-resolution MRI with ﬂow suppression not only provides useful information on luminal 
areas of the carotid artery and plaque size changes but also can identify the principal 
tissue components of the carotid atherosclerotic plaque. Our aim was to investigate the 
effects of prolonged lipid-lowering therapy on these MRI tissue characteristics in patients 
with carotid artery stenosis. 
Methods and Results: A total of 136 carotid atherosclerotic plaques were detected in 
45 hypercholesterolemic patients with documented 30% to 70% carotid artery stenosis 
who have been receiving prolonged lipid-lowering treatment for over 1 year (mean, 
19±7.5 months). Sixteen patients (36%) underwent carotid endarterectomy among them 
during the follow-up periods. Serial multi-sequence MR image of the carotid artery was 
performed at baseline and around 12 months after lipid-lowering therapy. Based on 
contrast enhanced MRI, vulnerable plaque was deﬁned in terms of a thin cap with a large 
lipid core accounting for > 50% of the plaque, ﬁssured cap or intraplaque hemorrhage. 
The effects of the statin on atherosclerotic lesions were measured as changes versus 
baseline in lumen area, vessel wall thickness. At 12 months, a signiﬁcant (p<0.001) 
reduction in total and LDL cholesterol levels (188± 26 vs. 158±50, p<0.001, 125± 23 vs. 
110(42, p<0.001) and signiﬁcant reductions in vessel wall thickness (4.2±1.0 vs. 3.4±1.3, 
p<0.001), without changes in lumen area (55±15 vs. 53±15, p=0.281), were observed 
in carotid arteries. In comparisons of individual carotid plaque tissue components and 
composition based on MRI signal intensities, the 1 year-treated plaques contained 
stabilized plaques in 7 patients (16%). 
Conclusion: Multi-sequence high resolution MR imaging of carotid atheroma provides 
good assessment and characterization of plaque, and has the potential to identify 
stabilization of the vulnerable plaques in a non-invasive manner.
1099-120 The Prognostic Value Of Plasma Lipoprotein A Levels 
On The Long-term Cardiovascular Mortality In Patients 
With Acute Coronary Syndromes. Results From The 
Biochemical Indices And Outcome In Acute Coronary 
Syndromes (Bias) Study.
Alexander Kardoulas, Michael N. Zairis, Kostas Mainas, George Bibis, Olga 
Ampartzidou, Stamatis Makrygiannis, Pelagia Batika-Zairis, Charalampos Apostolatos, 
Demetrios Beldekos, Evdokia Adamopoulou, Neophytos Kassinos, Stefanos Foussas, 
Tzanio Hospital, Piraeus, Greece
Background-Although an elevated plasma level of lipoprotein a Lp(a) has been 
considered as a cardiovascular disease risk factor, its impact on the long term prognosis 
in patients with acute coronary syndromes remains controversial. We evaluated this 
possible association in the BIAS (Biochemical Indices and outcome in Acute coronary 
Syndromes) study.
Methods-The BIAS study was designed to evaluate prospectively the impact of several 
biochemical indices including Lp(a) on the long term cardiovascular mortality in patients 
who hospitalised due to either ST elevation myocardial infarction (STEMI) or non-ST 
elevation acute coronary syndromes (NSTACS). For the purpose of this study 458 and 
476 consecutive pts with STEMI and NSTACS respectively were recruited. All biochemical 
indices were estimated upon pts’ admission and cardiovascular mortality during 5 years of 
follow up was the primary study endpoint. The pts were divided according to plasma Lp(a) 
levels upon admission in those <30mg/dl and in those with >=30mg/dl.
Results- The incidence of cardiovascular mortality at the end of the follow up was 23.1% 
and 21.4% in pts with STEMI and NSTACS respectively. There were no signiﬁcant 
differences between pts with Lp(a)<30mg/dl and those with >=30mg/dl. By Kaplan Mayer 
analysis pts with a plasma Lp(a)>=30mg/dl upon admission were at signiﬁcantly higher risk 
of cardiovascular mortality during the 5 years of follow up, and it was valid in pts with either 
STEMI (31.2% vs 20.1%; RR/95%CI=1.7/1.2-2.5;p=0.01) or NSTACS (27.9% vs 18.5%; 
RR/95%CI=1.6/1.1-2.3;p=0.02). It is of interest that an elevated plasma Lp(a) confers an 
increased risk of cardiovascular death beyond to the ﬁrst year following the acute event.
Conclusions-The results of the BIAS study suggest that elevated plasma Lp(a) level 
upon admission confers an increased risk of cardiovascular death beyond to the ﬁrst year 
following the acute event in pts with either STEMI or NSTACS.
1099-121 Increased Inﬂammation and Neovascularization in 
Diabetes Atherosclerosis is no Longer Present in 
Fibrocalciﬁc Plaques: A Marker of Stabilization?
Pedro R. Moreno, K-Raman Purushothaman, William N. O’Connor, Annapoorna S. Kini, 
Marc Sirol, Samin K. Sharma, Valentin Fuster, Mount Sinai Medical Center, New York, 
NY, Univeristy of Kentucky, Lexington, KY
Background: As previously reported, high-risk atherosclerosis in diabetes mellitus (DM) 
is characterized by increased inﬂammation and neovascularization, which may contribute 
to plaque rupture and thrombosis. Calciﬁcation may change plaque composition 
reducing inﬂammation and neovascularization. We tested this hypothesis by comparing 
macrophages, T-cell lymphocytes (Macs/T-cells) and neovessels in high-risk and 
ﬁbrocalciﬁc (FC) plaques from patients with and without DM.
Methods: Autopsy human aortic plaques from DM (142) and non-DM (119) patients 
classiﬁed as ruptured, lipid-rich, and FC were processed for double immunohistochemistry 
with CD-68/CD-3 (Macs/T-cells) and CD-34 (neovessels). Macs/T-cells were quantiﬁed 
using a score of 0 (0-5 cells), 1 (6-25 cells), and 2 (>25 cells). Neovessel density was 
quantiﬁed using numbers divided by area (mm2).
Results: Ruptured and lipid-rich plaques from patients with DM were characterized by 
increased inﬂammation and neovascularization (P<0.05). However, FC plaques from 
patients with DM were characterized by reduced inﬂammation and neovascularization, 
similar to non-DM plaques (Figure).
Conclusion: Diabetes-related increase in inﬂammation and neovascularization in high-risk 
plaques is no longer present in ﬁbrocalciﬁc plaques. These results suggest that calciﬁcation may 
be a marker of stabilization, reducing the risk of complications in diabetic atherosclerosis. 
1099-122 Do Statins Increase the Risk of Idiopathic 
Polyneuropathy? An Epidemiologic Study From 
Intermountain Health Care
Tami L. Bair, Joseph B. Muhlestein, Donald L. Lappé, Dale G. Renlund, Robert R. 
Pearson, Steven Morris, Kurt R. Jensen, Jeffrey L. Anderson, LDS Hospital, Salt Lake 
City, UT, University of Utah, Salt Lake City, UT
Background: Statins are standard therapy for which clinical trials show beneﬁt for primary 
and secondary prevention. Statin use is increasing through prescription and future over-
the-counter use. With widespread use, there is growing concern for rare, adverse reactions 
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(e.g., rhadomyolysis). A recent Danish case-control study (Neurology 2002; 58:1333) linked 
statin use with idiopathic polyneuropathy (IPN) based on only 166 cases (35 deﬁnite, 54 
probable, 77 possible) and suggested an odds ratio (OR) for IPN with statin use of 3.7. This 
association, if true, might importantly impact statin safety and IPN etiology.
Methods: We tested the hypothesis that statin use predisposes to IPN. A search of 
the IHC electronic database (1.2 million covered lives) was performed to ﬁnd patients 
(pts) with an initial diagnosis of IPN within the last 4 y. To eliminate secondary PN, pts 
were excluded who ever had a diagnosis of diabetes, renal insufﬁciency, alcohol abuse, 
cancer, hypothyroidism, AIDS, Lyme disease, or heavy metal intoxication. A total of 272 
pts met IPN criteria and had pharmacy claims data. Each case was matched to 5 controls 
(N=1360) for age, sex, and entry date. Statin use was compared between cases and 
controls by chi-square and analysis of variance.
Results: Age of cases/controls averaged 47±13 y; 57% were female. Statins were 
prescribed for 7.2% overall. Mean duration of statin use in these pts was 10.1 mo. Statins 
were prescribed for 8.8% of cases and 6.9% of controls, OR 1.30 (95% CI 0.82-2.08, 
p=0.27). Duration of statin use did not differ between treated cases and controls (p=0.22), 
and average statin dose-equivalents were similar (1.63 vs. 1.83, respectively, p=0.72).
Conclusion: In this large medical database of cases and controls, a link between IPN and 
statin use could not be conﬁrmed. Although we cannot exclude a modest increase in risk 
of up to 2-fold, the dramatic reported increase to one case per 2,200 person-y of statin 
use is unlikely. These observations are reassuring in view of increasingly widespread 
statin use, but additional observations are warranted to more clearly deﬁne or exclude a 
modest association of IPN with statin therapy.
1099-123 Carotid Atherosclerosis Identiﬁes Cardiovascular 
Events in Young to Middle-Aged Adults
Kwame O. Akosah, Vicki McHugh, Ana Schaper, Sharon Barnhart, Michelle Mathiason, 
Gundersen Luthearn Health System, La Crosse, WI
Background: Primary prevention of coronary heart disease remains a challenge. Non-
invasive cardiac imaging, including MRI, CT scan, and ultrasound, have been suggested 
as possible adjuncts to clinical risk stratiﬁcation. However, their ability to predict the ﬁrst 
cardiovascular event in low to intermediate risk young to middle-aged adults has not been 
demonstrated. The purpose was to study the ability of carotid atherosclerosis (CA) in 
predicting future events.
Methods: Men (≤ 55 years) and women (≤65 years) without prior coronary heart disease 
scheduled for elective cardiac catheterization were studied. Subjects on anti-lipid therapy 
were excluded. Subjects underwent carotid ultrasound and had fasting lipids drawn. 
Framingham risk scores were calculated. CA was deﬁned as the presence of plaque or 
maximal IMT ≥ 1.0 mm. Endpoints included hard events (myocardial infarction (MI), death, 
and stroke) or any event (hard and future revasculariation)
Results: Men (n=110; mean age 48±7) and women (n=136; mean age 53±8) completed 
all tests. CA was present in 149 subjects, and 124 subjects had coronary disease (77 
severe, 47 insigniﬁcant). 35 subjects had diabetes mellitus, and an additional 3 subjects 
had risk scores ≥ 20%. 76% stratiﬁed as low risk and 8% as intermediate risk. Median 
follow-up was 19 months. 25 subjects developed 35 events that included death (n=2), 
MI (n=5), percutaneous coronary intervention (n=14), bypass (n=9), and stroke (n=5). 
The rate of events were similar among Framingham risk groups. Lipid proﬁle, including 
total cholesterol, LDL, HDL and triglyceride were not different among subjects developing 
events compared to those without events. CA identiﬁed 80% of subjects with any event 
and 91% of subjects with hard events. Only one hard event occurred in 97 subjects with 
negative CA. The odds ratio of CA in predicting events was 2.9 (CI:1.0-7.9, p=0.043), and 
Kaplan-Meier analysis revealed signiﬁcant differences in event free survival (p=0.030).
Conclusion: Many young to middle-aged adults classiﬁed as low-risk have atherosclerosis 
and develop cardiovascular events. CA identiﬁed individuals at risk for future events. 
Negative CA is associated with excellent prognosis.
1099-124 Statin Treatment can Prevent Coronary Artery 
Remodeling: Intra-vascular Ultraound Assessment.
Takahiro Tsuji, Masato Nakamura, Masaya Yamamoto, Masanori Shiba, Masamichi 
Wada, Raisuke Iijima, Rintarou Nakajima, Hisao Hara, Hidehiko Hara, Takashi 
Yoshitama, Tarou Tsunoda, Kaoru Sugi, Toho Ohashi Hospital 2-17-6 Ohashi, Meguro-
ku, Tokyo, Japan
BACKGROUND: Randomized trials demonstrated beneﬁcial effects of statins on primary 
and secondary prevention of cardiac events. Furthermore, recent observational studies 
indicated that early statin administration improved the clinical outcomes of PCI in patients 
with acute coronary syndromes (ACS). Therefore, it has been supposed that statins may 
stabilize the vulnerability of unstable plaque.
PURPOSE: The purpose of this study was to assess the differences of lesion morphology 
based on the presence or absence of statins prescription before onset of ACS using 
intravascular ultrasound (IVUS).
METHODS AND RESULTS: A total of 90 ACS patients underwent PCI was evaluated. 
Statin group consisted of 45 patients who had been prescribed statins before the onset of 
ACS. The remaining ACS 45 patients had not been given statins (non-statin group). IVUS 
was performed at the time of PCI and vessel area was measured and plaque remodeling 
(remodeling index) was assessed. Also, plaque morphology (plaque characteristics, 
plaque rupture, thrombus, and calciﬁcation) was examined. Ruptured plaques on culprit 
lesion were observed in 12 patients (27%) of statin group, and 14 patients (31%) of non-
statin group (P=0.64). Remodeling index was signiﬁcantly lower in statin group than in 
non-statin group (1.10±0.22 versus 1.21±0.22; P=0.02).
CONCLUSION: These data may indicate that statin prevent the development of coronary 
remodeling and contribute to stabilization of plaque vulnerability.
Statin group Non-statin group P value
Vessel area (mm2)
Proximal reference 16.7±5.6 17.7±4.6 NS
Lesion site 16.6±6.7 19.2±5.3 0.05
Distal reference 13.2±4.3 13.7±4.7 NS
Lesion lumen area (mm2) 2.7±1.2 2.9±1.3 NS
Lesion plaque area (mm2) 14.0±6.0 16.4±4.9 0.04
Remodeling index 1.10±0.22 1.21±0.22 0.02
1099-125 Prediction of Cardiovascular Events in Women Using 
NMR LDL Particle Number is Improved by Measurement 
of VLDL Subclasses and HDL Cholesterol
Robert S. Rosenson, Lynda Lynda, James D. Otvos, Paul M. Ridker, Northwestern 
University, Chicago, IL
Background: Several prospective studies have shown that the magnitude of predictive 
value of LDL particle number (NMR) spectroscopy for future cardiovascular disease 
(CVD) events is different than LDL-C. Whether incremental prediction beyond that given 
by LDL particles is provided by VLDL, LDL, or HDL subclass measurement, or traditional 
lipid measures has not been investigated.
Methods: This is a prospective case-control study nested within the Women’s Health 
Study. Subjects were 130 women who experienced a CVD event (myocardial infarction, 
stroke, death from coronary heart disease) during 3 years of follow-up and 130 controls 
matched for age and smoking status. NMR lipoprotein subclass proﬁles provided particle 
concentrations of large, medium, and small VLDL, LDL, and HDL subclasses, and mean 
lipoprotein particle sizes. TG, LDL-C, and HDL-C were measured by standard chemical 
methods. Odds ratios (OR) for the upper versus lower quartile of each parameter were 
calculated using conditional logistic regression models that controlled for traditional non-
lipid risk factors inclusive of BMI and DM history. The ﬁts of non-nested models were 
compared using Akaike’s Information Criterion (AIC).
Results: Among lipid and lipoprotein parameters considered, LDL particle number 
(OR=4.7; 95% CI: 1.5-14.4) and the ratio of and total cholesterol/HDL-C ratio (4.8;1.5-
14.9), were the strongest predictors of incident CVD in non-lipid adjusted models. 
Signiﬁcant lipid predictors were HDL-C (0.2; 0.1-0.6), TG (3.1;1.0-9.4), non-HDLC (3.7; 
1.4-10.0), but not LDL-C (2.1; 0.8-5.4). As assessed by AIC, a model containing LDL 
particles only (AIC 105.3) ﬁt the data better than did a model containing chemically 
measured HDL-C, LDL-C and TG (AIC 116.2). When added singly to models containing 
LDL particles, improved prediction was given by medium-size VLDL subclass levels (5.9; 
1.5-22.8 [AIC 104.6]) and HDL-C (5.0;1.4-17.2 [AIC 103.9]).
Conclusions: In this cohort, LDL particle number measured a component of risk that 
was not detected by usual lipid measures. The magnitude of prediction with LDL particle 
number was further improved by measurement of HDL-C and medium-size VLDL 
subclass particles.
1099-126 Simvastatin Improves Triglyceride-Rich Lipoproteins in 
Patients With Type 2 Diabetic Dyslipidemia
Michael Miller, Adrian S. Dobs, Wendy Battisti, Zhong Yuan, Joanne Palmisano, Merck & 
Co., Inc., West Point, PA
Background: Metabolic disorders, such as diabetes mellitus (DM), are associated with 
multiple lipid abnormalities that raise coronary heart disease (CHD) risk. This combined 
hyperlipidemia often includes low levels of HDL-C and elevated levels of triglyceride (TG) 
and TG-rich lipoproteins (TGRLP), which include VLDL. Non-HDL (LDL+IDL+VLDL) is 
recognized as a secondary target (Adult Treatment Panel III) in patients with elevated TG 
and can be used as a measure of TGRLP. Small dense LDL particles (eg, LDL1 and LDL2) 
may also be proatherogenic.
Methods: We compared the effects of treatment with simvastatin 80 mg (S80), simvastatin 
40 mg (S40), and placebo in adult patients (N=151;mean age=58.9±9.8 years;71% male, 
29% female) with Type 2 DM and LDL-C>100mg/dL (mean=132.4 mg/dL), HDL-C<40mg/
dL (mean=34.5 mg/dL), and triglycerides between 150 and 700 mg/dL (median=273 
mg/dL) at baseline, on non-HDL and LDL-C. We used the Vertical Auto Proﬁle (VAP) 
expanded panel to directly assess TGRLP, including IDL and VLDL subclasses, as well 
as LDL subclasses, in this double blind, 3-period (6 weeks each) crossover study. Each 
patient was randomized to 1 of 6 possible treatment arms, so that each patient received 
S80, S40, and placebo over the 3 periods.
Results: Percentage Change from Baseline (6 weeks treatment) 
Lipid parameter 
[mg/dL (CI)]
Baseline 
(mean ±SD; mg/dL) Simvastatin 80 mg Simvastatin 40 mg Placebo 
VLDL-C 59.8 ± 34.2 -39.5 (-45.1, -33.8)*, † -31.6 (-37.2, -25.9)* 9.6 (4.0, 15.2)
VLDL3 22.4 ± 7.2 -34.6 (-38.5, -30.7)*, † -30.3 (-34.1, -26.5)* 1.3 (-2.5, 5.1)
IDL 20.0 ± 9.9 -56.8 (-66.6, -47.1)* -52.5 (-62.1, -42.9)* 7.7 (-1.8, 17.3)
LDL-C 132.4 ± 37.6 -47.3 (-50.4, -44.2)*, † -40.7 (-43.8, -37.6)* 2.3 (-0.8, 5.4)
LDL1 20.3 ± 6.9 -39.3 (-44.7, -34.0)* -37.1 (-42.4, -31.9)* 2.8 (-2.4, 8.1)
LDL2 (median) 15.9 -24.6 (-35.0, -11.6)* -19.2 (-25.5, -11.3)* -4.7 (-15.3, 2.9)
LDL3 48.4 ± 16.7 -39.6 (-46.4, -32.8)*, † -29.7 (-36.4, -22.9)* 4.8 (-1.9, 11.6)
LDL4 (median) 11.9 -47.9 (-57.6, -36.8)*, † -41.7 (-46.9, -32.8)* 6.4 (-3.5, 19.3)
Non-HDL-C 193.3 ± 43.8 -43.7 (-45.9, -41.5)*, † -37.8 (-40.0, -35.6)* 0.7 (-1.5, 2.9)
Apolipoprotein B 148.1 ± 26.0 -38.1 (-40.3, -35.9) *,† -32.2 (-34.4, -30.0) * 0.4 (-1.8, 2.6)
Values are means, unless speciﬁed; * p≤0.001 compared with placebo; †p≤0.04 compared with S40; An 
ANOVA model that included treatment, center, period, carryover effect, and patient (center), where patient 
(center) was a random effect, was used.
Conclusion: S40 and S80 reduced LDL-C and provided additional beneﬁts in reducing 
TGRLP and improving LDL composition, thereby improving the atherogenic proﬁle in 
these patients with Type 2 DM.
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1099-129 Metabolic Abnormalities Are Common in Patients at 
National Cholesterol Education Program Goals for Low 
and High-Density Lipoproteins and Triglycerides
Harvey S. Hecht, Chris Boggess, H. Robert Superko, Beth Israel Medical Center, New 
York, NY, Berkeley HeartLab, Burlingame, CA
Background: Patients who are at National Cholesterol Education Program Adult 
Treatment Plan III (NCEP) goals continue to have events. NCEP recommended lipid levels 
for patients with established cardiovascular disease and high risk primary prevention 
patients are: LDL < 100 mg/dl, HDL >40 mg/dl and triglycerides <150 mg/dl. Metabolic 
abnormalities involving LDL and HDL particle size, lipoprotein (a), homocysteine and 
apoprotein B may contribute to risk are not routinely evaluated, and most are considered 
emerging risk factors without speciﬁc therapeutic recommendations.
Methods: To evaluate the frequency of these potential contributors to risk in patients who 
have fulﬁlled NCEP goals, 945 primary and secondary prevention patients who fulﬁlled 
the above NCEP lipid criteria and underwent advanced lipid testing were analyzed.
Results: The routine plasma lipid levels in these patients were LDL-C 83.2+13.4 mg/dl, 
HDL-C 55.1+13.4 mg/dl, and triglycerides 93.7+29.1 mg/dl.
Small, dense LDL (LDL IIIa+b >20% by gradient gel electrophoresis) was present in 30.8%, 
impaired reverse cholesterol transport (HDL 2b<20% by gradient gel electrophoresis) 
was noted in 58.7%. Elevated lipoprotein (a) > 20 mg/dl, elevated homocyteine >10 
mmol/L, and elevated apoprotein B >80 mg/dl were found in 35.7%, 29.7% and 53.7% 
respectively.
Conclusions: 1) Metabolic abnormalities are commonly present in patients thought to 
be at ideal lipid levels by NCEP criteria; 2) Identiﬁcation and treatment of these other 
abnormalities may have a signiﬁcant impact in reducing cardiovascular risk.
1099-130 Impact of LDL Particle Size on Carotid Intima-Media 
Thickness in Patients With Type 2 Diabetes
Hideo Matsui, Yuzo Hayashi, Akiko Imamura, Katsuyuki Torigoe, Tomohiro Yoshida, 
Yasushi Numaguchi, Kenji Okumura, Toyoaki Murohara, Nagoya University Graduate 
School of Medicine, Nagoya, Japan
Background: Small, dense LDL particles and some modiﬁcation of LDL including 
glycation and oxidation have been linked to the pathogenesis of atherosclerosis in patients 
with diabetes. In this study, we investigated whether LDL particle size, glycated LDL, or 
malondialdehyde-modiﬁed LDL (MDA-LDL), one oxidized form of LDL, is associated with 
carotid artery intima-media thickness (IMT), a powerful predictor of future cardiovascular 
disease (CVD) events, in patients with type 2 diabetes.
Methods: Eighty-one consecutive patients with type 2 diabetes (aged 68.1±8.9 years) 
were enrolled in this study. We measured carotid IMT using high-resolution ultrasound. We 
also measured LDL particle size using gradient gel electrophoresis, and serum glycated 
LDL and MDA-LDL using sandwich enzyme-linked immunosorbent assays, respectively.
Results: The three parameters signiﬁcantly correlated with others (LDL particle size 
and glycated LDL, r=-0.314; LDL particle size and MDA-LDL, r=-0.258; glycated LDL 
and MDA-LDL, r=0.233; P<0.05, respectively). Univariate analyses deﬁned statistically 
signiﬁcant correlations between carotid IMT and fasting glucose (r=0.328, P<0.01), HbA1c 
(r=0.362, P<0.01), glycated LDL (r=0.243, P<0.05), MDA-LDL (r=0.232, P<0.05), and 
LDL particle size (r=-0.471, P<0.01). A stepwise multiple regression analysis revealed 
that LDL particle size and fasting glucose were independent predictors of carotid IMT 
(total R2=0.275). Both glycated LDL and MDA-LDL did not have a signiﬁcant independent 
contribution to variation in carotid IMT in the multivariate model.
Conclusions: LDL particle size but not glycated or oxidative modiﬁcation of LDL was 
independently associated with carotid IMT in patients with type 2 diabetes. These results 
suggest that the measurement of LDL particle size may be superior to that of modiﬁed 
LDLs to assess the risk of CVD in patients with type 2 diabetes.
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1100-127 Decrease in Carboxyhemoglobin in Patients With 
Prehypertension and Hypertension
Soon Jun Hong, Chang Gyu Park, Hong Seog Seo, Seung Woon Rha, Jin Won Kim, 
Dong Joo Oh, Young Moo Ro, Cardiovascular Center, Korea University Hospital, Seoul, 
South Korea
Background: Carbon monoxide (CO), produced within the blood vessel wall, is known 
as a ﬁne regulator of blood pressure. CO acts as a vasodilator, and altered metabolism of 
CO in vascular tissue could result in the development of hypertension. The implications of 
CO in patients at various stages of hypertension: prehypertension, stage 1 hypertension 
and stage 2 hypertension, have not been investigated.
Methods: Total of 272 participants (126 women and 146 men) were divided into four groups 
according to the JNC 7 Report: prehypertension (n=92), stage 1 hypertension (n=57), 
stage 2 hypertension (n=34), and normal blood pressure (n=89). CO has high afﬁnity to 
hemoglobin, and venous carboxyhemoglobin (COHb) was measured in all participants 
prior to administering antihypertensive medication when needed. Patients with chronic 
inﬂammatory lung diseases and CO intoxications were excluded from the study.
Results: COHb in normal blood pressure group was signiﬁcantly higher than those 
of prehypertension and stage 1, 2 hypertension (Figure). Variables such as age, sex, 
diabetes, hyperlipidemia, smoking, and body mass index showed no signiﬁcant 
differences among the four groups. Multiple regression analyses showed that COHb and 
fasting blood sugar were able to explain the 73.2% of systolic blood pressure variability 
(r=0.776, p<0.001).
Conclusion: Our results suggest that the decrease in endogenous CO production may 
contribute to the development of hypertension.
1100-128 ACE Inhibition and Angioedema: A Prospective 
Controlled Study in 12,557 Patients
John B. Kostis, Harold J. Kim, James Rusnak, Elliott Levy, UMDNJ-Robert Wood 
Johnson Medical School, New Brunswick, NJ, Bristol-Myers Squibb, Princeton, NJ
Background: Angioedema is an uncommon but potentially serious adverse event of ACE 
inhibition. However, there are no prospective, large, controlled studies on this entity.
Methods: In the Omapatrilat Cardiovascular Treatment Assessment vs. Enalapril trial, a 
double-blind, prospective study of blood pressure lowering and occurrence of angioedema, 
12,557 patients were given enalapril, 5 to 40 mg daily. Detailed information on the clinical 
features, severity, treatment and outcome of all potential angioedema events was collected 
and adjudicated by a panel of angioedema experts blind to treatment allocation.
Results: Angioedema occurred in 86 (0.68%) of the 12,557 subjects on enalapril during 
the 24-week study. Stepwise logistic regression identiﬁed black race (OR 2.88, 95% CI 
1.72, 4.82), history of drug rash (OR 3.78, 95% CI 1.80, 7.92), age over 65 years (OR 1.60 
95% CI 1.02, 2.53) and seasonal allergies (OR 1.79, 95% CI 1.06, 3.00) as independent 
risk factors for angioedema. The incidence of angioedema was higher after initiation of 
therapy (3.6 conﬁrmed events per 1,000 patients in the ﬁrst month) and declined to a level 
of approximately 0.4 per 1,000 events per month after 16 weeks of therapy. Angioedema 
occurred in the lips or face (in 50% of the cases), the tongue, neck or eyelids (20% each) 
and in 2 or more sites in 60%. No treatment was given in 51% of the cases, antihistamines 
were administered in 41%, corticosteroids in 23% and epinephrine in only 1 patient (1.2% 
of the angioedema cases). Two (0.2 per 1,000 subjects treated) were hospitalized but 
none had airway compromise. The duration of angioedema was less than 1 day in 24% of 
the patients and 1-7 days in 53%.
Conclusions: 1) Enalapril related angioedema is uncommon. 2) Although it is more likely 
to occur early after initiation of therapy, it may also occur at any time. 3) It is more likely 
to occur in blacks, patients older than 65 and those with history of drug rash or seasonal 
allergies. 4) Fatal angioedema or angioedema requiring airway protection did not occur 
among these 12,557 patients.
1100-131 Prothrombotic / Fibrinolytic Balance is Impaired Even in 
White-Coat Hypertension
Eva A. Karpanou, Gregory P. Vyssoulis, Konstantinos A. Aznaouridis, Sotirios T. 
Papathanassiou, Christodoulos I. Stefanadis, Dennis V. Cokkinos, Athens University, 
Hippokration Hospital, Athens, Greece, Onassis Cardiac Surgery Center, Athens, 
Greece
Background. Recent studies suggest that white-coat hypertension (WCH) is accompanied 
by increased cardiovascular risk. Fibrinogen and plasminogen activator inhibitor-1 (PAI-
1) are mediators of the coagulation pathway, that increase in essential hypertension 
(EH) and predict progression of atherosclerosis. In the present study we comparatively 
evaluated these markers of thrombogenicity in patients (pts) with EH and WCH.
Methods. We studied 4100 consecutive non-diabetic pts with uncomplicated EH (age 
53±12 years, 2401 men) and 1414 non-diabetic WCH pts (age 52±13 years, 614 men). 
Diagnoses were established according to repeated ofﬁce and 24-hour ambulatory 
BP measurements.WCH was deﬁned as ofﬁce BP>140/90 mmHg and mean daytime 
ambulatory BP<135/85 mmHg. Then plasma ﬁbrinogen and serum PAI-1 were measured. 
Pts in both cohorts were allocated in 5 groups according to their age (<40, 40-49, 50-59, 
60-69 and >70 years).
Results. Pts with EH differentiated from WCH pts in ofﬁce systolic BP (165 vs 156 mmHg, 
P<0.001), but not in ofﬁce diastolic BP (103 vs 101 mmHg, P=NS). In the EH pts we found 
a signiﬁcant stepwise increase across the 5 groups for both ﬁbrinogen (279, 290, 301, 
315 and 336 mg/dl for <40, 40-49, 50-59, 60-69 and >70 years respectively, p<0.00001) 
and PAI-1 (2.23, 2.47, 2.57, 2.6 and 2.85 IU/ml, P<0.00001). The same change was 
certiﬁed in WCH pts for ﬁbrinogen (266, 285, 295, 306 and 316 mg/dl, P<0.00001) and 
PAI-1 (1.99, 2.39, 2.46, 2.44 and 2.56 IU/ml, P<0.00001). When we compared ﬁbrinogen 
and PAI-1 levels within each age group, pts with EH aged 40-49 or 50-59 years did 
not differentiate from WCH pts of the same age, while if aged 60-69 years they were 
marginally more burdened from the corresponding WCH pts. Concerning ﬁbrinogen, P 
values for comparison between EH and WCH pts within the same age group were 0.003, 
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NS, NS, 0.05 and 0.002 for the 5 groups respectively. For PAI-1 the respective P values 
were 0.02, NS, NS, 0.04 and 0.01.
Conclusion. White-coat hypertension is not an innocent phenomenon. In contrast, WCH 
is related to an increased prothrombotic potential that is similar to the potential found in 
EH, except for pts <40 or >70 years old.
1100-132 Both Angiotensinogen M235T and α-Adducin Gly460Trp 
Polymorphisms Are Associated With Hypertension in 
the Japanese Population
Yasuyuki Nakamura, Yasuharu Tabara, Tetsuro Miki, Shinji Tamaki, Takako Yamamoto, 
Yoshikuni Kita, Tomonori Okamura, Hirotsugu Ueshima, Kyoto Women’s University, 
Kyoto, Japan, Shiga University of Medical Science, Otsu, Japan
Background: Both angiotensinogen (AGT) M235T and �-adducin (ADD) Gly460Trp 
polymorphisms have been reported to link to sodium retention. Studies on association 
between these polymorphisms and hypertension, however, have been reporting conﬂicting 
results. In order to clarify the controversies, we studied the association between these 
polymorphisms and hypertension in a large-scale general population in Japan.
Methods: We genotyped 4640 men and women, age >= 35 year, about half of them 
were from a Shiga Prefecture cohort, and the other half from an Ehime Prefecture cohort. 
Hypertension was deﬁned as systolic blood pressure (BP) >= 140 mmHg, or diastolic BP 
>= 90 mmHg, or on anti-hypertensive medication.
Results: Relative frequencies of AGT M235T polymorphisms (MM, MT and TT) were 
3.8, 28.8 and 67.4% in men, and 6.5, 28.1, and 64.7% in women, and those of ADD 
Gly460Trp polymorphisms (GlyGly, GlyTrp and TrpTrp) were 19.3, 45.9 and 34.8% in men, 
and 19.1, 47.4 and 33.5% in women. On logistic analyses including age, body mass index, 
current smoking, alcohol drinking and cohort effect as covariates, both polymorphisms 
were signiﬁcantly associated with hypertension in men and women (Table, OR=odd ratio, 
CI=conﬁdence interval).
Conclusions: Both AGT M235T and ADD Gly460Trp polymorphisms were associated 
with hypertension independent of classical hypertension risk factors in Japanese.
AGT M235T and ADD Gly460Trp Polymorphisms and Hypertension 
AGT M235T MM MT TT
Men, OR (95% CI) 1 1.75 (1.23-2.49) 1.76 (1.28-2.43)
Wome, OR (95% CI) 1 2.24 (1.65-3.04) 2.77 (2.10-3.66)
ADD Gly460Trp GlyGly GlyTrp TrpTrp
Men, OR (95% CI) 1 1.19 (0.93-1.53) 1.38 (1.07-1.80)
Wome, OR (95% CI) 1 1.69 (1.37-2.10) 1.82 (1.45-2.29)
1100-133 Efﬁcacy of Regular Exercise on Cardiovascular Risk 
Factors and Motor Development in Pre-School-Age 
Children: A 2-Year Controlled Intervention
Kerstin S. Ketelhut, Iman Mohasseb, Christian A. Gericke, Juergen Scholze, Reinhard 
G. Ketelhut, Humboldt-Universitaet, Berlin, Germany, Technische Universitaet, Berlin, 
Germany
Introduction: Even in young children a weakened motor development paralleled by 
impaired cardiovascular risk proﬁle can be observed in industrialized countries. Therefore 
3year old children were included in a prospective, 2-year controlled study to assess the 
efﬁcacy of a regular exercise program on body mass index (BMI), blood pressure (BP), 
heart rate (HR), and motor skills.
Methods: A total of 160 children out of 265 in 17 nursery schools in Germany participated 
in a regular exercise program (3x/week). 105 comparable subjects served as controls. BP 
and HR were evaluated at rest by standardized procedures. Standardized motor testing 
included jumping, running, balance and coordination skills.
Results: Before included in the study both groups were comparable in all tests and 
measurements. .After one year of intervention, no difference could be observed in BMI 
between interventions (INT) and controls (CON). In contrast, there was a already a 
tendency of lower BP in INT. Furthermore, INT came off signiﬁcantly better in all motor 
tests. After two years there were no signiﬁcant differences in HR and in systolic BP in both 
groups. In contrast, diastolic BP was signiﬁcantly lower in INT when compared with CON 
(65.7±6.9 vs. 68.1±7.6 mmHg; p=0.029). Furthermore, both INT and CON improved in 
all motor tests but with signiﬁcant differences between the two groups. When compared 
INT with CON INT came of better in the coordination-test (27.3 vs. 18.4 points; p<0.001), 
balance (195 vs. 139cm; p<0.001), jumping (103.9 vs. 83.7cm; p<0.001) and 6m-running 
(2.2 vs. 2.62seconds; p<0.001).
Conclusion: The study provides evidence of beneﬁts on motor development and 
cardiovascular risk factors attributable to regular exercise even in very early childhood. 
Therefore children should be encouraged to enter preventive programs as early as 
possible as a primary prevention against future cardiovascular morbidity and mortality.
1100-134 Differential Pulse Pressure Response To Various 
Antihypertensive Drug Families 
Evangelia Karpanou, Gregory Vyssoulis, Andreas Marinakis, Christodoulos Stefanadis, 
Dennis V. Cokkinos, Onassis Cardiac Surgery Center, Athens, Greece, University of 
Athens, Hyppokration Hospital, Athens, Greece
Introduction: Increased pulse pressure (PP) is currently considered an adverse 
prognostic factor. Few studies exist as to how various drugs can affect it. We investigated 
the action of the medications most widely used currently.
Methods: We studied 10185 untreated patients (pts) with essential hypertention, 5395 
men and 4790 women 56± 13 years old, after a 15-day wash-out period and after 6 
months of antihypertensive monotherapy; 31.5% were smokers, 12.6% were diabetics, 
while impaired glucose tolerance was present in 16%. According to the antihypertensive 
therapy given by the physicians who attended them in the Hypertension Clinics they were 
divided in 6 groups: 592 pts received diuretics, 2427 received b-blockers, 470 a-blockers, 
1961 received angiotensin-II receptor antagonists (ARB), 2328 received angiotensin 
converting enzyme inhibitors (ACE-I) and 3360 pts calcium antagonists (Ca-A). All were 
given the maximally tolerated monotherapy doses. The blood pressure prior to and post 
therapy was measured for all and the decrease in systolic (SBP) and diastolic blood 
pressure (DBP), PP and left ventricular mass index (LVMI) were calculated. 
Results: Maximal SBP and DBP fall was observed in pts who received either ARBs 
or Ca - A followed by ACEI, β-blockers and α-blockers while diuretics decreased DBP 
more. Maximal PP fall was observed in patients who received either ARB or Ca-A, (-
15mmHg), followed by ACE-I (-12mmHg), α-blockers (-10mmHg), β-blockers (-9mmHg) 
while diuretics minimally affected PP fall (-5mmHg). ARB Ca-A did not differ on PP (p=NS) 
but the change compared to all other drugs was highly signiﬁcant (p<0.0001). ACE-I and 
ARB achieved the greatest LVMI reduction (-13%), greater than Ca-A (-11%); α- and 
β- blockers (-7%), with diuretics the least effective (- 3%). All these differences were 
signiﬁcant (p<0.0001). LVMI decrease was related to the SBP and PP but not to DBP fall 
in all drug groups.
Conclusions: Commonly used drug groups affect PP in different degrees. ARB, Ca-A and 
ACE-I may be the preferred agents when an increased PP and LVMI is the main characteristic.
ORAL CONTRIBUTIONS
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819-3 DDAH Overexpression suppresses Graft Coronary 
Artery Disease in a Murine Heterotopic Heart 
Transplantation Model
Karsten Sydow, Masashi Tanaka, Feny Gunawan, Johannes Jacobi, Phil S. Tsao, Robert 
C. Robbins, John P. Cooke, Stanford University, Stanford, CA
Background: Graft coronary artery disease (GCAD) is the leading cause of death after 
the ﬁrst year of heart transplantation. The reduced bioavailability of endothelium-derived 
nitric oxide (NO) may play a role in the endothelial vasodilator dysfunction, and the 
structural changes, that are characteristic of GCAD. A potential contributor to endothelial 
pathobiology is asymmetric dimethylarginine (ADMA), an endogenous NOS inhibitor. We 
hypothesized that lowering ADMA concentrations by DDAH overexpression in the recipient 
suppresses GCAD and long-term immune response in murine cardiac allografts.
Methods and Results: In one series, donor hearts of C-H-2bm12KhEg (H-2bm12) wild-type 
mice were heterotopically transplanted into C57BL/6 (H-2b) transgenic mice overexpressing 
human DDAH-I or wild-type littermates and procured after 4 hours of reperfusion (WT and 
DDAH-I recipients; N=6 each). In a second series, donor hearts were transplanted into 
DDAH-I transgenic or WT mice and procured 30 days after transplantation (n=7 each). In 
DDAH-I recipients plasma ADMA concentrations were lower, in association with reduced 
myocardial generation of superoxide anion, inﬂammatory cytokines, adhesion molecules 
and chemokines. GCAD was markedly reduced in cardiac allografts of DDAH-I transgenic 
recipients as assessed by luminal narrowing (WT vs. DDAH: 78.5±1.8 vs. 33.1±7.0; 
p<0.01), intima/media ratio (WT vs. DDAH: 1.04±0.09 vs. 0.54±0.14; p<0.01), and the 
percentage of diseased vessels.
Conclusions: Overexpression of DDAH-I attenuated oxidative stress, inﬂammatory 
cytokines and GCAD in murine cardiac allografts. Elevated ADMA concentrations may 
play an important role in the pathophysiology of GCAD.
2:15 p.m.
819-4 Celecoxib Decreases Endothelial Tissue Factor 
Expression Through Inhibition of JNK Phosphorylation
Jan Steffel, Matthias Hermann, Helen Greutert, Steffen Gay, Thomas F. Luscher, Frank T. 
Ruschitzka, Felix C. Tanner, University of Zürich, Zurich, Switzerland, University Hospital 
Zurich, Zurich, Switzerland
Background: Selective COX-2 inhibitors (coxibs) have been proposed for treating 
atherosclerosis, a disease characterized by widespread inﬂammation. Despite potential 
anti-inﬂammatory therapeutic beneﬁt, the use of coxibs has been questioned over concern 
that they may be associated with an increased thrombotic risk. Tissue factor (TF) is a key 
protein for initiation of coagulation and has been implicated in the pathogenesis of acute 
coronary syndromes. Hence, the present study was designed to examine the inﬂuence of 
different coxibs on endothelial TF expression and activity.
Methods: Human aortic endothelial cells (HAEC) were cultured according to standard 
protocols. Protein expression was determined by Western blotting analysis; a colorimetric 
assay was used to measure TF surface activity.
Results: Celecoxib (10-7-10-5 mol/l, p<0.001), but not rofecoxib (10-7-10-5 mol/l, p=n.s.) 
or the experimental coxib NS-398 (10-7-10-5 mol/l, p=n.s.), decreased TNF-� induced TF 
expression and activity in HAEC. In contrast to rofecoxib (10-5 mol/l) and NS-398 (10-5 mol/l), 
celecoxib (10-5 mol/l) reduced activation of c-jun terminal NH2 kinase (JNK, p<0.01), but did 
not affect p38 MAP kinase (p38) or p44/42 MAP kinase (ERK). Preincubation with celecoxib 
did not affect total expression of JNK, p38, or ERK. Inhibition of JNK with SP600125 (10-6-
10-7 mol/l, p<0.0001) conﬁrmed its regulatory role in TNF-α-induced TF expression.
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Conclusions: Our study shows that celecoxib reduces tissue factor expression and 
activity through inhibition of JNK phosphorylation independent of COX-2 inhibition. 
These data indicate a distinct heterogeneity within this widely prescribed class of drugs. 
Reduced TF expression by celecoxib might account for some of the observed beneﬁts 
of this drug and may have therapeutic implications for the treatment of atherosclerotic 
vascular disorders.
2:30 p.m.
819-5 EnGEF: A Novel Guanine Nucleotide Exchange Factor 
Modulates Endothelial Cell Development
Shailan B. Shah, Huijian Wang, Thomas Quertermous, Stanford University, Stanford, CA
Background: Angiogenesis is a complex process that requires the coordination of cell 
movements, changes in cell morphology and adhesion, and the development of cellular 
polarity. Rho GTPases are intracellular molecular switches integral to these biological 
processes by tightly regulating the actin cytoskeleton in response to external signals. 
Little is known about the regulation of the Rho GTPase system in endothelial cells (ECs) 
during vascular development.
Methods: To identify novel endothelial-speciﬁc genes, we performed transcriptional 
proﬁling on ECs using DNA microarray technology. Gene expression in cell lines 
and murine embryonic and adult tissues was veriﬁed by TaqMan RT-PCR and in situ 
hybridization. We assessed morphological changes by transiently transfecting COS cells 
and bovine aortic endothelial cells (BAECs) with epitope-tagged cDNA constructs. We 
assessed the afﬁnity of EnGEF to various GTPases using an in vitro GTPase binding 
assay probed by Western blot.
Results: We identiﬁed an endothelial-restricted, guanine nucleotide exchange factor, 
termed EnGEF (EST N54398; full-length sequence AK097276; Gene name FGD5). By 
sequence analysis, this gene encodes a member of a large family of intracellular proteins 
that activate Rho GTPases. The murine homolog of EnGEF is expressed in developing 
blood vessels at embryonic day 9.5. Myc-tagged EnGEF, when transfected into COS cells 
and BAECs, induces long, spindle-like projections, suggesting activation of a GTPase 
pathway and subsequent actin cytoskeletal rearrangements. EnGEF has highest afﬁnity 
for TC10 and TCL, GTPases that are activated by the insulin signaling cascade in other 
systems. Interestingly, we also demonstrate the endothelial-restricted expression of TC10 
and TCL during early embryonic vascular development.
Conclusion: These results suggest an important role for the novel GTPase regulator EnGEF 
during angiogenesis, possibly by activating TC10 and/or TCL during EC migration and 
morphogenesis. Future studies will identify upstream activators and downstream effectors of 
this signal transduction pathway in ECs during angiogenesis and vascular pathobiology.
2:45 p.m.
819-6 Effects of Genetic Ablation of Bach1 Upon Smooth 
Muscle Cell Proliferation and Atherosclerosis After Cuff 
Injury
Shinji Omura, Yoshihiro Dohi, Kazuhiko Igarashi, Departments of Biomedical Chemistry, 
Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan
Objective; Bach1 is a transcriptional repressor of the cytoprotective enzyme heme 
oxygenase-1 (HO-1). Although HO-1 protects against atherosclerosis, the function of 
Bach1 in this process is poorly understood.
Methods and Results; We isolated peritoneal macrophages and aortic smooth muscle 
cells (SMC) from wild-type and Bach1-deﬁcient mice. Bach1-deﬁcient macrophages 
expressed increased levels of HO-1 and showed elevated phagocytic activity when co-
incubation with 0.75 µm microspheres. In SMC, the Bach1-ablation resulted in increased 
expression of HO-1 and decreased proliferation in bromodeoxyuridine incorporation assay 
as compared with the wild-type cells. The up-regulated phagocytic activity and reduced 
SMC proliferation of Bach1-deﬁcient cells were not restored by Zinc (II) protoporphyrin 
IX, an inhibitor of HO, suggesting that HO-independent mechanisms are involved in the 
regulation of phagocytosis of macrophages and proliferation of SMC by Bach1. In wild-
type mice, cuff placement causes pronounced intimal proliferation without affecting the 
media, resulting in the intimal to medial (I/M) volume ratio of 65.5%. Bach1-deﬁcient mice 
had a less degree of intimal growth (I/M ratio of 45.6%).
Conclusions; These results indicate that Bach1 plays a critical role in regulation of HO-
1 expression, macrophage function, SMC proliferation and neointimal formation. Bach1 
may regulate gene expression in these cells during inﬂammation and atherogenesis.
Effect of Bach1-ablation on Response to Vessel Injury 
WT KO P value
n 19 13
weight (g) 22.9 22.2 0.15
liminal diameter (µm) 156 155 0.95
intimal thickness (µm) 7.2 4.2 0.001
medial thickness (µm) 10.4 9.5 0.52
I/M volume ratio (%) 65.6 45.6 0.02
3:00 p.m.
819-7 Tissue Engineering Attenuates The Th2-Driven Immune 
Response Against Xenogeneic Endothelial Cells
Heiko Methe, Helen M. Nugent, Adam Groothuis, Elazer R. Edelman, Massachusetts 
Institute of Technology, Cambridge, MA
Background: Endothelial cell (EC) dysfunction is central to vascular disease. Vascular 
quiescence can be achieved with endothelial restoration. Yet, replacement of diseased 
endothelium with allogeneic or xenogeneic EC is hampered by immune reactions. EC 
have a sidedness, residing with their basal aspect on basement membrane. Matrix 
embedding allows EC to be implanted around and control hyperplasia, thrombosis and 
proliferation within injured vessels. We hypothesized that matrix embedding alters the 
nature of host immune response against non-vascularized EC xenografts.
Methods: B6-mice received porcine EC (PE) as s.c. implants as pelleted suspensions, 
embedded within 3-D Gelfoam matrices or as pellets on empty matrix implants (n=12 in 
each group). PE-speciﬁc IgG1, IgG2a, and IgM were characterized by ﬂow cytometry on 
days 0, 5, 12, 56 and 90, T cell cytokine proﬁles (ELISPOT) and lytic activity of recipient 
T cells on day 28.
Results: PE in suspension or injected on empty matrices evoked a marked humoral 
and cellular immune response in mice centered about PE-speciﬁc IgG1, IgM, but not 
IgG2a, and Th2, but not Th1, mediated cytokine expression (IL-4, IL-10; table) which was 
signiﬁcantly reduced when matrix-embedded EC were implanted.
Conclusions: Non-vascularized PE evoke a Th2 driven immune response in mice. 
Embedding EC within a 3-D matrix attenuates this response, perhaps as a result of 
mimicking basal anchorage, offering novel therapies and intriguing tools to study vascular 
and immune biology.
Table: Tissue engineering attenuates host immune responses
pelleted PE 
suspension
pelleted PE with 
empty matrix
matrix-
embedded PE P-value
PE-speciﬁc IgG1
[MFI] 735.3±344.9 622.5±186.0 210.2±101.6 <0.0001
PE-speciﬁc IgG2a
[MFI] 83.9±13.4 78.8±9.2 56.3±7.7 <0.0001
PE-speciﬁc IgM
[MFI] 62.6±5.1 63.5±4.0 60.5±3.7 0.83
IL-4 expressing cells [cells per ﬁeld ] 680.2±129.1 589.7±106.9 198.9±99.6 <0.0001
IL-10 expressing cells [cells per ﬁeld ] 888.0±151.3 756.8±77.6 493.8±134.9 <0.001
IL-2 expressing cells [cells per ﬁeld ] 290.8±177.1 246.3±90.4 242.9±112.9 0.68
INF-gamma expressing cells [cells per ﬁeld ] 182.1±146.9 281.9±119.7 233.9±111.2 0.39
PE-lysis, calcein release
[arbitrary ﬂuorescent units] 186.5±16.8 172.5±19.9 115.8±9.9 <0.0001
3:15 p.m.
819-8 Inhibition of the Endothelial Nitric Oxide Synthase 
Impairs Differentiation of CD133 Positive Progenitor 
Cells to Mature Endothelium
Thomas Thum, Daniela Fraccarollo, Dimitris Tsikas, Andreas Opitz, Georg Ertl, Johann 
Bauersachs, University of Wuerzburg, Wuerzburg, Germany
Background: Impaired mobilization and function of endothelial progenitor cells (EPCs) 
contribute to endothelial dysfunction and cardiovascular disease progression. The 
endothelial NO synthase (eNOS) regulates mobilisation and functional activity of bone 
marrow-derived stem and progenitor cells. However, little is known about expression, 
phosphorylation, enzyme activity or inhibition of eNOS during differentiation of CD133+ 
progenitors to mature functional endothelial cells.
Methods: We therefore characterized the level of endothelial differentiation in isolated 
and cultured CD133+ cells from healthy volunteers up to 21 days using an in-vitro tube 
formation assay and cellular uptake of Dil-labeled acetylated LDL. We correlated protein 
expression, phosphorylation (Ser1179) and enzyme activity of eNOS and the phospho-
kinase Akt to the level of endothelial differentiation.
Results: Protein expression of eNOS was detectable after 3 days of culture with 
endothelial growth medium and continuously increased peaking at day 21, whereas 
expression of phospho-eNOS as well as eNOS activity was only detectable at the end 
of the culture period. Akt and phospho-Akt were detectable in freshly isolated CD133+ 
cells and expression level increased 2-fold and 5-fold after culture for 7 and 21 days. 
Inhibition of NO production using N-nitro-L-arginine (100µM) signiﬁcantly impaired 
differentiation of CD133+ cells to mature endothelium, as tube formation and cellular 
uptake of Dil-acLDL was repressed to 6% and 14% of controls at day 21, respectively. Akt 
and eNOS expression were decreased to 30% and 25% upon NOS inhibition. Likewise, 
phosphorylation of both proteins was reduced to 50% of appropriate controls.
Conclusions: NOS inhibition interrupts the differentiation of EPCs to mature endothelium. 
Furthermore, Akt, phospho-Akt, eNOS and phospho-eNOS expression are repressed by 
inhibition of NO production. These data clearly demonstrate a unique role of the Akt/
eNOS system for differentiation of EPCs to functional mature endothelium.
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820  Noninvasive Assessment of 
Atherosclerosis: Using Ultrasound  
and New Tests
Monday, March 07, 2005, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room 231A
2:00 p.m.
820-3 Relationship of Sonographic Wall Thickness in the 
Carotid, Brachial, and Coronary Arteries
Matthias Frick, Benedikt Lackner, Wolfgang Sturm, Hannes Alber, Otmar Pachinger, 
Franz Weidinger, Innsbruck Medical University, Innsbruck, Austria
Background: The association between atherosclerosis among different vascular beds 
is still unclear. No study so far has compared the extent of atherosclerosis in 3 different 
vascular beds using ultrasound. The aim of this study was to investigate the relation of 
intima-media thickness (IMT) of brachial (BA) and common carotid artery (CCA) with 
plaque burden of coronary arteries assessed with intracoronary ultrasound (ICUS).
Methods: Intracoronary ultrasound was used in 40 patients, in whom coronary 
angiography revealed a ≥ 50% stenosis. An automated mechanic pullback was performed 
to allow exact volumetric measurements. Manual planimetry was used to calculate vessel 
area, lumen area and plaque area in an average of 35 images per patient. Plaque burden 
and plaque volume (using Simpson´s rule) were calculated. On the day after angiography, 
ﬂow-mediated vasodilation (FMD) of the BA and IMT of the CCA and the BA were 
examined with high-resolution ultrasound.
Results: IMT of the BA correlated signiﬁcantly with IMT of the CCA (r = 0.56, p<0.001). 
However, neither parameter showed a signiﬁcant correlation with ICUS measurements. 
Endothelial function (FMD) of the BA did not correlate with either plaque volume of 
coronary arteries or IMT in both peripheral vessels.
Conclusions: In this selected group of CAD patients, we found no signiﬁcant correlation 
between IMT of peripheral arteries with ICUS-derived plaque burden. Although IMT of 
peripheral arteries show a close correlation in their extent and have known prognostic 
impact, the lack of an association with coronary plaque burden suggests that the extent 
and perhaps the progression of atherosclerosis in these vascular beds is quite different.
2:15 p.m.
820-4 Skin Cholesterol Content Identiﬁes Subclinical 
Atherosclerosis in Asymptomatic Adults
Wendy S. Tzou, Maureen E. Mays, Claudia E. Korcarz, Susan E. Aeschlimann, James H. 
Stein, University of Wisconsin Medical School, Madison, WI
Background: An assay to measure skin total cholesterol content (Tc) that does not 
require a skin biopsy has recently become available for use as a cardiovascular (CV) risk 
prediction tool. Carotid intima-media thickness (CIMT) is a well-validated surrogate for 
subclinical atherosclerosis. Our objective was to determine if skin Tc levels are associated 
with increased CIMT after adjusting for known CV risk factors and Framingham CV risk.
Methods: Consecutive patients without known vascular disease who were referred for 
determination of CIMT underwent B-mode ultrasonography of the carotid arteries and 
measurement of skin Tc using a non-invasive assay. Use of medications, cardiac risk 
factors, and Framingham 10-year CV risk were determined prospectively. Multivariable 
regression was used to determine predictors of increased CIMT.
Results: Among 81 subjects, the mean (standard deviation) age was 55.6 (7.7) years and 
the mean skin Tc was 95.9 (18.3) units. CIMT was signiﬁcantly higher among individuals 
in the highest quartile of skin Tc (0.87 mm vs. 0.76 mm, p=0.011). In multivariable 
analyses, skin Tc was associated with increased CIMT even after adjusting for age, sex, 
glucose, systolic blood pressure, total:high-density lipoprotein cholesterol ratio, and use 
of lipid-lowering therapy (odds ratio [OR] per 10-unit increase=1.590, 95% conﬁdence 
intervals [CI]=1.525-1.658, p=0.031). Skin Tc also was associated with increased CIMT 
after adjustment for Framingham risk (OR=1.341, 95% CI=1.302-1.380, p=0.048).
Conclusions: Skin Tc is an easy-to-measure, non-invasive marker that can help identify 
subclinical atherosclerosis in asymptomatic middle-aged adults, even after controlling for 
risk factors and CV risk predicted by the Framingham model.
2:30 p.m.
820-5 Sex Differences in Carotid Atherosclerosis Progression 
in Young Adults: The Bogalusa Heart Study
Heather M. Matthews, Pamela S. Douglas, Sathanur R. Srinivasan, Wei Chen, Shengxu 
Li, Gerald S. Berenson, James H. Stein, University of Wisconsin Medical School, 
Madison, WI, Tulane University Health Sciences Center, New Orleans, LA
Introduction: Sex-related differences in risk factors for atherosclerosis progression in 
middle-aged and elderly adults are well known, but are less well understood in young 
adults. Carotid artery intima-media thickness (CIMT) is a validated measure of subclinical 
atherosclerosis. This study evaluated sex-related differences in predictors of CIMT 
progression in young adults from the Bogalusa Heart Study.
Methods: High-resolution B-mode ultrasound images of the far walls of the carotid 
arteries were obtained in 336 young adults (mean age 32.4, range 25-37 years). CIMT 
and risk factors were measured baseline (1995-96) and after a mean of 5.8 (range 4-8) 
years. Multivariable regression was used to determine predictors of CIMT progression.
Results: Age-adjusted composite CIMT progression rates in men (0.019 mm/year) and 
women (0.010 mm/year) were not statistically different, even after controlling for race and 
body-mass index (p=0.280). Smoking predicted CIMT progression in both sexes, however 
sex differences in predictors of progression were identiﬁed (table). Lipids, age, and white 
race were signiﬁcant predictors in women, but not men. Systolic blood pressure and family 
history of heart disease were predictors in men, but not women.
Conclusion: There are sex differences in predictors of atherosclerosis progression in 
young adults. Understanding these differences may help identify young adults at increased 
risk for cardiovascular disease and help individualize preventive strategies.
Predictors of CIMT Progression in Young Adults 
Women Men
Predictor Standardized Coefﬁcient p Predictor
Standardized 
Coefﬁcient p
Total:HDL Cholesterol Ratio 0.291 <0.001 Smoking 0.292 0.003
Smoking 0.236 0.001 Systolic Blood Pressure 0.246 0.015
Age 0.229 0.001 Family History 0.223 0.015
White Race 0.162 0.048
2:45 p.m.
820-6 Regional Aortic Function is Correlated With Intima 
Media Thickness- Insights From 3D-Echocardiography
Jaroslaw Drozdz, Maria Krzeminska-Pakula, Michal Orczykowski, Piotr Lipiec, Lukasz 
Chrzanowski, Michal Plewka, Anna Kopff, Jaroslaw D. Kasprzak, Medical University of 
Lodz, Lodz, Poland
Thickening of arterial intima, as well as the presence of atherosclerotic plaques may 
inﬂuence vessel pulsation by increasing the wall stiffness. There is no data available 
concerning regional changes in aortic elasticity in relation with local wall thickness and 
the magnitude of atherosclerosis.
The study group comprised 48 patients (33 men, 54±11 years) referred for transesophageal 
echocardiography. Reconstructions of two-centimeter-long segments of aorta were divided 
by coaxial planes into four longitudinal sections. Thereafter, diastolic and systolic radius, 
thickness of atherosclerotic plaques and intima-media thickness (IMT) in each section 
were measured. The relative change in regional aortic lumen (pulsation) was measured 
and regional β-index was calculated. In total, 192 aortic sections were analyzed.
The volume of the examined sections of the aortic segments ranged from 0.6 cm³ to 
4.1 cm³ (mean 1.6±0.7 cm³) in systole and from 0.5 cm³ to 3.7 cm³ (mean 1.4±0.7 cm³) 
in diastole. The pulsation of the aortic sections varied from 0.04 cm³ to 0.78 cm³ (mean 
0.21±0.13 cm³), which constituted 1 to 21% (mean 6±4%) of the section volume.
The thickness of atherosclerotic plaques in the studied aortic sections ranged from 0.03 
mm to 1.87 mm (mean 0.31±0.26 mm) and IMT was within the range 1.28 mm to 3.61 mm 
(mean 1.87±0.39 mm). The regional β-index of the individual section ranged from 1.6 to 
97.1 (mean 12.5±14.6). The regional β-index was statistically signiﬁcantly dependent on 
the intima-media thickness (r=0.43, p<0.001), but not on the thickness of atherosclerotic 
plaques (p=0.96).
The variability of regional β-index, deﬁned as the difference between the highest and the 
lowest β-index in the sections of the same aortic segment, ranged from 1.7 to 83.1 (mean 
20.0±20.7) and was borderline correlated with the IMT (r=0.26, p=0.07), but not with the 
thickness of atherosclerotic plaques (p=0.87).
Conclusions: Three-dimensional echocardiography facilitates quantitative analysis of 
aortic wall stiffness and regional β-index measurements. Local aortic wall β-index as well 
as its regional variability is dependent on intima-media thickness, but not on the thickness 
of atherosclerotic plaques.
3:00 p.m.
820-7 Attenuation of Digital Reactive Hyperemia in Patients 
with Early and Advanced Coronary Artery Disease
Piero O. Bonetti, Matthias Pﬁsterer, Amir Lerman, Division of Cardiovascular Diseases, 
Mayo Clinic, Rochester, MN, Division of Cardiology, University Hospital, Basel, 
Switzerland
Background Digital reactive hyperemia, as determined by Reactive Hyperemia 
Peripheral Arterial Tonometry (RHPAT), is attenuated in patients with coronary endothelial 
dysfunction, representing an early stage of coronary artery disease (CAD). The magnitude 
of digital reactive hyperemia in patients with advanced CAD is unknown. The aim of this 
study was to compare the RHPAT response of patients with the very early stage of CAD 
with that of patients with advanced CAD.
Methods/Results Using RHPAT, digital pulse volume was assessed at rest and during 
RH in patients without signiﬁcant CAD and normal (n=39) or abnormal (n=55) coronary 
endothelial function as well as in healthy volunteers (n=12) and patients with advanced 
CAD (n=12). RHPAT index, a measure of digital RH, was calculated as the ratio of the 
digital pulse volume during RH divided by that at rest. RHPAT index was similar in patients 
with normal coronary endothelial function and in healthy controls. RHPAT index did not 
differ between patients with coronary endothelial dysfunction and those with advanced 
CAD, whereby the values in these two groups were signiﬁcantly lower than those in 
patients with normal coronary endothelial function and in healthy controls (ﬁgure).
Conclusions Digital RH is similarly and signiﬁcantly attenuated in patients with early 
and advanced CAD compared with individuals with a healthy coronary endothelium. This 
ﬁnding further supports a role for RHPAT as a noninvasive tool to identify patients with 
various stages of CAD. 
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825  Endothelial Function: Clinical 
Investigations I
Monday, March 07, 2005, 4:00 p.m.-5:30 p.m.
Orange County Convention Center, Room 414A
4:00 p.m.
825-3 Direct Causative Link Between Inﬂammation, Vascular 
Dysfunction And Endogenous Tissue Plasminogen 
Activator Release
Simon D. Robinson, Christopher A. Ludlam, Nicholas A. Boon, David E. Newby, 
University of Edinburgh, Edinburgh, United Kingdom, Royal Inﬁrmary of Edinburgh, 
Edinburgh, United Kingdom
Background: Elevated plasma tissue-plasminogen activator (t-PA) and serum C-reactive 
protein (CRP) concentrations are associated with an adverse cardiovascular risk. We 
investigated whether acute local inﬂammation directly causes vascular dysfunction, and 
inﬂuences t-PA release in patients with stable coronary heart disease.
Methods: Serum CRP, plasma t-PA and plasminogen activator inhibitor type 1 (PAI-1) 
concentrations were determined in 95 patients with stable coronary heart disease. A 
representative sub-population of 12 male patients received an intra-brachial infusion of 
tumor necrosis factor (TNF)-α (80 ng/min) and saline placebo using a randomized double-
blind crossover study design. Forearm blood ﬂow, and plasma ﬁbrinolytic and inﬂammatory 
variables were measured in both arms using venous occlusion plethysmography and 
blood sampling respectively.
Results: Serum CRP concentrations correlated with plasma t-PA concentrations (r=0.37, 
P<0.001) and t-PA/PAI-1 ratio (r= -0.27, P<0.05). Intra-arterial TNF-� infusion caused a rise 
in plasma t-PA concentrations (9.4 ± 1.1 to 11.3 ± 1.2ng/mL, P<0.001) without affecting 
blood ﬂow or plasma PAI-1 concentrations. TNF-α pre-treatment impaired acetylcholine and 
nitroprusside-induced vasodilatation (P<0.001 for both) whilst doubling bradykinin induced t-
PA release (63.7 ± 14.8 versus 120.7 ± 26.1 ng/100 mL/min for peak response; P=0.005).
Conclusions: In patients with stable coronary heart disease, plasma ﬁbrinolytic factors 
correlate with a systemic inﬂammatory marker. For the ﬁrst time, we have shown that, 
in these patients, acute local vascular inﬂammation directly impairs vasomotor function 
whilst enhancing endothelial t-PA release. We conclude that the adverse prognosis 
associated with elevated plasma t-PA concentrations appears to be causally related to 
underlying vascular inﬂammation and endothelial injury.
4:15 p.m.
825-4 Association Of TNF Alpha R1 Receptor Levels With 
Impaired Endothelial Dysfunction: A Nomas Substudy
Edwin Lee, Cairistine Grahame-Clarke, Yumiko Miyake, Robert Sciacca, Kumiko Hirata, 
Carlos Rodriguez, Bernadette Boden-Albala, Mitchell Elkind, Marco Di Tullio, Ralph 
Sacco, Shunichi Homma, Columbia University Medical Center, New York, NY
Background: Recent evidence indicates that inﬂammatory cytokines in particular tumor 
necrosis factor alpha (TNFα) may play an important role in cardiovascular disease. TNFα 
is associated with atherosclerosis and an increased risk of cardiovascular events in some 
but not all studies. Because TNFα receptors (TNFα-R) which exist as two isoforms (TNFα-
R1 & TNFα-R2) are shed upon binding with their ligand TNFα, it has been suggested that 
TNFα-R levels may be a better indicator of the local action of TNFα. Indeed, TNFα-R1 and 
not TNFα-R2 has been shown to be associated with cardiovascular events. Endothelial 
dysfunction as determined by impaired ﬂow mediated dilatation (FMD) is known to 
precede and be a hallmark for atherosclerosis. If TNFα-R1 levels were associated with 
impaired FMD this would support the hypothesis that TNFα acting through TNFα-R1 has 
a role in atherosclerosis.
Methods: Flow-mediated vasodilatation and TNFα-R1 levels were determined in 355 
subjects in a multiethnic (68% Hispanics, 17% Black, 15% White) population of the 
Northern Manhattan Study (NOMAS). All subjects had no previous cardiovascular events, 
mean age 67.1 +/- 9.0 years, 57% female, body mass index (BMI) 27.7 +/- 4.7, 68% 
hypertensives, 22% diabetics, 50% hypercholesterolemics. Multiple regression analysis to 
ascertain the relationship between TNFα-R1 levels and impaired endothelial dysfunction 
was performed.
Results: TNFα-R1 levels were found to correlate with impaired FMD (r=-0.17, p=0.002). 
This relationship remained signiﬁcant after adjusting for age, gender, blood pressure, 
diabetes mellitus and BMI (p=0.04).
Conclusion: TNFα-R1 levels are associated with impaired FMD in a multiethnic 
population even after adjusting for known cardiovascular risk factors. TNFα-R1 levels 
may therefore be a better measure of the action of TNFα than TNFα itself. This ﬁnding 
would support the hypothesis that TNFα acting through TNFα-R1 has a role in endothelial 
dysfunction and ultimately atherosclerosis.
4:30 p.m.
825-5 Gender Difference in Nitric Oxide Synthase 
Polymorphism in Young Healthy Subjects
Umberto Paradossi, Maria Giovanna Colombo, Enrica Cioﬁni, Olivia Manfrini, Carmine 
Pizzi, Andrea Biagini, Raffaele Bugiardini, University Alma Mater, Bologna, Italy, CNR, 
Massa, Italy
BACKGROUND. Endothelial nitric oxide synthase (eNOS) regulates endothelial 
function. Endothelial dysfunction may play a role in the development of atherosclerosis. 
We conducted a gender-speciﬁc clinical investigation to assess the role of eNOS 
polymorphisms as predisposing factors for attenuation of endothelial function and early 
sub-clinical atheroscerosis in young people.
METHODS. We enrolled 118 young healthy subjects free of traditional risk factors 
(diabetes, hypertension, hypercholesterolemia, and smoking). Genotyping for the eNOS 
Glu298Asp polymorphisms was performed by means of polymerase chain ampliﬁcation. 
We used high-resolution ultrasounds to assess brachial artery ﬂow-mediated endothelium-
dependent dilation (FMD) and carotid artery intima-media thickness (IMT). The former is a 
marker of endothelial function the latter is an index of sub-clinical atherosclerosis.
RESULTS. Of the 146 subjects 72 were female (F, 29.7+4.9 year/old) and 74 were male 
(M, 31.6+6.8 year/old). Genotypic proportions were in Hardy-Weinberg equilibrium with 
the frequency of Glu/Glu 44%, Glu/Asp 43%, and Asp/Asp 13% being similar to that 
observed in previous studies. There was not signiﬁcant difference in the distribution of 
Glu298Asp polymorphism between genders. In women, Asp-carriers had a signiﬁcantly 
lower FMD than Glu298-homozygotes (13.4+6 % versus 16.5+7.1 %, p<0.05). In men, 
there was no difference in FMD between Asp-carriers and Glu298-homozygotes (11.1+4.6 
% versus 10.0+5.2%; p=ns). FMD correlated inversely with carotid IMT (r=-0.29, p<0.01). 
CONCLUSIONS. Glu298Asp polymorphism is associated with gender differences in 
endothelial function and sub-clinical atherosclerosis in young healthy subjects. Women 
with Glu298-homozygotes present better endothelial function than does women with Asp-
carriers. Men had the worst endothelial function that may be relevant to early development 
of clinical disease. eNOS Glu(298)/Asp polymorphism may contribute to gender difference 
in the incidence of cardiovascular disease.
4:45 p.m.
825-6 Divergent Effects of Laughter and Mental Stress on 
Endothelial Function: Potential Impact of Entertainment
Michael Miller, Charles Mangano, Young Park, Radha Goel, Gary Plotnick, Robert Vogel, 
University of Maryland Medical System, Baltimore, MD
Background: Endothelial function plays an important role in the pathogenesis of 
cardiovascular disease (CVD) and brachial artery (BA) ﬂow-mediated vasodilation (FMD) 
is impaired by CVD risk factors, including mental stress. However, positive physiologic 
responses (e.g., laughter) on endothelial function have not been studied.
Methods: BA FMD was measured as % diameter change in 20 healthy, non-smoking 
volunteers (10 M, 10 F; mean age: 33 yrs) after an overnight fast. Each volunteer was 
randomized to view a 30 min segment of a movie designed to induce either mental 
stress or laughter. Then, volunteers returned a minimum of 48 hr later to view the 30 
min segment not previously seen. BA measurements were obtained 4 times during each 
phase and a total of 160 measurements were made.
Results: 95% of volunteers had increased FMD during the laughter phase while 74% had 
decreased FMD during mental stress (P < 0.001). Overall, mean BA FMD increased 22% 
during laughter and decreased 35% during mental stress (P = 0.0007) (Figure). Average 
baseline diameter was unaffected during either phase suggesting internal consistency of 
measurements.
Conclusion: The overall difference in FMD (> 50%) between laughter and mental stress 
suggests that entertainment may affect endothelial function in healthy men and women. 
With 2/3 of U.S. children viewing at least 2 hrs of T.V. daily and movie attendance at record 
levels, entertainment may impact endothelial function and CVD health. 
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825-7 Heat Shock Protein 60 Is Detectable In The Plasma Of 
Healthy Children And Is Associated With Endothelial 
Dysfunction 
Julian Halcox, Alireza Tousi, Atul Singhal, Alan Lucas, Brian Henderson, John Deanﬁeld, 
University College London, London, United Kingdom
Background: The atherosclerotic disease process typically begins in the ﬁrst 2-3 decades 
of life, and is characterized by vascular inﬂammation and endothelial dysfunction. The in-
vivo interplay of inﬂammatory mediators speciﬁc to early atherogenesis has not been 
fully characterized in the clinical setting. We hypothesized that soluble human heat shock 
protein 60, a “stress-protein” that has pro-inﬂammatory effects on vascular and immune 
cells, would be detectable in the serum of teenage children and that its presence would 
be associated with early vascular dysfunction.
Methods: Noninvasive, high-resolution ultrasound was used to determine ﬂow-mediated, 
endothelium-dependent vasodilatation (FMD) and also distensibility of the brachial 
artery in 294 healthy teenagers (aged 13-16y). Anthropometric characteristics and 
blood pressure were recorded, and fasting levels of lipids, glucose, insulin and CRP 
were measured. sHSP60 was measured using highly speciﬁc, sandwich enzyme-linked 
immunosorbent assay.
Results: sHSP60 was detactable in 60 teenagers. No association was observed between 
sHSP60 and CRP levels. FMD was reduced in subjects with detectable sHSP60 compared 
to those without (0.198±0.010 vs 0.228±0.008mm, p=0.02). This relationship between 
sHSP60 and impaired endothelium-dependent vasodilatation remained after adjustment 
for age, baseline arterial diameter and other potentially confounding variables (p=0.03). 
Arterial distensibility was similar in subjects with and without detectable sHSP60.
Conclusions: sHSP60 is detectable in children and is associated with impaired vascular 
endothelial function in early life, supporting a potential role for this inﬂammatory mediator 
in the initiation of vascular dysfunction and atherogenesis. Determinants of sHSP60 
expression and the longer-term clinical implications of our ﬁndings require prospective 
evaluation. 
5:15 p.m.
825-8 ACE Inhibition and Endothelial Function in the Europa 
Trial: The Main Findings From the Perfect Substudy
Michiel L. BOTS, Willem J. Remme, Diederick E. Grobbee, Michel Bertrand, Roberto 
Ferrari, Kim Fox, Marteen L. Simoons, Julius Center for Health Sciences and Primary 
Care, Utrecht, The Netherlands, Sticares Cardiovascular Research Institute, Rhoon, The 
Netherlands
Background: ACE inhibitors effectively reduce morbidity and mortality among a variety 
of cardiovascular disease patients. Among mechanisms explaining their beneﬁcial effects 
are their action on local vasodilatating substances at endothelium level, such as nitric 
oxide and bradykinin.The PERindopril-Function of the Endothelium in Coronary artery 
disease Trial (PERFECT), a sub study of the EUropean trial on Reduction Of cardiac 
events with Perindopril in stable coronary Artery disease (EUROPA), was designed to 
evaluate whether long-term administration of perindopril improves endothelial dysfunction 
, one of the ﬁrst steps that contribute to the development and clinical expression of 
atherosclerosis in patients with coronary artery disease (CAD).
Methods: PERFECT is a three year double blind randomised placebo controlled trial 
to determine the effect of perindopril 8 mg once daily on the endothelial function of the 
brachial artery in patients with stable CAD and without clinical heart failure. Endothelial 
function in response to ischaemia (reactive hyperaemia) was assessed using brachial B-
mode ultrasonography. The primary endpoint was change in ﬂow-mediated vasodilatation 
(FMD) of the brachial artery assessed over 36 months. The statistical analyses were 
performed using a random effects model assuming improvement in endothelial function 
to be linear over time.
Results: In 20 centers, 333 patients were randomly assigned to perindopril 8mg once 
daily or placebo.Baseline characteristics of patients were well balanced in both groups 
and mean FMD, measured in response to ischemia, was 2.7% (SD 2.6).The mean FMD 
in perindopril group went from 2.6% at baseline to 3.3% at 36 months. For the placebo 
group FMD went from 2.8% to 3.0%. The rate of change in endothelial function per 6 
months was 0.14% (SE 0.05, p<0.05) in perindopril group and 0.02% (SE 0.05, p=0.74) 
in the placebo group. The difference in rate of change in endothelial function between the 
treatment arms was 0.12% (p=0.07).
Conclusion: Our ﬁndings support the notion that part of the beneﬁcial effects of perindopril 
on cardiovascular morbidity and mortality in the EUROPA study may be explained by 
improvement in endothelial function.
ORAL CONTRIBUTIONS
828  Experimental Models of 
Cardiomyopathy and Vascular Disease
Monday, March 07, 2005, 4:00 p.m.-5:30 p.m.
Orange County Convention Center, Room 230D
4:00 p.m.
828-3 Efonidipine, A Novel Ca2+ Channel Antagonist With 
T-type Activity, Prevents The Development Of Heart 
Failure In Cardiomyopathic Hamster
Tomoko Ohkusa, Satoshi Takebayashi, Takashi Sato, Shinsuke Suzuki, Tomo 
Matsumoto, Yuji Hisamatsu, Masafumi Yano, Katsushige Ono, Masunori Matsuzaki, 
Yamaguchi University, Ube, Japan, Oita University, Oita, Japan
It was reported the T-type Ca2+ channel (TCC) was activated and the abnormalities in 
TCC may be related to the pathogenesis of Ca2+ overload in cardiomyopathic hamster 
hearts. Our aims are to investigate the alteration in the expression of the TCC a-1G 
(TCCaG), and to examine the effects of TCC blockade (TCCB) on cardiac function and 
TCC during development of heart failure in cardiomyopathic hamster. 
Methods: UM-X7.1 (U) and golden (G) hamsters were examined, and efonidipine (EFO) 
was administered at the age of 20w for 4 weeks. We examined the cardiac function 
using echocardiography, measured the expression of TCCaG mRNA by RT-PCR, and 
ventricular myocytes were subjected to a patch-clamp study. 
Results: At 24 weeks, vehicle treated U hamsters exhibited signiﬁcant increases in 
left ventricular (LV) size with marked decreases in LV fractional shortening (FS) (17±3 
vs 45±6%, p<0.05) and ejection fraction (EF) (43±7 vs 82±6%, p<0.05) compared with 
G hamsters. In U group, EFO-treatment signiﬁcantly attenuated the decrease of LVFS 
(22±3%, p<0.05) and LVEF (50±5%, p<0.05) without affecting blood pressure compared 
with vehicle group. EFO-treatment decreased HR (by ~10%) in both groups. In G group, 
EFO-treatment did not affect LV function. The expression of TCCaG mRNA decreased 
with aging in G group, however in U group its expression markedly increased at the 
newborn stage and during development of heart failure compared with G group. The TCC 
current in ventricular myocytes was signiﬁcantly increased in U, and it was inhibited by 
TCCB in a dose-dependent manner. The treatment with EFO did not affect the expression 
of TCCaG mRNA in both groups. 
Conclusions: In cardiomyopathic hamster hearts, abnormalities in TCC may be related 
to the pathogenesis of Ca2+ overload, and TCCB-treatment may decrease the TCC 
current, resulting in an improvement of cardiac function. TCCB therapy might be a new 
therapeutic strategy against heart failure.
4:15 p.m.
828-4 Rescue of Beta(2)-Adrenergic Receptor 
Overexpression-Induced Cardiomyopathy by Dominant-
Negative p38 Mitogen Activated Protein Kinase
Jennifer E. Brady, Wei Chen, Jing Liu, Jill Thaisz, Gui-Ping Yang, Yibin Wang, Jun 
Sadoshima, Stephen F. Vatner, Dorothy E. Vatner, University of Medicine and Dentistry 
of New Jersey, Newark, NJ
Background: Whereas β-adrenergic receptor (β-AR) blockers are assuming increased 
importance in the treatment of heart failure, the cellular mechanism of these beneﬁcial 
effects is not entirely known. There are several transgenic mouse models of enhanced 
β-AR signaling that develop cardiomyopathy as they age. Since the mechanism of the 
cardiomyopathy in these models involves chronically enhanced β-AR signaling, we 
reasoned that determining the cellular mechanism that rescues the cardiomyopathy could 
also provide insight into the mechanism of β-AR blockade treatment in heart failure.
Methods: To accomplish this goal, we examined mice with β2-AR overexpression which 
demonstrate enhanced left ventricular function at a young age and develop impaired left 
ventricular function and cardiomyopathy as they age.
Results: In young mice (4-5 months) overexpressing the β2-AR (β2 TG), the left ventricular 
ejection fraction (LVEF) was 82 ± 0.02%, which was higher than young wild type (68 ± 
0.2%, p < 0.001). In old β2 TG mice (10-17 months), LVEF fell to 53 ± 0.03% (p < 0.05), 
which was lower than old wild type (71 ± 0.2%, p < 0.001). In old β2 TG mice there was 
increased ﬁbrosis by 10 fold, as quantiﬁed by Picric Sirius Red, and abnormal histological 
architecture. Western blotting revealed that phosphorylated p38 MAPK (Pp38 MAPK) was 
increased in young β2 TG compared with young wild type by 1.7 fold (p < 0.05). Similarly, 
Pp38 MAPK was increased in old β2 TG by 2.0 fold (p < 0.05) compared with old wild type. 
Accordingly, we crossed β2 TG with dominant-negative p38α mice (DNp38α TG). In these 
mice, as expected, Pp38 MAPK was not increased compared with wild type. Interestingly, 
in old β2 TG x DNp38α TG the cardiomyopathy was rescued, i.e. LVEF did not fall and 
remained at normal levels (77 ± 0.01%).
Conclusion: These results support the hypothesis that the cardiomyopathy, which 
develops in mice overexpressing the β2-AR, is due to activation of p38 MAPK. It is 
conceivable that this pathway could also be involved in the salutary effects of β-AR 
blockade therapy in patients with heart failure.
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4:30 p.m.
828-5 Gender Speciﬁc Effects of Calcitonin Gene-Related 
Peptide and Substance P Gene Knockout Mice on 
Coronary Blood Flow Rates
Hongbao Ma, Ruiping Huang, Amrita Karve, Ibrahim Shah, Scott C. Supowit, Donald 
J. DiPette, George S. Abela, Michigan State University, East Lansing, MI, Texas A&M 
University, Temple, TX
Background: The sensory neuropeptides, calcitonin gene-related peptide (CGRP) and 
substance P (SP) are potent vasodilators. Evidence indicates that CGRP is critical in 
regulation of basal coronary ﬂow rates. To determine if SP has a similar role and if there 
are any gender differences between CGRP and SP, we investigated coronary ﬂow rates 
among wild type (WT) and knockout (KO) mice.
Methods: 109 WT, α-CGRP-KO and SP receptor (NK-1 receptor) KO mice were studied 
in a Langendorff preparation at various perfusion pressures (50, 40, 30, 20 mmHg). The 
aorta was cannulated and coronary ﬂow rates measured by pressure differences on both 
sides of a glass capillary in the perfusion line.
Results: In males, ﬂow rates were decreased 14% and 5% in α-CGRP-KO and NK-1-KO 
mice respectively, compared to WT controls (p<0.01, 50 mmHg). In females, ﬂow rates in 
α-CGRP-KO mice were decreased 16% compared to WT controls. In contrast, ﬂow rates 
in NK-1-KO females were increased 19% compared to WT controls (p<0.01, 50 mmHg).
Conclusions: In males, both CGRP and SP were signiﬁcant vasodilators. In females, 
CGRP was similar to males, however SP appears to be a vasoconstrictor. Thus, there 
appears to be signiﬁcant gender speciﬁc differences between CGRP and SP in the 
regulation of the coronary circulation. 
Pressure
(mmHg)
Coronary Flow Rates (ml/min/g)
Control
Female
α-CGRP-KO
Female
NK-1-KO
Female
Control
Male
α-CGRP-KO
Male
NK-1-KO
Male
n=24 n=13 n=11 n= 15 n=27 n=19
50 11.45±1.44 9.61± 2.17 13.57±2.11 12.23 ±0.93 10.54±0.93 11.59±1.64
40 9.17±1.08 7.61±1.69 10.57±1.70 10.09±0.75 8.27±0.75 8.89±1.27
30 6.31± 0.80 5.27±1.19 6.97± 1.14 6.98±0.74 5.58± 0.74 5.99±0.90
20 3.89± 0.54 3.11±0.83 3.89± 0.68 5.99±0.54 2.98± 0.57 3.10± 0.55
4:45 p.m.
828-6 Transgenic Inhibition of Cardiac NF-kB Activation 
Protects Against TNF-a-induced Left Ventricular 
Dysfunction
Adam B. Stein, Greg Hunt, Sumit Tiwari, Justin R. Kingery, Arash Rezazadeh, Roberto 
Bolli, Buddhadeb Dawn, University of Louisville, Louisville, KY
Background: Tumor Necrosis Factor (TNF)-α, a pleiotropic cytokine with diverse biological 
actions, has been implicated in the development of congestive heart failure. Although 
TNF-α is known to activate nuclear factor-kappaB (NF-κB), the association between NF-
κB activation and LV systolic dysfunction has thus far relied upon pharmacologic inhibition 
of NF-κB activation.
Methods: We used a transgenic mouse line that overexpresses a dominant negative 
mutant of IκBα in a cardiac-speciﬁc manner. In these mice, NF-κB cannot be activated 
in cardiomyocytes in response to various stimuli. Age-matched male transgenic (Tg) and 
nontransgenic (NTg) littermates received TNF-α (120 µg/kg i.p.) and cardiac function was 
assessed by echocardiography at 6 h, 24 h, and 6 d after TNF-α administration.
Results: In NTg mice, TNF-α administration was associated with a sustained decrement 
in LV fractional shortening, fractional area change, and ejection fraction that failed to 
recover at 6 d. In contrast, TNF-α administration did not cause any signiﬁcant change in 
LV systolic function in Tg mice. These data constitute the ﬁrst conclusive genetic evidence 
that NF-κB activation in cardiomyocytes is crucial for the induction of negative inotropic 
effects by TNF-α.
Conclusion: We conclude that NF-κB activation in cardiomyocytes is critical for the 
TNF-α-induced LV systolic dysfunction. 
5:00 p.m.
828-7 ß2 Adrenergic Receptor Coupled Phosphoinositide-3 
Kinase Constrains cAMP/Protein Kinase A Dependent 
Increases in Cardiac Inotropy Through cAMP Dependent 
Phosphodiesterase Activation
Chris J. Gregg, Shubha Raju, Carlo Gabriele Tocchetti, Lili Barouch, Joshua M. Hare, 
Dan E. Berkowitz, Johns Hopkins University, Batlimore, MD
Background: Emerging evidence suggests that Phosphoinositide-3 Kinase (PI3K) may 
modulate cardiac inotropy, however the mechanism(s) underlying this phenomenon is not 
understood. We hypothesize that ß2 adrenergic receptor coupled PI3K constrains cAMP/
PKA dependent increases in cardiac inotropy through cAMP dependent, PDE Activation.
Methods: We tested the effect of PI3K inhibition on myocardial contractility by measuring 
simultaneous sarcomere shortening (SS) and intracellular Ca2+ transients in fura-2 loaded 
isolated mouse myocytes at 37°C using a spectroﬂuorimeter/ videodimension analyzer 
(Ionoptix Corp).
Results: PI3K inhibition with the speciﬁc reversible inhibitor LY294002 ([LY]=10µM) 
resulted in a marked increase in SS (2.21±0.12 fold increase over baseline, n=14, p<.0001) 
and Ca2+ transient (1.68±0.10 fold increase, n=12, p<.0001). This response could be 
washed out conﬁrming the reversibility of the inhibition. Since we hypothesized that PI3K 
modulates the catalytic activity of certain PDE isoforms and therefore the breakdown 
of adrenergic cAMP, we used the PDE3,4 inhibitor milrinone ([mil]=10µM) alone, and in 
combination with LY (5µM). Mil alone increased basal SS (1.35±0.08, n=13), however 
mil+LY showed no added or synergistic effect over LY alone (2.25±0.18 vs. 2.27±0.25, 
milLY vs. LY, n=13, ns). This supports the hypothesis that mil and LY act through the same 
pathway. To elucidate the roles of an adrenergic receptor in this basal regulation of PDE 
activity, we used the ß2 inverse agonist, ICI 118,551 (ICI) (100nM), to suppress the basal 
agonist independent coupling of this receptor to its Gsa and Gia machinery. The increase 
in contractility induced by PI3K inhibition ([LY]=10µM) was markedly suppressed in a time 
dependent manner, with the myocyte SS returning to baseline (2.07±.23 vs. 1.06±0.11, LY 
SS vs. LY-ICI SS over baseline, n=9, p<.001) after 5 min incubation.
Conclusion: These ﬁndings demonstrate that PI3K plays a pivotal role in the Gia coupled, 
basally active, regulation of sympathetically mediated myocardial contractility, through 
regulation of the catalytic activity of certain PDE isoforms, responsible for the breakdown 
of adrenergic cAMP.
5:15 p.m.
828-8 Generation of Cyclosporine A-Resistant 
Anticytomegalovirus-Speciﬁc Cytotoxic T Lymphocytes 
for Transplant Arteriopathy by Dual Gene Delivery Into 
T cells and Dendritic Cells by Adeno-Associated Virus 
Vectors
Yong Liu, Jawahar L. Mehta, Maurizio Chiriva-Internati, Paul L. Hermonat, University of 
Arkansas for Medical Sciences, Little Rock, AR
Background: Transplant patients (and other immunosuppressed persons) are at a very 
high risk for a variety of opportunistic infections, and most importantly fulminant transplant-
associated atherosclerosis. In normal persons cytotoxic T lymphocytes (CTL) clear viral 
infections by killing virally infected cells. Unfortunately these T cells are speciﬁcally 
affected by the immuno-suppressive drugs such as cyclosporin A (CsA) commonly used 
to prevent transplant rejection, and have reduced expression of IL-2 and IFN�, and limited 
ability to kill antigen-positive, HLA Class I-restricted target cells. 
Methods and Results: Our novel approach is directed at the generation of CsA-resistant, 
anti-CMV CTL. This can be done as CsA-resistant CTL are known to naturally arise and 
reject transplants. Here we show development of CsA-resistant, anti-CMV CTL by dual 
gene therapy of dendritic cells (DC) and T cells. We had hypothesized that a combination of: 
1) transferring the CSA-resistance and Th 1 response-promoting IL-2 cytokine gene into T 
cells by AAV vector and 2) transferring the CMV pp85 antigen gene into DC by AAV vector 
will result in a CSA-resistant anti-CMV CTL. Our preliminary data strongly shows that AAV/
pp89 gene delivery into dendritic cells did allow these DC to stimulate anti-pp89/antiCMV 
CTL, which were able to kill 38% of pp89+ target cells (human ﬁbroblasts made positive 
by AAV/pp89 infection) after only one stimulation. Killing was speciﬁc as non-pp89/CMV-
positive cells were not killed (eg. normal ﬁbroblasts, lung, breast, and liver cancer cells 
[5-8% killing]). Intracellular staining showed that 90% of the DC were positive for pp89. 
Furthermore AAV/IL-2 gene delivery into the pp89 stimulated CTL allowed these T cells to 
proliferate unimpeded in the presence of 1 µg/ml CsA as measured by 3H incorporation.
Conclusion: These data suggest that this dual antigen/IL-2 gene delivery strategy will 
be successful. Anti-CMV CTL can easily be generated and be made CsA resistant by the 
transduction of the IL-2 gene. The approach of dual antigen and cytokine gene delivery 
offers many possibilities as a novel approach for addressing transplant arteriopathy.
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829  Venous Thromboembolism and 
Pulmonary Hypertension
Monday, March 07, 2005, 4:00 p.m.-5:30 p.m.
Orange County Convention Center, Room 231A
4:00 p.m.
829-3 What Deﬁnition of Vasoreactivity to Inhaled Nitric Oxide 
Best Predicts Mortality Risk in Patients With Pulmonary 
Hypertension?
Richard A. Krasuski, Brad Smith, Andrew Wang, J. Kevin Harrison, Michelle Johnson, 
Cynthia Pierce, Victor F. Tapson, Thomas M. Bashore, Wilford Hall Medical Center, San 
Antonio, TX, Duke University Medical Center, Durham, NC
Background: The presence of reactive pulmonary vasculature is associated with an 
improved prognosis in patients with pulmonary hypertension (PH), and vasodilator testing 
has evolved into an important diagnostic tool. Unfortunately the impact is limited by the 
numerous deﬁnitions of positive vasodilator response currently in use. The ideal deﬁnition 
should provide the widest discrepancy in clinical outcomes between responders and 
nonresponders in the modern therapeutic era.
Methods: We prospectively followed a cohort of 93 patients with PH referred for 
pulmonary vasodilator testing with inhaled nitric oxide at 40 ppm. Complete clinical follow-
up was achieved in 99% of patients.
Results: Baseline characteristics of the cohort included age 54 ± 14 years, 80% 
women, 56% with primary PH, NYHA function class 2.9 ± 0.7, mean right atrial pressure 
11 ± 6 mm Hg, pulmonary artery (PA) systolic pressure 73 ± 24 mm Hg, and arterial 
O2 saturation 90 ± 6%. Long-term therapies included epoprostinol 34%, treprostinol 
7%, bosentan 17%, calcium channel blockers 37%, and warfarin 57%; and these were 
evenly distributed throughout the cohort. Over a median follow-up of 39.5 months, there 
were 33 deaths (35%). The differential in mortality rate was greatest when deﬁning a 
positive response as a ≥30% drop in mean PA pressure and a concomitant ≥30% drop 
in pulmonary vascular resistance (PVR); responders had a mortality rate of 6%, 1/7th the 
rate of nonresponders (42%). Mortalities for responders and nonresponders (in narrowing 
degrees of discrepancy) were 10% and 42% for a ≥30% drop in PA pressure alone, 29% 
and 48% for either a ≥20% drop in PA pressure or a ≥20% drop in PVR, 29% and 45% for 
a ≥20% drop in PVR, 28% and 43% for either a ≥30% drop in PA pressure or a ≥30% drop 
in PVR, 29% and 40% for a ≥20% drop in PA pressure, 29% and 39% for a ≥20% drop in 
PA pressure and a ≥20% drop in PVR, and 30% and 40% for a ≥30% drop in PVR.
Conclusions: Patients with PH who experience a ≥30% drop in PA pressure concomitant 
with ≥30% drop in PVR to iNO have approximately 1/7th the mortality of patients who 
do not. The “30/30 deﬁnition” of vasoreactivity appears to be an excellent manner of 
predicting long-term outcome in patients with PH.
4:15 p.m.
829-4 Decreased Arginine Bioavailability Contributes To The 
Pathogenesis Of Pulmonary Arterial Hypertension
Claudia R. Morris, Carla Teehankee, Gregory Kato, Jennifer Gardner, Dana McGlothlin, 
Mary Malloy, Teresa DeMarco, Children’s Hospital and Research Center at Oakland, 
Oakland, CA, University of California, San Francisco, San Francisco, CA
Background: L-Arginine (Arg), the substrate for nitric oxide (NO) production, is deﬁcient 
in sickle cell disease patients with pulmonary hypertension (PH), while arginase, an 
enzyme that converts Arg to ornithine (Orn) and urea is elevated. Arginase limits NO 
bioavailability through increased utilization of Arg. Since Arg and Orn compete for the 
same cellular uptake transport system, a decrease in the Arg-to-Orn ratio could also 
impair Arg bioavailability for NO production. The Arg-to-Orn ratio is a biomarker of 
arginase activity that correlates with the severity of PH in sickle cell disease.
Methods: We investigated alterations in amino acid metabolism occurring in pulmonary 
artery hypertension (PAH) that could be impacted by elevated arginase activity. Plasma 
amino acids were determined in normal controls and patients with primary PH or PAH 
associated with scleroderma or systemic lupus erythematosis.
Results: Plasma Arg levels were low, Orn levels were high, and the Arg-to-Orn ratio 
was low in PAH. Consistent with a shift in Arg metabolism away from NO production 
and towards the ornithine-dependent pathways, both glutamic acid and proline levels 
were also elevated in PAH. Proline plays a role in collagen deposition and vascular 
smooth muscle proliferation, and is thus likely to contribute to the pathogenesis of 
PAH. Citrulline levels were high in PAH. Since Arg is produced from citrulline in the 
kidneys, renal dysfunction may also contribute to decreased Arg bioavailability. The 
Arg/[Orn+Citrulline] ratio correlated with mean pulmonary artery pressure measured on 
cardiac catheterization (r=-0.68, p<0.01), and likely incorporates the impact of arginase 
activity and renal impairment.
Conclusions: Decreased Arg bioavailability and a shift of metabolism towards ornithine-
dependent pathways are novel mechanisms that play a role in PAH. Therapies that 
maximize Arg and NO bioavailability might be promising for the treatment of PAH.
Variable: Control (n=36) Vs. PAH (n=20) 
Arginine 67±18 Vs. 50±15, p<0.01
Ornithine 62±22 Vs. 102±30, p<0.001
Arg/Orn ratio 1.1±0.5 Vs. 0.6±0.4, p<0.001
Glutamic acid 38±15 Vs. 127±75, p<0.001
Proline 161±48 Vs. 202±65, p<0.01
Citrulline 25±11 Vs. 38±14, p<0.001
4:30 p.m.
829-5 High Mortality After Discharge Among Patients 
with High Risk for Developing Heparin-Induced 
Thrombocytopenia or Thrombosis: 6-Month Follow-up 
Results of the Complications after Thrombocytopenia 
Caused by Heparin (CATCH) Registry
E. Magnus Ohman, Charles S. Abrams, Emily F. Honeycutt, Richard C. Becker, Eric M. 
Crespo, Kevin J. Anstrom, David J. Moliterno, Lawrence Rice, Jo E. Rodgers, Steven R. 
Steinhubl, Christopher B. Granger, University of North Carolina at Chapel Hill, Chapel 
Hill, NC, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background. Patients suspected of having or being at high risk for developing heparin-
induced thrombocytopenia (HIT) have a high risk of morbidity or mortality. We explored the 
long-term consequences for pts at high risk for developing HIT. Methods. We performed a 
multicenter registry among 50 hospitals analyzing 3 strata of pts with, or at high risk for, HIT: 
pts receiving heparin >96 hours (n=2439), pts treated with heparin in whom thrombocytopenia 
develops (platelet count <150,000 or >50% drop) in the CCU (n=1132), or pts who had 
serological tests for HIT (n=486). Follow-up was carried out at 6 months by telephone and 
veriﬁcation of medical records. Current follow-up data have been obtained for 1912 pts. 
Results. Six-month outcomes were available in 53% (1912/3616) of the pts. The median 
(25th,75th percentile) age of the follow-up population was 66 (56,76) years, 44% were 
female, and 22% were non-white (15% black and 3% Hispanic). Median number of days 
from discharge to death was 70 (25,130). In-hospital and 6-month outcomes are shown 
in the Table. Six-month mortality was high across all strata ranging from 13.4% in the 
prolonged heparin pts to 20.6% in serological testing pts. Rehospitalization rates were 
similar across the 3 strata with an overall rate of 38.8%. 
Conclusions. The majority of deaths occur after discharge among pts suspected of 
having, or at high risk for developing, HIT. New therapeutic strategies need to be developed 
to enhance the outcomes among this high-risk and resource-intensive group.
Heparin >96 h
N=1481
Thrombocytopenia 
in CCU
N=477
Serological 
HIT test
N=226
Cumulative mortality (%) 13.4 16.2 20.6
Mortality after discharge (%) 11.3 10.9 17.0
Cardiac cause of death (%) 27.9 50.0 50.0
Non-cardiac death (%) 50.8 33.9 33.3
Rehospitalization (%) 39.8 35.1 37.0
Stroke (%) 0.9 1.5 1.1
DVT (%) 1.6 0.7 1.1
Pulmonary emboli (%) 1.2 0.5 1.1
Limb amputation (%) 1.7 0.7 1.7
4:45 p.m.
829-6 Reproductive Factors and the Development of Venous 
Thromboembolism
Christiana Iyasere, Michelle A. Albert, Paul M. Ridker, Robert J. Glynn, Brigham and 
Women’s Hospital/Harvard Medical School, Boston, MA
Methods and Results: We examined the relationship between incident VTE and self-
reported age of menarche, age of menopause, length of menses, and parity among 
19,219 postmenopausal women participating in the Women’s Health Study (WHS) over 
ten years of follow-up. Compared to those participants who were in the highest category 
for age of menarche (age > 15), those in the lowest category (age < 10 years) were 
more likely to be heavy, hypertensive and diabetic (all p trend < 0.001). Increasing parity 
and duration of menses were both associated with greater body mass index, increased 
likelihood of hypertension and diabetes (each p trend < 0.001). Overall, 107 participants 
(0.6%) developed unprovoked VTE. In four increasing categories of age of menarche, 
we observed no signiﬁcant difference in the development of VTE across groups after 
adjustment for potential confounders including age, body mass index, oral contraceptive 
use, hormone replacement therapy, history of hypertension, diabetic status, smoking 
status, and frequency of exercise (group 1: age < 10: hazard ratio (HR) = 1.00 group 2: 
ages 11-12: HR = 2.77, group 3: ages 13-14: HR = 2.38; age > 15: HR= 1.99; p trend = 
0.91). A similar relationship between incident VTE and increasing categories of age of 
menopause was observed (group 1: age 35-39 years: HR= 1.00; group 2: ages 40-44: HR 
=0.76, group 3: ages 45-49: HR= 1.02, group 4: age 50-54: HR=0.91, group 5: age 55+ 
HR= 1.06; p trend = 0.77). Additionally, there were no signiﬁcant relationships between 
duration of menses (p trend = 0.21) or parity (p trend = 0.18) and incident VTE.
Conclusion: There were no signiﬁcant relationships between incident VTE and age of 
menarche, age of menopause, duration of menses or parity.
5:00 p.m.
829-7 Reduction in Mortality in Patients With Acute 
Pulmonary Embolism and Right Ventricular Dilatation 
by Pulmonary Embolectomy Compared With 
Thrombolytic Therapy Plus Intravenous Heparin
Wilbert S. Aronow, Rishi Sukhija, Jooyun Lee, John A. McClung, James A. Levy, Robert 
N. Belkin, New York Medical College, Valhalla, NY
Background: Right ventricular (RV) dilatation has been associated with increased 
hospital mortality in patients with acute pulmonary embolism (PE).
Methods: We investigated in 104 women and 86 men, mean age 58 years, with acute 
PE diagnosed by contrast-enhanced spiral computed tomographic scanning in-hospital 
mortality in 64 patients with RV dilatation diagnosed by 2-dimensional echocardiography 
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and in 126 patients without RV dilatation. The 126 patients without RV dilatation were 
hemodynamically stable and were treated with intravenous heparin. Of the 64 patients 
with RV dilatation, 18 (28%) were hemodynamically unstable, and these 18 patients 
underwent pulmonary embolectomy. Of the other 46 patients with RV dilatation, 6 (13%) 
were treated with thrombolytic therapy plus intravenous heparin, and 40 patients (87%) 
were treated with intravenous heparin.
Results: Twenty-one of 64 patients with acute PE and RV dilatation (33%) and 6 of 126 
patients with acute PE and no RV dilatation (5%) died during hospitalization (p<0.001). Of 
the 64 patients with acute PE and RV dilatation , in-hospital mortality occurred in 2 of 18 
hemodynamically unstable patients (11%) treated with pulmonary embolectomy, in 2 of 6 
hemodynamically stable patients (33%) treated with thrombolytic therapy plus intravenous 
heparin, and in 17 of 40 hemodynamically stable patients (43%) treated with intravenous 
heparin (p<0.025 comparing pulmonary embolectomy with no pulmonary embolectomy).
Conclusion: In-hospital mortality is signiﬁcantly increased in patients with acute PE if RV 
dilatation is present (p<0.001). In patients with acute PE and RV dilatation, compared 
to treatment with heparin with or without thrombolytic therapy, pulmonary embolectomy 
signiﬁcantly reduced in-hospital mortality (p<0.025).
5:15 p.m.
829-8 Development of the First Spontaneously Beating Vein
Wangde Dai, Sharon L. Hale, Robert A. Kloner, The Heart Institute, Good Samaritan 
Hospital, Los Angeles, CA
Purpose: Venous thrombosus, vein graft thrombosus, pulmonary embolism, and venous 
insufﬁciency remain major causes of morbidity and mortality. While anticoagulant 
therapies exist there have been no therapies to directly treat venous stasis. The purpose 
of this study was to determine whether it is feasible to develop a vein that rhythmically 
beats by implanting immature cardiomyocytes in its wall.
Methods and Results: Female Fisher rats were anesthetized and the inferior vena cava 
exposed just below the renal veins. Five million neonatal cardiomyocytes isolated from 2 
day old neonatal Fisher rats were puriﬁed and injected with a 28 gauge needle into the 
wall of the inferior vena cava to form a cuff about 5 mm in length around the circumference 
of the vessel (n=6). Six rats received injection of culture media only as a control. Rats 
then were allowed to recover for three weeks at which time they were reanesthetized. 
The abdominal cavity was exposed and videotaped. Distinct rhythmic beating of the vena 
cava at the site of cell injection (at a rate lower than aortic beating) was observed in 6 of 
6 in neonatal cardiomyocytes treated rats but 0 of 6 animals receiving media. The vena 
cava continued to beat spontaneously and rhythmically after the aortas were clamped and 
after the heart was excised. The beating was manifest by visual contraction and relaxation 
of the vessel wall. The spontaneous beating rate was 101 ± 7 beats per minute at 1~3 
minutes after excision of the heart. Hematoxylin and eosin staining showed viable grafts 
in the wall of the vena cava in 6/6 vena cava implanted with neonatal cardiac cells; but in 
0/6 vena cava receiving medium. Neonatal cardiomyocytes in the graft matured with cross 
strations and developed a high degree of vascularization.
Conclusions: The present study for the ﬁrst time demonstrates that neonatal 
cardiomyocytes survive, mature, and function in the wall of a vein and can spontaneously 
and rhythmically contract a vein. The pulsatile vein has the potential to limit venous stasis 
and its deleterious consequences.
ORAL CONTRIBUTIONS
831FO  Featured Oral Session...Pros and Cons 
of Aggressive Lipid Lowering Therapy
Tuesday, March 08, 2005, 8:30 a.m.-10:00 a.m.
Orange County Convention Center, Hall E2A
8:45 a.m.
831-4 Validating the New NCEP III LDL Target of <70mg/dl 
Among Elderly Patients:an Analysis From PROVE IT-
TIMI 22
Kausik K. Ray, Richard Bach, Christopher P. Cannon, Ajay J. Kirtane, Richard Cairns, 
Sabina Murphy, Carolyn Hoss McCabe, Eugene Braunwald, C. Michael Gibson, Brigham 
and Women’s Hospital, Boston, MA, Harvard Medical School, Boston, MA
Background: Elderly patients are at high risk of cardiovascular events and show beneﬁt 
from statin therapy (PROSPER study). It is however unclear whether elderly patients will 
beneﬁt from the new NCEP III LDL guidelines.
Methods: In PROVE IT-TIMI 22, 3784 patients free from death, myocardial infarction (MI) 
or unstable angina (UA) at 30 days were evaluated. LDL was measured at 30 days as per 
the study protocol. The beneﬁts of on treatment LDL<70mg/dl (NCEP III) at 30 days were 
compared in patients <70 years (n=3150) and = 70 years (n=634) on the subsequent 
combined clinical endpoints of death, (MI), UA requiring hospitalization.
Results: Overall analyses from PROVE IT-TIMI 22 suggest that patients = 70 years 
randomized to intensive statin therapy may derive clinical beneﬁt (reduction in death, MI 
or unstable angina) HR 0.8 (CI 0.58,1.11), similar to those seen in patients <70 years, 
HR 0.79 (CI 0.65,0.97). In patients = 70 years, an achieved on treatment LDL of <70mg/dl 
at 30 days after an ACS was associated with an 8% absolute risk reduction (13.5% vs 
21.5%), compared with patients who failed to achieve this target (HR 0.60, CI 0.41, 0.87 
p=0.008). In patients <70 y age the comparable absolute risk reduction was 2.3% (8.1% 
vs 10.4%) in those who achieved an LDL <70mg/dl (HR 0.74 CI 0.59, 0.94 p=0.01).
Conclusions:The NCEP III LDL target of <70mg/dl, is applicable to older patients with 
ACS >70 years of age who may show increased beneﬁt from these LDL targets.
9:00 a.m.
831-5 Risk of Muscular Symptoms With High Dosage Statin 
Therapy in 7,924 Hyperlipidemic Patients in French 
Clinical Practice
Eric Bruckert, Gilles Hayem, Sylvie Dejager, Caroline Yau, Hôpital de La Pitié-
Salpétrière, Assistance Publique-Hôpitaux de Paris, Paris, France, Novartis Pharma SA, 
Rueil Malmaison, France
Background: Mild to moderate muscular symptoms associated with HMG-CoA 
reductase inhibitor (statin) therapy may have important clinical consequences, as patients 
who experience adverse effects are more likely to discontinue statin therapy. However, the 
potential causes and impact of these symptoms are poorly understood.
Methods: The Prédiction du Risque Musculaire en Observationnel (PRIMO) study 
was a countrywide observational study of the risk, presentation and impact of muscular 
symptoms in a large, unselected population of 7924 hyperlipidemic men and women 
(aged 18-75 years) receiving high dosage statin therapy in a usual care, outpatient setting 
in France. Eligible patients were receiving high dosage statin treatment for at least 3 
months prior to the study, or had stopped high dosage statin therapy due to muscular 
side effects during the same period. Patient demographic data, treatment history and 
speciﬁc information on muscular symptoms were obtained by questionnaire. Odds ratios 
for muscular symptoms were calculated for individual statins, and comparison between 
groups was carried out using Pearson’s Chi-square test.
Results: Overall, muscular symptoms were reported by 832 patients (10.5%). Muscular 
pain was reported as continuous by 210 (25%) of these patients, and 324 (39%) had used 
analgesics for relief of muscular symptoms. Moreover, 315 patients (38%) reported that 
their muscular symptoms prevented even moderate exertion during everyday activities, 
while 31 patients (4%) were either conﬁned to bed or unable to work due to muscular pain. 
Treatment with ﬂuvastatin 80 mg/day was associated with the lowest rate of muscular 
symptoms (5.1%) among individual statins. A signiﬁcantly higher (P<0.001) rate of 
muscular symptoms was observed in patients receiving pravastatin 40 mg/day (10.9%), 
atorvastatin 40-80 mg/day (14.9%) or simvastatin 40-80 mg/day (18.2%).
Conclusion: Mild to moderate muscular symptoms in patients receiving statin therapy 
may be more common, and exert a greater impact on patients’ everyday lives, than was 
previously thought. The risk of muscular symptoms with high dosage ﬂuvastatin treatment 
may be lower than with high dosages of other statins.
9:15 a.m.
831-6 Endothelial Function, Low-Density Lipoprotein 
Cholesterol, and Moderate and Intensive Cholesterol 
Lowering in Coronary Artery Disease: A REVERSAL 
Trial Substudy
Robert A. Vogel, Steven E. Nissen, Robert J. Weiss, University of Maryland School of 
Medicine, Baltimore, MD, Cleveland Clinic Foundation, Cleveland, OH
BACKGROUND: Endothelial dysfunction is thought to contribute to the development and 
clinical expression of coronary artery disease (CAD). Although elevated LDL cholesterol 
is associated with endothelial dysfunction in healthy individuals, the speciﬁc relationship 
between these parameters in patients with CAD is uncertain.
METHODS: As part of a study comparing the effect of atorvastatin 80 mg and pravastatin 
40 mg on the progression of coronary atherosclerosis in 654 subjects, 214 subjects at 21 
study sites had brachial artery ﬂow-mediated dilation (FMD) and nitroglycerin-mediated 
dilation (NTGD) assessed using high-resolution ultrasound before and 3 months after 
randomization to the two study drugs.
RESULTS: Pretreatment FMD correlated directly (P=0.015) with baseline LDL 
cholesterol, i.e. a lower LDL cholesterol was associated with worse endothelial function. 
This association was not explained by differences in other risk factors. Atorvastatin 80 
mg and pravastatin 40 mg respectively increased median FMD from 5.6 + 4.8% to 10.3 
+ 5.2% (84%) and from 6.6 + 4.3 to 8.7 + 6.5% (32%) (both P<0.0001). At 3 months, 
FMD trended towards a difference (P=0.13) between the two treatment groups. Overall, 
the improvement in FMD correlated signiﬁcantly with the magnitude of LDL cholesterol 
lowering (P=0.022). Neither treatment was associated with a change in NTGD.
CONCLUSIONS: Endothelial function is more impaired at lower LDL cholesterol levels in 
subjects with CAD, a ﬁnding that may explain the presence of CAD in patients with low 
LDL cholesterol. Both atorvastatin 80 mg and pravastatin 40 mg improve FMD in CAD 
subjects, with a trend toward more improvement with atorvastatin 80 mg. Overall, more LDL 
cholesterol lowering is associated with a greater improvement in endothelial function.
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831-7 Elevations in Creatine Kinase (CK) with Intensive Statin 
Treatment: a PROVE IT - TIMI 22 Substudy
Stephen D. Wiviott, Christopher P. Cannon, David A. Morrow, Benjamin Scirica, Carolyn 
H. McCabe, Eugene Braunwald, Brigham and Women’s Hospital, Boston, MA
Background: Intensive lipid lowering therapy reduces clinical events following ACS. High 
dose statins have been associated with severe muscle side effects including rhabdomyolysis. 
We examined the extent, and timing of CK elevation in PROVE IT - TIMI 22.
Methods: The study compared intensive (atorva 80 mg) v standard (prava 40 mg) statin 
therapy following ACS. CK was measured centrally at 30 d, 4, 8, 16 months and at study 
end (up to 28 months), or with muscle symptoms. Any CK > 10 x the upper limit of normal 
(ULN) was repeated in 1 week. For repeat CK > 10 x ULN study drug was stopped.
Results: Elevations greater than 3X ULN were infrequent; (23 (1.0%) on prava, 32 (1.5%) 
on atorva, P=NS). Prespeciﬁed cutoffs are shown in the table. Features associated with 
elevated CK include male gender, non-white race, and elevated baseline CK. Most ﬁrst 
time CK elevations were seen by 8 months, but new cases (17.2 % of 1st elevations with 
atorva, and 28.6% of 1st elevations with prava were after 16 months). Among subjects 
with CK > 3X ULN, 3 (0.15%) on atorva and 2 (0.1%) on prava discontinued study drug for 
CK elevation. No cases of rhabdomyolysis (CK > 10,000) were seen.
Conclusions: CK elevations > 3X ULN were infrequent in both standard and intensive 
therapy arms. A strategy of monitoring and down-titration/ discontinuation for persistent 
elevations resulted in no episodes of rhabdomyolysis. These data suggest that intensive 
lipid therapy can be given safely without major muscle related complications when 
monitored appropriately. 
CK Value X ULN
Pravastatin
N=2054
n (%)
Atorvastatin
N=2086
n (%)
P-Value
>1.5 X 164 (8) 193 (9) NS
3-5 X 13 (0.6) 22 (1.1%) NS
5-9 X 5 (0.2) 7 (0.3%) NS
>9 X 5 (0.2) 3 (0.1) NS
9:45 a.m.
831-8 Myotoxic Reactions to Lipid Lowering Therapies Are 
Mediated by Impaired Oxidation of Fats
Paul S. Phillips, Theodore Ciaraldi, Kim Dong-Lim, Keith Anthony Somma, Henry R. 
Robert, Scripps Mercy Hospital, San Diego, CA, Veterans Affairs San Diego Health Care 
System, La Jolla, CA
Background: Concern about muscle toxicity is a major reason that statin therapy is 
prescribed for less than half of patients indicated. Little is known about the mechanism 
of statin muscle toxicity. Clinical, physiological and pathological evidence suggests 
a possible defect in fatty acid oxidation. In order to test the hypothesis that fatty acid 
oxidation is adversely affected by statins in patients suffering statin myopathy (SAM), 
we performed fatty acid oxidation studies on myocyte cultures of patients with known 
intolerance of statins and compared them to control myocyte cultures. 
Methods: 11 patients with SAM and an abnormal fasting respiratory exchange ratio 
(RER) > 0.81 and 8 controls with no history of intolerance of lipid lowering theapies 
underwent quadriceps muscle biopsy. Myocytes were cultured by standard techniques 
and fatty acid oxidation studies were performed using [9,10-3H] palmitic acid (PALM) once 
the cells were fused. Fatty acid oxidation of both SAM and Control cells was measured 
with and without exposure to 20 µM lovastatin. 
Results: PALM oxidation with statin is expressed as a percent of the basal oxidation 
without statin exposure. Control myocytes’ PALM oxidation increased signiﬁcantly 
(257 ± 106%) with statin while SAM myocytes oxidation was unchanged (123 ± 84%), 
(p=0.008).
Conclusions: SAM cultured myocytes express different fat oxidation responses to 
statin than controls. Statin exposure doubles fatty acid oxidation in myocytes from control 
patients while no change occurs in SAM myocytes. This supports clinical ﬁndings that SAM 
patients have a defect in fatty acid oxidation that is exacerbated by statins. That cultured 
myocytes raised in normolipemic conditions demonstrate this abnormality argues for a 
genetic defect rather than a pharmocokinetic interaction to explain statin myotoxicity.
ORAL CONTRIBUTIONS
836  Genomics and Vascular Disease
Tuesday, March 08, 2005, 8:30 a.m.-10:00 a.m.
Orange County Convention Center, Room 230B
8:30 a.m.
836-3 Replicated Associations of Common Genetic Variants 
With Coronary Artery Disease And Myocardial Infarction 
From a 7,500 Gene Study
May M. Luke, James J. Devlin, Mary J. Malloy, Charles M. Rowland, Dongming M. Liu, 
Linda B. McAllister, June Cassano, Joseph J. Catanese, Diane U. Leong, Carmen H. 
Tong, Clive R. Pullinger, Bradley E. Aouizerat, Christian Zellner, John J. Sninsky, Eric 
J. Topol, John P. Kane, Stephen G. Ellis, Celera Diagnostics, Alameda, CA, Cleveland 
Clinic Foundation, Cleveland, OH
Background: Common genetic variants associated with high coronary artery disease 
(CAD) and myocardial infarction (MI) risks that are independent of traditional risk factors 
should be useful for risk prediction.
Methods: After evaluating angiographic stenosis severity in ten coronary artery segments, 
we determined the allele frequencies of 12,000 single nucleotide polymorphisms (SNPs) 
from 7,500 genes in pooled DNA (average 50 subjects) from cases with the most severe 
stenosis (n=782) and controls with no detectable stenosis and no history of MI (n=254, 
Cleveland Clinic). SNPs associated with CAD (p value < 0.05, OR > 1.3, and allele 
frequency > 2%) were analyzed in a second population of cases with the most severe 
(n=472) and controls with the least severe stenosis and without a history of MI (n=298, 
University of California San Francisco). The genotypes of the individual subjects were 
determined for SNPs with replicated CAD association (p value <0.05 and same risk allele 
in both studies).
Results: We previously reported CAD associations discovered using control groups 
that included subjects with mild as well as undetectable stenosis. The current analysis 
revealed additional SNPs with replicated CAD associations in genes encoding follistatin-
like 4 (FSTL4, Thr757Met) and centromere protein E (CENPE, Thr2088Met). These 
associations remained signiﬁcant after adjusting simultaneously for sex, age, smoking 
history, dyslipidemia, diabetes, and hypertension. The common FSTL4 allele (Thr) was 
the risk allele; carriers (92% of controls) had higher CAD risk (meta analysis adjusted 
OR=1.86, 95% CI 1.15-3.01). CENPE Met allele carriers (32% of controls) had higher 
risk than Thr allele homozygotes (meta analysis adjusted OR=1.49, 95% CI 1.15-1.93). 
Consistent with the notion that CAD contributes to MI, we found that carriers of these risk 
alleles also had increased risk of MI in these two populations (meta analysis OR=2.29, 
95% CI 1.39-3.76 for FSTL4 and OR=1.34, 95% CI 1.05-1.72 for CENPE).
Conclusion: Two prevalent genotypes were associated with 86% and 49% increases 
in CAD risk after adjusting for traditional risk factors. The same genotypes were also 
associated with 129% and 34% increases in MI risk.
8:45 a.m.
836-4 Replicated Association of a Purinergic Receptor Variant 
With Risk of Myocardial Infarction
Bradford A. Young, Lance A. Bare, Mary J. Malloy, Andre R. Arellano, Marc L. Short, May 
M. Luke, Charles M. Rowland, Olga A. Iakoubova, June Cassano, Bradley E. Aouizerat, 
Clive R. Pullinger, James J. Devlin, Stephen G. Ellis, John J. Sninsky, John P. Kane, 
Celera Diagnostics, Inc., Alameda, CA, University of California, San Francisco, San 
Francisco, CA
Background: Myocardial infarction (MI) is a complex disease promoted by both genetic 
and enviromental factors. A differential diagnosis that includes genetic markers associated 
with MI could improve both the prediction and prevention of MI.
Methods: Single nucleotide polymorphisms (SNPs) associated with MI were ﬁrst identiﬁed 
in two independent case control studies using Caucasian subjects from the University 
of California, San Francisco Genomic Resource (UCSF) and the Cleveland Clinic 
Foundation Heart Center (CCF). The allele frequencies of SNPs predicted to either alter 
mRNA transcription, stability or processing, or an amino acid residue were determined in 
pools of case and control DNA. We then made a multiplex panel of oligonucleotide ligation 
assays using the Luminex® 100TM system for a set of SNPs associated with MI in both 
studies (p-value <0.05). This panel of assays was then used to individually genotype the 
same samples used in the initial pooling studies, speciﬁcally: 780 cases and 975 controls 
from UCSF and 425 cases and 571 controls from CCF.
Results: One of the SNPs associated with MI in both sample sets causes an arginine 
to histidine substitution at position 232 in the purinergic receptor, P2X-Like 1 receptor. 
The carriers of the risk allele (~18% of the population) have an odds ratio for MI in the 
UCSF and CCF sample sets of 1.21 (95% CI 1.01-1.43) and 1.29 (95% CI 1.03-1.61), 
respectively.
Conclusion: We have identiﬁed a P2X-Like 1 receptor variant associated with MI. 
This receptor is expressed in vascular tissue and co-localizes with vascular endothelial 
cadherin at cell-cell adherens junctions. This ATP-dependent receptor belongs to a class 
of cation-selective ligand-gated channels expressed in vascular smooth muscle cells and 
involved in regulating vasoconstriction. Thus, this variant may affect coronary blood ﬂow. 
Identifying these types of genetic markers associated with complex diseases could lead 
to improved diagnostics and potentially to new therapeutic targets.
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9:00 a.m.
836-5 Quantitative Differences in the Expression of 
Inﬂammatory Genes in Coronary Atherosclerotic 
Plaques From Patients With Stable Angina Pectoris and 
Acute Coronary Syndromes
Marco L. Rossi, Nicola Marziliano, Piera Angelica Merlini, Eloisa Arbustini, Belli Guido, 
Patrizia Presbitero, Diego Ardissino, Istituto Clinico Humanitas, MILAN, Italy, Ospedale 
Maggiore, PARMA, Italy
Background. The underlying pathophysiology of unstable angina and myocardial 
infarction involves the abrupt thrombotic occlusion of an epicardial coronary artery due to 
spontaneous plaque rupture or ﬁssuring, and the exposure of highly thrombotic material. 
It has been proposed that inﬂammation might be the mechanism triggering both plaque 
rupture and thrombotic response.
Methods. We have performed transcriptional proﬁling with microarray and subsequently 
5’ nuclease assays in coronary plaques collected by means of therapeutic directional 
coronary atherectomy from 15 patients with stable angina (SA) and 15 with acute coronary 
syndromes without ST elevation (ACS). To clarify the source of mRNAs, we performed on 
the plaques in situ RT-PCR coupled with immunocytotochemistry.
Results. Analysis of the results conﬁrmed that the expression of pro-inﬂammatory genes 
was signiﬁcantly higher (p<0.001) in the plaques from the ACS patients, whereas the 
anti-inﬂammatory genes were more expressed (p<0.001) in the plaques from the SA 
patients. Furthermore, we found a substantial overlap between the above mRNAs and the 
monocyte cell type for both the inﬂammatory and anti-inﬂammatory pathways.
Conclusions. All of the pro-inﬂammatory genes were found to be more expressed in 
plaques from patients with acute coronary syndromes without ST elevation (ACS), 
whereas the anti-inﬂammatory genes were signiﬁcantly over-expressed in plaques from 
patients with stable angina (SA).The results of this study conﬁrm the existence of different 
inﬂammatory response/activation pathways between ACS and SA atherosclerotic plaques, 
and encourage the use of high-throughput gene proﬁling techniques in order to obtain 
data that may become clinically relevant to asses more focused pharmacotherapies.
9:15 a.m.
836-6 Gene Expression Proﬁle in Circulating Leukocytes 
Identiﬁes Patients With Coronary Artery Disease
Peter R. Sinnaeve, Mark Donahue, Peter Grass, Jacky Vonderscher, David Seo, Pascal 
Goldschmidt, Christopher B. Granger, Duke University, Durham, NC, University of 
Leuven, Leuven, Belgium
Introduction. Inﬂammation plays a prominent pathogenetic role in atherosclerotic 
coronary artery disease (CAD), but the relationship bewteen phenotypic changes in 
circulating leukocytes and CAD remains unclear. We have investigated whether gene 
expression patterns in circulating leukocytes are associated with the extent of CAD. 
Methods. Patients undergoing coronary angiography were selected according to 
their Duke CAD index (CADi), an angiographical measure of the extent of coronary 
atherosclerosis that correlates with outcome. RNA was extracted from 110 patients with 
CAD and 112 matched controls without CAD. Gene expression was assessed using 
Affymetrix U133A chips. Genes correlating with CAD were identiﬁed using Spearman’s 
rank correlation, and predictive gene expression patterns were identiﬁed using a partial 
least squares (PLS) regression analysis. 
Results. 160 individual genes were found to signiﬁcantly correlate with CADi (rho>0.2, 
P<0.0027), although changes in individual gene expression were relatively small (1.2 to 
1.5 fold). Using these 160 genes, the PLS multivariate regression resulted in a highly 
predictive model (r2=0.764, P<0.001). Cross-validation showed that most of the predictive 
model was carried by only 8 genes (r2=0.752) (table 1). 
Conclusion. Simultaneous expression pattern of 8 genes appears to be highly predictive 
for CAD. Peripheral leukocyte gene expression pattern could be a novel non-invasive 
biomarker for CAD and lead to new pathophysiologic insights.
Table 1. 
Gene Fold Change P Value Rho
Ferritin light chain 1.2 0.008 0.24
FK506 binding protein 8 1.4 0.079 0.25
Tubulin alpha 1.2 0.020 0.28
Transport-secretion protein 2.2 1.5 0.019 0.24
UBX domain-containing 1 1.5 0.015 0.21
Hypothetical protein LOC51257 1.4 0.002 0.24
Inositol 1,3,4-triphosphate 5/6 kinase 1.3 0.002 0.30
PTEN induced putative kinase 1 1.5 0.001 0.22
 
 
 
 
9:30 a.m.
836-7 Pharmacogenetic Modulation Of Clopidogrel 
Antiplatelet Effects: Role of Gene Sequence Variations 
Of The CYP3A4 Enzyme
Dominick J. Angiolillo, Esther Bernardo, Celia Ramirez, Antonio Fernández-Ortiz, Manel 
Sabaté, Pilar Jimenez-Quevedo, Ugo Cavallari, Fernando Alfonso, Raul Moreno, Rosana 
Hernandez-Antolin, Javier Escaned, Camino Bañuelos, Elisabetta Trabetti, Marco A. 
Costa, Theodore A. Bass, Pier F. Pignatti, Carlos Macaya, The Cardiovascular Center-
Shands Jacksonville-University of Florida, Jacksonville, FL, San Carlos University 
Hospital, Madrid, Spain
Clopidogrel is activated by cytochrome P450 (CYP) 3A4, which activity contributes to 
variability of clopidogrel’s antiplatelet effects. Since metabolic activity of CYP3A4 is 
under genetic control, we assessed if gene sequence variations of CYP3A4 inﬂuences 
clopidogrel antiplatelet effects. 
Methods: The CYP3A4*1B, CYP3A4*3 and IVS10+12G>A polymorphisms of the 
CYP3A4 gene were assessed in 127 pts: 45 receiving a 300 mg clopidogrel loading-dose 
(Group A) and 82 on long-term (>1 month) clopidogrel (75 mg/d) treatment (Group B). 
All pts were on aspirin (100 mg/d). Patients were divided into 2 subgroups according to 
the presence or absence of the mutant allele. Activated GPIIb/IIIa (anti-Fibrinogen-FITC; 
expressed as % of positive platelets) was assessed by whole blood ﬂow cytometry in ADP 
(2 µM)-stimulated platelets at baseline, 4 and 24 hours after loading-dose (Group A) and 
following long-term treatment (Group B).
Results: Only the IVS10+12G>A polymorphism was sufﬁciently polymorphic (in Hardy-
Weinberg equilibrium). Carriers and non-carriers of the mutant allele of this polymorphism 
were present in 9/45 (20%) and 36/45 (80%) of Group A, and in 14/82 (17%) and 68/82 
(83%) of Group B. Carriers of the mutant allele had a greater inhibition of the GP IIb/IIIa 
receptor in groups A and B.
GP IIb/IIIA activation 
Non-carriers
(GG genotype)
Carriers
(AG and AA genotypes) p
Group A
Baseline 66.2±21 57.1±31 0.7
4 hours 53.4±29 31.5±24 0.06
24 hours 50.4±25 26.7±27 0.05
MANOVA (multivariate analysis of 
variance) 0.025
Group B 50.4±25 27.0±27 0.026
Conclusions: Gene sequence variations of CYP3A4 modulate clopidogrel antiplatelet 
effects in both the acute and chronic phases of treatment, which may contribute to 
individual variability of clopidogrel effects.
9:45 a.m.
836-8 Deﬁnition of the PON1 Haplotype Block Linked to 
Coronary Artery Disease in the Caucasian Population
Nicola Marziliano, Marco L. Rossi, Eloisa Arbustini, Piera Angelica Merlini, Maurizia 
Grasso, Emanuele Porcu, Patrizia Presbitero, Diego Ardissino, Ospedale San Matteo, 
PAVIA, Italy, Istituto Clinico Humanitas, MILAN, Italy
Background. Several authors have established that the PON1 polymorphisms show 
a strong relationship to coronary artery disease (CAD). Linkage disequilibrium (LD) 
is present between the mutation leu54 (L allele) and arg191 (B allele): highly active 
paraoxanase alleles are associated thus leading to increased risks of cardiovascular 
and coronary artery disease. Furthermore, the -108C/T polymorphism can account for 
the 22.8% of the observed variability in PON1 expression levels, which is much higher 
than that attributable to other PON1 polymorphisms. This study outline the evidence of a 
haplotype linked to the CAD in the PON 1 gene.
Methods and Results. We here report an association study in a southern Italy cohort 
population of seventy subjects who underwent coronary atherectomy and seventy control 
individuals. Genotypes were made by TaqMan and conventional sequencing. We could 
detect linkage disequilibrium between leu54 and arg191 (P=0.0003); also leu54 was in 
LD with the -108C polymorphism (P=0.0001) but, surprisingly, the serum levels either 
of cHDL and the paraoxanase were in line with the control population. Therefore, we 
carried out a detail sequencing analysis of the PON1 gene in the patients who showed 
one additional gene variation leading a Lys to Asn substitution in position 262 (C262G). 
This mutation has been analysed in the two populations and was present in the 8% of the 
healthy subjects and in the 80% of the patients. In vitro studies showed a 30% increased 
mRNA stability in cells transfected by C262G construct and also a 35% increased levels 
of transcription in PON1 wt and PON1 carrying the C262G constructs done by Real Time 
PCR (p<0.0001).
Conclusions. We characterised a novel mutation localised in the coding sequence 
leading to an increase of PON1 gene expression by increasing the transcription efﬁciency 
conferring to the carriers a protection effect to carotid artery disease. This novel mutation 
is in strong linkage disequilibrium with the leu54 and arg191 mutations, thus deﬁning and 
haplotype block in the studied population.
2005_10_VascularDiseaseHyper.indd   414 12/23/04   10:16:10 AM
JACC February 1, 2005 ABSTRACTS - Vascular Disease, Hypertension, and Prevention   415A 
Vascular D
isease, H
ypertension, and P
revention 
POSTER SESSION
1126  Vascular Function and 
Atherothromboembolism
Tuesday, March 08, 2005, 9:00 a.m.-12:30 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 9:00 a.m.-10:00 a.m.
1126-131 Endogenous Methylated Arginine Ratio Portends 
Coronary Atherosclerotic Risk In Patients Referred For 
Cardiac Catheterization.
Cyril Ruwende, Sunitha Yanamadala, Lou D’Alecy, Vineet Chopra, Jonathan D. Marmur, 
Erdal Cavusoglu, David J. Pinsky, University of Michigan, Ann Arbor, MI, SUNY - 
Downstate Medical Center, New York, NY
Background/Aims: Derangements of the nitric oxide synthase (NOS) pathway are 
believed to be a central mechanism of endothelial dysfunction leading to atherosclerosis. 
A key endogenous plasma inhibitor of NOS, asymmetric dimethyl arginine ADMA, is a 
by-product of the methylation of arginine residues by type I of the two endogenous protein 
arginine N-methyl transferases (PRMT-I and PRMT-II). Elevated ADMA levels have been 
reported in individuals with peripheral arterial disease but there is paucity of data on the 
effects of ADMA levels on the severity of coronary atherosclerosis. Moreover, the effect 
of symmetric dimethyl arginine (SDMA), another endogenous arginine metabolite which 
is the product of the other transferase (PRMT-II), does not inhibit NOS and its functions 
are largely unknown. We investigated the relationship between the relative levels of these 
methylated arginines with severity of coronary artery disease (CAD) in a cohort of 393 
individuals referred with a variety of indications for cardiac catheterization.
Methods: Demographic and clinical information was obtained and fasting plasma 
collected and stored at -70oC prior to angiography. The CAD score was determined using 
a standard angiographic scoring system.
Results: A statistically signiﬁcant correlation was found between the ADMA/SDMA ratio 
and the CAD score (r=0.3, p=0.018). CAD score did not correlate with ADMA and SDMA 
levels. In multivariate analysis, CAD score (p=0.0369), angiotensin converting enzyme 
inhibitor use (ACE-I)(p=0.0166) and chronic renal insufﬁciency (p=0.0003) were all 
signiﬁcantly predictive of the ADMA/SDMA ratio. 
Conclusions: These data suggest that it is not ADMA levels alone but rather the ADMA/
SDMA ratio, reﬂecting the relative plasma concentrations of the two by-products of PRMT-
I and II that correlates signiﬁcantly with the burden of coronary atherosclerosis. These 
data conﬁrm the prognostic importance of ACE-I and chronic renal insufﬁciency but more 
importantly, they identify the potential utility of the ADMA/SDMA ratio as a clinical tool for 
risk stratifying patients with suspected atherosclerotic disease.
1126-132 Assessment of Platelet Aggregation and Platelet 
Activation Over Time in Patients on Combined Aspirin 
and Clopidogrel Treatment
Esther Bernardo, Dominick J. Angiolillo, Celia Ramirez, Antonio Fernández-Ortiz, Manel 
Sabaté, Pilar Jimenez-Quevedo, Fernando Alfonso, Raul Moreno, Javier Escaned, 
Camino Bañuelos, Rosana Hernandez-Antolin, Marco A. Costa, Theodore A. Bass, 
Carlos Macaya, University of Florida. Shands-Jacksonville, Jacksonville, FL, Hospital 
Clinico San Carlos Madrid, Madrid, Spain
Background: Response to antiplatelet therapy is not homogeneous and low-responders 
to dual antiplatelet therapy have been described in the early phases of treatment. 
Aim of this study was to assess the response over time to sustained (>1 month) dual 
antiplatelet.
Methods: Three blood samples at one-month intervals were obtained from 53 pts with 
stable coronary artery disease treated with aspirin (100mg/d) plus clopidogrel (75mg/d). 
Platelet aggregation (light transmittance aggregometry in platelet rich plasma following 
6 and 20µM ADP stimuli) and platelet activation (GPIIb/IIIa activation by whole blood 
ﬂow cytometry following 2µM ADP stimuli using PAC-1 monoclonal and antiﬁbrinogen 
policlonal antibodies), were assessed. 
Results: All parameters of platelet reactivity assessed in the ﬁrst sample (S1) correlated 
with those in the second (S2) and third (S3) samples.
ADP 6µM ADP 20µM Antiﬁbrinogen PAC-1
S1 vs S2 r=0.56 (p<0.0001) r=0.46 (p<0.0001) r=0.41 (p=0.001) r=0.43 (p=0.001)
S1 vs S3 r=0.56 (p<0.0001) r=0.57 (p<0.0001) r=0.40 (p=0.003) r=0.58 (p<0.0001)
S2 vs S3 r=0.70 (p<0.0001) r=0.81 (p<0.0001) r=0.32 (p=0.03) r=0.47 (p=0.001)
Following stratiﬁcation into tertiles according to 20µM ADP-induced platelet aggregation 
in S1, 8/18 (44%) pts in the highest tertile (low-responders) remained in the highest tertile 
in both S2 and S3; 1/18 (6%) pts changed from the highest to the lowest tertile (high-
responders) in S2 or S3; 9/18 (50%) pts located variously in different tertiles in S2 and S3. 
Conclusion: Although antiplatelet effects are patient-speciﬁc over time and platelet 
reactivity is well predicted in most patients by one sample analysis, multiple assessments 
of platelet function better identify patients with a low response to dual antiplatelet 
treatment.
1126-133 Relationship of Novel Oxidative Stress Markers to 
Vascular Endothelial Function in Healthy Adults
Salman Ashfaq, Dean P. Jones, Paul Kolm, Steven D. Rhodes, Jerome L. Abramson, 
Viola Vaccarino, Umma Reddy, William S. Weintraub, David G. Harrison, Arshed A. 
Quyyumi, Emory Universiy School of Medicine, Atlanta, GA, University of Kansas-
School of Medicine, Wichita, KS
Background: Endothelial dysfunction precedes the development of atherosclerosis 
and independently predicts poor long term outcome. While vascular oxidative stress 
is considered an important cause of endothelial dysfunction, its measurement in vivo 
has been problematic. We hypothesized that determination of thiol redox and lipid 
hydroperoxides would provide a novel strategy for estimating vascular oxidant/antioxidant 
state, and thus be predictive of endothelial function in humans.
Methods: 124 healthy non smokers, aged 30 to 65 years, without known atherosclerosis 
had endothelial function determined using brachial artery ﬂow-mediated vasodilation 
(FMD). Plasma oxidative stress was estimated using: 1) Cysteine (Cys), an important 
extracellular anti-oxidant thiol, and its oxidized disulﬁde form (CySS). The redox state 
(Eh) of the Cys/CySS couple was also estimated using the Nernst equation. 2) Plasma 
hydroperoxides: estimated using the d-ROMs (Determination of Reactive Oxygen 
Metabolites) test that uses spectrophotometric techniques (Diacron International, Italy) 
to quantify lipid hydroperoxides.
Results: There was a correlation between FMD and Eh Cys/CySS, CySS and d-ROMs. 
Thus, oxidative stress measured by Eh Cys/CySS (-69.7±7 vs. -72.7±8 p=0.03), CySS 
(88±18 vs. 80±13 p=0.003) and d-ROMs (377±151 vs. 319±114 p=0.02) was signiﬁcantly 
higher in patients with abnormal endothelial function (<7% FMD) compared to those 
with normal endothelial function (>7% FMD), respectively. After multivariate analysis 
adjusting for age, sex, hypertension, diabetes, body mass index, triglycerides, HDL, and 
LDL-cholesterol, only d-ROMS (p=0.049) and Eh Cys/Cyss (p=0.04) were independent 
predictors of FMD.
Conclusions: The measurement of these novel plasma biomarkers of oxidative 
stress, that estimate either extracellular thiol redox potential (Eh Cys/CySS), or lipid 
hydroperoxides (d-ROMs), provides an index of vascular endothelial function in healthy 
humans. This study not only strengthens the association between oxidative stress and 
endothelial dysfunction in vivo, but provides a novel means of assessing endothelial 
function in humans.
1126-134 Viral Respiratory Tract Infections Increase Platelet 
Reactivity and Activation- An Explanation for Higher 
Rates of Myocardial Infarction and Stroke During Viral 
Illness
Rolf P. Kreutz, Kevin P. Bliden, Udaya Tantry, Paul A. Gurbel, Sinai Center for Thrombosis 
Research, Baltimore, MD
Background: Multiple epidemiologic studies have shown increased rates of myocardial 
infarction and stroke during or shortly after episodes of nonspeciﬁc upper respiratory 
tract infections. The cause of this relation remains unclear. We hypothesized that viral 
respiratory tract infections cause increased platelet reactivity and activation.
Methods: Previously healthy subjects with signs and symptoms consistent with viral upper 
respiratory tract infections were studied (n=16). There were no subjects on antiplatelet 
therapy. A group of 8 healthy subjects served as controls. Venous blood samples were 
obtained during the time of infection and again after 6 weeks. Platelet aggregation in 
response to ADP was determined by light transmittance aggregometry. Platelet activation 
was measured by P-selectin (CD62) expression on resting platelets with ﬂow cytometry.
Results: Platelet reactivity was higher during viral upper respiratory tract infection as 
measured by low dose ADP-induced aggregation. Greater platelet aggregation was 
observe at presentation (45 ± 7 %) vs. 26 ± 4 % after 6 weeks (p=0.017) and 22% ± 8 in 
the control group (p=0.009)). This represents a mean 97 % increase in aggregation after 
stimulation with ADP as compared to baseline.. P-selectin expression was also higher 
during times of viral infection (2.3% ± 0.2 of platelets CD62 positive vs. 1.7% ± 0.2 in the 
control group (p=0.047) and 1.8% ± 0.1 after recovery (p=0.017)) indicating an increase 
in platelet activation during illness.
Conclusions: Our study demonstrates that viral respiratory infections are associated with 
increased platelet reactivity and activation. These ﬁndings support a pro-aggregatory state 
that may contribute to the higher rates of myocardial infarction and stroke as evidenced by 
epidemiological data. Larger studies are necessary to conﬁrm our ﬁndings and address 
the role of antiplatelet therapy in patients at risk.
1126-135 Alterations in Endothelial Derived Free Radicals in 
Hypercholesterolaemic Patients following an HMG CoA 
Reductase Inhibitor
Sinead M. Hughes, Lana J. Dixon, Richard D. Plumb, Fiona O’Prey, Naglaa El-Sherbeeny, 
G. Dennis Johnston, Gary E. McVeigh, Queen’s University, Belfast, United Kingdom
Background: HMG CoA Reductase inhibitors (Statins) are known to lower LDL-
Cholesterol. Statins have been shown in animal/ human in vitro studies to have additional 
or Pleiotropic effects including inhibition of inﬂammation and reduction in isoprenylation 
(hence membrane association) of the GTPase proteins Rac and Rho.The relevance of 
these in humans is challenged. We have studied the effects of statins on endothelial 
function in patients and also examined biochemistry thought to be mechanistically linked. 
We have employed platelets as a model of endothelial cells (ECs) as the former contain 
endothelial Nitric Oxide Synthase as a source of Nitric Oxide(NO)and NADPH Oxidases 
as the main source of Superoxide.
Methods: 40 patients with hypercholesterolaemia (total cholesterol>6.5mmol/L) and 20 
healthy controls were recruited. The patients were randomised in a double-blind manner 
to receive either Atorvastatin 10mg (increased to 20 mg after 4 weeks) or matched 
placebo for 8 weeks.
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NO was detected in platelet samples via a NO-speciﬁc probe. Nitrite, a stable product of 
NO, was also quantiﬁed. Superoxide was detected in platelet samples via a lucigenin-
chemilluminescence technique. Western blotting analysis was used to quantify membrane 
and cytosolic concentrations of Rac and Rho post-statin.
Results: Platelet NO increased from 0.4 to 1.1 nmol/108 platelets (p<0.05) in those on a 
statin and Platelet Nitrite also increase from 98.2 to 148 nmol/108 platelets (p<0.05) post 
statin. Platelet Superoxide was decreased post statin from 6.84 to 2.98 nmol/108 platelets 
(p<0.05). Serum total cholesterol was reduced as expected following the drug from 7.3 to 
4.85mmol/L. We detected a signiﬁcant reduction in Rac and Rho which was membrane 
associated post drug
Conclusions: This study shows improvements in the balance between NO and 
Superoxide post statin in patients taking clinically relevant doses of a commonly 
prescribed agent.Whilst cholesterol was reduced in this study we feel that this can not 
totally explain changes in biochemical mediators of endothelial function nor alterations in 
subcellular localisation of measured proteins.
1126-136 Inhibition of Platelet Aggregation With Prasugrel (CS-
747, LY640315), a Novel Thienopyridine P2Y12 Receptor 
Antagonist, Compared With Clopidogrel in Aspirin-
Treated Patients With Atherosclerotic Vascular Disease
Lars Wallentin, Tomas Jernberg, Phillip T. Leese, Lars Goran Nilsson, Christopher D. 
Payne, Christelle Darstein, John T. Brandt, Joseph A. Jakubowski, Kenneth J. Winters, 
Agneta Siegbahn, Uppsala Clinical Research Center, University Hospital, Uppsala, 
Sweden, Eli Lilly and Company, Indianapolis, IN
Background: Prasugrel (CS-747, LY640315), a new P2Y12 antagonist, achieves more 
potent inhibition of platelet aggregation (IPA) vs. clopidogrel in preclinical studies. This 
phase 1b study investigated the level of IPA and safety of prasugrel dose ranging compared 
with clopidogrel in aspirin-treated subjects with atherosclerotic vascular disease, primarily 
stable coronary artery disease.
Methods: After a 7-day run-in on 325 mg aspirin, 101 subjects were randomly assigned 
to one of ﬁve oral dosing regimens; a day 1 loading dose (LD) and a maintenance dose 
(MD) on days 2-28: 1) CS-747 40 mg LD/5 mg MD, 2) CS-747 40 mg LD/7.5 mg MD, 3) 
CS-747 60 mg LD/10 mg MD, 4) CS-747 60 mg LD/15 mg MD, and 5) clopidogrel 300 
mg LD/75 mg MD. IPA to 20 µM ADP was measured by turbidometric aggregometry on 
day 1 and day 28 (at pre-dose and at 2, 4, and 6 h post-dose) and between days 7-14 
(twice, post-dose).
Results: At 2-6 h the 40 mg and the 60 mg LD of prasugrel both generated signiﬁcantly 
higher mean IPA than the 300 mg LD of clopidogrel (p<0.05). The prasugrel MD regimens 
achieved stable and dose-proportional increases in IPA with signiﬁcantly greater mean 
IPA for 7.5, 10, and 15 mg vs. 75 mg clopidogrel MD (p<0.05). Bleeding times were not 
different. However, there was more bruising and minor bleeding with the 15 mg MD of 
prasugrel.
Conclusion: In aspirin-treated subjects with atherosclerotic disease, prasugrel (40-60 
mg LD and 7.5-10 mg MD) provides higher IPA with comparable safety vs. the standard 
300 mg LD and 75 mg MD regimen of clopidogrel. 
1126-137 Relationship Between the -374T/A RAGE Gene 
Polymorphism and Angiographic Coronary Artery 
Disease.
Colomba Falcone, Enzo Emanuele, Paola Buzzi, Ilaria Campo, Michele Zorzetto, Ilaria 
Sbarsi, Mariaclara Cuccia, IRCCS San Matteo Hospital, Pavia, Italy, University of Pavia, 
Pavia, Italy
Background: The receptor for advanced gycation end products (RAGE) is thought to play 
a critical role in diabetic atherosclerosis. Accordingly, a functional -374T/A polymorphism 
in RAGE gene promoter has been associated with macrovascular complications in type 1 
diabetic patients. However, the extent to which this common variant inﬂuences the risk of 
coronary artery disease (CAD) in the general population remains to be determined.
Methods: We genotyped the -374T/A RAGE polymorphism in 259 non-diabetic individuals, 
of whom 175 had angiographically documented CAD and 84 had normal coronary 
angiography.
Results: Homozygosity for the -374A allele was found in 9.7% of the CAD patients 
versus 22.6% of the CAD-free subjects (p=0.005), and the -374A allele frequencies of the 
two populations were respectively 34.6% versus 44.6% (p=0.026). By means of a multiple 
logistic regression analysis, the AA genotype of the -372T/A polymorphism was shown to 
be independently associated with a reduced risk of CAD (adjusted odds ratio 0.33, 95% 
CI 0.15-.073; p=0.006).
Conclusions: Our observations suggest that the -374T/A polymorphism of the RAGE 
gene may reduce susceptibility to CAD, thus exerting a protective effect on coronary risk.
1126-138 Inverse Relationship between Local Wall Shear Stress 
and Plaque Thickness in Coronary Arteries is Retained 
by Compensatory Enlargement in Early Atherosclerosis
Andreas Wahle, John J. Lopez, Mark E. Olszewski, Sarah C. Vigmostad, Kathleen C. 
Braddy, Theresa M.H. Brennan, Syed Bokhari, J. Gray Bennett, Elizabeth M. Holper, 
James D. Rossen, Krishnan B. Chandran, Milan Sonka, The University of Iowa, Iowa 
City, IA, The University of Chicago, Chicago, IL
Background: In coronary arteries, it is hypothesized that areas of low wall shear stress 
(WSS) are associated with increasing plaque thickness (PT) during atherosclerotic 
progression. This dynamic relationship cannot be observed directly, since obstructive 
plaque development affects WSS distribution. Therefore, we investigated if this relationship 
could be seen in areas of compensatory enlargement (outward remodeling) without 
luminal narrowing, thus representing the pre-disease WSS. We determined the point of 
atherosclerotic disease progression at which the inverse relationship diminishes.
Methods: 39 in-vivo intravascular-ultrasound (IVUS) pullbacks (16 LAD, 8 LCX, 15 RCA) 
from 22 male and 9 female patients were reconstructed by geometrically correct 3-D 
fusion with X-ray angiography, and computational ﬂuid dynamics methods were employed. 
After excluding branches, calciﬁed and stented regions, a total of 3,046 cross sections 
were automatically analyzed; of these, 1,357 were within the 10-40% area-stenosis range 
(plaque+media area over vessel area) associated with compensatory enlargement. WSS 
and PT were calculated at 72 circumferential locations within each cross section, and for 
each location the existence of an inverse WSS/PT relationship was assessed.
Results: In 24 of 39 vessels, at least 35% of the cross sections were in the compensatory-
enlargement range. In 18 of those vessels (75%), inverse WSS/PT relationships were 
observed signiﬁcantly more frequently in the segments within the compensatory-enlargement 
range than in the vessel as a whole (p<0.005). When also including the 15 vessels with less 
than 35% of the cross sections within the compensatory-enlargement range, a statistical 
difference in inverse-relationship presence was no longer observed (p>0.4).
Conclusions: The inverse relationship between WSS and PT is signiﬁcantly more 
pronounced in vessel cross sections within the compensatory-enlargement range as 
compared to the full spectrum of vessel stenosis severity. If less than 35% of a vessel 
segment remains without luminal narrowing, thus advanced atherosclerosis, the strength 
of this inverse relationship diminishes and is no longer signiﬁcant.
1126-141 Atherosclerotic Markers Increase Early in Systemic 
Lupus Erythematosus
Elisa Y. Rhew, David D. McPherson, Alan R. Dyer, George T. Kondos, Daniel 
Edmundowicz, Kim Sutton-Tyrrell, Anh Chung, Beverly Smulevitz, Trina Thompson, 
Rosalind Ramsey-Goldman, Northwestern University, Chicago, IL, University of 
Pittsburgh, Pittsburgh, IL
Purpose: Improved survival of systemic lupus erythematosus (SLE) women over the past 
2 decades has led to focusing on long term complications. The goal of this study was to 
assess the occurence of subclinical markers of atherosclerosis (ATH) and associated risk 
factors in SLE women.
Methods: Data were collected on 42 subjects, aged 25-70 yrs, meeting American College 
of Rheumatology criteria for SLE. Subclinical ATH was measured as carotid intima-medial 
thickness (IMT) and plaque index (PI) (a composite measure of plaque number and 
severity) using B-mode ultrasound, and coronary artery calciﬁcation score (CAC) using 
EBCT and compared to Systemic Lupus International Collaborating Clinics damage index 
(SLICC-DI).
Results: Age 46 ±11.1 yrs (mean ±SD); SLE disease duration 12 ±7.8 yrs; 74% Caucasian, 
26% African-American; and 60% premenopausal. Risk factors were hypertension (24%), 
hypercholesterolemia (19%), diabetes (7%), and current tobacco use (7%). Mean 
cumulative corticosteroid dose was 12 ± 7.6 mg/day with a mean duration of 7 ±6.9 yrs.
Over 40% had PI ≥1 or CAC ≥10. CAC correlated with SLICC-DI score (r= 0.43 p=0.005) 
even when variables related to ATH (angina/CABG, MI, CVA) were removed (r=0.39 
p=0.01).
Conclusions: ATH is highly prevalent in this young population of systemic lupus 
erythematosus women. Coronary artery calciﬁcation score is associated with cumulative 
SLE disease damage. Despite their age, subjects with SLE must be monitored and 
treated more closely for cardiovascular disease. 
1126-142 The D9N Polymorphism of Lipoprotein Lipase Gene Is a 
Marker for Myocardial Infarction in Diabetics
Maria C. Izar, Tatiana Helfenstein, Waldir G. Relvas, Andreza O. Santos, Simone C. 
Matheus, Marilia I. Fonseca, Licia Queiroz, Silvia S. Ihara, Sang W. Han, Francisco A. 
Fonseca, GOLD Investigators, Federal University of São Paulo, São Paulo, Brazil
Background: Although type 2 diabetes is a risk equivalent for coronary events, it has 
been debated if all diabetic patients should be considered at higher risk. Polymorphisms 
of different genes affecting lipid metabolism may predispose diabetic patients to 
myocardial infarction (MI). We investigated whether multiple genetic testing could add in 
the determination of risk in diabetics.
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Methods: A prospective multicenter study was conducted in 990 diabetic middle-aged 
patients of both sexes (386 with MI, 604 without MI) from 27 Institutions in Brazil. Eight 
polymorphisms (Apo AI-Msp I, Apo C3-Sst I, CETP-Taq I, Apo E, LPL-D9N, PON 1-
Gly192Arg, and both Mwo I and Avr II of LCAT) were studied by PCR-RFLP.
Results: Among all studied polymorphisms, D9N was associated with a 62% increase in 
risk, while Sst I of Apo C3 exerted a very modest protective effect on the occurrence of MI. 
The odds ratios are presented in ﬁgure 1. In statin naive patients, Apo AI-M2- allele was 
associated with higher HDL-C levels. A logistic regression model revealed that age as risk 
factor, male sex, smoking habit, BMI and D9N were signiﬁcantly associated with MI.
Conclusions: Genetic predisposition for myocardial infarction in diabetics can be based, 
at least in part, in genes regulating key enzymes or apolipoproteins related to metabolism 
of triglyceride-rich- lipoproteins, namely, LPL-D9N and Apo C3-Sst I. Analysis of multiple 
genetic polymorphisms is reasonable to assess the individual genetic burden of MI in 
diabetics.
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1127-95 Clinical Signiﬁcance of a “High” Ankle-Brachial Index: 
Insights from the Atherosclerosis Risk in Communities 
Study
Keattiyoat Wattanakit, Aaron R. Folsom, Daniel A. Duprez, Beth D. Weatherley, Alan T. Hirsch, 
University of Minnesota, Minneapolis, MN, University of North Carolina, Chapel Hill, NC
BACKGROUND: An ankle-brachial index (ABI) < 0.9 has been extensively documented 
to indicate peripheral arterial disease (PAD) and increased future risk of cardiovascular 
disease (CVD). Some have suggested high ABI values, often arbitrarily deﬁned as greater 
than 1.3, may also be a marker of increased CVD risk, but this has not been evaluated 
completely.
METHODS: We categorized participants from the Atherosclerosis Risk in Communities 
(ARIC) Study into 2 groups: normal (ABI 0.9-1.3) and high (ABI > 1.3) and compared 
their baseline atherosclerosis risk factors, subclinical arterial disease markers, and sex-
speciﬁc CVD event rates. Plots of ankle blood pressure by arm blood pressure across 
a range of ABI values (0.9-1.5) were created to understand the contribution of blood 
pressures to high ABI values.
RESULTS: The prevalence of high ABI was 5.5%. Compared with participants with normal 
ABI (n=13,969), those with high ABI (n=808) had a lower prevalence of hypertension and 
current smoking. The high ABI group had a greater mean body mass index, but fewer 
cigarette pack years and lower brachial systolic and diastolic blood pressures than the 
normal ABI group. The prevalences of diabetes, left ventricular hypertrophy, intermittent 
claudication, and coronary heart disease, as well as mean ﬁbrinogen, factor VIII activity, 
von Willebrand factor, lipoprotein (a) and carotid and popliteal intima-media thickness 
were quite similar between the two ABI groups. For men, cardiovascular events occurred 
at a rate of 12.7 per 1000 person-years in the normal ABI group, which was similar to 
the 11.6 per 1000 person-years in the high ABI group. For women, the corresponding 
rates were 6.4 and 5.9 per 1000 person-years, respectively. The plot showed that lower 
brachial systolic blood pressure, more than higher ankle blood pressure, contributed to 
greater ABI values.
CONCLUSION: In the general population with a low prevalence of PAD, people with 
a high ABI are characterized by a less adverse atherosclerosis risk factor proﬁle and 
do not suffer greater CVD event rates than those with a normal ABI. As the ABI test 
becomes more widely used in ofﬁce practice, a high ABI value should not automatically 
be considered as a marker of CVD.
1127-96 Risk Proﬁle and Undertreatment of Peripheral Arterial 
Disease - 7,013 Patients from the International REACH 
REGISTRY
Deepak L. Bhatt, Philippe Gabriel Steg, E. Magnus Ohman, Joachim Rother, Peter W. 
F. Wilson, on Behalf of the REACH Registry Investigators, Cleveland Clinic Foundation, 
Cleveland, OH
Background: Peripheral arterial disease (PAD) is a serious manifestation of 
atherothrombosis that is underdetected and undertreated.
Methods: As part of the REACH (Reduction of Atherothrombosis for Continued Health) 
Registry which recruited >63,000 patients from 43 countries from December 2003 to July 
2004, 7,013 patients with symptomatic PAD were studied. Baseline characteristics and 
treatments were examined across several geographic regions. Prevalence of polyvascular 
disease (concomitant symptomatic cerebrovascular or cardiovascular disease or both) 
was determined.
Results: Of the 7,013 patients with symptomatic PAD, the mean age was 69 years, 42% 
were female, 44% were diabetic, 83% were hypertensive, 71% were hypercholesterolemic, 
25% were current smokers, and 50% were former smokers. Excluding patients with known 
diabetes, 42% had fasting hyperglycemia (37% had glucose ≥100mg/dl and <126mg/dl; 
5% had glucose ≥126mg/dl). At baseline, 82% were receiving antiplatelet therapy and 
66% were receiving statins; this pattern was evident in all geographical areas. A signiﬁcant 
63.1% of patients with PAD had symptomatic polyvascular disease (Figure). 
Conclusions: Patients with symptomatic PAD have multiple risk factors for 
atherothrombosis, including prediabetes and undiagnosed diabetes, and have a high 
prevalence of polyvascular disease. Appropriate medications to treat cardiovascular risk 
in PAD patients are underutilized throughout the world.
1127-97 Multifactors Affect Pulse Wave Velocity And Ankle-
brachial Pressure Index: The Effects Of Heart Rate And 
Heart Rhythm
Kun-Tai Lee, Chih-Sheng Chu, Ho-Ming Su, Tsung-Hsien Lin, Hsueh-Wei Yen, Sheng-
Hsiung Sheu, Wen-Ter Lai, Kaohsiung Medical University Hospital, Kaohsiung, 
Taiwan,ROC
Background:The pulse wave velocity (PWV) and ankle-brachial pressure index (ABI) 
were considered as predictors of atherosclerosis.The aim of this study is to determine 
effects of heart rate(HR) and heart rhythm on PWV and ABI.
Methods: 29 patients (18 males,11 females, mean age 52±12 years)underwent 
electrophysiological study due to palpitation were enrolled. After completing 
electrophysiological study, the brachial-pulse PWV, ABI and systolic blood pressure(SBP) 
were measured(BP-203 PRE II; Nihon Colin-Japan) at (1) the baseline sinus HR; 
(2)under right atrial pacing (RAP) with 1:1 AV conduction, and (3) under right ventricular 
pacing (RVP) respectively. The pacing rates of RAP and RVP were 90, 110 and 120 
bpm, respectively. The PWV, ABI and SBP were compared at different pacing rates and 
different pacing sites.
Results: The mean baseline HR, PWV, ABI and SBP were 79±12 bpm, 1547.75±369.43 
cm/sec,1.05±0.08, and133.54±19.91 mmHg respectively. At RAP, the mean values of 
PWV were 1640.39±443.74, 1706.32±523.24, 1784.25±471.19 cm/sec, the mean values 
of ABI were1.03±0.12, 0.99±0.09, 0.95±0.08, and the mean SBP were133.16±19.31, 
135.16±18.56, and 135.00±19.08 mmHg at rates of 90,110 and120 bpm respectively. 
There was signiﬁcant linear trend of increase of HR with increase of PWV and decrease 
of ABI (P=0.02 and <0.01, respectively). However, the mean values of SBP were not 
signiﬁcant changed in different RAP rates (P=0.434). At RVP, the mean values of PWV 
were 1597.20±492.06, 1588.93.±304.98, 1624.00±319.63 cm/sec, the mean values of 
ABI were 0.97±0.09, 0.96±0.17, 0.95±0.05, and the mean SBP were 125.80±13.71, 
126.14±15.68, 127.29±16.65 mmHg at rates of 90, 110 and 120 bpm, respectively. There 
was also signiﬁcant linear trend of increase of HR with increase of PWV and decrease of 
ABI (P=0.039 and 0.005, respectively). However, the SBP were not signiﬁcantly changed 
during different HR (P=0.073).
Conclusions: The HR and heart rhythm either origin from RA or RV could affect the 
values of PWV and ABI. Using PWV and ABI to predict the risk of atherosclerosis, these 
affecting factors should be under consideration.
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1127-98 Combined Glycoprotein IIb/IIIa with Tiroﬁban and Direct 
Thrombin Inhibition with Bivalirudin in PVD: A Safety 
and Feasibility Report in Critical Limb Ischemia
David E. Allie, Chris Hebert, Craig Walker, Cardiovascular Institute of the South, 
Lafayette, LA
Background: The combination of glycoprotein (GP) IIb/IIIa inhibition and direct thrombin 
inhibition (DTI) with bivalirudin (Angiomax, The Medicines Company, Cambridge, MA) have 
shown ischemic and hemorrhagic outcomes beneﬁt in coronary interventions and may 
have similar beneﬁts in PVD. The high incidence of platelet dysfunction, hypercoagulability, 
and a thrombus rich environment make a GPIIb/IIIa and DTI combination with tiroﬁban 
(Aggrastat, Guilford Pharmaceuticals, Baltimore, MD) an attractive treatment strategy in 
critical limb ischemia (CLI).
Methods: Between May 1, 2001 and January 31, 2003, a CLI treatment group (CTG) 
of 149 patients received percutaneous infrainguinal revascularization with bivalirudin 
(0.75mg/kg bolus with 1.75mg/kg/hr infusion) and tiroﬁban (0.4 ug/kg/min bolus with 8-
12 hour 0.1 ug/kg/min infusion) and were compared to a matched heparin control group 
(HCG) without IIb/IIIa’s. Clinical and hemostasis outcomes were analyzed.
Results:Procedural success (PS), time to hemostasis (TTH), vascular access 
complications (VAC), sheath removal time (SRT), vascular closure device (VCD) use, 30-
day secondary reinterventions (SI) and limb salvage (LS) are reported (Table).
Conclusion: Simultaneous GPIIb/IIIa and DTI is a safe, feasible, alternative to heparin 
and may offer improved clinical and hemostasis outcomes in treating CLI. 
Variables HCGN= 149
CTG
N= 149 p-value
PS 143 (95.9%) 145 (97.3%) 0.279
TTH (min.) 39.2 ± 19.1 24.6 ± 9.4 0.036
SRT < 60 min 54 (36.2%) 95 (63.7%) > 0.001
VAC (minor)** 14 (9.3%) 16 (10.7%) 0.358
VAC (major)* 5 (3.3%) 2 (1.3%) 0.143
VCD 35 (23.4%) 33 (22.1%) 0.395
SI 6-month 24 (16.1%) 14 (9.4%) 0.043
LS 132 (88.5%) 140 (93.9%) 0.053
Death 5 (3.3%) 3 (2.0%) 0.259
1127-99 National Healthcare Costs of Peripheral Arterial Disease 
in the Medicare Population
Alan T. Hirsch, Lacey Hartman, Beth Virnig, Keattiyoat Wattanakit, Robert Town, 
University of Minnesota School of Public Health, Minneapolis, MN, Minneapolis Heart 
Institute, Minneapolis, MN
Peripheral arterial disease (PAD) is prevalent in the Medicare population and is associated 
with a high incidence of myocardial infarction, stroke, amputation, and death. Nevertheless, 
health expenditures for PAD have not previously been calculated. We hypothesized that 
the US PAD-related cost would be high, increase with age, and be underestimated as 
compared to the epidemiology of PAD. 
Methods: The cost of PAD treatment was calculated in the elderly, non-disabled 
Medicare population. The cost analysis relies on the linked SEER-Medicare data and 
an algorithm to identify PAD cases that uses ICD-9, CPT, and DRG codes. Costs were 
aggregated separately for inpatient/outpatient treatment sites and claims were adjusted 
to reﬂect national estimates. 
Results: Total Medicare expenditures for PAD (inpatient, outpatient, and physician) were 
$1.8 billion, 85% of which was expended for inpatient care. PAD-related costs thus reﬂect 
approximately 1.2% of Medicare Part A and B expenditures. We estimate that 6.8% of 
the non-disabled elderly Medicare population received some treatment for PAD in 2001. 
PAD treatment prevalence increased with age, with rates of 4.5%, 7.5%, and 11.8% for 
individuals 65-74, 75-84, and > 85 years, respectively. 
Conclusion: US national PAD-related costs are high, associated with the use of inpatient 
care, and increase with age. PAD is treated at rates lower than the known age-related 
PAD prevalence. The impact of preventive strategies to diminish total US PAD health care 
costs is unknown.
USA Medicare and Non-Medicare Expenditures on PAD
Outpatient Inpatient
PAD Cost Facility Professional Facility Professional Total
Medicare $173,978,746 $106,926,511 $1,488,124,286 $65,314,693 $1,834,344,236
Non-Medicare 
(co-payments & 
deductibles)
$100,244,659 $33,073,599 $118,007,143 $16,481,619 $267,807,019
$2,102,151,254
1127-102 Preventing Cardiovascular Events in Young to Middle-
Aged Adults: Are We Asking the Right Questions?
Kwame O. Akosah, Vicki McHugh, Michelle Mathaison, Sharon Barnhart, Ana Schaper, 
Gundersen Lutheran Health System, La Crosse, WI
Background: Improvements have been made in management of secondary prevention. 
Guidelines have been updated to reﬂect recent ﬁndings that subjects with established 
disease beneﬁt from more aggressive lipid therapy. However, primary prevention of 
coronary events remains difﬁcult. Our objective was to study the sensitivity, speciﬁcity 
and predictive values of carotid ultrasound (CU) versus clinical risk score and coronary 
angiography for future cardiovascular (CV) events.
Method: Men (≤55 years) and women (≤65 years) without prior coronary heart disease 
scheduled for elective cardiac catheterization were studied. Those on anti-lipid therapy 
were excluded. Subjects underwent carotid ultrasound, had fasting lipids drawn, and 
Framingham risk scores calculated. Positive coronary angiogram (CAD) was deﬁned as 
stenosis ≥ 50%. CU was deﬁned as the presence of plaque or maximal IMT ≥ 1.0 mm. 
Endpoints included hard events (myocardial infarction, death, and stroke) or any event 
(hard and future revasculariation)
Results: 246 subjects (mean age 51±8) completed all tests. Subjects were followed for 
median of 19 months. 25 subjects experienced 35 events (group 1). Group 2 had no 
events (n=221). There were no differences between groups for total cholesterol (204±38 
vs. 207±43 mg/dL), LDL (124 ±31 vs. 124±39 mg/dL), HDL (47±12 vs. 50±15 mg/dL), 
triglyceride (172±91 vs. 171±124 mg/dL), or glucose (124±64 vs. 118±41 mg/dL). Of the 
major risk factors, only age (54±8 vs. 50±7 years, p=0.007) and hypertension (70% vs. 
40%, p=0.010) were different for group1 and group 2. Framingham scores identiﬁed 38 
subjects at high risk, of whom 5 had events, compared with 7 of 21 at intermediate risk 
and 13 of 183 at low risk. The sensitivity of CU and CAD in predicting hard events was 
91% versus 60%, speciﬁcity 41% versus 71%, and negative predictive value (NPV) 99% 
versus 98%, respectively. For any event, the sensitivity and NPV for CU were 80% and 
95%, compared to 84% and 98% for CAD.
Conclusion: CV events occur regardless of Framingham classiﬁcation and lipid values. 4 
of 25 subjects with negative CAD had events compared to one with negative CU. The high 
sensitivity and NPV implies CU may be reliable tool for primary prevention.
1127-103 Oscillometric Determination Of The Ankle-Brachial 
Provides Accuracy Necessary For Ofﬁce Practice
Caitlin O. Higgins, Marie Gerhard-Herman, Joshua Beckman, Brigham and Women’s 
Hospital, Boston, MA
Peripheral arterial disease is under-diagnosed by primary care and cardiovascular 
physicians. Doppler ultrasound measurement (DM) of the ankle-brachial index (ABI) is 
the diagnostic gold standard, and requires training, time, and specialized equipment 
preventing its common use in ofﬁce practice. We hypothesized that the oscillometric 
measurement (OM) of arm and ankle pressures would provide an accurate and faster 
method of ABI determination than the gold standard. We approached 205 consecutive 
subjects scheduled for Segmental Doppler Pressure (SDP) measurements and enrolled 
201, comparing ABI measurement by both methods. Subjects were typical of those 
referred to a vascular laboratory with a mean age of 66 years, 47% men, 36% had 
diabetes mellitus, and 78% Caucasian. All ABI measurements by each technique were 
made by one investigator. Subjects with evidence of vascular calciﬁcation artifact (ABI > 
1.4 or ankle pressures > 250 mm Hg) were excluded (n = 31). DM of the ABI used the 
higher of the two ankle pressures in each leg as the ABI numerator and the higher of 
two arm pressures as the denominator. Oscillometry determines limb blood pressure by 
measuring the magnitude of pressure oscillation in the cuff with decreasing cuff pressure. 
OM was made via automated sphygmomanometric cuff on each brachium and each 
ankle, using the highest arm pressure as the ABI denominator. We compared the left leg 
only to avoid the interrelation of the lower extremities. For the left leg, the correlation of the 
two measurement (R2) was 0.62. Assuming that DM is the gold standard, the sensitivity 
of OM was 88%, speciﬁcity was 85%, positive predictive value was 65%, and negative 
predictive value was 96%. The values for the right leg were similar to the left: sensitivity 
of 73%, speciﬁcity of 95%, positive predictive value of 88%, and negative predictive value 
of 86%. Age, diabetes, end-stage renal disease, and edema did not decrease detection 
of PAD with oscillometry. Therefore, we conclude that oscillometric measurement of the 
ankle-brachial index is a valid ABI screening measure that can be translated easily to the 
ofﬁce setting.
1127-104 Propionylcarnitine Prevents Endothelial Dysfunction 
Induced by Acute Exercise in Patients with Intermittent 
Claudication
Antonio Silvestro, Vittorio Schiano, Michele Flocco, Gregorio Brevetti, Francesco 
Scopacasa, Massimo Chiariello, University “Federico II”, Napoli, Italy
Background. In patients with peripheral arterial disease (PAD), exercise-induced 
intermittent claudication causes acute deterioration of endothelial function, which is 
prevented by antioxidant vitamin C. Because propionylcarnitine (PLC), besides being a 
metabolic enhancer, has free radical-scavenging properties, we investigated its effect, on 
the endothelial dysfunction associated with intermittent claudication.
Methods. A double blind, placebo-controlled study was carried-out in 36 PAD patients 
randomly assigned to placebo or PLC (600 mg as a single iv bolus followed by an infusion 
of 1 mg/Kg/min for 60 min). Before and after treatment, we measured brachial artery 
ﬂow mediated dilation (FMD) and plasma levels of the soluble form of the vasocellular 
adhesion molecule-1 (sVCAM-1), at rest and following treadmill exercise.
Results. In the 18 patients receiving placebo, FMD decreased with exercise before (from 
6.8±0.4% to 4.0±0.4 %; p< .001) and after treatment (from 6.5±0.4% to 4.4±0.5%; p< 
.001). Conversely, in the PLC group, it signiﬁcantly decreased before (from 8.0±0.7% 
to 4.4±0.4%; p< .001), but not after drug administration (from 7.1±0.7% to 6.0±0.6%). 
However, difference between treatments only approach statistical signiﬁcance (p= .099 by 
ANOVA). In the PLC group, we observed that the greater the exercise-induced reduction 
in FMD before treatment, the greater the protective effect of PLC on endothelium (r= 
- 0.50, p= .034), which was measured as the difference between post-exercise change 
in FMD after PLC and post-exercise change in FMD before treatment. Thus, data were 
analyzed in the 19 patients who before-treatment had with exercise a decrease in FMD ≥ 
45% (the median FMD reduction in the entire group of 36 patients). Results showed that, 
compared to placebo (n=10), PLC (n=9) blunted the exercise-induced reduction in FMD 
(p= .046). Similarly, post-exercise increase in plasma levels of sVCAM-1 before treatment 
(23±5%) was reduced by PLC (15±7%, p= .008), but not by placebo.
Conclusion. PLC, which was shown to improve walking capacity of patients with 
intermittent claudication, also prevents the acute deterioration of endothelial function 
associated with maximal exercise.
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1127-139 Atheromatous Plaque Presence in Both Common 
Carotid and Femoral Arteries Is Highly Suggestive of 
Severe Coronary Artery Disease
Spyridon Koulouris, Konstantinos Triantafyllou, Phivos Symeonides, Ioannis Michaelides, 
Athanasios Kranidis, Vasiliki Tsagou, Ilias Konstantinidis, Dimitra Kardara, Fotios 
Kardaras, Antonios Manolis, Evagelismos Hospital, Athens, Greece
Background: Peripheral vascular disease has not been extensively studied as a predictor 
of coronary artery disease (CAD) severity. We assessed the hypothesis that simultaneous 
atherosclerosis of carotid and femoral arteries can reliably predict the presence of 3-
vessel CAD.
Methods: A coronary angiogram to diagnose suspected CAD was performed in 136 
patients < 65 years old (120 men and 16 women). Each one was also submitted to a 
bilateral B-mode ultrasound of common carotid and common femoral arteries to assess 
the following indices: intima-media thickness (IMT), plaque presence (PP) and plaque 
thickness (PT). Detection of plaque in both carotid and femoral arteries was deﬁned as 
Bifocal PP. Maximum values of continuous variables were used for subsequent analysis. 
Demographic data, risk factors and lipid proﬁle were also obtained for each patient. After 
constructing Receiver Operating Curves for the accuracy of all the above variables to 
diagnose 3-vessel CAD, the areas under the curve (AUC) were calculated. Paired 
comparisons of all AUC were performed with the use of t-test (Hanley & McNeil, 1983). 
Finally, logistic regression analysis was used to demonstrate the independent predictors 
of 3-vessel CAD.
Results: Fifty seven patients (41.9%) had 3-vessel disease. The AUCs of the ultrasound 
indices for the diagnosis of 3-vessel disease were the following: Bifocal PP=0.888, 
Carotid IMT=0.652, Carotid PP=0.817, Carotid PT=0.820, Femoral IMT=0.613, Femoral 
PP=0.687, Femoral PT=0.771. In paired comparisons, the AUC for Bifocal PP was 
signiﬁcantly higher from the other AUCs (p<0.05). All the AUCs for the non-ultrasound 
variables were <0.6. In the various logistic regression models which included all the above 
parameters as independent variables, Bifocal PP was the only signiﬁcant predictor of 3-
vessel disease (p<0.01).
Conclusion: Among non-elderly patients with CAD-related symptoms of recent onset, 
ultrasonic detection of atheromatous plaque in both carotid and femoral vascular beds is 
highly suggestive of severe coronary atherosclerosis.
1127-140 Comparison of a Novel Atherosclerosis Screening 
Technique, Carotid Plaque Area, Versus Coronary 
Calcium Score for Identifying Underlying Coronary 
Artery Disease
Robert D. Brook, Robert L. Bard, Nicholas Clark, Nhien Duong, Smita Patel, Melvyn 
Rubenﬁre, Thomas Wakeﬁeld, Kim Eagle, University of Michigan, Ann Arbor, MI
Introduction: Carotid plaque area (CPA) measured by ultrasound is an independent 
predictor of future cardiovascular events. Due to relatively low cost and ease of 
measurement, CPA could prove to be a practical technique for enhancing cardiovascular 
risk assessment. However, the ability of CPA to correctly identify patients with underlying 
coronary atherosclerosis remains unclear. We therefore sought to compare the predictive 
ability of CPA versus the more validated technique of coronary calcium score (CCS).
Methods: Fifty patients who had a 16-slice computed tomography coronary angiogram 
(CTA) performed were invited to have a CPA measured by carotid ultrasound. CPA was 
deﬁned as the sum of all the cross-sectional areas of all plaques > 1mm in diameter 
found in the external, bulb, internal, and common carotid arteries bilaterally. CCS and 
the number plus degree of stenotic coronary arteries were determined from the CTA. The 
presence of coronary artery disease (CAD) was deﬁned as the existence of any coronary 
stenosis ≥ 20% on CTA. 
Results: The mean subject age was 57±8 years. CTA revealed the presence of CAD 
in 51% of the patients. The average CCS and CPA were 159±260 and 20.3±30.1mm2, 
respectively. Both CPA and CCS were positively correlated to the presence of CAD 
(r=0.466, p< 0.01 for both). The areas under the receiver operator curve (c-statistic) for 
CPA and CCS were 0.82 and 0.96, respectively. The sensitivity of CPA > 0 (any carotid 
plaque) to correctly identify CAD was 73% with a speciﬁcity of 76% and a negative 
predictive value of 62%. The false negative rate for CPA was 27% (8 of 30 patients with 
a CPA=0 had CAD). CCS > 0 was 96% sensitive, 63% speciﬁc, had a negative predictive 
value of 91% and a low false negative rate of 4%. The results were similar when CAD was 
deﬁned as the presence of any 40% lesion on CTA. 
Conclusion: CPA is correlated with the presence and extent of underlying CAD. 
However, a poor negative predictive value and a high false negative rate suggest that the 
absence of carotid plaque does not rule out the presence of underlying CAD. Therefore, 
CPA determination does not appear to be a good CAD screening technique and is clearly 
less effective than CCS.
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1128-119 Orally Available BNP: A Newly Developed Conjugated 
Form of Human BNP Lowers Blood Pressure and 
Activates cGMP When Administered Orally in Normal 
Conscious Dogs
Alessandro Cataliotti, John A. Schirger, Fernando L. Martin, Horng H. Chen, Lisa C. 
Costello-Boerrigter, Guido Boerrigter, Kenneth D. James, Mark A. Miller, Navdeep 
B. Malkar, Nnoch N. Ekwuribe, John C. Burnett, Jr., Mayo Clinic and Foundation, 
Rochester, MN, Nobex Corporation, Durham, NC
Background: The objective of the current study was to address the feasibility and the 
biological activities of orally administered human BNP (hBNP). Proprietary technology 
(Nobex, Durham NC) has developed amphiphilic oligomers covalently attached to 
peptides, which protect peptides from proteolysis. These conjugated peptides have an 
improved pharmacokinetic proﬁle enabling oral administration. We hypothesized that 
a novel conjugated oral hBNP (BNP021) increases plasma hBNP and cGMP, with a 
reduction in mean arterial pressure (MAP) thus demonstrating biological activity.
Methods: In this crossover designed study we tested the bioavailability and efﬁcacy 
of oral conjugated BNP021 compared to vehicle and to native form of hBNP randomly 
administered in 6 normal dogs. Baseline measurements of MAP and plasma hBNP and 
cGMP were made. MAP and blood sampling was repeated at 10, 30, 60, 120, 180, and 
240 min after oral administration. 
Results: hBNP was not detectable in canine plasma at baseline, but was present and 
increased after oral BNP021 (peak concentration 2509 ± 370 pg/ml, p<0.01) throughout 
the time course of the study in each of 6 dogs. hBNP was not detectable after vehicle 
administration (p<0.0008 between groups). hBNP was detectable after administration of 
native form of BNP. However, hBNP concentration was signiﬁcantly lower after native BNP 
as compared to BNP021 (p<0.0376 between groups). Plasma cGMP increased after oral 
BNP021 for 60 min (from baseline 10.8±3 to 36.8±26 pmol/ml, p<0.05), and decreased 
in the vehicle group (p<0.0001 between groups), while it did not change after native 
BNP administration (p<0.0006 between native and BNP021 group). MAP decreased 
at 10 minutes and remained decreased for 60 minutes after oral BNP021 (from 113±8; 
to 101±12 after 10 min to 97.5±10 after 30 min; to 99±13 mmHg after 60 min), while 
remaining unchanged in the vehicle group (p<0.05 between groups). MAP did not change 
after native BNP (p<0.0387 between native and BNP021 group). 
Conclusions: This study reports for the ﬁrst time that a novel conjugated oral BNP 
activates cGMP and induces a signiﬁcant reduction of MAP. These data advance a new 
concept for BNP therapy for cardiovascular diseases.
1128-120 Design, Synthesis, and Cardiorenal Actions of a Novel 
Small Natriuretic Peptide: CT-DNP
Ondrej Lisy, Paul Kurlansky, John C. Burnett, Jr., Mayo Clinic and Mayo Clinic College of 
Medicine, Rochester, MN
Background: Dendroaspis natriuretic peptide (DNP) is a recently discovered 38-amino 
acid (AA) peptide isolated from the venom of Dendroaspis angusticeps snake. DNP is 
structurally similar to ANP, BNP and CNP and has potent natriuretic and vasoactive 
actions. Data suggest that among natriuretic peptides (NP), DNP, due to its unique 15-
AA C-terminus, may be the most resistant to degradation by neutral endopeptidase, 
thereby contributing to its enhanced biological actions. The goal of the current study was 
to identify a small AA sequence of DNP which could be a candidate for drug development. 
We designed, synthesized, puriﬁed and veriﬁed by mass spectrometry CT-DNP which is 
the 15-AA sequence of C-terminus DNP. We then assessed the cardiorenal actions of 
CT-DNP with the hypothesis that this novel peptide, which, unlike other NP has a linear 
structure, would be biologically active.
Methods: In 6 normal anesthetized dogs, compared to a placebo control group (n=7) 
which received saline, CT-DNP was infused at three doses (4, 20 and 40 ng/kg/min). 
Within group data were analyzed by comparing peak responses during drug infusion to 
baseline (by paired t-test or Wilcoxon test). * p<0.05 vs. Baseline.
Results: CT-DNP decreased MAP (from 135±4 to 122±2* mmHg) with no changes in 
cardiac ﬁlling pressures. CT-DNP was natriuretic (UNaV from 17±6 to 43±12* µEq/min) 
and diuretic (UV from 0.4±0.1 to 1.0±0.1* ml/min) and activated cGMP in plasma (from 
12.9±1.8 to 15.0±2.3* pmol/ml) and urine (UcGMPV from 1674±213 to 2453±182* pmol/
min). While no changes in renal hemodynamics were noted, we localized decreases in 
tubular reabsorption of sodium to the proximal (PFRNa from 77.9±2.7 to 68.7±2.5* %) 
and distal (DFRNa from 98.7±0.3 to 97.6±0.4* %) nephrones. There was a strong trend to 
decrease plasma renin activity. There were no changes in the placebo group.
Conclusions: We report that CT-DNP, a 15-AA small synthetic peptide derived from 
the 38-AA native DNP, is biologically active in vivo. CT-DNP possesses natriuretic, 
diuretic, hypotensive and cGMP enhancing properties. These ﬁndings support a 
possible therapeutic role for this new designer peptide in the treatment of cardiovascular 
diseases.
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1128-121 C-type Natriuretic Peptide, a Novel Antiﬁbrotic Agent, 
Attenuates Cardiac Remodeling and Improves Left 
Ventricular Dysfunction in Dilated Cardiomyopathy
Takeshi Soeki, Ichiro Kishimoto, Takeshi Tokudome, Takeshi Horio, Kenji Kangawa, 
National Cardiovascular Center Research Institute, Suita, Japan
Background: Impairment of cardiac function in dilated cardiomyopathy (DCM) has been 
postulated to be related to increased collagen synthesis. Recently, we have shown that C-
type natriuretic peptide (CNP), the third member of the natriuretic peptide family, inhibited 
both DNA and collagen synthesis of cardiac ﬁbroblasts more potently than atrial and 
brain natriuretic peptides (ANP and BNP) in vitro. In the present study, we assessed 
the hypothesis that the administration of CNP might attenuate the progressive cardiac 
dysfunction and ﬁbrosis in DCM. In addition, we investigated the action of CNP/cGMP/
cGMP-dependent protein kinase (PKG) pathway in cardiac ﬁbroblasts. 
Methods: DCM hamsters (Bio TO2) at 12 weeks of age were treated for 4 weeks with 
CNP at 0.1µg/kg/min (DCM+CNP, n=15) or vehicle (DCM+vehicle, n=15). F1B hamsters 
at same age served as normal controls (n=17). 
Results: Left ventricular fractional shortening (LVFS) was decreased and LV end-
diastolic dimension (LVDd) was increased in untreated DCM hamsters compared to 
normal hamsters in echocardiograms. CNP was found to cause an increase in LVFS 
(Normal; 38.3±0.9%, DCM+vehicle; 18.6±1.2%, DCM+CNP; 24.0±1.7%) and a decrease 
in LVDd (Normal; 4.6±0.1mm, DCM+vehicle; 5.6±0.1mm, DCM+CNP; 5.2±0.1mm). In a 
hemodynamic study, the systolic and diastolic LV dysfunction in DCM was signiﬁcantly 
improved by CNP, although arterial pressure was not affected. Furthermore, CNP markedly 
attenuated an increase in morphometrical collagen volume fraction in LV. The increased 
mRNA levels of collagen I, collagen III, and ANP in LV were also suppressed by CNP. In in 
vitro study, CNP and 8-Bromo cGMP, an analog of cGMP, decreased the incorporation of 
[3H]proline into cardiac ﬁbroblasts. The decrease of [3H]proline incorporation by CNP was 
completely blocked by RP-8-pCPT-cGMP, an inhibitor of PKG. 
Conclusion: Continuous administration of CNP improved LV dysfunction and ﬁbrosis 
in DCM hamsters. Since CNP did not perturb systemic hemodynamics, these beneﬁcial 
effects of CNP might be mediated by direct inhibition of collagen synthesis via the cGMP/
PKG pathway, suggesting the potential usefulness of CNP as a novel anti-remodeling 
agent for DCM.
1128-122 Glucagon-Like Peptide-1 (GLP-1) Restores Myocardial 
Insulin Signaling and Preserves Left Ventricular (LV) 
Function in Spontaneously Hypertensive Heart Failure-
prone (SHHF) Rats
Indu G. Poornima, Lazaros A. Nikolaidis, Laurie Machen, Carol Stolarski, Teresa 
Hentosz, Richard P. Shannon, Allegheny General Hospital, Pittsburgh, PA
Background: The SHHF rat is a genetic model of leptin resistance, resulting in 
hyperleptinemia, obesity, insulin resistance and hypertension. We have previously 
demonstrated alterations in the insulin-signaling cascade in the myocardium of SHHF 
rats. Speciﬁcally, there is impaired basal and insulin stimulated phosphorylation of Akt-1 
and GLUT-4 translocation. GLP-1 is an incretin that has insulinotropic, insulinomimetic, 
and glucagonostatic properties and is effective in overcoming cellular insulin resistance. 
The GLP-1 receptor (GLP-1R) is a 7 transmembrane G-protein coupled receptor whose 
functional signiﬁcance in the myocardium is uncertain.
Objective: To determine whether GLP-1R exists in the myocardium of the SHHF rat and 
whether treatment with GLP-1 would restore altered insulin signaling.
Methods: 10 SHHF rats (9 months old) were treated with 3 months of continuous 
subcutaneous infusion of GLP-1 [7-36] amide (1.5 pmol/kg/min) (GLP-1) compared to 10 
SHHF treated with vehicle (Con). LV function was assessed before and after treatment 
by 2-D echo. At 12 months of age, the animals were euthanized and myocardium was 
snap frozen in liquid nitrogen for analysis of GLP-1R and the insulin-signaling cascade 
using Western blots.
Results: GLP-1 increased plasma insulin levels (Con: 2898±680; GLP-1: 4190±710 
pmol/L, p<0.05) and suppressed plasma triglycerides (Con: 1669±488; GLP-1: 934±287 
µmol/L, p<0.05). GLP-1 increased LV mass (Con: -0.2±0.1 from 2.1±0.1 g; GLP-1: 
+0.7±0.2 from 2.0±0.2 g, p<0.05) while preserving LVEF (Con: -7±3 from 68±8%; GLP-
1: -1±3 from 71±6%, p<0.05) compared to control. GLP-1Rs were found in abundance 
in the myocardium from both groups. GLP-1 treatment signiﬁcantly increased GLUT-4 
translocation (+ 46±7%, p<0.05) in association with increased serine 473 (+63±5%, 
p<0.05) and threonine 308 (+58±5%, p<0.05) phosphorylation of Akt-1. GLP-1 treatment 
also increased membrane insulin receptor abundance.
Conclusion: GLP-1Rs are present in the myocardium of SHHF rats and chronic GLP-
1 treatment restores myocardial insulin signaling in association with increased Akt-1 
phosphorylation and GLUT-4 translocation, at least in part through insulinotropic effects.
1128-123 Blockade of Beta3-Adrenoceptors by Carvedilol in Rat 
Myocardium
Che-Ping Cheng, Chunxian Zhang, Qing-Hua Han, Heng-Jie Cheng, Robert J. Applegate, 
William C. Little, Wake Forest University School of Medicine, Winston-Salem, NC
Background. There is upregulation of cardiac functional β3-adrenergic receptors (AR) 
in the failing myocardium. Since stimulation of β3-AR depress contraction, there is a shift 
in the balance between β1-AR-mediated positive and β3-AR-mediated negative inotropic 
pathways in heart failure (HF). The β-AR selective blocker, metoprolol, has very limited 
β3-AR blocking activity. The efﬁcacy of carvedilol in blocking β3-AR is not known.
Methods. We examined the antagonizing actions of clinically relevant levels of carvedilol 
on β3-AR activation-induced changes on left ventricular (LV) and myocyte contractile 
performance and L-type Ca2+ current (ICa,L) response in 12 normal adult rats.
Results. In normal rats, stimulation of β3-AR with the selective agonist, BRL (0.3 mg/kg, 
iv), caused rightward shifts and more than 15% decreases in the slopes of pressure (P)-
volume (V) relations (EES, 3.6 vs 4.4 mmHg/ml) and MSW (38.8 vs 46.2 mmHg). In isolated 
myocytes, superfusion of BRL (10-8 M) signiﬁcantly reduced the amplitude of myocyte 
contraction with decreased percent shortening (SA, 10.1 vs 12.3%), velocity of shortening 
(dL/dtmax, 123.6 vs 149.1 µm/s) and ICa,L (4.9 vs 6.2 pA/pF). In contrast, after carvedilol (0.3 
mg/kg, iv), BRL-induced decreases in EES (4.8 mmHg/ml) and MSW (48.3 mmHg) were 
completely prevented. Similarly, in the presence of BRL, the addition of carvedilol (5x10-6 
M) in the superfusion of myocytes completely reversed these BRL-induced changes and 
caused increases in SA (13.9%), dL/dtmax (169.1 µm/s), and ICa,L (6.8 pA/pF). Activation 
of β3-AR with isoproterenol (ISO, 10-8 M) in the presence of a β1- and β2-AR antagonist, 
nadolol (10-5 M), reversed ISO-induced positive inotropic responses and caused 17%, 
19%, and 22% decreases in SA, dL/dtmax, and ICa,L, respectively, when compared with 
controls. These responses were abolished in the presence of carvedilol. 
Conclusion. Carvedilol blocks β3-AR in rat myocardium. This property may contribute to 
its beneﬁcial effect in HF.
1128-124 Adrenomedullin Administration Immediately After 
Myocardial Infarction Ameliorates Progression of Heart 
Failure in Rats
Ryosai Nakamura, Jhoji Kato, Takuroh Imamura, Kazuo Kitamura, Hisamitsu Onitsuka, 
Cao Yuanning, Tanenao Eto, Miyazaki Medical College, Miyazaki, Japan
Background: Adrenomedullin (AM) is expressed in cardiac tissue, and plasma AM 
levels increase in patients with acute myocardial infarction (MI) and heart failure. We 
previously reported that continuous infusion of AM for 4 weeks had beneﬁcial effects on 
left ventricular remodeling and hemodynamics in MI rats. This study was performed to 
determine whether AM administration immediately after acute MI inhibits progression of 
heart failure in rats.
Methods and Results: Rats were intraperitoneally infused with 1.0 µg/h of AM or 
saline over 7 days immediately after MI inducted by left coronary ligation, and they were 
examined 9 weeks after MI. When compared with the saline infusion, the AM infusion 
signiﬁcantly improved survival (59 vs. 81%, P<0.05) and body weight gain (2.8±0.2 vs 
3.7±0.1 g/day, mean±SEM, P<0.01), and reduced heart weight (4.7±0.2 vs 3.4±0.1 g/kg 
BW, P<0.01), lung weight (6.5±0.6 vs. 4.8±0.5 g/kg BW, P<0.01), left ventricular (LV) 
end-diastolic pressure (11.4±2.0 vs. 4.0±0.6 mmHg, mean±SEM, P<0.01), collagen 
volume fraction of non-infarct LV (-39%, P<0.05) and plasma levels of endogenous rat 
AM (-38%, P<0.05), without affecting the infarct size. To investigate the mechanism of AM 
actions, another series of MI rats infused with AM were sacriﬁced at Day 7. Tissue mRNA 
levels of angiotensin-converting enzyme (ACE) and p-22 phox, a critical component of 
nicotinamide adenine dinucleotide/ nicotinamide adenine dinucleotide phosphate (NADH/
NADPH) oxidase, were measured by a Real-Time-quantitative PCR method, and urinary 
isoprostane, a marker of oxidative stress, were measured by an enzyme immunoassay. 
The AM infusion had no effect on organ weights and hemodynamic parameters at Day 7 
of MI, but signiﬁcantly reduced urinary excretion of isoprostane (-61%, P<0.01) and non-
infarct LV mRNA levels of ACE (-31%, P<0.05) and p22-phox (-30%, P<0.05).
Conclusions: AM administration during the early period of MI improved the survival and 
ameliorated progression of LV remodeling and heart failure. This beneﬁcial effect was 
accompanied by reductions in oxidative stress and ACE mRNA expression of non-infarct 
LV in the AM infusion period.
1128-125 The Differential Effect of Amiodarone, Quinidine and 
Dofetilide on IKr Inhibition With Hyperkalemia
Congrong Lin, Xiaogang Ke, Ivana Cvetanovic, Vasant Ranade, John C. Somberg, Rush 
University, Chicago, IL
Hyperkalemia is a potentially life-threatening disorder occurring in 8% of hospitalized 
patients. We evaluated the inﬂuence of increased extracellular potassium concentration 
[K+]e on IKr inhibition by amiodarone (A), dofetilide (D) and quinidine(Q). The effect of A, 
D, and Q were evaluated at room temperature, using HERG gene expressed in Xenopus 
oocytes employing a two electrodes voltage clamp technique. The recording bath solutions 
contained 5 or 10 mmol/L KCl. A, D and Q all produced a dose dependent inhibition of 
HERG current. At 5mmol/L [K+]e, 10µM A, Q and 1µM D inhibited HERG current by 43 ± 
4, 55 ± 4 and 42 ± 2% respectively. At 10mmol/L [K+]e, 10µM A produced 45 ± 4% HERG 
inhibition, while 10µM Q and 1µM D inhibited HERG current by 29 ± 4 and 24 ± 3%. The 
IC50 was 37 ± 12 µM for A, 9 ±2 µM for Q and 1.5 ± 0. 2 µM for D at 5mmol/L [K
+]e. At 10 
mmol/L [K+]e, the IC50 were 25 ± 7 µM for A, 28 ± 4 µM for Q and 2.7 ± 0.2 µM for D. There 
were no signiﬁcant differences in the percentage of current block by A between 5 and 10 
mmol/L [K+]e, while there were signiﬁcant differences in the HERG inhibition by D and Q 
(p<0.05). With increased [K+]e, block of IKr by Q and D was diminished, but the block by 
A was unchanged.
Regional differences in [K+]e could contribute to differences in the refractiveness and 
repolarization, leading to arrhythmias with Q or D treatment. Regional differences in [K+]e 
would not be proarrhythmic with A.
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1128-126 Potent Cardiorenal Actions in Experimental Heart 
Failure With Dual Activation of Soluble and Particulate 
Guanylate Cyclases by BAY 58-2667 and BNP: A Novel 
Therapeutic Strategy
Guido Boerrigter, Lisa C. Costello-Boerrigter, Gail J. Harty, Harald Lapp, Johannes-
Peter Stasch, John C. Burnett, Jr., Mayo Clinic and Mayo Clinic College of Medicine, 
Rochester, MN, Bayer HealthCare AG, Wuppertal, Germany
Background: Cyclic guanosine monophosphate (cGMP) is a second messenger generated 
by both soluble and particulate guanylate cyclase (sGC and pGC, respectively). BAY 58-
2667 is a novel direct sGC activator and may have advantages over nitrovasodilators 
as it does not induce tachyphylaxis and does not have cGMP-independent actions. BAY 
58-2667 is vasodilating but has no natriuretic or diuretic actions. In contrast, the pGC 
activator BNP is vasodilating, natriuretic, and diuretic. Little is known about the effects of 
simultaneous activation of sGC and pGC. We hypothesized that coadministration of BAY 
58-2667 and BNP in experimental heart failure (HF) would complement the beneﬁcial 
cardiac unloading actions of BAY 58-2667 with the beneﬁcial renal actions of BNP without 
inducing deleterious hemodynamic depression.
Methods: HF was induced in 3 groups of dogs (N=7) by tachypacing at 240 bpm. After 10 
days, cardiorenal parameters were measured at baseline and with two intravenous doses 
of BAY 58-2667 (0.1 and 0.3 µg/kg/min) or human BNP (10 and 50 ng/kg/min) alone 
or combined. Cardiorenal function was compared within groups by analysis of variance, 
while groups were compared qualitatively.
Results: BNP alone reduced mean arterial pressure and cardiac ﬁlling pressures, and 
induced natriuresis and diuresis. BAY 58-2667 alone potently decreased mean arterial 
pressure, cardiac ﬁlling pressures, and systemic and renal vascular resistance, while 
cardiac output and renal blood ﬂow increased. These actions occurred to a similar degree 
when BNP was added to BAY 58-2667. While BAY 58-2667 alone did not change urine 
ﬂow, urinary sodium excretion, or glomerular ﬁltration rate, these parameters increased 
with additional pGC activation. There was no further activation of the renin-angiotensin-
aldosterone system.
Conclusion: Direct sGC activation by BAY 58-2667 alone has potent beneﬁcial cardiac 
unloading actions in experimental HF. Additional pGC activation with BNP enhances 
renal function without inducing deleterious hemodynamic depression. These ﬁndings 
suggest that coactivation of sGC and pGC may be a beneﬁcial and a novel strategy in the 
treatment of HF to enhance cardiorenal function.
1128-127 Effects of Urotensin II Inhibition on Smooth Muscle Cell 
Proliferation and Apoptosis
Giovanni Esposito, Emma Sanzari, Antonio Rapacciuolo, Luigi Di Seraﬁno, Elisa di 
Pietro, Veruska Papaleo, Marianna Andreozzi, Dario Leosco, Paolo Grieco, Massimo 
Chiariello, Federico II University, Naples, Italy
Urotensin II (UT-II) is a somatostatin-like peptide whose receptor was recently identiﬁed in 
mammals as the orphan G protein-coupled receptor-14. UT-II has potent vasoconstrictor 
effects and in addition to the potent hemodynamic effects it has been implicated in 
myocardial ﬁbrogenesis through increased collagen synthesis by cardiac ﬁbroblast. UT-II 
and its receptor have also been found to be upregulated in patients with heart failure. 
The cardiovascular responses to systemic urotensin II administration are variable and the 
biological effects of UT-II are not completely understood. Furthermore, the effects of UT-II 
on cell proliferation has not been investigated.
We have recently synthesized a peptide (Urantide) a potent UT receptor antagonist. The 
goal of our study is be to explore the role of UT-II in the smooth muscle cell proliferation in 
vitro and in vivo and the ability of the antagonist peptide to rescue these effects.
To study the effect of UT-II on cell proliferation, Vascular Smooth Muscolar Cells (VSMC) 
were cultured in presence of UT-II and Urantide and in these conditions we observed 
respectively a signiﬁcant increased (30%, p<0.05) and a decrease (10%) of cell number. 
This effect is associated to ERK-MAPK phosphorilation as conﬁrmed by western blot.In 
order to investigate of UT-II on apoptosis, rat-VSMC were cultured in absence of growth 
factors and the percentages of cell death, measured as hypodiploidy in ﬂow cytometry, 
showed UT-II rescue VSMCs from apoptosis. In Cycloheximide-induced apoptosis, UT-
II does not show this protective effect indicating that is necessary a de novo protein 
synthesis. The pathway of cell-death in absence of FBS involved normally caspase 3 
and not caspase 8 activation showing that UT-II treatment inhibits the cleavage of 
caspase 3 and have no effect on caspase 8 activation. These effects of UT-II on apoptosis 
are inhibited by UT-II inhibitor, Urantide. Our data show that urotensin II may have an 
important role in the pathogenesis of vasculoproliferative disorders. Blocking UT-II effects 
by Urantide may have important therapeutical implications.
1128-128 Anti-Fibrotic Effect of Adrenomedullin on Coronary 
Adventitia in Angiotensin II-induced Hypertensive Rats
Toshihiro Tsuruda, Johji Kato, Kinta Hatakeyama, Hiroyuki Masuyama, Yuan-Ning 
Cao, Takuroh Imamura, Kazuo Kitamura, Yujiro Asada, Tanenao Eto, Miyazaki Medical 
College, University of Miyazaki, Miyazaki, Japan, Minami-Kyushu University, Miyazaki, 
Japan
Objectives: The extracellular matrix (ECM) is an important component that determines 
structural integrity of the heart and vasculature, participating in cardiovascular remodeling. 
We have previously reported that adrenomedullin (AM) inhibited cellular proliferation and 
protein synthesis in cardiac ﬁbroblasts of neonatal rats; however, the precise mechanisms 
of AM actions as an anti-ﬁbrotic factor remain unknown. The purpose of this study was 
to examine the biological actions of AM against the pro-ﬁbrotic factor angiotensin II (Ang 
II) in coronary adventitia.
Methods and Results: Rats with hypertension induced by Ang II infusion were 
administered 0.06 µg/kg/min recombinant human AM subcutaneously for 14 days. The 
AM infusion signiﬁcantly (p<0.05) reduced Ang II-induced increase of coronary adventitial 
ﬁbroblasts expressing Ki-67, a marker for proliferation and �-smooth muscle actin, a 
marker for myoﬁbroblast differentiation in the left ventricle, by 65%, and 62%, respectively. 
Meanwhile, AM had no signiﬁcant effects on systolic blood pressure, left ventricle/body 
weight or myocyte size. Collagen deposition of coronary arteries as determined by sirius 
red staining was reduced by the AM infusion (-24%, p<0.01). These effects of AM were 
accompanied by signiﬁcant reductions in gene expressions of transforming growth factor-
β1 (-55%, p<0.01) and type 1 collagen (-49%, p<0.05).
Conclusion: AM decreased Ang II-induced collagen deposition surrounding the coronary 
arteries, inhibiting myoﬁbroblast differentiation and ECM-related genes expression in rats. 
These in vivo ﬁndings further support the biological action of AM as an anti-ﬁbrotic factor 
in the vascular remodeling.
1128-129 A Common Platelet G-Protein Splice Variant Inﬂuences 
Response to Antithrombotic Therapy
Andrew O. Maree, Ronan Curtin, Michelle Dooley, John O’Brien, Peter Crean, Dermot 
Cox, Denis C. Shields, Desmond J. Fitzgerald, The Royal College of Surgeons in Ireland, 
Dublin, Ireland, Beaumont Hospital, Dublin, Ireland
Background: G-proteins are important for platelet activation. A common SNP (825 
C>T) in the GNB3 gene linked to a splice variant of the platelet G-protein beta3 subunit 
is associated with variable epinephrine aggregation. 825T allele carriage is linked to 
coronary artery disease (CAD) and obesity. We hypothesized that GNB3 genotype may 
inﬂuence response to antiplatelet therapy.
Methods: Stable CAD patients (n=200) on aspirin (ASA) (75-300mg) were screened 
by Platelet Function Analyser (PFA)-100 and serum thromboxane (TX)B2 level. Platelet 
aggregation to arachidonic acid (1.6mM) and TRAP (5uM) was determined in 130 of these 
patients. Aggregation to epinephrine (5uM), collagen (0.5ug/ml), serum TXB2 level and 
glycoprotein (GP)IIb/IIIa receptor expression were measured in 58. In addition, effect of 
GNB3 genotype on bleeding in an “Oral GPIIb/IIIa inhibition with orboﬁban in Patients with 
Unstable coronary Syndromes (OPUS-TIMI 16)” sub-population (Orboﬁban (n=567) vs 
placebo (n=305)) was evaluated.
Results: In stable CAD patients GNB3 genotype was similar to previous Caucasian 
studies (CC/CT/TT=99/80/21) . Table 1 shows effect of genotype on platelet function in 
ASA treated stable CAD patients and association with bleeding events in OPUS study.
Conclusion: GNB3 825T allele carriage is associated with reduced platelet aggregation 
to epinephrine and TRAP and decreased GPIIb/IIIa expression in stable CAD patients 
and increased bleeding in ACS patients taking an oral GPIIb/IIIa antagonist.
GNB3 Genotype and Platelet Function Assay (Mean +/- SE) 
Assay CC CT/TT p-value
Epinephrine Aggregation
(Max %) 41.5+/-4 26.9+/-3.4 0.01
TRAP Aggregation
(Max %) 86.4+/-1.6 82.4+/-1.5 0.04
GPIIb/IIIa Receptor No. 55115+/-1637 49809+/-2056 0.04
Arachidonic Acid Aggregation
(Max %) 13.1+/-2.1 13.3+/-2.4 n/s
Collagen Aggregation
(Max %) 12.4+/-2.7 12.8+/-3.3 n/s
Serum TXB2
(ng/ml) 5.1+/-2.6 4.9+/-2.1 n/s
OPUS Bleeding (%)
(Orboﬁban group) 16.5 25.8 / 26.2 p 0.025
1128-130 The Impact of Pentobarbital, Isoﬂurane, and 
Tribromoethanol Anesthesia on Echocardiographic LV 
Function and Anatomy in Three Common Strains of 
Mice
Adam B. Stein, Sumit Tiwari, Greg Hunt, Justin R. Kingery, Cemil Levent, Roberto Bolli, 
Buddhadeb Dawn, University of Louisville, Louisville, KY
Background: Anesthetic agents are used by most investigators to keep mice immobile 
during echocardiographic studies. However, the alterations in LV anatomy and function 
associated with the use of anesthetic agents during echocardiographic studies are largely 
unknown.
Methods: Accordingly, we investigated the effects of three common anesthetics 
(pentobarbital [PB, 50mg/kg i.p.], isoﬂurane [ISF, 1.0% inhaled], and tribromoethanol 
[TBE, 15µl/g i.p. of a 2.5% solution]) on age-matched C57BL/6J, FVB/N, and ICR mice 
(n=10-12 / group).
Results: ISF resulted in a signiﬁcant increase in LV chamber size as compared to PB and 
TBE in C57BL/6J mice and FVB/N mice (Table). LV chamber size was also increased in 
ICR mice, but the difference did not reach statistical signiﬁcance. In C57BL/6J mice, TBE 
anesthesia preserved LV function better compared with ISF or PB anesthesia (Table). 
In FVB/N mice, ISF anesthesia preserved cardiac function better than TBE and PB 
anesthesia (Table). In ICR mice, ISF and TBE were both superior to PB anesthesia for the 
preservation of LV function.
Conclusion: In summary, ISF increased LV chamber size more than PB and TBE, 
and PB depressed cardiac function more than ISF and TBE in all three strains of mice. 
These differences among anesthetics have important implications for studies using 
echocardiography in speciﬁc strains of mice.
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LV anatomical and functional parameters by echocardiography
HR
(bpm)
LVEDD
(mm)
EDV
Teichholz
(µl)
FS
(%)
FAC
(%)
EF
(%)
Vcfc
(cir/s) MPI
C57BL6J 
PB 483±18 3.53±0.07 52.6±2.4 34.3±1.7 45.6±1.6 63.1±1.8 2.35±0.13 0.46±0.04
ISF 469±10 3.72±0.05 ‡ 59.2±1.8 ‡ 35.3±1.1 46.0±1.0 64.3±1.2 2.31±0.10 0.41±0.04
TBE 544±17*# 3.44±0.08 49.1±2.7 42.1±1.4*# 53.9±1.1*# 71.4±1.3*# 2.79±0.11*# 0.31±0.03*#
FVBN
PB 532±20 3.37±0.08 46.9±2.7 40.8±1.6 51.6±2.5 69.9±1.7 2.7±0.14 0.37±0.04
ISF 498±18 3.62±0.04 * 55.1±2.1 * 46.4±1.6‡ 56.4±1.1‡ 74.7±1.5‡ 3.2±0.12‡ 0.27±0.03
TBE 492±18 3.40±0.06 47.5±2.2 39.0±2.2 49.1±1.8 67.9±2.2 2.6±0.17 0.32±0.03
ICR
PB 462±16 3.68±0.07 57.8±2.7 31.0±1.0 43.2±1.2 59.4±1.2 2.13±0.07 0.49±0.04
ISF 500±21 3.87±0.06 64.7±2.3 38.3±1.3* 48.6±1.1* 67.3±1.4* 2.56±0.13* 0.27±0.03*
TBE 504±24 3.69±0.08 57.9±2.9 36.4±1.8* 47.4±1.8 65.3±1.8* 2.50±0.10* 0.41±0.05
* P<0.05 vs. PB, # P<0.05 vs. ISF, ‡ P<0.05 vs. AVE
POSTER SESSION
1129  Lipid, Lifestyle, Ethnicity, and Other 
Risk Factors
Tuesday, March 08, 2005, 9:00 a.m.-12:30 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 9:00 a.m.-10:00 a.m.
1129-100 Clinical Effectiveness of Therapeutic Lifestyle Changes 
in African Americans Versus Caucasians
Neil F. Gordon, Richard D. Salmon, Kevin S. Reid, William E. Saxon, George C. Faircloth, 
Ivan Levinrad, Brenda S. Mitchell, Richard F. Leighton, Anil Verma, Martin R. Berk, 
Laurence S. Sperling, William L. Haskell, Barry A. Franklin, St. Joseph’s/Candler Health 
System, Savannah, GA, INTERVENT Coordinating Center, Savannah, GA
Background: Despite impressive medical advances during the past century, striking 
differences remain in cardiovascular disease (CVD) mortality rates by race/ethnicity. 
Although national guidelines promulgate therapeutic lifestyle changes (TLC) as a 
cornerstone in CVD risk reduction, scarce data are available on the effectiveness of TLC 
in minority subpopulations in the U.S.
Methods: In this study, we compared the effectiveness of TLC in 1,967 consecutive, 
unmedicated, African American (Group A; n=412; age=44+/-9 years) and Caucasian 
(Group B; n=1,555; age=47+/-11 years) patients with an elevated blood pressure (BP), 
LDL cholesterol, and/or fasting plasma glucose level. Patients were evaluated at baseline 
and after ~12 weeks of participation in a community-based lifestyle management program. 
TLC included exercise training, nutrition, weight management, stress management, and 
smoking cessation interventions. All patients remained unmedicated throughout the 
study.
Results: Among patients with abnormal baseline risk factors (based on national 
guidelines), improvements were observed for multiple variables, as follows (p <0.05, 
unless otherwise noted): systolic BP (Group A, -9 mmHg; Group B, -10 mmHg; p=NS 
for Group A versus B); diastolic BP (Group A, -6 mmHg; Group B, -7 mmHg; p<0.05 for 
Group A versus B); total cholesterol (Group A, -20 mg/dl; Group B, -27 mg/dl; p=NS for 
Group A versus B); LDL cholesterol (Group A, -10 mg/dl; Group B, -15 mg/dl; p=NS for 
Group A versus B); HDL cholesterol (Group A, 5 mg/dl; Group B, 3 mg/dl; p=NS for Group 
A versus B); triglycerides (Group A, -10 mg/dl, p=NS; Group B, -55 mg/dl; p<0.05 for 
Group A versus B); fasting glucose (Group A, -3 mg/dl, p=NS; Group B, -11 mg/dl; p=NS 
for Group A versus B); and weight (Group A, -3 lbs; Group B, -7 lbs; p<0.05 for Group A 
versus B). In patients with a Framingham 10-year coronary heart disease risk score >10% 
at baseline, the score decreased signiﬁcantly (p <0.05) in Group A (-13%) and Group B 
(-19.4%); p=NS for Group A versus B.
Conclusions: These data indicate that while both African Americans and Caucasians 
beneﬁt substantially from TLC, the magnitude of beneﬁt may be greater for Caucasians 
for certain CVD risk factors.
1129-101 Charge-based Major Low-density Lipoprotein 
Subfraction Associated with Alzheimer’s Disease and 
Mild Cognitive Impairment
Bo Zhang, Seigo Nakano, Akira Matsunaga, Tatsuo Yamada, Keijiro Saku, Fukuoka 
University, Fukuoka, Japan
Background: Alzheimer’s disease (AD) is the most common form of dementia. Mild 
cognitive impairment (MCI) is a cognitive disorder in transition between normal cognition 
and AD. Since apolipoprotein (apo) E isoform E4 and increased cholesterol levels 
are known risk factors of AD and MCI, we examined the associations among plasma 
lipoprotein subfractions as characterized by capillary isotachophoresis (cITP), apo E 
isoforms, MCI, and AD.
Methods: This study included patients with MCI (n=28) and AD (n=47) and non-demented 
control subjects (n=26). Plasma lipoproteins were prestained with NBD-ceramide, a 
lipophilic dye, for cITP analysis.
Results: The frequency of the apo E4 isoform was higher in AD patients than in MCI 
patients and controls. Serum levels of low density lipoprotein cholesterol (LDL-C) 
and apo B in patients with MCI and AD were higher than those in controls. The major 
LDL fraction, cITP slow LDL (ﬁgure), was higher in patients with MCI and AD than in 
controls (peak area relative to internal control: 3.32 ± 0.15 and 3.39 ± 0.13 vs. 2.24 ± 
0.19, p<0.05). The results of a multiple logistic regression analysis indicated that the 
association between cITP slow LDL and AD was independent of the apo E isoform, 
suggesting that an increased synthesis of cholesterol is important in the pathogenesis 
of cognitive impairment.Conclusion: Increased cITP slow LDL was associated with MCI 
and AD, suggesting that active lipid-lowering may be useful in the treatment of cognitive 
impairment.
1129-105 Lipoprotein Associated Phospholipase A2 (LpPLA2) is 
Signiﬁcantly Associated with Carotid Intimal Medial 
Thickness in Asian Indian Population: Arizona Heart 
Institute Multiple Emerging Risk Factor aSsessment of 
Atherosclerosis Among Asian Indians (AHIMSA) Study
Kris Vijayaraghavan, Peter Reaven, Ranjita Misra, Michelle Jeffries, Vicky Camacho, 
Krishnankutty Sudhir, Arizona Heart Institute, Phoenix, AZ
Introduction: Asian Indians are at a high risk for coronary artery disease (CAD). Carotid 
intimal medial thickness (CIMT) is strongly associated with CAD and is a risk factor for 
myocardial infarction and stroke. Traditional risks do not appear to be strong predictors of 
risk for CAD in Asian Indians. Lp (PLA2) has been shown to an independent risk factor for 
CAD in WOSCOPS Study. However, the relationship of LpPLA2 and CIMT is unknown in 
the general population and speciﬁcally among Asian Indians.
Methods: 250 subjects were randomly selected to participate from a large multicenter 
randomized population based prevalence study of Asian Indians. Of these, 105 randomly 
selected subjects underwent assessment of traditional, and emerging risk factor 
assessment. CIMT was measured using B mode images of anterior and posterior walls of 
common carotid artery proximal to the bifurcation using a 7.5 MHz linear probe. Plasma 
concentrations of LpPLA2 were determined by ELISA (diaDexus Inc., USA). Relationship 
between LpPLA2 and traditional, emerging risk as well as CIMT were evaluated.
Results: Of the 95 patients who completed the study, (mean age 49 ± 9; M 62%, F 38%), 
mean LpPLA2 was 189 ± 70 ng/ml. Mean anterior and posterior CIMT thickness was 0.16 
± 0.15 mm and 0.16 ± 0.18 mm respectively. LpPLA2 showed signiﬁcant correlation with 
total cholesterol (r= 0.43, p <.001), LDL cholesterol (r=0.45, p <.001), CIMT (r= 0.22, p 
= .04) matrix metalloproteinase (MMP) (r= .246, p = .016) and homocysteine (r=.217, p 
= .037). In patients with LDL >100 compared to those with LDL <100, mean LpPLA2 was 
signiﬁcantly higher (202.18 vs 125.6 ng/ml, p <.001). In a multivariate regression model, 
LpPLA2 was an independent predictor of CIMT (p = .005). This was independent of age, 
gender, HbA1C, LDL, total cholesterol, homocysteine, HsCRP, fasting triglyceride and 
mean systolic BP. In patients with either low LDL(<110 mg/dl) or high LDL(>110), LpPLA2 
remained an independent predictor of CIMT (t=2.43; p=0.017)
Conclusion: 1. LpPLA2 is signiﬁcantly associated with total cholesterol, LDL, MMP and 
homocysteine levels. 2. LpPLA2 is an independent predictor of risk of atherosclerosis as 
detected by CIMT in Asian Indians at all levels of LDL.
1129-106 Plasma Adiponectin Concentration and Renal Function, 
and its Predictive Role in Cardiovascular Disease
Yoshio Iwashima, Takeshi Horio, Masahiro Kumada, Yoshihiko Suzuki, Shinji Kihara, 
Hiromi Rakugi, Yuhei Kawano, Tohru Funahashi, Toshio Ogihara, Osaka University 
Graduate School of Medicine, Suita City, Osaka, Japan, National Cardiovascular Center, 
Suita City, Osaka, Japan
Background: Adiponectin is one of the key molecules in the metabolic syndrome. The 
plasma concentration of adiponectin is known to decrease in coronary artery disease. In 
contrast, its plasma level has been shown to increase in several renal diseases. However, 
the mutual relations of renal function and cardiovascular complications to adiponectin 
level remain unclear. Thus, we conducted the present study to examine the clinical and 
biochemical associations between adiponectin and renal function, and to prospectively 
investigate the predictive power of adiponectin for cardiovascular events.
Methods: A total of 125 subjects with normal renal function (Control) and 25 patients with 
non-dialysis chronic renal failure (CRF) were enrolled and monitored for 32±2 months.
Results: After adjustment for confounding factors, adiponectin was signiﬁcantly higher in 
CRF patients (13.7±2.2 vs. 7.0±0.7 µg/ml in Control, p<0.02). Even in control subjects, 
adiponectin was strongly correlated with creatinine clearance (r=-0.48, p<0.01) and 
24 hour-urinary protein excretion (r=0.41, p<0.01). Multiple linear regression analysis 
revealed that creatinine clearance was independently associated with adiponectin 
in control subjects (p<0.001). In a follow-up study, Kaplan-Meier curves showed a 
signiﬁcantly lower event-free survival rate in subjects with lower adiponectin (<7.7 µg/ml, 
p<0.02). By Cox regression analysis, lower adiponectin was associated with a 57% higher 
risk for cardiovascular events, even after adjustment for confounding factors (p<0.03). 
Furthermore, the relative distribution of isoforms of adiponectin was analyzed in CRF 
patients. The percentage of the high molecular weight form in total adiponectin was 
signiﬁcantly higher than that of the hexamer or trimer.
Conclusions: Renal function is a signiﬁcant regulator of adiponectin not only in patients 
with renal failure, but also in subjects with normal renal function. However, we also 
demonstrated that low adiponectin is an independent predictor of cardiovascular disease, 
separate from the increase in its level induced by renal dysfunction.
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1129-107 Losartan has Positive Effects on Lipid Metabolism 
Compared to Atenolol in Patients with HYpertension 
and Electrocardiographic Left Ventricular Hypertrophy. 
The LIFE Study.
Michael H. Olsen, Kristian Wachtell, Gareth Beevers, Björn Dahlöf, Richard Devereux, 
Ulf de Faire, Frej Fyhrquist, Hans Ibsen, Stevo Julius, Sverre Kjeldsen, Ole Lederballe-
Pedersen, Lars Lindholm, Markku Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel, 
Glostrup University Hospital, Glostrup, Denmark
Background: We wanted to investigate the effects of beta-blockers and angiotensin 
receptor antagonists on lipids and their effect on outcome in the LIFE study.
Methods: Total (TC) and high-density lipoprotein (HDL) cholesterol were measured at 
baseline and annually during losartan (L) - or atenolol (A) - based treatment in 9193 
hypertensive patients with left ventricular (LV) hypertrophy. The composite endpoint (CEP) 
was cardiovascular (CV) death, stroke and myocardial infarction.
Results: TC decreased comparably in the groups (Table). HDL decreased in the ﬁrst 2 
years then increased in both groups but remained higher on L than on A at each annual 
follow-up independently of statin use. Less decrease in HDL from baseline to the mean 
in-study value was associated with fewer CEPs (hazard ratio 0.32 per mmol/l. P<0.001) 
independent of high logUACR (1.39 per log(mg/mmol, P<0.001), Framingham risk score 
(1.04 per unit, P<0.001), Sokolow-Lyon voltage (1.01 per mm, P<0.001), Cornell product 
(1.01 per 100 mm*ms, P<0.05), baseline HDL (0.79 per mmol/l, P=0.08), CV disease 
(1.88, P<0.001) and diabetes (1.33, P<0.001) but not treatment allocation. Treatment was 
signiﬁcant when excluding change in HDL .
Conclusions: L reduced the drop in HDL during antihypertensive treatment. Less 
decrease in HDL was associated with fewer CEPs independently of other CV risk factors. 
The maintenance of HDL may partly explain the better outcome on L-based treatment 
in LIFE.
Compared to prior year: *P<0.05, **P<0.01, ***P<0.001.
Baseline 1 year 2 year 3 year 4 year 5 year
TC L 6.04(n=4321)
5.95***
(n=4256)
5.99*
(n=4100)
5.84***
(n=3961)
5.72***
(n=3818)
5.71**
(n=2802)
TC L vs. A NS <0.001 0.06 <0.05 NS NS
TC A 6.05(n=4290)
6.08
(n=4237)
6.04**
(n=4058)
5.90***
(n=3917)
5.76***
(n=3779)
5.75***
(n=2696)
HDL L 1.50(n=4317)
1.38***
(n=4254)
1.37***
(n=4099)
1.42***
(n=3960)
1.47***
(n=3818)
1.48**
(n=2802)
HDL L vs. A NS <0.001 <0.001 <0.001 <0.001 <0.001
HDL A 1.49(n=4289)
1.32***
(n=4234)
1.31**
(n=4055)
1.36***
(n=3915)
1.41***
(n=3779)
1.42***
(n=2696)
1129-108 The Omega-3 Index: Effects of Age, BMI, Diabetes and 
Fish Intake
William S. Harris, Scott A. Sands, Saint Luke’s Mid America Heart Institute, Kansas City, 
MO, University of Missouri-Kansas City, Kansas City, MO
Background: Increased intakes of omega-3 fatty acids (FA) reduce risk for death from 
coronary heart disease (CHD). We have recently proposed that a validated biomarker of 
omega-3 FA status (the Omega-3 Index) be considered as a potential new risk marker 
for CHD. The Omega-3 Index is the percent of total erythrocyte membrane FA present as 
eicosapentaenoic and docosahexaenoic acids (EPA and DHA). The Omega-3 Index can 
vary from 2% to 12% in unsupplemented individuals, and is believed to be largely driven 
by omega-3 FA intake. The purpose of this study was to explore other factors inﬂuencing 
the variance in this biomarker.
Methods: We measured the Omega-3 Index in blood samples and collected demographic 
data from 163 healthy adults in Kansas City who were not taking ﬁsh oil supplements.
Results: The average Omega-3 Index in this population was 4.9 ± 2.1%. On multivariable 
analysis, four factors signiﬁcantly (and independently of all others) inﬂuenced the Omega-
3 Index: the number of servings of tuna/non-fried ﬁsh per month, age, body mass index 
(BMI) and the presence of diabetes. Other factors in the model were ethnicity, smoking 
status, and gender; these did not inﬂuence the Index. The Omega-3 Index rose 0.24 
units with each additional serving of tuna/non-fried ﬁsh (p<0.0001), and 0.5 units for 
each decade in age ((p<0.0001). The Index fell by 1.13 units in the presence of diabetes 
(p=0.015), and by 0.1 units with each unit increase in BMI (p=0.001).
Conclusion: While the association between the Omega-3 Index and ﬁsh intake was 
expected, the rise in the Index with age was not and could indicate that omega-3 FA 
slowly accumulate in tissues over time. The inverse associations with BMI and diabetes 
suggest that reduced tissue levels of omega-3 FA may explain at least part of the increase 
in CHD risk associated with these conditions.
1129-109 Association Between Electronegative Low Density 
Lipopotein Subfraction and Insulin Resistance in Non-
Diabetic Children
Bo Zhang, Takuya Kaneshi, Takao Ohta, Koichiro Kumagai, Keijiro Saku, Fukuoka 
University, Fukuoka, Japan, Ryukyus University, Fukuoka, Japan
Background: Insulin resistance is associated with metabolic syndrome, a clustering of 
metabolic risk factors for cardiovascular diseases, including dyslipidemia. The present study 
examined the relation between charge-based lipoprotein subfractions and insulin resistance.
Methods: Seventy-ﬁve 10-year-old boys were included in the study. Plasma lipoprotein 
subfractions were quantiﬁed by capillary isotachophoresis (cITP) analysis. Levels of each 
cITP lipoprotein subfraction were presented as the peak area relative to an internal marker.
Results: Plasma lipoprotein was separated into subfractions including 3 high density 
lipoprotein (HDL) fractions [fast (i)-, intermediate (i)-, and slow (I)-migrating HDL], a very low 
density lipoprotein (VLDL)/intermediate density lipoprotein (IDL) fraction, and 2 low density 
lipoprotein (LDL) fractions (fast- and slow-migrating LDL) according to electric charges by 
cITP. Insulin resistance as assessed by the homeostasis model assessment (HOMA-IR) 
was negatively correlated with levels of cITP fHDL (r=-0.34, p<0.01), an apo A-I-containing 
lipoprotein, and positively correlated (p<0.01) with levels of cITP VLDL/IDL (r=0.47) and 
fLDL (r=0.41), an electronegative LDL subfraction. The relation between HOMA-IR and cITP 
fLDL was independent of body mass index and LDL size, but dependent on TG levels.
Conclusion: Altered charge-based lipoprotein subfractions are an integral part of insulin 
resistance. These factors may contribute to the well-known relationship between insulin 
resistance and risk of cardiovascular diseases and might become therapeutic targets in 
insulin-resistant subjects.
1129-110 Apolipoprotein B Levels are Raised in the Metabolic 
Syndrome
Tora Leong, Anthony P. Fitzgerald, Catherine McGorrian, Ian M. Graham, The European 
COMAC Group, Adelaide & Meath Hospital, Dublin, Ireland
Background: Low HDL cholesterol and raised triglycerides are part of the metabolic 
syndrome (MS). We determined if apolipoproteins B and AI (ApoB and ApoAI) levels are 
altered in the MS independent of traditional lipid markers.
Methods: The European Concerted Action Project Homocysteinaemia and vascular 
disease COMAC case-control study was used to examine this association. The NCEP 
deﬁnition of the MS was used, with BMI ≥ 30 as a proxy for waist circumference. ApoB and 
ApoAI levels were compared in patients with and without the MS, both with and without 
vascular disease using the Krushal-Wallis rank sum test.
Results:
Table 1 - Median ApoB and ApoAI levels in mmol/L with inter-quartile ranges in brackets
With vascular disease
(N=750, MS=219 or 29%)
With the metabolic 
syndrome
Without the 
metabolic syndrome P values
ApoB levels
ApoAI levels
1.4 (1.2, 1.7)
1.2 (1.1, 1.5)
1.2 (1.0, 1.5)
1.3 (1.1, 1.5)
P=0.0001
P=0.1000
Without vascular disease
(N=800, MS=67 or 8%)
With the metabolic 
syndrome
Without the 
metabolic syndrome P values
ApoB levels
ApoAI levels
1.5 (1.2, 1.7)
1.2 (1.0, 1.4)
1.1 (0.9, 1.4)
1.3 (1.1, 1.5)
P=0.0001
P=0.0002
Median ApoB levels increased (1.0, 1.15, 1.2, 1.5, 1.4, 1.5) while median ApoAI levels 
decreased (1.3, 1.3, 1.2, 1.2, 1.2, 1.1) with 0 to 5 components of the MS, showing a 
graded association with the MS (P<0.001 for trend) in patients without vascular disease. 
The adjusted odds ratio for a 0.1 mmol/L change in ApoB and ApoAI was 1.3 and 0.72 
respectively (P<0.001) in patients without vascular disease. Using logistic regression 
analysis, this remained signiﬁcant after adjusting for age, sex, homocysteine, creatinine, 
total and LDL cholesterol. Results were similar in patients with vascular disease.
Conclusions: Raised ApoB and decreased ApoAI levels are found in patients with the 
MS, independent of total and LDL cholesterol. Further studies are needed to examine their 
added predictive values over conventional lipid markers in cardiovascular risk prediction 
associated with the metabolic syndrome.
1129-111 Attainment of Optimal National Cholesterol Education 
Program Adult Treatment Panel III Treatment Goals 
in High Risk Patients: Dose Comparison of VYTORIN 
(Ezetimibe/Simvastatin) and Atorvastatin
Christie M. Ballantyne, Nicola Abate, Zhong Yuan, Thomas King, Joanne Palmisano, 
Merck & Co., Inc., West Point, PA
Background: The recent update to NCEP ATP III reinforces the importance of an LDL-C 
goal of <100 mg/dL in high risk patients (those with CHD or CHD risk equivalent), and 
an optional LDL-C goal of <70 mg/dL in very high risk patients. Achievement of the <70 
mg/dL goal is considered to be very difﬁcult to attain in these patients.
Methods: A multicenter, double blind, randomized, 8-arm parallel group study that 
compared the LDL-C reducing efﬁcacy of milligram-equivalent (10, 20, 40, and 80 mg) 
statin doses of ezetimibe/simvastatin (E/S) and atorvastatin (A) in 1902 patients with 
hypercholesterolemia was performed. This analysis compares patients with CHD/CHD 
risk equivalents who attained a treatment target of <100 mg/dL and <70 mg/dL across 
treatment groups.
Results: Baseline characteristics for this patient subgroup by treatment were balanced 
by risk category characteristics, including diabetes, smoking, waist circumference, and 
lipids [LDL-C, HDL-C, TG] (data not shown). Goal attainment for LDL-C levels <100 mg/dL 
and <70 mg/dL in high risk patients treated with E/S and A at each dose comparison is 
shown in the ﬁgure.
Conclusions: Dual inhibition of cholesterol biosynthesis and absorption provided by E/S 
was a superior option than A for achievement of NCEP ATP III LDL-C goal of <100 mg/dL 
and the optional goal of <70mg/dL. The alternative start dose of E/S (10/40 mg) gets 90% 
of patients to a goal of <100 mg/dL and the majority of high risk patients to the optional 
LDL-C goal of <70 mg/dL. 
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1129-112 Agreement Between World Health Organization and 
National Cholesterol Education Program Deﬁnitions of 
the Metabolic Syndrome Depends Upon Sex and Ethnic 
Group
Dhananjay Vaidya, Moyses Szklo, Jingzhong Ding, Russell Tracy, Pamela Ouyang, 
Johns Hopkins University, Baltimore, MD
The metabolic syndrome (MS) is a cluster of abnormalities that increases the risk of 
cardiovascular mortality. Of the two clinical deﬁnitions of MS currently in use, the World 
Health Organization (WHO) emphasizes insulin resistance while the NCEP Adult 
Treatment Panel 3 (ATP3) emphasizes dyslipidemias. This study quantiﬁes the agreement 
between deﬁnitions in the Multi-Ethnic Study of Atherosclerosis (MESA). 
Methods: MESA is a 6-center cohort study. We analyzed 2605 Caucasians (C; 48% 
male), 800 Chinese-Americans (Ch; 48% male), 1879 African-Americans (A; 45% male) 
and 1492 Hispanic Americans (H; 48% male) who had complete data for medications, 
anthropometry, blood pressure, lipid proﬁle, glucose and insulin and classiﬁed them by 
ATP3/WHO criteria. 
Results: Agreement between the two deﬁnitions was 82% (kappa = 0.57). Among 
subjects classiﬁed as MS by ATP3 alone, 74% of 784 subjects were not MS by WHO 
solely because they were not insulin resistant. Conversely, 90% of 468 subjects those that 
were MS by WHO alone lacked only one risk criterion to be MS by ATP3. Among women 
of all ethnicities, ATP3 detects a greater percentage as MS (p<0.001, table). Among Ch, 
A and H men, WHO classiﬁes a greater number as MS (p<0.001). 
Conclusion: Though the WHO and ATP deﬁnitions approximately coincide, the 
agreement of MS classiﬁcations differs by sex and ethnic group. These differences may 
make a particular deﬁnition better suited for predicting events in different sexes and ethnic 
groups.
Percentage of subjects classiﬁed as MS by WHO and ATP3 deﬁnitions
Sex Male Female
Ethnicity C Ch A H C Ch A H
ATP3 only 16% 12% 12% 17% 11% 5% 8% 6%
WHO only 2% 4% 8% 3% 7% 13% 11% 11%
Both ATP3 and WHO 16% 21% 27% 33% 18% 15% 24% 30%
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842-3 Stroke Risk in Hypertensive Patients with Coronary 
Artery Disease (CAD): The International Verapamil SR-
Trandolapril Study (INVEST)
Carl Pepine, Antonio Coca, Franz Messerli, Athanase Benetos, Qian Zhou, Annette 
Champion, Rhonda Cooper-DeHoff, University of Florida College of Medicine, 
Gainesville, FL
Background: Patients with CAD and hypertension are at increased risk of atherothrombotic 
events including MI and stroke. In INVEST a verapamil SR (Ve) strategy was as effective 
as an atenolol (At) strategy in reducing CV outcomes in 22,576 hypertension patients 
with CAD. Few data are available on how BP control with these agents impacts the risk 
of stroke in this population.
Methods: Assessed stroke risk by baseline conditions, systolic BP (SBP), BP control, 
and drug strategy.
Results: Strokes (fatal + nonfatal) occurred in 176 (1.6%) and 201 (1.8%) patients [HR 
0.88, CI 0.72,1.08] in the Ve and At strategies, respectively. Mean SBP reduction and BP 
control were similar between strategies. Mean treatment SBP was higher in patients who 
developed stroke than in those who did not (142 vs 135 mmHg, P<0.001), and BP control 
was lower (36.9 vs 60.4%, P<0.001). Frequencies of nonfatal stroke (20.3 vs 9.5%) and 
total stroke (5.0 vs 1.5%) were higher in patients with prior stroke than without stroke. A 
stepwise Cox proportional hazards model identiﬁed prior stroke/TIA, US residency, black 
race, increased age, diabetes, arrhythmia, revascularization, smoking, and prior MI as 
factors associated with increased stroke risk (Figure).
Conclusion: There was a nonsigniﬁcant trend of reduced stroke risk in the Ve strategy 
compared to the At strategy. A verapamil SR-based strategy is at least as effective as an 
atenolol-based strategy for reducing risk of adverse CV outcomes, including stroke, in 
hypertensive CAD patients. 
10:45 a.m.
842-4 Independent Components of Chronic Kidney Disease as 
a Cardiovascular Risk Factor: Results from the Kidney 
Early Evaluation Program (KEEP)
Peter A. McCullough, Wendy W. Brown, Janet B. McGill, Allan J. Collins, Shu-Cheng 
Chen, Suying Li, Ajay K. Singh, Andrew S. Narva, William H. Herman, George L. 
Bakris, Claudine T. Jurkovitz, Keith C. Norris, Pablo E. Pergola, Michael J. Klag, KEEP 
Investigators, William Beaumont Hospital, Royal Oak, MI, Johns Hopkins School of 
Medicine, Baltimore, MD
Background. Chronic kidney disease (CKD) is recognized as an independent 
cardiovascular disease (CVD) risk state and has been deﬁned by levels of estimated 
glomerular ﬁltration rate (GFR) and the presence of microalbuminuria. Anemia is a 
common comorbidity in CKD. The relative independent relationship between these three 
CKD-related measures, and CVD is not fully known.
Methods. The Kidney Early Evaluation Program is a multicenter screening program of 
individuals at risk for CKD. Estimated GFR was computed using the 4-variable MDRD 
equation based on serum creatinine, age, gender, and race. Of 24,070 (age 52.6±15.8 
years, 68.9% female, 39.4% African American) who volunteered for screening, 3,883 
(16.1%) had a self-reported history of CVD (myocardial infarction, stroke, peripheral artery 
disease). Multivariate analysis found that age > 75 years (referent: 46-60), OR=2.17, 
95% CI 1.89-2.50, p<0.0001; male gender, OR=1.20, 95% CI 1.09-1.33, p=0.0004; 
urine microalbumin > 30 mg/L (referent: ≤ 10); OR=1.63, 95% CI 1.46-1.82, p<0.0001; 
GFR 30-59 ml/min (referent: ≥ 90), OR=1.37, 95% CI 1.20-1.57, p<0.0001; GFR<30 
ml/min (referent: ≥ 90), OR=1.84, 95% CI 1.31-2.59; p=0.0004; and hemoglobin < 12.8 
g/dl (referent: >14.6), OR=1.45, 95% CI 1.27-1.66, p<0.0001, were all independently 
associated with CVD. Conversely, African American race was inversely related to self-
reported CVD (referent: white), OR=0.83, 95% CI 0.75-0.92, p=0.0003. Those with all 
three CKD-related factors had a 35.8% prevalence of CVD.
Conclusions: Among individuals who volunteered for this screening program, CVD 
was common. Estimated GFR, microalbuminuria, and anemia contribute to the reported 
cardiovascular risk in CKD patients, and when all three are present, over one-third of 
individuals had known CVD.
11:00 a.m.
842-5 Risk Predictors for Cardiovascular Outcomes in 
Patients With Hypertension and Left Ventricular 
Hypertrophy: The LIFE Study
Sverre E. Kjeldsen, Stevo Julius, Steven Snapinn, Paulette A. Lyle, Richard B. Devereux, 
Bjorn Dahlof, Merck & Co., Inc., West Point, PA
Background: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) 
study showed superiority of losartan over atenolol for reduction of risk of the primary 
composite endpoint (cardiovascular death, stroke, and myocardial infarction) in 
hypertensives with left ventricular hypertrophy (n=9193) aged 55-80 years treated for an 
average of 4.8 years. We aimed to investigate baseline characteristics as predictors of 
outcome and to construct a risk prediction model.
Methods: Univariate analyses identiﬁed 12 baseline variables that had a signiﬁcant 
impact on the development of the composite endpoint. Multivariate analysis used a Cox 
regression model with stepwise selection process. P<0.001 was required for inclusion 
in ﬁnal model. A risk score was developed from the coefﬁcients of the risk factors from 
the multivariate analysis and from the development of the composite endpoint, and was 
internally validated using naïve and jackknife procedures.
Results: Ranked by chi-square values, the 12 variables that fulﬁlled these criteria were 
age (hazard ratio [HR] per 10 years: men 1.54, women 2.19), and the following age-
adjusted predictors: male sex (HR 2.02), albuminuria (10-fold, HR 1.44), current smoker 
(HR 1.61), previous stroke/transient ischemic attack (HR 1.71), diabetes (HR 1.61), atrial 
ﬁbrillation (HR 1.91), ischemic heart disease (HR 1.47), total cholesterol (per mmol/L, 
HR 1.12), exercise >30 minutes twice per week (HR 0.77, P<0.001), and LVH measured 
by Sokolow-Lyon (per 10 units, HR 1.12) and Cornell product (CP, per 1000 units, HR 
1.09, P=0.0008) methodologies. P-value for all <0.0001 except as noted. This model 
achieved far better separation of highest and lowest quartiles and deciles of risk than did 
the Framingham risk score.
Conclusion: A multivariate model of characteristics easily ascertained at treatment 
baseline strongly predicted outcomes in hypertensive patients with left ventricular 
hypertrophy treated for almost 5 years in the LIFE study.
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842-6 Population Trends in Hypertension Detection, Treatment 
and Control 1980-2002: The Minnesota Heart Survey
Russell V. Luepker, David R. Jacobs, Jr., Susan J. Duval, Christopher Armstrong, Donna 
K. Arnett, University of Minnesota, Minneapolis, MN
Background: Hypertension (HTN) is an established risk factor for cardiovascular 
disease. With effective treatment available, HTN treatment is a national health objective. 
However, the majority of hypertensives are inadequately detected, treated and controlled 
despite decades of effort.
Hypothesis: Population levels of HTN detection, treatment and control are not 
improving.
Methods: To determine blood pressure (BP) patterns, adult residents of the Minneapolis/
St. Paul metropolitan area (2.6 million population) age 25-74 were randomly selected at 
ﬁve-year intervals from 1980-82 to 2000-02. Standardized blood pressure measurements, 
medication inventories and other health data were collected.
Results: In a cross-sectional design with an average participation rate of 65%, 10,207 
men and 11,566 women were measured in ﬁve surveys. Using a standard of 160/95 
mmHg, treatment and control of hypertension was 58% in men and 67% in women in 
1980-82, ﬂattened during the 1990’s and reached 88% in men and 87% in women in 
2000-02. At this BP criterion, unaware, untreated and uncontrolled HTN was rare. Using 
the lower standard of 140/90mmHg, treatment and control of hypertension was 20% in 
men and 27% in women in 1980-82, also ﬂattened during the 1990’s but reached 44% 
of men and 55% of women controlled for hypertension in 2000-02. Those unaware, 
untreated and uncontrolled fell signiﬁcantly. The change was largely associated with 
increased use of medications. Steady decreases in non-pharmacologic methods of HTN 
control (weight loss, diet and exercise) were observed. Parallel patterns in stroke mortality 
in the metropolitan area were also observed.
Conclusion: After a leveling of HTN detection, treatment and control in the 1990’s, 
improving patterns are observed throughout the general population in Minneapolis-St. 
Paul. These observations suggest improved medical detection and HTN care.
11:30 a.m.
842-7 Infection and Inﬂammation Are Associated With 
Hypertension: The GOCADAN Study
Jianhui Zhu, Richard R. Fabsitz, Daniel A. Canos, Katharine A. Gutman, Ranjith 
Shetty, Yetunde Famogun, David R. Robinson, Barbara V. Howard, Stephen E. Epstein, 
Washington Hospital Center, Washington, DC
Background--Hypertension is an important risk factor for cardiovascular morbidity and 
mortality. Recent evidence has implicated possible roles of inﬂammation. We examined 
whether inﬂammation is associated with hypertension, and whether this association 
is, in part, related to infection. Methods--Serum levels of C-reactive protein (CRP) and 
homocysteine, IgG antibodies to cytomegalovirus, herpes simplex virus type 1 and type 
2, H. pylori, C. pneumoniae, and coronary risk factors (age, male sex, smoking, diabetes 
and hypercholesterolemia) were measured in 610 Eskimos (mean age 43±15 years; 45% 
men). These were a subset of patients who participated in the GOCADAN (Genetics of 
Coronary Artery Disease in Alaska Natives) study, which includes 1,214 Eskimos who are 
members of approximately 40 families in several villages on Norton Sound. Hypertension 
was deﬁned as an arterial pressure >140/90 mmHg and/or the patient was being treated 
for hypertension. Results--Of the 610 study subjects, 21 % had hypertension. Mean levels 
of CRP and homocysteine in the hypertensive and in the non-hypertension individuals 
were 3.6±6.5 vs. 2.7±6.6 mg/L (p=0.16) and 9.0±3.8 vs.7.1±2.7 micro mol/L (p<0.01), 
respectively. High levels of CRP and homocysteine (≥75th percentile values) were 
signiﬁcantly associated with the presence of hypertension. The associations remained 
signiﬁcant after adjustment for coronary risk factors, including age, male sex, smoking, 
diabetes and hypercholesterolemia. Adjusted odds ratios (95% conﬁdence interval) 
were 1.69 (1.03-2.76) for high CRP, and 1.71 (1.03-2.84) for high homocysteine levels. 
Interestingly, elevated levels of homocysteine were related to C. pneumoniae antibody 
serpositivity even after adjustment for covariates (p<0.01). In contrast, although high CRP 
levels were positively associated with C. pneumoniae infection on univariate analysis 
(p=0.02), signiﬁcance was lost after adjustment for other infections. 
Conclusion--These results demonstrated signiﬁcant associations between inﬂammation 
and the risk of hypertension, and suggest that the risk posed by inﬂammation is, in part, 
related to infection.
11:45 a.m.
842-8 Irbesartan Reduces Common Carotid Artery Intima-
Media Thickness and Area in Hypertensive Patients, as 
Compared to Atenolol
David Mörtsell, Clas Held, Karin Malmqvist, Thomas Kahan, Karolinska Institutet at 
Danderyd Hospital, Stockholm, Sweden
Background: Angiotensin II promotes cell growth and has been implicated in the 
development and maintenance of left ventricular (LV) hypertrophy and of structural 
vascular changes, including hypertrophy and atherosclerosis. We hypothesized that 
blockade of the renin-angiotensin-aldosterone system would reduce structural arterial 
changes beyond the effects of BP reduction.
Methods: Hypertensive patients with LV hypertrophy (age 55±9 ys, BP 162±19/104±8 mm 
Hg, LV mass index 148±31 g/m2) were randomized to receive double-blind the angiotensin 
receptor blocker (ARB) irbesartan (n=52) or the beta-1 receptor blocker atenolol (n=56). 
Ultrasonography of the left and right common carotid artery (CCA) and echocardiography 
was performed at week 0 and 48. Data are given as means ± SD.
Results: With similar reductions in BP, irbesartan reduced LV mass more than atenolol 
(-26±29 vs -14±21g/m2, p=0.028). CCA intima-media thickness was non-signiﬁcantly 
reduced by irbesartan (from 0.92±0.14 mm, by -0.013±0.100 mm), whereas it increased by 
atenolol (from 0.94±0.21 mm, by +0.030±0.120 mm, p=0.018; p=0.003 between groups). 
CCA lumen diameter was less reduced by irbesartan (from 6.4±0.9 mm, by -0.2±0.3 mm, 
p=0.007) than by atenolol (from 6.2±0.7 mm, by -0.3±0.3 mm, p<0.001; p=0.005 between 
groups). Thus, CCA intima-media area was reduced by irbesartan (from 21.3±5.0 mm2, by 
-0.90±2.45 mm2, p=0.034) but unchanged by atenolol (from 21.3±6.1 mm, by -0.18±2.71 
mm; p=0.041 between groups). CCA intima-media thickness and area related to LV mass 
index (both r=0.32, p<0.001) and systolic BP (both r=0.36, p<0.001). Changes in CCA 
intima-media thickness and area did, however, not relate to changes in LV mass.
Conclusions: The favorable effects by irbesartan on CCA intima-media thickness and 
area indicate a role for angiotensin II in the control of structural vascular changes, beyond 
the effects of BP alone. The smaller concomitant reduction in CCA lumen diameter 
by irbesartan suggests an outward vascular remodeling. These effects by an ARB, in 
addition to reduction in BP, may improve cerebral blood ﬂow and thus be important in the 
prevention of cerebrovascular events.
POSTER SESSION
1155  Endothelial Function, Atherosclerosis, 
and Thrombosis: Clinical Investigation
Tuesday, March 08, 2005, 1:30 p.m.-5:00 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 1:30 p.m.-2:30 p.m.
1155-95 Sildenaﬁl Prevents Endothelial Dysfunction Induced by 
Ischemia and Reperfusion via Opening of ATP-Sensitive 
K Channels. A Human in vivo Study.
Tommaso Gori, Silvia Sicuro, Saverio Dragoni, Giovanni Donati, Sandro Forconi, John D. 
Parker, Università degli Studi di Siena, Siena, Italy, Mount Sinai Hospital and University 
Health Network Hospitals, Toronto, Canada
Background. Animal studies have demonstrated that administration of sildenaﬁl can 
limit myocardial damage induced by prolonged ischemia, an effect that appears to 
be mediated by opening of ATP-sensitive potassium (K-ATP) channels. No study has 
investigated whether sildenaﬁl can also prevent the impairment in endothelium-dependent 
vasodilatation induced by ischemia-reperfusion (IR) in humans.
Methods and Results: In a double-blind, placebo-controlled, cross-over design, 10 
healthy male volunteers (age 25-45 years) were randomized to oral sildenaﬁl (50 mg) 
or placebo. Two hours later, endothelium-dependent, ﬂow-mediated dilatation (FMD) of 
the radial artery was measured before and after IR (15 minutes of ischemia at the level 
of the brachial artery followed by 15 minutes of reperfusion). Seven days later, subjects 
received the other treatment (i.e., placebo or sildenaﬁl) and underwent the same protocol. 
Pre-IR radial artery diameter and FMD, as well as baseline radial artery diameter after IR, 
were similar between visits (P=ns). After placebo administration, IR signiﬁcantly blunted 
FMD (before IR: 7.9±1.1%; after IR: 1.2±0.7%, P<0.01). Importantly, Sildenaﬁl limited 
this impairment in endothelium-dependent vasodilatation (before IR: 7.0±0.9%; after IR: 
6.2±1.1%, P=ns; P<0.01 compared to placebo). In a separate protocol, this protective 
effect was completely prevented by prior administration of the sulfonylurea glibenclamide 
(glyburide, 5 mg), a blocker of K-ATP channels (n=7; FMD before IR: 10.3±1.5%; after IR: 
1.3±1.4%, P<0.05).
Conclusions: In humans, oral sildenaﬁl induces potent protection against IR-induced 
endothelial dysfunction through opening of K-ATP channels. Further studies are needed 
to test the potential clinical implications of this ﬁnding.
1155-96 Platelet Function Assessment In Diabetic Patients On 
Dual Antiplatelet Treatment 
Dominick J. Angiolillo, Esther Bernardo, Celia Ramirez, Antonio Fernandez-Ortiz, Manel 
Sabaté, Pilar Jimenez-Quevedo, Raul Moreno, Rosana Hernández, Fernando Alfonso, 
Javier Escaned, Camino Bañuelos, Marco A. Costa, Theodore A. Bass, Carlos Macaya, 
University of Florida Shands-Jacksonville, Jacksonville, FL, Hospital Clinico San Carlos 
Madrid, Madrid, Spain
Background: Diabetics (D) have increased platelet reactivity and reduced aspirin-induced 
platelet inhibition compared to non-diabetics (ND). The effects on platelet reactivity of 
adding clopidogrel to aspirin therapy in the diabetic population is still unknown. The aim 
of this study was to compare platelet function in D and ND on sustained dual antiplatelet 
treatment. 
Methods: A total of 120 (60 D and 60 ND) patients (pts) were included. All pts had a 
known history of coronary artery disease and were on sustained treatment (>1 month) 
with aspirin (100 mg/d) and clopidogrel (75 mg/d). Pts were matched for baseline 
characteristics. D status was deﬁned according to WHO criteria. Platelet function 
assessment included platelet aggregation (PA) and platelet activation (PAc). PA was 
assessed by light transmittance aggregometry in platelet-rich plasma stimulated with 
ADP (6 and 20 µM) and collagen (6 µg/ml). PAc was assessed by P-selectin expression 
and PAC-1 binding to GPIIb/IIIa using whole blood ﬂow cytometry in platelets stimulated 
with ADP 2 µM. 
Results (mean±SD): PA (expressed as % of PA) and PAc (expressed as % of positive 
platelets) were signiﬁcantly increased in D compared to ND for all platelet function 
assessments.
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D (n=60) ND (n=60) p
ADP 6 µM (%) 36.5±13.5 31.2±14.6 0.04
ADP 20µM (%) 51.0±12.1 45.5±15.8 0.03
Collagen 6µg/ml (%) 41.9±17.3 31.9±18.5 0.003
PAC-1 (%) 39.5±20.4 30.4±18.6 0.01
P-selectin (%) 24.2±16.0 16.7±11.8 0.005
No differences in platelet function were observed among D on oral hypoglycemic (n=43) 
or insulin (n=17) therapy.
Conclusions: Platelet function, including both PA and PAc, remains increased in D 
compared to ND patients, even when dual antiplatelet treatment is used.
1155-100 Association of Plasma Interleukin-6 and Soluble Tumor 
Necrosis Factor-α Receptor 2 to C-Reactive Protein, the 
Metabolic Syndrome and Coronary Atherosclerosis in 
Asymptomatic Subjects.
Anand K. Rohatgi, Megan L. Wolfe, Kimberly McMahon, Thomas Rhodes, Cynthia J. 
Girman, Daniel J. Rader, Muredach P. Reilly, University of Pennsylvania, Philadelphia, 
PA, Merck Research Laboratories, Philadelphia, PA
Background: Interleukin-6 (IL-6) and tumor necrosis factor (TNF)-alpha are pro-
inﬂammatory cytokines that have been implicated in the pathogenesis of both insulin 
resistance and atherosclerosis and may predict cardiovascular disease (CVD) beyond 
current strategies.
Methods: In 894 asymptomatic subjects with a positive family history of premature 
CVD in the Study of Inherited Risk of Coronary Atherosclerosis (SIRCA), we examined 
the relationship of plasma levels of IL-6 and soluble TNF-� receptor 2 (sol-TNFR2) to 
NCEP-deﬁned metabolic syndrome (MetSyn), plasma C-reactive protein levels (CRP), 
and coronary artery calciﬁcation (CAC), measured by electron beam tomography, a non-
invasive index of coronary atherosclerosis.
Results: Plasma levels of IL-6 (chi2 = 132.5, p for trend <0.001) and sol-TNFR2 (chi2= 
51.2, p for trend <0.001) increased with increasing MetSyn features. Both IL-6 (rho=0.5, 
p<0.001) and sol-TNFR2 (rho=0.28, p<0.001) were correlated (Spearman) with CRP 
levels. IL-6 and sol-TNFR2 levels were positively associated [odds ratio (95% conﬁdence 
interval) per quartile of IL-6 or sol-TNFR2 in ordinal regression of CAC categories] with 
CAC after adjusting for age, gender, and traditional risk factors (e.g., smoking, physical 
activity, etc.) [1.24 (1.11 to 1.40) p<0.001 (IL-6) and 1.18 (1.05 to 1.32) p<0.01 (sol-
TNFR2)] and even after further adjusting for plasma CRP levels and the MetSyn [1.16 
(1.02 to 1.32) p=0.03 (IL-6) and 1.12 (1.00 to 1.26) p=0.05 (sol-TNFR2)]. In subjects with 
the MetSyn (n=283), IL-6 [1.37 (1.06 to 1.77) p=0.02] and sol-TNFR2 [1.33 (1.07 to 1.65) 
p<0.01] were both predictive of CAC in fully adjusted models whereas CRP was not [1.00 
(0.80 to 1.25) p=0.99]
Conclusions: Plasma levels of IL-6 and sol-TNFR2 are associated with CAC even after 
accounting for traditional risk factors, plasma CRP levels and NCEP-deﬁned MetSyn. 
Both markers may provide incremental information regarding CVD risk, particularly in 
deﬁning high-risk subjects beyond current strategies. 
1155-101 Altered Regulation of Circulating Endothelial Progenitor 
Cell Pool in Patients with Cardiac Syndrome X
Hylton Miller, Jacob George, Haim Shmilovich, Anastasia Abashidze, Varda Deutsch, 
Gad Keren, Tel-Aviv Medical Center, Tel-Aviv, Israel
Background: Cardiac Syndrome X (CSX) presents as a typical chest pain with 
electrocardiographic changes suggestive of myocardial ischemia despite normal coronary 
arteriograms and its pathogenesis remains elusive. Endothelial progenitor cells (EPC) 
are present in the peripheral circulation, and promote angiogenesis an vasculogenesis. 
Herein, we investigated numbers and functional properties of circulating EPC in patients 
with CSX.
Methods: Fifteen patients (pts) with CSX and 20 healthy controls were studied. EPC 
numbers were evaluated by ﬂow cytometry, and functional properties of EPC were 
assayed including proliferative and adhesive capacity as well as their ability to support tube 
formation in the matrigel assay. High sensitivity C-reactive protein (CRP), erythropoietin, 
vascular endothelial growth factor (VEGF) and adiponectin were determined in the sera 
of all pts. There were no differences in the clinical proﬁle and use of medications. Results: 
Circulating EPC (CD34+/VEGFR-2+) were signiﬁcantly more abundant in CSX patients 
as compared with controls (mean of 0.0104% vs. 0.0004%, respectively p=0.0004). The 
ability of EPC to adhere to immobilized-ﬁbronectin was increased by 6.3-fold (p<0.0001) 
and to human umbilical vein endothelial cells, by 1.7-fold (p=0.01) as compared with 
controls. EPC from CXS patients had a signiﬁcantly reduced proliferative phenotype as 
compared with controls, evident by reduced colony forming unit numbers (6.9±1.1 vs. 
38.1±8.3, respectively p=0.0003). The ability of cultured media obtained from 10 day EPC 
of CSX patients to promote in-vitro tube formation in the matrigel assay was signiﬁcantly 
reduced as compared with controls. Adiponectin but not CRP or erythropoietin serum 
levels correlated with the number and functional properties EPC from CSX patients. 
Conclusions: Pts with CSX, similar to pts with acute coronary syndromes, exhibit 
increased numbers of EPC suggesting that true ischemia is present. However, functional 
properties of EPC from CSX pts are compromised and may partially account for the 
ﬁndings of abnormal coronary reserve in imaging modalities.
1155-102 Is Adrenomedullin-induced Vasodilation Largely 
Dependent On Endothelium-derived Nitric Oxide In 
Coronary Circulation In Humans?
Kentaro Ueda, Hiroki Teragawa, Katsuji Okano, Takayuki Hidaka, Hiroshi Takemoto, 
Yukiko Nakano, Tetsuji Shingu, Kazuaki Chayama, Yukihito Higashi, Masao Yoshizumi, 
Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
Backgroud: Adrenomedullin (AM) is a vasodilator peptide produced by vascular 
endothelium and smooth muscle cells. Several experimental studies have shown that AM 
causes vasodilation, in part, mediated by endothelium-derived nitric oxide (NO). However, 
it remains to be clariﬁed how NO contributes to AM-induced coronary vasoreactivity 
in humans. We examined whether NO contributes to the vasodilatory effects of AM on 
coronary arteries both at the level of conduit and resistance vessels. 
Methods: Ten patients undergoing coronary angiography to evaluate chest pain were 
enrolled. All patients had angiographically normal smooth epicardial coronary arteries. 
Patients with vasospastic angina, a history of previous myocardial infarction, or other 
serious diseases were excluded. AM (1 and 10 ng/kg/min) was infused into the left 
coronary ostium for two minutes. To assess the bioavailability of NO, after infusion of 
NG-monomethyl-L-arginine (L-NMMA, 40µmol/min for 5 minutes), AM was infused again 
at the same doses. Epicardial coronary diameter and coronary blood ﬂow (CBF) were 
evaluated by quantitative angiography and Doppler ﬂow velocity measurements. Changes 
in coronary diameter and CBF in response to AM were expressed as percent changes 
from baseline values. 
Results: Neither the intracoronary administration of AM nor L-NMMA altered the baseline 
hemodynamics. AM at a dose of 10 ng/kg/min dilated epicardial coronary arteries (4.3 ± 1.2 
%, p < 0.01) although AM at 1 ng/kg/min did not induce signiﬁcant vasodilation (1.1 ± 1.1 
%). AM increased the CBF both at the dose of 1 ng/kg/min (56.3 ± 13.8 %, p < 0.01) and 
at that of 10 ng/kg/min (49.3 ± 9.7 %, p < 0.01). After the infusion of L-NMMA, AM did not 
cause coronary vasodilation (1 ng/kg/min: 0.4 ± 0.7 %; 10 ng/kg/min: 0.0 ± 0.7 %, p <0.05 
vs. before). The increase in CBF in response to AM was attenuated after the infusion of L-
NMMA (1 ng/kg/min: 9.4 ± 4.0 %; 10 ng/kg/min: 14.5 ± 2.7 %, p < 0.01 vs. before). 
Conclusions: These ﬁndings suggest that L-NMMA attenuated AM-induced vasodilation of 
coronary arteries both at the levels of conduit and resistance vessels to large extent, indicating 
that AM-induced coronary vasodilation in humans may be largely mediated by NO.
1155-103 Early Renal Dysfunction Is Associated With 
Hypoadiponectinemia, and Subclinical Inﬂammation in 
Essential Hypertensive Subjects
Kyriakos Dimitriadis, Konstantinos Tsiouﬁs, Iﬁgenia Kaltsi, Carmen Vasiliadou, Dimitris 
Tousoulis, Nikos Zakopoulos, Pavlos Toutouzas, Christodoulos Stefanadis, Ioannis 
Kallikazaros, Hippokration Hospital, Athens, Greece
Background: Microalbuminuria (MA), and augmented levels of inﬂammatory mediators 
are related to atherosclerosis progression, while adiponectin is an emerging modulator 
of endothelial inﬂammatory response. We examined the relationships of urinary albumin 
excretion expressed as the albumin to creatinine ratio (ACR) with high-sensitivity C-
reactive protein (hs-CRP), soluble intercellular adhesion molecule-1 (sICAM-1), soluble 
vascular adhesion molecule-1 (sVCAM-1), and plasma adiponectin levels, in essential 
hypertensives.
Methods: 64 newly diagnosed untreated, non-diabetic, and with normal insulin sensitivity 
patients with stage I to II essential hypertension [40 men, aged 44 years, ofﬁce blood 
pressure (BP)=148/95 mmHg], on the basis of the mean of two non-consecutive spot 
urine ACR were divided into two groups: patients with MA (n=19) (mean ACR=30-300 
mg/g), and patients without MA (n=45) (mean ACR<30 mg/g).
Results: Microalbuminurics compared to normoalbuminurics had higher levels of hs-
CRP (2.38±1.12 vs 1.48±0.52 mg/l, p<0.001), sICAM-1 (252.88±80 vs 210±51 mg/dl, 
p<0.05), sVCAM-1 (1166±127 vs 972±261 ng/ml, p<0.0001), and lower adiponectin 
values (6.91±0.8 vs 12.15±4.62 µg/ml, p<0.0001). In the hypertensive group, ACR was 
associated with hs-CRP (r=0.582, p<0.0001), sICAM-1 (r=0.406, p<0.001), sVCAM-1 
(r=0.620, p<0.001), and negatively related to adiponectin (r=-0.514, p<0.001). By analysis 
of covariance, MA was associated with augmented hs-CRP, and attenuated adiponectin 
levels (p<0.005 for both cases). Moreover, the crude data showed a signiﬁcant percentage 
increase in hs-CRP values with increasing ACR quartiles (10, 19, and 41%, p<0.0001), 
and an attenuation of adiponectin levels with augmenting ACR quartiles (15, 30, and 18 
%, p<0.0001).
Conclusions: MA seems to reﬂect diverse microinﬂammatory processes, including 
adipose tissue-derived protein secretion, beyond the renal glomerulus, in essential 
hypertension. Further studies are needed to elucidate the pathophysiological mechanisms 
of these interrelationships.
1155-104 A Study of High-sensitivity C-Reactive Protein in Variant 
Angina Pectoris
Juyong Lee, Jeong-Uk Kim, Yunseok Choi, Sang-sig Cheong, Gangneung Asan 
Hospital, Gnagneung-si, South Korea
Background: Chest pain in variant angina pectoris (VAP) is related to vasospasm. Most 
spastic coronary segments have minimal coronary artery disease (CAD). Therefore 
coronary inﬂammation seems to play an important role in VAP also. Studies of inﬂammatory 
marker, high-sensitivity C-reactive protein (hs CRP) in VAP is rare. The aim is to compare 
the concentration of hs CRP in between VAP and normal persons.
Methods: 133 VAPs have been diagnosed with ergonovin (ERG) provocation coronary 
angiography (CAG)(n=71,51.4%) and ERG stress echocardiography (n=67,48.6%). 
Absence of ﬁxed CAD (> 50% of diameter stenosis) was conﬁrmed in both groups. 
Age, sex matched controls(n= 111) who have no history of any angina like chest pain 
were randomly selected from health screenig center. The control has no diabetes 
mellitus(DM), hypertension(HNT), hypercholesterolemia, current systemic infection. hs 
CRP concentration was checked by immunonephelometry in two groups.
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Results: 
Group(n) Mean of hs-CRP(mg/dl) p
Control(111) vs. VAP(138) 0.09±0.12 vs. 0.18±0.19 0.000
Control(111) vs. VAP without DM, HNT, 
Hypercholesterolemia, and smoking(53) 0.09±0.12 vs. 0.20±0.21 0.000
Control(111) vs. VAP without minimal CAD(58) 0.09±0.12 vs. 0.23±0.23 0.000
VAP with minimal CAD(25) vs.
VAP without minimal CAD(58) 0.17±0.18 vs. 0.23±0.23 0.317
Multiple logistic regression analysis showed hs CRP is the strong risk factor(odds 
ratio20.68, p=0.03).
Conclusion: hs CRP level was signiﬁcantly higher in VAP compared to control and was still 
higher in VAP without DM, HNT, hypercholesterolemia, and smoking. VAP without minimal 
CAD had higher hs CRP compared to control. hs CRP was the strong risk factor. Therefore, 
coronary inﬂammation might have a crucial role in the pathophysiology of VAP.
1155-105 Effect of Hypoxia on Coronary Vasomotor Response in 
Patients With Coronary Artery Disease
Armin Arbab-Zadeh, Joaquin E. Cigarroa, Jeffrey Trost, Richard A. Lange, Ellen C. 
Keeley, Benjamin D. Levine, Univ. Texas Southwestern Medical Center, Dallas, TX, 
Presbyterian Hospital, Dallas, TX
Background: Non-invasive assessment of coronary blood ﬂow in normal subjects 
suggests that moderate to severe hypoxia may result in coronary vasodilation. However 
patients with coronary atherosclerosis have abnormal endothelial function, which impairs 
the vasodilatory response to stimuli such as exercise or acetylcholine. Whether such 
patients also have impaired vasodilation in response to hypoxia, is unknown. We tested 
the hypothesis that hypoxia induced coronary vasodilation would be diminished in vessel 
segments with coronary artery disease.
Methods: Twelve patients (50+/-6.7 years old) with known or suspected coronary artery 
disease underwent coronary angiography for evaluation of chest pain. After exclusion of 
left main coronary artery disease subjects breathed hypoxic gas mixtures (FIO2 = 0.15 
and 0.10) corresponding to altitudes of 2500 and 5500m for 10 min each. Quantitative 
coronary angiography was employed in a blinded fashion to assess the effect of hypoxia 
on coronary diameter in normal (n=80) and diseased (n=63) artery segments. Arterial 
blood gas analysis was obtained to monitor the degree of hypoxemia.
Results: Average arterial pO2 concentrations were 82.4 +/- 10.6 at room air, 62.3 +/- 14.0 
at 15%, and 41.5 +/- 10.7 mmHg at 10% O2 concentration. Average coronary diameter 
was similar at room air and at 15% O2 (2.48 +/- 0.59 vs. 2.51 +/- 0.57mm, p=0.25); 
however it increased with 10% O2 (2.56 +/- 0.64mm, P<0.005). Further analysis revealed 
that only non-diseased vessel segments responded with vasodilation to hypoxemia (2.71 
+/- 0.69 vs. 2.87 +/- 0.64mm, p<0.05) whereas diseased segments did not (2.23 +/- 0.43 
vs. 2.30 +/- 0.52mm, p=0.18).
Conclusions: Hypoxemia induces coronary vasodilation in humans. This normal coronary 
vasomotor response is absent in blood vessel segments with coronary atherosclerosis. 
The combination of vasodilation in angiographically normal segments but not in diseased 
segments may result in a coronary steal phenomenon, and put such patients at risk for 
myocardial ischemia during exposure to hypoxia, and/or high altitude.
1155-106 Impaired Fasting Glucose Is Associated With Greater 
Subclinincal Coronary Atherosclerosis In Asymptomatic 
Men Without Diabetes
Khurram Nasir, Roger S. Blumenthal, Joel B. Braunstein, Jose AM Carvalho, Raul D. 
Santos, Johns Hopkins Medical Institutions, Baltimore, MD, Lipid Clinic Heart Institute 
(InCor) University, São Paulo, Brazil
Introduction: Impaired fasting glucose (IFG) is considered an intermediate stage in 
the natural history of disordered glucose metabolism. Recently the American Diabetic 
Association has proposed that the cutoff for IFG should be reduced from 110 to100 mg/dl. 
In this study we evaluate whether IFG is associated with subclinical atherosclerosis as 
measured by coronary artery calciﬁcation (CAC) .
Method & Results: We studied 539 asymptomatic men (46±7 yrs) without diabetes ( 
FBG<126 mg/dl as well in absence of any utilization of glucose lowering medication) 
who presented for electron-beam tomography in San Paulo, Brazil. The population were 
calssiﬁed as 1) normal FG (NFG) with FG<100 mg/dl (n=479), and 2) IFG with FBG≥100 
mg/dl (n=60). In this study, men with IFG showed higher values of systolic blood pressure, 
body mass index, TG and lower HDL as compared to participants with FBG<100 mg/dl. 
Overall, 221 (41%) and 60 (11%) of men had any CAC and CAC≥100 respectively. The 
prevalence on any CAC as well CAC≥100 was signiﬁcantly higher among individuals with 
IFG (table) .In multivariate regression analyses adjsuting for CHD risk factors, compared 
with NFG, IFG were signiﬁcantly more likely to have any CAC (OR: 1.9, 95% CI: 1.2-3.6, 
p=0.02) as well as CAC≥100 (2.6, 1.4-5.3, p=0.01).
Conclusion: FBG in the upper normal range appears to be an independently associated 
with presence and severity of CAC in apparently healthy adult men. Our ﬁnding lend 
support to the new IFG criteria as a risk marker for macrovascualr disease.
Prevalence of any CAC and moderate CAC according to FBG categories
IFG NFG P value
CAC>0 60% 39% <0.0001
CAC>100 29% 9% <0.0001
1155-107 Differential Effects of Acute Systemic Inﬂammation in 
Elastic and Muscular Type Arteries
Charalambos Vlachopoulos, Ioanna Dima, Konstantinos Aznaouridis, Nikolaos 
Ioakeimidis, Christodoulos Stefanadis, Athens Medical School, Athens, Greece
Background. Arterial stiffness and wave reﬂections are independent predictors of 
cardiovascular risk. Although recent evidence suggests an association between 
inﬂammation and increased atherosclerotic burden, the impact of inﬂammation on arterial 
elastic properties has not been thoroughly investigated.
Methods. We studied 22 healthy volunteers (mean age 35.7 yrs) after Salmonella Typhi 
vaccination that produces a mild, systemic inﬂammation, and after sham-vaccination. 
Aortic stiffness was evaluated with carotid-femoral pulse wave velocity (PWV, Complior©). 
Augmentation index (AIx) was measured as an index of wave reﬂections with high-ﬁdelity 
arterial tonometry and appropriate computer software (Sphygmocor©).
Results. Inﬂammation did not change heart rate, central and peripheral systolic, diastolic 
and pulse pressures. Inﬂammation produced a signiﬁcant increase in PWV (by 0.39 m/sec, 
P<0.05) at 8 hours (ﬁgure). PWV values returned towards, but not completely, baseline 
values at 32 hours (increase by 0.16 m/sec, P=NS). In contrast, AIx was reduced both at 
8 and 32 hours (absolute decrease by 5.6% and 4.7%, P<0.01 and P<0.05, respectively, 
ﬁgure) indicating a decrease in wave reﬂections due to peripheral vasodilation.
Conclusions. Acute systemic inﬂammation leads to deterioration of large, elastic-type 
arteries stiffness. In contrast, inﬂammation leads to decreased wave reﬂections apparently 
due to dilatation of peripheral muscular medium and small size arteries. 
1155-108 Overestimation of Aspirin Resistance
Udaya Tantry, Kevin Bliden, Kevin Hayes, Jason Yoho, Paul A. Gurbel, Sinai Center for 
Thrombosis Research, Baltimore, MD
Background: Various studies have reported a signiﬁcant incidence of aspirin resistance 
utilizing various techniques and have related this ﬁnding to cardiovascular events. The 
most widely used technique is the measurement of platelet aggregation induced by 
arachidonic acid (AA).
Methods: 5 normal subjects were studied before and 1 day after 325 mg aspirin. 143 
patients taking long term aspirin ( 325 mg ) qd were studied. 1 mM AA induced platelet 
aggregation was measured by conventional aggregometry (LTA) and thrombelestography 
(TEG) at baseline and after treatment. Aspirin resistance was deﬁned as > 50 % 
aggregation by LTA and > 85% by TEG..Results were expressed as mean +/- SD.
Results: In controls, 1 mM AA- induced aggregation by LTA was 82+/-10% at baseline 
and 1.7 +/- 1.0 % 1 day post-treatment ( p < 0.001), and by TEG was 100% at baseline 
and 3.5 +/-9 %at 1 day post-treatment ( p < 0.001). In patients, LTA aggregation was 3+/-2 
% and TEG aggregation was 4 +/- 7 %. Out of 143 patients, 1 patient was aspirin resistant 
by both methods.
Conclusion: Aspirin resistance is rare in patients treated with a full adult dose despite 
stringent criteria used in our deﬁnition. Our data suggest that the incidence reported in the 
literature is an overestimate. A uniform methodology and deﬁnition are indicated in order 
to assess those patients who are truly resistant to aspirin therapy.
1155-109 Correlation Between Apoptotic Endothelial 
Microparticles And Subclinical Inﬂammation In Healthy 
Individuals
Salim S. Virani, Julio A. Chirinos, Juan P. Zambrano, Joaquin Jimenez, Wenche Jy, 
Eugene Ahn, Arley Peter, Lawrence L. Horstman, Agustin Castellanos, Robert J. 
Myerburg, Yeon S. Ahn, Jackson Memorial Hospital, University of Miami, Miami, FL, 
Coulter Platelet Research laboratory, Miami, FL
Background: Markers of inﬂammation have been associated with increased 
cardiovascular risk in a broad spectrum of patients. In addition, endothelial cell (EC) 
apoptosis has been implicated in atherogenesis. However, an association between 
subclinical inﬂammation and EC apoptosis has not been studied. We investigated the 
correlation between circulating concentrations of Interleukin-6 (IL6), C-reactive protein 
(CRP), and endothelial microparticles (EMP) expressing an apoptotic or activation 
phenotype in healthy individuals.
Methods: Venous blood was obtained from 20 healthy nonsmoking male subjects aged 
between 20 and 35 years with no prior history of cardiovascular disease, hypertension, or 
diabetes. The constitutive marker CD31 (EMP31, apoptotic phenotype) and the activation 
marker CD62E (EMP62E, activation phenotype) were labeled by antibody ﬂuorescence. 
Flow cytometry was used to measure circulating EMP. We evaluated the association 
between IL6, CRP and the levels of EMP31, EMP62E, and the EMP31/EMP62 ratio.
Results: IL6 signiﬁcantly correlated with EMP31 (r=0.6; r2=0.36; p=0.004). There was no 
correlation between IL6 and EMP62E levels (r2=0.03; p>0.05). After adjusting for EMP62 
levels, the correlation between EMP31 and IL6 persisted (partial correlation r=0.61; 
r2=0.37; p=0.004). After adjusting for body mass index (BMI) and CRP, IL-6 signiﬁcantly 
predicted EMP31 levels (r2 increase=0.39; p=0.004). When the sample was divided in 
2 equally sized groups according to the 50th percentile of IL6 (53.8 pg/mL), subjects 
with higher IL6 had signiﬁcantly higher EMP31 (1337 ± 311 vs. 5702 ± 1878 counts/uL; 
p=0.03) and EMP31/EMP62E ratio (16.3 ± 5.4 vs 3.2±0.74; p=.0.02). C-reactive protein 
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signiﬁcantly correlated with the BMI (r= 0.49; r2= 0.24; p= 0.02), but not with EMP31, 
EMP62E, or the EMP31/EMP62E ratio.
Conclusion: EC apoptosis is associated with subclinical inﬂammation in healthy middle-
aged males. Increased EC apoptosis might be partially responsible for the increased 
cardiovascular risk associated with subclinical inﬂammation. Further studies are needed 
to deﬁne the mechanisms underlying this association.
1155-110 Vascular and Metabolic Effects of Fenoﬁbrate In 
Hypertriglyceridemic Patients
Kwang K. Koh, Seung H. Han, Michael J. Quon, Woong C. Kang, Mi-Seung Shin, Eak K. 
Shin, Gachon Medical School, Incheon, South Korea, NIH, Bethesda, MD
Background: We investigated the effects of fenoﬁbrate on vascular and metabolic 
aspects in patients with hypertriglyceridemia.
Methods: We administered placebo or fenoﬁbrate 200 mg daily to 46 patients with 
primary hypertriglyceridemia for 8 weeks. This study was randomized, double-blind, 
placebo-controlled, crossover in design.
Results: Study subjects had a mean age of 57±1 years and 18 (39%) were male. 
Compared with placebo, fenoﬁbrate decreased total cholesterol, non-HDL cholesterol, 
apolipoprotein B, and triglycerides, and increased HDL-C and apolipoprotein A-I (all 
P<0.001) while tending to decrease LDL cholesterol (P=0.069). Fenoﬁbrate signiﬁcantly 
improved percent ﬂow-mediated dilator response to hyperemia by 48±5% (P<0.001), 
lowered plasma levels of high sensitivity C-reactive protein (hsCRP) relative to baseline 
measurements from 0.80 to 0.70 mg/l (P=0.001), and ﬁbrinogen levels by 16±3% 
(P<0.001). There were inverse correlations between body mass index and baseline 
plasma adiponectin levels (r=-0.283, p=0.057). There were signiﬁcant correlations 
between baseline adiponectin levels and baseline triglycerides (r=-0.331, p=0.025), 
HDL-cholesterol (r=0.339, p=0.021), insulin (r=-0.337, p=0.022), or Quantitative Insulin-
Sensitivity Check Index (QUICKI) (r=0.391, p=0.007). Compared with placebo, fenoﬁbrate 
therapy signiﬁcantly increased plasma levels of adiponectin by 14±5% (P=0.008) and 
increased insulin sensitivity (assessed by QUICKI) by 6±2% (P=0.048). There were 
signiﬁcant correlations between percent changes in adiponectin levels and percent 
changes in ﬂow-mediated dilation (r=0.401, p=0.006), hsCRP (r=-0.443, p=0.002), insulin 
(r=-0.273, p=0.067), or QUICKI (r=0.292, p=0.049).
Conclusions: Fenoﬁbrate therapy signiﬁcantly improved the percent ﬂow-mediated 
dilator response to hyperemia and reduced levels of inﬂammation markers and increased 
adiponectin levels and improved insulin sensitivity in hypertriglyceridemic patients.
1155-111 Favourable Pleiotropic Effects of Ramipril and 
Telmisartan on Vascular Endothelium of Diabetic 
Patients
Phivos Symeonides, Spyridon Koulouris, Konstantinos Triantafyllou, Ekaterini Vratsista, 
Ilias Karabinos, Athanasios Kranidis, Nikolaos Thalassinos, Ioannis Nanas, Stamatios 
Stamatelopoulos, Pavlos Toutouzas, Evagelismos Hospital, Athens, Greece, Euroclinic, 
Athens, Greece
Background: The aim of this study was to compare the effect of an angiotensin converting 
enzyme inhibitor (ramipril), an angiotensin II receptor antagonist (telmisartan) and their 
combination on endothelial function parameters of diabetic patients.
Methods: Fourty patients, 57.3±8.5 years old (17 men, 23 women) with well controlled type 2 
diabetes mellitus, without hypertension, coronary artery disease, left ventricular dysfunction 
or microalbuminuria, were recruited in this double blind cross-over trial. They were started 
randomly on ramipril (2.5mg/day), or telmisartan (40mg/day) for 3 months. After a 2 week 
wash out period they crossed over to the alternative regimen. Finally, they received both 
agents for 3 more months. The following parameters were assessed at baseline and after 
each treatment period (i.e. at 3,6,9 months): ﬂow mediated dilation (FMD) of brachial artery 
(7.5 MHz ultrasound probe), serum levels of tissue plasminogen activator (t-PA) measured 
with ELISA, and von Willebrand factor (vWF) % plasma activity (ristocetin cofactor activity). 
Statistical analysis was done with Friedman’s analysis of variance.
Results: FMD and t-PA levels increased, while vWF levels decreased by all treatments 
(Table 1). Blood pressure and blood glucose levels were unaffected.
Table 1 
%FMD t-PA vWF(%)
Baseline 9±3.4 6.9±2.7 136.2±26
Ramipril 12.2±3.7 7.1±2.3 127.6±36
Telmisartan 17.6±7.6 7±2.3 127.9±28
Combination therapy 19±5.8 7.8±2.3 118.6±17.9
P <0.001 <0.001 <0.001
Conclusion: Both ramipril and telmisartan favourably affect vascular endothelial function 
in diabetic patients by improving FMD and ﬁbrinolysis.
1155-112 Antibody Against Synthetic Peptide From Oxidized 
Apolipoprotein B Decreases in Acute Coronary 
Syndromes
Ana M. Medeiros, Luiz Carlos Bodanese, Daniel Francisco Ketelhuth, Franca Stedile 
Angeli, Magnus Ake Gidlund, Faculdade de Medicina PUCRS, Porto Alegre, Brazil, 
Universidade de São Paulo, São Paulo, Brazil
Background: Oxidative modiﬁcation of low density lipoprotein (LDL), which plays a 
key role in atherogenesis, induces immunogenic epitopes in peptides derived from 
apolipoprotein B (apoB) molecule fragmentation. The presence of autoantibodies against 
these peptides has been demonstrated in sera of coronary artery disease (CAD) patients, 
but their role in the pathophysiology of acute coronary syndromes (ACS) and clinical 
signiﬁcance remains unclear. This study acess the hypothesis that autoantibodies against 
D-peptide (anti-D pept), an apoB fragmentation derived peptide, have a protective role on 
atherosclerotic lesions progression, and that anti-D pept titers are lower in ACS patients 
compared to chronic CAD patients.
Methods: Synthetic peptides obtained from the disintegration of the apoB particule in 
copper oxidized LDL were separeted by chromatography. Four major peaks were detected 
and the so called D peptide was choosen as antigen according to known methods for 
prediction of immunogenic peptides. IgG antibody titers against D-peptide were measured 
by enzyme-linked immunosorbent assay in 90 patients within the ﬁrst twelve hours of an 
ACS without ST segment elevation, deﬁned by clinical presentation, electrocardiogram 
and biochemical markers of myocardial damage (cases), and 90 patients with chronic 
CAD, deﬁned by a more than three months history of acute myocardial infarction or 
coronary revascularization procedure (controls). Sample size was calculated a priori. 
Results are presented in mean values and standard deviations of the optical absorbance 
measured at 605 nm
Results: Anti-D pept titers were signiﬁcantly lower (p<0.001) in case group (0.28± 0.23) 
than in control group (0.45± 0.30). The difference between groups was independent of 
age, gender, total IgG titers, history of hypertension, diabetes, body mass index, current 
smoking status, lipid proﬁle and familial history of CAD.
Conclusion: Anti-D pept may be an independent predictor of acute coronary syndromes 
and a biomarker of plaque instability. It´s reduction might be related to immune-complexes 
formation or to a reduced clearence of atherogenic oxidized particules from circulation or 
from the arterial wall.
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1156-97 Circulating Monocytes and Coronary Plaque 
Progression in Acute Myocardial Infarction - A 
Volumetric Intravascular Ultrasound Analysis
Naoki Nozawa, Kiyoshi Hibi, Kazuo Kimura, Masami Kosuge, Tomoaki Shimizu, Noritaka 
Toda, Toshiaki Ebina, Shinich Sumita, Masahiko Kanna, Kengo Tukahara, Jun Okuda, 
Eri Furukawa, Satoshi Umemura, Cardiovascular Division, Yokohama City University 
Medical Center, Yokohama, Japan
Background; Monocytes and macropharges have been shown to play a major role in 
the progression of atherosclerosis. Recently, an intravascular ultrasound (IVUS) study 
has shown that higher circulating monocyte count following percutaneous coronary 
intervention (PCI) was associated with in-stent neointimal volume. The aim of this 
study was to investigate whether circulating monocytes could predict coronary plaque 
progression of non-culprit intermediate lesion in acute myocardial infarction (AMI).
Methods; IVUS interrogation was performed in 60 patients with AMI who admitted within 
24 hours from onset. All patients underwent PCI to culprit lesions. IVUS ﬁndings for non-
culprit intermediate plaque were analyzed at acute phase and at 6-month follow up. The 
target plaque had to be a minor lesion (ie, a diameter stenosis of <50% on angiography) 
and had to be at least 10mm apart from any PCI site. The percent plaque volume changes 
(%ΔPV) were calculated. Peripheral blood was obtained from all patients every 6 hours 
until 48 hours, and then every 12 hours for 3 days. Each white blood cells (WBC) fraction 
count was analyzed. Patients were classiﬁed into terciles according to the maximum 
monocyte count.
Results; Average lesion length was 10.6±3.1mm. Monocyte count at admission was 
409±203 /mm3 and reached its peak at a mean of 42 hours after admission (maximum 
monocyte count: 815±265 /mm3). According to the maximum monocyte count, 20 patients 
were classiﬁed as low group (mean 555±93, range 383 to 684 /mm3), 20 as medium group 
(790±69, range 688 to 904 /mm3), and 20 as high group (1100±220, range 908 to 1876 
/mm3). There was a stepwise increase in %�PV (-5.45±9.55 % in low group, -3.75±9.07 % 
in medium group, and 2.13±9.11 % in high group, P=0.03). Multivariate analysis showed 
that higher maximum monocyte count >907 /mm3 was an independent predictor of plaque 
progression (odds ratio 5.67, 95% CI 1.34 to 24.0, p=0.018).
Conclusion; Our results suggest that circulating monocytes may play an important 
role in the progression of coronary plaque in AMI and maximum monocyte count during 
hospitalization may predict plaque progression.
1156-98 Increased Isoprostane Content in Urine and Coronary 
Lesions Obtained from Patients with Acute Coronary 
Syndrome
Akira Nishibe, Yusuke Nakagawa, Megumu Fukunaga, Shoichi Senda, Noboru 
Nishiwaki, Nobuyuki Ogasawara, Tamayo Ishiko, Megumi Kunishige, Hiroko Hanasaki, 
Takeshi Hata, Yoshiyuki Kijima, Higashi-osaka City General Hospital, Osaka, Japan, 
Kagawa University Hospital, Takamatsu, Japan
Enhanced oxidant stress has been proposed as a trigger for transition of stable into 
vulnerable plaques. Isoprostanes are formed at biomembranes through free radical-
catalyzed lipid peroxidation (membrane-bound form) and released into blood and urine 
(free form). 8-Iso-prostaglandin F2α (8-iso-PGF2α), a representative isoprostane, is widely 
accepted as a reliable marker for oxidant stress in vivo. In this study, we measured: 1) its 
free form in urine and 2) total 8-iso-PGF2α content (free plus membrane-bound form) in 
directionally atherectomized-coronary lesions from patients with coronary heart diseases. 
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First, urinary excretion of immunoreactive 8-iso-PGF2α at their hospital admission was 429 
± 170 for patients with acute myocardial infarction (AMI, n = 28), 405 ± 107 for unstable 
angina pectoris (UAP, n = 11), 248 ± 89 for stable effort angina (SEA, n = 89), and 256 ± 
89 pg/mg creatinine for controls (n = 60), indicating signiﬁcantly greater excretion in acute 
coronary syndrome (ASC) (P < 0.001). Second, 11 patients with SEA and 10 patients with 
UAP were subjected to directional coronary atherectomy. Peripheral artery specimens 
(PA) obtained during CABG served as control (5 internal thoracic and 2 radial arteries). 
8-Iso-PGF2α content was 17.6 ± 11.8 for UAP, 2.27 ± 1.41 for SEA, and 0.39 ± 0.25 ng/g 
tissue for PA (P=0.0002 for UAP versus SEA, P<0.003 for PA versus UAP or SEA). These 
results indicate that 8-iso-PGF2α is enriched in vulnerable plaques and excreted more into 
urine in patients with ACS. In conclusion, enhanced oxidant stress is a sensitive marker 
for vulnerable patients.
1156-99 Positive Correlation between Oxidized Low Density 
Lipoprotein and Pro-Oxidant Enzyme Myeloperoxidase 
in Human Coronary Unstable Plaques Obtained by 
Atherectomy
Masashi Nakagawa, Takahiko Naruko, Akira Itoh, Kazuo Haze, Michihiko Hirayama, 
Takehisa Suekane, Yoshimi Sugama, Hiroko Fukushima, Nobuyuki Shirai, Shoichi 
Ehara, Yoshihiro Ikura, Masahiko Ohsawa, Makiko Ueda, Osaka City University 
Graduate School of Medicine, Osaka, Japan, Osaka City General Hospital, Osaka, Japan
Background: Oxidized low density lipoprotein (ox-LDL) is a key factor in the pathogenesis 
of coronary plaque destabilization. We have recently demonstrated that neutrophils play 
a role in mediating destabilization of human coronary atherosclerotic plaques (Naruko T 
et al, Circulation 106, 2002). Recent studies have demonstrated the presence of active 
pro-oxidant enzyme myeloperoxidase (MPO) and products of MPO-mediated reaction in 
human atherosclerosis. To elucidate the correlation between ox-LDL and MPO expression 
in plaque destabilization in human coronary arteries, we immunohistochemically studied 
the presence of ox-LDL and expression of MPO in coronary atherectomy specimens 
obtained from patients with stable angina (SAP) and unstable angina pectoris (UAP).
Methods: All these patients underwent atherectomy at primary atherosclerotic lesions 
responsible for SAP (n=15) and UAP (n=24). Atherectomy specimens were studied with 
antibodies against smooth muscle cells, macrophages, endothelial cells, neutrophils, ox-
LDL (DLH3), and MPO. The presence of ox-LDL, macrophages, and MPO immunoreactivity 
was quantiﬁed, respectively, using computer-aided planimetry. For the identiﬁcation of cell 
types which stain positive for MPO, immunodouble staining was also performed. 
Results: Quantitative analysis demonstrated that ox-LDL, macrophage, and MPO 
positive area in patients with UAP was signiﬁcantly (P<0.001) higher than in patients 
with SAP. Furthermore, we observed that the percentage of ox-LDL positive area was 
positively correlated with MPO positive area (r=0.73, p<0.0001). Immunodouble staining 
revealed that the vast majority of MPO-positive cells were neutrophils, and only occasional 
macrophages were also positive. 
Conclusions: These results demonstrate that in human coronary unstable plaques 
ox-LDL localization shows a positive correlation with an inﬁltration of MPO-positive 
neutrophils. These observations suggest that both ox-LDL and MPO may be key factors in 
triggering unstable coronary events.
1156-135 The Functional And Prognostic Role Of The C242T 
P22phox Nad(p)h Oxidase Gene Variant In White 
Patients Of The “Genica” Study
Gian Paolo Rossi, Silvia Zavattiero, Maurizio Cesari, Mario Zanchetta, Giuseppe 
Maiolino, Daniele Sticchi, Luigi Pedon, Pietro Maiolino, Achille C. Pessina, University of 
Padua, Padova, Italy, Ospedale di Cittadella, Cittadella, Italy
Background. The exon 4 C242T single nucleotide polymorphism (SNP) of the NAD(P)H 
oxidases p22phox subunit gene has been associated with coronary artery disease (CAD), 
but its association with outcome remained undetermined. Therefore, in the longitudinal 
branch of the GENICA study we investigated if this SNP predicted acute myocardial infarction 
(MI). Methods. We genotyped at the C242T SNP 1123 consecutive white patients undergoing 
coronary angiography with melting curve analysis of amplicons from allele-speciﬁc FRET 
probes. CAD was assessed by coronary angiography and graded with a modiﬁed Duke 
Index score. Occurrence of fatal and nonfatal acute MI (as deﬁned in ESH/ACC consensus 
document for the redeﬁnition of MI, JACC 2000) was assessed at follow-up (median 1280 
days) in 1063 patients (95% of the cohort) based on medical charts and phone interviews 
of family doctors, patients, or relatives. Logistic regression was used to assess the relation 
of the C242T SNP with CAD and Kaplan-Meier and Cox analyses to assess its impact on 
event-free survival. Results. The logistic regression analysis showed that well-known CV 
risk factors signiﬁcantly predicted CAD, while the C242T SNP did not. Kaplan-Meier revealed 
that TT homozygous patients had a signiﬁcantly (p<0.05 by log rank test) worse MI-free 
survival than CC and CT patients independently on all major CV risk factors, including the 
score of CAD, at Cox analysis. Conclusions. In white high-risk patients the TT homozygosity 
at the C242T p22phox SNP implies a higher risk of fatal and nonfatal acute MI.
1156-136 Coronary Inﬂammation and Culprit Activity of Matrix 
Metalloproteinases in Acute Coronary Syndromes
Makoto Suzuki, Masamichi Tanaka, Eiki Hirose, Hideyuki Saeki, Tsuyoshi Matsunaka, 
Shinichi Hiramatsu, Yukio Kazatani, Ehime Prefectural Central Hospital, Ehime, Japan
Background The present study was undertaken to ascertain the possible association 
between coronary levels of inﬂammation and culprit activity of matrix metalloproteinases 
(MMP) in acute coronary syndromes (ACS).
Methods A total of 82 patients (62 men and 20 women, 64±12 years) with an early phase 
of ACS showing minimal elevated creatine kinase (367±335 IU/L) were studied. Before 
coronary angioplasty, culprit coronary thrombus was sampled to measure coronary levels 
of high sensitive C-reactive protein (hs-CRP), interleukin (IL)-6, MMP-9 and tissue inhibitor 
of MMP (TIMP)-1. Relation of coronary levels of MMP-9 to culprit coronary morphology 
was evaluated by intravascular ultrasonography.
Results When divided patients by median levels of IL-6 (high vs. low IL-6 groups, 
123±104 vs. 14±7 pg/mL, p<0.0001), levels of hs-CRP were higher in the high IL-6 group 
than in the low IL-6 group (6.2±8.4 vs. 1.7±2.8 mg/L, p=0.002). Both levels of MMP-9 and 
TIMP-1 showed signiﬁcantly elevated in the high IL-6 group as compared with the low IL-6 
group (197±114 vs. 110±115 ng/mL, p=0.0001 and 110±39 vs. 86±26 ng/dL, p=0.005). 
Levels of MMP-9 showed a modest relation with levels of TIMP-1 (r=0.410, p=0.001). In a 
multivariate regression analysis, levels of IL-6 and culprit plaque area were independently 
correlated with levels of MMP-9 (p=0.0004 and 0.0026).Conclusions These results 
suggest the culprit link between coronary inﬂammation and MMP/TIMP activity, which is 
also associated with vulnerable coronary morphology in the pathogenesis of ACS.
1156-137 Systemic Plaque Vulnerability in Metabolic Syndrome: 
Assessment of Coronary and Carotid Artery 
Morphology
Masaya Kato, Keigo Dote, Shota Sasaki, Seiji Habara, Daiji Hasegawa, Osamu 
Matsuda, Hiroshima City Asa Hospital, Hiroshima, Japan
A condition constituted by multiple risk factors of atherogenesis was identiﬁed as 
metabolic syndrome (MS) in Adult Treatment Panel III (ATP-III) of National Cholesterol 
Education Program. We investigated the relationship between MS and the coronary and 
carotid artery morphologies in acute coronary syndrome (ACS).
Methods: Consecutive ACS patients (N=248) underwent emergent coronary angiography 
(CAG) and B-mode ultrasonography within 1 week of the acute coronary event. Using a 7.5-
MHz linear array transducer, the common carotid intima-media thickness (IMT), interadventitial 
diameter, and luminal diameter were examined. Carotid plaques were also assessed. 
Coronary plaque morphology was identiﬁed by CAG. Patients were divided into two groups 
based on the presence or absence of MS. MS was identiﬁed by modiﬁed ATP-III criteria.
Results: MS was identiﬁed in 80 patients (32%). Carotid IMT, interadventitial diameter, 
and luminal diameter in patients with MS were signiﬁcantly larger than patients without 
the syndrome using the univariate analysis. Furthermore, multiple complex coronary 
plaques were more often observed in MS (41% vs. 60%, p<0.007). Using multivariate 
analysis, carotid IMT>1.1mm and the presence of MS were independent predictors of 
multiple complex coronary plaques (OR, 1.54; 95%CI 1.10 to 2.17 and OR, 1.39; 95% 
CI, 1.04 to 1.85).
Conclusions: Carotid positive remodeling and vulnerable coronary plaques are more 
frequently observed in MS, suggesting that systemic plaque vulnerability exists under 
the condition.
1146-138 Anatomic Right Atrial Characteristics As Predictors Of 
Cryptogenic Stroke
Alan Zajarias, Srihari Thanigaraj, John M. Lasala, Julio Perez, Washington University 
School of Medicine, St. Louis, MO
Background: Atrial septal aneurysm associated with patent foramen ovale (PFO) is 
known to increase the risk for paradoxical embolization and cryptogenic stroke. Other 
anatomical variants may predispose to paradoxical interatrial shunting. In utero, the 
Eustachian valve (EV) funnels oxygenated blood through the fossa ovalis. We hypothesize 
that incomplete regression or persistence of the EV in conjunction with PFO, may 
predispose to cryptogenic stroke.
Methods: The transesophageal echocardiographic (TEE) images of 84 consecutive 
patients (male / Female = 40 / 44 ; age: 18 to 85 years; mean 51 years) with cryptogenic 
stroke and PFO as demonstrated by two-dimensional images and saline contrast study 
were reviewed. Eighty-four patients (male / female = 44 / 40; age 16 to 85 years; mean age 
57 years) who underwent TEE for reasons other than cryptogenic stroke and who did not 
have evidence of PFO served as controls. Echocardiographic characterization of the right 
atrial chamber and interatrial septum were performed in the bicaval view.
Results: Prominent EV were seen more frequently in patients with PFO and cryptogenic 
stroke than in controls (22 vs. 7; p<0.0002). Furthermore, the risk of crytpogenic stroke was 
increased signiﬁcantly (OR = 3.9) in patients with persistent EV and a PFO as compared 
to the control group. Atrial septal aneurysm was seen more commonly in patients with 
PFO and cryptogenic stroke (19 vs. 3; p<0.0007) as described previously.
Conclusions: The presence of EV substantially increases the likelihood of cryptogenic 
stroke in patients with PFO. The recognition of a persistent EV in association with a PFO 
may identify patients at higher risk for paradoxical embolization who may beneﬁt from 
early intervention.
1156-139 Increased Isoprostane Content in de novo Versus 
Restenotic Coronary Lesions Atherectomized from 
Patients with Angina Pectoris
Tamayo Ishiko, Akira Nishibe, Megumu Fukunaga, Shoichi Senda, Noboru Nishiwaki, 
Yusuke Nakagawa, Nobuyuki Ogasawara, Megumi Kunishige, Hiroko Hanasaki, Takeshi 
Hata, Yoshiyuki Kijima, Higashi-osaka City General Hospital, Osaka, Japan, Kagawa 
University Hospital, Takamatsu, Japan
In the progression of de novo atherosclerotic lesions, phagocytosis of oxidized LDL by 
foam cells is a crucial step. In contrast, restenotic lesions after percutaneous coronary 
intervention are composed mainly of extracellular matrix and of a few cellular components. 
Isoprostanes, reliable markers for oxidant stress in vivo, are formed in situ at membrane 
phospholipids through free radical-catalyzed lipid peroxidation (membrane-bound form), 
and released into blood and urine (free form). There have been few reports with regards to 
content of lipid peroxides in human coronary artery specimens. In this study we quantiﬁed 
content of 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha), a representative isoprostane, in 
coronary artery specimens atherectomized percutaneously from patients with angina 
pectoris. Fourteen patients with angina pectoris (mean age 68-y.o., 11 male and 3 female) 
were subjected to directional coronary atherectomy (6 de novo and 8 restenotic lesions). 
Peripheral artery specimens obtained during CABG served as control (7 specimens 
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including 5 internal thoracic arteries and 2 radial arteries, from 5 male patients, mean 
age 63-y.o.). We measured both membrane-bound and free forms of 8-iso-PGF2alpha as 
total isoprostane content in each specimen by enzyme immunoassay. Amounts of tissue 
obtained by coronary atherectomy and during CABG were 8.7+/-4.6 and 27.9+/-7.9 mg, 
respectively. Total isoprostane content was 20.9+/-27.7 ng/g tissue in de novo coronary 
lesions, being greater than in restenotic lesions (2.32+/-1.84 ng/g tissue, P<0.05). Total 
isoprostane content in peripheral artery specimens was 0.39+/-0.25 ng/g tissue, being 
lower than in coronary artery specimens (P<0.01). De novo coronary lesions contain 
more isoprostanes than restenotic lesions, suggesting that oxidant stress in plaques 
may play a crucial role in de novo progression of coronary atherosclerosis but not in the 
process of restenosis.
1156-140 Microvessel Sprouting, Red Blood Cell Extravasation, 
and Peri-vascular Inﬂammation Are Increased in 
Plaques From Patients With Diabetes Mellitus
Pedro R. Moreno, K-Raman Purushothaman, Willliam N. O’Connor, Annapoorna S. Kini, 
Marc Sirol, Samin K. Sharma, Valentin Fuster, Mount Sinai Medical Center, New York, 
University of Kentucky, Lexington, KY
Background: Our group have previously documented increased neovascularization 
and inﬂammation in atherosclerotic plaques from patients with diabetes mellitus (DM). 
Aggressive neovascularization is characterized by sprouting of vasa vasorum leading to 
red blood cell (RBC) extravasation and perivascular inﬂammation. In addition, neovessels 
have been postulated as a pathway for macrophages to inﬁltrate the vessel wall. We 
quantiﬁed microvessel sprouting, RBC extravasation, and perivascular inﬂammation in 
plaques from patients with and without DM.
Methods: Five hundred and thirty microvessels (264 from DM and 266 from non-DM) 
were identiﬁed by CD-34 immunostaining (blue chromogen). Macrophages/T-cells were 
identiﬁed by CD-68/CD3 immunostaining (red chromogen). Microvessel sprouting, RBC 
extravasation, and perivascular inﬂammation were identiﬁed.
Results: See Figure. The percentages of microvessels with sprouting, RBC extravasation 
and perivascular inﬂammation were increased in DM plaques when compared to non-
DM plaques (P<0.01 for all comparisons; See upper Figure). Examples of sprouting and 
perivascular inﬂammation are provided (lower Figure).
Conclusion: Microvessel sprouting, RBC extravasation and perivascular inﬂammation 
are increased in plaques from patients with diabetes mellitus. These results suggest a 
more severe form of neovessel microangiopathy in diabetic atherosclerosis.
1156-141 The Role of Oxidative Stress and Asymmetric 
Dimethylarginine (ADMA) in Endothelial Dysfunction 
and Inﬂammatory Cytokines Expression, During 
Methionine-Induced Homocysteinemia
Charalambos Antoniades, Dimitris Tousoulis, Kyriakoula Marinou, Carmen Vasiliadou, 
Costas Tentolouris, Stella Brilli, Charalambos Vlachopoulos, Chrysoula Tselika, Christos 
Pitsavos, Christodoulos Stefanadis, Athens university Medical School, A Cardiovascular 
Department, Athens, Greece
Background. Homocysteinemia is associated with increased inﬂammatory process 
and endothelial dysfunction. We examined the role of oxidative stress and asymmetric 
dimethylarginine (ADMA), in inﬂammatory response and endothelial cells injury, during 
methionine-induced homocysteinemia.
Methods. Thirty healthy subjects (aged 23±2 yrs) received methionine (100 mg/Kg BW). 
Fifteen of them also received vitamin C (2gr) and E (800IU) before methionine loading. 
Forearm blood ﬂow was measured by gauge-strain plethysmography at baseline and 4 hours 
post methionine loading (4h-PML). Endothelium dependent dilation (EDD) was expressed as 
the %change of ﬂow from rest to the maximum during reactive hyperemia. EDD, homocysteine 
(Hcy), E-selectin, vonWillebrand factor (vWF), interleukin-6 (IL-6), tumor necosis factor (TNF-
a), ADMA and oxidized-LDL (ox-LDL) were determined at baseline and 4h-PML
Results. Hcy was increased in both vitamins-treated and controls (from 9.6±1.31 and 
8.3±0.80 to 27.6±3.0 and 28.0±2.9 µmol/L, p<0.01 for both), at 4h-PML. EDD was 
decreased in both vitamin-treated and controls (from 104±18.8 and 102±10.5 to 53.4±6.4 
and 60±8.2%, p<0.01 for both), while vWF, E-selectin and ADMA were also increased 
in both vitamin-treated (from 49.6±8.8, 23.8±4.7 and 0.58±0.04 to 70.8±5.7%, 34.3±3.2 
ng/ml and 0.76±0.05 µmol/L p<0.05 for all) and controls (from 51.0±5.25, 24.2±2.45 and 
0.62±0.03 to 71.5±4.4%, 32.2±3.3 ng/ml and 0.82±0.03 µmol/L p<0.01 for all), at 4h-
PML. However, ox-LDL, IL-6 and TNF-a were increased in only controls (from 43.7±6.7, 
1.19±0.18 and 1.83±0.26 to 92.43±9.5 IU/L, 1.57±0.18 pg/ml and 2.31±0.22 pg/ml, p<0.01 
for all), but not in the vitamin-treated group (from 52.7±4.2, 1.49±0.22 and 2.08±0.28 to 
58.2±12.0 IU/L, 1.44±0.22 pg/ml and 2.18±0.29 pg/ml, p=NS for all) at 4h-PML.
Conclusion. Antioxidants depress oxidative stress and proinﬂammatory cytokines 
expression but fail to prevent endothelial dysfunction and the release of vWF, E-selectin 
and ADMA during methionine-induced homocysteinemia, providing evidence for an 
additional mechanism of endothelial dysfunction, not directly affected by oxidative stress.
1156-142 Antioxidant Enzymes in Coronary Artery Disease.  
A Study on Superoxide Dismutase
Carmine Pizzi, Olivia Manfrini, Umberto Paradossi, Maria Giovanna Colombo, 
Alessandra Vitali, Paola Boni, Raffaele Bugiardini, University Alma Mater, Bologna, Italy
Background: Coronary artery disease (CAD) and myocardial ischemia cause oxidative 
stress. Superoxide dismutase (SOD) is one of the major antioxidant enzyme systems of 
the arterial wall and its activity has a central role in the control of reactive oxygen species. 
The aim of this study was to investigate whether SOD antioxidant defense is involved in 
patients with coronary artery disease and exercise-induced myocardial ischemia.
Methods and Results: We studied 20 patients with documented CAD. Twenty cardiac 
syndrome X (SX, chest pain, normal coronary angiograms) and 20 healthy volunteers 
served as controls. All subjects underwent technetium-imaging study during exercise test. 
SOD levels were measured before testing, at peak exercise and 30 minutes later during 
recovery. All CAD and SX patients experienced ischemia during exercise. They showed 
chest pain, ST depression and reversible radionuclide perfusion defects. Baseline SOD 
(U/ml) concentration was signiﬁcantly (p<0.001) greater (269.7±29.4) in SX and lower 
(94.3±32.3) in CAD pts, as compared with healthy volunteers (183.1±17.6). At peak 
testing SOD signiﬁcantly (p<0.001) increased (from 1.9 to 2.3 times) in all subjects (SX: 
544.5±83.8; CAD: 187.2±27.6; volunteers: 355.5±34.9). Thirty minutes after the beginning 
of the recovery phase SOD levels decreased in all subjects. SOD levels, however, were 
still lower in CAD patients, as compared with SX (257.0±33.7) and healthy volunteers 
(296.9±34.7). 
Conclusions: SOD plasma levels are remarkably lower in patients with CAD both at rest 
and during effort ischemia, as compared to patients with SX and controls. SOD activity is 
a compensatory response to increased oxidative stress both at rest and during exercise. 
This mechanism is preserved in healthy volunteers and SX but is exhausted in CAD.
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1157-119 Non-invasive, Simultaneous Evaluation of Both 
Coronary Artery Stenoses and Left Ventricular Function 
With Multi-Slice Computed Tomography in Patients With 
Hypertension.
Joanne D. Schuijf, Jeroen J. Bax, J. Wouter Jukema, Hildo J. Lamb, Hubert W. Vliegen, 
Albert de Roos, Ernst E. van der Wall, Leiden University Medical Center, Leiden, 
The Netherlands, Interuniversity Cardiology Institute of the Netherlands, Utrecht, The 
Netherlands
Background: Early and non-invasive identiﬁcation of the presence of coronary artery 
disease (CAD) is important in patients with hypertension, since these patients are at 
increased risk for developing CAD. Multi-slice computed tomography (MSCT) has been 
demonstrated recently to allow both non-invasive coronary angiography and assessment 
of left ventricular (LV) function. The purpose of the present study therefore was to validate 
this approach in patients with hypertension and compare the results to invasive coronary 
angiography and 2D echocardiography respectively.
Methods: MSCT was performed in 31 patients (28 men, mean age 63 ± 11 years) with 
conﬁrmed hypertension. From the MSCT images, the presence of signiﬁcant coronary 
stenoses (≥50% luminal narrowing) and LV function (LV ejection fraction and regional 
wall motion) were evaluated and compared with invasive coronary angiography and 2D 
echocardiography.
Results: A total of 243 (88%) coronary artery segments could be evaluated with MSCT. 
Sensitivity and speciﬁcity for the detection of signiﬁcant coronary artery stenoses were 
93% and 96%. For the assessment of LV ejection fraction, a close correlation between 
MSCT and 2D echocardiography was demonstrated (y = 0.96x + 0.91, r=0.97, p<0.01); 
the agreement for assessing regional wall motion was 91% (kappa statistic 0.81).
Conclusions: In patients with hypertension, simultaneous, non-invasive evaluation 
of coronary artery stenoses and LV function with MSCT is accurate. This non-invasive 
approach may allow optimal identiﬁcation of high-risk patients.
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1157-120 Body Mass Index, Hypertension and Diabetes: Do They 
Have Additive Effects on LV Structure and Function In 
Extreme Obesity?
Erick Avelar, Ted D. Adams, Richard Gress, Steven C. Hunt, Robert Pendleton, Michael 
Strong, Sheldon E. Litwin, The University of Utah, Salt Lake City, UT
Background: Severe obesity has been associated with LV hypertrophy and systolic 
dysfunction. We hypothesized that the effect of BMI on LV mass and function would be 
affected by the presence of diabetes and hypertension.
Methods: Echocardiography was performed in 461 severely obese subjects BMI’s (35-92 
kg/m2) and 60 nonobese controls.
Results: Data are mean±SEM. 80% were females. Age was 44±10 yrs. Hypertension 
was present in 47% and diabetes in 18%. Systolic BP was 123±18. Fasting glucose was 
103±35 mg%. LVH was present in 70% using gender-speciﬁc criteria. Multivariate linear 
regression analysis showed that BMI was the best independent predictor of LVH followed 
by systolic blood pressure. There was a signiﬁcant interaction between HTN and BMI 
on LV mass (p interaction < 0.001), but not between diabetes and BMI (ﬁgure). Despite 
the high prevalence of LVH these severely obese subjects had preserved LV systolic 
function (LV fractional shortening 35±6% and midwall fractional shortening 27± 9%). 
Circumferential wall stress was also normal (172±46 kdyne/cm2).
Conclusions:1) Hypertension and body mass index interact synergistically to increase 
LV mass in obese subjects. Diabetes does not appear to contribute directly to the 
development of LVH. 2) Despite the high prevalence of LVH in extreme obesity, systolic 
function and wall stress are normal. This suggests that the LV hypertrophy associated with 
obesity is a physiological adaption rather than a cardiomyopathy of obesity. 
1157-121 Left Ventricular Mass Among Offsprings of 
Hypertensive Adults: The Hypertension Genetic 
Epidemiology Network Study
Felizen S. Agno, Donna K. Arnett, Jonathan N. Bella, Albert Oberman, Paul N. Hopkins, 
Dalane W. Kitzman, Dabeeru C. Rao, Richard B. Devereux, Weill Medical College of 
Cornell University, New York, NY
Background: Left ventricular mass (LVM) has been shown to be associated with different 
demographic, hemodynamic and echocardiographic factors, but the strength and independence 
of these associations in the offspring of hypertensive parents is not well described.
Methods and Results: Clinical and echocardiographic parameters were measured 
in 421 offspring of hypertensive participants (33±8 years old, 55% female, 58% black, 
6.4% hypertensive, and 2.4% diabetic) in the population-based HyperGEN study. There 
were 37.8% participants with history of alcohol use, 28% who currently drank, 32.5% 
previous smokers, and 19.2% current smokers. Bivariate correlation followed by linear 
regression analyses assessed the relationship of LVM to demographic variables (age, 
gender, ethnicity, hypertension, diabetes, alcohol use, smoking, body mass index (BMI), 
fat-free mass (FFM), waist/hip ratio, systolic (SBP) and diastolic blood pressures, lipid 
proﬁle, fasting blood glucose and plasma creatinine) and echocardiographic variables 
(ejection fraction, Doppler stroke volume (SV) and myocardial contractility using midwall 
shortening as percent predicted (MWSPC). Demographic variables associated with 
LVM were male gender, BMI, SBP and white ethnicity (r=0.666, r2=0.443, N= 310) while 
the echocardiographic variables associated with LVM were SV and MWSPC (r=0.585, 
r2=0.342, N=358). Signiﬁcant demographic and echo variables together yielded a 
multivariate regression model that explained 55% (r=0.741) of the variance of LVM with 
positive associations in order of decreasing importance with male gender, SV, BMI, (all 
p<0.001), SBP (p=0.001) and white ethnicity (p=0.015) whereas MWSPC (p<0.001) was 
negatively related to LVM. 
Conclusions: In a population-based sample of predominantly normotensive offspring 
of hypertensive adults, 55% of the variability in LVM can be explained by male gender, 
increased LV volume load, obesity, lower contractile efﬁciency, higher SBP and white 
ethnicity. In addition, systolic function was negatively related to LVM in this normotensive 
group. These ﬁndings stress the importance of risk factor modiﬁcation in persons 
genetically at risk for hypertension.
1157-122 Left Ventricular Mass Among Hypertensive Adults 
Without Clinical Disease: The Hypertension Genetic 
Epidemiology Network Study
Felizen S. Agno, Jonathan N. Bella, Donna K. Arnett, Albert Oberman, Paul N. Hopkins, 
Dalane W. Kitzman, Dabeeru C. Rao, Richard B. Devereux, Weill Medical College of 
Cornell University, New York, NY
Background: Left ventricular mass (LVM) has been shown to be associated with 
different demographic, hemodynamic and echocardiographic factors, but the strength 
and independence of these associations in a population of adult hypertensive without 
prevalent cardiovascular (CV) disease, valvular regurgitation/stenosis/prostheses, wall 
motion abnormalities by echocardiogram or stroke remains uncertain.
Methods and Results: Clinical and echocardiographic parameters were measured in 
1,327 hypertensive participants (53±11 years of age, 64% women, 66% black, 18% 
diabetic) without overt CV disease in the population-based HyperGEN study. Bivariate 
correlation followed by linear regression analyses assessed the relationship of LVM to 
demographic variables (age, gender, ethnicity, history of diabetes, hypercholesterolemia 
and smoking, body mass index (BMI), fat-free mass (FFM), waist/hip ratio, systolic 
and diastolic blood pressures (SBP and DBP) high-density lipoprotein cholesterol, 
fasting blood glucose, plasma creatinine and number of antihypertensive medications 
(HYPMED) and echocardiographic variables (ejection fraction, Doppler stroke volume 
(SV) and myocardial contractility using midwall shortening (MWS). Demographic 
variables associated with LVM were FFM, SBP, smoking, HYPMED, BMI and creatinine 
(r=0.606, r2=0.367, N=1,126) while the echocardiographic variables associated with LVM 
were SV and MWS (r=0.665, r2=0.443, N=1,244). Clinical and echo variables together 
yielded a multivariate regression model that explained 54% (r=0.735) of the variance of 
LVM with positive associations in order of decreasing importance with SV, FFM, SBP, 
smoking (all p<0.001), BMI (p=0.002) and HYPMED (p=0.038) whereas MWS (p<0.001) 
was negatively related to LVM.
Conclusions: In a population-based sample of hypertensive adults without clinical 
disease, 54% of the variability in LVM can be explained by increased LV volume load, 
lower contractile efﬁciency, obesity, severe hypertension and smoking. The above ﬁndings 
may all contribute to the increased risk for all-cause and CV morbidity and mortality 
associated with increased LVM.
1157-123 Effect of Left Ventricular Hypertrophy on Human 
Coronary Artery Haemodynamics.
Justin E. Davies, Zachary I. Whinnett, Darrel P. Francis, Keith Willson, Rodney A. Foale, 
Iqbal Malik, Alun D. Hughes, Kim H. Parker, Jamil Mayet, ICCH, Imperial College, 
London, United Kingdom
Background Left ventricular hypertrophy is associated with increased mortality, 
independent of coronary artery disease. We have explored the relationship between LVH 
and intracoronary pressure-ﬂow dynamics using Wave Intensity Analysis.
Method and Results In 15 patients (mean age 54 years, 7 males) with angiographically 
normal coronary arteries, we used intracoronary Doppler and pressure wires simultaneously 
to measure blood ﬂow and pressure in the proximal left main stem, left anterior descending 
and circumﬂex arteries. Echocardiography was used to assess LV wall thickness and to 
exclude structural cardiac abnormality. The four types of energy wave in the coronary 
circulation (see ﬁg) can be observed and quantiﬁed by applying Wave Intensity Analysis 
to simultaneous pressure and ﬂow recordings. We identiﬁed the early diastolic backward 
expansion wave and expressed it as a percentage of the total wave energy in the cardiac 
cycle. This backward expansion wave signiﬁcantly decreased with increasing LV wall 
thickness (r=-0.74, p<0.001, -18.8%/cm). As the LV wall thickness increases from 0.7cm to 
1.6cm the backward expansion wave is reduced from 28% to 11%.
Conclusion From simultaneous pressure and ﬂow data, it is possible to observe and 
separate the individual energy waves within the coronary circulation. The backward 
expansion wave, which is normally the dominant wave in forward coronary ﬂow, is markedly 
reduced in LVH. We speculate that this may result from less vigorous myocardial recoil.
1157-124 Correlates of High Pulse Pressure in Hypertensive 
Adults for a Population-Based Sample: The HyperGen 
Study
Tatiana Krasikov, Richard B. Devereux, Donna K. Arnett, Albert Oberman, Paul N. Hopkins, 
Dalane W. Kitzman, DC Rao, Weill Medical College of Cornell University, New York, NY
Background: High pulse pressure (PP) has been associated with increased risk of 
cardiovascular events in hypertensive patients, but the hemodynamic determinants of 
high PP and the degree to which it is associated with preclinical abnormalities of cardiac 
structure and function are unclear.
Methods and Results: 2154 hypertensive patients studied by echocardiography in the 
HyperGEN Study, without signiﬁcant valvular disease, were divided into tertiles of PP 
(cutoffs of 14, 48, 60 mmHg.) Compared to the lowest tertile, patients in the highest PP 
tertile were older (60±9 vs. 50±11 years, p<0.001), more likely to be white (53 vs. 22%, 
p<0.0001), diabetic (40 vs 26%, p<0.001), and had higher systolic (146±22 vs.124±19 
mmHg, p<0.001) but not diastolic (74±12 mmHg) blood pressure or body mass index(32). 
Higher PP was associated with greater PP/Stroke Volume index(1.9±0.46 mmHg/ml/m2, 
p< 0.0001), a measure of arterial stiffness, and higher stroke index (40.9±8.2 vs.38.1± 
7.2). Adjusted for age, gender, and race, patients in the highest PP tertile had more prior 
myocardial infarctions (10 vs. 5.8%, p<0.0001) and revascularization procedures 11.2 vs. 
6.9%, p<0.006), but not strokes (5.7 vs. 4.4%), or heart failure (2.6 vs. 2.3%). Higher PP 
was associated with greater posterior wall thickness (0.91±0.12 cm, p<0.001), relative 
wall thickness (0.35±0.06 vs. 0.34±0.05), longer isovolumic relaxation time (86±18 vs. 
81±17 msec,p<0.0001) and prevalence of concentric left ventricular (LV) geometry (42.2 
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vs.23.1%, p<0.001) without difference in LV chamber size.
Conclusion: In a population-based sample of hypertensive patients, higher PP reﬂects 
higher stroke volume, as well as arterial stiffness and is associated, adjusted for age, 
race, gender, prior myocardial infarction and revascularization, with higher LV mass, more 
concentric LV geometry, and worse LV relaxation.
1157-125 Increased Levels of Urinary Albumin Excretion Are 
Accompanied by Adverse Left Ventricular Geometric 
Adaptations in Essential Hypertensive Patients Without 
Left Ventricular Hypertrophy
Kyriakos Dimitriadis, Konstantinos Tsiouﬁs, Efstathios Taxiarchou, Pavlos Stougiannos, 
Ioannis Vlasseros, Elena Triantaﬁllidou, Dimitris Tousoulis, Christodoulos Stefanadis, 
Ioannis Kallikazaros, Hippokration Hospital, Athens, Greece
Background: Unfavorable spectrum of left ventricular (LV) geometry, and increased 
urinary albumin excretion (UAE) are both related to augmented cardiovascular risk. In 
this study we examined the possible association between LV concentric remodeling, and 
UAE, in essential hypertensive subjects.
Methods: From 95 consecutive newly diagnosed, untreated non-diabetic patients with 
stage I to II essential hypertension, we selected 57 hypertensives [42 men, mean age=48 
years, ofﬁce blood pressure (BP)=147/95 mmHg] with normal LV mass. All participants 
were divided into two groups, according to relative wall thickness (RWT) values: group 
A-normal LV geometry (RWT<0.45), and group B-LV concentric remodeling (RWT≥0.45). 
Additionally, UAE was determined in three non-consecutive 24h urine samples by 
nephelometric methods, and all subjects underwent 24-h BP monitoring.
Results: For the pooled population, body mass index (BMI) was 26.93±2.5 kg/m2, 
total cholesterol was 241±31 mg/dl, triglycerides were 134±63 mg/dl, low density 
lipoprotein-cholesterol was 153±14 mg/dl, and UAE was 20.3±9 mg/24h. Regarding 
the echocardiographic data, left ventricular mass index (LVMI) was 104.5±22 g/m2, 
RWT was 0.42±0.07, and left atrial diameter was 3.5±0.31 cm. UAE was correlated with 
ofﬁce systolic BP (r=0.27, p<0.05), 24-h systolic BP (r=0.39, p<0.001), ambulatory pulse 
pressure (r=0.38, p<0.01), and LVMI (r=0.32, p<0.05). Furthermore, the group with LV 
concentric remodeling (n=27), compared to the group with normal geometry (n=30) had 
signiﬁcantly increased age (50±7 years vs 45±5 years, p<0.03), BMI (28.2±4 kg/m2 vs 
27.5±2 kg/m2, p<0.05), ofﬁce systolic BP (154±9 mmHg vs 145±4 mmHg, p<0.05), and 
higher UAE (21.5±6 mg/24h vs 19.7±8 mg/24h, p<0.05). Conclusions: LV concentric 
remodeling is accompanied by increased UAE, even in newly diagnosed essential 
hypertensive patients. UAE measurement, in conjunction with evaluation of LV geometric 
adaptations, may improve cardiovascular risk stratiﬁcation, in this setting.
1157-126 Comparison of Gene Expression Proﬁling in 
Pressure and Volume Overload-Induced Myocardial 
Hypertrophies in Rats
Haruya Ohmura, Naoki Oka, Hiroshi Miyazaki, Tamenobu Ueda, Tsutomu Imaizumi, 
Kurume University School of Medicine, Kurume, Japan
Background: Pressure (PO) or volume overload (VO) results in morphologically and 
functionally distinct forms of cardiac hypertrophy. However, a molecular basis leading to 
these forms remains largely unknown. We compared gene expression proﬁling in the 
hypertrophied myocardium of PO and VO by the DNA chip technology. 
Methods and Results: Constriction of the abdominal aorta and abdominal aortocaval 
shunting were used to induce PO and VO, respectively. After four weeks, there were 
comparable increases in left ventricular weight/body weight ratio in PO and VO. 
Echocardiography revealed concentric hypertrophy in PO, whereas eccentric hypertrophy 
in VO. DNA chip analysis (Affymetrix, 3X3 chips) showed that expressions of many genes 
were altered in VO and PO either selectively or similarly. Among those genes, greatly 
increased expressions of BNP, lysyl oxidase-like protein 1 (LOXL) and metallothionein-1 
(MT), and the decreased expression of GMP reductase in VO but not in PO, were conﬁrmed 
by real-time PCR. Because free radicals are increased in the hypertrophied heart and they 
may contribute to apoptosis, we ﬁrst examined a role of MT in apoptosis associated with 
hypertrophy. The overexpression of MT in cardiomyocytes attenuated the norepinephrine 
(NE)-induced increase of TUNEL positive cells. Moreover, the augmented caspase-
3 activity and the production of reactive oxygen species in NE-treated myocytes were 
inhibited by the overexpression of MT. These results suggest that MT may play protective 
roles via the suppression of ROS production in hypertrophied myocytes. We next examined 
the regulation and role of LOXL in hypertrophied myocardium. LOXL mRNA levels in PO 
showed a biphasic response, i.e., an initial increase and a later gradual increase. In cultured 
cardiomyocytes, Gq-dependent agonists and IGF-1 increased the expression of LOXL 
mRNA. The addition of beta-aminopropionitrile, an inhibitor of LOX, to the cardiomyocyte 
culture suppressed the agonist-induced increase of [H3] leucine-incorporation. Conclusion: 
We found that many genes were regulated in VO and PO either selectively or similarly. Novel 
roles of MT and LOXL in the hypertrophied myocardium are suggested.
1157-127 Obstructive Sleep Apnea Is Accompanied by More 
Pronounced Impairment of Aortic Elastic Properties 
in Untreated Newly Diagnosed Essential Hypertensive 
Patients
Kostas Thomopoulos, Konstantinos Tsiouﬁs, Anastasia Amﬁlochiou, Dimitris Chatzis, 
Pavlos Stougiannos, Apostolis Kakavas, Dimitris Tousoulis, Christodoulos Stefanadis, 
Ioannis Kallikazaros, Hippokration Hospital, Athens, Greece
Background: Obstructive sleep apnea syndrome (OSAS) may be involved in the 
pathophysiology of cardiovascular diseases through several mechanisms. Also, aortic 
stiffness seems to be an independent predictor of adverse cardiovascular prognosis in 
various clinical settings. We assessed the hypothesis that arterial stiffness is increased in 
untreated hypertensives with OSAS compared to a control hypertensive group.
Methods: We studied 33 consecutive subjects (23 men, aged 49±6 years, 15 smokers) 
with stage I-II untreated essential hypertension [ofﬁce blood pressure (BP)= 150±7/98±10 
mmHg], and OSAS diagnosed by polysomnography [apnea/hypopnea index (AHI)>5], 
and a control group of 27 untreated essential hypertensive subjects matched for age, BP, 
smoking status, and sex with negative polysomnography. All patients underwent aortic 
pulse wave velocity (PWV) measurement by a computerized device (Complior SP).
Results: OSAS group, compared to controls, exhibited increased body mass index 
(BMI), and homocysteine levels (30.9±4 vs 28.5±4 kg/m2 and 14.4±3 vs 11.7±4 µmol/
L, respectively, p<0.05 for both cases) while the two groups did not differ regarding left 
ventricular mass index (LVMI) (107±20 vs 106±28 gr/m2, p=NS). In contrast, OSAS 
group, compared to controls, had greater relative wall thickness, and PWV (0.48±0.06 
vs 0.42±0.06, and 7.93±0.9 vs 7.40±0.7 m/sec, p<0.05 for both cases). In the OSAS 
group, PWV was positively correlated with age, and AHI (r=0.38, and r=0.47, respectively, 
p<0.05). Multiple linear regression analysis revealed that AHI was signiﬁcantly related to 
BMI, ofﬁce systolic BP, smoking status, and PWV (P<0.05).
Conclusions: Aortic PWV were signiﬁcantly increased in hypertensive patients with OSAS 
compared to those without OSAS. These results may partially explain the augmented risk 
for adverse cardiovascular events associated with OSAS.
1157-128 The Emerging Role of Subclinical Inﬂammation in 
Essential Hypertensive Subjects With Obstructive Sleep 
Apnea Syndrome: A Working Hypothesis
Costas Thomopoulos, Konstantinos Tsiouﬁs, Anastasia Amﬁlochiou, Carmen Vasiliadou, 
Dimitris Chatzis, Apostolis Kakavas, Maria Papavasiliou, Christodoulos Stefanadis, 
Ioannis Kallikazaros, Hippokration Hospital, Athens, Greece
Background: It had been suggested that obstructive sleep apnea syndrome (OSAS) 
induced hypoxic stress, might contribute to cardiovascular disorders by promoting 
subclinical inﬂammation. Our hypothesis was to assess the possible associations 
between increased inﬂammatory markers such as hsCRP, and the severity of OSAS in 
hypertensive subjects.
Methods: Toward this end, we assessed plasma hsCRP, and P selectin levels in 33 
consecutive essential hypertensive subjects [23 men, aged 49±6 years, 15 smokers, ofﬁce 
blood pressure (BP)=150±7/98±10 mmHg] with OSAS diagnosed by polysomnography 
[apnea/hypopnea index (AHI)>5]. A group of 27 essential hypertensive subjects with 
negative polysomnography study, matched for age, BP, smoking status, and sex were 
used as controls.
Results: Hypertensives with OSAS, compared to hypertensives without OSAS, exhibited 
increased body mass index (BMI) (30.9±4 vs 28.5±4 kg/m2, p<0.05), and greater relative 
wall thickness (0.48±0.06 vs 0.42±0.06, p<0.05) while the two groups did not differ 
regarding left ventricular mass index (LVMI) (107±20 vs 106±28 gr/m2, p=NS). Also, 
hypertensives with OSAS, compared to hypertensives without OSAS had greater levels 
of homocysteine, hsCRP and P selectin (14.4±3 vs 11.7±4 µmol/L, 4.8±0.9 vs 2.1±0.9 
mg/dl, and 62±11 vs 45±9 ng/ml, respectively, p<0.05 for all cases). In the OSAS group, 
hsCRP was signiﬁcantly correlated to BMI (r=0.25, p<0.05), ofﬁce systolic BP (r=0.33, 
p<0.001), and AHI (r=0.41, p<0.005). By multivariate analysis it was revealed that BMI, 
ofﬁce systolic BP, hs CRP, and P selectin were signiﬁcant determinants of AHI (p<0.05).
Conclusions: OSAS hypertensive patients exhibited notably increased levels of hsCRP, 
and P selectin compared to the control group. The presence of systemic low-grade 
inﬂammation may predispose for an adverse cardiovascular outcome related to OSAS 
hypertensive state.
1157-129 Evaluation of Concentric Left Ventricular Geometry 
in Humans: Evidence for Age-Related Systematic 
Underestimation.
Giovanni de Simone, Stephen R. Daniels, Thomas R. Kimball, Mary J. Roman, Maurizio 
Galderisi, Oreste de Divitiis, Richard B. Devereux, Federico II University, Naples, Italy, 
Weill Medical College, New York, NY
Background: The most common LV geometric abnormality in hypertensive patients 
is eccentric hypertrophy. However, the standard method of identifying concentric LV 
geometry, using a single cutoff for the ratio of posterior wall thickness (WTp) to ½ LV 
diastolic dimension (LVIDd), or relative wall thickness (RWTp), might present limitations, 
due to confounding effect of aging. This study has been undertaken to evaluate the impact 
of age on assessment of concentric LV geometry. 
Methods: LVIDd, WTp, the mean of septal and posterior wall thickness (WTm), RWTp and 
RWTm (WTm/½LVIDd) were assessed in 766, 1 to 85-year old, normotensive, non-obese 
subjects. A clinical population of 331 hypertensive Italians was used as a test series. 
RWTp>0.43 deﬁned “traditional” concentric LV geometry. 
Results: In normals, WTm and WTp were linearly related to LVIDd in the whole population 
and in age strata (up to 17 yrs and ≥ 18 yrs; r between 0.26 and 0.69). RWTm and RWTp 
increased by 0.005 and 0.006 per year of age in the young age stratum and by 0.002 (both) in 
the older age stratum (all p<0.0001). Thus, RWTm and RWTp were normalized to the average 
age in both age strata (10 and 46 yrs), by the age-sperciﬁc regression coefﬁcients. The 90th 
and 95th percentiles of normalized RWTp or RWTm were 0.40 and 0.42 or 0.41 and 0.43, 
respectively in adults; 0.36 and 0.39 or 0.36 and 0.38 in young subjects. In hypertensive test 
series, “traditional” RWTp cutoff identiﬁed 74 subjects (24%) with concentric LV geometry, 
whereas normalized RWTm identiﬁed 112 (34%), or 149 (45%) subjects for partitions at the 
95th or 90th normal percentiles (both p<0.0001 vs traditional RWTp partition). Prevalence of 
concentric LV geometry for age-normalized RWTp was 29% and 39%, by 95
th or 90th normal 
percentiles, respectively (both p<0.0001 vs traditional RWTp partition). 
Conclusions: The prevalence of concentric LV geometry is increased by age-
normalization of relative wall thickness, especially when septal thickness is considered 
in the computation. Further studies are required to establish pathophysiological and 
prognostic implications of our ﬁndings.
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1157-130 Impact of Stent-Revascularisation of Renal Artery 
Stenosis on Left Ventricular Mass and Left Ventricular 
Function
Thomas Zeller, Aljoscha Rastan, Uwe Schwarzwaelder, Ulrich Frank, Karlheinz 
Buergelin, Pietro Amantea, Franz-Josef Neumann, Herz-Zentrum Bad Krozingen, Bad 
Krozingen, Germany
Background: Stent supported angioplasty of atherosclerotic renal artery stenosis has 
become an accepted therapeutic option. We analyzed the impact of this therapy on left 
ventricular diameters, left ventricular mass, and myocardial function.
Patients and methods: During a 5 year period we treated 241 patients with 355 ostial 
renal artery stenoses > 70% with stent supported angioplasty. For 103 of these patients 
(43%) preinterventional and 12-month echo data were available (Group A). A matched 
group of 100 patients with essential hypertension served as control group (Group B).
Results: Left ventricular mass index was signiﬁcantly reduced in Group A (139 + 35 
g/m2 to 130 + 34 g/m2, p = 0.001) while it was signiﬁcantly increased in group B (117 
+ 33 g/m2 to 125 + 37 g/m2, p = 0.009). In Group A mean arterial blood pressure was 
signiﬁcantly reduced from 99 + 11 mmHg to 91 + 11 mmHg (p < 0.0001) after 12 months 
whereas it was signiﬁcantly increased from 102 + 11 mmHg to 105 + 11 mmHg (p = 0.02) 
in Group B. Medication was signiﬁcantly reduced in Group A (3.1 + 1.0 to 2.8 + 1.2, p = 
0.006) while it was signiﬁcantly increased in Group B (3.0 + 1.0 to 3.4 + 1.1, p < 0.0001). 
Left ventricular fractional shortening fraction was unchanged in both groups (Group A: 
30 + 9% vs. 30 + 10%, p = 0.9; Group B: 33 + 9% vs. 36 + 18%, p = 0.06). Multivariate 
analysis including blood pressure, various risk factors, age, gender, and drugs found stent 
supported angioplasty the only independent predictor for regression of left ventricular 
hypertrophy (OR 3.13; 95% CI 1.39-7.04, p = 0.006).
Conclusion: Stent supported angioplasty of atherosclerotic renal artery stenosis leads besides 
a signiﬁcant improvement of blood pressure control to a signiﬁcant regression of myocardial 
hypertrophy and myocardial mass index. This regression was independent of the reduced 
blood pressure and may therefore be affected by a reduced activity of the renin-angiotensin-
aldosterone system. Left ventricular function was not affected by the intervention.
1157-131 Coronary Microvascular Remodeling in Hypertension: 
Role of Oxidative Stress
Xiang-Yang Zhu, Martin Rodriguez-Porcel, Alejandro R. Chade, Erik L. Ritman, Amir 
Lerman, Lilach O. Lerman, Mayo Clinic, Rochester, MN
Background: The mechanisms that modulate myocardial microvascular architecture in 
early hypertension (HT) are unclear. We tested the hypothesis that HT-induced oxidative 
stress leads to myocardial neovascularization. 
Methods: Three groups of pigs were studied after 12 weeks: normal, untreated renovascular 
HT, or HT+ chronic antioxidant supplementation (HT+A, 100 IU/kg vitamin E and 1g vitamin 
C daily) (n=6 each group). Left ventricular muscle mass (LVMM) was determined in vivo 
using electron beam CT, and myocardial samples then scanned ex-vivo with a micro CT 
scanner for measurement of the spatial density of myocardial microvessels (<500µm) in 
situ. Superoxide production, the expression of NADPH oxidase (p67 phox), and vascular 
endothelial growth factor (VEGF) were determined in myocardial tissue.
Results: HT and HT+A had normal LVMM and similarly increased arterial pressure. 
Compared to normal, HT showed increased spatial density of myocardial microvessels 
(177.1±16.5 vs. 95.3±8.2 vessels/cm2, p<0.05), which was preserved in HT+A (106.4±6.1 
vessels/cm2). HT also increased in situ superoxide production, p67 phox, and VEGF 
expression, which were all preserved by antioxidants.
Conclusions: Myocardial microvascular remodeling in early HT is accompanied 
by increased oxidative stress and VEGF expression, and attenuated by antioxidant 
intervention. This study underscores a role of increased oxidative stress in modulating 
myocardial microvascular architecture in early atherogenesis. 
1157-132 Assessment of Potassium Homeostasis and Vascular 
Function in the Management of Essential Hypertension: 
2002-2004 Follow-up
Carlos L. Delgado-Leon, II, Antonio Rafael Delgado-Almeida, Antonio Javier Delgado-
Leon, Susana Isabel Celis, Hypertension Research Unit, Valencia, Venezuela, University 
of Carabobo Medical School, Valencia, Venezuela
Following our description of a hereditable defect in red blood cell potassium (RBC 
K) content in essential hypertension, a prospective 2 years study was conducted in 
hypertensives (n=300, aged 31-70 y, 41% males, BP 169 ±13/ 99±11) to assess: a) K 
homeostasis (K in plasma, 12-hrs urine overnight, RBC K, Transtubular K Gradient [TTKG] 
& total body K (TBK) by bio-impedance Analysis), and b) Non-invasive hemodynamic 
(DynaPulse 200A) for cardiac (LV dP/dT, LVET, SV, CI), Systemic Vascular Resistance 
and Compliance (SVR,SVC) and Brachial Artery Resistance, Compliance, Distensibility 
(BAR, BAC, BAD) before and after treatment (1,6,12 months). Patients received: (I) 
Indapamida (2,5 mg) + Propranolol (40 mg), (II) CCB (5 mg), (III) ACE inhibitor (20 mg), 
(IV) AT1 receptor blocker (40). In all, Amiloride (5 mg) was added to improve RBC K, 
Calcium (1 g) if ionized Ca <1.2 mmol/l. 
Results: a) all had RBCK↓ (84.2±6 mmol/l vs 96 ±4 in normal, <p 0.0001) despite normal 
RBC Na (7.1 ±.08 mmol/l in 67%) & plasma K. TTKG was↓ (4.3 ±0.3 vs 7.1± .7 ± in 
normal, p 0.006) with TBK↓ (3157 ±285 mmol vs 3479± 511 in control, p 0.005). b) Drugs 
(I-IV) ↓BP (<140/90 mmHg) in 38% with favorable hemodynamics & little changes in K 
homeostasis. Adding amiloride for 3 months, ↑RBCK (>92 mmol/l, p 0.005), TTKG (>6.2, 
p 0.03) in 87% of cases with ↓BP (≤150/90 in 72%), lower LV dP/dT (1345 ±175 mmHg, 
p 0.002), SVR 1349 ±102 dy.scm5, p 0.002) and ↑SVC (1.34 ±0.03, p 0.003), BAC 
0.089± 0.022, p 0.03 & BAD (5.8 ±0.5, p 0.03). Amiloride & Calcium help to achieve better 
BP and hemodynamics in the reaming 13% of cases. Most patients remained stable 
during 12 months period and 265 subjects entered 2nd year. At 2 year, in 1 out 2 cases 
antihypertensive doses or drugs were reduced, ECG improved including ST-T changes 
of LVH or ischemia, quality of life became normal and 81% were symptoms free; none 
patients on antihypertensive + amiloride had complications or hospitalization. 
Conclusion: a) RBCK, TTKG & TBK are signiﬁcant↓ in hypertensives and related to BP 
control and hemodynamic alterations; b) Adding amiloride remarkable improved effects 
of antihypertensive medication.
1157-133 Differential Effects of Angiotensin-Type I Receptor 
Blockers on Endothelial Function and Prothrombotic 
State
Gregory P. Vyssoulis, Georgios C. Antonakoudis, Konstantinos A. Aznaouridis, Stefanos 
Zezas, Christodoulos I. Stefanadis, Athens University, Hippokration Hospital, Athens, Greece
Background. Recent evidence suggests that angiotensin II receptor blockade has 
beneﬁcial effects on the endothelial function and prothrombotic state of hypertensive 
patients (pts). Fibrinogen and plasminogen activator-inhibitor-1 (PAI-1) have been shown 
to predict cardiovascular risk. Aim of the present study was to evaluate the effect of 
different angiotensin-II receptor blockers (ARBs) on these markers of thrombogenicity.
Methods. We studied retrospectively 2007 consecutive pts (age 58.8±12.9 years, 1127 
men) with mild to moderate chronic uncomplicated essential hypertension. After a two-
week wash-out period, ofﬁce blood pressure (BP) was determined. Plasma ﬁbrinogen 
and serum PAI-1 levels were measured before and 6 months after the initiation of ARB 
antihypertensive treatment. 539 pts received losartan 50 mg, 425 irbesartan 150 mg, 321 
valsartan 80 mg, 363 candesartan 16 mg, 138 eprosartan 600 mg and 219 telmisartan 
80 mg. All pts enrolled were responders to ARB monotherapy, with double-dosing when 
necessary to achieve optimal BP control.
Results. All ARBs decreased BP efﬁciently (P<0.001) to a similar degree (P=NS). In all, 
both ﬁbrinogen and PAI-1 decreased signiﬁcantly after 6 months of ARBs monotherapy 
(321 to 311 mg/dl and 3.02 to 2.90 IU/ml respectively, P<0.00001). The 6 ARBs 
differentiated in total ﬁbrinogen decrease (% pre/postreatment change -1.7 vs -2.8 vs 0.1 
vs -3.2 vs -0.2 vs 0.3%, P=0.01), with losartan, irbesartan and candesartan showing the 
most beneﬁcial effect (pre/postreatment values 311 to 301 mg/dl, P=0.00003, 325 to 311, 
P<0.00001 and 330 to 315, P<0.00001 respectively). Drugs differentiated also in PAI-1 
level change (1.4 vs -3.7 vs 0.0 vs -3.1 vs -0.5 vs -0.7%, P=0.02). Losartan, irbesartan 
and candesartan also decreased PAI-1 levels the most (2.96 to 2.84 IU/ml, P=0.002, 3.11 
to 2.94, P<0.00001 and 3.07 to 2.92, P<0.0001 respectively).
Conclusions. Antihypertensive treatment with ARBs is associated with a favorable effect 
on the endothelial function and prothrombotic state. Losartan, irbesartan and candesartan 
seem to inﬂuence positively the prothrombotic state of hypertensives the most.
1157-134 Serum Uric Acid Levels Correlate With Impaired 
Arteriole Resistance Detected by Color Dopple 
Energy Imaging in Kidneys of Hypertension Patients 
Complicated With Type 2 Diabetes Mellitus 
Wu Wodong, Sr., Guangzhou Second Municipal People’s Hospital, Guangzhou, People’s 
Republic of China
background: To investigate the relationship between serum uric acid levels and arteriole 
resistance detected with the color Doppler energy imaging(CDEI) and to explore the risks 
of impaired regulation of vascular tone by uric acid in kidneys of hypertension patients 
complicated with type 2 diabetes mellitus. 
Methods In 12 healthy control cases, 28 none diabete hypertension (nNIDDM+H) 
cases and 25 type 2 diabete hypertension (NIDDM+H) cases, uric acid levels (UA) were 
measured with uricase-peroxidase method. Arteriole resistance index (RI) and pulsate 
index (PI) in separate sections of renal artery included MAR, SRA, IRA were detected 
using color Doppler energy imaging with 2.1~4.2 Hz Doppler transducer in kidneys. 
Results In comparison, UA was signiﬁcantly higher in none diabete hypertension group 
and diabete hypertension group than in control group, both p<0.01. UA levels was also 
signiﬁcantly higher in NIDDM+H group than in nNIDDM+H, p<0.029. RI in separate 
sections of renal artery was signiﬁcantly higher in nNIDDM+H, or NIDDM+H group than 
in control group, all p<0.01, and it was signiﬁcantly higher in NIDDM+H than nNIDDM+H 
groups, p<0.05 or p<0.01. In nNIDDM+H and NIDDM+H groups UA levels and IRA-RI 
could be elevated signiﬁcantly following with the impaired heart function being aggravated 
χ2=13.028, p=0.005, χ2=13.29, p=0.004; the dosage of HCT being increased, χ2 =14.216, 
p=0.001, χ2 =14.661, p=0.001; the levels of GHbA1 being excessed unnormally, p=0.000. 
The correlation between UA and IRA-RI in both hypertension groups were directly related, 
in nNIDDM+H group r=0.842, p=0.000, in NIDDM+H group, r=0.797, p=0.000. 
Conclusions Uric acid levels and IRA-RI in hypertension patients complicated with type 
2 diabetes mellitus were directly related. Uric acid levels and IRA-RI could be partly 
dependent on the severity of heart function, diuretic dose, and serum glucose status of 
diabete patients in long-term. Uric acid and the xanthine oxidase metabolic pathway may 
contribute to impaired regulation of arteriole tone in hypertension patients complicated 
with type 2 diabetes mellitus.
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854  Improving Cardiovascular Risk 
Predictors
Tuesday, March 08, 2005, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room 231A
2:00 p.m.
854-3 Race and Sex Differences in C-Reactive Protein Levels: 
The Dallas Heart Study
Amit Khera, Darren K. McGuire, Sabina A. Murphy, Harold G. Stanek, Sandeep R. 
Das, Wanpen Vongpatanasin, Frank H. Wians, Jr., Scott M. Grundy, James A. de 
Lemos, Donald W. Reynolds Cardiovascular Clinical Research Center, Dallas, TX, UT 
Southwestern Medical Center, Dallas, TX
Background: Few data are available comparing C-reactive protein (CRP) distributions in 
different race and sex groups. Recent recommendations for CRP testing for cardiovascular 
(CV) risk assessment suggest a uniform threshold to deﬁne high relative risk (>3 mg/L).
Methods: We measured high-sensitivity CRP (Roche/Hitachi Tina quant® CRP), in 2749 
white and black men and women age 30-65 participating in the Dallas Heart Study, a 
multiethnic, population-based, probability sample, and compared levels of CRP between 
different race and sex groups.
Results: Blacks had higher CRP levels than whites (median 3.6 v. 2.3 mg/L; p<0.001) and 
women had higher CRP levels than men (4.1 v. 2.0 mg/L; p<0.001). The sample-weight 
adjusted proportion of subjects with CRP levels >3 mg/L was 31%, 40%, 51%, and 58% 
in white men, black men, white women, and black women, respectively (p< 0.05 each 
group v. white men). After adjustment for traditional CV risk factors and for BMI, a CRP 
level >3 mg/L remained more common in white women (OR 1.7, 95% CI 1.2-2.6) and 
black women (OR 1.9, 95% CI 1.3-2.9) but not in black men (OR 1.3, 95% CI 0.9-2.0) 
compared with white men.
Conclusion: Signiﬁcant race and sex differences exist in the proportions of individuals 
with CRP levels above the suggested high relative risk value. Further studies are needed 
to determine if race and sex differences in CRP levels are associated with differences 
in CV outcomes, and if thresholds for CV risk assessment may need to be adjusted for 
different race and sex groups.
2:15 p.m.
854-4 Microalbuminuria shows additional value to the 
Framingham Risk Score in the detection of Coronary 
Heart Disease.
Christiane A. Geluk, Hans L. Hillege, Folkert W. Asselbergs, Paul E. de Jong, Felix Zijlstra, 
Wiek H. van Gilst, Groningen University Medical Center, Groningen, The Netherlands
Objectives: To assess the additive predictive value of microalbuminuria to the Framingham 
Risk Score (FRS) in the detection of prevalent coronary heart disease (CHD).
Background: The FRS is recommended for global coronary risk prediction. 
Microalbuminuria may reﬂect generalized vascular dysfunction and is regarded as a risk 
marker for CHD. However, it is not known whether microalbuminuria shows additional 
value on the FRS for detection of CHD.
Methods: Baseline levels of urinary albumin excretion (UAE) and traditional risk factors 
(for determination of FRS) were measured in all 8592 participants in the population based 
Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Microalbuminuria 
was deﬁned as UAE between 30-300 mg/24h. CHD was deﬁned as history of myocardial 
infarction or infarct pattern on the ECG.
Results: Prevalence of previous CHD was 6.4% (n=546). The median FRS (%10 year 
CHD risk) was 15.2 (6.4-27.1)% in subjects with previous CHD versus 6.5 (2.5-14.1)% 
in those without (p<0.001). Median UAE was 13.9 (7.0-36.3) mg/24h and 9.1 (6.2-16.5) 
mg/24h respectively (p<0.001) In a logistic regression model, we found FRS a statistically 
signiﬁcant predictor of prevalent CHD. A signiﬁcant improvement has been made when 
the model was constructed with microalbuminuria.
Conclusions: Microalbuminuria is associated with CHD independently from traditional 
risk factors as expressed by the FRS. It needs to be studied whether this observation can 
be conﬁrmed prospectively. 
Table: Odds ratios for detection of CHD. 
Univariate Model with FRS quintiles and Microalbuminuria
FRS 5-10% 1.65 (95%CI 1.24-2.20 ) 2.74 (95%CI 1.64-4.60 )
FRS 10-15% 2.33 (95% CI 1.72-3.17) 3.87 (95% CI 2.27-6.25)
FRS 15-20% 3.64 (95% CI 2.65-4.99) 6.04 (95% CI 3.50-10.43)
FRS >20% 5.27 (95% CI 4.13-6.72) 8.75 (95% CI 5.45-14.04)
2:30 p.m.
854-5 An Association Between Proteinuria and Coronary 
Atherosclerosis in Patients With Abnormal Glucose 
Tolerance
Yu Kataoka, Satoshi Yasuda, Masaysohi Takeno, Shinzo Miyamoto, Isao Morii, Atsushi 
Kawamura, Shunichi Miyazaki, National Cardiovascular Center, Osaka, Japan
Background: Altered renal function (decrease in creatinine clearance or proteinuria) is 
an independent risk factor of cardiovascular morbidity and mortality. The present study 
investigated whether a signiﬁcant association exists between proteinuria and the extent of 
coronary atherosclerosis in patients with angina pectoris.
Methods: A total of 490 patients were studied and divided into the following three groups 
according to the urinary protein (UP) level; normal (UP < 30mg/dl, n=381), low (30<= 
UP = 100mg/dl, n=66) and high (UP >= 100mg/dl, n=43). Metabolic proﬁles including 
hemoglobin (Hb) A1c, fasting glucose and postprandial glucose levels were measured. 
All major coronary trees were assessed by computer-assisted quantitative coronary 
angiography. We deﬁned segments with an absolute diameter of <= 1.5mm as diseased 
lesions and determined average lesion length (ALL).
Results: Patients in the high UP group showed longer ALL and higher levels of HbA1c, 
fasting and postprandial glucose than other two groups. By multivariate analysis, the UP 
and postprandial glucose levels were independent determinant of long coronary artery 
lesions (ALL > 10mm).
Conclusion: These ﬁndings indicate that proteinuria is strongly associated with diffuse 
coronary narrowing. Postprandial hyperglycemia may contribute to a preferential link 
between atherosclerotic macrovascular disease and renal microvascular disease.
2:45 p.m.
854-6 Age Over 30 Becomes a Cardiovascular Risk Factor in 
Patients Screened for Chronic Kidney Disease: Results 
from the Kidney Early Evaluation Program (KEEP)
Peter A. McCullough, Michael J. Klag, Janet B. McGill, Allan J. Collins, Shu-Cheng Chen, 
Suying Li, Ajay K. Singh, Andrew S. Narva, William H. Herman, George L. Bakris, Claudine 
T. Jurkovitz, Keith C. Norris, Pablo E. Pergola, Wendy W. Brown, KEEP Investigators, 
William Beaumont Hospital, Royal Oak, MI, Meharry Medical College, Nashville, TN
Background. Chronic kidney disease (CKD) is recognized as an independent 
cardiovascular disease (CVD) risk state. There is an age-related decline in renal function 
down to an estimated GFR of 60 ml/min during normative aging. Among patients with 
CKD, the inﬂuence of age on the risk of CVD is unknown.
Methods. The Kidney Early Evaluation Program is a multicenter screening program 
of individuals at risk for CKD but not on dialysis. Estimated GFR was computed using 
the 4-variable MDRD equation based on serum creatinine, age, gender, and race. Of 
24,070 (age 52.6±15.8 years, 68.9% female, 39.4% African American) who volunteered 
for screening, 3,883 (16.1%) had a self-reported history of CVD (myocardial infarction, 
stroke, peripheral artery disease). Multivariate analysis set age 18-30 as the referent. With 
each increasing age group there was a linear increase in the risk of CVD after age 30 
(Table). Other signiﬁcant factors in the model were male gender, OR=1.27; hypertension, 
OR=1.64; diabetes, OR=1.73; smoking, OR=1.56; microalbuminuria >30 (reference: ≤10), 
OR=1.34; anemia (Hb ≤12.8) (referent: >14.6 g/dl), OR=1.42; and body mass index > 30 
(referent: <25 kg/m2), OR=1.33 (all p<0.0001).
Conclusions: Among individuals who volunteered for kidney disease screening, age acts 
as a CVD risk factor starting at age 31. These data suggest CKD ampliﬁes the age effect 
on atherosclerosis and potentially accelerates its course in young individuals.
Independent odds ratio (OR) for CVD according to age group. 
Age OR P-value
18-30 reference -
31-45 1.444 0.0077
46-60 2.396 <.0001
61-75 4.019 <.0001
>75 6.398 <.0001
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854-7 A Complete Blood Count-Derived Risk Score Greatly 
Improves Predictive Ability for Mortality
Brianna S. Ronnow, Joseph B. Muhlestein, John F. Carlquist, Dale G. Renlund, Donald 
L. Lappé, Heidi Thomas, Benjamin D. Horne, Tami L. Bair, Kurt R. Jensen, Jeffrey L. 
Anderson, LDS Hospital, Salt Lake City, UT, University of Utah, Salt Lake City, UT
Background: The complete blood count (CBC) is a relatively inexpensive, frequently 
obtained blood test that is potentially underutilized. Hematocrit (Hct) and total white blood 
cell (WBC) count have been proposed as cardiovascular risk markers, but a total score 
combining all CBC parameters has not been reported.
Methods: Patients undergoing coronary angiography and entered in our cardiovascular 
registry from 1993-2003 were studied if they received a baseline CBC (N=19,044). Time 
to event or follow up averaged 3.8 years. Simple and expanded CBC mortality risk models 
were developed using multivariable Cox regressions. CBC parameters included: Hct, 
hemoglobin (Hgb), red cell distribution width (RDW), mean corpuscular Hgb (MCH), MCH 
concentration (MCHC), mean corpuscular volume (MCV), RBC, platelets (plt), WBC, and 
WBC differential (N=4924). Variables were divided into quartiles. Hgb, RBC, and MCH 
were eliminated in ﬁnal models due to collinearity.
Results: Mean age was 63 years; 64% were male. The simple CBC score, using Hct, WBC, 
and plt, predicted mortality with a model chi-square of 800, p<<0.001. This model separated 
sub-groups with risk differences up to ten-fold (comparing all lowest quartile with all highest 
quartile patients, HR=9.9, CI 3.1-31, p<<0.001). Substantially greater predictive value was 
achieved with the expanded CBC score, using Hct, MCV, RDW, MCHC, plt, and WBC 
(χ2=1570, p<<0.001). Predictive ability was further improved after age and sex adjustment 
(χ2=1705, p<<0.001 for simple CBC model, ROC AUC=0.716; χ2=2270, p<<0.001 for 
expanded model, ROC AUC=0.722) or adjustment for all 7 traditional risk factors (χ2=1957, 
p<<0.001, and χ2=2474, p<<0.001, respectively). Model chi-square for all CBC models 
greatly exceeded those containing only Hct (χ2=535) or WBC (χ2=125).
Conclusion: In a large, prospective database, we demonstrated greatly improved 
predictive ability for mortality using both a simple and an expanded CBC model. The 
predictive ability was incremental beyond age, sex, and traditional risk factors. We 
propose a total CBC Score as an important new addition to risk prediction, which can be 
easily computer-generated for clinical use.
3:15 p.m.
854-8 Endothelin-1 Lys198Asn and ET-A Receptor H323H 
Polymorphisms act Synergistically on the Risk for 
Coronary Artery Disease
Enrica Cioﬁni, Concetta Prontera, Umberto Paradossi, Maria Grazia Andreassi, Aldo 
Clerico, Andrea Biagini, Maria Giovanna Colombo, CNR Institute of Clinical Physiology, 
G. Pasquinucci Hospital, Massa, Italy
Background. Endothelin-1 (ET-1) plays an important role in vascular pathophysiology. 
Our objective was to examine whether genetic variations of ET-1 (a Lys/Asn change at 
codon 198) and its receptor ET-A (C/T in exon 6, H323H) were involved in the susceptibility 
to coronary artery disease (CAD) in the Italian population.
Methods. We enrolled 635 subjects who underwent coronary angiography (n= 443 with 
CAD; n=192 without CAD). The severity of CAD was expressed by means of the Duke 
score. Both polymorphisms were analyzed by PCR/restriction fragment analysis. Plasma 
ET-1 was assayed by Elisa in 60 randomly selected subjects (n=36 with CAD).
Results. The ET-1 polymorphism was borderline associated with the presence of CAD 
(p=0.06), whereas the ET-A variant was equally distributed among groups (p=0.75). 
However, a signiﬁcant interactive effect was observed between ET-1 and ET-A 
polymorphisms (adjusted OR=10.3, 95% CI, 1.2-90.6, p<0.01, for Asn/Asn and TT double 
homozygotes with respect to Lys and C carriers).
Moreover, among TT carriers of the ET-A variant, Asn/Asn homozygotes of the ET-1 
polymorphism displayed a signiﬁcantly higher Duke score in comparison to Lys allele 
(50.4±6.2 vs 34.5±1.8, p=0.02). ET-1 plasma levels signiﬁcantly correlated with the 
severity of CAD (r=0.35, p=0.04) and the ET-1 Lys198Asn variation (Lys/Lys:0.7±0.3, Lys/
Asn 5.1±1.9, Asn/Asn 16.2±15.7, pg/ml, p=0.005 by Scheffe).
Conclusions. The ET-1 Lys198Asn and ET-A H323H polymorphisms could act 
synergistically to increase the risk of CAD in the Italian population. This genetic interaction 
may merit further investigation as potential therapeutic target.
ORAL CONTRIBUTIONS
856  Stem Cell and Gene Therapy Strategies 
for Ischemic Heart Disease
Tuesday, March 08, 2005, 4:00 p.m.-5:00 p.m.
Orange County Convention Center, Room 304A
4:00 p.m.
856-3 Comparison Between Intracoronary Infusion and Direct 
Transendocardial Injection of Mesenchymal Stem Cells 
in a Dog Acute Ischemia Model
Emerson Carvalho Perin, Guilherme V. Silva, Joao A. Assad, Silvio Litoswski, Stephanie 
Coulter, Rodrigo VC Branco, Andre L. Sousa, Deborah Vela, Bradley J. Martin, Edie M. 
Oliveira, Franca S. Angeli, Judy Ober, Willian K. Vaughn, Yong Geng, James T. Willerson, 
Texas Heart Institute, Houston, TX, OSIRIS Therapeutics, Baltimore
Background: Mesenchymal stem cell’s (MSC) may have a role in the treatment of acute 
myocardial infarction (AMI). The ideal route of administration is still controversial.
Methods: 15 dogs were divided in :a)Control group (CTG) n=5; b) Intracoronary group 
(ICG) n=6 and c) NOGA guided transendocardial injection group (TEIG) n=6. AMI was 
induced by ligation of LAD artery for three hours and then reperfused. The animals 
received cell therapy 1 wk after AMI and sacriﬁced 2 wks after cell therapy. 2D-echo 
and NOGA mapping were performed pre and post-cell therapy. Ischemic area (IA) was 
measured by NOGA.ANOVA and paired T-test were performed.
Results: The echodata are presented in table 1. The TEIG had a signiﬁcant increase in EF 
(p=0.01) when compared to the CTG and a signiﬁcant decrease in end systolic dimension 
at f/u (p=0.02). All other comparisons p>0.05. The TEIG had a signiﬁcant reduction in IA 
(27+12%) when compared to the CTG (2+9%) (p=0.006). The ICG had a trend towards 
decrease in IA (18+7%) when compared to the CTG(p>0.05). The TEIG had signiﬁcantly 
less amount of ﬁbrosis (37+ 9%) when compared to the CTG (52+9 %) (p=0.03 ). The ICG 
had a similar amount of ﬁbrosis (48+25%) to the CTG (p>0.05).
Conclusion: There were no complications associated with TEI after AMI.TEI of MSC’s 
may improve healing of acute myocardial infarcts. This preliminary data suggests that 
NOGA guided TEI may be superior to IC delivery. Future studies with larger sample sizes 
are needed to conﬁrm this preliminary data.
Control TEI IC
Pre-cells Post-cells Pre-cells Post-cells Pre-cells Post-cells
EDD(mm) 4.2+0.1 3.9+0.2 4.1+0.5 3.8+0.5 4.2+0.3 4.0+0.2
ESD(mm) 3.2+0.5 2.9+0.4 3.2+0.3 2.7+0.4 3.2+0.3 3.1+0.3
EF(%) 35+6 36+5 32+4 45+12 35+3 36+10
4:15 p.m.
856-4 Persistent Antiangiogenic Therapy with Integrin-
Targeted Fumagillin Nanoparticles in Early 
Atherosclerosis
Patrick M. Winter, Anne M. Morawski, Shelton D. Caruthers, Thomas D. Harris, Grace 
Hu, Ralph W. Fuhrhop, Huiying Zhang, John S. Allen, Elizabeth K. Lacy, Todd A. 
Williams, Samuel A. Wickline, Gregory M. Lanza, Washington University Medical School, 
Saint Louis, MO
Angiogenesis is an integral feature in the progression of atherosclerosis, which is 
characterized by the expression αvβ3-integrin. In the present study, we characterized 
the drug entrapment and retention of αvβ3-targeted fumagillin nanoparticles in vitro and 
measured the persistence of the anti-neovascular effects in vivo. 
Method: Male New Zealand White rabbits were fed a 0.25% cholesterol diet for 75 days. 
Following initial baseline MR imaging, atherosclerotic animals received αvβ3-targeted 
paramagnetic nanoparticles incorporating 0 (n=18) or 0.2mole% (n=18) fumagillin and 
were rescanned four hours later. Transverse black-blood MRI (250 µm x 250 µm x 5 mm 
resolution) of the thoracic aorta was performed (Philips Medical Systems). Half of the 
rabbits remained on the high-cholesterol diet and the remainder switched to normal chow. 
All animals were imaged weekly with αvβ3-targeted paramagnetic nanoparticles (no drug) 
over the next month to quantify neovascular αvβ3-integrin expression in the aorta. 
Result: Fumagillin nanoparticles incorporated ~ 87% of the theoretic drug payload (30 
µg fumagillin / ml) for a net payload of ~ 26 µg/ml and released less than 9% of the 
incorporated dosage under sink conditions during in vitro dissolution. Baseline MRI signal 
enhancement among all fat-fed rabbits across the entire descending thoracic aorta was 
23.9 ± 3.7% and did not differ (p>0.05) between fumagillin-treated (25.2 ± 4.9%) and no 
drug (22.2± 6.0%) groups. One week after fumagillin treatment, MRI enhancement was 
lower, 5.5 ± 2.7%, in fumagillin-treated animals versus control rabbits, 21.7±4.7% (p<0.05). 
This pharmacologic effect persisted for two weeks. MR signal from the neovasculature 
increased among fumagillin-treated animals in week three and completely recrudesced 
by week 4 (16.3 ± 3.0 % fumagillin vs. control 17.8 ± 2.5%). 
Conclusion: A single-dose of fumagillin-bearing nanoparticles induced an acute anti-
neovascular response that persisted 2 weeks and began to recrudesce thereafter. 
Fumagillin-bearing nanoparticles may provide rapid stabilization of atherosclerotic lesions 
as part of a chronic therapeutic strategy.
2005_10_VascularDiseaseHyper.indd   435 12/23/04   10:16:22 AM
436A ABSTRACTS - Vascular Disease, Hypertension, and Prevention JACC February 1, 2005
Va
sc
ul
ar
 D
is
ea
se
, 
H
yp
er
te
ns
io
n,
 a
nd
 P
re
ve
nt
io
n 
4:30 p.m.
856-5 Intracoronary Transplantation of labelled Mesenchymal 
Stem Cells post Myocardial Infarction is associated with 
Increased Angiogenesis but fails to enhance Functional 
Recovery.
Christophe Dubois, Peter Jans, Witold Streb, Peter Pokreisz, Glenn Marsboom, Hilde 
Gillijns, Desire Collen, Frans Van de Werf, Stefan Janssens, Center for Transgene 
Technology and Gene Therapy, Leuven, Belgium, University of Leuven, Leuven, Belgium
Background: Allogeneic mesenchymal stem cells (MSCs) may differentiate to a 
cardiomyocyte-like phenotype in the adult murine healthy heart. The effect of intracardiac 
MSC transplantation on myocardial repair after acute myocardial infarction (AMI) remains 
unknown.
Methods: In a blinded, randomized, sham-controlled study, transplantation of allogeneic 
AdGFP-infected porcine MSCs (group A, n=8, 21.1+/-14.6x10E6 cells) or sham injection 
(group B, n=4) was performed in the infarct related artery 1 week after AMI induced by 
90 min balloon occlusion of the circumﬂex artery. Left ventricular function was analyzed 
invasively (dP/dtmax) and using echocardiography (maximal systolic strain) at baseline, at 
MSC/sham delivery and before sacriﬁce at 7 weeks. Immunohistochemistry and confocal 
analysis were performed on sections from infarct, peri-infarct and remote areas using 
speciﬁc antibodies against GFP, von Willebrand Factor (vWF) and desmin.
Results: Culture-expanded allogeneic MSCs (CD29+, CD44+, CD90+, CD31-) retained 
plasticity as evidenced by in vitro adipogenic differentiation, irrespective of adenoviral 
labelling. Following transplantation, GFP-labelled MSCs mainly localized within areas of 
myocardial necrosis at 7 weeks and were associated with a marked increase in blood 
vessels. Transplanted MSCs in part coexpressed GFP and vWF, but did not adapt a 
cardiomyocyte-like phenotype. During follow-up, dP/dtmax equally decreased in both 
groups (from 1687+/-582 mmHg/s to 1436+/-165 in A and from 1572+/-145 to 1452+/294 
in B, p=NS). Maximal systolic strain decreased from 0.58+/-0.12 at baseline to 0.23 +/-
0.23 1 week after AMI and recovered to 0.39+/-0.24 at 7 weeks in A with a similar trend in 
B (from 0.66+/-0.21 to 0.31+/-0.14 to 0.46+/-0.28) (p=NS).
Conclusion: Selective targeting of areas of myocardial necrosis by transplanted MSCs is 
associated with a greater angiogenic response, in part due to transdifferentiation of MSCs 
to an endothelial cell phenotype and in part due to vessel recruitment. The angiogenic 
response was not associated with improved functional recovery suggesting the need for 
strategies to enhance MSC survival and/or to mediate cellular cardiomyoplasty.
4:45 p.m.
856-6 DDAH Overexpression Enhances Insulin Sensitivity  
in a Transgenic Murine Model
Karsten Sydow, Carl E. Mondon, John P. Cooke, Stanford University, Stanford, CA
Background: Asymmetric dimethylarginine (ADMA) is an endogenous NO synthase 
inhibitor. Elevated ADMA concentrations impair endothelium-dependent vasodilation. 
An intriguing relationship has been shown between ADMA and insulin resistance. In 
humans, plasma ADMA is positively correlated with an impairment in insulin-mediated 
glucose disposal. We hypothesized that lowering plasma ADMA concentrations by DDAH-
I overexpression may enhance insulin sensitivity in a transgenic murine model.
Methods: Studies were performed in age-, sex- and weight-matched male DDAH-I 
transgenic (DDAH) mice and wild-type littermates (WT) at baseline, 10 and 22 weeks. 
To assess insulin sensitivity, glucose tolerance tests (GTT; 1g/kg body weight i.p.) were 
performed after an overnight fast, and glucose and insulin plasma concentrations were 
measured over 2.5 hours. The insulin resistance (IR) index was calculated in order to 
compare the resistance to insulin action between groups.
Results: DDAH mice had signiﬁcantly lower ADMA plasma levels compared with WT 
mice (DDAH vs. WT: 0.63±0.03 vs. 1.00±0.04 µmol/l; 37% decrease). Both groups showed 
a signiﬁcant increase in ADMA plasma concentrations during the course of the test. 
However, the increase in ADMA was 2.4 fold higher in WT mice. DDAH mice showed a 
38% decrease in total mean ADMA compared with WT animals following an acute glucose 
challenge. Although the glucose levels at baseline between the groups were the same, the 
decline of glucose was faster in DDAH mice. Intriguingly, the insulin concentrations were 
not only signiﬁcantly lower in DDAH mice at baseline, the maximal insulin response was 
less and the decline of insulin was faster with insulin levels signiﬁcantly lower at the end 
of the GTT. In accordance to the sustained reduction in ADMA in the DDAH transgenic 
mice, we saw a sustained reduction in the IR index in DDAH animals (DDAH vs. WT: 30.1 
vs. 46.6; 34%; p<0.01).
Conclusions: These ﬁndings indicate that lowering ADMA plasma concentrations by 
enhanced DDAH activity is associated with improved insulin-induced glucose uptake. 
Further studies are on going to determine which tissues (i.e. liver, skeletal muscle) are 
responsible for the ADMA effect.
ORAL CONTRIBUTIONS
859  Prognostic Importance of Lipids in 
Persons With Insulin Resistance
Tuesday, March 08, 2005, 4:00 p.m.-5:00 p.m.
Orange County Convention Center, Room 414C
4:00 p.m.
859-3 Smoking Habit Decreases Plasma Adiponectin 
Concentration in Men
Yoshio Iwashima, Tomohiro Katsuya, Takeshi Horio, Koji Ohashi, Shinji Kihara, Tohru 
Funahashi, Hiromi Rakugi, Toshio Ogihara, Osaka University Graduate School of 
Medicine, Suita City, Osaka, Japan
Background: Adiponectin is one of the key molecules in the metabolic syndrome, and 
its concentration is decreased in diabetes and coronary artery disease. On the other 
hand, smoking habit is well known to be related to these diseases. In this study, we 
demonstrated the suppressive effect of smoking on the expression and secretion of 
adiponectin in vivo and in vitro.
Methods and Results: A total of 328 male subjects were enrolled in this study. Total 
subjects were divided into three groups by smoking habit as follows; current smokers 
(CS), past smokers (PS), and non-smokers (NS). Adiponectin was signiﬁcantly lower 
in CS (CS: 5.4±0.3 µg/ml, PS: 5.9± 0.3 µg/ml, NS: 6.4±0.4 µg/ml, p<0.05). Even after 
adjustment for confounding factors (age, BMI, total cholesterol, HDL-cholesterol and 
HOMA), adiponectin was signiﬁcantly lower in CS than in NS (CS: 5.0± 0.3 µg/ml, PS: 
5.5± 0.3 µg/ml, NS: 6.0± 0.4 µg/ml, p=0.04). Multiple linear regression analysis was 
performed in the subgroups except PS (n=190), and revealed that smoking habit was 
independently associated with adiponectin concentration (F=4.3, p=0.04). In CS (n=76), 
adiponectin was inversely associated with the number of cigarettes smoked per day (r=-
0.21, p<0.04). Furthermore, when the analysis was restricted to subjects not receiving any 
medication and without diabetes (n=98), adiponectin was signiﬁcantly lower in CS than 
NS (CS: 6.1±0.7 µg/ml, PS: 7.1± 0.6 µg/ml, NS: 8.3±0.8 µg/ml, p<0.05). In cultured mouse 
3T3-L1 adipocytes, hydrogen peroxide and nicotine reduced the mRNA expression and 
secretion of adiponectin in a dose-dependent manner.
Conclusions: These results suggest that smoking habit decreases adiponectin 
concentration in part through direct inhibition of adiponectin expression in adipocytes. 
With respect to cessation of habitual smoking, in this study, adiponectin level was in the 
middle between non-smokers and current smokers, even after adjustment for confounding 
factors. Our results also suggested that the decreasing effect of smoking on adiponectin 
concentration might remain even after smoking cessation.
4:15 p.m.
859-4 Diagnostic Accuracy of the Adult Treatment Panel-III 
Criteria for Metabolic Syndrome to Identify Insulin 
Resistance
Justo Sierra Johnson, Bruce D. Johnson, Kent R. Bailey, Gary L. Schwartz, Stephen T. 
Turner, Mayo Clinic, Rochester, MN
Background: The metabolic syndrome is a cluster of coronary heart disease risk factors 
that share an association with insulin resistance, which appears to be the underlying 
pathophysiologic disturbance. The aim of the present study was to assess the relationship 
between the diagnosis of the metabolic syndrome based on the Adult-Treatment Panel-III 
(ATP-III) criteria and a validated measure of insulin sensitivity obtained from the frequently 
sampled intravenous glucose tolerance test (FSIVGTT) and analyzed by Bergman’s 
minimal model.
Material and Methods: FSIVGTT were performed in 256 asymptomatic subjects from 
the white non-Hispanic population of Rochester MN (age 19-60 years; 123 men and 133 
women) to estimate the insulin sensitivity index (SI) by FSIVGTT and the minimal model. 
Waist circumference, blood pressure, fasting plasma glucose, triglycerides, and HDL 
cholesterol concentrations were measured. Insulin resistance was deﬁned by values of 
the SI index of less than 2.
Results: Based on the ATP-III criteria the overall prevalence of the metabolic syndrome 
was 15.6% (16.3% in men; 15.1% in women). Components of the metabolic syndrome 
(in descending order of prevalence) were in men low HDL-cholesterol (73%), high 
triglycerides (26%), and high waist circumference (19%); and in women low HDL-
cholesterol (69%), high waist circumference (28%) and hypertension (14%). Presence of 
the metabolic syndrome was signiﬁcantly associated with insulin resistance (chi-square, 
P<0.001). In men, presence of the metabolic syndrome had a sensitivity of 45% (14 of 31) 
positive predictive value of 82% (14 of 17), and speciﬁcity of 93% (86 of 92) in predicting 
insulin resistance; in women, the sensitivity was 39% (15 of 38), positive predictive value 
65% (15 of 23), and speciﬁcity 95% (90 of 95). Overall, the odds of being insulin resistant 
were 12-fold higher in subjects that meet the ATP-III criteria for having the metabolic 
syndrome (odds ratio 11.8; 95% CI 8.72-14.87).
Conclusions: Among asymptomatic white adults, the ATP-III criteria for the metabolic 
syndrome provide reasonably good speciﬁcity but poor sensitivity for the identiﬁcation of 
insulin resistant individuals.
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859-5 Effect of Statin Therapy on C-Reactive Protein 
Levels Among African American Patients With 
Hypercholesterolemia: Results From the ARIES Trial
Keith C. Ferdinand, Karol E. Watson, Joseph Ycas, Alex Gold, Philip T. Sager, ARIES 
Study Group, Heartbeats Life Center, New Orleans, LA, UCLA School of Medicine, Los 
Angeles, CA
Background: The inﬂammatory biomarker C-reactive protein (CRP) is linked with 
increased coronary heart disease (CHD) risk. National statistics show that African 
Americans have a higher CHD prevalence than white Americans, and black women in the 
Women’s Health Study had signiﬁcantly higher median CRP levels than white, Hispanic, 
and Asian women. Thus, we analyzed changes in CRP with rosuvastatin (RSV) and 
atorvastatin (ATV) in hypercholesterolemic African American patients in the ARIES trial 
(4522US/0002).
Methods: After a 6-wk dietary lead-in, African American adults with low-density lipoprotein 
cholesterol >160 and <300 mg/dL and triglycerides <400 mg/dL were randomized to open-
label RSV 10 or 20 mg or ATV 10 or 20 mg for 6 wks. Median % change from baseline 
in CRP at 6 wks was assessed by Wilcoxon sign rank test. A subgroup analysis was 
performed in 510 (71%) patients with baseline CRP >2.0 mg/L because these patients 
are at increased CHD risk.
Results: Of 774 patients randomized, 723 had paired 6-wk samples (mean age, 55 
y; mean BMI, 33 kg/m2; 64% women). Figure shows median % changes in CRP from 
baseline for the overall and subgroup populations. All treatments were well tolerated.
Conclusion: The majority of African American patients in the ARIES trial had an 
increased risk of CHD events (baseline CRP >2.0 mg/L). Both RSV 10 and 20 mg and 
ATV 20 mg signiﬁcantly reduced CRP from baseline in this patient subgroup. The trend 
favoring RSV was also seen in the overall population.
4:45 p.m.
859-6 The Association of Cardiovascular Disease Risk and 
Increased High-Density Lipoprotein Cholesterol With 
Prescribed Fibrates: An Observational Study
Gregory A. Nichols, Carol E. Koro, Wiley Chan, Steven J. Bowlin, Dennis L. Sprecher, 
Kaiser Permanente Northwest, Portland, OR, Glaxosmithkline, Collegeville, PA
Background: Although the relationship between baseline high-density lipoprotein 
cholesterol (HDL-C) and cardiovascular disease (CVD) has been established in clinical 
trials, real-world data demonstrating CV beneﬁt from HDL-C modiﬁcation remains scant. 
We studied a cohort of patients who received a treatment known to increase HDL-C to 
determine if observed HDL-C increases were associated with lowering CVD risk.
Methods: The study site was Kaiser Permanente Northwest, a 480,000 member HMO. We 
identiﬁed a cohort of 1899 subjects who initiated ﬁbrate therapy between July 1, 1996 and 
December 31, 2000. The outcome was a CV event (primary or secondary) occurring after 
ﬁbrate initiation and requiring hospitalization with a ﬁrst-listed diagnosis of acute myocardial 
infarction, unstable angina, or stroke. Subjects were followed until the earliest of CVD event, 
plan termination, or December 31, 2003. Using generalized linear modeling that accounts 
for differential follow-up, we estimated CVD event rates as a function of change in HDL-C, 
adjusting for age, gender, smoking history, previous CVD diagnosis, diabetes, systolic blood 
pressure, body weight, other lipid fractions, and use of CVD medications (ACE inhibitors, 
beta blockers, calcium channel blockers, diuretics, and statins).
Results: The study population averaged 57 years of age; 57% were men. Over an average 
of 51 months of follow-up, 5.9% (n=108) experienced a CVD event. Mean baseline HDL-C 
was 37 mg/dl and mean baseline lipid levels did not differ signiﬁcantly between those with and 
without CVD events. Most subjects had substantial HDL-C increases during follow-up; 78% 
increased their HDL-C by > 10%. However, 11% of subjects did not increase their HDL-C, 
and CVD event rates differed markedly between the two groups. Those who increased by > 
10% had CVD event rate of 7.2 per 1,000 person-years, compared to 26.2 events per 1,000 
person-years for those whose HDL-C did not increase (rate ratio=3.64; 95% CI=2.65-5.01).
Conclusions: Our results demonstrate an inverse association between increasing HDL-
C and CVD event rates. Thus, patients in the setting of a prescribed ﬁbrate may enjoy a 
substantial CVD beneﬁt from raising HDL-C.
ORAL CONTRIBUTIONS
869  Endothelial Function, Plaque 
Formation, and Regression
Wednesday, March 09, 2005, 8:30 a.m.-10:00 a.m.
Orange County Convention Center, Room 414C
8:30 a.m.
869-3 Vasa Vasorum Density of Human Coronary Arteries in 
Different Stages of Atherosclerosis
Offer Galili, Katherine J. Sattler, Lilach O. Lerman, Amir Lerman, Mayo Clinic College of 
Medicine, Rochester, MN
Introduction: Atherosclerosis is a diffuse and progressive disease of the vascular wall. 
The role of the adventitia and speciﬁcally the vasa vasorum (VV) in the progression of 
atherosclerosis and plaque stability continues to emerge. Nevertheless, the relationship 
between adventitial VV, atherosclerotic lesion progression and calcium deposition in 
human coronary vessels is not explored.
Methods: 12 coronary arteries, obtained at autopsy from patients (age 37-92 yrs.) were 
scanned by novel microCT yielding tomographic images with a 3D matrix of 21µm cubic 
voxels (Panel B). Arterial segments were deﬁned as normal segments from patient with no 
risk factors (N-N), segments from patient with risk factors (N-HR), segments with plaque 
(P) and segments with calciﬁed plaque (P-Ca). Images were analyzed for the following 
parameters: vessel wall area, VV count, VV density (no./mm2), and calcium area. 
Results: VV density increased signiﬁcantly from N-N to N-HR and further to P segments, 
but signiﬁcatly decreased in the P-Ca segments (Panel A). A signiﬁcant negative correlation 
was observed between the area of calcium deposits in the plaque and the VV density.
Conclusion: The current study demonstrates the segmental heterogeneity of adventitial 
VV and their relationship with plaque formation in human coronaries. These observations 
support a role for the human coronary VV not only in the initiation of atherosclerosis but in 
the progression and complication phases of coronary atherosclerosis in humans.
8:45 a.m.
869-4 Regression of Coronary Atherosclerotic Plaque is 
Commonly Associated with Constrictive Arterial 
Remodeling. A Serial Intravascular Ultrasound Study
Ilke Sipahi, Stephen J. Nicholls, Paul Schoenhagen, Timothy Crowe, William Magyar, 
Tammy Churchill, Samir Kapadia, E. Murat Tuzcu, Steven E. Nissen, The Cleveland 
Clinic Foundation, Cleveland, OH
Background: Expansive arterial remodeling, a phenomenon commonly observed in 
atherosclerotic vessel segments is considered to be a marker of the plaque vulnerability. 
Although the relationship between plaque growth and remodeling has been well studied, 
little is known about the course of remodeling process during plaque regression. Our aim 
was to characterize this process through serial intravascular ultrasound (IVUS).
Methods: In a multi-center IVUS study comparing the effects of intensive vs. moderate 
lipid lowering therapy on progression of atherosclerosis in 502 patients (REVERSAL 
study), we identiﬁed 73 subjects with a focal, mildly stenotic (<50% diameter stenosis on 
angiogram) lesion with a relatively normal proximal reference site that had a >5% decrease 
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in atheroma area at the 18 month follow-up IVUS. Proximal and distal ﬁduciary branches 
and automatic pullback were used to match lesion and reference sites at baseline and 
follow-up. For the serial assessment of remodeling, a decrease in the external elastic 
membrane area (EEM) greater than the decrease in atheroma area was considered as 
constrictive, a decrease in the EEM area less than the decrease in atheroma area as no 
and an increase in EEM area as expansive remodeling. Remodeling index (EEM area of 
lesion/EEM area of reference) was also calculated at baseline and follow-up.
Results: EEM area of lesions decreased from 15.0±5.2 mm2 to 13.8±5.0 mm2 (p<0.001), 
and lumen area did not change signiﬁcantly (7.2±3.1 vs. 7.4±3.3 mm2, p=0.23). With 
a stable EEM area at the reference site (14.1±4.8 mm2 vs. 14.0±4.9 mm2, p=0.73) 
remodeling index decreased signiﬁcantly at follow-up (1.08±0.13 vs. 1.0±0.13, p<0.001). 
On serial assessment, 49% of lesions had constrictive, 29% had no and 22% had 
expansive remodeling.
Conclusions: Plaque regression is commonly associated with constrictive arterial 
remodeling. This association may help to explain the lower event rates in patients with no 
evidence of angiographic progression as opposed to those who have disease progression 
in clinical trials of lipid lowering. Absence of change in luminal area can explain the 
limitation of coronary angiography in detecting regression of atherosclerosis.
9:00 a.m.
869-5 Impaired Renal Function Is Associated With Attenuated 
Vasorelaxation In Human Internal Mammary Arteries
Tom D. Smilde, Pim Van Der Harst, Hendrik Buikema, Adriaan A. Voors, Dirk J. 
Van Veldhuisen, Wiek H. Van Gilst, University Hospital Groningen, Groningen, The 
Netherlands, University of Groningen, Groningen, The Netherlands
Background. Renal dysfunction has thus far only been associated with impaired 
endothelial function by FMD and indirect endothelial serum markers. Therefore, we 
assessed in vitro endothelial dependent vasorelaxation of human internal mammary 
arteries (IMA) in CABG patients with various degrees of renal function.
Methods. Renal function (GFRc) was estimated by the Cockcroft-Gault formula. IMA 
segments of 111 patients undergoing coronary bypass surgery were harvested and 
evaluated in organ baths. Endothelium-dependent relaxation was measured by adding 
cumulative doses of Metacholine (ME, 10nM-100µM) and was expressed as percentage 
of response to phenylephrine (PE) to be correlated with renal function by Pearson 
Correlation (2-tailed). A comparison between the complete concentration-response 
curves of ME was made by repeated measures analyses of variances.
Results. Maximal relaxation in response to ME correlated with GFRc (r=0.25, p<0.01). Multiple 
comparisons analysis of variance between ME concentration-response curves demonstrated 
endothelium-dependent relaxation was reduced when GFRc (as continuous variable) was 
reduced (p<0.0001). Figure 1., shows vasorelaxation in the tertiles of GFRc (p<0.01) 
Conclusions. We demonstrated in CABG patients that a decline in renal function was 
associated with an impaired endothelium dependent vasorelaxation of the IMA.
 
9:15 a.m.
869-6 Short-Term Atorvastatin Treatment Improves Vasomotor 
Function in a Dose-Dependent Manner in Internal 
Thoracic Arteries of Coronary Bypass Surgery Patients
Pim van der Harst, Lodewijk J. Wagenaar, Hendrik Buikema, Adriaan A. Voors, H.W. 
Thijs Plokker, H.W. Thijs Plokker, Wim J. Morshuis, A. Jacob Six, Piet W. Boonstra, Georg 
Nickenig, Sven Wassmann, Dirk J. van Veldhuisen, Wiek H. van Gilst, University of 
Groningen, Groningen, The Netherlands, Universitat des Saarlandes, Homburg, Germany
Background: Several studies have shown a relation between increased lipids and the 
activated renin-angiotensin system. In a prospective randomized, double-blind, placebo 
controlled study we investigated the dose-dependent effects of short-term statin therapy 
on endothelial function and its relation to angiotensin II responsiveness.
Methods and Results: We treated 156 patients, scheduled to undergo elective coronary 
bypass surgery, with atorvastatin 10 or 80 mg, or placebo for 2 to 8 weeks. At the time of 
surgery, excess internal thoracic artery segments were obtained, and studied in vitro as 
vascular rings to assess endothelium dependent relaxation and angiotensin II induced 
contraction.
Atorvastatin 10 and 80 mg treatment for a mean of 31 days resulted in a decrease of LDL-
cholesterol of 39% and 53%, respectively, versus a 1% increase in the placebo allocated 
patients. Analysis of dose-response curves to methacholine demonstrated improved 
relaxation in arteries of atorvastatin 80 mg treated patients compared to placebo (P=0.001) 
and atorvastatin 10 mg (p=0.05) treated patients. This improvement in atorvastatin treated 
patients was accompanied by a reduced response angiotensin II (p=0.039). In addition, 
responsiveness to angiotensin II was related to pre-operative cholesterol levels, either as 
cholesterol levels divided in tertiles (p=0.002) or as a continuous variable (p=0.03).
Conclusions: Reduction of LDL-cholesterol with atorvastatin over a 31 day period in 
coronary bypass patients improved dose dependently endothelium dependent relaxation 
and decreased vascular angiotensin II responsiveness in human thoracic arteries. These 
data provide supporting evidence for an effect of statins on the vasomotor function and 
the activity of the renin-angiotensin system in particular.
9:30 a.m.
869-7 Electrocardiogrphic and Ankle Brachial Index 
Abnormalities are poor predictors of Coronary 
Atherosclerosis in Asymptomatic Type 2 Diabetics
Roshanak Bagheri, Mark Schutta, Reshmaal Gomes-Cumarantunge, Megan L. 
Wolfe, Karen Trembula, Barry Hoffman, Stan Schwartz, Stephen E. Kimmel, Daniel J. 
Rader, Nayyar Iqbal, Muredach P. Reilly, University of Pennsylvania Medical Center, 
Philadelphia, PA, Pennsylvania Hospital, Philadelphia, PA
Background. Sub-clinical atherosclerosis is increased in type 2 Diabetes Melitus (DM) 
and predicts future cardiovascular disease (CVD). The extent to which electrocardiographic 
(EKG) and ankle brachial index (ABI) abnormalities reﬂect the burden of sub-clinical 
atherosclerosis in type 2 DM is unknown.
Methods. We examined the association of EKG and ABI abnormalities with coronary 
artery calciﬁcation (CAC), at electron beam tomography, in a sample of 589 prospectively 
recruited, asymptomatic, type 2 DM subjects without CVD (62.5% Caucasian, 31.7% 
African-American; 75% male; aged 58.7±9.2 (mean±SD)). EKG abnormalities were deﬁned 
as presence of Q waves, left ventricular hypertrophy, bundle branch block, non-speciﬁc ST 
or T changes and any rhythm abnormalities; abnormal ABI was deﬁned as ABI < 0.9 or 
>1.3. CAC scores were grouped by ordinal categories (0, 1-10, 11-100, 101-400, >400). The 
association of EKG and ABI abnormalities with CAC was analyzed by multivariable ordinal 
regression and sensitivity and speciﬁcity for CAC cut-points was assessed.
Results. CAC was prevalent (69.3% CAC>0; 44.1% CAC >100; 22.9%CAC >400) in this 
sample despite most subjects having normal EKGs (64%) and ABIs (80%). In unadjusted 
analysis, EKG (P = 0.0034) but not ABI abnormalities (P = 0.25) were associated with 
CAC scores; however neither predicted CAC following adjustment for age and gender 
(P = 0.81 and 0.34 respectively). EKG abnormalities were neither sensitive nor speciﬁc 
for detection of CAC >100 or >400 (sensitivity =0.43 & 0.45 and speciﬁcity =0.69 & 0.66 
respectively). ABI abnormalities were not sensitive for detection of CAC >100 and >400 
(0.21 and 0.24 respectively) but had moderate speciﬁcity (0.80 and 0.80 respectively). 
Furthermore, in subjects with both normal EKG and normal ABI extensive CAC was still 
prevalent (CAC >100 in 38.3%; CAC > 400 in 18.4%).
Conclusion. In this type 2 DM sample, EKG and ABI abnormalities did not identify most 
subjects with extensive sub-clinical coronary atherosclerosis and, therefore, may be of 
limited value in detecting asymptomatic type 2 DM patients at increased CVD risk.
9:45 a.m.
869-8 Patterns of Atherosclerosis in Different Vascular 
Territories
Søren Dalager-Pedersen, William Paaske, Ingrid Bayer Kristensen, Erling Falk, Aarhus 
University Hospital, Skejby Sygehus, Aarhus, Denmark, University of Aarhus, Aarhus, 
Denmark
Information about the relationship between atherosclerosis in different vascular territories 
is needed because measures of atherosclerosis in the carotid (IMT, intima-media 
thickness) and lower limb arteries are used to assess coronary atherosclerotic burden 
and cardiovascular risk.
Methods: Predeﬁned segments of coronary (LAD, RCA) and bilateral carotid and 
superﬁcial femoral arteries were harvested at 100 forensic autopsies (70 men; 20-82 
years, mean age 47.1±1.4). The segments were sectioned and processed for microscopy 
(~48 sections/individual). Blinded typing of the sections (n=4755) was performed using 
the classiﬁcation by Stary et al, and the distribution of lesion types in the arterial segments 
was tabulated. Plaque densities were calculated based on the percentage of sections with 
types IV+ in each arterial segment.
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Table 
Distribution of Lesion Types (%)
Distribution of Carotid Artery 
Lesion Type (%, mean of right 
and left)
Lesion Types* LAD RCA Right Carotid
Left 
Carotid
Right 
Femoral
Left 
Femoral
Common 
Carotid
Carotid 
Bifurcation
Internal 
Carotid
0 No 
Atherosclerosis 38.7 48.1 32.9 33.9 73.9 73.8 19.7 10.3 62.1
I-II
Foam Cell 
Lesions
3.3 4.0 28.9 28.7 4.4 4.6 48.2 25.5 16.1
III
Intermediate 
Lesion
5.5 5.2 8.9 7.0 1.1 1.5 10.2 9.6 5.0
IV-V
Lipid Core 
Plaques
30.7 22.4 22.3 21.4 8.0 8.8 19.7 38.2 10.8
VII
Calciﬁed Plaque 2.8 1.3 0.1 0.1 0.5 0.4 0.0 0.2 0.1
VIII
Fibrous Plaque 18.9 17.9 6.3 7.9 11.0 10.1 1.7 15.5 4.8
IX
Chronic 
Occlusion
0 1.2 0.6 1.0 1.0 0.8 0.5 0.8 1.0
* The acute type VI lesions (thrombus, hemorrhage, rupture) were typed as the underlying “chronic” lesions
Results: Lesions types were symmetrically distributed with highly signiﬁcant correlations 
(r>0.82, p<1x10-25) between plaque densities when comparing right and left carotid and 
femoral segments. Plaques were most prevalent and lipid-rich in the coronary arteries, 
and least prevalent in the femoral arteries. The carotid arteries were diseased in a distinct 
pattern, dominated by early lesions (common), lipid core plaques (bifurcation) and normal 
intima (internal).
Conclusion: LAD and the carotid bifurcation develop plaques ﬁrst, while the femoral 
arteries develop plaques late. The common carotid (site of IMT measurements) is 
dominated by early lesions.
ORAL CONTRIBUTIONS
875  Peripheral Arterial and 
Cerebrovascular Disease
Wednesday, March 09, 2005, 10:30 a.m.-Noon
Orange County Convention Center, Hall E2A
10:30 a.m.
875-3 Histological Evidence for Atherosclerotic 
Neovascularization as a Pathway for Macrophage 
Inﬁltration in Diabetes Mellitus.
K-Raman Purushothaman, Pedro R. Moreno, William N. O’Connor, Annapoorna S. Kini, 
Samin K. Sharma, Valentin Fuster, Mount Sinai Medical Center, New York, NY, University 
of Kentucky, Lexington, KY
Background: Our group have previously reported neovascularization in diabetes 
atherosclerosis as a contributor to plaque disruption. Neovessels provide a pathway for 
inﬂammatory cells to access the plaque. Therefore, the transition from neovascularization 
to plaque disruption may include increased macrophage inﬁltration. This study evaluated 
macrophage (macs) inﬁltration as a function of plaque neovascularization in diabetes 
mellitus (DM).
Methods: Double immunohistochemistry was performed in 142 necropsy aortic plaques 
from patients with DM. Neovessels (blue), were deﬁned as CD-34 positive capillaries 
were quantiﬁed in the plaque and in the tunica media. Macs (red), were deﬁned as CD-68 
positive cells in the ﬁbrous cap and plaque shoulders. Macs were quantiﬁed in the high 
power ﬁeld and scored as follows: 0 (<6 cells), 1 (6-25 cells), and 2 (>25 cells).
Results: Plaques were distributed in tertiles according to neovessel content. Macs scores 
increased signiﬁcantly from the lowest to the highest neovessel tertile (P<0.0001; see 
Figure, upper panel). Furthermore, intravascular macs within neovessels were identiﬁed 
in the highest tertile (Figure, lower panel)
Conclusion: Macrophage inﬁltration increases as a function of plaque neovascularization. 
Novel documentation of macs within neovessels was identiﬁed, providing the ﬁrst 
histological evidence for atherosclerotic neovascularization as a pathway for macrophage 
inﬁltration in diabetes mellitus.
10:45 a.m.
875-4 Plasma Angiopoietin-2 Is an Independent Predictor of 
Adverse Outcome in Patients With Peripheral Arterial 
Disease
Indran Davagnanam, Hoong Sern Lim, Andrew D. Blann, Gregory Y. Lip, University 
Department of Medicine, Birmingham, Birmingham, United Kingdom
Background: Vascular endothelial growth factor (VEGF) and Angiopoietin-2 (Ang-2) 
are regulators of angiogenesis. Raised plasma VEGF and Ang-2 have been reported in 
patients with peripheral arterial disease (PAD), but the prognostic implications are unclear. 
We hypothesised that raised plasma VEGF and Ang-2 are associated with adverse 
events, independent of indices of endothelial damage/dysfunction (with von Willebrand 
Factor, vWf) and thrombosis (Fibrinogen) in patients with PAD.
Methods: Plasma vWf, VEGF, Ang-2 and Fibrinogen were measured in 176 patients with 
PAD recruited from vascular clinics, and were followed up for a mean of 4 years. We 
deﬁned an adverse event as death, myocardial infarction, stroke and amputation.
Results: Over the study period, 50 of 176 patients developed adverse events. These patients 
were comparable with patients who did not develop an event in their age, gender and lipid 
proﬁle. Plasma vWf, VEGF, Ang-2 and Fibrinogen were higher in patients who developed an 
event [Table]. On stepwise multivariate regression analysis, plasma Ang-2 (0.027) and vWf 
(p=0.02), but not VEGF (p=0.912) and Fibrinogen (p=0.059) were independent predictors 
of adverse events. Patients with both plasma vWf and Ang-2 above median had a hazard 
ratio of 2.88 (95% CI: 1.43-5.81) compared to the remaining patients.
Conclusion: Plasma Ang-2 is an independent predictor of adverse outcome in patients 
with PAD. This suggests a wider role for Ang-2 in the pathophysiology of atherosclerosis.
Table: Data as mean (SD) or median (IQR) 
No Event (n=126) Developed Event (n=50) p-value
Current Smokers (n) 62 (49%) 23 (46%) 0.701
Diabetes (n) 74 (59%) 37 (74%) 0.058
Previous CHD (n) 38 (30%) 17 (34%) 0.620
Statin Therapy (n) 45 (36%) 14 (28%) 0.328
Ankle-Brachial Index 0.53 (0.43-0.67) 0.50 (0.36-0.57) 0.057
Ang-2 (ng/ml) 1.8 (1.4-2.4) 2.5 (1.6-4.2) 0.007
VEGF (pg/ml) 100 (70-153) 110 (90-168) 0.033
vWf (IU/dl) 127 (27) 137 (20) 0.010
Fibrinogen (g/l) 3.1 (2.7-3.6) 3.4 (3.1-4.2) 0.001
11:00 a.m.
875-5 Stenting in Patients with Subacute or Acute Vertebro-
basilar Insufﬁciency and Stroke Dramatically Improves 
Clinical Outcomes; Long Term Follow-Up
R. Stefan Kiesz, Pawel Buszman, Oscar Munoz, Merila Ann Walker, San Antonio 
Endovascular & Heart Institute, San Antonio, TX, Silecian Medical School, Katowice, Poland
Background: Acute or subacute Vertebro-basilar insufﬁciency is a dismal ailment with 
poor outcomes and no viable medical or surgical treatments. We hypothesized that 
aggressive diagnostic, angiographic approach with stenting will result in signiﬁcant clinical 
improvement in this group of patients.
Methods: We established a prospective registry for patients with symptoms ranging 
from vertigo and ataxia to acute stroke. All patients were treated with balloon expandable 
stents. During procedure patients received 70 U/kg of unfractionated heparin, 325 mg of 
aspirin and 375 mg loading dose of clopidogrel.
Results: Baseline patients characteristics: mean age 69.9, 55.2% were males, 82.8% 
presented with hypertension, 78.9% with hypercholesterolemia, 31.0% were smokers, 
39.4% with diabetes mellitus, obese (BMI over 30) 20.7%, coexisting CAD 76.3%, and 
PVD 48.3%, previous MI 21.1%, transient ischemic attacks 82.8%, CVA 55.2%. Among 
38 patients enrolled into the study, we treated 46 vessels. In all, but 4 patients, the disease 
was limited to ostial location. There was no neurological peri-operative complications, 
one patient had surgical repair of brachial pseudo-aneurysm and required cessation 
of clopidogrel. All patients demonstrated resolution of symptoms, in 27.6% there was 
dramatic improvement, allowing bedridden to resume normal life style. Short term post 
procedure outcomes (0-30 days) demonstrated no incidence of major or minor stroke, 
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MI, restenosis, TIA or death. Long term follow up demonstrated no incidence of major or 
minor stroke, surgery, MI, or death. Over the courses of one year one patient exhibited 
a 50% restenosis in the right vertebral (the original stenosis was 95%) and one patient 
experienced a TIA.
Conclusions: Aggressive angiographic evaluation and stenting should be considered in 
all patients with symptoms of vertebro-basilar insufﬁciency. Such approach is associated 
with dramatic and lasting neurological improvement. These results call for nationwide trial/
registry in these very high risk patients.
11:15 a.m.
875-6 Comparison of High and Low Dose Atorvastatin for 
the Reduction of Carotid Intimo-Medial Thickness in 
Patients With Coronary Heart Disease-The ANIMATE 
Study
Cheuk-Man Yu, Qing Zhang, Linda Lam, Shun-Ling Kong, Hong Lin, Wilson WM Chan, 
Kenny KK Cheng, John E. Sanderson, Stephen WL Lee, The Chinese University of 
Hong Kong, Hong Kong, Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
Background: Carotid intimo-medial thickness (IMT) is a non-invasive marker of 
atherosclerotic disease severity, which also predicts the prognosis in patients with 
coronary heart disease (CHD). Recently high dose statin therapy has been shown to 
prevent atherosclerotic plaque progression in the coronary arteries in patients with 
CHD. This study examined if High dose (80mg daily) atorvastatin may regress carotid 
atherosclerotic plaque better than Low dose regimen (10mg daily) in patients with CHD.
Methods: The ANIMATE study is a double-blind, randomized study. 112 CHD patients 
(mean age 66±10 years, 82% male) who had either previous myocardial infarction or 
received percutaneous coronary intervention were randomized to either high or low dose 
atorvastatin for a period of 6 months. Carotid artery images at both sides of the neck 
were acquired by B-mode ultrasound before and after atorvastatin therapy, and carotid 
IMT were measured ofﬂine at a level before the carotid bulb in a randomized and blinded 
fashion by a dedicated software.
Results: The plasma total cholesterol, LDL-cholesterol and triglyceride levels were 
reduced in both treatment groups, but the LDL-cholesterol after treatment was lower in 
the High dose group (2.24±0.68 Vs 1.67±0.60 mmol/L, p<0.001). There was a trend but 
insigniﬁcant reduction of carotid IMT in the Low dose group (Left: 1.25±0.55 Vs 1.20±0.51 
mm, p=NS; Right: 1.18±0.54 Vs 1.15±0.41 mm, p=NS). On the other hand, in the High 
dose group, 6-month therapy was associated with signiﬁcant reduction of IMT in both 
carotids (Left: 1.24±0.48 Vs 1.15±0.35 mm, p=0.02; Right: 1.12±0.41 Vs 1.01±0.26 mm, 
p=0.01). High sensitive C-reactive protein level (hsCRP) was signiﬁcantly reduced only in 
the High dose group (4.32±7.69 to 1.65±1.83 mg/L, p=0.01), but not the Low dose group 
(1.84±1.84 to 2.95±6.15 mg/L, p=NS).
Conclusion: Treatment with high dose atorvastatin (80mg daily) in patients with CHD 
resulted in regression of carotid atherosclerotic plaque as evident by lower IMT values, 
which was associated with a lower hsCRP level. On the other hand, a low dose (10mg 
daily) regimen may only prevent the progression of the disease.
11:30 a.m.
875-7 The Pivotal Inﬂuence of Peripheral Vascular Disease 
on Coronary Intervention Outcomes: A Pooled 
Analysis of Mortality Outcomes in 8 Large Randomized 
Percutaneous Coronary Intervention Trials.
Jacqueline Saw, Eric J. Topol, David J. Moliterno, Sorin J. Brener, Steven R. Steinhubl, A. 
Michael Lincoff, Ting Fei Hu, Deepak L. Bhatt, Vancouver General Hospital, Vancouver, 
BC, Canada, Cleveland Clinic Foundation, Cleveland, OH
Background: A signiﬁcant proportion of patients with coronary artery disease (CAD) 
have concomitant peripheral vascular disease (PVD). We sought to evaluate clinical 
outcomes among PVD patients following percutaneous coronary intervention (PCI).
Methods: A pooled analysis of 8 contemporary randomized PCI trials was performed. 
We included multicenter PCI trials that compared antiplatelet therapies (EPIC, EPILOG, 
EPISTENT, RAPPORT, CAPTURE, IMPACT-II, TARGET, CREDO), and had baseline 
PVD variable recorded. The Breslow-Day test was performed to ensure homogeneity of 
the studies. Multivariable analyses were performed with stepwise logistic regression for 7 
and 30-day outcomes, and stepwise Cox regression for 6 month and 1 year events.
Results: In our pooled analysis of 19,867 patients undergoing PCI, 1602 (8.1%) were 
previously diagnosed with PVD. Patients with PVD were older, more frequently female, 
had lower body mass index, more atherosclerotic risk factors (diabetes, hypertension, 
current smoker, hyperlipidemia), more prior history of myocardial infarction (MI), stroke 
and congestive heart failure, and lower baseline creatinine clearance. Patients with PVD 
had higher incidences of 7-day death (1.0 vs. 0.4%, p<0.001) or MI (6.8% vs. 5.6%, 
p=0.047), 30-day death (1.7% vs. 0.7%, p<0.001) or MI (7.4% vs. 6.1%, p=0.05), 6-month 
death (4.2% vs. 1.5%, p<0.001) or MI (9.1%, vs. 7.7%, p=0.048), and 1-year death (5.0% 
vs. 2.1%, p<0.001). There was a trend towards higher major bleeding risk with PVD (4.8% 
vs. 3.9%, p=0.06). With multivariable analyses, PVD remains a signiﬁcant predictor of 
mortality at 30 days (hazard ratio 1.69, CI 1.07-2.75, p=0.034), 6 months (HR 1.77, CI 
1.31-2.39, p<0.001), and 1 year (HR 1.48, CI 1.11-1.99, p=0.01).
Conclusions: The presence of PVD is associated with higher rates of periprocedural 
death and MI following PCI, and is an independent predictor of short and long-term 
mortality.
11:45 a.m.
875-8 Prognostic Value of Cardiac Troponin After Elective 
Major Vascular Surgery in Patients Perioperatively 
Evaluated According to the ACC/AHA Guidelines for 
non Cardiac Surgery
Andrea Barbieri, Francesca Bursi, Luigi Politi, Mauro Zennaro, Teresa Grimaldi, Antonio 
Rumolo, Mauro Gargiulo, Andrea Stella, Maria Grazia Modena, University of Modena, 
Modena, Italy
Background: Observational studies reported that cardiac troponin (cTn) after vascular 
surgery (VS) was associated with a higher incidence of death, but its incremental value 
after perioperative risk stratiﬁcation is unknown.
Methods: All consecutive elective major VS candidates were prospectively screened 
according to the ACC/AHA guidelines for perioperative cardiovascular evaluation for non 
cardiac surgery. In addition cTn I was dosed on postoperative days 1-2-3. Follow-up for 
death and major cardiac events (clinical acute myocardial infarction, unstable angina, and 
acute heart failure) was blindly provided by review of death certiﬁcates, hospital charts, 
and phone interview.
Results: Among 402 consecutive pts, elevation of cTn I (> 10% coefﬁcient of variation) 
occurred in 17%. After 46 ± 15 months, 60 deaths or major cardiac events occurred. Pts 
with elevated cTn I had a signiﬁcantly worse survival free from cardiac events, p<0.0001 
(Fig). cTn I was an independent predictor after adjusting for age, sex, type of surgery, 
diabetes, history of ischemic heart disease, chronic heart failure and chronic renal failure 
(adjusted RR = 3.0, 95% CI = 1.7-5.3). This association was even stronger acutely (in-
hospital adjusted RR = 9.5, 95% CI = 3.6-25.0).
Conclusions: cTnI is an independent prognostic marker after VS in pts risk stratiﬁed. 
Postoperative cTnI should be considered in the perioperative evaluation of VS candidates 
to identify subjects in whom a more aggressive strategy could be implemented.
ORAL CONTRIBUTIONS
881  Hypertension: Molecular and 
Physiologic Mechanisms
Wednesday, March 09, 2005, 10:30 a.m.-Noon
Orange County Convention Center, Room 230D
10:30 a.m.
881-3 Apoptosis, Survivin and Remodeling in the 
Spontaneously Hypertensive Rat
Antonio Abbate, Daniele Santini, Mei Zhang, Susanna Scarpa, John Miller, Min Jiang, 
Fortunata Vasaturo, Henry Clemo, Alfonso Baldi, George W. Vetrovec, Gea-Ny Tseng, 
Virginia Commonwealth University, Richmond, VA, University La Sapienza, Rome, Italy
Background. The Spontaneously Hypertensive Rat (SHR) with the Wistar Kyoto rat 
(WKY) as the normotensive control has become an accepted model to study the effects 
of hypertensive heart disease. Apoptosis plays a signiﬁcant role in cardiac remodeling 
resulting in the transition from stable hypertrophy to heart failure in SHRs, but the 
mechanisms are poorly understood. The survivin pathway has emerged as a potent 
physiologic apoptosis inhibitor, but its role in heart disease is largely unknown.
Methods and Results. In the current study we evaluated the apoptotic rate in the 
myocardium of 16 SHR and 9 WKY age-matched rats in order determine the correlation 
of echocardiographic parameters with apoptotic rate, and of the latter with the survivin 
expression index. The SHRs had signiﬁcantly increased signs of adverse cardiac 
remodeling such as elevated heart weight (HW), lung weight (LuW), HW/BW, and LuW/
body weight (BW) compared with WKY. This ﬁnding corresponded well with the signiﬁcantly 
nearly 4-fold higher apoptotic rate found in SHR compared to the WKY (0.15% vs 0.04%, 
P<0.001). Survivin was expressed in all of the SHR and WKY rats; however, the survivin 
index was considerably lower in the SHR compared to the WKY and expression of survivin 
was inversely associated with markers of adverse cardiac remodeling.
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Conclusions. Increased expression of survivin in the myocardium with aging may 
represent a protective factor toward heart failure. This ﬁnding could identify a potentially 
useful new target for the treatment of cardiomyocyte remodeling in heart failure
10:45 a.m.
881-4 Sympathetic Overactivity and Adrenoreceptor 
Polymorphisms Predict Weight Gain and Blood 
Pressure Elevation
Kazuko Masuo, Tomohiro Katsuya, Yuxiao Fu, Toshio Ogihara, Michael L. Tuck, Osaka 
University Graduate School of Medicine, Suita, Osaka, Japan, Sepulveda VA Medical 
Center and UCLA School of Medicine, Sepulveda, CA
Background Obesity and hypertension are documented as a cardiovascular risk. 
In the present study, we evaluated the relations of α2-adrenoreceptor and β2, β3-
adrenorecotors polymorphism, sympathetic activity to weight gain and blood pressure 
(BP) elevation over 2 yrs.
Methods In 214 young, non-obese (BMI<25 kg/m2, at entry 23.1±1.1 kg/m2), normotensive 
(BP<140/90 mmHg, mean BP 94±12 mmHg) Japanese men, BMI, total body fat mass, 
BP, plasma norepinephrine (NE), leptin, insulin and genotype of α2 (418C/G, ADRA), β2 
(Arg16Gly, ADRB2-16; Gln27Gly, ADRB2-27), β3 (Try64Arg, ADRB3) -adrenoreceptor 
polymorphisms were measured annually for 2 yrs. Weight gain and BP elevation were 
deﬁned as ≥10% increases in BMI or mean BP for 2 years.
Results Signiﬁcant weight gain at 2 years was noted in 77 subjects (36% of all subjects). 
Subjects with weight gain had greater total fat mass (P<.001), diastolic BP (P=.004) and 
plasma NE (P=.001) at entry and throughout the study than those without weight gain, but 
BMI and leptin at entry were similar. Weight gain was frequently observed in the subjects 
with G allele in ADRA (χ2=12.96, P<.001), C allele in ADRB2-16 (χ2=8.26, P=.004) or 
T allele in ADRB3 (χ2=13.11, P<.001) than subjects without weight gain. Signiﬁcant BP 
elevation at 2 yrs was noted in 43 subjects (20%), and all subjects whose BP rose had 
signiﬁcant weight gain. Subjects with BP elevation had higher NE, mean BP at entry 
and throughout the study, but BMI, total fat mass, leptin and insulin at entry were similar. 
Subjects with BP elevation had higher frequency of carrying G allele in ADRB2-27 
(χ2=6.73, P=.007) than those without BP elevation.
Conclusions These results demonstrate that greater adiposity and sympathetic 
overactivity as results from down-regulation in α2-adrenoreceptor, β2 and β3 
adrenoreceptors, predict weight gain (obesity). Sympathetic overactivity related with 
β2-adrenoreceptor polymorphism appears to link to BP elevation (hypertension). The 
genotypes of α2-adrenoreceptor and β2, β3-adrenorecotors polymorphism appears to link 
independently to the onset of obesity and hypertension, whereas sympathetic overactivity 
predicts both obesity and hypertension.
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881-5 Differential Effects of ß-Blockers in Addition to Blockers 
of the Renin Angiotensin System on the Cardiovascular 
Risk Marker, Microalbuminuria, in Patients With Type 2 
Diabetes and Hypertension
George L. Bakris, David Bell, Vivian Fonseca, Richard Katholi, Janet McGill, Robert 
Phillips, Philip Raskin, Jackson T. Wright, Jr., Mary Ann Lukas, Karen M. Anderson, Fred 
K. Holdbrook, Rush University Medical Center, Chicago, IL
Background: The presence of microalbuminuria [(MAU), urine albumin:creatinine ratio 
(ACR) 30-300 mg/g], in hypertensive persons with type 2 diabetes (T2DM) increases 
risk for cardiovascular morbidity and mortality. Reduction of blood pressure (BP) to 
recommended levels commonly requires multiple agents, with renin-angiotensin blockers 
(ACE/ARBs) accepted initial therapy. The effects of ß-blockade on the presence and 
progression of MAU in patients with HTN and T2DM who were receiving an ACE/ARB 
was a pre-speciﬁed endpoint of the GEMINI trial. 
Methods: ß1-selective blockade (metoprolol, 50-200 mg bid) was compared to the ß1-
ß2-α1-blocker carvedilol (6.25-25 mg bid). After wash-out of all antihypertensives except 
ACE/ARBs patients were randomized (metoprolol:737; carvedilol:498) to blinded study 
medication, titrated to target BP (<130/80) and followed for 5 months. Hydrochlorothiazide 
(HCTZ, 12.5 mg) and dihydropyridine calcium antagonist (CA) were added if needed to 
achieve goal BP. Evaluable patients (metoprolol:542; carvedilol:388) were deﬁned as 
having valid paired ACR at screening and month 5 (M5). 
Results: MAU was present in 20% (carvedilol) and 18% (metoprolol) of patients at 
screening. At M5, carvedilol signiﬁcantly reduced ACR (%change; 95%CI; p-value): -14.0%; 
-22.3, -5.0, 0.003. Metoprolol had no effect (2.5; -6.1, 11.9; 0.579). The resultant treatment 
difference between carvedilol and metoprolol was 16.2%, 95%CI -25.3,-5.9, p=0.003. 
Importantly, signiﬁcantly fewer participants with normoalbuminuria progressed to MAU on 
carvedilol (6.4% carvedilol vs 10.5% metoprolol, p:<0.05). BP at M5 was similar in the two 
treatment groups (SBP/DBP± sd) carvedilol:131.4±13.0/ 77.6±8.8; metoprolol:132.3±14.4
/76.9±8.4). Mean dose required to achieve target BP was 17.5 mg bid (carvedilol) and 128 
mg bid (metoprolol); ~ 50% of each group received HCTZ and/or CCB. 
Conclusion: Carvedilol reduces the CV risk marker, MAU compared to metoprolol. 
This effect cannot be explained by differences in blood pressure or α1-antagonism. The 
antioxidant properties of this agent may contribute to this beneﬁt.
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881-6 The Identiﬁcation of a New Candidate Gene for 
Hypertension: A Polymorphism in the Promoter Region 
of CYP4A11 Gene Is Associated With Its Transcriptional 
Activity and Hypertension
Ken Sugimoto, Tomohiro Katsuya, Koichi Node, Osamu Yasuda, Kazuhiko Ishikawa, 
Akiko Matsuo, Hiroshi Akasaka, Hiromi Rakugi, Toshio Ogihara, Osaka University 
Graduate School of Medicine, Suita, Japan, Saga University Faculty of Medicine, Saga, 
Japan
In human kidney, CYP4A11, ω/ω-1 hydroxylase that regulates the synthesis from 
arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) in renal afferent arteries 
and proximal tubules, etc. Previous reports showed that 20-HETE is the principal renal 
eicosanoid that interacts with several hormonal systems to regulate blood pressure. 
As the transcriptional regulation of the CYP4A11 gene has not been clariﬁed yet, we 
examined the sequence of CYP4A11 gene promoter region and the effect of promoter 
SNPs on its transcriptional regulation.
Methods: We sequenced the promoter region of the CYP4A11 gene to identify the 
polymorphism using 32 Japanese healthy volunteers with the informed consent. Two 
SNPs in promoter region were identiﬁed: -533A/G, -23T/C. As the frequency of wild type 
homozygote of -23T/C polymorphism was very high (94%), we only determined -533A/G 
polymorphism to examine the association with hypertension. After obtained the informed 
consent, we compared the frequency of -533A/G polymorphisms between hypertensives 
(n=300) and normotensives (n=430) using TaqMan PCR method. Using renal proximal 
tubular epithelium cells (RPTEC), transcriptional activity of the CYP4A11 gene promoter 
with or without -533A/G was measured by luciferase assay and electrophoretic mobility 
shift assay (EMSA).
Results: The distribution of -533A/G polymorphism was as follows; AA 59%. AG 38%, 
GG 3%. Prevalence of hypertension was signiﬁcantly lower in subjects with AG or GG 
genotypes than in those with AA homozygotes (34.3% vs. 45.8%, p<0.001, Odds ration = 
0.54 (95%CI; 0.39-0.75)). The luciferase activity of the constructs contained the CYP4A11 
promoter with -533G in RPTEC was 28% lower than that with -533A (p<0.01). Using the 
oligonucleotide with -533G (31bp) in EMSA, the afﬁnity of a transcriptional factor binding 
with the size of 30 kD signiﬁcantly reduced compared to that with -533A nucleotide, 
moreover the -533G oligonucleotide with had other transcriptional factor binding (55kD) 
with the oligonucleotide with -533A.
Conclusion: We concluded that a functionally relevant gene polymorphism of the 
CYP4A11 is a new candidate which is associated with decrease of the susceptibility to 
hypertension.
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881-7 The Effect of Losartan Versus Atenolol on Brachial 
Artery Vasodilatory Capacity and Hypertrophy in 
Essential Hypertension: A LIFE Substudy
Michael H. Olsen, Kristian Wachtell, Keld Neland, Jens Rokkedal, Hans Ibsen, Harriet 
Dige-Pedersen, Department of Internal Medicine, Glostrup University Hospital, Glostrup, 
Denmark, Department of Clinical Physiology and Nuclear Medicine, Glostrup University 
Hospital, Glostrup, Denmark
Background: It is unknown whether treatment with angiotensin II receptor blockers 
can reduce brachial artery hypertrophy and improve vasodilatory capacity in essential 
hypertension as seen with ACE-inhibitor treatment.
Methods: In 36 patients recruited for the LIFE Study with stage II-III hypertension 
and ECG left ventricular hypertrophy we measured intima-media thickness (IMTb), 
internal diameter (Db), ﬂow-mediated dilatation (FMD) after 5 minutes of ischemia and 
nitroglycerin-induced dilatation (NID) after 10 minutes of intra-venous nitroglycerin 
infusion in the brachial artery by ultrasound, 24-hour ambulatory systolic blood pressure 
(24h-SBP), minimal forearm vascular resistance (MFVR) by plethysmography, intima-
media thickness (IMTc) and internal diameter (Dc) in the common carotid arteries by 
ultrasound at baseline and after one year of anti-hypertensive treatment with either 
atenolol- or losartan-based regimens.
Results: Despite marked, but equal blood pressure reductions, there were no signiﬁcant 
changes in IMTb, FMD nor NID in patients treated with losartan (0.49 to 0.46 mm, P=0.06, 
4.9 to 4.8%, NS and 15.5 to 16.3%, NS) nor atenolol (0.46 to 0.46 mm, NS, 5.4 to 5.6%, 
NS and 15.0 to 14.2%, NS). FMD was at baseline independently related to MFVR (β=-
0.33*) and NID (β=0.41*) (Adj.R2=0.24***) and after one year to Db (β=-0.28, P=0.09) 
and NID (β=0.45**) (Adj.R2=0.36**). NID was at baseline related to Dc (β=-0.44*), Db 
(β=-0.30*) and 24h-SBP (β=-0.24, P=0.09) (Adj.R2=0.55***) and after one year to Db (β=-
0.48**) and MFVR (β=-0.28, P=0.09) (Adj.R2=0.22*).
The relative change in FMD was inversely related to the relative change in IMTc (r=0.36, 
P=0.06) and the relative change in NID was inversely related to the relative change in 
MFVR (r=0.47**). *P<0.05, **P<0.01, ***P<0.001
Conclusion: Neither one year of losartan- nor atenolol-based anti-hypertensive 
regimens could reduce vascular hypertrophy or improve vasodilatory capacity in patients 
with hypertension and left ventricular hypertrophy. The lack of improvement in vasodilatory 
capacity may be due to its relation to vascular hypertrophy, which might need more time 
to regress.
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881-8 N-terminal pro-Brain Natriuretic Peptide is a Powerful 
Predictor of Stroke in Patients with Hypertension and 
Preserved Left Ventricular Systolic Function in the 
General Population.
Ilan E. Raymond, Frants Pedersen, Caroline Kistorp, Per Rossen Hildebrandt, 
Frederiksberg Hospital, Copenhagen, Denmark
Background: N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) has been shown to 
be a strong predictor of mortality and morbidity in heart failure populations and in the 
general population. The aim of the study was to evaluate NT-proBNP as a marker of stroke 
in patients with hypertension and preserved left ventricular systolic function (LVSF) in the 
general population.
Methods: 658 unselected subjects (374 women) older than 50 years (median age 68 
years, range: 50-90 years) from randomly selected general practitioners participated 
in the study. Participants ﬁlled in a heart failure questionnaire, an ECG was recorded 
and echocardiography was performed, blood pressure and NT-proBNP were measured. 
Hypertension was deﬁned as history of hypertension or blood pressure > 150/90 mmHg. 
Preserved LVSF was deﬁned as left ventricular ejection fraction > 0.50.
Results: 309 subjects fulﬁlled the criteria of hypertension and preserved LVSF. Median 
(range) follow-up was 60.4 (2.9-63.3) months, 15 events (stroke) were registered.
In a Cox proportional hazards analyses age, gender, systolic and diastolic blood 
pressures, atrial ﬁbrillation, myocardial infarction, diabetes, smoking and log (NT-proBNP 
) were evaluated as potential prognostic factors of stroke. Log NT-proBNP (hazard ratio 
(HR) =4.1, 95th-CI: 1.4-12.0, p=0.01) was an independent marker of stroke. In a different 
Cox proportional hazards analyses discriminating subjects with NT-proBNP below and 
above the median value (35.6 pmol/l) and including the same variables, NT-proBNP 
(HR=4.2, 95th-CI: 1.2-15, p=0.027) was an independent marker of stroke, while traditional 
risk factors were found not to be independent predictors.
Conclusion: In this unselected sample of individuals from the general population, NT-
proBNP was a powerful independent predictor of stroke within the population suffering 
from hypertension.
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